PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SHAH, NM; MARCHIONNI, MA; ISAACS, I; STROOBANT, P; ANDERSON, DJ				SHAH, NM; MARCHIONNI, MA; ISAACS, I; STROOBANT, P; ANDERSON, DJ			GLIAL GROWTH-FACTOR RESTRICTS MAMMALIAN NEURAL CREST STEM-CELLS TO A GLIAL FATE	CELL			English	Article							RAT SCHWANN-CELLS; NEURONAL DIFFERENTIATION; DORSAL-ROOT; COMMITMENT; LINEAGE; GLUCOCORTICOIDS; IDENTIFICATION; DERIVATIVES; POPULATIONS; SEGREGATION	Growth factors and cytokines are thought to influence the development of uncommitted progenitor cell populations, but the issue of how these factors act on individual cells remains controversial. Such factors may act simply as selective mitogens or survival factors for cells that undergo lineage restrictions stochastically. Alternatively, they may instruct or bias multipotent cells to choose one lineage at the expense of others. Here we show that glial growth factor (GGF), previously defined as a Schwann cell mitogen, strongly suppresses neuronal differentiation of rat neural crest stem cells while promoting or allowing glial differentiation. Quantitative clonal analysis suggests that the action of GGF is likely to be instructive rather than selective. Taken together with the expression pattern of GGF, these data suggest a lateral signaling model for the diversification of cell types within developing peripheral ganglia.	CAMBRIDGE NEUROSCI INC, CAMBRIDGE, MA 02139 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research	SHAH, NM (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL 216-76, PASADENA, CA 91125 USA.							Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAROFFIO A, 1992, J CELL SCI, V103, P581; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMENT G, 1990, COMMENTS DEV NEUROBI, V1, P207; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRANK E, 1991, DEVELOPMENT, V111, P895; FRASER SE, 1991, DEVELOPMENT, V112, P913; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOLTON B, 1982, DEV BIOL, V89, P72, DOI 10.1016/0012-1606(82)90295-0; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LEMKE GE, 1984, J NEUROSCI, V4, P75; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; NAWA H, 1990, COLD SH Q B, V55, P247; OGAWA M, 1993, BLOOD, V81, P2844; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SELLECK MAJ, 1993, DEV BIOL, V159, P1, DOI 10.1006/dbio.1993.1217; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTON JA, 1991, CURR TOP DEV BIOL, V25, P133; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	58	445	455	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 6	1994	77	3					349	360		10.1016/0092-8674(94)90150-3	http://dx.doi.org/10.1016/0092-8674(94)90150-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	7910115				2022-12-01	WOS:A1994NK97000006
J	DAS, KM; PRASAD, I; GARLA, S; AMENTA, PS				DAS, KM; PRASAD, I; GARLA, S; AMENTA, PS			DETECTION OF A SHARED COLON EPITHELIAL EPITOPE ON BARRETT EPITHELIUM BY A NOVEL MONOCLONAL-ANTIBODY	ANNALS OF INTERNAL MEDICINE			English	Article						EPITHELIUM; BARRETT ESOPHAGUS; EPITOPES; COLON; ESOPHAGITIS, PEPTIC	COLUMNAR-LINED ESOPHAGUS; ADENOCARCINOMA; DIAGNOSIS	Objective: To determine if there is a reactive epitope common to colonic epithelium and Barrett epithelium, a premalignant metaplastic columnar-lined esophagus, usually arising as a complication of chronic reflux esophagitis. Design: A monoclonal antibody, 7E(12)H(12) (IgM isotype), developed against a colonic epithelial protein was used in a sensitive immunoperoxidase assay using formalin-fixed, paraffin-embedded tissue. One hundred sixteen tissue specimens from the esophagus, stomach, duodenum, and jejunum were examined. Twenty-two biopsy specimens were taken from 22 patients with benign Barrett epithelium, and 12 specimens were obtained from 12 patients with adenocarcinoma of the esophagus arising in Barrett epithelium. The remaining 85 tissue specimens were obtained from various parts of the upper gastrointestinal tract of patients with or without disease states. Results: 21 of 22 (95%) Barrett epithelium specimens and all 12 adenocarcinomas arising from Barrett epithelium reacted with the 7E(12)H(12) monoclonal antibody. Other tissues from esophagus, gastroesophageal junction, stomach, duodenum, or jejunum did not react. Squamous cell carcinoma of the esophagus also did not react. Conclusions: Barrett epithelium shares phenotypic expression of colonic epithelium. The 7E(12)H(12) monoclonal antibody may provide insight into the origin and cellular lineage of Barrett epithelium.	ROBERT WOOD JOHNSON UNIV HOSP, NEW BRUNSWICK, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	DAS, KM (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, 1 ROBERT WOOD JOHNSON PL, NEW BRUNSWICK, NJ 08903 USA.				NIDDK NIH HHS [R01 DK 44314] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044314] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMENTA PS, 1987, METHOD ENZYMOL, V145, P133; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; DAS KM, 1987, J IMMUNOL, V139, P77; FEURLE GE, 1990, DIGEST DIS SCI, V35, P86, DOI 10.1007/BF01537228; GOTTFRIED MR, 1989, AM J CLIN PATHOL, V92, P741, DOI 10.1093/ajcp/92.6.741; Goyal RK, 1985, BARRETTS ESOPHAGUS P, P1; Haggitt RC, 1985, BARRETTS ESOPHAGUS P, P153; HALSTENSEN TS, 1993, GUT, V34, P650, DOI 10.1136/gut.34.5.650; HAMILTON SR, 1987, AM J CLIN PATHOL, V87, P301, DOI 10.1093/ajcp/87.3.301; KALISH RJ, 1984, GASTROENTEROLOGY, V86, P461; LEVINE DS, 1989, LAB INVEST, V60, P418; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; POST AB, 1993, AM J GASTROENTEROL, V88, P877; ROBERTSON DAF, 1989, BRIT MED J, V298, P650, DOI 10.1136/bmj.298.6674.650; SONTAG SJ, 1985, LANCET, V1, P946; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605	16	75	76	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					753	756		10.7326/0003-4819-120-9-199405010-00006	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	7511878				2022-12-01	WOS:A1994NH25100006
J	FIRTH, HV; BOYD, P; CHAMBERLAIN, P; MACKENZIE, I; MORRISSKAY, GM; HUSON, SM				FIRTH, HV; BOYD, P; CHAMBERLAIN, P; MACKENZIE, I; MORRISSKAY, GM; HUSON, SM			ANALYSIS OF LIMB REDUCTION DEFECTS IN BABIES EXPOSED TO CHRONIC VILLUS SAMPLING	LANCET			English	Article							ABNORMALITIES; CVS	In 1991 we reported a cluster of babies with limb abnormalities and suggested that chorionic villus sampling (CVS) was aetiologically associated with these defects. To address the issue more objectively, we have assessed reported limb reduction defects in 75 babies exposed to CVS in utero. 13 babies had an absent limb or a defect through the humerus or femur; 9 had defects through the radius or tibia; 22 defects of the carpus, tarsus, metacarpus, or metatarsus; 25 defects of the digits; and 6 defects of the terminal phalanx or nail only. There was a strong correlation between the severity of the defects and the duration of gestation when CVS was done. The median gestational age at CVS ranged from 56 (range 49-65) postmenstrual days for the most severe category to 72 (51-98) days for the least severe. The relation was seen for both isolated limb defects and for cases with oromandibular-limb hypogenesis syndromes. This relation is further evidence that CVS has an aetiological role in some limb reduction anomalies.	JOHN RADCLIFFE HOSP,OXFORD REG PRENATAL DIAG SERV,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT HUMAN ANAT,OXFORD OX1 3QX,ENGLAND	University of Oxford; University of Oxford; University of Oxford	FIRTH, HV (corresponding author), CHURCHILL HOSP,OXFORD REG GENET SERV,OXFORD OX3 7LJ,ENGLAND.							BRAMBATI B, 1992, PRENATAL DIAG, V12, P789, DOI 10.1002/pd.1970121004; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BURTON BK, 1993, PEDIATRICS, V91, P989; CHRISTIAENS GCML, 1989, PRENATAL DIAG, V9, P67, DOI 10.1002/pd.1970090110; CORLISS CE, 1976, PATTENS HUMAN EMBRYO; DOLK H, 1992, LANCET, V339, P876, DOI 10.1016/0140-6736(92)90325-W; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FIRTH HV, 1991, LANCET, V338, P51, DOI 10.1016/0140-6736(91)90036-O; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GHIRARDINI G, 1991, LANCET, V338, P695, DOI 10.1016/0140-6736(91)91271-U; HSIEH FJ, 1991, LANCET, V337, P1092; IBBA RM, 1992, PRENATAL DIAGN S, V12, pS98; JACKSON LG, 1991, LANCET, V337, P1423; Lin S. P., 1992, American Journal of Human Genetics, V51, pA261; LOS FJ, 1993, LANCET, V342, P1559, DOI 10.1016/S0140-6736(05)80137-0; MAHONEY MJ, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93117-R; MASTROIACOVO P, 1992, AM J MED GENET, V44, P856, DOI 10.1002/ajmg.1320440639; MONNI G, 1991, LANCET, V337, P1091; PLANTEYDT HT, 1986, LANCET, V2, P756; QUINTERO RA, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90272-5; RICHMAN JM, 1992, DEV BIOL, V154, P299, DOI 10.1016/0012-1606(92)90069-S; RODECK CH, 1993, LANCET, V341, P500, DOI 10.1016/0140-6736(93)90259-J; SCHLOO R, 1992, AM J MED GENET, V42, P404, DOI 10.1002/ajmg.1320420338; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; WEBSTER WS, 1987, TERATOLOGY, V35, P253, DOI 10.1002/tera.1420350212; WILSON RD, 1992, AM J HUMAN GENET S, V51, pS176	26	115	124	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1069	1071		10.1016/S0140-6736(94)90182-1	http://dx.doi.org/10.1016/S0140-6736(94)90182-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909100				2022-12-01	WOS:A1994NJ69400010
J	HOFFMAN, DM; OSULLIVAN, AJ; BAXTER, RC; HO, KKY				HOFFMAN, DM; OSULLIVAN, AJ; BAXTER, RC; HO, KKY			DIAGNOSIS OF GROWTH-HORMONE DEFICIENCY IN ADULTS	LANCET			English	Article							BINDING-PROTEIN; SOMATOMEDIN-C; RADIOIMMUNOASSAY; AGE; MEN; GH; SECRETION; PROFILES; PLASMA	There is no consensus as to the most appropriate method of diagnosing growth-hormone (GH) deficiency in adults. We have evaluated the relative diagnostic merits of measuring peak GH response to insulin-induced hypoglycaemia (insulin tolerance test), mean 24 h GH concentration derived from 20 min sampling, serum insulin-like growth factor I (IGF-I) concentrations, and serum IGF binding protein 3 (IGFBP-3) concentrations. These tests were undertaken in 23 patients considered GH deficient from extensive organic pituitary disease, and in 35 sex-matched normal subjects of similar age and body-mass index. Hypopituitary subjects had significantly lower stimulated peak GH, mean 24 h GH, IGF-I, and IGFBP-3 concentrations than normal subjects. The ranges of stimulated peak GH responses were clearly separated between the hypopituitary (<0.2-3.1 ng/mL) and normal (5.3-42.5 ng/mL) groups, but mean 24 h GH, IGF-I, and IGFBP-3 concentrations overlapped. Mean 24 h GH concentrations were below assay sensitivity in 80% of hypopituitary subjects and 16% of normal subjects. 70% and 72%, respectively, of the IGF-I and IGFBP-3 values in hypopituitary subjects were within the range for normal subjects. We conclude that GH deficiency in adults is most reliably identified by stimulatory testing, and that IGF-I and IGFBP-3 are poor diagnostic tests of adult GH deficiency.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,SYDNEY,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney			Ho, Ken KY/E-5832-2011; Ho, Ken/AAA-7428-2019; Baxter, Robert C/F-3927-2012	Ho, Ken/0000-0002-2508-9588; Baxter, Robert C/0000-0001-5061-2142				BARKAN AL, 1988, J CLIN ENDOCR METAB, V67, P69, DOI 10.1210/jcem-67-1-69; BAXTER RC, 1982, CLIN CHEM, V28, P488; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610; BLUM WF, 1990, J CLIN ENDOCR METAB, V70, P1292, DOI 10.1210/jcem-70-5-1292; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; GREENWOO.FC, 1966, J CLIN INVEST, V45, P429, DOI 10.1172/JCI105357; HINTZ RL, 1993, GROWTH HORMONE REPLA, P157; HO KKY, IN PRESS CLIN ENDOCR; HO KY, 1989, CLIN ENDOCRINOL, V30, P335, DOI 10.1111/j.1365-2265.1989.tb00431.x; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; JORGENSEN JOL, 1989, LANCET, V1, P1221; LANDON J, 1966, J CLIN INVEST, V45, P437, DOI 10.1172/JCI105358; LAUGHLIN GA, 1993, 75TH P ANN M END SOC; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SAINI S, 1991, CLIN ENDOCRINOL, V34, P455, DOI 10.1111/j.1365-2265.1991.tb00325.x; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51; VERMEULEN A, 1987, J CLIN ENDOCR METAB, V64, P884, DOI 10.1210/jcem-64-5-884; ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/jcem-60-3-513	23	417	422	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1064	1068		10.1016/S0140-6736(94)90181-3	http://dx.doi.org/10.1016/S0140-6736(94)90181-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7512681				2022-12-01	WOS:A1994NJ69400009
J	JELLINEK, EH				JELLINEK, EH			TRAUMA AND MULTIPLE-SCLEROSIS	LANCET			English	Editorial Material																		BAMFORD C, 1978, CAN J NEUROL SCI, V5, P41, DOI 10.1017/S0317167100024732; BAMFORD CR, 1981, NEUROLOGY, V31, P1229, DOI 10.1212/WNL.31.10.1229; Dawson J.W, 1916, EARTH ENV SCI T R SO, V50, P517, DOI [10.1007/978-3-319-02735-7, DOI 10.1007/978-3-319-02735-7]; EBERS GC, 1994, LANCET, V343, P275, DOI 10.1016/S0140-6736(94)91119-3; ENGELL T, 1989, ACTA NEUROL SCAND, V79, P428, DOI 10.1111/j.1600-0404.1989.tb03811.x; GEORGI W, 1961, SCHWEIZ MED WSCHR, V91, P605; GILBERT JJ, 1983, ARCH NEUROL-CHICAGO, V40, P533, DOI 10.1001/archneur.1983.04050080033003; KELLY R, 1985, HDB CLIN NEUROLOGY, P49; KELLY RE, 1961, BRIT MED J, V2, P421, DOI 10.1136/bmj.2.5249.421; MATTHEWS WB, 1991, MCALPINES MULTIPLE S, P112; MILLER DH, 1993, BRAIN, V116, P1077, DOI 10.1093/brain/116.5.1077; POSER CM, 1993, J NEUROL SCI S, V115, P3; SIBLEY W, 1993, NEUROLOGY, V41, P1871; SIBLEY WA, 1985, LANCET, V1, P1313; SIBLEY WA, 1991, J NEUROL NEUROSUR PS, V54, P584, DOI 10.1136/jnnp.54.7.584; SIVA A, 1993, NEUROLOGY, V43, P1878, DOI 10.1212/WNL.43.10.1878; VOST A, 1964, J PATHOL BACTERIOL, V88, P463, DOI 10.1002/path.1700880209	17	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1053	1054		10.1016/S0140-6736(94)90178-3	http://dx.doi.org/10.1016/S0140-6736(94)90178-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909097				2022-12-01	WOS:A1994NJ69400006
J	MALLIDIS, C; LIM, TC; HILL, ST; SKINNER, DJ; BROWN, DJ; JOHNSTON, WIH; BAKER, HWG				MALLIDIS, C; LIM, TC; HILL, ST; SKINNER, DJ; BROWN, DJ; JOHNSTON, WIH; BAKER, HWG			COLLECTION OF SEMEN FROM MEN IN ACUTE-PHASE OF SPINAL-CORD INJURY	LANCET			English	Note							ELECTROEJACULATION; STATE; ART	In chronic spinal cord injury, semen obtained by assisted ejaculation is usually abnormal. We have assessed electroejaculation early after injury in seven patients. There were no adverse effects. Initial samples contained few or no spermatozoa but as patients emerged from spinal shock, semen improved and five had specimens cryopreserved. Thereafter sperm motility and viability decreased towards the pattern of chronic spinal cord injury by day 16. Cryopreservation was not possible in one patient with many medical complications and another who started electroejaculation 15 days after injury. Semen storage within the first 2 weeks after spinal cord injury is recommended for future fertility treatment.	AUSTIN HOSP,SPINAL INJURIES UNIT,MELBOURNE,VIC 3084,AUSTRALIA; UNIV MELBOURNE,DEPT OBSTET & GYNECOL,MELBOURNE,VIC,AUSTRALIA; ROYAL WOMENS HOSP,REPROD BIOL UNIT,CARLTON,AUSTRALIA; MELBOURNE IVF,MELBOURNE,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne				Mallidis, Con/0000-0001-9531-3808				BRINDLEY GS, 1981, J NEUROL NEUROSUR PS, V44, P9, DOI 10.1136/jnnp.44.1.9; HALSTEAD LS, 1987, PARAPLEGIA, V25, P120, DOI 10.1038/sc.1987.21; LIM TC, 1994, PARAPLEGIA, V32, P142, DOI 10.1038/sc.1994.27; Linsenmeyer T A, 1991, J Am Paraplegia Soc, V14, P116; SARKARATI M, 1987, J UROLOGY, V138, P59, DOI 10.1016/S0022-5347(17)42988-0; SHERMAN JK, 1973, FERTIL STERIL, V24, P397; SIOSTEEN A, 1990, PARAPLEGIA, V20, P96; TALBOT HS, 1955, J UROLOGY, V73, P91, DOI 10.1016/S0022-5347(17)67370-1; WOLF DP, 1989, J IN VITRO FERTIL EM, V6, P325, DOI 10.1007/BF01138770; 1992, WHO LABORATORY MANUA	10	41	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1072	1073		10.1016/S0140-6736(94)90183-X	http://dx.doi.org/10.1016/S0140-6736(94)90183-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909101				2022-12-01	WOS:A1994NJ69400011
J	COX, AL; SKIPPER, J; CHEN, Y; HENDERSON, RA; DARROW, TL; SHABANOWITZ, J; ENGELHARD, VH; HUNT, DF; SLINGLUFF, CL				COX, AL; SKIPPER, J; CHEN, Y; HENDERSON, RA; DARROW, TL; SHABANOWITZ, J; ENGELHARD, VH; HUNT, DF; SLINGLUFF, CL			IDENTIFICATION OF A PEPTIDE RECOGNIZED BY 5 MELANOMA-SPECIFIC HUMAN CYTOTOXIC T-CELL LINES	SCIENCE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; AUTOLOGOUS MELANOMA; HLA-A; ANTIGENS; EXPRESSION; RESPONSES; MOLECULE; CLONES; ALLELE; INTERLEUKIN-2	Of several thousand peptides presented by the major histocompatibility molecule HLA-A2.1, at least nine are recognized by melanoma-specific cytotoxic T lymphocytes (CTLs). Tandem mass spectrometry was used to identify and to sequence one of these peptide epitopes. Melanoma-specific CTLs had an exceptionally high affinity for this nine-residue peptide, which reconstituted an epitope for CTL lines from each of five different melanoma patients tested. Recognition by multiple CTL lines suggests that this may be a promising candidate for use in peptide-based melanoma vaccines.	UNIV VIRGINIA,HLTH SCI CTR,DEPT SURG,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; DUKE UNIV,DEPT SURG,DURHAM,NC 27710; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia; University of Virginia; Duke University; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Engelhard, Victor/0000-0002-1741-0925; Cox, Andrea/0000-0002-9331-2462	NCI NIH HHS [CA57653] Funding Source: Medline; NIAID NIH HHS [AI33993] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057653, R29CA057653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033993, R37AI033993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANICHINI A, 1993, J EXP MED, V177, P989, DOI 10.1084/jem.177.4.989; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CHEN QY, 1992, INT J CANCER, V51, P218, DOI 10.1002/ijc.2910510209; CHEN Y, IN PRESS J IMMUNOL; COULIE PG, 1992, INT J CANCER, V50, P289, DOI 10.1002/ijc.2910500220; CROWLEY NJ, 1991, J IMMUNOL, V146, P1692; DARROW TL, 1989, J IMMUNOL, V142, P3329; ENGELHARD VH, UNPUB; EVERSON T, 1966, SPONTANEOUS REGRESSI; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; HAYASHI Y, 1992, CANCER IMMUNOL IMMUN, V34, P419, DOI 10.1007/BF01741754; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; HOM SS, 1991, J IMMUNOTHER, V10, P153; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IOANNIDES CG, 1991, J IMMUNOL, V146, P1700; IOANNIDES CG, 1993, SCAND J IMMUNOL, V37, P413, DOI 10.1111/j.1365-3083.1993.tb03312.x; KAWAKAMI Y, 1992, J IMMUNOL, V148, P638; KRADIN RL, 1989, LANCET, V1, P577; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, MOL BIOL MED, V4, P339; MITCHELL MS, 1993, ANN NY ACAD SCI, V690, P153; MUUL LM, 1987, J IMMUNOL, V138, P989; PEOPLES GE, 1993, SURGERY, V114, P227; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SLINGLUFF CL, 1988, J NATL CANCER I, V80, P1016, DOI 10.1093/jnci/80.13.1016; SLINGLUFF CL, 1993, J IMMUNOL, V150, P2955; SLINGLUFF CL, IN PRESS CANCER RES; STORKUS WJ, 1993, J IMMUNOL, V151, P3719; STOVIN SF, 1986, J IMMUNOL, V137, P3042; TOPALIAN SL, 1992, J IMMUNOTHER, V12, P203, DOI 10.1097/00002371-199210000-00013; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UTZ U, 1992, J IMMUNOL, V149, P214; VANBLEEK GM, 1990, NATURE, V348, P213; VOSE BM, 1982, NATURE, V296, P359, DOI 10.1038/296359a0; WOLFEL T, 1993, INT J CANCER, V55, P237, DOI 10.1002/ijc.2910550212; WOLFEL T, IN PRESS EUR J IMMUN; YASUMURA S, 1993, CANCER RES, V53, P1461	46	792	853	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					716	719		10.1126/science.7513441	http://dx.doi.org/10.1126/science.7513441			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	7513441				2022-12-01	WOS:A1994NH71300036
J	BOLOTINA, VM; NAJIBI, S; PALACINO, JJ; PAGANO, PJ; COHEN, RA				BOLOTINA, VM; NAJIBI, S; PALACINO, JJ; PAGANO, PJ; COHEN, RA			NITRIC-OXIDE DIRECTLY ACTIVATES CALCIUM-DEPENDENT POTASSIUM CHANNELS IN VASCULAR SMOOTH-MUSCLE	NATURE			English	Article							K+ CHANNELS; SKELETAL-MUSCLE; RELAXING FACTOR; ENDOTHELIUM; CELLS; RELAXATION; TONE	NITRIC oxide is the major endothelium-derived relaxing factor (EDRF)(1-3), and it is thought to relax smooth muscle cells by stimulation of guanylate cyclase, accumulation of its product cyclic GMP, and cGMP-dependent modification of several intracellular processes(4-5), including activation of potassium channels through cGMP-dependent protein kinase(6,7). Here we present evidence that both exogenous nitric oxide and native EDRF can directly activate single Ca2+-dependent K+ channels (K-Ca(+)) in cell-free membrane patches without requiring cGMP. Under conditions when guanylate cyclase was inhibited by methylene blue, considerable relaxation of rabbit aorta to nitric oxide persisted which was blocked by charybdotoxin, a specific inhibitor of K-Ca(+) channels. These studies demonstrate a novel direct action of nitric oxide on K-Ca(+) channels.			BOLOTINA, VM (corresponding author), BOSTON UNIV,MED CTR,ROBERT DAWSON EVANS DEPT CLIN RES,VASC BIOL UNIT,BOSTON,MA 02118, USA.		Pagano, Patrick/GYO-2619-2022	/0000-0002-1070-6408; Bolotina, Victoria/0000-0001-5862-181X				BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BOLOTINA V, 1989, PFLUG ARCH EUR J PHY, V415, P262, DOI 10.1007/BF00370875; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; COWAN CL, 1993, J PHARMACOL EXP THER, V266, P1482; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KRIPPEITDREWS P, 1992, J CARDIOVASC PHARM, V20, pS72, DOI 10.1097/00005344-199204002-00022; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; NAJIBI S, 1994, AM J PHYSL, V266; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; SINGER JJ, 1987, PFLUG ARCH EUR J PHY, V408, P98, DOI 10.1007/BF00581337; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; TARE M, 1990, NATURE, V346, P69, DOI 10.1038/346069a0; TORO L, 1991, J BIOENERG BIOMEMBR, V23, P561, DOI 10.1007/BF00785811; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WOLIN MS, 1990, J PHARMACOL EXP THER, V254, P872	28	1445	1481	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					850	853		10.1038/368850a0	http://dx.doi.org/10.1038/368850a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512692				2022-12-01	WOS:A1994NH71700070
J	FUMAGALLI, S; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA				FUMAGALLI, S; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA			A TARGET FOR SRC IN MITOSIS	NATURE			English	Article							TYROSINE KINASES; GROWTH-FACTOR; SIGNAL TRANSDUCTION; C-SRC; PROTEIN; PHOSPHORYLATION; ACTIVATION; GAP; IDENTIFICATION; ASSOCIATION	THE activity of the c-Src protein is increased during cell-cycle stage G1 in fibroblasts stimulated with certain growth factors(1-4), and at the G2/M transition(5), but little is known about Src substrates in these circumstances. In contrast, cells transformed with activated Src contain many tyrosine-phosphorylated proteins. We compared the phosphotyrosine content of growing and mitotically arrested Src-transformed cells. We report here that although phosphorylation of most proteins was unchanged during mitosis, phosphorylation of one of about 68K was greatly enhanced. The p68. was physically associated with activated c-Src, and it bound to the SH3 domain of c-Src in vitro. Tyrosine-phosphorylated p68 was also present in mitotic extracts of normal cells, suggesting that its phosphorylation was not just a consequence of transformation; Purification and microsequencing of p68 showed that it was related to the previously described GAP-associated protein p62 (ref. 6).	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; LUDWIG INST CANC RES,MIDDLESEX BRANCH,LONDON W1P 8BT,ENGLAND	European Molecular Biology Laboratory (EMBL); Ludwig Institute for Cancer Research			FUMAGALLI, Stefano/C-2914-2019; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; , Stefano/0000-0001-5832-8680				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	24	336	347	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					871	874		10.1038/368871a0	http://dx.doi.org/10.1038/368871a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512695				2022-12-01	WOS:A1994NH71700076
J	TAYLOR, SJ; SHALLOWAY, D				TAYLOR, SJ; SHALLOWAY, D			AN RNA-BINDING PROTEIN ASSOCIATED WITH SRC THROUGH ITS SH2 AND SH3 DOMAINS IN MITOSIS	NATURE			English	Article							MOLECULAR-CLONING; ACTIVATION; P60C-SRC; PHOSPHORYLATION; PP60C-SRC	THE tyrosine kinase activity of c-Src is stimulated during mitosis by dephosphorylation of its regulatory tyrosine residue(1-3). This is associated with increased accessibility of its Src homology-2 (SH2) domain for binding a phosphotyrosine-containing peptide(4). But physiological targets of activated c-Src in mitosis have not yet been identified. Here we report that a 68K protein (p68) becomes tyrosine-phosphorylated and physically associates with Src during mitosis in mouse fibroblasts. p68 independently binds the Src SH2 and SH3 domains in vitro and both domains are required for p68 phosphorylation and binding in vivo. p68 is closely related to the p62 protein that is associated with the Ras GTPase-activating protein (GAP)(5) and selectively binds, directly or indirectly, polyribonucleotides. Because the Src SH3 domain also binds heterogeneous nuclear ribonucleoprotein K, these results raise the intriguing possibility that c-Src may regulate the processing, trafficking or translation of RNA in a cell-cycle-dependent manner.			TAYLOR, SJ (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XING Z, IN PRESS MOL BIOL CE	26	391	400	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					867	871		10.1038/368867a0	http://dx.doi.org/10.1038/368867a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512694				2022-12-01	WOS:A1994NH71700075
J	WEYAND I; GODDE, M; FRINGS, S; WEINER, J; MULLER, F; ALTENHOFEN, W; HATT, H; KAUPP, UB				WEYAND, I; GODDE, M; FRINGS, S; WEINER, J; MULLER, F; ALTENHOFEN, W; HATT, H; KAUPP, UB			CLONING AND FUNCTIONAL EXPRESSION OF A CYCLIC-NUCLEOTIDE-GATED CHANNEL FROM MAMMALIAN SPERM	NATURE			English	Article							OLFACTORY EPITHELIUM; ROD PHOTORECEPTORS; IONIC SELECTIVITY; EXCISED PATCHES; MEMBRANE; RECEPTOR; PORES; CELL; DNA	CYCLIC nucleotide-gated (CNG) channels serve as downstream targets of signalling pathways in vertebrate photoreceptor cells and olfactory sensory neurons (see ref. 1 for review). Ca2+ ions that enter through CNG channels(2-5) intimately control these signalling pathways by regulating synthesis(6) or hydrolysis(7) of cyclic nucleotides, and by decreasing ligand sensitivity of CNG channels(8). Several lines of evidence suggest that cyclic nucleotides and Ca2+ play important roles in chemotaxis of invertebrate sperm and fertilization (see ref. 9 for review), whereas their mechanisms of action in vertebrate sperm are largely unknown. Here we report the cloning and functional expression of a novel CNG channel from bovine testis. The channel polypeptide was functionally localized in sperm, but is also specifically expressed in cone photoreceptor cells. These channels might be involved in chemotaxis of sperm by controlling Ca2+ entry through a cyclic-nucleotide signalling pathway.	RUHR UNIV BOCHUM, INST PHYSIOL, D-44780 BOCHUM, GERMANY	Ruhr University Bochum	WEYAND I (corresponding author), FORSCHUNGSZENTRUM JULICH, INST BIOL INFORMAT VERARBEITUNG, POSTFACH 1913, D-52425 JULICH, GERMANY.		Mueller, Frank/I-7196-2013	Mueller, Frank/0000-0001-7264-1227				ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; CERVETTO L, 1988, J PHYSIOL-LONDON, V406, P181, DOI 10.1113/jphysiol.1988.sp017375; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HINSCH KD, 1992, BIOL REPROD, V47, P337, DOI 10.1095/biolreprod47.3.337; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	30	232	243	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 28	1994	368	6474					859	863		10.1038/368859a0	http://dx.doi.org/10.1038/368859a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512693				2022-12-01	WOS:A1994NH71700073
J	SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ				SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ			THYROID-HORMONE USE AND BONE-MINERAL DENSITY IN ELDERLY WOMEN - EFFECTS OF ESTROGEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE THERAPY; PREMENOPAUSAL WOMEN; LEVOTHYROXINE; HYPOTHYROIDISM; METABOLISM	Objective.-To determine the effect of long-term use of thyroid hormone on bone mineral density (BMD) in elderly women and the potential mitigating effects of estrogen replacement therapy. Design.-Cross-sectional, community-based study. Setting.-Rancho Bernardo, Calif. Participants.-A total of 991 white women aged 50 to 98 years who participated in a study of osteoporosis. Main Outcome Measures.-Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry and at the hip and lumbar spine using dual-energy x-ray absorptiometry. Results.-A total of 196 women taking thyroid hormone for a mean duration of 20.4 years were compared with 795 women who were not using thyroid hormone. Women taking daily thyroxine-equivalent doses of 200 mu g or more had significantly lower BMD levels at the midshaft radius and hip compared with those taking less than 200 mu g. Daily doses of 1.6 mu g/kg and greater were associated with lower bone mass at ail four sites compared with nonuse, whereas doses less than 1.6 mu g/kg were not associated with lower BMD levels. These associations were independent of age, body mass index, smoking status, and use of thiazides, corticosteroids, and estrogen. Women taking both estrogen and a thyroid hormone dose of 1.6 mu g/kg or greater had significantly higher BMD levels at all four sites than women taking the same thyroid hormone dose alone. Women taking both thyroid hormone and estrogen had BMD levels comparable with those observed in women taking only estrogen. Conclusions.-Long-term thyroid hormone use at thyroxine-equivalent doses of 1.6 mu g/kg or greater was associated with significant osteopenia at the ultradistal radius, midshaft radius, hip, and lumbar spine. Estrogen use appears to negate thyroid hormone-associated loss of bone density in postmenopausal women,	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIA NIH HHS [AG 07181] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AUWERX J, 1986, Q J MED, V60, P737; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; CHRISTIANSEN C, 1991, OSTEOPOROSIS INT, V1, P7; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; COLSTON KW, 1989, J BONE MINER RES, V4, P625; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DIAMOND T, 1990, J CLIN ENDOCR METAB, V72, P1184; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; GILMAN AG, 1980, GOODMAN GILMANS PHAR, P1406; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSENBAUM RL, 1982, ANN INTERN MED, V96, P53, DOI 10.7326/0003-4819-96-1-53; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SIMONSEN LLP, 1993, PHARM TIMES, V59, P29; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1988, SAS STAT USERS GUIDE	23	135	137	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1245	1249		10.1001/jama.271.16.1245	http://dx.doi.org/10.1001/jama.271.16.1245			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	7848399				2022-12-01	WOS:A1994NG36200023
J	DONDERO, TJ; CURRAN, JW				DONDERO, TJ; CURRAN, JW			EXCESS DEATHS IN AFRICA FROM HIV - CONFIRMED AND QUANTIFIED	LANCET			English	Editorial Material							IVORY-COAST; ABIDJAN		CTR DIS CONTROL & PREVENT,OFF DIRECTOR,ATLANTA,GA	Centers for Disease Control & Prevention - USA	DONDERO, TJ (corresponding author), CTR DIS CONTROL & PREVENT,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341, USA.							DECOCK KM, 1991, AIDS, V5, P393, DOI 10.1097/00002030-199104000-00006; DECOCK KM, 1989, LANCET, V2, P408; RICHARDS SB, IN PRESS TUBERCULE L	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					989	990		10.1016/S0140-6736(94)90120-1	http://dx.doi.org/10.1016/S0140-6736(94)90120-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909087				2022-12-01	WOS:A1994NG68200003
J	GODFREY, R				GODFREY, R			THE NOSE AND THE LOWER AIRWAYS	LANCET			English	Editorial Material							EXERCISE; ASTHMA				GODFREY, R (corresponding author), SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON,ENGLAND.							ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V28, P31, DOI 10.1080/00039896.1974.10666429; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167, DOI 10.1152/jappl.1988.64.5.2167; Proctor DF, 1982, NOSE UPPER AIRWAY PH; RUBINSTEIN I, 1988, AM REV RESPIR DIS, V138, P1164, DOI 10.1164/ajrccm/138.5.1164; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SERRABATLLES J, 1994, THORAX, V49, P128, DOI 10.1136/thx.49.2.128; WIDDICOMBE JG, 1990, EUR RESPIR J S12, V3, P564	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					991	992		10.1016/S0140-6736(94)90122-8	http://dx.doi.org/10.1016/S0140-6736(94)90122-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909089				2022-12-01	WOS:A1994NG68200005
J	HASLAM, PL; HUGHES, DA; MACNAUGHTON, PD; BAKER, CS; EVANS, TW				HASLAM, PL; HUGHES, DA; MACNAUGHTON, PD; BAKER, CS; EVANS, TW			SURFACTANT REPLACEMENT THERAPY IN LATE-STAGE ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Note								In four adult patients with late-stage acute respiratory distress syndrome (ARDS), a single dose of the artificial surfactant ALEC was given by intrabronchial instillation. There was no sustained clinical improvement, but bronchoalveolar lavage measurements indicated that phosphatidylcholine (PC) at 24 h after treatment had increased up to 4.4 fold and phosphatidylglycerol up to 34.7 fold. However, PC relative to total phospholipid remained below normal, and protein contamination relative to PC remained above normal. Thus, therapeutic formulations and regimens to achieve greater and more sustained supplementation of PC may be required in patients with late-stage ARDS.	ROYAL BROMPTON NATL HEART & LUNG HOSP,ADULT INTENS CARE UNIT,LONDON SW3 6NP,ENGLAND	Imperial College London	HASLAM, PL (corresponding author), NATL HEART & LUNG INST,CELL BIOL UNIT,LONDON SW3 6LY,ENGLAND.							HUGHES DA, 1990, EUR RESPIR J, V3, P1128; IKEGAMI M, 1993, AM REV RESPIR DIS, V148, P837, DOI 10.1164/ajrccm/148.4_Pt_1.837; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; LACHMANN B, 1989, EUR RESPIR J S3, V2, pS98; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; Morley C J, 1989, Eur Respir J Suppl, V3, p81s; NOSAKA S, 1990, LANCET, V336, P947, DOI 10.1016/0140-6736(90)92325-C; RICHMAN PS, 1989, EUR RESPIR J S3, V2, pS109; SEEGER W, 1993, EUR RESPIR J, V6, P971; WIEDEMANN H, 1992, American Review of Respiratory Disease, V145, pA184	10	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1009	1011		10.1016/S0140-6736(94)90128-7	http://dx.doi.org/10.1016/S0140-6736(94)90128-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909050				2022-12-01	WOS:A1994NG68200011
J	LALLEMANT, M; BAILLOU, A; LALLEMANTLECOEUR, S; NZINGOULA, S; MAMPAKA, M; MPELE, P; BARIN, F; ESSEX, M				LALLEMANT, M; BAILLOU, A; LALLEMANTLECOEUR, S; NZINGOULA, S; MAMPAKA, M; MPELE, P; BARIN, F; ESSEX, M			MATERNAL ANTIBODY-RESPONSE AT DELIVERY AND PERINATAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN AFRICAN WOMEN	LANCET			English	Article							TO-INFANT TRANSMISSION; VERTICAL TRANSMISSION; HIV-1; GP120; INFECTION; MOTHER; SEQUENCE; DOMAIN; PHENOTYPE; CHILDREN	Prospective cohort studies indicate that 13-45% of human immunodeficiency virus type 1 (HIV-1)-infected pregnant women transmit the virus to their infants. Although factors that influence perinatal transmission are not well understood, drug and immunotherapy trials to interrupt transmission are underway. The identification of women most at risk is essential for prevention, counselling, and medical intervention. We assessed 70 HIV-1-infected pregnant women enrolled in a prospective study of perinatal transmission in Brazzaville, Congo. The relations between maternal health status, antibody levels to selected HIV-1 structural antigens at delivery, and infant outcome were explored. Independent of clinical stage, higher maternal antibody titres to peptides corresponding to the V3 region of gp120 and the immunodominant domain of gp41 were correlated with a higher risk of perinatal transmission. In a logistic regression model, the predicted risk of transmission for symptom-free women whose antibody titres to V3 and gp41 were lowest was 0.02, whereas it was 0.88 for symptomatic women whose antibody titres to V3 and TMSP18 were highest. These associations may give new insight into the mechanisms of perinatal transmission and they may also provide a powerful means of identifying women who would most benefit from intervention trials to halt perinatal transmission.	BRETONNEAU HOSP, VIROL LAB, TOURS, FRANCE; MINIST HLTH, NATL PROGRAM AIDS, Brazzaville, REP CONGO; MINIST HLTH, DEPT MOTHER & CHILD HLTH, Brazzaville, REP CONGO	CHU Tours	LALLEMANT, M (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, FRENCH RES INST DEV COOPERAT, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; BAILLOU A, 1991, J CLIN MICROBIOL, V29, P1387, DOI 10.1128/JCM.29.7.1387-1391.1991; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BORKOWSKY W, 1992, PEDIATRICS, V90, P133; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GOEDERT JJ, 1989, LANCET, V2, P1351; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; LALLEMANT M, 1989, AIDS, V3, P643, DOI 10.1097/00002030-198910000-00004; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; NEWELL ML, 1992, LANCET, V339, P1007; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROBERTSON CA, 1992, J INFECT DIS, V166, P704, DOI 10.1093/infdis/166.4.704; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; UKWU HN, 1992, OBSTET GYNECOL, V80, P458; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; 1986, WKLY EPIDEMIOL REC, V61, P69; 1992, J ACQUIR IMM DEFIC S, V5, P1019	30	42	42	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					1001	1005		10.1016/S0140-6736(94)90126-0	http://dx.doi.org/10.1016/S0140-6736(94)90126-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909048				2022-12-01	WOS:A1994NG68200009
J	LUNDGREN, JD; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; PHILLIPS, A; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; OLSSON, C; GLAUSER, M; HIRSCHEL, B; HAWKES, S; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D				LUNDGREN, JD; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; PHILLIPS, A; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; OLSSON, C; GLAUSER, M; HIRSCHEL, B; HAWKES, S; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D			SURVIVAL DIFFERENCES IN EUROPEAN PATIENTS WITH AIDS, 1979-89	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; VIRUS INFECTION; TERM SURVIVAL; DOUBLE-BLIND; ZIDOVUDINE; EFFICACY; TRENDS; AZT	Objectives-To examine the pattern of survival and factors associated with the outcome of disease in patients with AIDS. Design-Inception cohort. Data collected retrospectively from patients' charts. Setting-52 clinical centres in 17 European countries. Subjects-6578 adults diagnosed with AIDS from 1 January 1979 to 31 December 1989. Main outcome measures-Survival after the time of diagnosis. Results-The median survival after diagnosis was 17 months, with an estimated survival at three years of 16% (95% confidence interval 15% to 17%). Patients diagnosed in southern Europe had a shorter survival, particularly immediately after the time of diagnosis, compared with patients diagnosed in central and northern Europe (survival at one year (95% confidence interval) 54% (52% to 56%) 66% (64% to 68%), 65% (63% to 66%), respectively. The three year survival, however, was similar for all regions. The regional differences in survival were less pronounced for patients diagnosed in 1989 compared with earlier years. Improved survival in recent years was observed for patients with a variety of manifestations used to define AIDS but was significant only for patients diagnosed with Pneumocystis carinii pneumonia. The three S ear survival, however, remains unchanged over time. Conclusions-Survival of AIDS patients seems to vary within Europe, being shorter in southern than central and northern Europe. The magnitude of these differences, however, has declined gradually over time. Short term survival has improved in recent years, but the long term prognosis has remained equally poor, reflecting the fact that the underlying infection with HIV and many of the complicating diseases remains essentially uncontrolled.	UNIV COPENHAGEN, HVIDOVRE HOSP, DK-2650 HVIDOVRE, DENMARK; FREE UNIV BRUSSELS, HOP ST PIERRE, BRUSSELS, BELGIUM; UCL, UNIV COLL & MIDDLESEX SCH MED, LONDON, ENGLAND; SWISS HIV COHORT STUDY, ZURICH, SWITZERLAND; IST SUPER SANITA, VIROL LAB, I-00161 ROME, ITALY; FREDERIKSBERG UNIV HOSP, COPENHAGEN, DENMARK; RIGSHOSP, DK-2100 COPENHAGEN, DENMARK; UNIV HELSINKI, CENT HOSP, HELSINKI, FINLAND; HOP LA PITIE SALPETRIERE, PARIS, FRANCE; BERNHARD NOCHT INST TROP MED, HAMBURG, GERMANY; MED POLIKLIN, MUNICH, GERMANY; LAIKO ATHENS GEN HOSP, ATHENS, GREECE; IKA HOSP 1, ATHENS, GREECE; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY; ST JAMES HOSP, DUBLIN 8, IRELAND; ICHILOV HOSP, IL-64239 TEL AVIV, ISRAEL; RAMBAM MED CTR, HAIFA, ISRAEL; KAPLAN HOSP, IL-76100 REHOVOT, ISRAEL; HADASSAH UNIV HOSP, IL-91120 JERUSALEM, ISRAEL; UNIV ANCONA, ANCONA, ITALY; OSPED CIVILE, PADUA, ITALY; ARCISPEDALE SANTA MARIA NUOVA, REGIO EMILIA, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED INFERMI RIMINI, RIMINI, ITALY; OSPED CASA DEL SOLE, PALERMO, ITALY; OSPED CIVILE, VICENZA, ITALY; OO RR BERGAMI, BERGAMO, ITALY; OSPED INFERMI FAENZA, FAENZA, ITALY; OSPED RIUNITI PARMA, PARMA, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; OSPED AMEDEO SAVOIA, TURIN, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED SANTA ANDREA, LA SPEZIA, ITALY; UNIV CATANIA, CATANIA, ITALY; UNIV CATTOLICA SACRO CUORE, ROME, ITALY; UNIV SASSARI, I-07100 SASSARI, ITALY; POLICLIN MONTELUCE, PERUGIA, ITALY; OSPED GALLIERA, GENOA, ITALY; OSPED SANTA MARIA CROCI, RAVENNA, ITALY; OSPED MAGGIORE NOVARA, NOVARA, ITALY; OSPED SANTA MARIA MADDALENA, TRIESTE, ITALY; CTR HOSP, LUXEMBOURG, LUXEMBOURG; UNIV AMSTERDAM, ACAD ZIEKENHUIS, AMSTERDAM, NETHERLANDS; HOSP SANTA MARIA, LISBON, PORTUGAL; HOSP CURRY CABRAL, LISBON, PORTUGAL; INST SALUD CARLOS 3, MADRID, SPAIN; HOSP CLIN BARCELONA, BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL, BARCELONA, SPAIN; KAROLINSKA INST, STOCKHOLM, SWEDEN; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; UNIV GENEVA, HOP CANTONAL, CH-1211 GENEVA, SWITZERLAND; CHELSEA & WESTMINSTER HOSP, ST STEPHENS CLIN, LONDON, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND	University of Copenhagen; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; University College London; Istituto Superiore di Sanita (ISS); Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Bernhard Nocht Institut fur Tropenmedizin; Laiko General Hospital; Trinity College Dublin; Tel Aviv University; Rambam Health Care Campus; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Marche Polytechnic University; IRCCS Arcispedale S. Maria Nuova; University of Milan; Luigi Sacco Hospital; Hospital of Rimini; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Milan; Luigi Sacco Hospital; University of Catania; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Sassari; Ente Ospedaliero Ospedali Galliera; Luxembourg Hospital Center; University of Amsterdam; Universidade de Lisboa; Hospital Santa Maria; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; Hospital Germans Trias i Pujol; Karolinska Institutet; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; Imperial College London; Imperial College London			Stergiou, George/J-3083-2019; VELLA, STEFANO/ABI-3368-2020; Phillips, Andrew N/B-4427-2008; Lundgren, Jens/AAE-6876-2019; Hawkes, Sarah/AAK-7375-2020; Ledergerber, Bruno/B-5656-2009; Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/D-4912-2015	Stergiou, George/0000-0002-6132-0038; Phillips, Andrew N/0000-0003-2384-4807; Ledergerber, Bruno/0000-0002-6881-4401; VELLA, STEFANO/0000-0003-2347-5984; Lundgren, Jens/0000-0001-8901-7850; Johnson, Anne/0000-0003-1330-7100				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARRIS J E, 1990, Journal of the American Medical Association, V263, P397, DOI 10.1001/jama.263.3.397; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; PEDERSEN C, 1990, AIDS, V4, P1111, DOI 10.1097/00002030-199011000-00009; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, MMWR S5, V38, P1; 1987, MMWR S, V36, P3; 1990, NEW ENGL J MED, V323, P1500	19	94	95	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	1994	308	6936					1068	1073		10.1136/bmj.308.6936.1068	http://dx.doi.org/10.1136/bmj.308.6936.1068			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	7909698	Green Published			2022-12-01	WOS:A1994NH48900021
J	MARKUS, HS; DROSTE, DW; BROWN, MM				MARKUS, HS; DROSTE, DW; BROWN, MM			DETECTION OF ASYMPTOMATIC CEREBRAL EMBOLIC SIGNALS WITH DOPPLER ULTRASOUND	LANCET			English	Note								Can asymptomatic cerebral emboli be detected? With transcranial doppler ultrasonography of the middle cerebral artery, short-duration high-intensity asymptomatic embolic signals were detected in 6 of 25 patients with carotid stenosis and in 9 of 24 with prosthetic cardiac valves, but not in 20 normal controls. In carotid stenosis the signals were usually unilateral and ipsilateral to the stenosis. Embolic signals were significantly more common in patients with mechanical valves than with pig xenografts (8/13 vs 1/11). With mechanical valves embolic signals were usually bilateral. Detection of asymptomatic emboli may allow identification of and preventive treatment in at-risk patients.			MARKUS, HS (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DIV CLIN NEUROSCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			Brown, Martin M/0000-0002-3273-1356				AUSTEN WG, 1965, J SURG RES, V5, P283; Bland M., 1987, INTRO MED STAT, P276; HALL RJC, 1989, DISEASES CARDIAC VAL; MARKUS H, 1993, STROKE, V24, P1667, DOI 10.1161/01.STR.24.11.1667; MARKUS H, 1994, J NEUROL SCI, V122, P117, DOI 10.1016/0022-510X(94)90061-2; RUSSELL D, 1991, STROKE, V22, P253, DOI 10.1161/01.STR.22.2.253; RUSSELL D, 1992, RECENT ADV NEUROSONO, P57; RUSSELL RW, 1963, LANCET, V2, P1354; SIEBLER M, 1992, STROKE, V23, P1652, DOI 10.1161/01.STR.23.11.1652; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; TEGLER CH, 1991, J NEUROIMAGING, V1, P61	11	63	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1011	1012		10.1016/S0140-6736(94)90129-5	http://dx.doi.org/10.1016/S0140-6736(94)90129-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909051				2022-12-01	WOS:A1994NG68200012
J	MULDER, DW; NUNN, AJ; KAMALI, A; NAKIYINGI, J; WAGNER, HU; KENGEYAKAYONDO, JF				MULDER, DW; NUNN, AJ; KAMALI, A; NAKIYINGI, J; WAGNER, HU; KENGEYAKAYONDO, JF			2-YEAR HIV-1-ASSOCIATED MORTALITY IN A UGANDAN RURAL-POPULATION	LANCET			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; HIV INFECTION; AFRICAN CITY; AIDS; ZAIRE; EMPLOYEES; KINSHASA	The mortality in 15 villages in South-West Uganda was studied in relation to HIV infection. After a population census, serum samples were tested for antibodies to HIV-1. Deaths were ascertained over 2 years. Unequivocal HIV-1 serology results were available for 9389 individuals. The prevalence of infection was 4.8% for all ages and 8.2% for adults (aged 13 or more). 198 deaths were recorded during 15725 person years of observation. Mortality among seronegative adults was 7.7 per 1000 and among seropositive adults 115.9 per 1000. The excess annual death rate associated with HIV-1 infection was 5.3 per 1000 and in adults 7.9 per 1000. Highest excess mortality was 16.9 per 1000 in the age group 25-34. Among adults, half of all deaths and among those aged 13-44 over 80% of deaths were attributable to HIV-1 infection. These results show the strong im pact that HIV-1 infection is having on mortality in a rural area of Uganda where the overall HIV-1 adult prevalence rate is below 10%-a rate lower than in many other parts of East Africa.	UGANDA VIRUS RES INST,ENTEBBE,UGANDA	Uganda Virus Research Institute	MULDER, DW (corresponding author), MRC UK,ODA,UVRI,PROGRAMME AIDS UGANDA,POB 49,ENTEBBE,UGANDA.			Nunn, Andrew/0000-0002-9158-4595				ANDERSON RM, 1991, AIDS, V5, pS37; ANZALA A, 1991, 7 INT C AIDS FLOR; BONGAARTS J, 1989, STAT MED, V8, P103, DOI 10.1002/sim.4780080111; COLEBUNDERS RL, 1991, AIDS, V5, pS103; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; KNOWANE BM, 1991, AIDS, V5, pS7; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; MANN JM, 1986, JAMA-J AM MED ASSOC, V255, P3255, DOI 10.1001/jama.255.23.3255; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; NUNK AJ, 1994, IN PRESS METH INFORM, V33; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; PIOT P, 1991, AIDS, V5, pS1; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; SERWADDA D, 1992, AIDS, V6, P983, DOI 10.1097/00002030-199209000-00012; WAY PO, 1992, 8 INT C AIDS AMST; 1990, CURRENT FUTURE DIMEN; 1986, WKLY EPID REC, V61, P72	22	111	112	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1021	1023		10.1016/S0140-6736(94)90133-3	http://dx.doi.org/10.1016/S0140-6736(94)90133-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909054				2022-12-01	WOS:A1994NG68200015
J	SUTHERLAND, LR; VERHOEF, M; WALLACE, JL; VANROSENDAAL, G; CRUTCHER, R; MEDDINGS, JB				SUTHERLAND, LR; VERHOEF, M; WALLACE, JL; VANROSENDAAL, G; CRUTCHER, R; MEDDINGS, JB			A SIMPLE, NONINVASIVE MARKER OF GASTRIC DAMAGE - SUCROSE PERMEABILITY	LANCET			English	Article							CROHNS-DISEASE; INTESTINAL PERMEABILITY; MISOPROSTOL; SUGARS	Disaccharides do not cross intact gastrointestinal mucosa to any appreciable extent unless there is damage to the epithelium. Furthermore, since sucrose is rapidly broken down in the small intestine, the absorption of intact sucrose implies damage to proximal epithelium. We have reported that measurement of sucrose permeability detects gastric damage in animals. Whilst such a non-specific test could not replace endoscopy, it might represent a clinically useful technique to identify patients who would benefit from endoscopy. 189 patients underwent endoscopy and assessment of sucrose permeability to evaluate the effectiveness of increased sucrose permeability in the prediction of endoscopic findings. The endoscopist was blinded to results of the sucrose assay. Gastric damage, particularly ulcers and severe gastritis, was successfully detected with this technique. Increased sucrose permeability, however, did not reliably detect mild gastritis, oesophagitis, or duodenal disease. The sensitivity of the test for gastric ulceration was 84% and specificity in predicting an abnormal endoscopy was 96%. Measurement of sucrose permeability is a simple way of screening for gastric damage. It has a sensitivity similar to that for upper gastrointestinal radiology and provides a new way to effectively screen large populations at risk of gastric damage.	UNIV CALGARY, GASTROINTESTINAL RES GRP, CALGARY T2N 4N1, AB, CANADA	University of Calgary								DAWSON DJ, 1988, CLIN SCI, V74, P427, DOI 10.1042/cs0740427; GRAHAM DY, 1988, LANCET, V2, P1277; HERLINGER H, 1977, CLIN RADIOL, V28, P307, DOI 10.1016/S0009-9260(77)80187-6; LAUFER I, 1976, GASTROENTEROLOGY, V71, P874; MEDDINGS JB, 1993, GASTROENTEROLOGY, V104, P1619, DOI 10.1016/0016-5085(93)90637-R; MURPHY MS, 1989, ARCH DIS CHILD, V64, P321, DOI 10.1136/adc.64.3.321; ROTH S, 1989, ARCH INTERN MED, V149, P775, DOI 10.1001/archinte.149.4.775; UKABAM SO, 1983, DIGESTION, V27, P70, DOI 10.1159/000198932; VANELBURG RM, 1992, SCAND J GASTROENTERO, V27, P19, DOI 10.3109/00365529209096021	9	120	122	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					998	1000		10.1016/S0140-6736(94)90125-2	http://dx.doi.org/10.1016/S0140-6736(94)90125-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909091				2022-12-01	WOS:A1994NG68200008
J	COHEN, FE; PAN, KM; HUANG, Z; BALDWIN, M; FLETTERICK, RJ; PRUSINER, SB				COHEN, FE; PAN, KM; HUANG, Z; BALDWIN, M; FLETTERICK, RJ; PRUSINER, SB			STRUCTURAL CLUES TO PRION REPLICATION	SCIENCE			English	Editorial Material							CREUTZFELDT-JAKOB DISEASE; TRANSGENIC MICE; PRP ISOFORMS; PROTEIN GENE; SCRAPIE; HAMSTERS; LINKAGE; CELLS		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1990, P NATL ACAD SCI USA, V87, P7240, DOI 10.1073/pnas.87.18.7240; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, IN PRESS P NATL ACAD; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; GABIZON R, 1993, AM J HUM GENET, V33, P828; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUANG Z, IN PRESS P NATL ACAD; LIFSON S, 1980, PROTEIN FOLDING, P289; MCKINLEY MP, 1991, J VIROL, V65, P1440; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1992, EMBO J, V11, P863; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WESTAWAY D, IN PRESS P NATL ACAD	42	430	451	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					530	531		10.1126/science.7909169	http://dx.doi.org/10.1126/science.7909169			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7909169				2022-12-01	WOS:A1994NH01000025
J	JOHNSON, TL; CHAMBERLIN, MJ				JOHNSON, TL; CHAMBERLIN, MJ			COMPLEXES OF YEAST RNA-POLYMERASE-II AND RNA ARE SUBSTRATES FAR TFIIS-INDUCED RNA CLEAVAGE	CELL			English	Article							TRANSCRIPTION ELONGATION-FACTOR; RHO-INDEPENDENT TERMINATORS; ESCHERICHIA-COLI; INFLUENZA-VIRUS; FACTOR-SII; INVITRO; ENZYME; DNA	In the absence of DNA, purified yeast RNA polymerase II can bind RNA to form a binary complex. RNA in such RNA-RNA polymerase complexes undergoes reactions previously thought to be unique to nascent RNA in ternary complexes with DNA, including TFIIS-dependent cleavage and elongation by 3'-terminal addition of NMP from NTP. Both of these reactions are inhibited by alpha-amanitin. Hence, by several criteria the RNA in binary complexes is bound to the polymerase in a manner quite similar to that in ternary complexes in which the catalytic site for nucleotide addition is positioned at or near the 3'-OH terminus of the RNA. These findings are consistent with a model for the RNA polymerase ternary complete in which the RNA is bound at the 3' terminus through two protein-binding sites located up to 10 nt apart.			JOHNSON, TL (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM34963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BREMER H, 1966, J MOL BIOL, V16, P94, DOI 10.1016/S0022-2836(66)80265-6; BUSBY S, 1981, EUR J BIOCHEM, V118, P443, DOI 10.1111/j.1432-1033.1981.tb05540.x; CHAMBERLIN M, 1994, IN PRESS HARVEY LECT; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; FOX CF, 1965, J BIOL CHEM, V240, P2101; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GU WG, 1993, J BIOL CHEM, V268, P25604; HONDA A, 1988, J BIOCHEM-TOKYO, V104, P1021, DOI 10.1093/oxfordjournals.jbchem.a122569; ISHIHAMA A, 1986, J BIOL CHEM, V261, P417; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANE CM, 1993, TRANSCRIPTION MECH R, P279; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAKOW JS, 1970, COLD SPRING HARB SYM, V35, P73, DOI 10.1101/SQB.1970.035.01.013; KURMMEL B, 1992, J MOL BIOL, V225, P221; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; ROSENBERG M, 1976, P NATL ACAD SCI USA, V73, P717, DOI 10.1073/pnas.73.3.717; SPENCER CA, 1990, ONCOGENE, V5, P777; STEVENS A, 1969, J BIOL CHEM, V244, P425; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEISSMAN.C, 1967, P NATL ACAD SCI USA, V57, P1870, DOI 10.1073/pnas.57.6.1870; WEIST DK, 1992, J BIOL CHEM, V267, P7733; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	40	68	69	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					217	224		10.1016/0092-8674(94)90314-X	http://dx.doi.org/10.1016/0092-8674(94)90314-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	7513257				2022-12-01	WOS:A1994NH63400007
J	PONZETTO, C; BARDELLI, A; ZHEN, Z; MAINA, F; DALLAZONCA, P; GIORDANO, S; GRAZIANI, A; PANAYOTOU, G; COMOGLIO, PM				PONZETTO, C; BARDELLI, A; ZHEN, Z; MAINA, F; DALLAZONCA, P; GIORDANO, S; GRAZIANI, A; PANAYOTOU, G; COMOGLIO, PM			A MULTIFUNCTIONAL DOCKING SITE MEDIATES SIGNALING AND TRANSFORMATION BY THE HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR FAMILY	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR SCATTER FACTOR; MET HGF RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PDGF RECEPTOR; SH2 DOMAINS; CELL-LINE; AUTOPHOSPHORYLATION; IDENTIFICATION	Signaling by tyrosine kinase receptors is mediated by selective interactions between individual Src homology 2 (SH2) domains of cytoplasmic effecters and specific phosphotyrosine residues in the activated receptor. Here, we report the existence in the hepatocyte growth factor/scatter factor (HGF/SF) receptor of a multifunctional docking site made of the tandemly arranged degenerate sequence YVH/NV. Phosphorylation of this site mediates intermediate- to high-affinity interactions with multiple SH2-containing signal transducers, including phosphatidylinositol 3-kinase, phospholipase C gamma, pp60(c-src), and the GRB-2-Sos complex. Mutation of the two tyrosines results in loss of biological function, as shown by abrogation of the transforming activity in the oncogenic counterpart of the receptor. The same bidentate motif is conserved in the evolutionarily related receptors Sea and Ron, suggesting that in all members of the HGF/SF receptor family, signal transduction is channeled through a multifunctional binding site.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research	PONZETTO, C (corresponding author), UNIV TURIN, SCH MED, DEPT BIOCHEM SCI & ONCOL, I-10126 TURIN, ITALY.		graziani, andrea/B-2554-2009; Maina, Flavio/J-9962-2019; Graziani, Andrea/AAB-6301-2022; Giordano, Silvia/J-9858-2018; BARDELLI, Alberto/J-9721-2018	graziani, andrea/0000-0002-6302-2317; Maina, Flavio/0000-0001-6100-4695; Graziani, Andrea/0000-0002-6302-2317; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BARDELLI A, 1992, ONCOGENE, V7, P1973; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1993, EXS, V65, P225; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RONSIN C, 1993, ONCOGENE, V8, P1195; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SONNENBERG E, 1993, HEPATOCYTE GROWTH FA, P381; STERN CD, 1990, DEVELOPMENT, V110, P1271; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	897	940	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					261	271		10.1016/0092-8674(94)90318-2	http://dx.doi.org/10.1016/0092-8674(94)90318-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	7513258				2022-12-01	WOS:A1994NH63400011
J	WEISSMANN, C				WEISSMANN, C			THE PRION CONNECTION - NOW IN YEAST	SCIENCE			English	Editorial Material							SCRAPIE; GENE; PROTEIN				WEISSMANN, C (corresponding author), UNIV ZURICH, INST MOLEC BIOL 1, CH-8093 ZURICH, SWITZERLAND.							AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1993, PHILOS T R SOC B, V339, P239, DOI 10.1098/rstb.1993.0022; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992	14	16	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					528	530		10.1126/science.7909168	http://dx.doi.org/10.1126/science.7909168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7909168				2022-12-01	WOS:A1994NH01000024
J	ECK, MJ; ATWELL, SK; SHOELSON, SE; HARRISON, SC				ECK, MJ; ATWELL, SK; SHOELSON, SE; HARRISON, SC			STRUCTURE OF THE REGULATORY DOMAINS OF THE SRC-FAMILY TYROSINE KINASE LCK	NATURE			English	Article							PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; SH3 DOMAIN; IDENTIFICATION; P60C-SRC; BINDING	THE kinase p56(lck) (Lck) is a T-lymphocyte-specific member of the Src family of non-receptor tyrosine kinases(1). Members of the Src family each contain unique amino-terminal regions, followed by Src-homology domains SH3 and SH2, and a tyrosine kinase domain. SH3 and SH2 domains mediate critical protein interactions in many signal-transducing pathways(2). They are small, independently folded modules of about 60 and 100 residues, respectively, and they are often but not always found together in the same molecule. Like all nine Src-family kinases (reviewed in ref. 3), Lck is regulated by phosphorylation of a tyrosine in the short C-terminal tail of its catalytic domain(4). There is evidence that binding of the phosphorylated tail to the SH2 domain inhibits catalytic activity of the kinase domain(5,6) and that the SH3 and SH2 domains may act together to effect this regulation(7). Here we report the crystal structures for a fragment of Lck bearing its SH3 and SH2 domains, alone and in complex with a phosphotyrosyl peptide containing the sequence of the Lck C-terminal regulatory tail. The latter complex represents the regulatory apparatus of Lck. The SH3-SH2 fragment forms similar dimers in both crystals, and the tail peptide binds at the intermolecular SH3/SH2 contact. The two structures show how an SH3 domain might recognize a specific target and suggest how dimerization could play a role in regulating Src-family kinases.	CHILDRENS HOSP MED CTR, MOLEC MED LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University	ECK, MJ (corresponding author), CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Brunger AT, 1992, X PLOR VERSION 3 0 S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1989, CRYSTALLOGRAPHIC COM; JONES TA, 1992, MOL REPLACEMENT, P91; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAVAZA J, 1992, AMORE NEW PACKAGE MO; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; Potts W M, 1988, Oncogene Res, V3, P343; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	263	268	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					764	769		10.1038/368764a0	http://dx.doi.org/10.1038/368764a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7512222				2022-12-01	WOS:A1994NG55300065
J	HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; CUNNINGHAM, GC; LUSTIG, LS; BOYD, PA				HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; CUNNINGHAM, GC; LUSTIG, LS; BOYD, PA			REDUCING THE NEED FOR AMNIOCENTESIS IN WOMEN 35 YEARS OF AGE OR OLDER WITH SERUM MARKERS FOR SCREENING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL SERUM; ALPHA-FETOPROTEIN; DOWNS-SYNDROME; UNCONJUGATED ESTRIOL; CHORIONIC-GONADOTROPIN; ABNORMALITIES; PREGNANCIES; DIAGNOSIS; WEIGHT; TRIAL	Background. As maternal age advances, the risk of fetal Down's syndrome increases. Pregnant women 35 years of age or older are routinely offered amniocentesis because of this risk. Recently, maternal serum markers have been reported to be useful in screening for Down's syndrome, primarily in younger women. We therefore investigated whether offering amniocentesis only to selected women 35 years of age or older who were identified by screening measurements in serum might prove a useful alternative to the current practice. Methods. We studied 5385 women with singleton pregnancies who were 35 years of age or older and were undergoing routine amniocentesis. Along with information about the pregnancy, we obtained a serum sample for measurement of alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Individual estimates of the risk of Down's syndrome in the fetus were calculated for each pregnancy before the karyotype was known. Results. If amniocentesis had been reserved for the women calculated to have a risk greater than 1 in 200 of having a fetus with Down's syndrome, 48 of the 54 cases of Down's syndrome (89 percent) would have been identified; 25 percent of the unaffected pregnancies would also have been identified as being at high risk for Down's syndrome (false positives). Seven of 15 fetuses (47 percent) with other trisomies, 11 of 25 (44 percent) with sex aneuploidy, and 1 of 9 (11 percent) with miscellaneous chromosomal abnormalities would also have been detected. In practice, such screening would have made 75 percent of the amniocenteses unnecessary, along with a proportion of the amniocentesis-associated fetal losses. If the cutoff for the risk of Down's syndrome were set higher than 1 in 200, both the rate of detection and the false positive rate would be lower. Conversely, these rates would be higher if the cutoff were set lower. Conclusions. Prenatal screening of serum to generate individual estimates of the risk of Down's syndrome in the fetus can provide a basis for decision making in the cases of women 35 years of age or older, as it does in younger pregnant women, and is an alternative to current testing practices.	CALIF PUBL HLTH FDN,BERKELEY,CA; CALIF DEPT HLTH SERV,GENET DIS BRANCH,BERKELEY,CA 94704	California Department of Health Care Services	HADDOW, JE (corresponding author), FDN BLOOD RES,SCARBOROUGH,ME 04074, USA.				PHS HHS [MCJ-237014-02-2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CANICK JA, 1990, J CLIN IMMUNOASSAY, V13, P30; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; CRANDALL BF, 1983, CLIN CHEM, V29, P531; CUCKLE HS, 1984, LANCET, V1, P926; DIMAIO MS, 1987, NEW ENGL J MED, V317, P342, DOI 10.1056/NEJM198708063170603; GREENE MF, 1988, LANCET, V2, P345; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HOLMESSIEDLE M, 1987, PRENAT DIAGN, V77, P239; HOOK EB, 1983, JAMA-J AM MED ASSOC, V249, P2034, DOI 10.1001/jama.249.15.2034; HOOK EB, 1981, TRISOMY, V21, P3; KNIGHT GJ, 1987, METHODS CLIN CHEM, P459; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; PALOMAKI GE, 1990, AM J HUM GENET, V47, pA282; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; ROBINSON A, 1989, AM J MED GENET, V34, P552, DOI 10.1002/ajmg.1320340420; ROBINSON A, 1992, GENETIC DISORDERS FE, P211; TABOR A, 1986, LANCET, V1, P1287; WALD NJ, 1988, BRIT MED J, V297, P1029; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALD NJ, 1993, PRENATAL DIAG, V13, P1149, DOI 10.1002/pd.1970131211; WARBURTON D, 1991, AM J HUM GENET, V49, P995; 1989, AM J OBSTET GYNECOL, V160, P575; 1976, JAMA-J AM MED ASSOC, V236, P1471; 1990, DHHS PHS901100 PUBL, P89	29	155	159	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1114	1118		10.1056/NEJM199404213301603	http://dx.doi.org/10.1056/NEJM199404213301603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	7510852				2022-12-01	WOS:A1994NF69900003
J	ROBERTS, CWM; SHUTTER, JR; KORSMEYER, SJ				ROBERTS, CWM; SHUTTER, JR; KORSMEYER, SJ			HOX11 CONTROLS THE GENESIS OF THE SPLEEN	NATURE			English	Article							T-CELL LEUKEMIA; HOMEOBOX GENE; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; EXPRESSION; MURINE; ORGANIZATION; HOX-1.6; CODES	MANY homeobox genes are clustered in a linear array along a chromosome, reflecting their ordered expression along the anterior-posterior axis of the embryo(1). Expression patterns(2,3) as well as grafting(4), ectopic expression(5,6) and loss-of-function experiments(7-11) suggest that the Hox genes encode a combinatorial system of positional specification along that axis. In contrast, the function of orphan homeobox genes(12) located at sites outside the four mammalian Hox clusters is less well understood. To assess the functional role of the orphan homeobox gene Hox11, we have generated Hox11-deficient mice through gene targeting. Hox11(-/-) mice have no spleen, but otherwise appear normal. Hox11 is normally expressed in the splenic anlage arising from the splanchnic mesoderm. Hox11(-/-) embryos have no cellular organization at the site of splenic development but all other splanchnic derivatives develop normally. Hox11 controls the genesis of a single organ, providing new insight into the genetic regulation of morphogenesis.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	ROBERTS, CWM (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110, USA.		Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896				BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CARTER TC, 1954, MOUSE NEWS LETT, V11, P16; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DUBE ID, 1991, BLOOD, V78, P2996; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREEN MC, 1967, DEV BIOL, V15, P62, DOI 10.1016/0012-1606(67)90006-1; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOYAMA A, 1960, ACTA HAEMATOL JPN, V23, P20; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NIEHRS C, 1990, CURR OPIN GENET DEV, V2, P550; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAJU R, 1993, MECH DEVELOP, V44, P51; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RUGH R, 1990, MOUSE ITS REPRODUCTI; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STERN CD, 1990, CURR OPIN GENET DEV, V2, P556; WALDMAN JD, 1977, J PEDIATR-US, V90, P555, DOI 10.1016/S0022-3476(77)80365-X; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	30	240	248	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					747	749		10.1038/368747a0	http://dx.doi.org/10.1038/368747a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7908720				2022-12-01	WOS:A1994NG55300060
J	WOO, DDL; MIAO, SYP; PELAYO, JC; WOOLF, AS				WOO, DDL; MIAO, SYP; PELAYO, JC; WOOLF, AS			TAXOL INHIBITS PROGRESSION OF CONGENITAL POLYCYSTIC KIDNEY-DISEASE	NATURE			English	Article							PROTOONCOGENE EXPRESSION; CYST FORMATION; CYCLIC-AMP; MICROTUBULES; CELLS; SECRETION; MEMBRANE; GROWTH; MOUSE; EPITHELIA	POLYCYSTIC kidney diseases (PKD) are the most common hereditary diseases of the human kidney and account for ten per cent of patients requiring renal transplantation or dialysis. Renal cyst formation has been attributed to enhanced cell proliferation, unbalanced cell death, abnormal targeting of membrane proteins; aberrant kidney development and tubular obstruction, but there is no treatment that blocks the formation and enlargement of renal cysts. We have now developed an in vitro model of spontaneous cyst formation that distinguishes polycystic kidney epithelium from its normal counterpart. Inhibitors of DNA, RNA and protein synthesis did not prevent in vitro cyst formation, but this was reversibly inhibited by ouabain, amiloride and the microtubule-specific agents colchicine, vinblastine and taxol. The cpk mouse is a well-characterized recessive PKD model(1-3) and we find that cpk/cpk mice develop PKD and die from uraemia by 4-5 weeks of age, but when treated weekly with taxol they survive for more than 200 days with minimal loss of renal function, show limited collecting-dust cyst enlargement, and attain adult size. Our results indicate that the microtubule cytoskeleton has a central role in the pathogenesis of PKD in cpk mice and that taxol may also be useful in treating human PKD.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PAEDIAT,LOS ANGELES,CA 90024; INST CHILD HLTH,DEV BIOL UNIT,LONDON WC1N 1EH,ENGLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of London; University College London	WOO, DDL (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,7-155 FACTOR BLDG,LOS ANGELES,CA 90024, USA.		Woolf, Adrian S./AAZ-1075-2020	Woolf, Adrian S./0000-0001-5541-1358				AVNER ED, 1988, PEDIATR NEPHROL, V2, P210, DOI 10.1007/BF00862593; AVNER ED, 1987, PEDIATR NEPHROL, V1, P587, DOI 10.1007/BF00853593; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BLOOM TL, 1989, DEVELOPMENT, V106, P159; BRENNER BM, 1983, KIDNEY INT, V23, P647, DOI 10.1038/ki.1983.72; CARONE FA, 1989, KIDNEY INT, V35, P1351, DOI 10.1038/ki.1989.134; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; DEALMEIDA JB, 1991, AM J PHYSIOL, V260, pC691, DOI 10.1152/ajpcell.1991.260.4.C691; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; GATTONE VH, 1988, LAB INVEST, V59, P231; KELLY R, 1990, CELL, V60, P5; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260; MARO R, 1991, DEVELOPMENT S1, V1, P17; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PREMINGER GM, 1982, J UROLOGY, V127, P556, DOI 10.1016/S0022-5347(17)53911-7; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Russell E, 1977, MOUSE NEWSLETTER, V56, P40; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLOT C, 1965, SCAND J CLIN LAB INV, V17, P381, DOI 10.3109/00365516509077065; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; VALENTICH JD, 1979, J CELL PHYSIOL, V100, P291, DOI 10.1002/jcp.1041000210; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; YANG AH, 1987, IN VITRO CELL DEV B, V23, P34	26	129	147	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					750	753		10.1038/368750a0	http://dx.doi.org/10.1038/368750a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7908721				2022-12-01	WOS:A1994NG55300061
J	CLINTON, JJ				CLINTON, JJ			BENIGN PROSTATIC HYPERPLASIA (BPH) - DIAGNOSIS AND TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AGCY HLTH CARE POLICY & RES,POB 8547,SILVER SPRING,MD 20907, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1151	1151		10.1001/jama.271.15.1151	http://dx.doi.org/10.1001/jama.271.15.1151			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	7512166				2022-12-01	WOS:A1994NF20700006
J	BESSLER, M; MASON, P; HILLMEN, P; LUZZATTO, L				BESSLER, M; MASON, P; HILLMEN, P; LUZZATTO, L			SOMATIC MUTATIONS AND CELLULAR-SELECTION IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	LANCET			English	Note							RED-CELLS; HEMOGLOBINURIA	Patients with paroxysmal nocturnal haemoglobinuria (PNH) have in their blood two red-cell populations, one normal and one deficient in proteins anchored to the membrane through a glycan phosphatidylinositol (GPI) structure. The PNH abnormality is due to a somatic mutation in the PIG-A gene, whose product is required for an early step in GPI anchor biosynthesis. We show that in two patients, two PNH clones with different mutations co-exist, and must therefore have arisen independently. This finding supports the concept that PNH develops under the pressures of a positive selection mechanism whereby GPI-anchor-deficient haemopoietic cells have a survival advantage.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,LRF LEUKAEMIA UNIT,LONDON,ENGLAND	Imperial College London	BESSLER, M (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,DU CANE RD,LONDON W12 ONN,ENGLAND.		Mason, Philip J/B-1087-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; DACIE JV, 1972, SER HAEMATOL, V3, P3; HILLMEN P, 1993, BLOOD, V81, P193; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; ROSSE WF, 1973, BRIT J HAEMATOL, V24, P327, DOI 10.1111/j.1365-2141.1973.tb01657.x; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T	10	146	148	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					951	953		10.1016/S0140-6736(94)90068-X	http://dx.doi.org/10.1016/S0140-6736(94)90068-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909012				2022-12-01	WOS:A1994NF70000012
J	FRERICHS, RR				FRERICHS, RR			PERSONAL SCREENING FOR HIV IN DEVELOPING-COUNTRIES	LANCET			English	Editorial Material											FRERICHS, RR (corresponding author), UNIV CALIF LOS ANGELES,DEPT EPIDEMIOL,LOS ANGELES,CA 90024, USA.							BAMBER SD, 1993, GENITOURIN MED, V69, P148; COHEN J, 1993, SCIENCE, V260, P1254, DOI 10.1126/science.8493564; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; FRERICHS RR, 1993, NEW ENGL J MED, V328, P1717, DOI 10.1056/NEJM199306103282318; FRERICHS RR, 1994, J ACQ IMMUN DEF SYND, V7, P552; KALLINGS LO, 1993, VACCINE, V11, P525, DOI 10.1016/0264-410X(93)90223-K; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; TAMASHIRO H, 1993, LANCET, V342, P87, DOI 10.1016/0140-6736(93)91289-X; TAMASHIRO H, IN PRESS B WHO; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P20, DOI 10.2307/2135721; WELLER SC, 1993, SOC SCI MED, V36, P1635, DOI 10.1016/0277-9536(93)90352-5; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	14	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					960	962		10.1016/S0140-6736(94)90072-8	http://dx.doi.org/10.1016/S0140-6736(94)90072-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909015				2022-12-01	WOS:A1994NF70000016
J	GOODALE, MA				GOODALE, MA			PERCEIVING THE WORLD AND GRASPING IT - IS THERE A DIFFERENCE	LANCET			English	Editorial Material							OPTIC ATAXIA; PERCEPTION; OBJECTS		UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario)	GOODALE, MA (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON N6A 3K7,ONTARIO,CANADA.		Goodale, Melvyn A/M-5907-2013	Goodale, Melvyn A/0000-0001-6748-0561				BRIDGEMAN B, 1981, PERCEPT PSYCHOPHYS, V34, P149; BRIDGEMAN B, IN PRESS BEHAV BRAIN; Goodale M. A, 1988, COMPUTATIONAL PROCES, P262; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GOODALE MA, 1991, NATURE, V349, P154, DOI 10.1038/349154a0; JAKOBSON LS, 1991, NEUROPSYCHOLOGIA, V29, P803, DOI 10.1016/0028-3932(91)90073-H; MILNER AD, 1991, BRAIN, V114, P405, DOI 10.1093/brain/114.1.405; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549	9	2	2	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					930	931		10.1016/S0140-6736(94)90061-2	http://dx.doi.org/10.1016/S0140-6736(94)90061-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF700	7909006				2022-12-01	WOS:A1994NF70000005
J	KANKI, PJ; TRAVERS, KU; MBOUP, S; HSIEH, CC; MARLINK, RG; GUEYENDIAYE, A; SIBY, T; THIOR, I; HERNANDEZAVILA, M; SANKALE, JL; NDOYE, I; ESSEX, ME				KANKI, PJ; TRAVERS, KU; MBOUP, S; HSIEH, CC; MARLINK, RG; GUEYENDIAYE, A; SIBY, T; THIOR, I; HERNANDEZAVILA, M; SANKALE, JL; NDOYE, I; ESSEX, ME			SLOWER HETEROSEXUAL SPREAD OF HIV-2 THAN HIV-1	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; VERTICAL TRANSMISSION; WEST-AFRICA; AIDS; INFECTION	Because of the similar virological properties of HIV types 1 and 2, HIV-2 was assumed to be as infectious and capable of inducing AIDS as HIV-1. Seroepidemiological studies have shown significant rates of HIV-2 infection in West Africa, and surveys from other regions of the world indicate that the spread of HIV-2 infection continues. However the pathogenic potential of HIV-2 is considered to be lower than that of HIV-1. It is therefore important to understand the transmission properties of HIV-2 and its contribution to the AIDS pandemic. Since 1985, we have prospectively studied 1452 registered female prostitutes in Dakar, Senegal, with sequential evaluation of their antibody status to HIV-1 and HIV-2. During the study the overall incidence of HIV-1 and HIV-2 was the same (1-11 per 100 person-years of observation [pyo]). However, the annual incidence of HIV-1 increased substantially: there was a 1.4-fold increased risk per year and thus a 12-fold increase in risk over the entire study period. The incidence of HIV-2 remained stable, despite higher HIV-2 prevalence. In our population the heterosexual spread of HIV-2 is significantly slower than that of HIV-1, which strongly suggests differences in the viruses' infectivity potential.	NATL INST PUBL HLTH,CUERNAVACA,MEXICO; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; UNIV CHEIKH ANTA DIOP,VIROL & BACTERIOL LAB,DAKAR,SENEGAL; INST SOCIAL HYG,DAKAR,SENEGAL	Instituto Nacional de Salud Publica; Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar	KANKI, PJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115, USA.			Travers, Karin/0000-0002-9097-1710; Essex, M./0000-0002-4576-7841	NATIONAL CANCER INSTITUTE [R35CA039805] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39805] Funding Source: Medline; PHS HHS [P01 A1 30795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RM, 1989, AIDS, V3, P333, DOI 10.1097/00002030-198906000-00001; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; Breslow N.E., 1987, STATISTICAL METHODS, VII, P1; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; KANKI P, 1992, AM J EPIDEMIOL, V136, P895, DOI 10.1093/aje/136.7.895; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; Marlink Richard, 1994, P47; MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685; 1990, WKLY EPIDEMIOL REC, V65, P281	15	281	289	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					943	946		10.1016/S0140-6736(94)90065-5	http://dx.doi.org/10.1016/S0140-6736(94)90065-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909009				2022-12-01	WOS:A1994NF70000009
J	LIENS, D; DELMAS, PD; MEUNIER, PJ				LIENS, D; DELMAS, PD; MEUNIER, PJ			LONG-TERM EFFECTS OF INTRAVENOUS PAMIDRONATE IN FIBROUS DYSPLASIA OF BONE	LANCET			English	Note								Nine patients with symptomatic and severe fibrous dysplasia were treated with intravenous pamidronate (60 mg per day over 3 days every sixth month), and were followed up for 18-48 months. The major effect was decreased bone pain (complete remission in 12 of 14 sites). Radiological changes were seen in four patients, with thickening of cortices, refilling of osteolytic lesions, or both. The initial increased bone remodelling was reduced, as shown by decrease of raised serum alkaline phosphatase and urinary hydroxyproline. The treatment was well tolerated, but a 13-year-old patient showed widening of knee growth-plates which is consistent with a transient mineralisation defect.	HOP EDOUARD HERRIOT,INSERM,U403,PAVILLON F,F-69437 LYON,FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)								ADAMSON BB, 1993, LANCET, V342, P1459, DOI 10.1016/0140-6736(93)92935-M; BELL NH, 1970, J CLIN ENDOCR METAB, V31, P283, DOI 10.1210/jcem-31-3-283; COLE DEC, 1983, AM J MED GENET, V14, P725, DOI 10.1002/ajmg.1320140414; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; HJELMSTEDT A, 1979, ACTA ORTHOP SCAND, V50, P251, DOI 10.3109/17453677908989764; JIANG Y, 1993, CALCIF TISSUE INT S2, V52, pS44; LONG A, 1988, IRISH J MED SCI, V157, P229, DOI 10.1007/BF02949307; MORII H, 1971, ENDOCRINOL JAPON, V18, P81; YAMAMOTO K, 1983, ENDOCRINOL JAPON, V30, P651	9	156	159	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					953	954		10.1016/S0140-6736(94)90069-8	http://dx.doi.org/10.1016/S0140-6736(94)90069-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909013				2022-12-01	WOS:A1994NF70000013
J	RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ; MANSON, JE; VAUGHAN, DE				RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ; MANSON, JE; VAUGHAN, DE			PROSPECTIVE-STUDY OF ENDOGENOUS-TISSUE PLASMINOGEN-ACTIVATOR AND RISK OF STROKE	LANCET			English	Article							MYOCARDIAL-INFARCTION; RAPID INHIBITOR; DISEASE; PLASMA; FIBRINOGEN	Few haematological or lipid risk factors have been identified for stroke, by contrast with coronary heart disease. To find out whether a marker of endogenous fibrinolytic function might be associated with stroke risk, we measured tissue plasminogen activator (tPA) antigen concentrations in baseline plasma samples from 88 healthy participants in the Physicians' Health Study who subsequently had first-ever strokes (71 thromboembolic, 12 haemorrhagic, 5 indeterminate) and from 471 participants who remained free of cardiovascular disease during 5 years of follow-up (controls). Mean baseline tPA concentrations were significantly higher among men who later had strokes than in the controls (11.14 [SE 0.80] vs 9.59 [0.27] ng/mL, p = 0.03). The difference was largely due to an excess of abnormally high values among stroke cases. The age-adjusted relative risk for stroke among men with baseline tPA concentrations above the 95th percentile of the control distribution was 3 51 (95% CI 1.72-7.17, p=0.0006) for total stroke and 3.89 (1.83-8.26, p-0.0004) for thromboembolic stroke.These findings did not change substantially in analyses that also controlled for stroke risk factors (high blood pressure, body-mass index, smoking, presence of diabetes, and parental history of myocardial infarction) or the plasma lipid profile. This prospective study shows that high concentrations of tPA antigen among apparently healthy men are independently associated with high risks of future stroke, especially thromboembolic stroke. This finding is consistent with the hypothesis that activation of the endogenous fibrinolytic system occurs years in advance of arterial vascular occlusion.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,CTR RES THROBOLYSIS,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY & PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), BRIGHAMS & WOMENS HOSP,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; [Anonymous], 1989, NEW ENGL J MED, V321, P129; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; DYKEN ML, 1984, STROKE, V15, P1105; ELIASSON M, 1993, FIBRINOLYSIS, V7, P316, DOI 10.1016/0268-9499(93)90147-N; FEINBERG WM, 1989, STROKE, V20, P592, DOI 10.1161/01.STR.20.5.592; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HART RG, 1990, STROKE, V21, P1111, DOI 10.1161/01.STR.21.8.1111; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LUCURE CL, 1991, CORONARY ARTERY DIS, V2, P157; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MARTINEZ HR, 1993, STROKE, V24, P19, DOI 10.1161/01.STR.24.1.19; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; RANBY M, 1986, CLIN CHEM, V32, P2160; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1992, CURR OPIN LIPIDOL, V3, P285; SALOMAA VV, 1993, CIRCULATION, V87, P22; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; SMOKOVITIS A, 1908, HAEMOSTASIS, V18, P146; UNDERWOOD MJ, 1993, CARDIOVASC RES, V27, P882, DOI 10.1093/cvr/27.5.882; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942; 1993, EUR HEART J, V14, P8	26	281	286	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					940	943		10.1016/S0140-6736(94)90064-7	http://dx.doi.org/10.1016/S0140-6736(94)90064-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909008				2022-12-01	WOS:A1994NF70000008
J	ROBINSON, IA; MCKEE, G; NICHOLSON, A; DARCY, J; JACKSON, PA; COOK, MG; KISSIN, MW				ROBINSON, IA; MCKEE, G; NICHOLSON, A; DARCY, J; JACKSON, PA; COOK, MG; KISSIN, MW			PROGNOSTIC VALUE OF CYTOLOGICAL GRADING OF FINE-NEEDLE ASPIRATES FROM BREAST CARCINOMAS	LANCET			English	Article							TERM FOLLOW-UP; CANCER; INDEX	Because neoadjuvant therapy, including preoperative chemotherapy and tamoxifen, is becoming increasingly common for early breast cancer, it is desirable to grade tumours before surgery so that the most appropriate medical regimen can be selected. We have used a cytological grading system for ductal carcinoma of type not otherwise specified (NOS). Wet-fixed Papanicolaou-stained breast aspirates are examined for the extent of cell dissociation, cell size and uniformity, and the appearance of nucleoli, the nuclear margin, and chromatin. 377 invasive breast carcinomas were removed after preoperative diagnostic fine-needle aspiration. cytology (FNAC) during the 25 months of the study. 286 tumours were ductal carcinomas NOS on histology. We established three cytological grades and found that cytological grade corresponded well with the established histological grades (Elston's modified Bloom and Richardson method). All cytological features included in the score were equally important on regression analysis. This study shows that grading of breast cancer on FNAC is feasible and reproducible. Cytological grade may substitute for histological grade, so a combination of FNAC and mammography can provide information on tumour type, grade, and size before surgery. We recommend this grading system to centres that use FNAC for the diagnosis of breast cancers.	ROYAL SURREY CTY HOSP, DEPT CYTOPATHOL, EGERTON RD, GUILDFORD GU2 5XX, SURREY, ENGLAND; ROYAL SURREY CTY HOSP, DEPT SURG, GUILDFORD GU2 5XX, SURREY, ENGLAND; ROYAL SURREY CTY HOSP, DEPT HISTOPATHOL, GUILDFORD GU2 5XX, SURREY, ENGLAND	Royal Surrey County Hospital; Royal Surrey County Hospital; Royal Surrey County Hospital								BLACK MM, 1955, SURG GYNECOL OBSTET, V100, P543; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CIATTO S, 1993, DIAGN CYTOPATHOL, V9, P160, DOI 10.1002/dc.2840090210; DOUSSAL V, 1989, CANCER, V64, P1914; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; Eichner W J, 1970, Nebr State Med J, V55, P405; ELLIS IO, 1992, HISTOPATHOLOGY, V20, P479; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300; FISHER E, 1984, SURG CLIN N AM, V64, P361; Fisher E R, 1980, Pathol Annu, V15, P239; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Hunt C M, 1990, Cytopathology, V1, P287, DOI 10.1111/j.1365-2303.1990.tb00362.x; MORGAN D, 1993, BREAST, V2, P206; MOSSLER JA, 1982, ACTA CYTOL, V26, P417; MOURIQUAND J, 1986, J CLIN PATHOL, V39, P489, DOI 10.1136/jcp.39.5.489; NIH, 1991, ONCOLOGY, V5, P120; Page DL, 1987, DIAGNOSTIC HISTOPATH; POWLES T, 1993, BREAST, V2, P187; SCHULTE E, 1987, DIAGN CYTOPATHOL, V3, P256, DOI 10.1002/dc.2840030316; SMITH IE, 1993, EUR J CANCER, V29A, P1796, DOI 10.1016/0959-8049(93)90133-Z; SNEIGE N, 1989, DIAGN CYTOPATHOL, V5, P371, DOI 10.1002/dc.2840050406; THOMAS JS, 1989, J CLIN PATHOL, V42, P28, DOI 10.1136/jcp.42.1.28; TODD JH, 1987, BRIT J CANCER, V56, P489, DOI 10.1038/bjc.1987.230; ZAJDELA A, 1984, ACTA CYTOL, V23, P75; ZAJICEK J, 1974, ASPIRATION BIOPSY CY, P166; ZURRIDA S, 1993, BREAST, V2, P187	28	134	137	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					947	949		10.1016/S0140-6736(94)90066-3	http://dx.doi.org/10.1016/S0140-6736(94)90066-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909010				2022-12-01	WOS:A1994NF70000010
J	STEEL, M				STEEL, M			CYCLINS AND CANCER - WHEELS WITHIN WHEELS	LANCET			English	Editorial Material							CELL-CYCLE				STEEL, M (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9ST,FIFE,SCOTLAND.							COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hagan Iain, 1992, Trends in Cell Biology, V2, P245, DOI 10.1016/0962-8924(92)90313-C; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KEYOMARSI K, 1994, CANCER RES, V54, P380; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; STURZBECHER HW, 1990, ONCOGENE, V5, P795	13	9	11	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					931	932		10.1016/S0140-6736(94)90062-0	http://dx.doi.org/10.1016/S0140-6736(94)90062-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909007				2022-12-01	WOS:A1994NF70000006
J	WATSON, BA; STARR, SE				WATSON, BA; STARR, SE			VARICELLA VACCINE FOR HEALTHY-CHILDREN	LANCET			English	Editorial Material											WATSON, BA (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV ALLERGY IMMUNOL & INFECT DIS,PHILADELPHIA,PA 19104, USA.							ASANO Y, 1985, PEDIATRICS, V75, P667; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; PREBLUD SR, 1985, POSTGRAD MED J, V61, P17; WATSON B, 1974, J INFECT DIS, V164, P197; WATSON BM, 1993, PEDIATRICS, V91, P17; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					928	929		10.1016/S0140-6736(94)90058-2	http://dx.doi.org/10.1016/S0140-6736(94)90058-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909003				2022-12-01	WOS:A1994NF70000002
J	VANDERVIES, SM; GATENBY, AA; GEORGOPOULOS, C				VANDERVIES, SM; GATENBY, AA; GEORGOPOULOS, C			BACTERIOPHAGE-T4 ENCODES A CO-CHAPERONIN THAT CAN SUBSTITUTE FOR ESCHERICHIA-COLI GROES IN PROTEIN-FOLDING	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; MORPHOGENESIS; INTERACTS; MUTATION; GENE-31; ATP	SEVERAL bacteriophages use the Escherichia coli GroES and GroEL chaperonins for folding and assembly of their morphogenetic structures1. Bacteriophage T4 is unusual in that it encodes a specialized protein (Gp31) that is thought to interact with the host GroEL and to be absolutely required for the correct assembly of the major capsid protein (Gp23) in vivo2-4. Here we show that despite the absence of amino-acid sequence similarity between Gp31 and GroES5,6 Gp31 can functionally substitute for the GroES co-chaperonin in the morphogenesis of bacteriophages lambda and T5, the in vivo and in vitro chaperonin-dependent assembly of ribulose bisphosphate carboxylase (Rubisco), as well as overall bacterial growth at the non-permissive temperature. Like GroES, the bacteriophage Gp31 protein forms a stable complex with the E. coli GroEL protein in the presence of Mg-ATP and inhibits the ATPase activity of GroEL in vitro.	DUPONT CO INC,CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont	VANDERVIES, SM (corresponding author), UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND.							CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GATENBY AA, 1985, NATURE, V314, P617, DOI 10.1038/314617a0; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LORIMER GH, 1977, ANAL BIOCHEM, V78, P65; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	19	90	92	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					654	656		10.1038/368654a0	http://dx.doi.org/10.1038/368654a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	7908418				2022-12-01	WOS:A1994NF39200066
J	ZHUO, M; HU, YH; SCHULTZ, C; KANDEL, ER; HAWKINS, RD				ZHUO, M; HU, YH; SCHULTZ, C; KANDEL, ER; HAWKINS, RD			ROLE OF GUANYLYL CYCLASE AND CGMP-DEPENDENT PROTEIN-KINASE IN LONG-TERM POTENTIATION	NATURE			English	Article							CYCLIC-GMP FORMATION; NITRIC-OXIDE; CORTICAL-NEURONS; INVOLVEMENT; CEREBELLUM; DEPRESSION; RELEASE	SEVERAL lines of evidence suggest that cyclic GMP might be involved in long-term potentiation (LTP) in the hippocampus1-6. Arachidonic acid, nitric oxide and carbon monoxide, three molecules that have been proposed to act as retrograde messengers in LTP7-9, all activate soluble guanylyl cyclase1,10,11. We report here that an inhibitor of guanylyl cyclase blocks the induction of LTP in the CA1 region of hippocampal slices. Conversely, cGMP analogues produce long-lasting enhancement of the excitatory postsynaptic potential if they are applied at the same time as weak tetanic stimulation of the presynaptic fibres. The enhancement is spatially restricted, is not blocked by valeric acid (APV), nifedipine, or picrotoxin, and partially occludes LTP. This synaptic enhancement may be mediated by the cGMP-dependent protein kinase (PKG). Inhibitors of PKG block the induction of LTP, and activators of PKG produce activity-dependent long-lasting enhancement. These results suggest that guanylyl cyclase and PKG contribute to LTP, possibly as activity-dependent presynaptic effectors of retrograde messengers.	NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	New York State Psychiatry Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	ZHUO, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241; Schultz, Carsten/0000-0002-5824-2171				Arancio O., 1993, Society for Neuroscience Abstracts, V19, P241; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRONS JF, 1980, J NEUROPHYSIOL, V44, P605, DOI 10.1152/jn.1980.44.3.605; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; DEVENTE J, 1992, ACTA HISTOCHEM, V92, P13, DOI 10.1016/S0065-1281(11)80138-8; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FLEISCH JH, 1984, J PHARMACOL EXP THER, V229, P681; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, IN PRESS J NEUROBIOL; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; Ito M, 1990, Neuroreport, V1, P129; SCHLICHTER DJ, 1978, NATURE, V273, P61, DOI 10.1038/273061a0; SCHULTZ C, 1993, J BIOL CHEM, V268, P6316; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNIDER RM, 1984, P NATL ACAD SCI-BIOL, V81, P3905, DOI 10.1073/pnas.81.12.3905; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WOODY CD, 1978, BRAIN RES, V158, P373, DOI 10.1016/0006-8993(78)90682-0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZHUO M, IN PRESS NEURO REPOR	28	331	347	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					635	639		10.1038/368635a0	http://dx.doi.org/10.1038/368635a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	7908417				2022-12-01	WOS:A1994NF39200061
J	OSMOND, D; CHARLEBOIS, E; LANG, W; SHIBOSKI, S; MOSS, A				OSMOND, D; CHARLEBOIS, E; LANG, W; SHIBOSKI, S; MOSS, A			CHANGES IN AIDS SURVIVAL-TIME IN 2 SAN-FRANCISCO COHORTS OF HOMOSEXUAL MEN, 1983 TO 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; TRIMETHOPRIM SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; INCUBATION PERIOD; HIV-INFECTION; ZIDOVUDINE; RISK; PROPHYLAXIS	Background.-During the first decade since the recognition of the acquired immunodeficiency syndrome (AIDS), new therapies have been introduced and the frequency of clinical manifestations has changed. The impact of these changes on AIDS survival, however, has not been well characterized. Design.-A prospective cohort study of the outcomes of human immunodeficiency virus (HIV) infection. Setting.-Homosexual and bisexual men residing in San Francisco, Calif, recruited in 1983 and 1984 for two prospective studies and followed up for more than 9 years with clinical examinations. Participants.-A total of 761 HIV-positive homosexual and bisexual men. MaIn Outcome Measures.-Survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L (200/muL) and from a clinical AIDS diagnosis to death. Results.-Median survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L increased from 28.4 months in the October 1983 to November 1986 period to 40.1 months in the November 1986 to November 1988 period and is estimated at 38.1 months in the November 1988 to February 1993 period. Patients diagnosed with Pneumocystis carinii pneumonia (PCP) accounted for most of this increase with a gain in median survival time of 9.7 months (P=.0009), compared with a nonsignificant decline in the survival time of those patients without a PCP diagnosis. Multivariate analysis showed that rate of CD4 lymphocyte loss (P<.001) and receipt of both PCP prophylaxis and antiretroviral therapy (P=.04) were significantly associated with longer survival time, whereas antiretroviral therapy alone was not (P=.81). Time to death from a clinical AIDS diagnosis was 14.7 months in the 1983 to 1986 period, 19.1 months in the 1986 to 1988 period, and an estimated 15.7 months in the 1988 to 1993 period. Conclusions.-Survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L has improved significantly by about 1 year, yet survival time using the 1987 AIDS case definition has shown small improvement. The largest increase in survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L was in patients diagnosed with PCP, suggesting that PCP prophylaxis and treatment were more important factors in longer survival time than antiretroviral therapy.	CALIF PACIFIC MED CTR,SAN FRANCISCO,CA	California Pacific Medical Center	OSMOND, D (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT EPIDEMIOL & BIOSTAT,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI082515] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID N01-AI-82515] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BACCHETTI P, 1988, J INFECT DIS, V157, P104; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1090; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; LANG W, 1989, LANCET, V1, P1397; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; LANGE N, 1992, J AM STAT ASSOC, V87, P615, DOI 10.2307/2290194; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; LUNDGREN JD, 1993, 9TH INT C AIDS BERL; Miller R.G., 1981, SURVIVAL ANAL; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MOSS AR, 1987, AM J EPIDEMIOL, V125, P1035, DOI 10.1093/oxfordjournals.aje.a114619; PHILLIPS AN, 1992, JAMA-J AM MED ASSOC, V268, P2662, DOI 10.1001/jama.268.19.2662; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SEAGE GR, 1990, AM J PUBLIC HEALTH, V80, P835, DOI 10.2105/AJPH.80.7.835; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1987, SAS STAT GUIDE PERSO; 1987, MMWR MORB MORTAL WKL, V34, P373; IN PRESS HIV AIDS SU	28	98	98	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1083	1087		10.1001/jama.271.14.1083	http://dx.doi.org/10.1001/jama.271.14.1083			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	7908703				2022-12-01	WOS:A1994NE22800029
J	MAHAN, MJ				MAHAN, MJ			REVEALING BACTERIAL-INFECTION STRATEGIES	LANCET			English	Editorial Material							INTEGRATION HOST FACTOR; SALMONELLA-TYPHIMURIUM; VIRULENCE; AVIRULENT; STRAINS				MAHAN, MJ (corresponding author), UNIV CALIF SANTA BARBARA,SANTA BARBARA,CA 93106, USA.							CAMILLI A, IN PRESS P NATL ACAD; DORMAN CJ, 1987, J BACTERIOL, V169, P3840, DOI 10.1128/jb.169.8.3840-3843.1987; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; LEUNK RD, 1982, INFECT IMMUN, V36, P1168, DOI 10.1128/IAI.36.3.1168-1174.1982; LOCKMAN HA, 1992, INFECT IMMUN, V60, P491, DOI 10.1128/IAI.60.2.491-496.1992; MAHAN MJ, 1993, SCIENCE, V259, P666; MAHAN MJ, 1994, INFECTIOUS AGENTS DI, V2, P263; Makela P. H., 1984, HDB ENDOTOXIN, P59; MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; NNALUE NA, 1990, INFECT IMMUN, V58, P2493, DOI 10.1128/IAI.58.8.2493-2501.1990; PLUM G, 1994, INFECT IMMUN, V62, P476, DOI 10.1128/IAI.62.2.476-483.1994	15	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					869	870		10.1016/S0140-6736(94)90005-1	http://dx.doi.org/10.1016/S0140-6736(94)90005-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908355				2022-12-01	WOS:A1994NF21300005
J	OZEL, M; DIRINGER, H				OZEL, M; DIRINGER, H			SMALL VIRUS-LIKE STRUCTURE IN FRACTIONS FROM SCRAPIE HAMSTER BRAIN	LANCET			English	Note							PROTEIN	The scrapie model in hamsters has been used to search for the agents that cause Creutzfeldt-Jakob disease in man and similar transmissible encephalopathies in animals. We found structures that are extraordinarily small for a virus, but exhibit viral structural properties in negatively stained samples, by electron microscopy in fractions containing scrapie-associated fibrils.	BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,D-13353 BERLIN,GERMANY	Robert Koch Institute								DIRINGER H, 1992, EXP CLIN IMMUNOGENET, V9, P212; DIRINGER H, 1983, EUR J BIOCHEM, V134, P550; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; MERZ PA, 1983, NATURE, V306, P474, DOI 10.1038/306474a0; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TISCHER I, 1982, NATURE, V295, P64, DOI 10.1038/295064a0	8	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					894	895		10.1016/S0140-6736(94)90010-8	http://dx.doi.org/10.1016/S0140-6736(94)90010-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908360				2022-12-01	WOS:A1994NF21300010
J	STEEL, C; GUINEA, A; MCCARTHY, JS; OTTESEN, EA				STEEL, C; GUINEA, A; MCCARTHY, JS; OTTESEN, EA			LONG-TERM EFFECT OF PRENATAL EXPOSURE TO MATERNAL MICROFILAREMIA ON IMMUNE RESPONSIVENESS TO FILARIAL PARASITE ANTIGENS	LANCET			English	Article							LYMPHATIC FILARIASIS; ONCHOCERCA-VOLVULUS; ENDEMIC FILARIASIS; BRUGIA-PAHANGI; PACIFIC ISLAND; INFECTION; UNRESPONSIVENESS; SENSITIZATION; RESPONSES; TOLERANCE	To identify long-term effects of prenatal exposure to maternal filarial-parasite infection, we assessed lymphocyte responses in 21 Polynesian children born 17-19 years previously to mothers diagnosed as being microfilaraemic or infection-free. All children lived on an island endemic for bancroftian filariasis but were free from infection at the ti me of study. While children (n = 10) of infection-free mothers responded vigorously to microfilarial antigen with lymphocyte proliferation, production of interleukin 2 (IL-2), IL-5, IL-10, granulocyte macrophage colony-stimulating factor (GM-CSF), and interferon gamma (IFN-gamma), cellular hyporesponsiveness was seen in children (n = 11) born to microfilaraemic mothers. The hyporesponsiveness appeared restricted to microfilarial antigens and did not extend to non-parasite antigens. These findings suggest that hyporesponsiveness resulted from in-utero acquisition of tolerance to microfilarial antigens in chronically-infected mothers.	HLTH DEPT,MAUKE,COOK ISLANDS		STEEL, C (corresponding author), NIH,PARASIT DIS LAB,BLDG 4 ROOM 126,BETHESDA,MD 20892, USA.		McCarthy, James S/C-1681-2009	McCarthy, James/0000-0001-6596-9718				BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; ELOISANTOS SM, 1989, J CLIN INVEST, V84, P1028, DOI 10.1172/JCI114225; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; GUSMAO RD, 1981, EXP PARASITOL, V52, P147, DOI 10.1016/0014-4894(81)90070-9; HAQUE A, 1988, EUR J IMMUNOL, V18, P1167, DOI 10.1002/eji.1830180804; HAQUE A, 1982, NATURE, V299, P361, DOI 10.1038/299361a0; KAUSHAL NA, 1984, CLIN EXP IMMUNOL, V56, P567; KING CL, 1992, J CLIN INVEST, V89, P1403, DOI 10.1172/JCI115729; KING CL, 1993, J CLIN INVEST, V92, P1667, DOI 10.1172/JCI116752; KLEI TR, 1986, T ROY SOC TROP MED H, V80, P214, DOI 10.1016/0035-9203(86)90014-3; KLION AD, 1991, J INFECT DIS, V163, P1318, DOI 10.1093/infdis/163.6.1318; LAMMIE PJ, 1991, LANCET, V337, P1005, DOI 10.1016/0140-6736(91)92661-K; NUTMAN TB, 1987, J CLIN INVEST, V79, P1516, DOI 10.1172/JCI112982; NUTMAN TB, 1987, J IMMUNOL, V138, P3954; OTTESEN E A, 1989, American Journal of Tropical Medicine and Hygiene, V41, P9; OTTESEN EA, 1977, IMMUNOLOGY, V33, P413; OTTESEN EA, 1981, ACTA TROP, V38, P205; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; OTTESEN EA, 1982, AM J TROP MED HYG, V31, P953, DOI 10.4269/ajtmh.1982.31.953; PARTONO F, 1978, AM J TROP MED HYG, V27, P910, DOI 10.4269/ajtmh.1978.27.910; PETRALANDA I, 1988, AM J TROP MED HYG, V38, P372, DOI 10.4269/ajtmh.1988.38.372; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; PROST A, 1979, TROPENMED PARASITOL, V30, P477; RAGHAVAN N. G. S., 1958, Bulletin of the National Society of India for Malaria and Other Mosquito-Borne Diseases, V6, P147; STEEL C, 1991, J INFECT DIS, V164, P581, DOI 10.1093/infdis/164.3.581; WARTMAN WB, 1947, MEDICINE, V12, P181; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WEIL GJ, 1987, J INFECT DIS, V156, P350, DOI 10.1093/infdis/156.2.350; WELLER PF, 1982, AM J TROP MED HYG, V31, P942, DOI 10.4269/ajtmh.1982.31.942; ZIMMERMAN PA, 1993, NUCLEIC ACIDS RES, V21, P4541, DOI 10.1093/nar/21.19.4541	30	134	134	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					890	893		10.1016/S0140-6736(94)90009-4	http://dx.doi.org/10.1016/S0140-6736(94)90009-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908359				2022-12-01	WOS:A1994NF21300009
J	SAWYERS, CL; MCLAUGHLIN, J; GOGA, A; HAVLIK, M; WITTE, O				SAWYERS, CL; MCLAUGHLIN, J; GOGA, A; HAVLIK, M; WITTE, O			THE NUCLEAR TYROSINE KINASE C-ABL NEGATIVELY REGULATES CELL-GROWTH	CELL			English	Article							PHILADELPHIA-CHROMOSOME; PROTO-ONCOGENE; CANCER-CELLS; GENE-PRODUCT; B-CELL; BCR; TRANSFORMATION; SUPPRESSION; MICE; MUTATIONS	c-Abl is a tyrosine kinase localized primarily in the nucleus. Previous assays for abl function rely on cellular transformation by abl mutants, which are cytoplasmic. Using a conditional overexpression strategy, we have developed a functional assay for c-abl. Overexpression of c-abl inhibits growth by causing cell cycle arrest. Growth suppression requires tyrosine kinase activity, nuclear localization, and an intact SH2 domain. Overexpression of dominant negative c-abl disrupts cell cycle control and enhances transformation by tyrosine kinases, G proteins, and transcription factor oncogenes. These findings suggest that c-abl acts as a negative regulator of cell growth. This growth suppressive activity is functionally similar to that of tumor suppressor genes such as p53 and Rb.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	SAWYERS, CL (corresponding author), UNIV CALIF LOS ANGELES, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA.		Sawyers, Charles/G-5327-2016					BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BRUNET LJ, 1988, MOL CELL BIOL, V8, P4799, DOI 10.1128/MCB.8.11.4799; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PHILIPSON L, 1991, J CELL BIOCHEM, V46, P95, DOI 10.1002/jcb.240460202; REITH AD, 1993, ONCOGENE, V8, P45; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHTLVELMAN E, 1986, CELL, V47, P277; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YANG Z, 1987, MOL CELL BIOL, V7, P3923, DOI 10.1128/MCB.7.11.3923; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	56	247	255	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					121	131		10.1016/0092-8674(94)90240-2	http://dx.doi.org/10.1016/0092-8674(94)90240-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	7512450				2022-12-01	WOS:A1994NF21100015
J	CHEN, TY; YAU, KW				CHEN, TY; YAU, KW			DIRECT MODULATION BY CA2+-CALMODULIN OF CYCLIC NUCLEOTIDE-ACTIVATED CHANNEL OF RAT OLFACTORY RECEPTOR NEURONS	NATURE			English	Article							SENSITIVE ADENYLATE-CYCLASE; GATED CHANNELS; CELLS; CILIA; TRANSDUCTION; CONDUCTANCE; ODORANTS; NEWT; CURRENTS; CALCIUM	OLFACTORY receptor neurons depolarize in response to odorant stimulation of their sensory cilia1-3. One transduction mechanism involves a G-protein-mediated increase in adenylate cyclase activity4-8, raising the internal cyclic AMP concentration to open a cyclic nucleotide-activated cation channel on the plasma membrane9-14. An influx of Ca2+ through this channel, which is permeable to both monovalent and divalent cations, triggers olfactory adaptation15. Previous work has indicated that at least art of this Ca2+ mediated adaptation resides in the channel itself15-17, but the mechanism remains unclear and controversial16-18. Here we use the cloned channel from rat19 expressed in a cell line and the native channel from rat olfactory receptor cells to show that Ca2+ reduces the apparent affinity of the channel for cAMP by up to 20-fold in the presence of calmodulin, an abundant protein in olfactory cilia20. This decrease in apparent affinity appears to involve a direct interaction between Ca2+-calmodulin and the channel, and it can reduce the activation of the channel by cAMP by up to a few hundred-fold, suggesting that it may be a key component of the Ca2+-triggered olfactory adaptation.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	CHEN, TY (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.							ANHOLT RRH, 1990, BIOCHEMISTRY-US, V29, P4049, DOI 10.1021/bi00469a004; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BORISY FF, 1992, J NEUROSCI, V12, P915; BRADLEY J, 1992, NEUR ABSTR, V18, P596; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JAWORSKY DE, IN PRESS J NEUROSCI; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEENE SJ, 1994, BRIT J PHARMACOL, V111, P469, DOI 10.1111/j.1476-5381.1994.tb14760.x; KLEENE SJ, 1993, J MEMBRANE BIOL, V131, P237, DOI 10.1007/BF02260112; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LIMAN ER, 1994, BIOPHYS J, V66, pA350; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	31	269	274	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					545	548		10.1038/368545a0	http://dx.doi.org/10.1038/368545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	7511217				2022-12-01	WOS:A1994NE33500054
J	DISANTO, JP; MARKIEWICZ, S; GAUCHAT, JF; BONNEFOY, JY; FISCHER, A; DESAINTBASILE, G				DISANTO, JP; MARKIEWICZ, S; GAUCHAT, JF; BONNEFOY, JY; FISCHER, A; DESAINTBASILE, G			PRENATAL-DIAGNOSIS OF X-LINKED HYPER-IGM SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN T-CELLS; HYPERIMMUNOGLOBULINEMIA-M; CLOSE LINKAGE; LIGAND; CD40; IMMUNODEFICIENCY; ACTIVATION; RECEPTOR; LOCUS; FORM		GLAXO INST MOLEC BIOL,GENEVA,SWITZERLAND	GlaxoSmithKline	DISANTO, JP (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U132,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Di Santo, James P/M-4298-2014; de Saint Basile, Genevieve/G-9731-2017	Di Santo, James P/0000-0002-7146-1862; de Saint Basile, Genevieve/0000-0002-1913-5269				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PEAKMAN DC, 1977, J MED GENET, V14, P37, DOI 10.1136/jmg.14.1.37; ROSEN FS, 1961, PEDIATRICS, V28, P182; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1992, IMMUNODEFIC REV, V3, P195	19	38	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					969	973		10.1056/NEJM199404073301404	http://dx.doi.org/10.1056/NEJM199404073301404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	7510042				2022-12-01	WOS:A1994ND79300004
J	ANKUM, WM; VONK, J				ANKUM, WM; VONK, J			THE SPRING BALANCE - A SIMPLE MONITORING-SYSTEM FOR FLUID OVERLOAD DURING HYSTEROSCOPIC SURGERY	LANCET			English	Article							ABSORPTION; ETHANOL	Fluid overload may arise during hysteroscopic surgery, caused by absorption of fluid used to distend the uterus. continuous monitoring of the fluid balance is required to prevent this serious complication. Commercial equipment does not serve this purpose adequately. We describe a simple solution. We weigh the inflow and outflow volumes together on a spring balance; this method provides information about fluid balance, since any fluid lost as spillage or by absorption is reflected by a loss of weight on the balance. The method is simple, accurate, and inexpensive, and the components can be purchased readily.			ANKUM, WM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT OBSTET & GYNAECOL,MELBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547				DUFFY S, 1992, OBSTET GYNECOL, V79, P300; GARRY R, 1990, LANCET, V336, P1013, DOI 10.1016/0140-6736(90)92480-6; HARRISON RH, 1956, J UROLOGY, V75, P95, DOI 10.1016/S0022-5347(17)66783-1; HULTEN JO, 1986, SCAND J UROL NEPHROL, V20, P245, DOI 10.3109/00365598609024506; MACDONALD R, 1989, LANCET, V335, P1387; MAGOS AL, 1990, LANCET, V336, P44; MOLNAR BG, 1992, GYNAECOL ENDOSC, V1, P133; VULGAROPULOS SP, 1992, AM J OBSTET GYNECOL, V167, P386, DOI 10.1016/S0002-9378(11)91417-3; 1991, LANCET, V338, P606	9	7	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					836	837		10.1016/S0140-6736(94)92030-3	http://dx.doi.org/10.1016/S0140-6736(94)92030-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908082				2022-12-01	WOS:A1994ND79200013
J	FANG, JWS; BIRD, GLA; NAKAMURA, T; DAVIS, GL; LAU, JYN				FANG, JWS; BIRD, GLA; NAKAMURA, T; DAVIS, GL; LAU, JYN			HEPATOCYTE PROLIFERATION AS AN INDICATOR OF OUTCOME IN ACUTE ALCOHOLIC HEPATITIS	LANCET			English	Article							LIVER-DISEASE; THERAPY; GROWTH; TRIAL; DNA	To determine whether clinical outcome in patients with acute alcoholic hepatitis is related to the regenerative capability of the liver, liver biopsy specimens from 25 prospectively recruited patients with acute alcoholic hepatitis were studied for hepatic expression of mRNA for two proliferation markers, proliferating cell nuclear antigen and human histone, and for transforming growth factor alpha (TGFalpha) and TGFbeta1 and hepatocyte growth factor (HGF), which regulate hepatocyte proliferation. Proliferation markers were detected to varying degrees in 0-80% of hepatocytes and occasionally in sinusoidal cells and bile-duct epithelium in 19 patients (76%). Patients who survived for 6 months had greater expression of proliferation markers than those who did not survive (p < 0.01). TGFalpha was detected in hepatocytes and bile-duct epithelium, whereas TGFbeta1 was detected mainly in sinusoidal cells and was associated with perivenular fibrosis. Patients who survived for 6 months had greater expression of TGFs than non-survivors (p < 0.02). HGF was detected in sinusoidal cells in 7 patients and correlated with survival (p < 0.01). These data indicate that hepatocyte proliferation, which is possibly related to the pattern of hepatotrophic factor expression, is a good indicator of outcome in acute alcoholic hepatitis.	UNIV FLORIDA,DEPT MED,HEPATOBILIARY DIS SECT,POB 100214 JHMHC,GAINESVILLE,FL 32610; OSAKA UNIV,SCH MED,SUITA,OSAKA 565,JAPAN; GARTNAVEL ROYAL HOSP,MED UNIT A,GLASGOW G12 0YN,SCOTLAND	State University System of Florida; University of Florida; Osaka University; Gartnavel Royal Hospital								BAKER AL, 1981, GASTROENTEROLOGY, V80, P1410; BAPTISTA A, 1981, Lancet, V1, P707; BIRD GLA, 1988, MOL ASPECTS MED, V10, P97, DOI 10.1016/0098-2997(88)90017-9; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; DALKE DD, 1990, HEPATOLOGY, V12, P1085, DOI 10.1002/hep.1840120502; FAIRMAN MP, 1990, J CELL SCI, V95, P1; FAUSTO N, 1989, LAB INVEST, V60, P4; LAU JYN, 1991, J CLIN PATHOL, V44, P905, DOI 10.1136/jcp.44.11.905; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; THEODOSSI A, 1982, GUT, V23, P75, DOI 10.1136/gut.23.1.75	12	61	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					820	823		10.1016/S0140-6736(94)92025-7	http://dx.doi.org/10.1016/S0140-6736(94)92025-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908077				2022-12-01	WOS:A1994ND79200008
J	JOBST, KA; SMITH, AD; SZATMARI, M; ESIRI, MM; JASKOWSKI, A; HINDLEY, N; MCDONALD, B; MOLYNEUX, AJ				JOBST, KA; SMITH, AD; SZATMARI, M; ESIRI, MM; JASKOWSKI, A; HINDLEY, N; MCDONALD, B; MOLYNEUX, AJ			RAPIDLY PROGRESSING ATROPHY OF MEDIAL TEMPORAL-LOBE IN ALZHEIMERS-DISEASE	LANCET			English	Note							DEMENTIA; TOMOGRAPHY	The symptoms of Alzheimer's disease are associated with pathological change and loss of neurons in the medial temporal lobe. By yearly temporal-lobe-oriented computed tomograms the average rate of atrophy of the medial temporal lobe was 15.1% per year (95% CI 10.0, 20.2) in 20 patients with histopathologically, confirmed Alzheimer's disease and 1.5% (0.2, 2.8) in 47 healthy ageing controls. Such excessive atrophy presumably reflects the vulnerability of the medial temporal lobe to a catastrophic event, probably a pathological cascade process. Thus, Alzheimer's disease may not be due simply to an acceleration of normal ageing but, rather, is the consequence of a true disease process.	UNIV OXFORD,DEPT PHARMACOL,OXFORD PROJECT INVESTIGATE MEMORY & AGEING,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,DEPT CLIN NEUROL,OXFORD OX1 3QT,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND; RADCLIFFE INFIRM,DEPT NEURORADIOL,OXFORD OX2 6HE,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; Radcliffe Infirmary			Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722				BOWEN DM, 1979, LANCET, V1, P11; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAYNE C, 1988, LANCET, V1, P1265; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DECARLI C, 1992, NEUROLOGY, V42, P2029; DELEON MJ, 1989, LANCET, V2, P672; JOBST KA, 1992, LANCET, V340, P1179; JORM AF, 1990, EPIDEMIOLOGY ALZHEIM; LUXENBERG JS, 1987, NEUROLOGY, V37, P1135, DOI 10.1212/WNL.37.7.1135; MANN DMA, 1988, NEW ENGL J MED, V318, P789	10	189	190	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					829	830		10.1016/S0140-6736(94)92028-1	http://dx.doi.org/10.1016/S0140-6736(94)92028-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908080				2022-12-01	WOS:A1994ND79200011
J	MOTT, MG; BOYSE, J; HEWITT, M; RADFORD, M				MOTT, MG; BOYSE, J; HEWITT, M; RADFORD, M			DO MUTATIONS AT THE GLYCOPHORIN-A LOCUS IN PATIENTS TREATED FOR CHILDHOOD HODGKINS-DISEASE PREDICT SECONDARY LEUKEMIA	LANCET			English	Note							SOMATIC MUTATIONS; SURVIVORS	Childhood Hodgkin's disease has a high cure rate but second cancers are common, related to treatment and perhaps genetic predisposition. The glycophorin-A (GPA) mutation assay measures the frequency of NO and NN mutant erythrocytes of MN blood-group heterozygous individuals. Mutant frequencies in Hodgkin's disease patients were compared with controls. No significant difference from controls was found pretreatment or in patients treated with radiotherapy only. Patients who received chemotherapy had a significantly increased frequency (total mutation frequency per 10(6) cells: 31 vs 11, p < 0.001), which may be relevant to their known increased risk of secondary leukaemia.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; SOUTHAMPTON GEN HOSP,DEPT CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Nottingham; University of Southampton	MOTT, MG (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,ST MICHAELS HILL,BRISTOL BS2 8BJ,ENGLAND.							BOICE JD, 1993, J NATL CANCER I, V85, P4, DOI 10.1093/jnci/85.1.4; CAGGANA M, 1991, ENVIRON MOL MUTAGEN, V18, P6, DOI 10.1002/em.2850180103; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; HEWITT M, 1992, BRIT J CANCER, V66, P143, DOI 10.1038/bjc.1992.232; LANGLOIS RG, 1990, CYTOMETRY, V11, P513, DOI 10.1002/cyto.990110410; LANGLOIS RG, 1987, SCIENCE, V236, P445, DOI 10.1126/science.3563520; RADFORD M, 1991, MED PEDIATR ONCOL, V19, P400; SALATREPAT M, 1993, MUTAT RES, V289, P115, DOI 10.1016/0027-5107(93)90137-5; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; TARBELL NJ, 1993, LANCET, V341, P1428, DOI 10.1016/0140-6736(93)90880-P	10	27	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					828	829		10.1016/S0140-6736(94)92027-3	http://dx.doi.org/10.1016/S0140-6736(94)92027-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908079				2022-12-01	WOS:A1994ND79200010
J	RAVINE, D; GIBSON, RN; WALKER, RG; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; GIBSON, RN; WALKER, RG; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			EVALUATION OF ULTRASONOGRAPHIC DIAGNOSTIC-CRITERIA FOR AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY DISEASE-1	LANCET			English	Article							CHROMOSOME-16; LOCUS; PKD1; MARKERS; GENE	Although ultrasound is commonly used for screening subjects at risk of polycystic kidney disease 1 (PKD1), there has been no evaluation of ultrasonographic diagnostic criteria. We used DNA linkage among subjects from 128 sibships within 18 PKD1 families as the basis for an assessment of ultrasound sensitivity. Positive and negative predictive values were calculated to allow assessment of different diagnostic cut-off points in previously undiagnosed cases. Currently used criteria (bilateral cysts with at least two in one kidney) provided good sensitivity (88.5% at age 15-29 years and 100% at 30 years and above) but performance could be improved by less stringent criteria in subjects aged 15-29 years and more stringent criteria in older family members, in whom simple renal cysts are frequent. The presence of at least two renal cysts (unilateral or bilateral) in individuals at risk and younger than 30 years may be regarded as sufficient to establish a diagnosis; among those aged 30-59 years, the presence of at least two cysts in each kidney may be required, and among those aged 60 years and above, at least four cysts in each kidney should be required.	ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT RADIOL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT NEPHROL,PARKVILLE,VIC 3050,AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital			Ravine, David/A-6797-2008					BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BEAR JC, 1992, AM J MED GENET, V43, P548, DOI 10.1002/ajmg.1320430309; BENNETT WM, 1990, SEMIN NEPHROL, V10, P552; BREUNING MH, 1990, NUCLEIC ACIDS RES, V18, P3106, DOI 10.1093/nar/18.10.3106-a; BREUNING MH, 1987, LANCET, V2, P1359; COTO E, 1992, J MED GENET, V29, P243, DOI 10.1136/jmg.29.4.243; DISNEY APS, 1990, ANZDATA13TH QUEEN EL, P22; FICK GM, 1993, J AM SOC NEPHROL, V3, P1863; GERMINO GG, 1990, AM J HUM GENET, V46, P925; HOGEWIND BL, 1980, CLIN GENET, V18, P168; HYLAND VJ, 1990, HUM GENET, V84, P286; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, AM J HUM GENET, V42, P498; MCHUGH K, 1991, RADIOLOGY, V178, P383, DOI 10.1148/radiology.178.2.1987597; MILUTINOVIC J, 1980, LANCET, V1, P1203; MILUTINOVIC J, 1989, AM J KIDNEY DIS, V13, P340, DOI 10.1016/S0272-6386(89)80043-5; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; RAVINE D, 1993, AM J KIDNEY DIS, V22, P803, DOI 10.1016/S0272-6386(12)70338-4; RAVINE D, 1992, LANCET, V340, P1300; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; ROMEO G, 1988, LANCET, V2, P8; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P88; SNIJDEWINT FGM, 1990, NUCLEIC ACIDS RES, V18, P3108, DOI 10.1093/nar/18.10.3108-a; THOMPSON AD, 1992, GENOMICS, V13, P402, DOI 10.1016/0888-7543(92)90260-Y; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5	30	441	464	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					824	827		10.1016/S0140-6736(94)92026-5	http://dx.doi.org/10.1016/S0140-6736(94)92026-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908078				2022-12-01	WOS:A1994ND79200009
J	THOMSON, AD				THOMSON, AD			ALCOHOLIC HEPATITIS	LANCET			English	Editorial Material											THOMSON, AD (corresponding author), GREENWICH DIST HOSP,DEPT MED,LONDON,ENGLAND.							ACHORD JL, 1993, AM J GASTROENTEROL, V88, P1822; BIRD GLA, 1990, ALCOHOL ALCOHOLISM, V25, P197, DOI 10.1093/oxfordjournals.alcalc.a044993; FANG JWS, 1994, LANCET, V343, P820, DOI 10.1016/S0140-6736(94)92025-7; LEEVY CM, 1973, LIVER REGENERATION M; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; THOMSON AD, 1974, NATURE, V252, P721, DOI 10.1038/252721a0; THOMSON AD, 1991, GUT, P97	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					810	810		10.1016/S0140-6736(94)92022-2	http://dx.doi.org/10.1016/S0140-6736(94)92022-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908075				2022-12-01	WOS:A1994ND79200005
J	WILSON, APR				WILSON, APR			DONOR SERUM FOR PERITONITIS	LANCET			English	Editorial Material											WILSON, APR (corresponding author), UNIV COLL HOSP LONDON,DEPT CLIN MICROBIOL,WC1 LONDON,ENGLAND.							BILLING AG, 1994, EUR J CLIN INVEST, V24, P28, DOI 10.1111/j.1365-2362.1994.tb02056.x; BOHNEN J, 1983, ARCH SURG-CHICAGO, V118, P285; BOHNEN JMA, 1988, ARCH SURG-CHICAGO, V123, P225; DUNN DL, 1987, ARCH SURG-CHICAGO, V122, P105; EDMONISTON CE, 1990, WORLD J SURG, V14, P176; ROTSTEIN OD, 1990, WORLD J SURG, V14, P159, DOI 10.1007/BF01664868; SCHEIN M, 1988, SURG GYNECOL OBSTET, V166, P187; SKAU T, 1986, J SURG RES, V40, P13, DOI 10.1016/0022-4804(86)90139-3	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					807	807		10.1016/S0140-6736(94)92019-2	http://dx.doi.org/10.1016/S0140-6736(94)92019-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908072				2022-12-01	WOS:A1994ND79200002
J	FALLON, JF; LOPEZ, A; ROS, MA; SAVAGE, MP; OLWIN, BB; SIMANDL, BK				FALLON, JF; LOPEZ, A; ROS, MA; SAVAGE, MP; OLWIN, BB; SIMANDL, BK			FGF-2 - APICAL ECTODERMAL RIDGE GROWTH SIGNAL FOR CHICK LIMB DEVELOPMENT	SCIENCE			English	Article							SKELETAL-MUSCLE; FACTOR RECEPTOR; BUD; EXPRESSION	The apical ectodermal ridge permits growth and elongation of amniote limb buds; removal causes rapid changes in mesodermal gene expression, patterned cell death, and truncation of the limb. Ectopic fibroblast growth factor (FGF)-2 supplied to the chick apical bud mesoderm after ridge removal will sustain normal gene expression and cell viability, and allow relatively normal limb development. A bioassay for FGFs demonstrated that FGF-2 was the only detectable FGF in chick limb bud extracts. By distribution and bioactivity, FGF-2 is the prime candidate for the chick limb bud apical ridge growth signal.	UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV CANTABRIA,DEPT ANAT & BIOL CELULAR,E-39011 SANTANDER,SPAIN; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Wisconsin System; University of Wisconsin Madison; Universidad de Cantabria; Purdue University System; Purdue University; Purdue University West Lafayette Campus	FALLON, JF (corresponding author), UNIV WISCONSIN,DEPT ANAT,1300 UNIV AVE,MADISON,WI 53706, USA.		Olwin, Bradley B/A-1333-2014; Ros, Maria A./K-8160-2014	Ros, Maria A./0000-0002-1224-7671	NICHD NIH HHS [HD20743] Funding Source: Medline; NIGMS NIH HHS [5T32GM07507] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007507] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON R, 1993, DEVELOPMENT, V117, P1423; AONO H, 1988, DEV BIOL, V128, P136, DOI 10.1016/0012-1606(88)90275-8; BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; CAIRNS JM, 1975, J EMBRYOL EXP MORPH, V34, P155; FALLON JF, 1993, LIMB DEV REGENERAT B; FALLON JF, 1993, LIMB DEV REGENERAT A; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; FOX JC, 1993, IN VITRO CELL DEV-AN, V29A, P228; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; KARDAMI E, 1985, P NATL ACAD SCI USA, V82, P8044, DOI 10.1073/pnas.82.23.8044; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROS MA, 1992, DEVELOPMENT, V116, P811; ROWE DA, 1982, DEV BIOL, V93, P83, DOI 10.1016/0012-1606(82)90241-X; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; SEED J, 1988, DEV BIOL, V128, P50, DOI 10.1016/0012-1606(88)90265-5; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TODT WL, 1984, J EMBRYOL EXP MORPH, V80, P21; WATANABE A, 1993, DEV BIOL, V159, P223, DOI 10.1006/dbio.1993.1235; ZWILLING E, 1956, J EXP ZOOL, V132, P219, DOI 10.1002/jez.1401320203; ZWILLING E, 1955, J EXP ZOOL, V128, P423, DOI 10.1002/jez.1401280304	30	416	425	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					104	107		10.1126/science.7908145	http://dx.doi.org/10.1126/science.7908145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7908145				2022-12-01	WOS:A1994ND53600041
J	GHIARA, JB; STURA, EA; STANFIELD, RL; PROFY, AT; WILSON, IA				GHIARA, JB; STURA, EA; STANFIELD, RL; PROFY, AT; WILSON, IA			CRYSTAL-STRUCTURE OF THE PRINCIPAL NEUTRALIZATION SITE OF HIV-1	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOUTH-DISEASE VIRUS; MONOCLONAL-ANTIBODY; V3 DOMAIN; DETERMINANT; GP120; INFECTIVITY; SEQUENCE; PROTEIN; RESOLUTION	The crystal structure of a complex between a 24-amino acid peptide from the third variable (V3) loop of human immunodeficiency virus-type 1 (HIV-1) gp120 and the Fab fragment of a broadly neutralizing antibody (59.1) was determined to 3 angstrom resolution. The tip of the V3 loop containing the Gly-Pro-Gly-Arg-Ala-Phe sequence adopts a double-turn conformation, which may be the basis ot its conservation in many HIV-1 isolates. A complete map of the HIV-1 principal neutralizing determinant was constructed by stitching together structures of V3 loop peptides bound to 59.1 and to an isolate-specific (MN) neutralizing antibody (50.1). Structural conservation of the overlapping epitopes suggests that this biologically relevant conformation could be of use in the design of synthetic vaccines and drugs to inhibit HIV-1 entry and virus-related cellular fusion.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; REPLIGEN CORP, CAMBRIDGE, MA 02139 USA	Scripps Research Institute			Stanfield, Robyn/AAH-3190-2019; Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; stanfield, robyn/0000-0001-9521-9184	NIGMS NIH HHS [GM-46192] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BAXT B, 1980, VIROLOGY, V104, P42, DOI 10.1016/0042-6822(80)90364-5; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; COHEN J, 1993, SCIENCE, V262, P1971, DOI 10.1126/science.7903478; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; ISOGAI Y, 1980, BIOPOLYMERS, V19, P1183, DOI 10.1002/bip.1980.360190607; IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Moore J P, 1991, AIDS, V5 Suppl 2, pS21, DOI 10.1097/00002030-199101001-00004; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STANFIELD RL, UNPUB; Stanfield RL., 1993, IMMUNOMETHODS, V3, P211, DOI 10.1006/immu.1993.1055; VERONESE FD, 1993, J BIOL CHEM, V268, P25894; Weiss R. A., 1992, Seminars in Virology, V3, P79; WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C	43	244	254	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	1994	264	5155					82	85		10.1126/science.7511253	http://dx.doi.org/10.1126/science.7511253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7511253				2022-12-01	WOS:A1994ND53600034
J	WHEELER, DB; RANDALL, A; TSIEN, RW				WHEELER, DB; RANDALL, A; TSIEN, RW			ROLES OF N-TYPE AND Q-TYPE CA2+ CHANNELS IN SUPPORTING HIPPOCAMPAL SYNAPTIC TRANSMISSION	SCIENCE			English	Article							LONG-TERM POTENTIATION; OMEGA-CONOTOXIN GVIA; CALCIUM CHANNELS; TRANSMITTER RELEASE; PERIPHERAL NEURONS; SENSORY NEURONS; P-TYPE; CURRENTS; INVITRO; DEPRESSION	Several types of calcium channels found in the central nervous system are possible participants in triggering neurotransmitter release. Synaptic transmission between hippocampal CA3 and CA1 neurons was mediated by N-type calcium channels, together with calcium channels whose pharmacology differs from that of L- and P-type channels but resembles that of the Q-type channel encoded by the alpha1A subunit gene. Blockade of either population of channels strongly increased enhancement of synaptic transmission with repetitive stimuli. Even after complete blockade of N-type channels, transmission was strongly modulated by stimulation of neurotransmitter receptors or protein kinase C. These findings suggest a role for alpha1A subunits in synaptic transmission and support the idea that neurotransmitter release may depend on multiple types of calcium channels under physiological conditions.	STANFORD UNIV, MED CTR,SCH MED,BECKMAN CTR MOLEC & GENET MED, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University				Randall, Andrew/0000-0001-8852-3671	NIMH NIH HHS [MH48108-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alger B.E., 1984, BRAIN SLICES, P381; ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSL, V299, P400; DEISZ RA, 1985, NEUROSCI LETT, V56, P205, DOI 10.1016/0304-3940(85)90130-2; DINGLEDINE R, 1981, BRAIN RES, V207, P218, DOI 10.1016/0006-8993(81)90697-1; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUTAR P, 1989, EUR J PHARMACOL, V174, P261, DOI 10.1016/0014-2999(89)90318-X; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; GAHWILER BH, 1987, NEUROSCI LETT, V76, P301, DOI 10.1016/0304-3940(87)90419-8; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MCKECHNIE K, 1989, BRIT J PHARMACOL, V98, pP673; MILLER RJ, 1993, CURR BIOL, V3, P481, DOI 10.1016/0960-9822(93)90364-T; MILLER RJ, 1990, INTRACELLULAR CALCIU, P97; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEUROPHARMACOLOGY, V32, P1161, DOI 10.1016/0028-3908(93)90010-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; MULKEEN D, 1988, BRAIN RES, V447, P234, DOI 10.1016/0006-8993(88)91124-9; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Randall A. D., 1993, Society for Neuroscience Abstracts, V19, P1478; RANDALL AD, 1993, FUNCT NEUROL S, V8, P44; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; Swartz K. J., 1993, Society for Neuroscience Abstracts, V19, P1478; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; WHEELER D, UNPUB; Wu L. G., 1993, Society for Neuroscience Abstracts, V19, P1518; WU LG, 1994, J NEUROSCI, V14, P645; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; ZHANG J, UNPUB; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	57	862	872	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	1994	264	5155					107	111		10.1126/science.7832825	http://dx.doi.org/10.1126/science.7832825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7832825				2022-12-01	WOS:A1994ND53600042
J	BOWCOCK, AM; RUIZLINARES, A; TOMFOHRDE, J; MINCH, E; KIDD, JR; CAVALLISFORZA, LL				BOWCOCK, AM; RUIZLINARES, A; TOMFOHRDE, J; MINCH, E; KIDD, JR; CAVALLISFORZA, LL			HIGH-RESOLUTION OF HUMAN EVOLUTIONARY TREES WITH POLYMORPHIC MICROSATELLITES	NATURE			English	Article							MITOCHONDRIAL-DNA; POPULATIONS; PERSISTENCE; LOCI	GENETIC variation at hypervariable loci is being used extensively for linkage analysis1 and individual identification2, and may be useful for inter-population studies2-5. Here we show that polymorphic microsatellites (primarily CA repeats) allow trees of human individuals to be constructed that reflect their geographic origin with remarkable accuracy. This is achieved by the analysis of a large number of loci for each individual, in spite of the small variations in allele frequencies existing between populations6,7. Reliable evolutionary relationships could also be established in comparisons among human populations but not among great ape species, probably because of constraints on allele length variation. Among human populations, diversity of microsatellites is highest in Africa, which is in contrast to other nuclear markers and supports the hypothesis of an African origin for humans.	STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Stanford University; Yale University	BOWCOCK, AM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PEDIAT, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Klein, Richard G/B-5910-2009; Ruiz-Linares, Andres/AAR-1104-2021	Ruiz-Linares, Andres/0000-0001-8372-1011; Bowcock, Anne/0000-0001-8691-9090				BARBUJANI G, 1990, P NATL ACAD SCI USA, V87, P1816, DOI 10.1073/pnas.87.5.1816; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; Bowcock A M, 1991, Gene Geogr, V5, P151; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CAVALLISFORZA LL, 1993, SCIENCE, V259, P639, DOI 10.1126/science.8430313; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; CAVALLISFORZA LL, 1967, EVOLUTION, V21, P550, DOI 10.1111/j.1558-5646.1967.tb03411.x; CAVALLISFORZA LL, IN PRESS HIST GEOGRA; CHAKRABORTY R, 1992, AM J HUM BIOL, V4, P387, DOI 10.1002/ajhb.1310040315; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; GILBERT DA, 1990, NATURE, V344, P764, DOI 10.1038/344764a0; HORAI S, 1993, MOL BIOL EVOL, V10, P23; Lewontin R.C., 1972, EVOLUTIONARY BIOL, P381, DOI DOI 10.1007/978-1-4684-9063-3_14; MITTON JB, 1977, AM NAT, V111, P203, DOI 10.1086/283155; NEI M, 1993, MOL BIOL EVOL, V10, P927; NEI M, 1972, SCIENCE, V177, P434, DOI 10.1126/science.177.4047.434; Pena Sergio D. J., 1993, DNA FINGERPRINTING S; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SMOUSE PE, 1982, AM NAT, V119, P445, DOI 10.1086/283925; TACHIDA H, 1992, GENETICS, V131, P471; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WALSH JB, 1987, GENETICS, V115, P553; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; ZEI G, 1993, ANN HUM GENET, V57, P123, DOI 10.1111/j.1469-1809.1993.tb00894.x; [No title captured]	28	1506	1559	2	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					455	457		10.1038/368455a0	http://dx.doi.org/10.1038/368455a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	7510853				2022-12-01	WOS:A1994ND12000063
J	GLEICHER, N				GLEICHER, N			AUTOANTIBODIES AND PREGNANCY LOSS	LANCET			English	Editorial Material							ANTIBODIES		FDN REPROD MED,CHICAGO,IL		GLEICHER, N (corresponding author), CTR HUMAN REPROD,CHICAGO,IL, USA.							AOKI K, 1993, AM J REPROD IMMUNOL, V29, P82, DOI 10.1111/j.1600-0897.1993.tb00570.x; BAKIMER R, 1992, J CLIN INVEST, V89, P1158; BLANK M, 1991, P NATL ACAD SCI USA, V88, P3069, DOI 10.1073/pnas.88.8.3069; CHRISTIANSEN OB, 1989, HUM REPROD, V4, P913, DOI 10.1093/oxfordjournals.humrep.a137011; CLARK DA, 1991, AM J REPROD IMMUNOL, V25, P18, DOI 10.1111/j.1600-0897.1991.tb01058.x; EROGLU GE, 1994, AM J REPROD IMMUNOL, V31, P1; GLEICHER N, 1992, AM J OBSTET GYNECOL, V167, P637, DOI 10.1016/S0002-9378(11)91563-4; GLINOER D, 1991, J CLIN ENDOCR METAB, V73, P421, DOI 10.1210/jcem-73-2-421; PRATT DE, 1993, FERTIL STERIL, V60, P1001; STAGNAROGREEN A, 1990, JAMA-J AM MED ASSOC, V264, P1422, DOI 10.1001/jama.264.11.1422; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; XU L, 1990, AM J OBSTET GYNECOL, V163, P1493, DOI 10.1016/0002-9378(90)90612-B	12	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					747	748		10.1016/S0140-6736(94)91833-3	http://dx.doi.org/10.1016/S0140-6736(94)91833-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907727				2022-12-01	WOS:A1994NC35100005
J	KUPFER, A; AESCHLIMANN, C; WERMUTH, B; CERNY, T				KUPFER, A; AESCHLIMANN, C; WERMUTH, B; CERNY, T			PROPHYLAXIS AND REVERSAL OF IFOSFAMIDE ENCEPHALOPATHY WITH METHYLENE-BLUE	LANCET			English	Note								The antineoplastic ifosfamide produces dose-dependent signs of neurotoxicity. After ifosfamide overdose in a patient, we found excessive urinary excretion of glutaric acid and sarcosine, which is compatible with glutaric aciduria type II, a defect in mitochondrial fatty acid oxidation that results from defective electron transfer to flavoproteins. We therefore used the electron-accepting drug methylene-blue as an antidote for ifosfamide encephalopathy. In one patient, ifosfamide neurotoxicity was rapidly reversed by methylene-blue 50 mg intravenously. In another patient with previous episodes of ifosfamide encephalopathy, methylene-blue was administered orally prophylactically. No symptoms of neurotoxicity were noted.	UNIV BERN,INSELSPITAL,DEPT CLIN CHEM,BERN,SWITZERLAND; UNIV HOSP BERNE,DEPT MED ONCOL,BERN,SWITZERLAND	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	KUPFER, A (corresponding author), UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND.							BHAT HK, 1991, TOXICOL LETT, V59, P203, DOI 10.1016/0378-4274(91)90073-F; CERNY T, 1992, ANN ONCOL, V3, P679, DOI 10.1093/oxfordjournals.annonc.a058317; GOODMAN SI, 1989, METABOLIC BASIS INHE, V1, P915; HARPEY JP, 1986, LANCET, V1, P391; KUPFER A, 1990, LANCET, V335, P1461, DOI 10.1016/0140-6736(90)91487-U; KUPFER A, 1990, N-S ARCH PHARMACOL S, V342, pR20; PETERS RA, 1952, PROC R SOC SER B-BIO, V139, P143, DOI 10.1098/rspb.1952.0001; SOOD C, 1993, BIOCHEM PHARMACOL, V46, P1621, DOI 10.1016/0006-2952(93)90332-Q; WOLFF SN, 1990, SEMIN ONCOL, V17, P2	9	138	138	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					763	764		10.1016/S0140-6736(94)91839-2	http://dx.doi.org/10.1016/S0140-6736(94)91839-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7510815				2022-12-01	WOS:A1994NC35100011
J	MCNULTY, A; KALDOR, JM; MCDONALD, AM; BAUMGART, K; COOPER, DA				MCNULTY, A; KALDOR, JM; MCDONALD, AM; BAUMGART, K; COOPER, DA			ACQUIRED IMMUNODEFICIENCY WITHOUT EVIDENCE OF HIV-INFECTION - NATIONAL RETROSPECTIVE SURVEY	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW,AUSTRALIA; UNIV SYDNEY,CENTENARY INST CANC MED & CELL BIOL,SYDNEY,NSW 2006,AUSTRALIA; TAYLOR SQ PRIVATE CLIN,DARLINGHURST,NSW,AUSTRALIA	University of New South Wales Sydney; Kirby Institute; University of Sydney; Centenary Institute			Kaldor, John M/D-4545-2011					GATENBY PA, 1989, LANCET, V1, P1027, DOI 10.1016/S0140-6736(89)92677-9; KALDOR J, 1993, MED J AUSTRALIA, V158, P10, DOI 10.5694/j.1326-5377.1993.tb121640.x; LAURENCE J, 1993, ANN INTERN MED, V119, P55, DOI 10.7326/0003-4819-119-1-199307010-00010; MULLER J, 1990, MYCOSES IN AIDS PATIENTS, P123; 1992, MMWR, V41, P541	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					825	826		10.1136/bmj.308.6932.825	http://dx.doi.org/10.1136/bmj.308.6932.825			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	7909464	Green Published			2022-12-01	WOS:A1994ND24300024
J	RODRIGUEZ, LAG; JICK, H				RODRIGUEZ, LAG; JICK, H			RISK OF UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION ASSOCIATED WITH INDIVIDUAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Article							DISEASE	Exposure to non-steroidal anti-inflammatory drugs (NSAIDs) is known to increase substantially the risk of upper gastrointestinal bleeding and perforation (UGIB). We have carried out a population-based retrospective case-control study to assess the variation in risk associated with various individual NSAIDs, with adjustment for features of use and other independent risk factors. The study sample comprised 1457 cases of UGIB and 10 000 control subjects identified from general practitioners' computerised records in the UK. The adjusted estimate of relative risk of UGIB associated with current NSAID use was 4.7 (95% CI 3.8-5.7). Previous UGIB was the single most important predictor of UGIB (relative risk 13.5 [10.3-17.7]). For all NSAIDs together, the risk was greater for high doses than for tow doses (7.0 [5.2-9.6] vs 2.6 [1.8-3.8]). The estimates of risk associated with the individual NSAIDs varied widely. Users of azapropazone (23.4 [6.9-79.5]) and piroxicam (18.0 [8.2-39.6]) had the highest risk of UGIB among the NSAIDs studied. All the other NSAIDs with sufficient data for individual analysis (ibuprofen, naproxen, diclofenac, ketoprofen, and indomethacin) had relative risks similar to that for overall NSAID use. NSAIDS should be used cautiously in patients who have other risk factors for UGIB; these include advanced age, smoking, history of peptic ulcer, and use of oral corticosteroids or anticoagulants.			RODRIGUEZ, LAG (corresponding author), BOSTON UNIV,BOSTON COLLABORAT DRUG SURVELLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.		rodriguez, luis a garcia/B-1980-2010	Jick, Hershel/0000-0003-4270-5992				BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Perry J, 1978, OXMIS PROBLEM CODES	7	817	840	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					769	772		10.1016/S0140-6736(94)91843-0	http://dx.doi.org/10.1016/S0140-6736(94)91843-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907735				2022-12-01	WOS:A1994NC35100015
J	ROSENSTEIN, BJ				ROSENSTEIN, BJ			GENOTYPE-PHENOTYPE CORRELATIONS IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material							DELTA-F508; ASSOCIATION; MUTATIONS; DELETION; DISEASE				ROSENSTEIN, BJ (corresponding author), JOHNS HOPKINS UNIV HOSP,CTR SYST FIBROSIS,BALTIMORE,MD 21205, USA.							CAMPBELL PW, 1991, J PEDIATR-US, V118, P239, DOI 10.1016/S0022-3476(05)80490-1; CURTIS A, 1991, J MED GENET, V28, P34, DOI 10.1136/jmg.28.1.34; DEARCE M, 1992, CLIN GENET, V42, P271; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KEREM E, 1989, J PEDIATR-US, V114, P767, DOI 10.1016/S0022-3476(89)80134-9; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; KUBESCH P, 1993, LANCET, V341, P189, DOI 10.1016/0140-6736(93)90062-L; LESTER LA, 1994, PEDIATRICS, V93, P114; LIECHTIGALLATI S, 1992, PEDIATR RES, V32, P175, DOI 10.1203/00006450-199208000-00010; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; TSIU LC, 1992, TRENDS GENET, V8, P392; 1993, NEW ENGL J MED, V329, P1308	13	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					746	747		10.1016/S0140-6736(94)91832-5	http://dx.doi.org/10.1016/S0140-6736(94)91832-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907726				2022-12-01	WOS:A1994NC35100004
J	ROUSSEAUXPREVOST, R; LESUR, P; COLLIER, F; RIGOT, JM; VENEZIA, ND; POL, PS; DELAUNAY, J; GAUTHIER, A; ROUSSEAUX, J				ROUSSEAUXPREVOST, R; LESUR, P; COLLIER, F; RIGOT, JM; VENEZIA, ND; POL, PS; DELAUNAY, J; GAUTHIER, A; ROUSSEAUX, J			ABNORMAL EXPRESSION OF PROTEIN-4.1 IN SPERMATOZOA OF INFERTILE MEN WITH TERATOSPERMIA	LANCET			English	Note							SPERM	Molecular defects responsible for morphologically abnormal spermatozoa (teratospermia) associated with male sterility are largely unknown. We report defective expression of protein 4.1, a cytoskeletal protein initially recognised in red cells. In some patients with severely amorphous sperm heads, protein 4.1 had an abnormal sub-cellular localisation (tail instead of head) and appeared as high-molecular-weight isoforms, especially a 135 kDa species instead of the 82 kDa isoform seen in fertile sperm. Because the 135 kDa isoform is characteristic of immature germ cells from testis, its presence in teratospermia suggests profoundly disturbed sperm differentiation.	LAB ANAL MED LIBERTE, LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, SERV GYNECOL SOCLALE, LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, SERV UROL, LILLE, FRANCE; CNRS, URA 1171, LYON, FRANCE; CTR HOSP REG & UNIV LILLE, CECOS NORD, LILLE, FRANCE	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; CHU Lille	ROUSSEAUXPREVOST, R (corresponding author), INST RECH CANC LILLE, PL VERDUN, F-59045 LILLE, FRANCE.		VENEZIA, Nicole DALLA/C-6542-2017	VENEZIA, Nicole DALLA/0000-0002-4553-3535				ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BACCETTI B, 1988, J SUBMICR CYTOL PATH, V20, P209; CHEVAILLIER P, 1987, LANCET, V2, P806; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; ESCALIER D, 1990, International Journal of Developmental Biology, V34, P287; MIRANDA PV, 1992, MOL REPROD DEV, V33, P443, DOI 10.1002/mrd.1080330411; VENEZIA ND, 1992, J CLIN INVEST, V90, P1713, DOI 10.1172/JCI116044; VIRTANEN I, 1984, J CELL BIOL, V99, P1083, DOI 10.1083/jcb.99.3.1083	8	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					764	765		10.1016/S0140-6736(94)91840-6	http://dx.doi.org/10.1016/S0140-6736(94)91840-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907733				2022-12-01	WOS:A1994NC35100012
J	VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL				VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL			TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN IMMUNOCOMPETENT PATIENTS - A SELF-PROTECTIVE MECHANISM	LANCET			English	Article							NONIMMUNOCOMPROMISED HOSTS; BLOOD-TRANSFUSIONS; T-CELLS; RESISTANCE; TRANSPLANTATION; HEART; RATS	Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but hazardous complication caused by transfusion of leucocyte-containing blood. It is not clear why some patients are at risk for TA-GVHD, but others are not. We studied TA-GVHD in immunocompetent individuals by looking at donor-anti-host reactivity after transfusion of leucocyte-containing blood. We tested reactivity in 62 donor-recipient combinations in vitro before and at different times after blood transfusion with mixed lymphocyte culture. One patient was studied in more detail. Reactivity of blood donors against hosts gradually decreased after blood transfusion. This decrease significantly correlated with time (p<0.001). Studies in a single patient showed that absence of donor-host reactivity was due to host T cells that inhibited the response. These data indicate that an active mechanism exists in immunocompetent individuals which inhibits the graft-versus-host reaction of the donor against the host. This mechanism might be exploited in organ transplantation by pre-transplant blood transfer.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL & BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)								ANDERSEN CB, 1992, HUM PATHOL, V23, P831, DOI 10.1016/0046-8177(92)90355-7; AVOY DR, 1990, TRANSFUSION, V30, P849, DOI 10.1046/j.1537-2995.1990.30991048795.x; BELGRAU DL, 1978, J EXP MED, V148, P103; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; DEGAST GC, 1991, BONE MARROW TRANSPL, V7, P293; DESFORGES JF, 1990, NEW ENGL J MED, V323, P315; GOULMY E, 1983, HLA TYPING METHODOLO, V2, P105; GREENBAUM BH, 1991, J CLIN ONCOL, V9, P1889, DOI 10.1200/JCO.1991.9.10.1889; KIMURA H, 1984, J EXP MED, V160, P652, DOI 10.1084/jem.160.3.652; KIMURA H, 1984, NATURE, V308, P463, DOI 10.1038/308463a0; KOSMATOPOULOS K, 1987, J IMMUNOL, V138, P1038; KOSMATOPOULOS K, 1988, TRANSPLANTATION, V46, P570, DOI 10.1097/00007890-198810000-00021; KOSMATOPOULOS K, 1987, TRANSPLANTATION, V44, P267, DOI 10.1097/00007890-198708000-00018; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LEHMANN PV, 1991, J EXP MED, V173, P333, DOI 10.1084/jem.173.2.333; MARCUS JN, 1989, NEW ENGL J MED, V322, P1004; OHTO H, 1992, TRANSFUSION, V32, P691, DOI 10.1046/j.1537-2995.1992.32792391051.x; OPELZ G, 1973, TRANSPLANT P, V5, P253; PIRENNE J, 1991, TRANSPLANTATION, V51, P51, DOI 10.1097/00007890-199101000-00007; SAKAKIBARA T, 1986, LANCET, V2, P1099; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SHIVDASANI RA, 1993, NEW ENGL J MED, V328, P766, DOI 10.1056/NEJM199303183281105; SPITZER TR, 1990, CANCER-AM CANCER SOC, V66, P2346, DOI 10.1002/1097-0142(19901201)66:11<2346::AID-CNCR2820661116>3.0.CO;2-T; SUZUKI K, 1992, TRANSFUSION, V32, P358, DOI 10.1046/j.1537-2995.1992.32492263452.x; VOGELSANG GB, 1990, TRANSFUSION, V30, P101, DOI 10.1046/j.1537-2995.1990.30290162892.x; WILSON DB, 1989, IMMUNOL REV, V107, P159, DOI 10.1111/j.1600-065X.1989.tb00008.x; 1989, LANCET, V2, P529	27	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					753	757		10.1016/S0140-6736(94)91836-8	http://dx.doi.org/10.1016/S0140-6736(94)91836-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907730				2022-12-01	WOS:A1994NC35100008
J	YU, RC; CHU, C; BULUWELA, L; CHU, AC				YU, RC; CHU, C; BULUWELA, L; CHU, AC			CLONAL PROLIFERATION OF LANGERHANS CELLS IN LANGERHANS CELL HISTIOCYTOSIS	LANCET			English	Note								X-chromosome-inactivation assays can be used to assess clonality. We used such an assay at the human androgen-receptor gene locus in th ree female patients with histologically proven Langerhans cell histiocytosis. All patients were heterozygous for this locus. Cells bearing the Langerhans cell phenotype were purified from involved tissue after fluorescence-activated cell sorting with monoclonal antibodies against the CD1a complex. After Hhal digestion of DNA, these CD1a positive cells demonstrated a non-random X-chromosome-inactivation pattern, whereas CD1a negative cells in the same tissue showed a random pattern. Our data suggest that Langerhans cell histiocytosis represents a clonal proliferation of cells bearing the Langerhans cell phenotype.	ROYAL HOSP SICK CHILDREN, DEPT CHILD HLTH, GLASGOW G3 8SJ, SCOTLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT BIOCHEM, LONDON W6, ENGLAND	University of Glasgow; Imperial College London	YU, RC (corresponding author), ROYAL POSTGRAD MED SCH, DERMATOL UNIT, LONDON W12 0NN, ENGLAND.							ALLEN RC, 1992, AM J HUM GENET, V51, P1229; [Anonymous], 1987, Lancet, V1, P208; BIRBECK MS, 1961, J INVEST DERMATOL, V37, P51, DOI 10.1038/jid.1961.80; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; MCLELLAND J, 1989, BRIT J DERMATOL, V120, P485, DOI 10.1111/j.1365-2133.1989.tb01321.x; STINGL G, 1978, J IMMUNOL, V121, P2005	6	291	305	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					767	768		10.1016/S0140-6736(94)91842-2	http://dx.doi.org/10.1016/S0140-6736(94)91842-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7510816				2022-12-01	WOS:A1994NC35100014
J	BENDELAC, A; KILLEEN, N; LITTMAN, DR; SCHWARTZ, RH				BENDELAC, A; KILLEEN, N; LITTMAN, DR; SCHWARTZ, RH			A SUBSET OF CD4(+) THYMOCYTES SELECTED BY MHC CLASS-I MOLECULES	SCIENCE			English	Article							CD8+ T-CELLS; CYTOPLASMIC TAIL; BINDING-SITE; IMMATURE THYMOCYTES; THYMIC SELECTION; ALPHA-3 DOMAIN; DEFICIENT MICE; GENE FAMILY; LINEAGE; CD4+	To complete their maturation, most immature thymocytes depend on the simultaneous engagement of their antigen receptor [alpha beta T cell receptor (TCR)] and their CD4 or CD8 coreceptors with major histocompatibility complex class II or I ligands, respectively. However, a normal subset of mature alpha beta TCR(+) thymocytes did not follow these rules. These thymocytes expressed NK1.1 and a restricted set of alpha beta TCRs that are intrinsically class I-reactive because their positive selection was class I-dependent but CD8-independent. These cells were CD4(+) and CD4(-)8(-) but never CD8(+), because the presence of CD8 caused negative selection. Thus, neither CD4 nor CD8 contributes signals that direct their maturation into the CD4(+) and CD4(-)8(-) lineages.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	BENDELAC, A (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892, USA.							ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; AUPHAN N, 1992, INT IMMUNOL, V4, P1419, DOI 10.1093/intimm/4.12.1419; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; Bendelac A, 1992, Semin Immunol, V4, P187; BENDELAC A, UNPUB; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FISCHER M, 1991, J IMMUNOL, V146, P3452; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KATIV I, 1993, J EXP MED, V177, P1429; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LANTZ O, UNPUB; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; MATZINGER P, 1993, IMMUNOL REV, V135, P81, DOI 10.1111/j.1600-065X.1993.tb00645.x; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAWADA S, UNPUB; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TAKAHAMA Y, 1991, J IMMUNOL, V147, P2883; TAKEDA K, 1993, J EXP MED, V177, P155, DOI 10.1084/jem.177.1.155; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VONBOEHMER H, 1991, J EXP MED, V176, P699; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	56	461	461	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1774	1778		10.1126/science.7907820	http://dx.doi.org/10.1126/science.7907820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	7907820				2022-12-01	WOS:A1994NC04000039
J	CHENG, JH; ZHOU, T; LIU, CD; SHAPIRO, JP; BRAUER, MJ; KIEFER, MC; BARR, PJ; MOUNTZ, JD				CHENG, JH; ZHOU, T; LIU, CD; SHAPIRO, JP; BRAUER, MJ; KIEFER, MC; BARR, PJ; MOUNTZ, JD			PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; RECEPTOR SUPERFAMILY; DNA FRAGMENTATION; CLONING; EXPRESSION; DEATH; CDNA; MICE	Fas is an apoptosis-signaling receptor molecule on the surface of a number of cell types. Molecular cloning and nucleotide sequence analysis revealed a human Fas messenger RNA variant capable of encoding a soluble Fas molecule lacking the transmembrane domain because of the deletion of an exon encoding this region. The expression of soluble Fas was confirmed by flow cytometry and immunocytochemical analysis. Supernatants from cells transfected with the variant messenger RNA blocked apoptosis induced by the antibody to Fas. Levels of soluble Fas were elevated in patients with systemic lupus erythematosus, and mice injected with soluble Fas displayed autoimmune features.	UNIV ALABAMA,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294; LXR BIOTECHNOL INC,RICHMOND,CA 94804	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003555, P60AR020614] Funding Source: NIH RePORTER; NIAID NIH HHS [P50 AI23694] Funding Source: Medline; NIAMS NIH HHS [P60 AR20614, P01 AR03555] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRIZZERA G, 1989, LEUKEMIA, V3, P1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOSIMOVICALASEV.O, 1988, EUR J IMMUNOL, V18, P855; KLINMAN DM, 1986, J EXP MED, V163, P1292, DOI 10.1084/jem.163.5.1292; KROWKA J, UNPUB; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OEHM A, 1992, J BIOL CHEM, V267, P10709; OHSAKA A, 1992, J CANCER, V69, P1259; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; TAKASHI S, 1993, CELL, V75, P1169; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1277; WALLACE DJ, 1992, NEW ENGL J MED, V327, P1029; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461	23	1063	1171	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1759	1762		10.1126/science.7510905	http://dx.doi.org/10.1126/science.7510905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	7510905				2022-12-01	WOS:A1994NC04000035
J	SHEPPARD, DN; OSTEDGAARD, LS; RICH, DP; WELSH, MJ				SHEPPARD, DN; OSTEDGAARD, LS; RICH, DP; WELSH, MJ			THE AMINO-TERMINAL PORTION OF CFTR FORMS A REGULATED CL- CHANNEL	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; NUCLEOTIDE-BINDING; CHLORIDE CHANNEL; ESCHERICHIA-COLI; R-DOMAIN; ATP; TRANSPORT; IDENTIFICATION; EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel consists of two motifs (each containing a membrane-spanning domain [MSD] and a nucleotide-binding domain [NBD]) linked by an R domain. We tested the hypothesis that one MSD-NBD motif could form a Cl- channel. The amino-terminal portion of CFTR (D836X, which contains MSD1, NBD1, and the R domain) formed Cl- channels with conductive properties identical to those of CFTR. However, channel regulation differed. Although phosphorylation increased activity, channels opened without phosphorylation. MgATP stimulated D836X more potently than CFTR and may interact at more than one site. These data and migration of D836X on sucrose density gradients suggest that D836X may function as a multimer. Thus, the amino-terminal portion of CFTR contains all of the structures required to build a regulated Cl- channel.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa	SHEPPARD, DN (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.		Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130; Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; Hille B., 1992, IONIC CHANNELS EXCIT; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARSHALL J, 1994, IN PRESS J BIOL CHEM; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WHITE MB, 1991, GENOMICS, V11, P778, DOI 10.1016/0888-7543(91)90092-S; 1993, NEW ENGL J MED, V329, P1308	32	103	105	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1091	1098		10.1016/0092-8674(94)90385-9	http://dx.doi.org/10.1016/0092-8674(94)90385-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511062				2022-12-01	WOS:A1994ND24600014
J	TAKAHASHI, T; TANAKA, M; BRANNAN, CI; JENKINS, NA; COPELAND, NG; SUDA, T; NAGATA, S				TAKAHASHI, T; TANAKA, M; BRANNAN, CI; JENKINS, NA; COPELAND, NG; SUDA, T; NAGATA, S			GENERALIZED LYMPHOPROLIFERATIVE DISEASE IN MICE, CAUSED BY A POINT MUTATION IN THE FAS LIGAND	CELL			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL RECEPTOR; GENETIC-LINKAGE MAP; SYSTEMIC AUTOIMMUNITY; NEGATIVE SELECTION; CLONAL ELIMINATION; MOUSE GENOME; FACTOR-ALPHA; LPR; ANTIGEN	Mice homozygous for lpr (lymphoproliferation) or gld (generalized lymphoproliferative disease) develop lymphadenopathy and suffer from autoimmune disease. The lpr mice have a mutation in a cell-surface protein, Fas, that mediates apoptosis. Fas ligand (FasL) is a tumor necrosis factor (TNF)-related type II membrane protein and binds to Fas. Here, mouse Fasl gene was isolated and localized to the gld region of mouse chromosome 1. Activated splenocytes from gld mice express Fasl mRNA. However, FasL in gld mice carries a point mutation in the C-terminal region, which is highly conserved among members of the TNF family. The recombinant gld FasL expressed in COS cells could not induce apoptosis in cells expressing Fas. These results indicate that lpr and gld are mutations in Fas and Fasl, respectively, and suggest important roles of the Fas system in development of T cells as well as cytotoxic T lymphocyte-mediated cytotoxicity.	NCI FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAKAHASHI, T (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVIDSON WF, 1985, P NATL ACAD SCI USA, V82, P1219, DOI 10.1073/pnas.82.4.1219; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; ECK MJ, 1989, J BIOL CHEM, V264, P17595; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GASE K, 1990, IMMUNOLOGY, V77, P368; GIESE T, 1992, J IMMUNOL, V149, P3097; Green EL, 1981, GENETICS PROBABILITY, P77; HANG LM, 1984, J IMMUNOL, V132, P1809; HERRON LR, 1993, J IMMUNOL, V151, P3450; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOTZIN BL, 1988, J EXP MED, V168, P2221, DOI 10.1084/jem.168.6.2221; MATSUMOTO K, 1991, J EXP MED, V173, P127, DOI 10.1084/jem.173.1.127; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUNTZ JD, 1986, J IMMUNOL, V137, P1029; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA S, 1994, IN PRESS ADV IMMUNOL; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SCOTT DE, 1993, J IMMUNOL, V150, P664; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SIRACUSA LD, 1991, GENOMICS, V10, P313, DOI 10.1016/0888-7543(91)90314-5; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUDA T, 1994, IN PRESS J EXP MED; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VIGNAUX F, 1994, IN PRESS EUR J IMMUN; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WATANABE T, 1991, BIOCHEM GENET, V29, P325, DOI 10.1007/BF00554140; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON ML, 1992, MAMM GENOME, V2, P158, DOI 10.1007/BF00302874; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; ZHOU T, 1993, J IMMUNOL, V150, P3651; [No title captured]	63	1445	1497	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					969	976		10.1016/0092-8674(94)90375-1	http://dx.doi.org/10.1016/0092-8674(94)90375-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511063				2022-12-01	WOS:A1994ND24600004
J	WIEDLOCHA, A; FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S				WIEDLOCHA, A; FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S			DUAL-MODE OF SIGNAL-TRANSDUCTION BY EXTERNALLY ADDED ACIDIC FIBROBLAST GROWTH-FACTOR	CELL			English	Article							DIPHTHERIA-TOXIN ENTRY; NUCLEAR TRANSLOCATION SEQUENCE; TYROSINE KINASE-ACTIVITY; FACTOR-I; VERO CELLS; LOW PH; A-FRAGMENT; HEPARIN; PROTEINS; ASSOCIATION	Acidic fibroblast growth factor (aFGF), fused to diphtheria toxin and translocated into cells, stimulated DNA synthesis in toxin-resistant cells lacking functional aFGF receptors while having a high number of diphtheria toxin receptors. In NIH 3T3 cells that lack diphtheria toxin receptors, but have receptors for aFGF, both aFGF and the fusion protein induced tyrosine phosphorylation, but only aFGF as such entered the nuclei and stimulated DNA synthesis. The results indicate that signaling occurs partly through cell surface receptors and partly by transport of the growth factor into the cell.			WIEDLOCHA, A (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO 3,NORWAY.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOYER B, 1993, J CELL BIOL, V120, P767, DOI 10.1083/jcb.120.3.767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FALNES PO, 1994, IN PRESS J BIOL CHEM; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIAG T, 1984, SCIENCE, V225, P902; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLSNES S, 1986, J BIOL CHEM, V261, P1553; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S., 1988, IMMUNOTOXINS, P39; OLWIN BB, 1992, J CELL BIOL, V118, P6323; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; SUNDAN A, 1982, J BIOL CHEM, V257, P9733; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	42	222	229	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1039	1051		10.1016/0092-8674(94)90381-6	http://dx.doi.org/10.1016/0092-8674(94)90381-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511061				2022-12-01	WOS:A1994ND24600010
J	FARRANT, M; FELDMEYER, D; TAKAHASHI, T; CULLCANDY, SG				FARRANT, M; FELDMEYER, D; TAKAHASHI, T; CULLCANDY, SG			NMDA-RECEPTOR CHANNEL DIVERSITY IN THE DEVELOPING CEREBELLUM	NATURE			English	Article							METHYL-D-ASPARTATE; NEURONS; RAT; GLUTAMATE; ACTIVATION; CURRENTS; ADULT; CELLS; DISTINCTION; RESPONSES	IN the cerebellum, NMDA (N-methyl-D-aspartate) receptors play an important role in neuronal differentiation(1,2) and excitatory synaptic transmission(3-5). During early cerebellar development, marked changes occur in the distribution of messenger RNAs encoding various NMDA-receptor subunits(6). To determine whether these changes result in the appearance of functionally distinct NMDA receptors(7-9), we have recorded single-channel currents in rat cerebellar granule cells during the period of their migration from the external germinal layer to the inner granular layer(10). Here we show that before synapse formation(10,11), pre-migratory and migrating granule cells express NMDA receptors possessing single-channel properties similar to those previously described for many central neurons(12,16). In contrast, mature post-migratory cells also express an atypical form of NMDA receptor that has a lower single-channel conductance and distinct kinetic behaviour. The properties of these 'low-conductance' channels correspond to those described(17) for recombinant NMDA receptors formed by coexpression of NR1 and NR2C subunits(8,9). The NR2C subunit appears postnatally and is found predominantly in the adult cerebellum(6-8). Our data demonstrate developmental changes in NMDA-receptor properties at the single-channel level, and suggest that is the cerebellum the expression of a specific subunit protein results in a distinct form of native receptor.	UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	FARRANT, M (corresponding author), UCL, DEPT PHARMACOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Feldmeyer, Dirk/H-5940-2013; Takahashi, Tomoyuki/G-5951-2015	Feldmeyer, Dirk/0000-0002-1716-8972; Takahashi, Tomoyuki/0000-0002-8771-7666; Farrant, Mark/0000-0002-9918-0376; Cull-Candy, Stuart G/0000-0002-0831-8326	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN J, 1972, J COMP NEUROL, V145, P465, DOI 10.1002/cne.901450403; BLANTON MG, 1992, J NEUROPHYSIOL, V67, P1185, DOI 10.1152/jn.1992.67.5.1185; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DANGELO E, 1993, NEUROSCIENCE, V53, P121, DOI 10.1016/0306-4522(93)90290-V; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GARTHWAITE J, 1989, NEUROSCIENCE, V29, P401, DOI 10.1016/0306-4522(89)90067-5; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMORI J, 1983, J COMP NEUROL, V220, P365, DOI 10.1002/cne.902200402; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; ROSSI DJ, 1993, NEUROPHARMACOLOGY, V32, P1239, DOI 10.1016/0028-3908(93)90018-X; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; TAKAHASHI T, 1992, NEURON, V9, P1155, DOI 10.1016/0896-6273(92)90073-M; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	31	265	267	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					335	339		10.1038/368335a0	http://dx.doi.org/10.1038/368335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	7907398				2022-12-01	WOS:A1994NB98500046
J	ARINAMI, T; ITOKAWA, M; ENGUCHI, H; TAGAYA, H; YANO, S; SHIMIZU, H; HAMAGUCHI, H; TORU, M				ARINAMI, T; ITOKAWA, M; ENGUCHI, H; TAGAYA, H; YANO, S; SHIMIZU, H; HAMAGUCHI, H; TORU, M			ASSOCIATION OF DOPAMINE D2 RECEPTOR MOLECULAR VARIANT WITH SCHIZOPHRENIA	LANCET			English	Note							GENE	We have examined a variant of the dopamine D2 receptor gene (Ser311-->Cys) in 156 Japanese schizophrenic patients and 300 controls. The allele frequency of Cys311 was significantly higher in the whole patient group (0.054), among patients with onset before age 25 (0.090), and among those with a family history (0.135) than in the controls (0.018). 3 patients were homozygous for Cys311. The patients with Cys311 showed significantly less severe thought disorder and negative symptoms of schizophrenia than those without Cys311. The Cys311 variant of the D2 receptor may be a genetic risk factor for some types of schizophrenia.	TOKYO MED & DENT UNIV,DEPT NEUROPSYCHIAT,TOKYO,TOKYO,JAPAN; HOKUSHIN GEN HOSP,DEPT PSYCHIAT,NAKANO,NAGANO,JAPAN	Tokyo Medical & Dental University (TMDU)	ARINAMI, T (corresponding author), UNIV TSUKUBA,INST BASIC MED SCI,DEPT MED GENET,TSUKUBA,IBARAKI 305,JAPAN.			Itokawa, Masanari/0000-0003-4433-8030				CATALANO M, 1992, NEUROPSYCHOBIOLOGY, V26, P1, DOI 10.1159/000118888; CROW TJ, 1980, BRIT MED J, V280, P66, DOI 10.1136/bmj.280.6207.66; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; ITOKAWA M, 1993, BIOCHEM BIOPH RES CO, V196, P1369, DOI 10.1006/bbrc.1993.2404; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; SARKAR G, 1991, GENOMICS, V11, P8, DOI 10.1016/0888-7543(91)90096-W; SEEMAN P, 1993, NEUROPSYCHOPHARMACOL, V8, P137, DOI 10.1038/npp.1993.15; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SU Y, 1993, ARCH GEN PSYCHIAT, V50, P205	10	168	173	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					703	704		10.1016/S0140-6736(94)91581-4	http://dx.doi.org/10.1016/S0140-6736(94)91581-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907680				2022-12-01	WOS:A1994NB80900010
J	BERKLEY, S				BERKLEY, S			DIAGNOSTIC-TESTS FOR SEXUALLY-TRANSMITTED DISEASES - A CHALLENGE	LANCET			English	Editorial Material											BERKLEY, S (corresponding author), ROCKEFELLER FDN,DIV HLTH SCI,NEW YORK,NY 10036, USA.								0	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					685	686		10.1016/S0140-6736(94)91575-X	http://dx.doi.org/10.1016/S0140-6736(94)91575-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907675				2022-12-01	WOS:A1994NB80900004
J	ELIAS, D; COHEN, IR				ELIAS, D; COHEN, IR			PEPTIDE THERAPY FOR DIABETES IN NOD MICE	LANCET			English	Note							PROTEIN; MOUSE	NOD mice spontaneously develop autoimmune diabetes that mimics insulin-dependent diabetes mellitus (IDDM) in man. A peptide of the 60 kDa heat shock protein (hsp60), designated p277, can serve as a target for diabetogenic T-cell clones, and diabetes was prevented by using the p277 peptide to turn off anti-p277 immunity early in life. We report that the p277 peptide, administered once, can arrest the autoimmune process even after it is far advanced. Successful therapy was associated with down-regulation of the autoimmune process and regression of islet inflammation. Thus the immune system is responsive to manipulation by a specific signal even in the face of a virulent, full-blown autoimmune process.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Cohen, Irun R/B-3542-2009					BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BRUDZYNSKI K, 1992, DIABETOLOGIA, V35, P316, DOI 10.1007/BF00401198; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; ZHANG JW, 1993, SCIENCE, V261, P1451, DOI 10.1126/science.7690157	10	176	191	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					704	706		10.1016/S0140-6736(94)91582-2	http://dx.doi.org/10.1016/S0140-6736(94)91582-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907681				2022-12-01	WOS:A1994NB80900011
J	FORD, D; EASTON, DF; BISHOP, DT; NAROD, SA; GOLDGAR, DE; HAITES, N; MILNER, B; ALLAN, L; PONDER, BAJ; PETO, J; SMITH, S; STRATTON, M; LENOIR, GM; FEUNTEUN, J; LYNCH, H; ARASON, A; BARKARDOTTIR, R; EGILSSON, V; BLACK, DM; KELSELL, D; SPURR, N; DEVILEE, P; CORNELISSE, CJ; VARSEN, H; BIRCH, JM; SKOLNICK, M; SANTIBANEZKOREF, MS; TEARE, D; STEEL, M; PORTER, D; COHEN, BB; CAROTHERS, A; SMYTH, E; WEBER, B; NEWBOLD, B; BOEHNKE, M; COLLINS, FS; CANNONALBRIGHT, LA; GOLDGAR, D				FORD, D; EASTON, DF; BISHOP, DT; NAROD, SA; GOLDGAR, DE; HAITES, N; MILNER, B; ALLAN, L; PONDER, BAJ; PETO, J; SMITH, S; STRATTON, M; LENOIR, GM; FEUNTEUN, J; LYNCH, H; ARASON, A; BARKARDOTTIR, R; EGILSSON, V; BLACK, DM; KELSELL, D; SPURR, N; DEVILEE, P; CORNELISSE, CJ; VARSEN, H; BIRCH, JM; SKOLNICK, M; SANTIBANEZKOREF, MS; TEARE, D; STEEL, M; PORTER, D; COHEN, BB; CAROTHERS, A; SMYTH, E; WEBER, B; NEWBOLD, B; BOEHNKE, M; COLLINS, FS; CANNONALBRIGHT, LA; GOLDGAR, D			RISKS OF CANCER IN BRCA1-MUTATION CARRIERS	LANCET			English	Article							BREAST-CANCER; OVARIAN	Germline mutations in a gene on chromosome 17q known as BRCA1 are responsible for a large proportion of inherited predispositions to breast and ovarian cancer. In 33 families with evidence of linkage to BRCA1, we estimated the risks of breast and ovarian cancer from the occurrence of second cancers in individuals with breast cancer, and examined the risks of other cancers in BRCA1 carriers. 26 contralateral primary breast cancers occurring more than 3 years after a first breast cancer were observed before age 70, giving an estimated cumulative risk of breast cancer in gene carriers of 87% by age 70. 23 primary ovarian cancers occurred in women with a previous breast cancer, resulting in an estimated cumulative risk of ovarian cancer of 44% by age 70. 87 cancers other than breast or ovarian cancer were observed in individuals with breast or ovarian cancer and their first-degree relatives compared with 69.3 expected, based on national incidence rates. Significant excesses were observed for colon cancer (estimated relative risk [RR] to gene carriers 4.11 [95% Cl 2.36-7.15]) and prostate cancer(3.33 [1.78-6.20]). No significant excesses (or deficits) were noted for cancers of other sites. Our study provides estimates of breast and ovarian cancer risks which are useful for counselling BRCA1-mutation carriers. It also shows that carriers are at increased risk of colon and prostate cancer, which may be of clinical significance in certain families if the risks are associated with specific mutations.	ST JAMES HOSP,ICRF,GENET EPIDEMIOL UNIT,LEEDS,ENGLAND; MONTREAL GEN HOSP,MONTREAL,PQ,CANADA; UNIV UTAH,DEPT MED INFORMAT,SALT LAKE CITY,UT 84112; UNIV ABERDEEN,ABERDEEN,SCOTLAND; CANC RES CAMPAIGN,LONDON,ENGLAND; INST CANC RES,LONDON,ENGLAND; INT AGCY RES CANC,LYON,FRANCE; UNIV ICELAND,REYKJAVIK,ICELAND; IMPERIAL CANC RES FUND,LEEDS,W YORKSHIRE,ENGLAND; LEIDEN UNIV,LEIDEN,NETHERLANDS; FDN DETECT HEREDITARY TUMOURS,LEIDEN,NETHERLANDS; CHRISTIE HOSP & HOLT RADIUM INST,MANCHESTER M20 9BX,LANCS,ENGLAND; IMPERIAL CANC RES FUND,LONDON,ENGLAND; MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV MICHIGAN,ANN ARBOR,MI 48109; INST CANC RES,CAMBRIDGE,CAMBS,ENGLAND	Saint James's University Hospital; McGill University; Utah System of Higher Education; University of Utah; University of Aberdeen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; World Health Organization; International Agency for Research on Cancer (IARC); University of Iceland; Leiden University; Leiden University - Excl LUMC; Christie NHS Foundation Trust; Christie Hospital; Cancer Research UK; University of Edinburgh; University of Michigan System; University of Michigan; University of London; Institute of Cancer Research - UK	FORD, D (corresponding author), INST CANC RES,EPIDEMIOL SECT,BLOCK D,BELMONT SM2 5NG,SURREY,ENGLAND.		Feunteun, Jean/AAZ-1267-2020; Kelsell, David P/F-8767-2011; DEVILEE, PETER/ABR-2140-2022; Narod, Steven A/AAA-6112-2022	Bishop, Tim/0000-0002-8752-8785	NCI NIH HHS [CA57601] Funding Source: Medline; NHGRI NIH HHS [HG00209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; Cannon L., 1982, CANCER SURV, V1, P47; EASTON DF, 1993, AM J HUM GENET, V52, P678; EASTON DF, 1992, THESIS U LONDON; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL JM, 1992, AM J HUM GENET, V53, P678; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NAROD SA, 1991, LANCET, V338, P82; TOBACMAN JK, 1982, LANCET, V2, P795; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a	12	1463	1493	4	107	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					692	695		10.1016/S0140-6736(94)91578-4	http://dx.doi.org/10.1016/S0140-6736(94)91578-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907678				2022-12-01	WOS:A1994NB80900007
J	LOEVINSOHN, ME				LOEVINSOHN, ME			CLIMATIC WARMING AND INCREASED MALARIA INCIDENCE IN RWANDA	LANCET			English	Article								Global climatic change is expected to increase the incidence of vector-borne diseases, especially malaria. This study assessed the contribution of climate to a malaria epidemic in Rwanda, focusing on the catchment area of one health centre where diagnosis was consistent and non-climatic variables well monitored. In late 1987 malaria incidence in the area increased by 337% over the 3 previous years. The increase was greatest in groups with little acquired immunity-children under 2 years (564%) and people in high-altitude areas (501%). Case-fatality rose significantly (relative risk = 485, p<0.001). 1987 also saw record high temperatures and rainfall. An autoregressive equation including lagged effects of these two variables explained 80% of the variance in monthly malaria incidence. Temperature (especially mean minimum) predicted incidence best at higher altitudes where malaria had increased most. Empirically derived relations were consistent with the estimated generation time of the disease and with the known sensitivity of the plasmodium parasite to temperature. The patterns of climatic warming between day and night and among seasons will be critical to the effect on malaria. These findings are most relevant to regions near the altitude or latitude limits of the disease, where several epidemics have lately been reported.	INST SCI AGRON RWANDA,BUTARE,RWANDA; APPL ECOL CONSULTANTS,BUTARE,RWANDA									[Anonymous], 1976, TIME SERIES ANAL; AULT SK, 1989, DEMOGRAPHY VECTOR BO, P283; Bennett R., 1979, SPATIAL TIME SERIES; BUGILIMFURA L, 1988, REV MED RWANDAISE, V20, P93; DETINOVA TS, 1962, WHO MONOGR SER, V47; DIETZ K, 1974, B WORLD HEALTH ORGAN, V50, P347; Folland CK, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P195; GASCON J, 1988, T ROY SOC TROP MED H, V82, P222, DOI 10.1016/0035-9203(88)90418-X; LEPERS JP, 1990, B SOC PATHOL EXOT, V83, P330; MALATRE X, 1990, REV MED RWANDAISE, V22, P31; Mitchell JFB, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P131; MOLINEAUX L, 1988, MALARIA PRINCIPLES P, P914; Munyantore S, 1989, REV MED RWANDAISE, V21, P14; MUNYANTORE S, 1993, INFLUENCE RIZICULTUR; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Wigley TML, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P239; 1991, ELEMENTS ELABORATION; 1983, RECENSEMENT GENERAL; 1990, WORLD HLTH STAT Q, V43, P68; 1990, WHO PEP9010; 1991, RECONSEMENT GENERAL	21	201	209	2	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					714	718		10.1016/S0140-6736(94)91586-5	http://dx.doi.org/10.1016/S0140-6736(94)91586-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907685				2022-12-01	WOS:A1994NB80900015
J	PAWLIKOWSKA, T; CHALDER, T; HIRSCH, SR; WALLACE, P; WRIGHT, DJM; WESSELY, S				PAWLIKOWSKA, T; CHALDER, T; HIRSCH, SR; WALLACE, P; WRIGHT, DJM; WESSELY, S			POPULATION-BASED STUDY OF FATIGUE AND PSYCHOLOGICAL DISTRESS	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY CARE; PREVALENCE; BEHAVIOR	Objectives-To determine the prevalence of fatigue in the general population and the factors associated with fatigue. Design-Postal survey. Setting-Six general practices in southern England. Subjects-31 651 men and women aged 18-45 years registered with the practices. Main outcome measures-Responses to the 12 item general health questionnaire and a fatigue questionnaire which included self reported measures of duration, severity, and causes of fatigue. Results-15 283 valid questionnaires were returned, giving a response rate of 48.3%, (64% after adjustment for inaccuracies in the practice registers). 2798 (18.3%) of respondents reported substantial fatigue lasting six months or longer. Fatigue and psychological morbidity were moderately correlated (r = 0.62). Women were more likely to complain of fatigue than men, even after adjustment for psychological distress. The commonest cited reasons for fatigue were psychosocial (40% of patients). Of 2798 patients with excessive tiredness, only 38 (1.4%) attributed this to the chronic fatigue syndrome. Conclusion-Fatigue is distributed as a continuous variable in the community and is closely associated with psychological morbidity.	KINGS COLL, SCH MED & DENT, DEPT PSYCHOL MED, LONDON SE5 9RS, ENGLAND; ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON, ENGLAND; CHARING CROSS HOSP, SCH MED, DEPT MED MICROBIOL, LONDON, ENGLAND; CHARING CROSS HOSP, SCH MED, DEPT PSYCHIAT, LONDON, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT GEN PRACTICE, LONDON NW3, ENGLAND	University of London; King's College London; Imperial College London; Imperial College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Chalder, Trudie/A-5717-2011; Wessely, Simon C/A-8713-2008	Chalder, Trudie/0000-0003-0775-1045; Wessely, Simon Charles/0000-0002-6743-9929				BEHAN P, 1988, CRIT REV NEURBIOL, V42, P157; BICKLER G, 1993, BRIT MED J, V306, P1167, DOI 10.1136/bmj.306.6886.1167; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHALDER T, 1993, H PSYCHOSOMATIC RES, V37, P147; CROFT P, 1993, J RHEUMATOL, V20, P710; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KATON W, 1992, ARCH INTERN MED, V152, P1604, DOI 10.1001/archinte.152.8.1604; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; SHARPE M, 1992, BRIT MED J, V302, P347; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940	19	463	470	0	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					763	766		10.1136/bmj.308.6931.763	http://dx.doi.org/10.1136/bmj.308.6931.763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	7908238	Green Published			2022-12-01	WOS:A1994NC34800024
J	SHEHADEH, N; CALCINARO, F; BRADLEY, BJ; BRUCHLIM, I; VARDI, P; LAFFERTY, KJ				SHEHADEH, N; CALCINARO, F; BRADLEY, BJ; BRUCHLIM, I; VARDI, P; LAFFERTY, KJ			EFFECT OF ADJUVANT THERAPY ON DEVELOPMENT OF DIABETES IN MOUSE AND MAN	LANCET			English	Note							NOD MICE; PREVENTION	Freund's complete adjuvant (CFA) and BCG vaccine modulate the development of type 1 diabetes in animal models. In non-obese diabetic mice, CFA and BCG significantly reduced the proportion developing diabetes compared with controls. Histological examination showed that autoimmune disease still developed but had been diverted to become nondestructive. In a preliminary trial in 17 newly diagnosed, type 1 diabetic patients, intracutaneous administration of 0.1 mL of BCG 1 mg/mL led to clinical remission in 11 (65%)-by week 4 in 6. Remission has been sustained in 3 for 6-10 months. No side-effects were reported. A double-blind trial of BCG is warranted.	RAMBAM MED CTR,JUVENLLE DIABET CTR,HAIFA,ISRAEL; BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO	Rambam Health Care Campus; Technion Israel Institute of Technology					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046621] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46621] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		GUYTINGCO R, 1991, DIABETES, V40, pA152; LAKEY JRT, 1992, TRANSPLANT P, V24, P2848; MCINERNEY MF, 1991, DIABETES, V40, P715, DOI 10.2337/diabetes.40.6.715; QIN HY, 1993, J IMMUNOL, V150, P2072; SHEHADEH NN, 1993, J AUTOIMMUN, V6, P291, DOI 10.1006/jaut.1993.1025; WANG T, 1992, DIABETES, V41, P114, DOI 10.2337/diabetes.41.1.114	6	140	149	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					706	707		10.1016/S0140-6736(94)91583-0	http://dx.doi.org/10.1016/S0140-6736(94)91583-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907682				2022-12-01	WOS:A1994NB80900012
J	TAKAHASHI, K; JUJI, T; MIYAMOTO, M; UCHIDA, S; AKAZA, T; TADOKORO, K; SHIBATA, Y; INO, T; HIDANO, A				TAKAHASHI, K; JUJI, T; MIYAMOTO, M; UCHIDA, S; AKAZA, T; TADOKORO, K; SHIBATA, Y; INO, T; HIDANO, A			ANALYSIS OF RISK-FACTORS FOR POSTTRANSFUSION GRAFT-VERSUS-HOST DISEASE IN JAPAN	LANCET			English	Article							ERYTHRODERMA; SURGERY	We distributed a questionnaire to highlight the effects of post transfusion graft-versus-host disease (PT-GVHD) and to elucidate the risk factors that would predispose people to the disease. The questionnaire described the pathogenesis and the clinical profiles of PT-GVHD and was distributed to doctors in Japan whose hospital conducted more than 1000 units of blood transfusions a year. Doctors were asked about their awareness and experience of PT-GVHD cases. Those who had seen cases of PT-GVHD were then asked to detail clinical course and laboratory data. Of the 14 083 doctors who replied to the first question, 47.4% did not realise that PT-GVHD could occur in immunocompetent hosts. From 304 cases where detailed information was supplied, 171 were considered clinically compatible with PT-GVHD. From these it seems that the risk factors linked to PT-GVHD are cardiovascular surgery, cancer, fresh and consanguineous blood transfusion, and being male. Patients with any of these factors should have some prophylactic therapy such as irradiation of blood before transfusion.	JAPANESE RED CROSS CENT BLOOD CTR,HIROO,TOKYO,JAPAN; UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,TOKYO,TOKYO,JAPAN; JICHI MED SCH,OOMLYA MED CTR,OMIYA,SAITAMA,JAPAN; TOKYO WOMENS COLL,FAC MED,DEPT DERMATOL,TOKYO,TOKYO,JAPAN	Japanese Red Cross Medical Center; University of Tokyo; Jichi Medical University; Tokyo Women's Medical University	TAKAHASHI, K (corresponding author), TORANOMON GEN HOSP,DEPT TRANSFUS MED & IMMUNOHEMATOL,MINATO KU,TORANOMON 2-2-2,TOKYO,TOKYO 105,JAPAN.							BUTTON LN, 1981, TRANSFUSION, V21, P419, DOI 10.1046/j.1537-2995.1981.21481275998.x; ITO K, 1988, LANCET, V1, P413; JUJI T, 1989, NEW ENGL J MED, V321, P56; LEITMANN SF, 1989, TRANSFUSION, V25, P293; MATSUSHITA H, 1988, VIRCHOWS ARCH B, V55, P237; OTSUKA S, 1989, TRANSFUSION, V29, P544, DOI 10.1046/j.1537-2995.1989.29689318456.x; SAKAKIBARA T, 1986, LANCET, V2, P1099; TAKAHASHI K, 1991, TRANSFUS SCI, V12, P281, DOI 10.1016/0955-3886(91)90108-F	8	37	38	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					700	702		10.1016/S0140-6736(94)91580-6	http://dx.doi.org/10.1016/S0140-6736(94)91580-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907679				2022-12-01	WOS:A1994NB80900009
J	WYLLIE, HR; DUNN, FG				WYLLIE, HR; DUNN, FG			PREHOSPITAL OPIATE AND ASPIRIN ADMINISTRATION IN PATIENTS WITH SUSPECTED MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									STOBHILL GEN HOSP, DEPT CARDIAC, GLASGOW G21 3UW, SCOTLAND									ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; FORD JL, 1988, TXB PHARM SCI DOSAGE, P362; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; YOUNG LY, 1992, TXB APPLIED THERAPEU, V3, P9	5	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					760	761		10.1136/bmj.308.6931.760a	http://dx.doi.org/10.1136/bmj.308.6931.760a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	7695672	Green Published			2022-12-01	WOS:A1994NC34800021
J	GHOSH, A; CARNAHAN, J; GREENBERG, ME				GHOSH, A; CARNAHAN, J; GREENBERG, ME			REQUIREMENT FOR BDNF IN ACTIVITY-DEPENDENT SURVIVAL OF CORTICAL-NEURONS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; NEUROTROPHIC FACTOR; SENSORY NEURONS; GANGLION-CELLS; SYMPATHETIC-GANGLION; CILIARY GANGLION; CALCIUM; CULTURE; DEATH	Cultured embryonic cortical neurons from rats were used to explore mechanisms of activity-dependent neuronal survival. Cell survival was increased by the activation of voltage-sensitive calcium channels (VSCCs) but not by activation of N-methyl-D-aspartate receptors. These effects correlated with the expression of brain-derived neurotrophic factor (BDNF) induced by these two classes of calcium channels. Antibodies to BDNF (which block intracellular signaling by BDNF, but not by nerve growth factor, NT3, or NT4/5) reduced the survival of cortical neurons and reversed the VSCC-mediated increase in survival. Thus, endogenous BDNF is a trophic factor for cortical neurons whose expression is VSCC-regulated and that functions in the VSCC-dependent survival of these neurons.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Amgen					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28829] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; Bayer S.A., 1991, NEOCORTICAL DEV, V1; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BLACK IB, 1972, J NEUROCHEM, V19, P1367, DOI 10.1111/j.1471-4159.1972.tb01461.x; BONNI A, UNPUB; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHALAZONITIS A, 1980, DEV BIOL, V78, P173, DOI 10.1016/0012-1606(80)90327-9; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; COLLINS F, 1991, J NEUROSCI, V11, P2582; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FURBER S, 1987, J NEUROSCI, V7, P1816; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GALLO V, 1987, J NEUROSCI, V7, P2203; Ghosh A., UNPUB; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GUILLERY RW, 1973, J COMP NEUROL, V149, P423, DOI 10.1002/cne.901490403; HASHISAKI GT, 1989, J COMP NEUROL, V283, P465, DOI 10.1002/cne.902830402; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LARMET Y, 1992, NEURON, V9, P563, DOI 10.1016/0896-6273(92)90193-H; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MADERDRUT JL, 1988, BRAIN RES, V444, P189, DOI 10.1016/0006-8993(88)90928-6; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; NISHI R, 1981, DEV BIOL, V87, P301, DOI 10.1016/0012-1606(81)90153-6; PASIC TR, 1989, J COMP NEUROL, V283, P474, DOI 10.1002/cne.902830403; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1992, J NEUROSCI, V12, P4793	38	814	834	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1618	1623		10.1126/science.7907431	http://dx.doi.org/10.1126/science.7907431			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	7907431				2022-12-01	WOS:A1994NB67300034
J	KAMIJO, R; HARADA, H; MATSUYAMA, T; BOSLAND, M; GERECITANO, J; SHAPIRO, D; LE, J; KOH, SI; KIMURA, T; GREEN, SJ; MAK, TW; TANIGUCHI, T; VILCEK, J				KAMIJO, R; HARADA, H; MATSUYAMA, T; BOSLAND, M; GERECITANO, J; SHAPIRO, D; LE, J; KOH, SI; KIMURA, T; GREEN, SJ; MAK, TW; TANIGUCHI, T; VILCEK, J			REQUIREMENT FOR TRANSCRIPTION FACTOR IRF-1 IN NO SYNTHASE INDUCTION IN MACROPHAGES	SCIENCE			English	Article							IFN-INDUCIBLE GENES; DNA-BINDING PROTEIN; NITRIC-OXIDE; BCG INFECTION; MYCOBACTERIUM-TUBERCULOSIS; MURINE MACROPHAGES; INTERFERON-ALPHA; BETA; ACTIVATION; CELLS	Production of nitric oxide (NO) by macrophages is important for the killing of intracellular infectious agents. Interferon (IFN)-gamma and lipopolysaccharide stimulate NO production by transcriptionally up-regulating the inducible NO synthase (iNOS). Macrophages from mice with a targeted disruption of the IFN regulatory factor-1 (IRF-1) gene (IRF-1(-/-) mice) produced little or no NO and synthesized barely detectable iNOS messenger RNA in response to stimulation. Two adjacent IRF-1 response elements were identified in the iNOS promoter. Infection with Mycobacterium bovis (BCG) was more severe in IRF-1(-/-) mice than in wild-type mice. Thus, IRF-1 is essential for iNOS activation in murine macrophages.	NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,OSAKA 565,JAPAN; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ON,CANADA; NYU MED CTR,INST ENVIRONM MED,TUXEDO PK,NY 10987; NYU MED CTR,KAPLAN CANC CTR,TUXEDO PK,NY; ENTREMED INC,ROCKVILLE,MD 20850	New York University; New York University; Osaka University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; New York University; New York University			Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289; le, junming/0000-0003-4726-521X; Kimura, Tohru/0000-0001-9227-0996; Green, Shawn J./0000-0003-4361-5454	NATIONAL CANCER INSTITUTE [R35CA049731, P30CA013343] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13343, R35CA49731] Funding Source: Medline; PHS HHS [A128993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BLANDEN RV, 1969, J EXP MED, V129, P1079, DOI 10.1084/jem.129.5.1079; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIART MA, 1986, J EXP MED, V164, P2113; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DENG WL, 1993, J IMMUNOL, V151, P322; DING AH, 1988, J IMMUNOL, V141, P2407; DUNGWORTH DL, 1985, PATHOLOGY DOMESTIC A, V2, P413; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GREEN SJ, 1993, INFECT IMMUN, V61, P689, DOI 10.1128/IAI.61.2.689-698.1993; GREEN SJ, 1993, CURR OPIN INFECT DIS, V6, P384; GREEN SJ, 1990, J IMMUNOL, V144, P278; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAMIJO R, UNPUB; KAMLJO R, 1993, P NATL ACAD SCI USA, V90, P6626; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KRUPIAH G, 1993, SCIENCE, V261, P1445; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PELLETIER M, 1982, J IMMUNOL, V129, P2179; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	45	774	794	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1612	1615		10.1126/science.7510419	http://dx.doi.org/10.1126/science.7510419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	7510419				2022-12-01	WOS:A1994NB67300032
J	CRYNS, VL; THOR, A; XU, HJ; HU, SX; WIERMAN, ME; VICKERY, AL; BENEDICT, WF; ARNOLD, A				CRYNS, VL; THOR, A; XU, HJ; HU, SX; WIERMAN, ME; VICKERY, AL; BENEDICT, WF; ARNOLD, A			LOSS OF THE RETINOBLASTOMA TUMOR-SUPPRESSOR GENE IN PARATHYROID CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUSCEPTIBILITY GENE; CELL-CYCLE; EXPRESSION; PROTEIN; CANCER; POLYMORPHISMS; PROGRESSION; DIAGNOSIS; FEATURES; SEQUENCE	Background. The origin and molecular pathogenesis of parathyroid carcinoma are unknown. This life-threatening cause of primary hyperparathyroidism cannot be reliably distinguished from its benign counterpart on the basis of histopathological features alone. Because the PRAD1, or cyclin D1, gene, a cell-cycle regulator, has been implicated in a subgroup of benign parathyroid tumors, we examined the possibility that another cell-cycle regulator with possible functional links to PRAD1, the retinoblastoma tumor-suppressor gene (RB), might be involved in the molecular pathogenesis of parathyroid carcinoma. Methods. Parathyroid carcinomas from 9 patients and adenomas from 21 were studied for evidence of tumor-specific loss of RB gene DNA (allelic loss) by analysis of four DNA polymorphisms and for evidence of altered expression of RB protein by immunohistochemical staining. Results. All of 11 specimens from 5 patients with parathyroid carcinoma and informative DNA patterns and 1 of 19 specimens from 19 patients with parathyroid adenoma and informative DNA patterns lacked an RB allele. Fourteen of 16 specimens (88 percent) from the nine patients with carcinoma had abnormal expression of RB protein (a complete or predominant absence of nuclear staining for the protein). None of the 19 adenomas, including the tumor with loss of an RB allele, had unequivocally abnormal staining for RB protein. Conclusions. Inactivation of the RB gene is common in parathyroid carcinoma and is likely to be an important contributor to its molecular pathogenesis. The presence of such inactivation may help to distinguish benign from malignant parathyroid disease and may have useful diagnostic, prognostic, and therapeutic implications.	MASSACHUSETTS GEN HOSP, DEPT MED, ENDOCRINE ONCOL LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BAYLOR COLL MED, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA; VET AFFAIRS MED CTR, ENDOCRINOL SECT, DENVER, CO USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL CANCER INSTITUTE [F32CA009381, K08CA001752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028] Funding Source: NIH RePORTER; NCI NIH HHS [1F32 CA-0938101, 1K08 CA-01752-01A1] Funding Source: Medline; NIDDK NIH HHS [5T32 DK-0702817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON BJ, 1983, SURGERY, V94, P906; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; IWAMURA Y, 1992, JPN J CLIN ONCOL, V22, P6; KAY S, 1973, ARCH PATHOL, V96, P316; LEVIN KE, 1987, SURGERY, V101, P649; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MALLETTE LE, 1992, AM J CLIN PATHOL, V98, P305, DOI 10.1093/ajcp/98.3.305; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MCGEE TL, 1990, NUCLEIC ACIDS RES, V18, P207, DOI 10.1093/nar/18.1.207-a; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; ROTH SI, 1962, ARCH PATHOL, V73, P495; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SANDELIN K, 1992, WORLD J SURG, V16, P724, DOI 10.1007/BF02067369; SCHANTZ A, 1973, CANCER-AM CANCER SOC, V31, P600, DOI 10.1002/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO;2-0; SHANE E, 1982, ENDOCR REV, V3, P218, DOI 10.1210/edrv-3-2-218; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH JF, 1984, J CLIN PATHOL, V37, P1370, DOI 10.1136/jcp.37.12.1370; SNOVER DC, 1981, AM J CLIN PATHOL, V75, P345; WANG CA, 1985, AM J SURG, V149, P522, DOI 10.1016/S0002-9610(85)80050-7; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; WYNNE AG, 1992, MEDICINE, V71, P197, DOI 10.1097/00005792-199207000-00002; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; YANDELL DW, 1989, AM J HUM GENET, V45, P547	35	233	238	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					757	761		10.1056/NEJM199403173301105	http://dx.doi.org/10.1056/NEJM199403173301105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	7906387	Bronze			2022-12-01	WOS:A1994NA74200005
J	FOTSIS, T; ZHANG, YM; PEPPER, MS; ADLERCREUTZ, H; MONTESANO, R; NAWROTH, PP; SCHWEIGERER, L				FOTSIS, T; ZHANG, YM; PEPPER, MS; ADLERCREUTZ, H; MONTESANO, R; NAWROTH, PP; SCHWEIGERER, L			THE ENDOGENOUS ESTROGEN METABOLITE 2-METHOXYOESTRADIOL INHIBITS ANGIOGENESIS AND SUPPRESSES TUMOR-GROWTH	NATURE			English	Article							METASTASIS; CELLS	THE formation of new blood vessels (angiogenesis) is critical for the growth of tumours(1-3) and is; a dominant feature in various angiogenic diseases such as diabetic retinopathy, arthritis, haemangiomas and psoriasis(4). Recognition of the potential therapeutic benefits of controlling pathological angiogenesis has led to a search for angiogenesis inhibitors. Here we report that 2-methoxyoestradiol, an endogenous oestrogen metabolite of previously unknown function, is a potent inhibitor of endothelial cell proliferation and migration as well as angiogenesis in vitro. Moreover, when administered orally in mice, it strongly inhibits the neovascularization of solid tumours and suppresses their growth. Unlike the angiostatic steroids of corticoid structure(5), it does not require the co-administration of heparin or sulphated cyclodextrins for activity. Thus, 2-methoxyoestradiol is the first steroid to have high antiangiogenic activity by itself. Our results suggest that this compound may have therapeutic potential in cancer and other angiogenic diseases.	UNIV HEIDELBERG,DEPT MED & PATHOL,D-69120 HEIDELBERG,GERMANY; UNIV GENEVA,MED CTR,INST HISTOL & EMBRYOL,DEPT MORPHOL,CH-1121 GENEVA 4,SWITZERLAND; UNIV HELSINKI,MEILAHTI HOSP,DEPT CLIN CHEM,SF-00290 HELSINKI,FINLAND	Ruprecht Karls University Heidelberg; University of Geneva; University of Helsinki; Helsinki University Central Hospital	FOTSIS, T (corresponding author), UNIV HEIDELBERG,CHILDRENS UNIV HOSP,DEPT ONCOL & HAEMATOL,INF 150,D-69120 HEIDELBERG,GERMANY.		Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380				BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056; DAMATO RJ, IN PRESS P NATN ACAD; EZEKOWITZ A, 1991, BRIT J HAEMATOL, V79, P67, DOI 10.1111/j.1365-2141.1991.tb08123.x; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; KLAGSBRUN M, 1990, PEPTIDE GROWTH FACTO, V2, P549; MACLUSKY NJ, 1983, CATECHOL ESTROGENS, P151; MAHADEVAN V, 1991, EUR J CANCER, V27, P679, DOI 10.1016/0277-5379(91)90163-8; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; SCHWEIGERER L, 1992, EUR J CLIN INVEST, V22, P260, DOI 10.1111/j.1365-2362.1992.tb01460.x; SEEGERS JC, 1989, J STEROID BIOCHEM, V32, P797, DOI 10.1016/0022-4731(89)90455-X; TAKAMIYA Y, 1993, J NEUROSURG, V78, P470, DOI 10.3171/jns.1993.78.3.0470; WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807	15	659	742	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					237	239		10.1038/368237a0	http://dx.doi.org/10.1038/368237a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7511798				2022-12-01	WOS:A1994NA87000053
J	KOMBIAN, SB; MALENKA, RC				KOMBIAN, SB; MALENKA, RC			SIMULTANEOUS LTP OF NON-NMDA-RECEPTER-MEDIATED AND LTD OF NMDA-RECEPTER-MEDIATED RESPONSES IN THE NUCLEUS-ACCUMBENS	NATURE			English	Article							LONG-TERM DEPRESSION; MOLECULAR MECHANISMS; MEMBRANE-PROPERTIES; NEURONS INVITRO; AREA CA1; RAT; HIPPOCAMPUS; POTENTIALS; ASPARTATE; DOPAMINE	THE nucleus accumbens (NA), a ventral extension of the striatum, plays a role in several complex behaviour patterns(1) and also is a major site of action of drugs of abuse such as cocaine(1-3). Intrinsic NA cells are predominantly quiescent(4,5) and their activity depends on excitatory input from cortical and subcortical limbic afferents(6,7). Here we examine the mechanisms of synaptic plasticity at the synapse between prelimbic cortical afferents and cells in the core region of the NA(8-10). Manipulations that induce a Ca2+- dependent long-term potentiation (LTP) of non-NMDA (N-methyl-D-aspartate)-receptor-mediated responses also produce a simultaneous long-term depression (LTD) of NMDA-receptor-mediated responses. These results indicate that in a single cell the same change in postsynaptic Ca2+ concentration can have opposite effects on non-NMDA- and NMDA-receptor-mediated synaptic responses. This may be particularly important in the NA, where NMDA receptors are critical for mediating the behavioural actions of drugs of abuse(11-13).	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,LPPI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHANG HT, 1986, BRAIN RES, V366, P392, DOI 10.1016/0006-8993(86)91326-0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHRISTIE MJ, 1987, NEUROSCIENCE, V22, P425, DOI 10.1016/0306-4522(87)90345-9; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KELLEY AE, 1992, BRAIN RES BULL, V29, P247, DOI 10.1016/0361-9230(92)90034-U; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODONNELL P, 1993, SYNAPSE, V13, P135, DOI 10.1002/syn.890130206; PENNARTZ CMA, 1991, EXP BRAIN RES, V86, P190, DOI 10.1007/BF00231053; PENNARTZ CMA, 1993, EUR J NEUROSCI, V5, P107, DOI 10.1111/j.1460-9568.1993.tb00475.x; PENNARTZ CMA, 1992, NEUROSCI LETT, V136, P109, DOI 10.1016/0304-3940(92)90660-Y; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PHILLIPSON OT, 1985, NEUROSCIENCE, V16, P275, DOI 10.1016/0306-4522(85)90002-8; PULVIRENTI L, 1992, BRAIN RES, V594, P327, DOI 10.1016/0006-8993(92)91145-5; PULVIRENTI L, 1991, PHARMACOL BIOCHEM BE, V40, P841, DOI 10.1016/0091-3057(91)90095-J; SWERDLOW NR, 1987, BEHAV BRAIN SCI, V10, P197, DOI 10.1017/S0140525X00047488; UCHIMURA N, 1991, J PHARMACOL EXP THER, V258, P663; UCHIMURA N, 1989, J NEUROPHYSIOL, V61, P769, DOI 10.1152/jn.1989.61.4.769	30	171	174	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					242	246		10.1038/368242a0	http://dx.doi.org/10.1038/368242a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7908412				2022-12-01	WOS:A1994NA87000055
J	SUKHAREV, SI; BLOUNT, P; MARTINAC, B; BLATTNER, FR; KUNG, C				SUKHAREV, SI; BLOUNT, P; MARTINAC, B; BLATTNER, FR; KUNG, C			A LARGE-CONDUCTANCE MECHANOSENSITIVE CHANNEL IN E. COLI ENCODED BY MSCL ALONE	NATURE			English	Article							ESCHERICHIA-COLI; ION CHANNELS; TRANSPORT; GENE	ALL cellular organisms respond to vibration, touch, gravity or changes in osmolarity, although the molecules on which such mechanosensations depend are unknown. Candidates include certain channels that gate in response to membrane stretch(1,2). Patch-clamp experiments with Escherichia coli envelope have revealed a mechanosensitive channel with very large conductance (MscL) and one with a smaller conductance (MscS)(3-6) which may be important in osmoregulation. Here we have solubilized and fractionated the envelope, reconstituted the MscL activity in vitro, and traced it to a small protein, whose gene, mscL, we then cloned. Insertional disruption of mscL removes the channel activity, whereas reexpression of mscL borne on an expression plasmid restores it. MscL-channel activities were observed in material from a cell-free expression system with mscL as the only template. The mscL nucleotide sequence predicts a unique protein of only 136 amino acids, with a highly hydrophobic core and very different from porins or other known proteins.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Martinac, Boris/A-7178-2018	Martinac, Boris/0000-0001-8422-7082; Sukharev, Sergei/0000-0002-4807-9665				BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANIELS DL, 1987, NATURE, V325, P831, DOI 10.1038/325831a0; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; HAMANN A, 1987, J BACTERIOL, V169, P3138, DOI 10.1128/jb.169.7.3138-3145.1987; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; SACHS F, 1992, SENSORY TRANSDUCTION, P241; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0	13	568	590	3	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					265	268		10.1038/368265a0	http://dx.doi.org/10.1038/368265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7511799				2022-12-01	WOS:A1994NA87000062
J	ZAHN, R; SPITZFADEN, C; OTTIGER, M; WUTHRICH, K; PLUCKTHUN, A				ZAHN, R; SPITZFADEN, C; OTTIGER, M; WUTHRICH, K; PLUCKTHUN, A			DESTABILIZATION OF THE COMPLETE PROTEIN SECONDARY STRUCTURE ON BINDING TO THE CHAPERONE GROEL	NATURE			English	Article							MOLECULAR CHAPERONE; BETA-LACTAMASE; CYCLOPHILIN; RECONSTITUTION; COOPERATIVITY; AGGREGATION; POLYPEPTIDE; INVITRO; ATP; NMR	PROTEIN folding in vivo is mediated by helper proteins, the molecular chaperones(1-3), of which Hsp60 and its Escherichia coli variant GroEL are some of the best characterized. GroEL is an oligomeric protein with 14 subunits each of M(r) 60K(4-6), which possesses weak, co-operative ATPase activity(7-9) and high plasticity(10). GroEL seems to interact with non-native proteins, binding one or two molecules per 14-mer(11-19) in a 'central cavity'(20), but little is known about the conformational state of the bound polypeptides. Here we use nuclear magnetic resonance techniques to show that the interaction of the small protein cyclophilin(21,22) with GroEL is reversible by temperature changes, and all amide protons in GroEL-bound cyclophilin are exchanged with the solvent, although this exchange does not occur in free cyclophilin. The complete secondary structure of cyclophilin must be disrupted when bound to GroEL.	MAX PLANCK INST BIOCHEM,PROT ENGN GRP,D-82152 MARTINSRIED,GERMANY; ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich			Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; ELLIS RJ, 1991, A REV BIOCH, V60, P621; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPITZFADEN C, 1992, 15 INT C MAGN RES BI, P192; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	32	146	148	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					261	265		10.1038/368261a0	http://dx.doi.org/10.1038/368261a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7908413				2022-12-01	WOS:A1994NA87000061
J	BANNER, AS				BANNER, AS			THEOPHYLLINE - SHOULD WE DISCARD AN OLD FRIEND	LANCET			English	Editorial Material							AMINOPHYLLINE				BANNER, AS (corresponding author), HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138, USA.							[Anonymous], 1990, BMJ, V301, P797; HUANG D, 1993, ANN INTERN MED, V119, P1155, DOI 10.7326/0003-4819-119-12-199312150-00001; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; MILGROM H, 1993, AM REV RESPIR DIS, V147, pS33, DOI 10.1164/ajrccm/147.6_Pt_2.S33; NEWHOUSE MT, 1990, CHEST, V98, P1, DOI 10.1378/chest.98.1.1; SHANNON M, 1993, ANN INTERN MED, V119, P1161, DOI 10.7326/0003-4819-119-12-199312150-00002; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241; 1991, 913042 US DEP HLTH H	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					618	618		10.1016/S0140-6736(94)92632-8	http://dx.doi.org/10.1016/S0140-6736(94)92632-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906808				2022-12-01	WOS:A1994NA09300005
J	BRANCH, DW; MITCHELL, MD; MILLER, E; PALINSKI, W; WITZTUM, JL				BRANCH, DW; MITCHELL, MD; MILLER, E; PALINSKI, W; WITZTUM, JL			PREECLAMPSIA AND SERUM ANTIBODIES TO OXIDIZED LOW-DENSITY-LIPOPROTEIN	LANCET			English	Note							PREGNANCY; PREECLAMPSIA	Oxidised low-density lipoprotein (Ox-LDL) has been associated with arterial foam-cell formation, and autoantibodies to Ox-LDL are present in human serum. Lipid peroxidation is enhanced in pre-eclampsia. We assessed whether the titre of IgG autoantibody to an epitope of Ox-LDL, malondialdehyde-conjugated low-density lipoprotein (MDA-LDL), was increased in the sera of pre-eclamptic patients. 16 such patients had significantly higher mean titres of autoantibodies to MDA-LDL than healthy pregnant women (p = 0.028). In a multiple regression model, pre-eclamptic patients still had a significantly higher mean titre (p = 0.048). Enhanced lipid peroxidation may be involved in the foam-cell formation of decidua and in the pathogenesis of pre-eclampsia.	UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego	BRANCH, DW (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT OBSTET & GYNECOL, ROOM 2B200 MED CTR, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.		Mitchell, Murray/A-8639-2010; Palinski, Wulf/AAW-8032-2021	Mitchell, Murray/0000-0002-6167-7176; Palinski, Wulf/0000-0002-5113-0169	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		HUBEL CA, 1989, AM J OBSTET GYNECOL, V161, P1025, DOI 10.1016/0002-9378(89)90778-3; ISHIHARA M, 1978, CLIN CHIM ACTA, V84, P1; MASEKI M, 1981, CLIN CHIM ACTA, V115, P155; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; WANG YP, 1991, AM J OBSTET GYNECOL, V165, P1695, DOI 10.1016/0002-9378(91)90017-L; WICKINS D, 1988, ANN CLIN BIOCHEM, V18, P158; WITZTUM JL, 1993, BRIT HEART J, V69, pS12	9	133	136	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					645	646		10.1016/S0140-6736(94)92639-5	http://dx.doi.org/10.1016/S0140-6736(94)92639-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7509433	Green Submitted			2022-12-01	WOS:A1994NA09300012
J	CASPARI, R; FRIEDL, W; MANDL, M; MOSLEIN, G; KADMON, M; KNAPP, M; JACOBASCH, KH; ECKER, KW; KREISSLERHAAG, D; TIMMERMANS, G; PROPPING, P				CASPARI, R; FRIEDL, W; MANDL, M; MOSLEIN, G; KADMON, M; KNAPP, M; JACOBASCH, KH; ECKER, KW; KREISSLERHAAG, D; TIMMERMANS, G; PROPPING, P			FAMILIAL ADENOMATOUS POLYPOSIS - MUTATION AT CODON-1309 AND EARLY-ONSET OF COLON-CANCER	LANCET			English	Article							GERM-LINE MUTATIONS; APC GENE; CHROMOSOME-5Q21; IDENTIFICATION; FAP	The clinical course of familial adenomatous polyposis (FAP) varies considerably between patients. Prediction of the severity of the disease is important in the interest of effective cancer prevention. We examined whether age at diagnosis of FAP due to gastrointestinal symptoms and age at death due to colorectal cancer are related to the site of mutation in the responsible gene. 225 families with FAP were screened for mutations. The deletion of 5 base pairs at codon 1309 within exon 15 (known to be the most common mutation) was identified in 20 families; other mutations within exons 7-15 were found in 49 families. In patients with the 5 base-pair deletion at codon 1309, gastrointestinal symptoms and death from colorectal cancer occurred about 10 years earlier than in patients with other mutations. The 1309 mutation leads to development of colonic polyps at a younger age, thus giving rise to an earlier malignant tranformation. This relationship should be taken into account in strategies for preventing cancer in patients with FAP.	UNIV BONN,INST HUMAN GENET,D-53111 BONN,GERMANY; UNIV DUSSELDORF,SURG CLIN,DUSSELDORF,GERMANY; UNIV HEIDELBERG,SURG CLIN,HEIDELBERG,GERMANY; UNIV BONN,INST MED STAT,BONN,GERMANY; UNIV CLIN RUDOLF VIRCHOW,BERLIN,GERMANY; UNIV HOMBURG SAAR,SURG CLIN,HOMBURG,GERMANY	University of Bonn; Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg; University of Bonn			Ecker, Karl-Wilhelm/ABF-6313-2020	Ecker, Karl-Wilhelm/0000-0002-9672-2504				CASPARI R, 1993, Z GASTROENTEROL, V31, P646; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; FRIEDL W, 1993, HUM MOL GENET, V2, P1481, DOI 10.1093/hmg/2.9.1481; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRODEN J, 1993, AM J HUM GENET, V52, P262; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KIRK RE, 1968, EXPT DESIGN PROCEDUR, P299; MANDL M, 1994, HUM MOL GENET, V3, P181, DOI 10.1093/hmg/3.1.181; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; PRESCIUTTINI S, 1993, ANN HUM GENET, V57, P105, DOI 10.1111/j.1469-1809.1993.tb00892.x; REED TE, 1955, AM J HUM GENET, V7, P236; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; UTSONOMIYA J, 1980, CANCER, V45, P198; VARESCO L, 1993, AM J HUM GENET, V52, P280; VEALE AMO, 1965, EUGEN LAB, V40, P1	26	191	196	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					629	632		10.1016/S0140-6736(94)92634-4	http://dx.doi.org/10.1016/S0140-6736(94)92634-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906810				2022-12-01	WOS:A1994NA09300007
J	JAVITT, NB; BUDAI, K; MILLER, DG; CAHAN, AC; RAJU, U; LEVITZ, M				JAVITT, NB; BUDAI, K; MILLER, DG; CAHAN, AC; RAJU, U; LEVITZ, M			BREAST GUT CONNECTION - ORIGIN OF CHENODEOXYCHOLIC ACID IN BREAST CYST FLUID	LANCET			English	Article							BILE-ACIDS; CANCER; IDENTIFICATION; ETIOLOGY; SERUM	The notion that a breast-gut connection might modulate the microenvironment of breast tissue was supported by the finding that breast cyst fluid contains bile acids that are characteristically found in the intestines. To establish that the gut, rather than circulating steroid precursors, is the source of bile acids in breast cyst fluid, we gave two patients deuterium-labelled chenodeoxycholic acid (three 200 mg doses by mouth), starting 9 days before aspiration of breast cysts. The chenodeoxycholic acid concentration of seven samples of aspirated cyst fluid ranged from 42 to 94 mu mol/L. The corresponding plasma concentrations of chenodeoxycholic acid on the same day were 0.80 and 2.90 mu mol/L, of which the labelled compound comprised 13.0% (0.38 mu mol/L) and 28.2% (0.23 mu mol/L). The deuterated chenodeoxycholic acid concentrations in cyst fluid were 1.8 and 1.4 mu mol/L in two samples from patient 1 and 4.7 mu mol/L in patient 2; these values are equivalent to 11-17% of the plasma concentrations. This study shows that intestinal bile acids rapidly gain access to cyst fluid. Further studies should investigate the mechanisms that govern the exchange processes and the maintenance of the high cyst fluid to plasma concentration gradients, and the biological half-lives of individual constituents.	NYU MED CTR, DEPT OBSTET & GYNECOL, NEW YORK, NY 10016 USA; STRANG CANC PREVENT CTR, NEW YORK, NY USA	New York University	JAVITT, NB (corresponding author), NYU MED CTR, DIV HEPAT DIS, NEW YORK, NY 10016 USA.			Javitt, Norman B/0000-0001-9265-3508	NATIONAL CANCER INSTITUTE [R01CA002071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032995] Funding Source: NIH RePORTER; NCI NIH HHS [CA02071] Funding Source: Medline; NIDDK NIH HHS [DK32995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI SS, 1970, CAN J BIOCHEM CELL B, V48, P1054, DOI 10.1139/o70-166; AXELSON M, 1988, J LIPID RES, V29, P629; BAKER PR, 1992, BRIT J CANCER, V65, P566, DOI 10.1038/bjc.1992.115; BAKER PR, 1988, BIOCHEM SOC T, V16, P741, DOI 10.1042/bst0160741; CHEAH PY, 1990, CANCER LETT, V49, P207, DOI 10.1016/0304-3835(90)90160-Y; DANIELSSON H, 1963, J BIOL CHEM, V238, P2299; GORBACH SL, 1984, REV INFECT DIS, V6, pS85; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; JAVITT NB, 1989, BIOMED ENVIRON MASS, V18, P624, DOI 10.1002/bms.1200180820; MAHMOODA SK, 1982, CANCER RES, V42, P2792; MODAN B, 1977, CANCER-AM CANCER SOC, V40, P1887, DOI 10.1002/1097-0142(197710)40:4+<1887::AID-CNCR2820400819>3.0.CO;2-E; PETRAKIS NL, 1981, LANCET, V2, P1203; RAJU U, 1990, J CLIN ENDOCR METAB, V70, P1030, DOI 10.1210/jcem-70-4-1030; RANG EH, 1983, LANCET, V1, P1014	14	36	37	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					633	635		10.1016/S0140-6736(94)92635-2	http://dx.doi.org/10.1016/S0140-6736(94)92635-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906811	hybrid			2022-12-01	WOS:A1994NA09300008
J	MELBYE, M; COTE, TR; KESSLER, L; GAIL, M; BIGGAR, RJ; LEMP, G; WEST, D; SINGLETON, J; YOUNG, J; KERNDT, P; DEAPEN, D; GINZBERG, M; ANTONCULVER, H; LIEB, S; HOPKINS, R; WILLIAMS, B; LIFF, J; MORGAN, D; PARKIN, W				MELBYE, M; COTE, TR; KESSLER, L; GAIL, M; BIGGAR, RJ; LEMP, G; WEST, D; SINGLETON, J; YOUNG, J; KERNDT, P; DEAPEN, D; GINZBERG, M; ANTONCULVER, H; LIEB, S; HOPKINS, R; WILLIAMS, B; LIFF, J; MORGAN, D; PARKIN, W			HIGH-INCIDENCE OF ANAL CANCER AMONG AIDS PATIENTS	LANCET			English	Article							IV HIV DISEASE; INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; HUMAN IMMUNODEFICIENCY; HOMOSEXUAL MEN; MARITAL-STATUS; CARCINOMA; ASSOCIATION; PARALLEL	Until now, the only cancers that have been strongly associated with AIDS are Kaposi's sarcoma and non-Hodgkin lymphoma. We used a linkage between AIDS (50 050 reports) and cancer (859 398 reports) registries in seven health departments in the USA to investigate the association between HIV infection and epidermoid anal cancer. We compared the numbers of observed cases and expected cases, calculated from general population rates with adjustment for age, sex, and race. The relative risk of anal cancer at and after AIDS diagnosis was 84.1 (95% CI 46.4-152) among homosexual patients (11 cases) and 37.7 (9.4-151) among non-homosexual patients (2 cases). The relative risk of anal cancer up to 5 years before the AIDS diagnosis (23 cases) was also increased; it was 13.9 (6.6-29.2) in the period 2-5 years before AIDS and 27.4 (15.9-47.2) during the 2 years before AIDS diagnosis (p for trend = 0.004). Among homosexual men, the relative risk of anal cancer was inversely related to age at AIDS onset (p for trend < 0.001). Excess risks were found in all geographical areas. This study establishes a strikingly increased risk of anal cancer among people with AIDS, These data are consistent with a previously hypothesised association between HIV-induced immunodeficiency and anal cancer development, but because homosexual men were at increased risk of anal cancer even before the AIDS epidemic, we cannot say how much of the increased risk is attributable to HIV infection. Nevertheless, clinicians should be aware that AIDS patients have an increased risk of anal cancer.	NCI,DIV CANC ETIOL,VIRAL EPIDEMIOL BRANCH,ROCKVILLE,MD 20852; STATE SERUM INST,DANISH EPIDEMIOL SCI CTR,COPENHAGEN,DENMARK; NCI,DIV CANC PREVENT & CONTROL,APPL RES BRANCH,ROCKVILLE,MD 20852; NCI,DIV CANC ETIOL,BIOSTAT BRANCH,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Aarhus University; Statens Serum Institut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				melbye, mads/0000-0001-8264-6785				ADAM YG, 1987, SURGERY, V101, P253; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BLOHME I, 1985, TRANSPLANTATION, V39, P23; Breslow NE., 1987, STATISTICAL METHODS, P48; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; COTE T, 1993, 9TH INT C AIDS BERL; COTE TR, 1993, J NATL CANCER I, V85, P1113; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FRAZER IH, 1986, LANCET, V2, P657; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; KIVIAT N, 1990, J INFECT DIS, V162, P358, DOI 10.1093/infdis/162.2.358; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MELBYE M, 1940, IN PRESS AM J EPIDEM; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PALEFSKY JM, 1992, J ACQ IMMUN DEF SYND, V5, P1258; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; PETERS RK, 1983, BRIT J CANCER, V48, P629, DOI 10.1038/bjc.1983.244; RABKIN CS, 1991, CANCER SURV, V10, P151; RABKIN CS, 1992, AM J EPIDEMIOL, V136, P54, DOI 10.1093/oxfordjournals.aje.a116420; RIES LG, 1983, JNCI-J NATL CANCER I, V70, P693; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1992, LANCET, V340, P1271, DOI 10.1016/0140-6736(92)92961-E; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; 1992, MMWR, V41, P1; 1980, INT CLASSIFICATION D	29	208	210	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					636	639		10.1016/S0140-6736(94)92636-0	http://dx.doi.org/10.1016/S0140-6736(94)92636-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906812				2022-12-01	WOS:A1994NA09300009
J	TAYLOR, CJ				TAYLOR, CJ			COLONIC STRICTURES IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material											TAYLOR, CJ (corresponding author), UNIV SHEFFIELD,DEPT PAEDIAT,SHEFFIELD,ENGLAND.							BAXTER PS, 1988, ARCH DIS CHILD, V63, P1496, DOI 10.1136/adc.63.12.1496; HEIJERMAN HG, 1991, ANN INTERN MED, V114, P200, DOI 10.7326/0003-4819-114-3-200; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; 1994, LANCET, V343, P109; 1994, LANCET, V343, P599	5	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					615	616		10.1016/S0140-6736(94)92629-8	http://dx.doi.org/10.1016/S0140-6736(94)92629-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906805				2022-12-01	WOS:A1994NA09300002
J	VANEIJCK, CHJ; KRENNING, EP; BOOTSMA, A; OEI, HY; VANPEL, R; LINDEMANS, J; JEEKEL, J; REUBI, JC; LAMBERTS, SWJ				VANEIJCK, CHJ; KRENNING, EP; BOOTSMA, A; OEI, HY; VANPEL, R; LINDEMANS, J; JEEKEL, J; REUBI, JC; LAMBERTS, SWJ			SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN PRIMARY BREAST-CANCER	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR; ENDOCRINE TUMORS; LOCALIZATION; CARCINOMAS; INHIBITION; HORMONE; INVIVO; ANALOG; SANDOSTATIN; TISSUE	Somatostatin-receptor (SS-R) scintigraphy successfully shows primary cancers and distant metastases in most patients with carcinoids, islet cells tumours, and paragangliomas. Previous in-vitro studies indicated that somatostatin receptors are present in human breast cancers. We report positive scintigraphy with [In-111-DTPA-D-Phe(1)]-octreotide in 39 of 52 primary breast cancers (75%). Parallel in-vitro autoradiography with [I-125-Tyr(3)]-octreotide of 30 of these showed a corresponding somatostatin-receptor status in 28. Significantly more invasive ductal cancers could be shown than invasive lobular carcinomas (85% vs 56%; p < 0.05). Also the number of T-1 cancers which were shown was higher than T-1 (86% vs 61%; p < 0.05). Imaging of the axillae showed non-palpable cancer-containing lymphnodes in 4 of 13 patients with subsequently histologically-proven metastases. In the follow-up after a mean of 2.5 yr, SS-R scintigraphy in 28 of the 37 patients with an originally SS-R-positive cancer, was positive in the 2 patients with clinically-recognised metastases, as well as in 6 of the remaining 26 patients who were symptom-free. Raised carcinoembryonic antigent (CEA) and CA 15-3 values were observed in only 2 and 1, respectively, of these patients. Most primary breast cancers can be shown by SS-R scintigraphy, especially invasive ductal cancers. This technique may be of value in selecting patients for clinical trials with somatostatin analogues or other medical treatments. Furthermore, SS-R scintigraphy is more sensitive than measurements of the usual serum cancer markers for detecting recurrences of SS-R-positive breast cancer.	ERASMUS UNIV ROTTERDAM,DEPT MED,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT NUCL MED,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT CLIN CHEM,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT PATHOL,ROTTERDAM,NETHERLANDS; UNIV BERN,INST PATHOL,BERN,SWITZERLAND	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; University of Bern	VANEIJCK, CHJ (corresponding author), UNIV HOSP DIJKZIGT,DEPT SURG,40 DR MOLEWATERPLEIN,3015 GD ROTTERDAM,NETHERLANDS.		Krenning, Eric P/L-1064-2013; van Eijck, casper/K-5983-2019; Van Eijck, Casper/ABD-1655-2020					BAKKER WH, 1991, LIFE SCI, V49, P1583, DOI 10.1016/0024-3205(91)90052-D; BUSSOLATI G, 1985, AM J PATHOL, V120, P186; COLOMER R, 1989, CANCER, V64, P1674, DOI 10.1002/1097-0142(19891015)64:8<1674::AID-CNCR2820640820>3.0.CO;2-V; FEKETE M, 1989, J CLIN LAB ANAL, V3, P137, DOI 10.1002/jcla.1860030302; FOEKENS JA, 1989, CANCER RES, V49, P7002; HAYNES DF, 1986, J CLIN ONCOL, V4, P1542; KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765; KRENNING EP, 1989, LANCET, V1, P242; LAMBERTS SWJ, 1990, J CLIN ENDOCR METAB, V71, P566, DOI 10.1210/jcem-71-3-566; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LAMBERTS SWJ, 1990, METABOLISM, V39, P152, DOI 10.1016/0026-0495(90)90235-5; NELSON J, 1989, BRIT J CANCER, V59, P739, DOI 10.1038/bjc.1989.154; PAPOTTI M, 1989, INT J CANCER, V43, P365, DOI 10.1002/ijc.2910430302; REUBI JC, 1987, CANCER RES, V47, P5758; REUBI JC, 1987, J CLIN ENDOCR METAB, V65, P1127, DOI 10.1210/jcem-65-6-1127; REUBI JC, 1989, CANCER, V64, P1254, DOI 10.1002/1097-0142(19890915)64:6<1254::AID-CNCR2820640615>3.0.CO;2-D; REUBI JC, 1987, CANCER RES, V47, P551; REUBI JC, 1986, NEUROSCIENCE, V18, P329, DOI 10.1016/0306-4522(86)90158-2; REUBI JC, 1990, METABOLISM, V39, P78, DOI 10.1016/0026-0495(90)90217-Z; REUBI JC, 1992, INT J CANCER, V47, P416; SCAMBIA G, 1988, J CANCER RES CLIN, V114, P306, DOI 10.1007/BF00405839; SETYONOHAN B, 1987, CANCER RES, V47, P1566; SZENDE B, 1989, BREAST CANCER RES TR, V14, P307, DOI 10.1007/BF01806302; VANBONMARTENS MJH, 1992, NED TIJDSCHR GENEES, V134, P287; WEBER C, 1989, SURGERY, V106, P416	25	126	128	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					640	643		10.1016/S0140-6736(94)92637-9	http://dx.doi.org/10.1016/S0140-6736(94)92637-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906813	Green Submitted			2022-12-01	WOS:A1994NA09300010
J	WILKINSON, D				WILKINSON, D			HIGH-COMPLIANCE TUBERCULOSIS TREATMENT PROGRAM IN A RURAL-COMMUNITY	LANCET			English	Note								The global tuberculosis epidemic is being fuelled by dual infection with human immunodeficiency virus type I, Short-course chemotherapy is effective but usually fails for operational reasons. A community-based treatment programme of twice-weekly fully-supervised treatment is described in which 89% of surviving patients completed treatment under programme conditions. Half the patients were successfully supervised by non-health workers. New approaches are needed to combat the global tuberculosis epidemic.	HLABLSA HOSP,HLABLSA 3937,SOUTH AFRICA				Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846	PHS HHS [1-D43-T200231-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chaulet P, 1987, Tubercle, V68, P19, DOI 10.1016/0041-3879(87)90016-X; CHOWDHURY AMR, 1992, LANCET, V339, P1181, DOI 10.1016/0140-6736(92)90788-5; CUNEO WD, 1989, CLIN CHEST MED, V10, P375; ELLIOTT AM, 1992, TROP DOCT, V22, P147, DOI 10.1177/004947559202200402; FOX W, 1981, BRIT J DIS CHEST, V75, P331, DOI 10.1016/0007-0971(81)90022-X; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LEOWSKI J, 1988, M WORKING GROUP SHOR; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; RODRIGUES LC, 1990, T ROY SOC TROP MED H, V84, P739, DOI 10.1016/0035-9203(90)90172-B; SUTHERLAND I, 1988, BRIT MED BULL, V44, P665, DOI 10.1093/oxfordjournals.bmb.a072275; 1992, TUBERCULOSIS TREATME	12	135	136	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					647	648		10.1016/S0140-6736(94)92640-9	http://dx.doi.org/10.1016/S0140-6736(94)92640-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906815				2022-12-01	WOS:A1994NA09300013
J	CARPOUSIS, AJ; VANHOUWE, G; EHRETSMANN, C; KRISCH, HM				CARPOUSIS, AJ; VANHOUWE, G; EHRETSMANN, C; KRISCH, HM			COPURIFICATION OF ESCHERICHIA-COLI RNASE-E AND PNPASE - EVIDENCE FOR A SPECIFIC ASSOCIATION BETWEEN 2 ENZYMES IMPORTANT IN RNA PROCESSING AND DEGRADATION	CELL			English	Article							BACTERIOPHAGE-T4 MESSENGER-RNA; SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; POLYNUCLEOTIDE PHOSPHORYLASE; NUCLEOTIDE-SEQUENCE; RIBONUCLEASE-E; RIBOSOMAL-RNA; AMS GENE; PROTEIN; DECAY	Ribonuclease E (RNAase E) was isolated in a complex that also contained polynucleotide phosphorylase (PNPase). Besides copurification, evidence for an association of these enzymes comes from sedimentation and immunoprecipitation experiments. Highly purified RNAase E correctly processed E. coli 5S ribosomal RNA, bacteriophage T4 gene 32 mRNA and E. coli ompA mRNA at sites known to depend on the rne gene for cleavage in vivo. The difference between previous smaller estimates of the size of RNAase E and that reported here apparently is due to the sensitivity of the enzyme to proteolysis during purification. The discovery of a specific association between RNAase E and PNPase raises the intriguing possibility that these enzymes act cooperatively in the processing and degradation of RNA.	CNRS,MICROBIOL & GENET MOLEC LAB,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	CARPOUSIS, AJ (corresponding author), UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND.		Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CHAUHAN AK, 1991, NUCLEIC ACIDS RES, V19, P125, DOI 10.1093/nar/19.1.125; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; LOAYZA D, 1991, MOL MICROBIOL, V5, P715, DOI 10.1111/j.1365-2958.1991.tb00742.x; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)80206-A; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MICZAK A, 1991, MOL MICROBIOL, V5, P1801, DOI 10.1111/j.1365-2958.1991.tb01929.x; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MISRA TK, 1980, J BACTERIOL, V142, P359, DOI 10.1128/JB.142.1.359-361.1980; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PEDERSEN C, 1992, MOL MICROBIOL, V6, P277; PORTIER C, 1975, EUR J BIOCHEM, V55, P573, DOI 10.1111/j.1432-1033.1975.tb02194.x; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROY MK, 1983, EUR J BIOCHEM, V131, P119, DOI 10.1111/j.1432-1033.1983.tb07238.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277	32	381	382	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					889	900		10.1016/0092-8674(94)90363-8	http://dx.doi.org/10.1016/0092-8674(94)90363-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7510217				2022-12-01	WOS:A1994NA89000014
J	JENISON, RD; GILL, SC; PARDI, A; POLISKY, B				JENISON, RD; GILL, SC; PARDI, A; POLISKY, B			HIGH-RESOLUTION MOLECULAR DISCRIMINATION BY RNA	SCIENCE			English	Article							STRANDED-DNA MOLECULES; THEOPHYLLINE; SELECTION; INVITRO; RECOGNITION; IMMUNOASSAY; POLYMERASE; LIGANDS; BIND	Species of RNA that bind with high affinity and specificity to the bronchodilator theophylline were identified by selection from an oligonucleotide library. One RNA molecule binds to theophylline with a dissociation constant K-d of 0.1 mu M. This binding affinity is 10,000-fold greater than the RNA molecule's affinity for caffeine, which differs from theophylline only by a methyl group at nitrogen atom N-7. Analysis by nuclear magnetic resonance indicates that this RNA molecule undergoes a significant change in its conformation or dynamics upon theophylline binding. Binding studies of compounds chemically related to theophylline have revealed structural features required for the observed binding specificity. These results demonstrate the ability of RNA molecules to exhibit an extremely high degree of ligand recognition and discrimination.	NEXAGEN INC,BOULDER,CO 80301; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033098] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03283] Funding Source: Medline; NIAID NIH HHS [AI33098, AI01051] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONI G, 1983, ANAL BIOCHEM, V129, P60, DOI 10.1016/0003-2697(83)90052-0; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BROUSSARD LA, 1981, CLIN CHEM, V27, P1931; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; JOLLEY ME, 1981, CLIN CHEM, V27, P1575; PLATEAU P, 1982, J AM CHEM SOC, V104, P731; PONCELET SM, 1990, J IMMUNOASSAY, V11, P77, DOI 10.1080/01971529008053259; REINECKE T, 1986, ANN EMERG MED, V15, P147, DOI 10.1016/S0196-0644(86)80009-9; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P; SKIENAR V, 1990, NATURE, V345, P836; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, IN PRESS GENE; VANDEVEN FJM, 1988, EUR J BIOCHEM, V178, P1; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875	23	857	930	5	206	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1425	1429		10.1126/science.7510417	http://dx.doi.org/10.1126/science.7510417			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	7510417				2022-12-01	WOS:A1994MZ92700028
J	YU, HT; CHEN, JK; FENG, SB; DALGARNO, DC; BRAUER, AW; SCHREIBER, SL				YU, HT; CHEN, JK; FENG, SB; DALGARNO, DC; BRAUER, AW; SCHREIBER, SL			STRUCTURAL BASIS FOR THE BINDING OF PROLINE-RICH PEPTIDES TO SH3 DOMAINS	CELL			English	Article							RECEPTOR TYROSINE KINASES; NMR-SPECTROSCOPY; GENE-PRODUCT; AMINO-ACID; PROTEIN; SRC; MAGNETIZATION; EXPRESSION; SPECTRA; CLONING	A common RXL motif was found in proline rich ligands that were selected from a biased combinatorial peptide library on the basis of their ability to bind specifically to the SH3 domains from phosphatidylinositol 3-kinase (PI3K) or c-Src. The solution structure of the PI3K SH3 domain complexed to one of these ligands, RKLPPRPSK (RLP1), was determined. Structure-based mutations were introduced into the PI3K SH3 domain and the RLP1 ligand, and the influence of these mutations on binding was evaluated. We conclude that SH3 domains recognize proline-rich motifs possessing the left-handed type II polyproline (PPII) helix conformation. Two proline residues directly contact the receptor. Other prolines in the ligands appear to function as a molecular scaffold, promoting the formation of the PPII helix. Three nonproline residues consisting of combinations of arginine and leucine interact extensively with the SH3 domain and appear to confer ligand specificity.	ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology	YU, HT (corresponding author), HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA.		Chen, James/G-9972-2011	Chen, James/0000-0002-9220-8436; Yu, Hongtao/0000-0002-8861-049X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BRUNGER AT, 1988, XPLOR VERSION 20 MAN; BRUNGER AT, 1992, XPLOR VERSION 30 MAN; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENTLEY LC, 1993, J AM CHEM SOC, V115, P12591; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, FEBS LETT, V324, P93, DOI 10.1016/0014-5793(93)81539-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARTINEZ R, 1987, SCIENCE, V237, P441; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDEL DC, 1992, MOL CELL BIOL, V12, P1835; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	62	938	995	1	56	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 11	1994	76	5					933	945		10.1016/0092-8674(94)90367-0	http://dx.doi.org/10.1016/0092-8674(94)90367-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7510218				2022-12-01	WOS:A1994NA89000018
J	SCOLNIK, D; NULMAN, I; ROVET, J; GLADSTONE, D; CZUCHTA, D; GARDNER, HA; GLADSTONE, R; ASHBY, P; WEKSBERG, R; EINARSON, T; KOREN, G				SCOLNIK, D; NULMAN, I; ROVET, J; GLADSTONE, D; CZUCHTA, D; GARDNER, HA; GLADSTONE, R; ASHBY, P; WEKSBERG, R; EINARSON, T; KOREN, G			NEURODEVELOPMENT OF CHILDREN EXPOSED IN-UTERO TO PHENYTOIN AND CARBAMAZEPINE MONOTHERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY; WOMEN; DRUG	Objective.-To compare pregnancy outcome prospectively after phenytoin and carbamazepine monotherapy with outcome in matched mother-child pairs exposed to nonteratogens to evaluate the relative fetal safety of these drugs. Design.-A prospective, controlled, and blinded observational study. Patients.-Thirty-six mother-child pairs exposed to carbamazepine monotherapy and 34 pairs exposed to phenytoin monotherapy, all prospectively studied, were compared with mother-child pairs exposed to nonteratogens. The controls were matched for maternal age, time of consultation, obstetric history, and socioeconomic status. Main Outcome Measure.-The primary end point of interest was the children's global IQ measured by either the Bayley or the McCarthy scale according to their ages. Setting.-A teratology consultation program and two neurology services in Toronto, Ontario. Results.- Children exposed to phenytoin in utero had a mean (+/-SD) global IQ 10 points lower (95% confidence interval, 4.9 to 15.8 points) than their matched controls (113.4+/-13.1 and 103.1+/-25.1; P=.038). The Reynell language development scores followed a similar trend, with children exposed to phenytoin scoring significantly lower than their controls. Phenytoin-exposed children had a global IQ of 84 or less significantly more often than the control group (P<.01). Children exposed in utero to carbamazepine did not differ from their controls on any of the neurobehavioral tests. Conclusions.-Our study suggests a clinically important negative effect of phenytoin on neurobehavioral development, independent of maternal or environmental factors, causing a substantial number of children to achieve a lower score than expected on cognitive tests. No similar effects could be shown after gestational use of carbamazepine.	HOSP SICK CHILDREN,DIV CLIN PHARMACOL,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DIV CLIN PHARMACOL TOXICOL,MOTHERISK PROGRAM,TORONTO,ON,CANADA; HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT PSYCHOL,TORONTO,ON,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ON,CANADA; GEN HOSP,GENET SERV,OSHAWA,ON,CANADA; GEN HOSP,DEPT NEUROL,N YORK,ON,CANADA; TORONTO HOSP,DEPT NEUROL,WESTERN DIV,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PHARM,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Ottawa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875; Gladstone, David/0000-0003-0612-5544				Bayley N, 1969, BAYLEY SCALES INFANT; BERTOLLINI R, 1987, EUR J EPIDEMIOL, V3, P164; ESCUETA AVD, 1992, NEUROLOGY S5, V42, P149; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; GAILY E, 1990, DEV MED CHILD NEUROL, V32, P403; GLADSTONE DJ, 1992, REPROD TOXICOL, V6, P257, DOI 10.1016/0890-6238(92)90181-R; HANSON JW, 1975, J PEDIATR-US, V87, P285, DOI 10.1016/S0022-3476(75)80604-4; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; KANEKO S, 1991, REPROD TOXICOL, V5, P179, DOI 10.1016/0890-6238(91)90050-P; McCarthy D., 1972, MCCARTHY SCALES CHIL; Reynell J., 1977, REYNELL DEV LANGUAGE; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; ROZA FW, 1991, NEW ENGL J MED, V324, P674; SAUNDERS M, 1989, BRIT MED J, V299, P581, DOI 10.1136/bmj.299.6699.581; SCHARDEIN JL, 1985, CHEM INDUCED BIRTH D, P142; STRICKLER SM, 1985, LANCET, V2, P746; VINING EPG, 1987, EPILEPSIA, V28, pS18, DOI 10.1111/j.1528-1157.1987.tb05767.x; VORHEES CV, 1986, NEUROTOXICOLOGY, V7, P235; Wechsler D, 1981, ADULT INTELLIGENCE S	20	190	193	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					767	770		10.1001/jama.271.10.767	http://dx.doi.org/10.1001/jama.271.10.767			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	7509419				2022-12-01	WOS:A1994MY28800031
J	BARNETT, DB				BARNETT, DB			BETA-BLOCKERS IN HEART-FAILURE - A THERAPEUTIC PARADOX	LANCET			English	Editorial Material							IDIOPATHIC DILATED CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CARDIAC-FUNCTION; DOUBLE-BLIND; BLOCKADE; BUCINDOLOL; METOPROLOL				BARNETT, DB (corresponding author), UNIV LEICESTER, DEPT MED & THERAPEUT, LEICESTER, LEICS, ENGLAND.							COHN JN, 1984, NEW ENGL J MED, V31, P28; CURRIE PJ, 1984, J AM COLL CARDIOL, V3, P203, DOI 10.1016/S0735-1097(84)80449-0; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GILBERT EM, 1990, AM J MED, V88, P223, DOI 10.1016/0002-9343(90)90146-5; IKRAM H, 1981, LANCET, V2, P490; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; NEMANICH JW, 1990, AM J CARDIOL, V66, P843, DOI 10.1016/0002-9149(90)90362-5; POLLOCK SG, 1990, AM J CARDIOL, V66, P603, DOI 10.1016/0002-9149(90)90488-M; SWEDBERG K, 1980, BRIT HEART J, V44, P134; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426	14	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 5	1994	343	8897					557	558		10.1016/S0140-6736(94)91518-0	http://dx.doi.org/10.1016/S0140-6736(94)91518-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906326				2022-12-01	WOS:A1994MY84300006
J	BEADLE, C; LONG, GW; WEISS, WR; MCELROY, PD; MARET, SM; OLOO, AJ; HOFFMAN, SL				BEADLE, C; LONG, GW; WEISS, WR; MCELROY, PD; MARET, SM; OLOO, AJ; HOFFMAN, SL			DIAGNOSIS OF MALARIA BY DETECTION OF PLASMODIUM-FALCIPARUM HRP-2 ANTIGEN WITH A RAPID DIPSTICK ANTIGEN-CAPTURE ASSAY	LANCET			English	Article							HISTIDINE-RICH PROTEINS; RADIOIMMUNOASSAY	Two field studies in Kenya and an experimental challenge study in the USA were done to assess the accuracy of a dipstick antigen-capture assay based on qualitative detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP-2) in peripheral blood for diagnosis of P fafciparum infection. In these studies, the assay was 96.5-100% sensitive for detection of greater than 60 P falciparum asexual parasites/ mu L blood, 70-81% sensitive for 11-60 parasites/mu L blood, and 11-67% sensitive for 10 parasites or less/mu L blood. Specificity was 95% (95% CI 85-105%; n = 20) among naive American volunteers, 98% (96-101%; n=112) among volunteers exposed to the bite of P falciparium-infected mosquitoes, and 88% (84-92%; n=285) among Kenyans living in an area with holoendemic malaria. Our results also indicated that PfHRP-2 antigen was not detectable in blood 6 days after initiation of curative chemotherapy, and suggest that such circulating antigens rarely lead to false-positive tests. The dipstick assay's sensitivity, specificity, simplicity, and speed may make it an important tool in the battle against malaria.	USN,MED RES INST,MALARIA PROGRAM,ROCKVILLE,MD 20852; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD; USN,NAVAL MED RES INSST DETACHMENT,KISUMU,KENYA; USA,ARMY MED RES UNIT,KISUMU,KENYA; BECTON DICKINSON CO,DIV ADV DIAGNOST,BALTIMORE,MD; KENYA GOVT MED RES CTR,VECTOR BIOL & CONTROL CLIN RES CTR,KISUMU,KENYA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Johns Hopkins University; Becton Dickinson; Kenya Medical Research Institute			Oloo, James Aggrey/CAF-3948-2022	Oloo, James Aggrey/0000-0001-7495-1827				AVIDOR B, 1985, J IMMUNOL METHODS, V82, P121, DOI 10.1016/0022-1759(85)90231-5; AVRAHAM H, 1983, AM J TROP MED HYG, V32, P11, DOI 10.4269/ajtmh.1983.32.11; BEIER JC, IN PRESS AM J TROP M; Fleiss JL, 1981, STAT METHODS RATES P, P218; HULLEY SB, 1988, DESIGNING CLIN RES E, P145; NAMSIRIPONGPUN V, 1993, T ROY SOC TROP MED H, V87, P32, DOI 10.1016/0035-9203(93)90410-R; Oaks SC, 1991, MALARIA OBSTACLES OP; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; ROCK EP, 1987, PARASITOLOGY, V95, P209, DOI 10.1017/S0031182000057681; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P13; TAYLOR DW, 1993, T ROY SOC TROP MED H, V87, P29, DOI 10.1016/0035-9203(93)90409-J; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065	12	236	249	4	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					564	568		10.1016/S0140-6736(94)91520-2	http://dx.doi.org/10.1016/S0140-6736(94)91520-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906328	Green Submitted, hybrid			2022-12-01	WOS:A1994MY84300008
J	BOOTH, IW				BOOTH, IW			COSTING MALNUTRITION - ADD OR MULTIPLY	LANCET			English	Editorial Material							CHILDREN; RISK				BOOTH, IW (corresponding author), UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BRIEND A, 1987, LANCET, V2, P725; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836, DOI 10.1093/ajcn/33.8.1836; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; PELLETIER DL, 1993, AM J PUBLIC HEALTH, V83, P1130, DOI 10.2105/AJPH.83.8.1130; VANDENBROECK J, 1993, LANCET, V341, P1491, DOI 10.1016/0140-6736(93)90632-Q; Waterlow JC, 1992, PROTEIN ENERGY MALNU	6	1	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					554	555		10.1016/S0140-6736(94)91514-8	http://dx.doi.org/10.1016/S0140-6736(94)91514-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906322				2022-12-01	WOS:A1994MY84300002
J	BUTLER, C				BUTLER, C			OVERPOPULATION, OVERCONSUMPTION, AND ECONOMICS	LANCET			English	Editorial Material							HEALTH						Butler, Colin D./H-2267-2019	Butler, Colin D./0000-0002-2942-5294				[Anonymous], 1973, SMALL IS BEAUTIFUL; BARBIER E, 1986, LIVING EC NEW EC MAK, P7; BUTLER CD, 1991, MED J AUSTRALIA, V155, P351, DOI 10.5694/j.1326-5377.1991.tb142316.x; Dalai Lama XIV, 1990, D LAMA POLICY KINDNE; EHRLICH PR, 1991, HEALING PLANET, P42; FELLOWS L, 1992, LANCET, V340, P1330; GORE A, 1992, EARTH BALANCE; HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; Henderson H., 1981, POLITICS SOLAR AGE; KELLY J, 1993, LANCET, V342, P808; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; LAST JM, 1993, LANCET, V342, P508, DOI 10.1016/0140-6736(93)91641-X; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; LOVELOCK J, 1988, AGES GAIA, P181; OMRAN AR, 1993, LANCET, V342, P808, DOI 10.1016/0140-6736(93)91574-6; ONEILL P, 1993, BRIT MED J, V307, P1162; PEETERS MA, 1993, LANCET, V342, P808; REDDY AKN, 1990, SCI AM, V263, P64; TROUNSON A, 1994, LANCET, V343, P59, DOI 10.1016/S0140-6736(94)90916-4; TYLLESKAR T, 1992, LANCET, V339, P208, DOI 10.1016/0140-6736(92)90006-O; VERKUYL DAA, 1993, LANCET, V342, P473, DOI 10.1016/0140-6736(93)91597-F; 1993, 1993 WORLD BANK WORL; 1993, LANCET, V342, P1125; 1993, LANCET, V342, P447	25	11	11	1	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					582	584		10.1016/S0140-6736(94)91526-1	http://dx.doi.org/10.1016/S0140-6736(94)91526-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MY843	7906334				2022-12-01	WOS:A1994MY84300014
J	CORMAN, ML				CORMAN, ML			UNDERSTANDING SURVEILLANCE COLONOSCOPY	LANCET			English	Editorial Material							ULCERATIVE-COLITIS; DYSPLASIA; CANCER; PROGRAM				CORMAN, ML (corresponding author), SANSUM MED CLIN,SANTA BARBARA,CA 93105, USA.							BERNSTEIN CN, 1994, LANCET, V343, P71; CHOI PM, 1993, GASTROENTEROLOGY, V105, P418, DOI 10.1016/0016-5085(93)90715-O; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; KIRSNER JB, 1982, NEW ENGL J MED, V306, P775, DOI 10.1056/NEJM198204013061304; LASHNER BA, 1992, AM J GASTROENTEROL, V87, P168; LEIDENIUS M, 1991, GUT, V32, P1521, DOI 10.1136/gut.32.12.1521; LENNARDJONES JE, 1986, GUT, V27, P1403, DOI 10.1136/gut.27.12.1403; LORBERG R, 1990, GASTROENTEROLOGY, V99, P1021; MORSON BC, 1967, GUT, V8, P423, DOI 10.1136/gut.8.5.423; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; NUGENT FW, 1979, GASTROENTEROLOGY, V76, P1; NUGENT FW, 1984, GASTROENTEROLOGY, V86, P1197; RUBIO CA, 1984, DIS COLON RECTUM, V27, P283, DOI 10.1007/BF02555626	13	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					556	557		10.1016/S0140-6736(94)91517-2	http://dx.doi.org/10.1016/S0140-6736(94)91517-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906325				2022-12-01	WOS:A1994MY84300005
J	KNOX, KK; CARRIGAN, DR				KNOX, KK; CARRIGAN, DR			DISSEMINATED ACTIVE HHV-6 INFECTIONS IN PATIENTS WITH AIDS	LANCET			English	Note							HUMAN HERPESVIRUS-6	Human herpesvirus 6 (HHV-6) infected cells were detected in all lung, lymph-node, spleen, liver, and kidney tissues obtained at necropsy from an unselected series of nine patients with AIDS. This infection rate was significantly higher than that for cytomegalovirus. Lung infection with HHV-6 was extensive enough in one patient to account for fatal pneumonitis. In other tissues increased numbers of HHV-6 infected cells were related to the presence of lymphocytic infiltrates or residual lymphoid tissue, with lymphocytes being predominantly infected. Thus HHV-6 is an important pathogen in patients with AIDS.			KNOX, KK (corresponding author), MED COLL WISCONSIN,DEPT PATHOL,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.							CARRIGAN DR, 1990, J INFECT DIS, V162, P844, DOI 10.1093/infdis/162.4.844; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P665; GALLO RC, 1988, J ACQ IMMUN DEF SYND, V1, P521; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PELLETT PE, 1992, ADV VIRUS RES, V41, P1, DOI 10.1016/S0065-3527(08)60034-2	10	115	120	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					577	578		10.1016/S0140-6736(94)91524-5	http://dx.doi.org/10.1016/S0140-6736(94)91524-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906332				2022-12-01	WOS:A1994MY84300012
J	BODMER, H; VIVILLE, S; BENOIST, C; MATHIS, D				BODMER, H; VIVILLE, S; BENOIST, C; MATHIS, D			DIVERSITY OF ENDOGENOUS EPITOPES BOUND TO MHC CLASS-II MOLECULES LIMITED BY INVARIANT CHAIN	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; T-CELL DETERMINANTS; HLA-DR MOLECULES; ANTIGEN PRESENTATION; PEPTIDE BINDING; SURFACE EXPRESSION; INFLUENZA-VIRUS; COMPLEX; PH; DISTINCT	The invariant chain (li) binds nascent major histocompatibility complex (MHC) class II molecules, blocking peptide binding until the complex dissociates in the endosomes. This may serve to differentiate the MHC class I and II antigen presentation pathways and enable class II molecules to efficiently bind peptides in the endosomes. This hypothesis was addressed by probing spleen cells from a combination of knock-out and transgenic mice with a large panel of T cell hybridomas. The li molecule blocked the presentation of a range of endogenously synthesized epitopes, but some epitopes actually required li. Thus, the influence of li on presentation does not follow simple rules. In addition, mice expressing li were not tolerant to epitopes unmasked in its absence, a finding with possible implications for autoimmunity.	INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES,F-67000 STRASBOURG,FRANCE; INST CHIM BIOL,INSERM,UNITE BIOL MOLEC 184,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Viville, Stephane/0000-0002-5088-3003				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1992, J IMMUNOL, V149, P1; BODMER H, UNPUB; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROOKS AG, 1993, J IMMUNOL, V150, P3690; CALINLAURENS V, 1992, INT IMMUNOL, V4, P1113, DOI 10.1093/intimm/4.10.1113; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; EISENLOHR LC, 1989, J EXP MED, V169, P921, DOI 10.1084/jem.169.3.921; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; HUMBERT M, 1993, EUR J IMMUNOL, V23, P3167, DOI 10.1002/eji.1830231219; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KONO DH, 1988, J EXP MED, V168, P213, DOI 10.1084/jem.168.1.213; KOUSKOFF V, IN PRESS METHODS IMM; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; LOSS GE, 1993, J EXP MED, V178, P73, DOI 10.1084/jem.178.1.73; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MOMBURG F, 1988, CLIN EXP IMMUNOL, V72, P367; MOMBURG F, 1986, J IMMUNOL, V136, P940; MOORE MJ, 1993, CELL BIOCH C S, V17, P70; MORENO J, 1991, J IMMUNOL, V147, P3306; MOURITSEN S, 1992, J IMMUNOL, V148, P1438; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAKAI K, 1988, P NATL ACAD SCI USA, V85, P8608, DOI 10.1073/pnas.85.22.8608; SETTE A, 1992, J IMMUNOL, V148, P844; TAKAHASHI N, 1985, CELL, V42, P139, DOI 10.1016/S0092-8674(85)80109-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VIDAL K, 1993, J IMMUNOL, V151, P4642; VIDARD L, 1992, J IMMUNOL, V149, P498; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; YAO XR, 1988, LEUKEMIA RES, V12, P787, DOI 10.1016/0145-2126(88)90030-6	41	112	112	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1284	1286		10.1126/science.7510069	http://dx.doi.org/10.1126/science.7510069			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	7510069				2022-12-01	WOS:A1994MY57000038
J	JAGOX, A; CARR, DB; PAYNE, R				JAGOX, A; CARR, DB; PAYNE, R			NEW CLINICAL-PRACTICE GUIDELINES FOR THE MANAGEMENT OF PAIN IN PATIENTS WITH CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MASSACHUSETTS GEN HOSP,CTR PAIN,DEPT ANESTHESIA,BOSTON,MA 02114; JOHNS HOPKINS UNIV,SCH NURSING,BALTIMORE,MD 21205; MD ANDERSON CANC CTR,HOUSTON,TX 77030	Harvard University; Massachusetts General Hospital; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center								ARCANGELI G, 1989, RADIOTHER ONCOL, V14, P95, DOI 10.1016/0167-8140(89)90053-4; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; FERRANTE FM, 1990, PATIENT CONTROLLED A; Field, 1990, CLIN PRACTICE GUIDEL, DOI DOI 10.17226/1626; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; Jacox A, 1994, CLIN PRACTICE GUIDEL; JACOX AK, 1994, AHCPR940594 AG HLTH; JACOX AK, 1994, AHCPR940593 PUBL; JACOX AK, 1994, AHCPR940596 AG HLTH; JACOX AK, 1994, AHCPR940595 AG HLTH; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; PATT RB, 1993, CANCER PAIN; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1986, CANCER PAIN RELIEF; 1994, CANCER FACTS FIGURES, P2	17	207	214	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					651	655		10.1056/NEJM199403033300926	http://dx.doi.org/10.1056/NEJM199403033300926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	7508094	Bronze			2022-12-01	WOS:A1994MY57300037
J	MENNERICK, S; ZORUMSKI, CF				MENNERICK, S; ZORUMSKI, CF			GLIAL CONTRIBUTIONS TO EXCITATORY NEUROTRANSMISSION IN CULTURED HIPPOCAMPAL CELLS	NATURE			English	Article							ELECTROGENIC GLUTAMATE UPTAKE; METHYL-D-ASPARTATE; TIME COURSE; RECEPTORS; NEURONS; ACTIVATION; MEMBRANE; CURRENTS; CHANNEL; PATCHES	ALTHOUGH many glial cells possess neurotransmitter receptors and transporters(1-5), little is known about glial participation in neurotransmission. To explore this issue, we recorded neuronal autaptic(6,7) and glial responses from cultured hippocampal single-neuron micro-islands(6,7). Excitatory synaptic events activate rapid electrogenic glial glutamate transporter currents similar to those elicited by exogenous glutamate in other preparations. We show here that glial transporter responses may be used to sense changes in presynaptic efficacy and that glial uptake helps to remove synaptically released glutamate, thereby contributing to the termination of excitatory synaptic currents under certain conditions. These observations provide a framework for understanding the role of glia in both normal and pathological processes.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,PROGRAM NEUROSCI,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	MENNERICK, S (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.		Mennerick, Steven/O-2806-2017	Mennerick, Steven/0000-0003-0868-0664				BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARRES BA, 1991, J NEUROSCI, V11, P3685; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; ECCLES JC, 1958, PROC R SOC SER B-BIO, V148, P38, DOI 10.1098/rspb.1958.0003; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; KARWOSKI CJ, 1989, SCIENCE, V244, P578, DOI 10.1126/science.2785716; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P496, DOI 10.1098/rspb.1965.0017; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LUCERO MT, 1990, J GEN PHYSIOL, V95, P523, DOI 10.1085/jgp.95.3.523; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; STEPHENS GJ, 1993, RECEPTOR CHANNEL, V1, P39; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; YAMADA KA, 1993, J NEUROSCI, V13, P3904; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	30	295	296	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					59	62		10.1038/368059a0	http://dx.doi.org/10.1038/368059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7906399				2022-12-01	WOS:A1994MY56900052
J	PRAGNELL, M; DEWAARD, M; MORI, Y; TANABE, T; SNUTCH, TP; CAMPBELL, KP				PRAGNELL, M; DEWAARD, M; MORI, Y; TANABE, T; SNUTCH, TP; CAMPBELL, KP			CALCIUM-CHANNEL BETA-SUBUNIT BINDS TO A CONSERVED MOTIF IN THE I-II CYTOPLASMIC LINKER OF THE ALPHA(1)-SUBUNIT	NATURE			English	Article							FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; MOLECULAR-CLONING; ALPHA-1 SUBUNIT; ALPHA-1-SUBUNIT; ALPHA-2-SUBUNIT	THE beta-subunit is an integral component of purified voltage-sensitive Ca2+ channels(1-3). Modulation of Ca2+ channel activity by the beta-subunit, which includes significant increases in transmembrane current and/or changes in kinetics, is observed on coexpression of six alpha(1)-subunit genes with four beta-subunit genes in all alpha(1)-beta combinations tested(4-12). Recent reports suggest that this regulation is not due to targeting of the alpha(1)-subunit to the plasma membrane but is probably a result of a conformational change induced by the beta-subunit(11,13). Here we report that the beta-subunit binds to the cytoplasmic linker between repeats I and II of the dihydropyridine-sensitive alpha(1)-subunits from skeletal (alpha(1S)) and cardiac muscles (alpha(1C-a)), and also with the more distantly related neuronal alpha(1A) and omega-conotoxin GVIA-sensitive alpha 1B-subunits. Sequence analysis of the beta-subunit binding site identifies a conserved motif (QQ-E--L-GY--WI---E) positioned 24 amino acids from the IS6 transmembrane domain in each alpha(1)-subunit. Mutations within this motif reduce the stimulation of peak currents by the beta-subunit and alter inactivation kinetics and voltage-dependence of activation. Conservation of the beta-subunit binding motif in these functonally distinct calcium channels suggests a critical role for the I-II cytoplasmic linker of the alpha(1)-subunit in channel modulation by the beta-subunit.	UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; KYOTO UNIV,DEPT MED CHEM,KYOTO 606,JAPAN; YALE UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06536; UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT NEUROSCI,VANCOUVER V6T 1Z3,BC,CANADA	University of Iowa; Kyoto University; Howard Hughes Medical Institute; Yale University; University of British Columbia; University of British Columbia; University of British Columbia	PRAGNELL, M (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,400 EMRB,IOWA CITY,IA 52242, USA.		Tuluc, Petronel/C-2527-2011; Snutch, Terrance P/L-3464-2019; De Waard, Michel/G-7406-2014	Snutch, Terrance P/0000-0001-5182-1296; De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754	23	532	551	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					67	70		10.1038/368067a0	http://dx.doi.org/10.1038/368067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7509046				2022-12-01	WOS:A1994MY56900055
J	WILSON, R; AINSCOUGH, R; ANDERSON, K; BAYNES, C; BERKS, M; BURTON, J; CONNELL, M; BONFIELD, J; COPSEY, T; COOPER, J; COULSON, A; CRAXTON, M; DEAR, S; DU, Z; DURBIN, R; FAVELLO, A; FRASER, A; FULTON, L; GARDNER, A; GREEN, P; HAWKINS, T; HILLIER, L; JIER, M; JOHNSTON, L; JONES, M; KERSHAW, J; KIRSTEN, J; LAISSTER, N; LATREILLE, P; LLOYD, C; MORTIMORE, B; OCALLAGHAN, M; PARSONS, J; PERCY, C; RIFKEN, L; ROOPRA, A; SAUNDERS, D; SHOWNKEEN, R; SIMS, M; SMALDON, N; SMITH, A; SMITH, M; SONNHAMMER, E; STADEN, R; SULSTON, J; THIERRYMIEG, J; THOMAS, K; VAUDIN, M; VAUGHAN, K; WATERSTON, R; WATSON, A; WEINSTOCK, L; WILKINSONSPROAT, J; WOHLDMAN, P				WILSON, R; AINSCOUGH, R; ANDERSON, K; BAYNES, C; BERKS, M; BURTON, J; CONNELL, M; BONFIELD, J; COPSEY, T; COOPER, J; COULSON, A; CRAXTON, M; DEAR, S; DU, Z; DURBIN, R; FAVELLO, A; FRASER, A; FULTON, L; GARDNER, A; GREEN, P; HAWKINS, T; HILLIER, L; JIER, M; JOHNSTON, L; JONES, M; KERSHAW, J; KIRSTEN, J; LAISSTER, N; LATREILLE, P; LLOYD, C; MORTIMORE, B; OCALLAGHAN, M; PARSONS, J; PERCY, C; RIFKEN, L; ROOPRA, A; SAUNDERS, D; SHOWNKEEN, R; SIMS, M; SMALDON, N; SMITH, A; SMITH, M; SONNHAMMER, E; STADEN, R; SULSTON, J; THIERRYMIEG, J; THOMAS, K; VAUDIN, M; VAUGHAN, K; WATERSTON, R; WATSON, A; WEINSTOCK, L; WILKINSONSPROAT, J; WOHLDMAN, P			2.2 MB OF CONTIGUOUS NUCLEOTIDE-SEQUENCE FROM CHROMOSOME-III OF C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EDITING PROGRAM; DNA; GENOME; GENES; ENCODES; SIMILARITY; PROTEIN; LIN-12; RNA	As part of our effort to sequence the 100-megabase (Mb) genome of the nematode Caenorhabditis elegans, we have completed the nucleotide sequence of a contiguous 2,181,032 base pairs in the central gene cluster of chromosome III. Analysis of the finished sequence has indicated an average density of about one gene per five kilobases; comparison with the public sequence databases reveals similarities to previously known genes for about one gene in three. In addition, the genomic sequence contains several intriguing features, including putative gene duplications and a variety of other repeats with potential evolutionary implications.	WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO 63110; MRC,MOLEC BIOL LAB,CAMBRIDGE CB10 1RQ,CAMBS,ENGLAND; SANGER CTR,CAMBRIDGE CB10 1RQ,CAMBS,ENGLAND; CNRS,CTR RECH BIOCHIM MACROMOLEC & PHYS MATH,F-34033 MONTPELLIER,FRANCE	Washington University (WUSTL); MRC Laboratory Molecular Biology; Wellcome Trust Sanger Institute; Centre National de la Recherche Scientifique (CNRS)	WILSON, R (corresponding author), WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110, USA.		Durbin, Richard/AAE-7178-2019; Smith, Andy/A-7512-2011; THIERRY-MIEG, Jean/F-1975-2017; Wilson, Richard K./AAF-4139-2019; Cooper, John/D-4448-2014	Durbin, Richard/0000-0002-9130-1006; Smith, Andy/0000-0001-8580-278X; THIERRY-MIEG, Jean/0000-0002-0396-6789; Wilson, Richard K./0000-0002-1992-1358; Cooper, John/0000-0002-0933-4571; Sonnhammer, Erik/0000-0002-9015-5588; Bonfield, James/0000-0002-6447-4112				Alschul S F, 1990, J Mol Biol, V215, P403; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COLLINS J, 1989, GENETICS, V121, P47; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; Dear S, 1992, DNA Seq, V3, P107, DOI 10.3109/10425179209034003; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GLEESON T, 1991, NUCLEIC ACIDS RES, V19, P6481, DOI 10.1093/nar/19.23.6481; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HALLORAN N, 1992, METHOD MOL BIOL, V10, P297; HAWKINS TL, 1992, ELECTROPHORESIS, V13, P552, DOI 10.1002/elps.11501301113; HILLENBRAND C, 1991, J ROY ASIATIC SOC, V1, P124, DOI 10.1017/S1356186300000201; KOOP BF, 1993, BIOTECHNIQUES, V14, P442; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; NAITO M, 1992, NUCLEIC ACIDS RES, V20, P2967, DOI 10.1093/nar/20.12.2967; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; SCHRIEFER LA, 1990, NUCLEIC ACIDS RES, V18, P7455, DOI 10.1093/nar/18.24.7455; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON J, 1992, NATURE, V357, P106; SULSTON JE, 1974, GENETICS, V77, P95; UBER DC, 1991, BIOTECHNIQUES, V11, P642; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WATERSTON RH, 1978, NATURE, V275, P715, DOI 10.1038/275715a0; WATERSTON RH, 1990, GENBANK LOCUS CESUP5; WATSON A, 1993, NATURE, V362, P569, DOI 10.1038/362569a0; WESTON K, 1989, NUCLEIC ACIDS RES, V17, P2138, DOI 10.1093/nar/17.5.2138; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; YUAN JY, 1991, P NATL ACAD SCI USA, V88, P3334, DOI 10.1073/pnas.88.8.3334	49	1297	1685	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					32	38		10.1038/368032a0	http://dx.doi.org/10.1038/368032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7906398				2022-12-01	WOS:A1994MY56900044
J	ASTROW, AB				ASTROW, AB			RETHINKING CANCER	LANCET			English	Editorial Material											ASTROW, AB (corresponding author), ST VINCENTS HOSP & MED CTR,DEPT MED,NEW YORK,NY 10011, USA.							BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; CHABNER BA, 1986, J CLIN ONCOL, V4, P625; DEVITA VT, 1993, PRINCIPLES CHEMOTHER, P289; LEDER P, 1993, 35TH ANN M; SCHIPPER H, 1993, CAN J ONCOL, V3, P207; SCHIPPER H, 1993, CAN J ONCOL, V3, P220; SCHNIPPER LE, 1986, NEW ENGL J MED, V314, P1423; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; 1993, NIH OBSERVER, V4, P1	9	20	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					494	495		10.1016/S0140-6736(94)91454-0	http://dx.doi.org/10.1016/S0140-6736(94)91454-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906753				2022-12-01	WOS:A1994MX88800002
J	CACCIATORE, B; STENMAN, UH; YLOSTALO, P				CACCIATORE, B; STENMAN, UH; YLOSTALO, P			EARLY SCREENING FOR ECTOPIC PREGNANCY IN HIGH-RISK SYMPTOM-FREE WOMEN	LANCET			English	Note								We screened 225 symptom-free pregnantwomen at increased risk for ectopic pregnancy with transvaginal sonography and human chorionic gonadotropin (hCG) assays. Among 55 (24.4%), who proved to have an ectopic pregnancy, 46 (84%) cases were diagnosed at the initial screening at a median of 37 days of gestation, and the rest at repeated scans. The false-positive rate was 1.2%. Early diagnosis prevented tubal rupture, substantial haemorrhage, and the need for emergency care, allowing elective treatment. Such early surveillance reduced the risk of complications and facilitated treatment, and should be offered to at-risk women.	HELSINKI UNIV,CENT HOSP,DEPT OBSTET & GYNAECOL 2,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital	CACCIATORE, B (corresponding author), HELSINKI UNIV,CENT HOSP,DEPT OBSTET & GYNAECOL 1,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							CACCIATORE B, 1990, BRIT J OBSTET GYNAEC, V97, P904, DOI 10.1111/j.1471-0528.1990.tb02445.x; CARSON SA, 1993, NEW ENGL J MED, V329, P1174; GRUDZINSKAS JG, 1993, BRIT J OBSTET GYNAEC, V100, P510, DOI 10.1111/j.1471-0528.1993.tb15298.x; LOWER AM, 1992, HUM REPROD, V7, P711, DOI 10.1093/oxfordjournals.humrep.a137723; SHEPHERD RW, 1990, OBSTET GYNECOL, V75, P417; Stabile I, 1990, Obstet Gynecol Surv, V45, P335, DOI 10.1097/00006254-199006000-00001; YLOSTALO P, 1992, OBSTET GYNECOL, V80, P345	7	62	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					517	518		10.1016/S0140-6736(94)91464-8	http://dx.doi.org/10.1016/S0140-6736(94)91464-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906763				2022-12-01	WOS:A1994MX88800012
J	GERLACH, H; ROSSAINT, R; PAPPERT, D; KNORR, M; FALKE, KJ				GERLACH, H; ROSSAINT, R; PAPPERT, D; KNORR, M; FALKE, KJ			AUTOINHALATION OF NITRIC-OXIDE AFTER ENDOGENOUS SYNTHESIS IN NASOPHARYNX	LANCET			English	Note								Exogenous nitric oxide (NO) reduces pulmonary vascular resistance after low-dose inhalation in patients. To estimate endogenous NO synthesis in the upper respiratory tract, we measured inhaled and exhaled NO in volunteers and patients during spontaneous or controlled ventilation, respectively. 20.3 nmol per min NO was synthesised in the nasopharnyx of non-smoking volunteers, leading to autoinhalation of 0.07-0.13 NO parts per million during inspiration; smokers had reduced NO synthesis. In volunteers, 50-70% of the NO was resorbed by the lungs; ventilated patients were deprived of NO autoinhalation. Bacteria in the nose may take part in endogenous NO synthesis.			GERLACH, H (corresponding author), FREE UNIV BERLIN,CLIN RUDOLF VIRCHOW,ANAESTHESIOL & INTENS CARE MED CLIN,D-13353 BERLIN,GERMANY.		Knorr, Michael/Q-3109-2019					CANNONS AC, 1993, J BIOL CHEM, V268, P3268; GERLACH H, 1993, INTENS CARE MED, V19, P443, DOI 10.1007/BF01711084; GERLACH H, 1993, EUR J CLIN INVEST, V23, P499, DOI 10.1111/j.1365-2362.1993.tb00797.x; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SUTTORP N, 1993, J EXP MED, V178, P337, DOI 10.1084/jem.178.1.337	7	221	225	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					518	519		10.1016/S0140-6736(94)91465-6	http://dx.doi.org/10.1016/S0140-6736(94)91465-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906764				2022-12-01	WOS:A1994MX88800013
J	HIRAOKA, M; KASUGA, K; HORI, C; SUDO, M				HIRAOKA, M; KASUGA, K; HORI, C; SUDO, M			ULTRASONIC INDICATORS OF URETERAL REFLUX IN THE NEWBORN	LANCET			English	Note							URINARY-TRACT; CHILDREN	There is controversy over the value of ultrasonic screening for detection of vesicoureteric reflux (VUR) in babies. We scanned 300 newborn babies and identified 53 with a dilated renal pelvis or other minor abnormalities. Eventually, 9 of these were investigated by voiding cystourethrography and 3 (5 kidneys) proved to have VUR exceeding grade II, In 3 babies the reason for cystourethrography was persistent renal pelvis dilation; in 3 it was urinary tract infection; and in 3 it was a new ultrasonic sign observed early in the series-ballooning of the renal pelvis during voiding. Whereas persistent dilation of the renal pelvis was a non-specific indicator (absent in 2 of the 5 affected kidneys and present in 5 of those unaffected), ballooning was consistently seen in all 5 affected renal pelvises. This sign, easily obtained in a baby who has been sleeping, deserves prospective assessment for its value in screening.	KASUGA LADLES CLIN,HARUE,FUKUI 91904,JAPAN		HIRAOKA, M (corresponding author), FUKUI MED SCH,DEPT PEDIAT,MATSUOKA,FUKUI 91011,JAPAN.							GORDON AC, 1990, BRIT J UROL, V65, P407, DOI 10.1111/j.1464-410X.1990.tb14766.x; HINCHLIFFE SA, 1992, PEDIATR NEPHROL, V6, P439, DOI 10.1007/BF00874007; SCOTT JES, 1991, LANCET, V338, P1571, DOI 10.1016/0140-6736(91)92385-F; STEELE BT, 1989, J PEDIATR-US, V115, P95, DOI 10.1016/S0022-3476(89)80337-3; STEINHART JM, 1988, PEDIATRICS, V82, P609; TSAI TC, 1989, J CLIN ULTRASOUND, V17, P647, DOI 10.1002/jcu.1870170906; VERBER IG, 1989, ARCH DIS CHILD, V64, P1533, DOI 10.1136/adc.64.11.1533; 1991, LANCET, V338, P1050	8	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					519	520		10.1016/S0140-6736(94)91466-4	http://dx.doi.org/10.1016/S0140-6736(94)91466-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906765				2022-12-01	WOS:A1994MX88800014
J	JACKSON, R				JACKSON, R			WHICH HYPERTENSIVE PATIENTS SHOULD BE TREATED	LANCET			English	Editorial Material							CORONARY				JACKSON, R (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1993, BMJ, V307, P1541; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; MACMAHON S, IN PRESS J VASC MED; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; 1993, ARCH INTERN MED, V153, P154; 1988, ARCH INTERN MED, V148, P1023	9	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					496	497		10.1016/S0140-6736(94)91456-7	http://dx.doi.org/10.1016/S0140-6736(94)91456-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906755				2022-12-01	WOS:A1994MX88800004
J	SHORT, RV				SHORT, RV			DARWIN, HAVE I FAILED YOU	LANCET			English	Editorial Material											SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,CLAYTON,VIC 3168,AUSTRALIA.							DAWKIN R, 1986, BLIND WATCHMAKER; DIAMOND J, 1991, RISE FALL 3RD CHIMPA; 1992, CAMBRIDGE ENCYCLOPAE; 1991, MANS PLACE EVOLUTION	4	5	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					528	529		10.1016/S0140-6736(94)91469-9	http://dx.doi.org/10.1016/S0140-6736(94)91469-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906767				2022-12-01	WOS:A1994MX88800017
J	WHEELER, T; SOLLERO, C; ALDERMAN, S; LANDEN, J; ANTHONY, F; OSMOND, C				WHEELER, T; SOLLERO, C; ALDERMAN, S; LANDEN, J; ANTHONY, F; OSMOND, C			RELATION BETWEEN MATERNAL HEMOGLOBIN AND PLACENTAL HORMONE CONCENTRATIONS IN EARLY-PREGNANCY	LANCET			English	Article							HIGH-ALTITUDES; HYPOXIA; FETAL	Environmental factors that influence placental development are of particular interest because of the reported association between adult hypertension, low birthweight, and large placental size. Maternal anaemia is one environmental factor that is associated with an increase in placental size at birth. We have examined the relation between haematological status and plasma concentrations of chorionic gonadotropin (hCG) and placental lactogen (hPL) in 175 women at about 10 weeks of pregnancy. There were significant negative correlations between maternal haemoglobin concentration and the levels of hCG (p=0.03) and hPL (p=0.02). Although 21% of women had low iron stores (ferritin < 13 mu g/L), no relation was found between serum ferritin and the two placental hormones. There was no association between plasma volume (calculated from maternal weight and height) and hCG or hPL concentrations.	SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of Southampton	WHEELER, T (corresponding author), UNIV SOUTHAMPTON, PRINCESS ANNE HOSP, DEPT OBSTET & GYNAECOL, SOUTHAMPTON, HANTS, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BERNSTEIN L, 1989, BRIT J OBSTET GYNAEC, V96, P92, DOI 10.1111/j.1471-0528.1989.tb01582.x; CLAPP JF, 1988, AM J OBSTET GYNECOL, V159, P1456, DOI 10.1016/0002-9378(88)90574-1; FLETCHER J, 1969, CLIN SCI, V36, P209; FOX H, 1970, AM J OBSTET GYNECOL, V107, P1058, DOI 10.1016/0002-9378(70)90629-0; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; Gregory F., 1990, DIETARY NUTR SURVEY; HAY DL, 1988, BRIT J OBSTET GYNAEC, V95, P1268, DOI 10.1111/j.1471-0528.1988.tb06817.x; HOWE D, IN PRESS J PHYSL; HUSTIN J, 1992, 1ST 12 WEEKS GESTATI, P97; JACKSON MR, 1987, J ANAT, V152, P173; KRUGER H, 1970, AM J OBSTET GYNECOL, V106, P586; LUND CJ, 1967, AM J OBSTET GYNECOL, V98, P393, DOI 10.1016/0002-9378(67)90160-3; MAYHEW TM, 1990, PLACENTA, V11, P493, DOI 10.1016/S0143-4004(05)80195-X; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; RESHETNIKOVA OS, 1993, J PHYSIOL-LONDON, V459, pP308; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; RYBO G, 1973, CLIN HAEMATOL, P269; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WHITTAKER PG, 1993, BRIT J OBSTET GYNAEC, V100, P587, DOI 10.1111/j.1471-0528.1993.tb15315.x	21	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	1994	343	8896					511	513		10.1016/S0140-6736(94)91461-3	http://dx.doi.org/10.1016/S0140-6736(94)91461-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906760				2022-12-01	WOS:A1994MX88800009
J	WITTEMAN, JCM; GROBBEE, DE; VALKENBURG, HA; VANHEMERT, AM; STIJNEN, T; BURGER, H; HOFMAN, A				WITTEMAN, JCM; GROBBEE, DE; VALKENBURG, HA; VANHEMERT, AM; STIJNEN, T; BURGER, H; HOFMAN, A			J-SHAPED RELATION BETWEEN CHANGE IN DIASTOLIC BLOOD-PRESSURE AND PROGRESSION OF AORTIC ATHEROSCLEROSIS	LANCET			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CALCIFICATION; MORTALITY; RISK	The J-shaped relation between diastolic blood pressure and mortality from coronary heart disease continues to provoke controversy. We examined the association between diastolic blood pressure and progression of aortic atherosclerosis in a population-based cohort of 855 women, aged 45-64 years at baseline. The women were examined radiographically for calcified deposits in the abdominal aorta, which have been shown to reflect intimal atherosclerosis. After 9 years of follow-up, slight progression of atherosclerosis was noted in 19% of women and substantial progression in 16%. The age-adjusted relative risk of substantial atherosclerotic progression in women with a decrease in diastolic pressure of 10 mm Hg or more was 2.5 (95% CI 1.3-5.6), compared with the reference group of women who had a smaller decrease or no change. The excess risk in this group was confined to women whose increase in pulse pressure was above the median (3.9 [1.5-9.9] vs 1.1 [0.3-4.2] in women with an increase in pulse pressure below the median). The relative risks for women with rises in diastolic pressure of 1-9 mm Hg and 10 mm Hg or more were 2.2 (1.1-4.3) and 3.5 (1.6-8.0), respectively. These findings suggest that a decline in diastolic blood pressure indicates vessel wall stiffening associated with atherosclerotic progression. They support the hypothesis that in low-risk subjects progression of atherosclerosis may be accompanied by a decrease in diastolic blood pressure rather than the opposing idea that low diastolic blood pressure precipitates the occurrence of atherosclerotic events.	UNIV HOSP LEIDEN,DEPT PSYCHIAT,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	WITTEMAN, JCM (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BOTS ML, 1993, ATHEROSCLEROSIS, V102, P99, DOI 10.1016/0021-9150(93)90088-C; COOPE J, 1988, J HUM HYPERTENS, V2, P79; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; Dixon W. J., 1990, BMDP STATISTICAL SOF; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; Fineberg MH, 1927, AM J MED SCI, V173, P835; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; HYMAN JB, 1954, AM HEART J, V47, P540; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEGNIEN JL, 1992, CIRCULATION, V85, P1799, DOI 10.1161/01.CIR.85.5.1799; SLEIGHT P, 1988, LANCET, V1, P235; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; VANHEMERT AM, 1990, AM J EPIDEMIOL, V132, P123, DOI 10.1093/oxfordjournals.aje.a115624; VANMERODE T, 1988, ULTRASOUND MED BIOL, V14, P563, DOI 10.1016/0301-5629(88)90122-6; Wiggers CJ, 1932, ANN INTERN MED, V6, P12, DOI 10.7326/0003-4819-6-1-12; WITTEMAN JCM, 1986, LANCET, V2, P1120; WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002-9149(90)90505-U; WITTEMAN JCM, 1993, CIRCULATION, V88, P2156, DOI 10.1161/01.CIR.88.5.2156	20	217	222	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					504	507		10.1016/S0140-6736(94)91459-1	http://dx.doi.org/10.1016/S0140-6736(94)91459-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906758	Green Submitted			2022-12-01	WOS:A1994MX88800007
J	CRITCHFIELD, JM; RACKE, MK; ZUNIGAPFLUCKER, JC; CANNELLA, B; RAINE, CS; GOVERMAN, J; LENARDO, MJ				CRITCHFIELD, JM; RACKE, MK; ZUNIGAPFLUCKER, JC; CANNELLA, B; RAINE, CS; GOVERMAN, J; LENARDO, MJ			T-CELL DELETION IN HIGH ANTIGEN DOSE THERAPY OF AUTOIMMUNE ENCEPHALOMYELITIS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; LYMPHOCYTES-T; CLONAL ANERGY; INVITRO; INTERLEUKIN-2; TOLERANCE; SUPPRESSION; ACTIVATION; RECEPTOR	Encounters with antigen can stimulate T cells to become activated and proliferate, become nonresponsive to antigen, or to die. T cell death was shown to be a physiological response to interleukin-2-stimulated cell cycling and T cell receptor reengagement at high antigen doses. This feedback regulatory mechanism attenuates the immune response by deleting a portion of newly dividing, antigen-reactive T cells. This mechanism deleted autoreactive T cells and abrogated the clinical and pathological signs of autoimmune encephalomyelitis in mice after repetitive administration of myelin basic protein.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,DIV NEUROPATHOL,BRONX,NY 10461; UNIV WASHINGTON,SCH MED,DEPT MOLEC BIOTECHNOL,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Yeshiva University; Albert Einstein College of Medicine; University of Washington; University of Washington Seattle			Zuniga-Pflucker, Juan C/H-1295-2012	Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178; Goverman, Joan/0000-0002-7361-9424				ALVORD EC, 1965, ANN NY ACAD SCI, V122, P333; BELL RB, 1993, J IMMUNOL, V150, P4085; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BOEHME SA, 1993, LEUKEMIA, V7, P545; BOEHME SA, 1903, EUR J IMMUNOL, V23, P152; BYERS VS, 1967, J EXP MED, V125, P307; CEREDIG R, 1986, EUR J IMMUNOL, V16, P30, DOI 10.1002/eji.1830160107; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; Cohen I R, 1993, Int Rev Immunol, V9, P243, DOI 10.3109/08830189309051209; COTRAN RS, 1988, J IMMUNOL, V140, P1883; CRITCHFIELD JM, UNPUB; EINSTEIN ER, 1968, IMMUNOCHEMISTRY, V5, P567, DOI 10.1016/0019-2791(68)90092-X; FELTON LD, 1949, J IMMUNOL, V61, P107; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; HECHT TT, 1983, J IMMUNOL, V131, P1049; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KYBURZ D, IN PRESS EUR J IMMUN; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LEVINE S, 1968, SCIENCE, V161, P1155, DOI 10.1126/science.161.3846.1155; LIDER O, 1989, J IMMUNOL, V142, P748; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LUPIN C, 1988, J EXP MED, V167, P752; MACDONALD HR, 1974, J EXP MED, V140, P718, DOI 10.1084/jem.140.3.718; MALEK TR, 1984, J IMMUNOL, V133, P1976; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; Miller S D, 1992, Int Rev Immunol, V9, P203, DOI 10.3109/08830189209061791; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULE JJ, 1990, BIOL THERAPY CANCER, P142; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OTTEN G, 1986, EUR J IMMUNOL, V16, P217, DOI 10.1002/eji.1830160302; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; RACKE MK, 1991, J IMMUNOL, V146, P3012; RADVANYI LG, 1993, J IMMUNOL, V150, P5704; RAINE CS, 1978, SCIENCE, V201, P445, DOI 10.1126/science.78524; RAZVI ES, 1993, J VIROL, V67, P5754, DOI 10.1128/JVI.67.10.5754-5765.1993; ROCHA B, 1991, SCIENCE, V251, P1255; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SERCARZ E., 1959, NATURE, V184, P1080, DOI 10.1038/1841080a0; SU MWC, 1993, J IMMUNOL, V151, P658; SU XM, 1991, J NEUROIMMUNOL, V34, P181; SUZUKI G, 1988, J IMMUNOL, V140, P1359; TALMAGE DW, 1956, J INFECT DIS, V98, P293, DOI 10.1093/infdis/98.3.293; UCKER DS, 1992, J IMMUNOL, V149, P1583; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VONBOEHMER H, 1993, NATURE, V362, P696, DOI 10.1038/362696a0; WALDEN PR, 1990, P NATL ACAD SCI USA, V87, P9015, DOI 10.1073/pnas.87.22.9015; WANG R, 1993, J IMMUNOL, V150, P3832; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WESSELBORG O, 1993, J IMMUNOL, V150, P4338; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	62	495	512	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1139	1143		10.1126/science.7509084	http://dx.doi.org/10.1126/science.7509084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	7509084				2022-12-01	WOS:A1994MX75900033
J	HOPPLER, S; BIENZ, M				HOPPLER, S; BIENZ, M			SPECIFICATION OF A SINGLE-CELL TYPE BY A DROSOPHILA HOMEOTIC GENE	CELL			English	Article							HOMEOBOX-CONTAINING GENES; ECTOPIC EXPRESSION; VISCERAL MESODERM; C-ELEGANS; DEVELOPMENTAL ANALYSIS; ANTENNAPEDIA-COMPLEX; SPATIAL EXPRESSION; BITHORAX COMPLEX; AUTO-REGULATION; NERVOUS-SYSTEM	Homeotic genes function in blocks of cells along the body axis to specify diverse developmental pathways. Among the Drosophila homeotic genes, only one is known to be expressed in the endoderm. We show here that expression of this gene, labial (lab), coincides with copper cells, highly specialized cells of the larval midgut. lab is strictly required for copper cell formation, a requirement that starts in the embryo and extends through larval stages. This implies a function of lab not only in the determination and differentiation of copper cells, but also in the maintenance of their differentiated state. Ectopic expression of lab during embryogenesis reprograms other midgut cells within and outside the lab domain to become copper cell-like. Thus, lab functions in the larval midgut to specify a single cell type.			HOPPLER, S (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, CAMBS, ENGLAND.			Hoppler, Stefan/0000-0003-0730-4798				AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1988, CELL, V53, P567, DOI 10.1016/0092-8674(88)90573-9; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; DIEDERICH RJ, 1991, DEVELOPMENT, V113, P273; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FILSHIE BK, 1971, TISSUE CELL, V3, P77, DOI 10.1016/S0040-8166(71)80033-2; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; HARTENSTEIN V, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P213, DOI 10.1007/BF00848248; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HEUER JG, 1992, DEVELOPMENT, V115, P35; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KAUFMAN TC, 1980, GENETICS, V94, P115; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; Lawrence P. A., 1992, MAKING FLY GENETICS; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MERRILL VKL, 1989, DEV BIOL, V135, P376, DOI 10.1016/0012-1606(89)90187-5; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; MURPHY P, 1991, DEVELOPMENT, V111, P61; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENVY L, 1991, NATURE, V349, P257; Poulsen D. F., 1952, Experimental Cell Research New York Supplement, VNo. 2, P161; Poulson D. F., 1950, BIOL DROSOPHILA, P168; POULSON DF, 1950, GENETICS, V35, P684; POULSON DF, 1960, AUST J BIOL SCI, V13, P540; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SKAER H, 1993, IN PRESS DEV DROSOPH; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TEUGELS E, 1985, NATURE, V314, P558, DOI 10.1038/314558a0; TREMML G, 1992, DEVELOPMENT, V116, P447; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; TREMML G, 1991, THESIS U ZURICH ZURI; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINZIERL R, 1987, GENE DEV, V1, P386, DOI 10.1101/gad.1.4.386; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2	71	89	93	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					689	702		10.1016/0092-8674(94)90508-8	http://dx.doi.org/10.1016/0092-8674(94)90508-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7907275				2022-12-01	WOS:A1994MZ28500011
J	IWASHIMA, M; IRVING, BA; VANOERS, NSC; CHAN, AC; WEISS, A				IWASHIMA, M; IRVING, BA; VANOERS, NSC; CHAN, AC; WEISS, A			SEQUENTIAL INTERACTIONS OF THE TCR WITH 2 DISTINCT CYTOPLASMIC TYROSINE KINASES	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; T-CELL; SIGNAL TRANSDUCTION; ZETA-CHAIN; ACTIVATION; CD4; PHOSPHORYLATION; P56LCK; COMPLEX; DOMAIN	The T cell antigen receptor (TCR) initiates signals by interacting with cytoplasmic protein tyrosine kinases (PTKs) through a 17-residue sequence motif [called the antigen recognition activation motif (ARAM)] that is contained in the TCRzeta and CD3 chains. TCR stimulation induces the tyrosine phosphorylation of several cellular substrates, including the ARAMs. Lck kinase activity is required for phosphorylation of two conserved tyrosine residues in an ARAM. This phosphorylation leads to the recruitment of a second cytoplasmic PTK, ZAP-70, through both of the ZAP-70 Src homology 2 domains and its phosphorylation. Thus, TCR signal transduction is initiated by the sequential interaction of two PTKs with TCR ARAMs.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAMS NIH HHS [AR-20684] Funding Source: Medline; NIGMS NIH HHS [GM39553] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; Iwashima M., UNPUB; Iwashima M., 1992, PROG IMMUNOL, V8, P205; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	47	668	679	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1136	1139		10.1126/science.7509083	http://dx.doi.org/10.1126/science.7509083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	7509083				2022-12-01	WOS:A1994MX75900032
J	JACK, T; FOX, GL; MEYEROWITZ, EM				JACK, T; FOX, GL; MEYEROWITZ, EM			ARABIDOPSIS HOMEOTIC GENE APETALA3 ECTOPIC EXPRESSION - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION DETERMINE FLORAL ORGAN IDENTITY	CELL			English	Article							FLOWER DEVELOPMENT; PLANT TRANSFORMATION; MADS-BOX; THALIANA; DEFICIENS; LEAFY; INTERACTS; PRODUCT	APETALA3 (AP3) specifies the development of petals and stamens in the Arabidopsis flower. We constructed a transgenic line, 35S-AP3, that ectopically expresses AP3 under the control of a constitutive promoter. The resulting flowers exhibit a replacement of carpels by stamens and resemble flowers homozygous for the previously described Arabidopsis mutation superman. Although AP3 RNA is detected at high levels throughout the flower and stem in 35S-AP3, AP3 protein is detected at high levels only in the second, third, and fourth floral whorls, demonstrating that AP3 is posttranscriptionally regulated. Ectopic expression of AP3 causes a second floral homeotic gene, PISTILLATA (PI), to function in the fourth whorl of 35S-AP3 flowers. AP3 and PI also activate an AP3 promoter-reporter gene fusion, demonstrating that AP3 positively autoregulates.	CALTECH, DIV BIOL 15629, PASADENA, CA 91125 USA	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009		NIGMS NIH HHS [GM13667-5] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CHAUDHURY AM, 1989, PLANT CELL REP, V8, P368, DOI 10.1007/BF00716676; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; HARLOW E, 1988, ANTIBODIES LABORATOR; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1988, GENE DEV, V2, P635, DOI 10.1101/gad.2.6.635; JEFFERSON RA, 1987, EMBO J, V6, P3901; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Stomp A., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P103; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	40	314	328	5	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					703	716		10.1016/0092-8674(94)90509-6	http://dx.doi.org/10.1016/0092-8674(94)90509-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7907276				2022-12-01	WOS:A1994MZ28500012
J	SAITOH, Y; LAEMMLI, UK				SAITOH, Y; LAEMMLI, UK			METAPHASE CHROMOSOME STRUCTURE - BANDS ARISE FROM A DIFFERENTIAL FOLDING PATH OF THE HIGHLY AT-RICH SCAFFOLD	CELL			English	Article							DNA TOPOISOMERASE-II; INDIAN MUNTJAC; MITOTIC CHROMOSOMES; ATTACHMENT SITES; HISTONE H-1; REGIONS; CONDENSATION; PROTEINS; BINDING; ORDER	Using the highly AT-specific fluorchrome daunomycin, a longitudinal optical signal called AT queue, thought to arise from a line-up of the highly AT-rich scaffold-associated regions (SARs) by the scaffolding, was identified in native chromosomes. Fluorescence banding is proposed to result from a differential folding path of the AT queue during its progression from telomere to telomere. The AT queue is tightly coiled or folded in a Q band, the resulting transverse striations across the chromatid, which also represent Giemsa subbands, generating a bright AT-rich signal over the Q region. The R bands, in contrast, contain a more central (unfolded) AT queue, yielding an AT-dull signal over the R regions. The AT queue is identified by immunofluorescence against topoisomerase II (topo II) and HMG-I/Y as the scaffold of native chromosomes; the fluorescence signal from both proteins is akin to a detailed Q-type banding pattern. Native chromosomes appear assembled according to the loop-scaffold model.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	SAITOH, Y (corresponding author), UNIV GENEVA,DEPT BIOCHEM,30 QUAI ERNEST ANSRMET,CH-1211 GENEVA 4,SWITZERLAND.			Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERNARDI G, 1988, J MOL EVOL, V28, P7, DOI 10.1007/BF02143493; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; COMINGS DE, 1971, EXP CELL RES, V67, P441, DOI 10.1016/0014-4827(71)90430-7; COMINGS DE, 1976, CHROMOSOMA, V56, P199, DOI 10.1007/BF00293185; COMINGS DE, 1978, ANNU REV GENET, V12, P25, DOI 10.1146/annurev.ge.12.120178.000325; CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1983, J CELL BIOL, V96, P84, DOI 10.1083/jcb.96.1.84; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; GARRARD WT, 1990, NUCL ACIDS MOL BIOL, P163; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSTON FP, 1978, CHROMOSOMA, V68, P115, DOI 10.1007/BF00287144; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; KEREM BS, 1984, CELL, V38, P493, DOI 10.1016/0092-8674(84)90504-X; KORENBERG JR, 1978, P NATL ACAD SCI USA, V75, P3382, DOI 10.1073/pnas.75.7.3382; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; PARDUE ML, 1975, J CELL BIOL, V64, P251, DOI 10.1083/jcb.64.1.251; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROTH MB, 1987, J CELL BIOL, V105, P1047, DOI 10.1083/jcb.105.3.1047; SAITOH Y, 1984, IN PRESS COLD SPRING, V85; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWEIZER D, 1981, HUM GENET, V57, P1; SCHWEIZER D, 1976, CHROMOSOMA, V58, P307, DOI 10.1007/BF00292840; SEN P, 1985, CYTOGENET CELL GENET, V39, P145, DOI 10.1159/000132124; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; Sumner A. T, 1990, CHROMOSOME BANDING; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	50	323	344	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					609	622		10.1016/0092-8674(94)90502-9	http://dx.doi.org/10.1016/0092-8674(94)90502-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7510215				2022-12-01	WOS:A1994MZ28500005
J	VONGERSDORFF, H; MATTHEWS, G				VONGERSDORFF, H; MATTHEWS, G			DYNAMICS OF SYNAPTIC VESICLE FUSION AND MEMBRANE RETRIEVAL IN SYNAPTIC TERMINALS	NATURE			English	Article							TRANSMITTER RELEASE; NERVE-TERMINALS; CALCIUM INFLUX; BIPOLAR CELLS; CAPACITANCE MEASUREMENTS; INTRACELLULAR CALCIUM; GOLDFISH RETINA; AMINO-ACIDS; EXOCYTOSIS; CURRENTS	COMMUNICATION among neurons occurs at specialized synaptic junctions, where neurotransmitter is released via calcium-dependent exocytosis from the synaptic terminal of the presynaptic cell onto the postsynaptic target neuron. Here we exploit the unique properties of giant synaptic terminals1-4 of bipolar neurons from goldfish retina to establish the kinetics and calcium-dependence of exocytosis, and the characteristics of membrane retrieval following secretion in presynaptic terminals. Simultaneous patch-clamp, calcium-indicator dye and time-resolved capacitance measurements reveal that activation of calcium current drives secretion at a rapid rate of about 10,000 vesicles per s and the, calcium level necessary to drive secretion is locally greater than 50 muM. Two components of membrane retrieval were observed following secretory stimulation. After strong stimulation, capacitance returned to rest with a time constant of about 30 s, but after weaker stimuli recovery was much faster, with a time constant of about 2 s. Secretion in a vertebrate central nervous system neuron was thus found to differ substantially from that in other secretory cells in its rapid rate of vesicle fusion, requirement for high levels of intracellular calcium, and the high speed and completeness of membrane retrieval. These distinctive features reflect the specialization of neuronal synaptic terminals for rapid and focally directed release of neurotransmitter.			VONGERSDORFF, H (corresponding author), SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794, USA.							ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P553, DOI 10.1113/jphysiol.1954.sp005128; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; ISHIDA AT, 1980, J COMP NEUROL, V191, P315, DOI 10.1002/cne.901910302; JAFFE LA, 1978, DEV BIOL, V67, P243, DOI 10.1016/0012-1606(78)90314-7; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P200; KANEKO A, 1985, J PHYSIOL-LONDON, V358, P131, DOI 10.1113/jphysiol.1985.sp015544; KELLY RB, 1993, NEURON S, V10, P43; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; MARC RE, 1989, NATO ASI SERIES H, V31, P53; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RYAN TA, 1993, NEURON, V11, P7132; SHERRY DM, 1993, J COMP NEUROL, V329, P188, DOI 10.1002/cne.903290204; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; TACHIBANA M, 1991, J NEUROSCI, V11, P2199; TACHIBANA M, 1993, J NEUROSCI, V13, P2898; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	30	383	389	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					735	739		10.1038/367735a0	http://dx.doi.org/10.1038/367735a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	7906397				2022-12-01	WOS:A1994MX63100058
J	CHESTER, KA; BEGENT, RHJ; ROBSON, L; KEEP, P; PEDLEY, RB; BODEN, JA; BOXER, G; GREEN, A; WINTER, G; COCHET, O; HAWKINS, RE				CHESTER, KA; BEGENT, RHJ; ROBSON, L; KEEP, P; PEDLEY, RB; BODEN, JA; BOXER, G; GREEN, A; WINTER, G; COCHET, O; HAWKINS, RE			PHAGE LIBRARIES FOR GENERATION OF CLINICALLY USEFUL ANTIBODIES	LANCET			English	Note							MONOCLONAL-ANTIBODIES; AFFINITY	Insertion of antibody genes into filamentous bacteriophage makes it possible to generate and screen libraries of 10(7) or more antibodies. Each phage expresses an antibody on its surface and contains the corresponding antibody gene. Genes that encode antibodies with desired characteristics are readily selected and their antibodies expressed as soluble proteins in Escherichia coli. We used this system to produce an antibody to carcinoembryonic antigen with higher affinity and better tumour specificity than antibodies currently in use.	ROYAL FREE HOSP,SCH MED,LONDON NW3 2PF,ENGLAND; CTR PROT ENGN,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,CTR PROT ENGN,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,DEPT CLIN ONCOL,CAMBRIDGE,CAMBS,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Chester, Kerry/AAE-2856-2020					BEGENT RHJ, 1990, SCI CANCER TREATMENT, V2, P161; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1992, BRIT MED J, V305, P1348, DOI 10.1136/bmj.305.6865.1348; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; NAP M, 1992, CANCER RES, V52, P2329	6	164	175	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					455	456		10.1016/S0140-6736(94)92695-6	http://dx.doi.org/10.1016/S0140-6736(94)92695-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905958				2022-12-01	WOS:A1994MW69000013
J	DZUBOW, LM				DZUBOW, LM			MOHS SURGERY	LANCET			English	Editorial Material							BASAL-CELL CARCINOMA; RECURRENCE; RATES; SKIN				DZUBOW, LM (corresponding author), UNIV PENN, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA.							CLOUSTON PD, 1990, ARCH NEUROL-CHICAGO, V47, P73, DOI 10.1001/archneur.1990.00530010091025; Mohs FE, 1991, MOHS MICROGRAPHIC SU, P1; ROBINSON JK, 1993, CLIN PLAST SURG, V20, P149; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; ROWE DE, 1992, J AM ACAD DERMATOL, V26, P976, DOI 10.1016/0190-9622(92)70144-5; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P424, DOI 10.1111/j.1524-4725.1989.tb03249.x; TROMOVITCH TA, 1974, ARCH DERMATOL, V110, P231, DOI 10.1001/archderm.110.2.231	7	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	1994	343	8895					433	434		10.1016/S0140-6736(94)92687-5	http://dx.doi.org/10.1016/S0140-6736(94)92687-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905951	hybrid			2022-12-01	WOS:A1994MW69000005
J	JAKEMAN, P; SMITH, WCS				JAKEMAN, P; SMITH, WCS			THALIDOMIDE IN LEPROSY REACTION	LANCET			English	Editorial Material											JAKEMAN, P (corresponding author), LEPROSY MISSION EVALUAT UNIT,SINGAPORE,SINGAPORE.							GHIGLIOTTI G, 1993, J AM ACAD DERMATOL, V28, P271, DOI 10.1016/S0190-9622(08)81153-X; GUTIERREZRODRIGUEZ O, 1989, J RHEUMATOL, V16, P158; HASTINGS R C, 1980, Ethiopian Medical Journal, V18, P65; Jadhav V H, 1990, Indian J Lepr, V62, P316; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; REA TH, 1978, ARCH DERMATOL, V114, P1023, DOI 10.1001/archderm.114.7.1023; SAGHER F, 1969, LEPROSY REV, V40, P126; Sheskin J, 1975, Med Cutan Ibero Lat Am, V3, P81; SHESKIN J, 1968, ISRAEL J MED SCI, V4, P901; TAMURA F, 1990, TRANSPLANTATION, V49, P20, DOI 10.1097/00007890-199001000-00005; 1993, THALIDOMIDE DRUG CAM; 1988, WHO TECH REP SER, V768	12	28	28	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					432	433		10.1016/S0140-6736(94)92686-7	http://dx.doi.org/10.1016/S0140-6736(94)92686-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905950				2022-12-01	WOS:A1994MW69000004
J	JOHNSON, A				JOHNSON, A			VOICE RESTORATION AFTER LARYNGECTOMY	LANCET			English	Editorial Material											JOHNSON, A (corresponding author), QUEEN ELIZABETH HOSP,DEPT OTOLARYNGOL,BIRMINGHAM,W MIDLANDS,ENGLAND.							DUGUAY MJ, 1989, J VOICE, V3, P265; GRASL MC, 1993, LARYNGOSCOPE, V103, P96; PARKER AJ, 1992, J LARYNGOL OTOL, V106, P154, DOI 10.1017/S0022215100118936; SCOTT PMJ, 1993, J LARYNGOL OTOL, V107, P430, DOI 10.1017/S0022215100123345; SINGER MI, 1980, ANN OTO RHINOL LARYN, V89, P529, DOI 10.1177/000348948008900608; SINGER MI, 1986, OTOLARYNGOLOGY HEAD, P2073; STGUILY JL, 1992, ARCH OTOLARYNGOL, V118, P252	7	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					431	432		10.1016/S0140-6736(94)92685-9	http://dx.doi.org/10.1016/S0140-6736(94)92685-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905949				2022-12-01	WOS:A1994MW69000003
J	ROBERTS, M; WILLISON, H; VINCENT, A; NEWSOMDAVIS, J				ROBERTS, M; WILLISON, H; VINCENT, A; NEWSOMDAVIS, J			SERUM FACTOR IN MILLER-FISHER VARIANT OF GUILLAIN-BARRE-SYNDROME AND NEUROTRANSMITTER RELEASE	LANCET			English	Note								Serum IgG autoantibodies to GQ1b ganglioside are associated with the acute phase of the Miller-Fisher syndrome (MFS). We investigated the effects of three anti-GQ1b-positive MFS sera in the mouse phrenic-nerve/diaphragm preparation. Miniature endplate potential frequencies increased eight-fold within 25 min, declined rapidly, and ceased altogether after 3 h, when nerve stimulation no longer evoked a response. One MFS convalescent serum (anti-GQ1b negative) and sera from healthy controls and from patients with other neurological diseases were without effect. Thus muscle weakness in MFS may be caused by a serum factor, likely to be GQ1b antibody, that leads to failure of acetylcholine release from motor nerve terminals.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,DEPT CLIN NEUROL,NEUROSCI GRP,OXFORD OX3 9DU,ENGLAND; UNIV GLASGOW,SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,SCOTLAND	University of Oxford; University of Glasgow			willison, hugh/HCI-7819-2022					CHIBA A, 1992, ANN NEUROL, V31, P677, DOI 10.1002/ana.410310619; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; LANG B, 1981, LANCET, V2, P224; MONTECUCCO C, 1988, BIOCHEM J, V251, P379, DOI 10.1042/bj2510379; WILLISON HJ, 1993, J NEUROIMMUNOL, V46, P105, DOI 10.1016/0165-5728(93)90239-U; WILLISON HJ, 1993, J NEUROL NEUROSUR PS, V56, P204, DOI 10.1136/jnnp.56.2.204; WILLISON HJ, IN PRESS J NEUROIMMU; YUKI N, 1993, NEUROLOGY, V43, P414, DOI 10.1212/WNL.43.2.414	8	151	153	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					454	455		10.1016/S0140-6736(94)92694-8	http://dx.doi.org/10.1016/S0140-6736(94)92694-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905957				2022-12-01	WOS:A1994MW69000012
J	TOFT, AD				TOFT, AD			IF I SHOULD LIVE TO BE 100	LANCET			English	Editorial Material											TOFT, AD (corresponding author), ROYAL INFIRM, EDINBURGH, SCOTLAND.							CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; MARRIOTTI S, 1993, J CLIN ENDOCR METAB, V77, P1130; MARTIN GR, 1993, ANNU REV MED, V44, P419, DOI 10.1146/annurev.me.44.020193.002223	3	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					434	434		10.1016/S0140-6736(94)92688-3	http://dx.doi.org/10.1016/S0140-6736(94)92688-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905952				2022-12-01	WOS:A1994MW69000006
J	VANLEEUWEN, FE; BENRAADT, J; COEBERGH, JWW; KIEMENEY, LALM; GIMBRERE, CHF; OTTER, R; SCHOUTEN, LJ; DAMHUIS, RAM; BONTENBAL, M; DIEPENHORST, FW; VANDENBELTDUSEBOUT, AW; VANTINTEREN, H				VANLEEUWEN, FE; BENRAADT, J; COEBERGH, JWW; KIEMENEY, LALM; GIMBRERE, CHF; OTTER, R; SCHOUTEN, LJ; DAMHUIS, RAM; BONTENBAL, M; DIEPENHORST, FW; VANDENBELTDUSEBOUT, AW; VANTINTEREN, H			RISK OF ENDOMETRIAL CANCER AFTER TAMOXIFEN TREATMENT OF BREAST-CANCER	LANCET			English	Article							ADJUVANT TAMOXIFEN; VAGINAL EPITHELIUM; PREVENTION; THERAPY; RADIOTHERAPY; DISEASE	Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer in healthy women, it has become important to investigate the drug's potential adverse effects, including occurrence of endometrial cancer. We undertook a case-control study in the Netherlands to assess the effect of tamoxifen on the risk of endometrial cancer after breast cancer. Through the population-based Netherlands Cancer Registry and two older, hospital-based, registries, we identified 98 patients who had endometrial cancer diagnosed at least 3 months after a diagnosis of primary breast cancer. Detailed information about treatment was obtained for all these patients, and for 285 controls, who were matched to the cases for age, year of breast cancer diagnosis, and survival time with intact uterus. Tamoxifen had been used by 24% of patients with subsequent endometrial cancer and 20% of controls (relative risk 1.3 [95% Cl 0.7-2.4]). Women who had used tamoxifen for more than 2 years had a 2.3 (0.9-5.9) times greater risk of endometrial cancer than never users. There was a significant trend of increasing risk of endometrial cancer with duration of tamoxifen use (p=0.049), and also with cumulative dose (p=0.046). The duration-response trends were similar with daily doses of 40 mg or 30 mg and less. These findings support the hypothesis that tamoxifen use increases the risk of endometrial cancer. This oestrogenic effect on the endometrium was not related to the dose intensity. Physicians should be aware of the higher risk of endometrial cancer in tamoxifen users.	COMPREHENS CANC CTR,AMSTERDAM,NETHERLANDS; COMPREHENS CANC CTR S NETHERLANDS,EINDHOVEN,NETHERLANDS; COMPREHENS CANC CTR MIDDLE NETHERLANDS,UTRECHT,NETHERLANDS; COMPREHENS CANC CTR,LIMBURG,NETHERLANDS; COMPREHENS CANC CTR,ROTTERDAM,NETHERLANDS; COMPREHENS CANC CTR STEDENDRIEHOEK,TWENTE,NETHERLANDS; DR DANIEL DEN HOED CANC CTR,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	VANLEEUWEN, FE (corresponding author), NETHERLANDS CANC INST,DEPT EPIDEMIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Schouten, Leo J/G-3713-2012; Kiemeney, Lambertus A./D-3357-2009; Schouten, Leo J/AAB-2275-2019	Kiemeney, Lambertus A./0000-0002-2368-1326; Schouten, Leo J/0000-0003-3361-7560; Coebergh, Jan Willem/0000-0002-2419-3930				ANDERSSON M, 1992, ACTA ONCOL, V31, P259, DOI 10.3109/02841869209088912; ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; BOCCARDO F, 1981, ONCOLOGY, V38, P281, DOI 10.1159/000225571; BOCCARDO F, 1984, TUMORI, V70, P61, DOI 10.1177/030089168407000110; BRESLOW N. E., 1980, STATISTICAL METHODS; BURING JE, 1986, AM J EPIDEMIOL, V124, P434, DOI 10.1093/oxfordjournals.aje.a114414; COLLETTE HJA, 1984, LANCET, V1, P1224; COLLINS J, 1980, LANCET, V2, P961; CREASMAN WT, 1990, OBSTET GYNECOL, V75, P287; DEMUYLDER X, 1991, INT J GYNECOL OBSTET, V36, P127, DOI 10.1016/0020-7292(91)90767-Y; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELWOOD JM, 1980, GYNECOL ONCOL, V10, P173, DOI 10.1016/0090-8258(80)90079-7; FERRAZZI E, 1977, BRIT MED J, V1, P1351, DOI 10.1136/bmj.1.6072.1351-e; FISHER B, 1991, J NATL CANCER I, V83, P1278, DOI 10.1093/jnci/83.18.1278; FISHER B, 1989, NEW ENGL J MED, V320, P489; FORNANDER T, 1989, LANCET, V1, P117; FUGHBERMAN A, 1992, LANCET, V340, P1143, DOI 10.1016/0140-6736(92)93161-F; GOTTARDIS MM, 1988, CANCER RES, V48, P812; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; MAGRIPLES U, 1993, J CLIN ONCOL, V11, P485, DOI 10.1200/JCO.1993.11.3.485; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NEVEN P, 1993, LANCET, V342, P452, DOI 10.1016/0140-6736(93)91590-I; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; STEWART HJ, 1989, LANCET, V1, P375; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; 1988, BRIT J CANCER, V57, P604; 1992, INCIDENCE CANCER NET; 1992, LANCET, V339, P71	30	491	497	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					448	452		10.1016/S0140-6736(94)92692-1	http://dx.doi.org/10.1016/S0140-6736(94)92692-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905955	Green Submitted			2022-12-01	WOS:A1994MW69000010
J	WETTER, LA; HAMADEH, RM; GRIFFISS, JM; OESTERLE, A; AAGAARD, B; WAY, LW				WETTER, LA; HAMADEH, RM; GRIFFISS, JM; OESTERLE, A; AAGAARD, B; WAY, LW			DIFFERENCES IN OUTER-MEMBRANE CHARACTERISTICS BETWEEN GALLSTONE-ASSOCIATED BACTERIA AND NORMAL BACTERIAL-FLORA	LANCET			English	Article							ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; HEMOLYSIN PRODUCTION; ANTI-GAL; STONES; HEMAGGLUTINATION; ERYTHROCYTES; RECOGNITION; MANNOSE; BILE	Previous studies with scanning electron microscopy (SEM) have suggested that pigment gallstones contain bacteria. We set out to culture these bacteria and to study their membrane characteristics. We studied gallstones from 54 patients (36 men, 18 women; mean age 55.4 years) admitted consecutively to two hospitals for cholecystectomy. SEM detected bacteria in all of 14 brown pigment stones, 2 of 14 black pigment stones, and in the pigmented centres of 9 of 19 mixed cholesterol stones; no bacteria were detected in 14 pure cholesterol stones or within the cholesterol portions of mixed stones. We were able to culture bacteria from all gallstones with bacteria seen on SEM and for which sufficient material was available (n=16). 20 bacterial species were recovered from these stones. Gallstones containing bacteria were associated with clinical sepsis and cholangitis. All bacteria obtained from gallstones agglutinated human O P1 erythrocytes, which reflects the presence of P1-specific fimbriae. 5 strains were positive for Forssman-antigen-specific fimbriae. None showed evidence of mannose-specific fimbriae. All of the organisms bound anti-Gal, a ubiquitous naturally occurring IgG specific for a-galactosyl residues. The presence of P1 fimbriae and alpha-galactosyl residues and the absence of mannose-specific fimbriae distinguish these organisms from gut flora. We postulate that possession of these unusual properties may enhance the ability of bacteria to colonise the biliary tree and initiate pigment gallstone formation.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR IMMUNOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI 21171] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021171] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYOSHI T, 1990, DIGEST DIS SCI, V35, P27, DOI 10.1007/BF01537218; BERNHOFT RA, 1984, AM J SURG, V148, P77, DOI 10.1016/0002-9610(84)90292-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CETTA F, 1991, ANN SURG, V213, P315, DOI 10.1097/00000658-199104000-00006; CETTA FM, 1986, HEPATOLOGY, V6, P482, DOI 10.1002/hep.1840060327; DONOVAN JM, 1991, GASTROENTEROL CLIN N, V20, P47; DUGUID JP, 1980, BACTERIAL ADHERENC B, V6, P185; EVANS DJ, 1979, INFECT IMMUN, V23, P336, DOI 10.1128/IAI.23.2.336-346.1979; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; GREEN CP, 1981, INFECT IMMUN, V31, P309, DOI 10.1128/IAI.31.1.309-315.1981; HAMADEH R, 1991, CLIN RES, V39, pA439; HAMADEH RM, 1990, J CLIN MICROBIOL, V28, P20, DOI 10.1128/JCM.28.1.20-26.1990; HAMADEH RM, 1992, J CLIN INVEST, V89, P1223, DOI 10.1172/JCI115706; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KIM JJ, 1989, INFECT IMMUN, V57, P602, DOI 10.1128/IAI.57.2.602-608.1989; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI T, 1966, ANN SURG, V164, P90, DOI 10.1097/00000658-196607000-00010; OHANLEY P, 1985, NEW ENGL J MED, V313, P414, DOI 10.1056/NEJM198508153130704; OKADA Y, 1988, J IMMUNOL METHODS, V112, P243, DOI 10.1016/0022-1759(88)90364-X; OLD DC, 1972, J GEN MICROBIOL, V71, P149, DOI 10.1099/00221287-71-1-149; SKAR V, 1988, SCAND J GASTROENTERO, V23, P83, DOI 10.3109/00365528809093853; SMITH AL, 1989, ARCH SURG-CHICAGO, V124, P629; STEWART L, 1987, ANN SURG, V206, P242, DOI 10.1097/00000658-198709000-00002; SUNG JY, 1992, DIGEST DIS SCI, V37, P689, DOI 10.1007/BF01296423; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VAISANEN V, 1981, LANCET, V2, P1366	29	35	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					444	448		10.1016/S0140-6736(94)92691-3	http://dx.doi.org/10.1016/S0140-6736(94)92691-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905954				2022-12-01	WOS:A1994MW69000009
J	WOODHOUSE, PR; KHAW, KT; PLUMMER, M; FOLEY, A; MEADE, TW				WOODHOUSE, PR; KHAW, KT; PLUMMER, M; FOLEY, A; MEADE, TW			SEASONAL-VARIATIONS OF PLASMA-FIBRINOGEN AND FACTOR-VII ACTIVITY IN THE ELDERLY - WINTER INFECTIONS AND DEATH FROM CARDIOVASCULAR-DISEASE	LANCET			English	Article							ISCHEMIC HEART-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; HEMOSTATIC VARIABLES; HYPERLIPEMIA	There are approximately 20 000 excess deaths from cardiovascular disease each winter in England and Wales, The reasons for the excess have not been fully elucidated. For one year, we studied 96 men and women aged 65-74 living in their own homes in order to examine seasonal variation in plasma fibrinogen and factor VII clotting activity (fVIIc), and to investigate relationships with infection and other cardiovascular-disease risk factors. Both fibrinogen and FVIIc plasma values were greater in winter with estimated winter-summer differences (confidence intervals) of 0.13 (0.05-0.20) g/L for fibrinogen and 4.2 (1.2-7.1)% of standard for FVIIc. These differences could account for 15% and 9% increases in ischaemic heart disease risk in winter respectively. After adjustment for confounding by season, fibrinogen was strongly related to neutrophil count (p<0.0001), C-reactive protein (p<0.0001), alpha 1-antichymotrypsin (p<0.0001), and self-reported cough (p<0.0001) and coryza (p=0.0004), but not to ambient temperature. Therefore, we suggest that seasonal variation in fibrinogen might be induced by winter respiratory infections via activation of the acute phase response. Seasonal variations in the cardiovascular risk factors fibrinogen and FVIIc provide further possible explanations for the marked seasonal variation in death from ischaemic heart disease and stroke in the elderly.	UNIV CAMBRIDGE, CLIN GERONTOL UNIT, CAMBRIDGE, CAMBS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, CAMBS, ENGLAND; WOLFSON INST PREVENT MED, MRC, EPIDEMIOL & MED CARE UNIT, LONDON, ENGLAND	University of Cambridge; MRC Biostatistics Unit; University of Cambridge; University of London; Queen Mary University London				Plummer, Martyn/0000-0001-5130-6497				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; CHOOI CC, 1989, THROMB RES, V53, P493, DOI 10.1016/0049-3848(89)90204-1; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COOK NS, 1990, TRENDS PHARMACOL SCI, V11, P444, DOI 10.1016/0165-6147(90)90125-R; Curwen M., 1991, HLTH TRENDS, V22, P169; DURRINGTON PN, 1990, SCAND J CLIN LAB INV, V50, P86, DOI 10.3109/00365519009091092; ELKELES RS, 1980, BRIT MED J, V281, P973, DOI 10.1136/bmj.281.6246.973; FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; ISO H, 1989, AM J EPIDEMIOL, V130, P925, DOI 10.1093/oxfordjournals.aje.a115425; KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; MARCKMANN P, 1990, ATHEROSCLEROSIS, V80, P227, DOI 10.1016/0021-9150(90)90030-M; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; MILLER GJ, 1985, BRIT J HAEMATOL, V59, P249, DOI 10.1111/j.1365-2141.1985.tb02991.x; NASKI MC, 1991, J BIOL CHEM, V266, P13003; PRICE CP, 1987, J IMMUNOL METHODS, V99, P205, DOI 10.1016/0022-1759(87)90129-3; QIZILBASH N, 1991, BRIT MED J, V303, P605, DOI 10.1136/bmj.303.6803.605; RAO CR, 1973, LINEAR STATISTICAL I, P418; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1993, AGE AGEING, V22, P273, DOI 10.1093/ageing/22.4.273; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	31	462	478	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	1994	343	8895					435	439		10.1016/S0140-6736(94)92689-1	http://dx.doi.org/10.1016/S0140-6736(94)92689-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7508540				2022-12-01	WOS:A1994MW69000007
J	LI, G; REGUNATHAN, S; BARROW, CJ; ESHRAGHI, J; COOPER, R; REIS, DJ				LI, G; REGUNATHAN, S; BARROW, CJ; ESHRAGHI, J; COOPER, R; REIS, DJ			AGMATINE - AN ENDOGENOUS CLONIDINE-DISPLACING SUBSTANCE IN THE BRAIN	SCIENCE			English	Article							BIOSYNTHETIC ARGININE DECARBOXYLASE; IMIDAZOLINE-PREFERRING RECEPTORS; VENTROLATERAL MEDULLA; ESCHERICHIA-COLI; BINDING-SITES; ALPHA-2-ADRENERGIC RECEPTOR; BOVINE BRAIN; PURIFICATION; RILMENIDINE; CDS	Clonidine, an antihypertensive drug, binds to alpha(2)-adrenergic and imidazoline receptors. The endogenous ligand for imidazoline receptors may be a clonidine-displacing substance, a small molecule isolated from bovine brain. This clonidine-displacing substance was purified and determined by mass spectroscopy to be agmatine (decarboxylated arginine), here-tofore not detected in brain. Agmatine binds to alpha(2)-adrenergic and imidazoline receptors and stimulates release of catecholamines from adrenal chromaffin cells. Its biosynthetic enzyme, arginine decarboxylase, is present in brain. Agmatine, locally synthesized, is an endogenous agonist at imidazoline receptors, a noncatecholamine ligand at alpha(2)-adrenergic receptors and may act as a neurotransmitter.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,DIV NEUROBIOL,NEW YORK,NY 10021; STERLING WINTHROP PHARMACEUT RES DIV,MALVERN,PA 19355	Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATLAS D, 1991, BIOCHEM PHARMACOL, V41, P1541, DOI 10.1016/0006-2952(91)90152-U; ATLAS D, 1984, EUR J BIOCHEM, V144, P287, DOI 10.1111/j.1432-1033.1984.tb08462.x; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; DIAMANT S, 1987, EUR J PHARMACOL, V144, P247, DOI 10.1016/0014-2999(87)90377-3; DIAMANT S, 1986, BIOCHEM BIOPH RES CO, V134, P184, DOI 10.1016/0006-291X(86)90545-0; EINARSSON S, 1983, J CHROMATOGR, V282, P609, DOI 10.1016/S0021-9673(00)91638-8; ERNSBERGER P, 1990, J PHARMACOL EXP THER, V253, P408; ERNSBERGER P, 1993, J PHARMACOL EXP THER, V264, P172; ERNSBERGER P, 1987, EUR J PHARMACOL, V134, P1, DOI 10.1016/0014-2999(87)90125-7; ERNSBERGER P, 1990, AM J HYPERTENS, V3, P90, DOI 10.1093/ajh/3.2.90; ERNSBERGER P, 1988, BRAIN RES, V441, P309, DOI 10.1016/0006-8993(88)91409-6; FELSEN D, 1987, EUR J PHARMACOL, V142, P453, DOI 10.1016/0014-2999(87)90087-2; GOMEZ RE, 1991, EUR J PHARMACOL, V195, P181, DOI 10.1016/0014-2999(91)90534-W; HIMSWICH WA, 1969, HDB NEUROCHEMISTRY, V1, P33; IVERSEN L, 1969, HDB NEUROCHEMISTRY, V4, P197; KAMISAKI Y, 1990, BRAIN RES, V514, P15, DOI 10.1016/0006-8993(90)90430-J; KAWABATA T, 1978, J AGR FOOD CHEM, V26, P334, DOI 10.1021/jf60216a038; LORING RH, 1990, BRIT J PHARMACOL, V99, P207, DOI 10.1111/j.1476-5381.1990.tb14680.x; MAJUMDER S, 1992, J PARASITOL, V78, P371, DOI 10.2307/3283493; MEELEY MP, 1986, LIFE SCI, V38, P1119, DOI 10.1016/0024-3205(86)90248-1; MEELEY MP, 1989, SOC NEUR ABSTR, V15, P1159; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; MICHEL MC, 1992, TRENDS PHARMACOL SCI, V13, P369; MOORE RC, 1990, J BACTERIOL, V172, P4631, DOI 10.1128/jb.172.8.4631-4640.1990; NICHOLS AJ, 1991, MOL BIOL BIOCH PHARM, P75; PARINI A, 1989, J BIOL CHEM, V264, P11874; QUIK M, 1985, BRAIN RES, V325, P79, DOI 10.1016/0006-8993(85)90304-X; REGUNATHAN S, 1993, BIOCHEM PHARMACOL, V45, P1667, DOI 10.1016/0006-2952(93)90308-J; REGUNATHAN S, 1993, J NEUROSCI RES, V34, P681, DOI 10.1002/jnr.490340611; REGUNATHAN S, 1991, MOL PHARMACOL, V40, P884; SCHAEFFER JM, 1990, BIOCHEM J, V270, P599, DOI 10.1042/bj2700599; SENER A, 1989, BIOCHEM PHARMACOL, V38, P327, DOI 10.1016/0006-2952(89)90044-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TESSON F, 1991, J BIOL CHEM, V266, P155; TIBIRICA E, 1991, EUR J PHARMACOL, V209, P213, DOI 10.1016/0014-2999(91)90172-M; WANG H, 1992, MOL PHARMACOL, V42, P762; WEITZEL G, 1980, HOPPESEYLERS Z PHYSL, V36, P51; WIKBERG JES, 1992, PHARMACOL TOXICOL, V70, P208; WU WH, 1973, J BIOL CHEM, V248, P1687	40	653	698	4	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					966	969		10.1126/science.7906055	http://dx.doi.org/10.1126/science.7906055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7906055				2022-12-01	WOS:A1994MX16500035
J	MASTROGIACOMO, A; PARSONS, SM; ZAMPIGHI, GA; JENDEN, DJ; UMBACH, JA; GUNDERSEN, CB				MASTROGIACOMO, A; PARSONS, SM; ZAMPIGHI, GA; JENDEN, DJ; UMBACH, JA; GUNDERSEN, CB			CYSTEINE STRING PROTEINS - A POTENTIAL LINK BETWEEN SYNAPTIC VESICLES AND PRESYNAPTIC CA2+ CHANNELS	SCIENCE			English	Article							CALCIUM CHANNELS; BETA-SUBUNIT; RELEASE; CELLS	Presynaptic calcium channels are key regulators of neurotransmitter release. Oocyte expression studies suggest that cysteine string proteins are essential subunits or modulators of these channels. Subcellular fractionation revealed that cysteine string proteins copurify with synaptic vesicles. An average vesicle had eight protein monomers with both the amino and carboxyl termini detected on the cytoplasmic face. Thus, docked synaptic vesicles may regulate presynaptic calcium channels and neurotransmitter release.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MOLEC & MED PHARMACOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Santa Barbara				Parsons, Stanley/0000-0001-7097-8221				ANDERSON DC, 1986, J NEUROCHEM, V46, P1207, DOI 10.1111/j.1471-4159.1986.tb00639.x; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BERTOLINO M, 1992, ANNU REV PHARMACOL, V32, P399, DOI 10.1146/annurev.pa.32.040192.002151; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1993, NEUR ABST, V19, P1329; HARLOW E, 1989, ANTIBODIES LABORATOR, P498; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; JENDEN DJ, 1973, ANAL BIOCHEM, V55, P483; Katz B., 1969, RELEASE NEURAL TRANS; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MASTROGIACOMO A, IN PRESS J NEUROCHEM; MCCLESKEY EW, 1986, J EXP BIOL, V124, P177; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; YAMAGATA SK, 1989, J NEUROCHEM, V53, P1354, DOI 10.1111/j.1471-4159.1989.tb08525.x; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	28	161	162	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					981	982		10.1126/science.7906056	http://dx.doi.org/10.1126/science.7906056			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7906056				2022-12-01	WOS:A1994MX16500040
J	MONTAGUE, PR; GANCAYCO, CD; WINN, MJ; MARCHASE, RB; FRIEDLANDER, MJ				MONTAGUE, PR; GANCAYCO, CD; WINN, MJ; MARCHASE, RB; FRIEDLANDER, MJ			ROLE OF NO PRODUCTION IN NMDA RECEPTOR-MEDIATED NEUROTRANSMITTER RELEASE IN CEREBRAL-CORTEX	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; D-ASPARTATE RECEPTORS; GLUTAMATE NEUROTOXICITY; NEURONAL MESSENGER; NERVOUS-SYSTEM; INTERCELLULAR MESSENGER; NORADRENALINE RELEASE; VISUAL-CORTEX; RAT-BRAIN	L-Glutamate and norepinephrine are examples of a major excitatory neurotransmitter and a neuromodulator in the cerebral cortex, respectively. Little is known of how chemical signaling between the anatomically distinct chemical pathways occurs. Specific activation of the N-methyl-D-aspartate (NMDA) class of glutamate receptor in synaptosomal preparations from guinea pig cerebral cortex caused release of both of these chemicals, and this release was blocked by agents that inhibit nitric oxide (NO) production or remove NO from the extracellular space. Furthermore, neurotransmitter release correlated with cortical NO production after NMDA receptor stimulation. These results suggest that NO production and its extracellular movement may be links in the pathway from NMDA receptor activation to changes in chemical signaling in surrounding synaptic terminals in the cerebral cortex.	UNIV ALABAMA, NEUROBIOL RES CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PHARMACOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NEI NIH HHS [EY05116, EY06714] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BEAR MF, 1990, J NEUROSCI, V10, P909; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELLAN JA, 1993, EUR J PHARMACOL, V234, P273, DOI 10.1016/0014-2999(93)90964-J; BETTACHE N, 1993, BIOPHYS J, V64, pA190; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, J NEUROSCI, V10, P2493; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; ERRINGTON ML, 1987, NEUROSCIENCE, V20, P279, DOI 10.1016/0306-4522(87)90019-4; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FARACI FM, 1990, AM J PHYSIOL, V259, pH1216, DOI 10.1152/ajpheart.1990.259.4.H1216; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FERKANY JW, 1982, NATURE, V298, P757, DOI 10.1038/298757a0; FINK K, 1990, EUR J PHARMACOL, V185, P115, DOI 10.1016/0014-2999(90)90219-V; FREGNAC Y, 1994, IN PRESS J NEUROPHYS, V71, P146; FRIEDLANDER MJ, 1993, PROG BRAIN RES, V95, P207, DOI 10.1016/S0079-6123(08)60370-2; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GORDON B, 1988, PROG NEUROBIOL, V30, P171, DOI 10.1016/0301-0082(88)90005-6; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KOVACH AGB, 1992, J PHYSIOL-LONDON, V449, P183, DOI 10.1113/jphysiol.1992.sp019081; LADECOLA C, 1993, BRAIN RES, V606, P148; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MANZONI O, 1993, J NEUROCHEM, V61, P368, DOI 10.1111/j.1471-4159.1993.tb03580.x; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; Montague PR, 1991, CEREB CORTEX, V1, P199, DOI 10.1093/cercor/1.3.199; MOORE PK, 1993, BRIT J PHARMACOL, V108, P296, DOI 10.1111/j.1476-5381.1993.tb12798.x; MUSLEH WY, 1993, SYNAPSE, V13, P370, DOI 10.1002/syn.890130409; NICHOLS RA, 1989, J NEUROCHEM, V52, P521, DOI 10.1111/j.1471-4159.1989.tb09151.x; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; RADI R, 1991, J BIOL CHEM, V266, P4244; REGIDOR J, 1993, NEUROREPORT, V4, P112, DOI 10.1097/00001756-199301000-00030; SCHARFMAN HE, 1990, P NATL ACAD SCI USA, V87, P4548, DOI 10.1073/pnas.87.12.4548; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHULZ D, 1992, J NEUROSCI, V12, P1301; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUTOR B, 1989, J NEUROPHYSIOL, V61, P621, DOI 10.1152/jn.1989.61.3.621; THOMSON AM, 1986, NEUROSCIENCE, V17, P37, DOI 10.1016/0306-4522(86)90223-X; THOMSON AM, 1986, J PHYSIOL-LONDON, V370, P531, DOI 10.1113/jphysiol.1986.sp015949; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; VALTSCHANOFF JG, 1993, J COMP NEUROL, V331, P111, DOI 10.1002/cne.903310107; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WANG JKT, 1992, J NEUROCHEM, V58, P204, DOI 10.1111/j.1471-4159.1992.tb09297.x; WILLIAMS JH, 1993, SEMIN NEUROSCI, V5, P149, DOI 10.1016/S1044-5765(05)80048-X; WINN MJ, 1991, J CARDIOVASC PHARM, V18, P68, DOI 10.1097/00005344-199107000-00010; WINN MJ, 1992, J PHARMACOL TOXICOL, V28, P49, DOI 10.1016/1056-8719(92)90065-9; WU WT, 1993, NEUROSCI LETT, V153, P121, DOI 10.1016/0304-3940(93)90303-3; ZHOU M, 1993, SCIENCE, V260, P1946	68	466	473	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					973	977		10.1126/science.7508638	http://dx.doi.org/10.1126/science.7508638			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7508638				2022-12-01	WOS:A1994MX16500038
J	LAPIDOT, T; SIRARD, C; VORMOOR, J; MURDOCH, B; HOANG, T; CACERESCORTES, J; MINDEN, M; PATERSON, B; CALIGIURI, MA; DICK, JE				LAPIDOT, T; SIRARD, C; VORMOOR, J; MURDOCH, B; HOANG, T; CACERESCORTES, J; MINDEN, M; PATERSON, B; CALIGIURI, MA; DICK, JE			A CELL INITIATING HUMAN ACUTE MYELOID-LEUKEMIA AFTER TRANSPLANTATION INTO SCID MICE	NATURE			English	Article							IMMUNE-DEFICIENT MICE; BONE-MARROW; PROGENITOR CELLS; LEUKEMIA; HEMATOPOIESIS; DIFFERENTIATION; CULTURE; GROWTH; MOUSE	MOST human acute myeloid leukaemia (AML) cells have limited proliferative capacity, suggesting that the leukaemic clone may be maintained. by a rare population of stem cells(1-5). This putative leukaemic stem cell has not been characterized because the available in vitro assays can only detect progenitors with limited proliferative and replating potential(4-7). We have now identified an AML-initiating cell by transplantation into severe combined immune-deficient (SCID) mice. These cells homed to the bone marrow and proliferated extensively in response to in vivo cytokine treatment, resulting in a pattern of dissemination and leukaemic cell morphology similar to that seen in the original patients. Limiting dilution analysis showed that the frequency of these leukaemia-initiating cells in the peripheral blood of AML patients was one engraftment unit in 250,000 cells. We fractionated AML cells on the basis of cell-surface-marker expression and found that the leukaemia-initiating cells that could engraft SCID mice to produce large numbers of colony-forming progenitors were CD34(+) CD38(-); however, the CD34(+) CD38(+) and CD34(-) fractions contained no cells with these properties. This in vivo model replicates many aspects of human AML and defines a new leukaemia-initiating cell which is less mature than colony-forming cells.	UNIV TORONTO, HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X8, ON, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, PQ, CANADA; PRINCESS MARGARET HOSP, DEPT MED, TORONTO M4X 1K9, ON, CANADA; PRINCESS MARGARET HOSP, DEPT ONCOL PATHOL, TORONTO M4X 1K9, ON, CANADA; ROSWELL PK CANC INST, DEPT MED, BUFFALO, NY 14263 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Roswell Park Cancer Institute			Lapidot, Tsvee/A-1812-2010; Vormoor, Josef/GPS-7248-2022	Vormoor, Josef/0000-0002-1825-1890; Dick, John/0000-0002-9527-8317				BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; CESANO A, 1992, ONCOGENE, V7, P827; CIVIN CI, 1984, J IMMUNOL, V133, P157; COULOMBEL L, 1985, J CLIN INVEST, V75, P961, DOI 10.1172/JCI111797; DELORD C, 1991, EXP HEMATOL, V19, P991; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; GRIER HE, 1993, HEMATOLOGY INFANCY C, P1288; GRIFFIN JD, 1986, BLOOD, V68, P1185; KAMELREID S, 1991, BLOOD, V78, P2973; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LOWENBERG B, 1993, BLOOD, V81, P281; MCCULLOCH EA, 1982, J CELL PHYSIOL, P103; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; SAWYERS CL, 1992, BLOOD, V79, P2089, DOI 10.1182/blood.V79.8.2089.bloodjournal7982089; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHIRO R, 1990, BLUT, V61, P267, DOI 10.1007/BF01732875; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156	24	3370	3654	14	239	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					645	648		10.1038/367645a0	http://dx.doi.org/10.1038/367645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	7509044				2022-12-01	WOS:A1994MW68800054
J	NICOLAOU, KC; YANG, Z; LIU, JJ; UENO, H; NANTERMET, PG; GUY, RK; CLAIBORNE, CF; RENAUD, J; COULADOUROS, EA; PAULVANNAN, K; SORENSEN, EJ				NICOLAOU, KC; YANG, Z; LIU, JJ; UENO, H; NANTERMET, PG; GUY, RK; CLAIBORNE, CF; RENAUD, J; COULADOUROS, EA; PAULVANNAN, K; SORENSEN, EJ			TOTAL SYNTHESIS OF TAXOL	NATURE			English	Article							SYSTEM; AGENT	TAXOL(1-4), a substance originally isolated from the Pacific yew tree (Taxus brevifolia) more than two decades ago, has recently been approved for the clinical treatment of cancer patients. Hailed as having provided one of the most significant advances in cancer therapy(5), this molecule exerts its anticancer activity by inhibiting mitosis through enhancement of the polymerization of tubulin and consequent stabilization of microtubules(6). The scarcity of taxol and the ecological impact of harvesting it have prompted extensive searches for alternative sources including semisynthesis, cellular culture production and chemical synthesis(2,3). The latter has been attempted for almost two decades, but these attempts have been thwarted by the magnitude of the synthetic challenge. Here we report the total synthesis of taxol by a convergent strategy, which opens a chemical pathway for the production of both the natural product itself and a variety of designed taxoids.	UNIV CALIF SAN DIEGO, DEPT CHEM, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego	NICOLAOU, KC (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Guy, Rodney/J-7107-2013; Yang, Zhen/GWQ-4960-2022; Yang, Zhen/J-6306-2015	Guy, Rodney/0000-0002-9638-2060; Yang, Zhen/0000-0001-8036-934X				Chamberlin A.R., 1990, ORG REACT, V39, P1; Griffith W. P., 1990, ALDRICHIM ACTA, V23, P13; GUENARD D, 1993, ACCOUNTS CHEM RES, V26, P160, DOI 10.1021/ar00028a005; MAGEE TV, 1992, J ORG CHEM, V57, P3274, DOI 10.1021/jo00038a008; MCMURRY JE, 1989, CHEM REV, V89, P1513, DOI 10.1021/cr00097a007; NICOLAOU KC, 1992, J CHEM SOC CHEM COMM, P1117, DOI 10.1039/c39920001117; NICOLAOU KC, 1993, J CHEM SOC CHEM COMM, P1024, DOI 10.1039/c39930001024; NICOLAOU KC, 1994, J CHEM SOC CHEM COMM, P295, DOI 10.1039/c39940000295; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; NICOLAOU KC, 1992, J CHEM SOC CHEM COMM, P1118, DOI 10.1039/c39920001118; OJIMA I, 1992, TETRAHEDRON, V48, P6985, DOI 10.1016/S0040-4020(01)91210-4; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sharpless K. B., 1979, ALDRICHIM ACTA, V12, P63; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; 1993, PACLITAXEL TAXOF S3, V20, P1	16	978	1098	16	693	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					630	634		10.1038/367630a0	http://dx.doi.org/10.1038/367630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	MW688	7906395				2022-12-01	WOS:A1994MW68800049
J	DONALDSON, YK; BELL, JE; IRONSIDE, JW; BRETTLE, RP; ROBERTSON, JR; BUSUTTIL, A; SIMMONDS, P				DONALDSON, YK; BELL, JE; IRONSIDE, JW; BRETTLE, RP; ROBERTSON, JR; BUSUTTIL, A; SIMMONDS, P			REDISTRIBUTION OF HIV OUTSIDE THE LYMPHOID SYSTEM WITH ONSET OF AIDS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEFICIENCY SYNDROME AIDS; INFECTED INDIVIDUALS; CELLS; BRAIN; MACROPHAGES; DISEASE; RNA; DNA	The basis for many of the symptoms and pathological changes found in patients with the acquired immunodeficiency syndrome (AIDS) remains poorly understood. We have used a quantitative polymerase chain reaction technique to investigate the extent to which direct infection with human immunodeficiency virus (HIV) produces the disease manifestations of AIDS. In five patients who died with AIDS-defining illnesses (Centers for Disease Control and Prevention class IV), we found variable, but in many cases extensive, infection by HIV at various sites, including brain, lung, colon, and liver. By contrast, in three HIV-positive subjects who died without HIV-related disease (CDC class II), we found no evidence of significant infection of any non-lymphoid organ. In both groups of patients there were high levels of infection in cells of the spleen, lymph nodes, and peripheral blood. Pathological examination of tissues from the AIDS patients revealed many abnormalities, of which some, such as giant-cell encephalitis in the brain, were specifically associated with the presence of high levels of HIV infection. These findings suggest that spread of HIV outside cells of the immune system is a late event in HIV infection and is extremely sensitive to the degree of immunosuppression in the patient.	UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; CITY HOSP EDINBURGH,REG INFECT DIS UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; MULRHOUSE GEN PRACTICE,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh				Ironside, James/0000-0001-5869-2108; Simmonds, Peter/0000-0002-7964-4700				BELL JE, 1993, J INFECT DIS, V168, P819; Budka H, 1991, BRAIN PATHOL, V1, P143, DOI 10.1111/j.1750-3639.1991.tb00653.x; CAOY, 1992, AIDS, V6, P65; CLARKE JR, 1990, AIDS, V4, P1133, DOI 10.1097/00002030-199011000-00012; DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HO DD, 1987, NEW ENGL J MED, V317, P278; HOUSSET C, 1990, HUM PATHOL, V21, P404, DOI 10.1016/0046-8177(90)90202-G; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; MACATONIA SE, 1990, IMMUNOLOGY, V71, P38; MOYER MP, 1990, AIDS RES HUM RETROV, V6, P1409, DOI 10.1089/aid.1990.6.1409; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SCHNEIDERMAN DJ, 1987, HEPATOLOGY, V7, P925, DOI 10.1002/hep.1840070522; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SINCLAIR E, 1992, J NEUROL, V239, P469, DOI 10.1007/BF00856814; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILLEY CA, 1986, P NATL ACAD SCI USA, V83, P7089	23	90	91	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					382	385		10.1016/S0140-6736(94)91222-X	http://dx.doi.org/10.1016/S0140-6736(94)91222-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905551				2022-12-01	WOS:A1994MW28300008
J	GRIFFITH, MJ; GARRATT, CJ; MOUNSEY, P; CAMM, AJ				GRIFFITH, MJ; GARRATT, CJ; MOUNSEY, P; CAMM, AJ			VENTRICULAR-TACHYCARDIA AS DEFAULT DIAGNOSIS IN BROAD COMPLEX TACHYCARDIA	LANCET			English	Article							DIFFERENTIAL-DIAGNOSIS; ELECTROCARDIOGRAPHIC CRITERIA; MIS-DIAGNOSIS	In the differential diagnosis of broad complex tachycardia, the most important decision is whether or not the tachycardia is ventricular, since this type carries the worst prognosis. However, the rules for a diagnosis of ventricular tachycardia are so complex that they are not satisfied in many cases, and the default diagnosis, supraventricular tachycardia, is erroneously accepted. We sought to reverse this strategy; unless simple rules for a positive diagnosis of supraventricular tachycardia were satisfied, ventricular tachycardia was diagnosed by default. The criterion for a diagnosis of supraventricular tachycardia was electrocardiographic (ECG) findings typical of bundle branch block (left = rS or QS wave in leads V1 and V2, delay to S wave nadir < 70 ms, and R wave and no Q wave in lead V6; right = rSR' wave in lead V1 and an RS wave in lead V6, with R wave height greater than S wave depth). Twelve-lead ECGs were done for 102 consecutive patients with broad-complex tachycardia (QRS width > 110 ms). Two observers, who were unaware of definitive diagnoses validated by electrophysiology, by our diagnostic rules made correct diagnosis of ventricular tachycardia in 63 and 62 of 69 patients, respectively, and correct diagnoses of supraventricular tachycardia in 28 and 22 of 33 patients (sensitivity for ventricular tachycardia 90% and 91%, specificity 67% and 85%). One observer then sought independent P waves in cases diagnosed as supraventricular tachycardia; sensitivity for the diagnosis of ventricular tachycardia rose to 96%, with a specificity of 64%. These criteria, which require only knowledge of typical bundle branch block patterns, were highly sensitive for the important diagnosis of ventricular tachycardia.	FREEMAN RD HOSP,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; ST GEORGE HOSP,LONDON,ENGLAND; GROBY RD HOSP,LEICESTER,W YORKSHIRE,ENGLAND	Newcastle Freeman Hospital; St Georges University London	GRIFFITH, MJ (corresponding author), QUEEN ELIZABETH HOSP,DEPT CARDIAC,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							BRUGADA P, 1991, CIRCULATION, V83, P1649, DOI 10.1161/01.CIR.83.5.1649; DANCY M, 1985, LANCET, V2, P320; DANCY M, 1985, BRIT MED J, V291, P1036, DOI 10.1136/bmj.291.6501.1036; GRIFFITH MJ, 1992, EUR HEART J, V13, P478, DOI 10.1093/oxfordjournals.eurheartj.a060200; GRIFFITH MJ, 1991, BRIT HEART J, V66, P166; GRIFFITH MJ, 1988, LANCET, V1, P672; KINDWALL KE, 1988, AM J CARDIOL, V61, P1279, DOI 10.1016/0002-9149(88)91169-1; Marriott H. J. L., 1966, PROG CARDIOVASC DIS, V9, P18; MARRIOTT HJ, 1970, GERIATRICS, V25, P91; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; TCHOU P, 1988, AM J MED, V84, P53, DOI 10.1016/0002-9343(88)90008-3; Wellens H J, 1987, Cardiol Clin, V5, P511	12	72	78	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					386	388		10.1016/S0140-6736(94)91223-8	http://dx.doi.org/10.1016/S0140-6736(94)91223-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905552				2022-12-01	WOS:A1994MW28300009
J	LAI, ME; MAZZOLENI, AP; ARGIOLU, F; DEVIRGILIS, S; BALESTRIERI, A; PURCELL, RH; CAO, A; FARCI, P				LAI, ME; MAZZOLENI, AP; ARGIOLU, F; DEVIRGILIS, S; BALESTRIERI, A; PURCELL, RH; CAO, A; FARCI, P			HEPATITIS-C VIRUS IN MULTIPLE EPISODES OF ACUTE HEPATITIS IN POLYTRANSFUSED THALASSEMIC CHILDREN	LANCET			English	Note							NON-B-HEPATITIS; NON-A	We investigated the course of distinct episodes of acute non-A, non-B (NANB) hepatitis in three polytransfused thalassaemic children. In each case, the first episode was associated with the appearance of serum hepatitis C virus (HCV) RNA and anti-HCV seroconversion. The second episode was accompanied by the reappearance of HCV viraemia, which in two patients was due to reinfection with a different HCV strain and in the third could be the result of either reactivation of primary infection or reinfection with a new but closely related strain. Thus HCV infection may not induce protective immunity, which has implications for vaccine development.	UNIV CAGLIARI,INST CLIN & BIOL DEV AGE,CAGLIARI,ITALY; UNIV CAGLIARI,CTR THALASSAEMIA,CAGLIARI,ITALY; NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892	University of Cagliari; University of Cagliari; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LAI, ME (corresponding author), UNIV CAGLIARI,INST INTERNAL MED,VIA SAN GIORGIO 12,I-09124 CAGLIARI,ITALY.							CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; FARCIP, 1992, SCIENCE, V258, P135; GALBRAITH RM, 1979, LANCET, V1, P951; HRUBY MA, 1978, JAMA-J AM MED ASSOC, V240, P1355; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAI ME, 1993, J PEDIATR GASTR NUTR, V16, P458, DOI 10.1097/00005176-199305000-00020; MOSLEY JW, 1977, NEW ENGL J MED, V296, P75, DOI 10.1056/NEJM197701132960204; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J	9	255	260	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					388	390		10.1016/S0140-6736(94)91224-6	http://dx.doi.org/10.1016/S0140-6736(94)91224-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905553				2022-12-01	WOS:A1994MW28300010
J	MARKHAM, RB; COBERLY, J; RUFF, AJ; HOOVER, D; GOMEZ, J; HOLT, E; DESORMEAUX, J; BOULOS, R; QUINN, TC; HALSEY, NA				MARKHAM, RB; COBERLY, J; RUFF, AJ; HOOVER, D; GOMEZ, J; HOLT, E; DESORMEAUX, J; BOULOS, R; QUINN, TC; HALSEY, NA			MATERNAL IGG1 AND IGA ANTIBODY TO V3 LOOP CONSENSUS SEQUENCE AND MATERNAL-INFANT HIV-1 TRANSMISSION	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120; MOTHERS	Maternal-infant transmission of HIV-1 occurs in 13-40% of pregnancies. Studies on transmission of maternal immunity to HIV antigens have used antigens from viruses not representative of clinical isolates and have been conflicting. Using a consensus peptide sequence based on HIV isolates found in Haiti, we found that Haitian mothers who transmitted infection to their offspring had significantly higher mean concentrations of IgG1 antibodies to the V3 loop of the primary neutralising domain of the viral envelope (gp 160) than non-transmitters (p = 0.02). Concentrations of IgA antibody to this domain were similar in transmitters and non-transmitters.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; CTR DEV & HLTH,PORT AU PRINCE,HAITI	Johns Hopkins University; Johns Hopkins University	MARKHAM, RB (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028748, R01AI032468] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32468, P30 AI28748] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; YERLY S, 1992, J INFECT DIS, V166, P269, DOI 10.1093/infdis/166.2.269; 1992, J ACQUIR IMMUN DEFIC, V5, P1019	9	31	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					390	391		10.1016/S0140-6736(94)91225-4	http://dx.doi.org/10.1016/S0140-6736(94)91225-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905554	hybrid			2022-12-01	WOS:A1994MW28300011
J	MORTIMER, PP				MORTIMER, PP			A LURKING ENDEMIC	LANCET			English	Editorial Material											MORTIMER, PP (corresponding author), CENT PUBL HLTH LAB,HEPATITIS & RETROVIRUS LAB,DIV VIRUS REFERENCE,LONDON,ENGLAND.							CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Flaum A., 1926, ACTA MED SCAND, V16, P544; HERSH S, 1993, AIDS, V7, P1617; Laird S. M., 1947, GLASGOW MED JOUR, V28, P199; MCNEE J, 1952, BMJ-BRIT MED J, V1, P1367, DOI 10.1136/bmj.1.4773.1367; PATRASCU IV, 1993, AIDS RES HUM RETROV, V9, P99, DOI 10.1089/aid.1993.9.99; POKROVSKY VV, 1989, 5 INT C AIDS MONTR; Salaman MH, 1944, LANCET, V2, P7; Sheehan HL, 1944, LANCET, V2, P8; VICKERS J, 1994, CDR REV, V4, P1; 1922, REPORTS SALVARSAN CO, V2; 1993, MMWR, V24, P969; 1943, LANCET, V1, P83	14	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					368	370		10.1016/S0140-6736(94)91216-5	http://dx.doi.org/10.1016/S0140-6736(94)91216-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905545				2022-12-01	WOS:A1994MW28300002
J	STEWART, THM; RETSKY, MW; TSAI, SCJ; VERMA, S				STEWART, THM; RETSKY, MW; TSAI, SCJ; VERMA, S			DOSE-RESPONSE IN THE TREATMENT OF BREAST-CANCER	LANCET			English	Editorial Material							GROWTH-FACTOR; CARCINOMA; CELLS; GLUCOCORTICOIDS; THERAPY; CULTURE; INVITRO; INVIVO	We present evidence that drugs that are effective in causing regression of metastatic breast cancer in a dose-dependent fashion also cause a dose-dependent reduction of cytokines produced by the immune system. This may be an important factor in the occasional induction of a complete remission.	UNIV COLORADO, COLORADO SPRINGS, CO USA; ROCHE DIAGNOST SYST, BRANCHBURG, NJ USA; OTTAWA REG CANC CTR, OTTAWA, ON, CANADA	University of Colorado System; University of Colorado at Colorado Springs; Roche Holding; University of Ottawa; Ottawa Hospital Research Institute	STEWART, THM (corresponding author), OTTAWA GEN HOSP, ROOM LM-18, 501 SMYTH RD, OTTAWA K1H 8L6, ON, CANADA.							BASOLO F, 1992, INT J CANCER, V51, P634, DOI 10.1002/ijc.2910510421; BESCH GJ, 1986, CANCER RES, V46, P2306; COOPER KD, 1990, J AM ACAD DERMATOL, V23, P1318, DOI 10.1016/0190-9622(90)70360-T; DEMICHELI R, 1991, TUMORI J, V77, P189, DOI 10.1177/030089169107700302; DEMICHELI R, 1992, P AN M AM SOC CLIN, V11, P100; DODWELL DJ, 1993, LANCET, V341, P614, DOI 10.1016/0140-6736(93)90366-O; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; HIRAOKA D, 1987, CANCER RES, V47, P6560; JORDAN VC, 1992, SEMIN ONCOL, V19, P299; KURTZ JM, 1990, J CLIN ONCOL, V8, P591, DOI 10.1200/JCO.1990.8.4.591; LARSSON EL, 1980, J IMMUNOL, V124, P2828; LIPPMAN M, 1976, CANCER RES, V36, P4602; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MCCULLOUGH JL, 1983, PSORIASIS CELL PROLI, P347; MEAKIN JW, 1979, CAN MED ASSOC J, V120, P1221; Meropol N J, 1992, Oncology (Williston Park), V6, P53; MICHIEL DF, 1992, CANCER BIOL, V3, P3; OLSEN GA, 1988, TRANSPLANTATION, V46, P57, DOI 10.1097/00007890-198807000-00009; PREHN RT, 1980, INSERM, V97, P297; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; RETSKY MW, 1993, ADJUVANT THERAPY BRE, P13; RUBENS RD, 1988, BRIT J CANCER, V58, P626, DOI 10.1038/bjc.1988.273; RUBENS RD, 1991, MED MANAGEMENT BREAS, P117; SHEARER WT, 1978, FED PROC, V37, P2385; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STOLL BA, 1963, BMJ-BRIT MED J, P210, DOI 10.1136/bmj.2.5351.210; WAAGE A, 1990, EUR J IMMUNOL, V20, P2439, DOI 10.1002/eji.1830201112; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x; WELTE K, 1984, BLOOD, V64, P380	31	15	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	1994	343	8894					402	404						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905558				2022-12-01	WOS:A1994MW28300015
J	BRAATEN, BA; NOU, XW; KALTENBACH, LS; LOW, DA				BRAATEN, BA; NOU, XW; KALTENBACH, LS; LOW, DA			METHYLATION PATTERNS IN PAP REGULATORY DNA CONTROL PYELONEPHRITIS-ASSOCIATED PILI PHASE VARIATION IN ESCHERICHIA-COLI	CELL			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; X-CHROMOSOME INACTIVATION; URINARY-TRACT; EXPRESSION; PROTEIN; MODEL; METHYLTRANSFERASE; TRANSPOSITION; REPLICATION; MECHANISM	We have examined the roles of pap DNA methylation patterns in the regulation of the switch between phase ON and OFF pyelonephritis-associated pill (Pap) expression states in E. coli. Two Dam methyltransferase sites, GATC(1028) and GATC(1130), were shown previously to be differentially methylated in phase ON versus phase OFF cells. In work presented here, these sites were mutated so that they could not be methylated, and the effects of these mutations on Pap phase variation were examined. Our results show that methylation of GATC(1028) blocks formation of the ON state by inhibiting the binding of Lrp and Papl regulatory proteins to this site. Conversely, methylation of GATC(1130) is required for the ON state. Evidence indicates that this occurs by the inhibition of binding of Lrp to sites overlapping the pilin promoter. A model describing how the transition between the phase ON and OFF methylation states might occur is presented.			BRAATEN, BA (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA.		Low, David A/M-7536-2014		NCI NIH HHS [5P30 CA42014-07] Funding Source: Medline; NIAID NIH HHS [5K04 AI881, 2R01 AI23348] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BAGA M, 1985, EMBO J, V4, P3887, DOI 10.1002/j.1460-2075.1985.tb04162.x; BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BLYN LB, 1989, EMBO J, V8, P613, DOI 10.1002/j.1460-2075.1989.tb03416.x; BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAATEN BA, 1992, P NATL ACAD SCI USA, V89, P4250, DOI 10.1073/pnas.89.10.4250; BRAATEN BA, 1991, J BACTERIOL, V173, P1789, DOI 10.1128/jb.173.5.1789-1800.1991; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; FEDOROFF N, 1989, BIOESSAYS, V10, P139, DOI 10.1002/bies.950100502; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GORANSSON M, 1989, MOL MICROBIOL, V3, P1557, DOI 10.1111/j.1365-2958.1989.tb00141.x; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Holliday R, 1993, EXS, V64, P452; Hultgren SJ, 1991, CURR OPIN GENET DEV, V1, P313, DOI 10.1016/S0959-437X(05)80293-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOW D, 1987, MOL MICROBIOL, V1, P335, DOI 10.1111/j.1365-2958.1987.tb01940.x; MARINUS MG, 1984, GENE, V28, P123, DOI 10.1016/0378-1119(84)90095-7; MODRICH P, 1989, J BIOL CHEM, V264, P6597; NOU XW, 1993, MOL MICROBIOL, V7, P545, DOI 10.1111/j.1365-2958.1993.tb01145.x; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; OHANLEY P, 1985, NEW ENGL J MED, V313, P414, DOI 10.1056/NEJM198508153130704; PETERSON KR, 1985, MOL GEN GENET, V201, P14, DOI 10.1007/BF00397979; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; ROBERTS JA, 1989, INFECTION, V17, P401, DOI 10.1007/BF01645559; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; VANDERWOUDE MW, 1992, MOL MICROBIOL, V6, P2429; WANG MX, 1992, NATURE, V360, P606, DOI 10.1038/360606a0; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806	41	156	161	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					577	588		10.1016/0092-8674(94)90120-1	http://dx.doi.org/10.1016/0092-8674(94)90120-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	7906204				2022-12-01	WOS:A1994MX20700017
J	CAPOVILLA, M; BRANDT, M; BOTAS, J				CAPOVILLA, M; BRANDT, M; BOTAS, J			DIRECT REGULATION OF DECAPENTAPLEGIC BY ULTRABITHORAX AND ITS ROLE IN DROSOPHILA MIDGUT MORPHOGENESIS	CELL			English	Article							HOMEODOMAIN RECOGNITION HELIX; DNA-SEQUENCE RECOGNITION; HOMEOTIC GENE-EXPRESSION; VISCERAL MESODERM; BITHORAX COMPLEX; HOMEOBOX GENE; ANTENNAPEDIA HOMEODOMAIN; ECTOPIC EXPRESSION; PATTERN-FORMATION; GERM LAYERS	Drosophila homeotic genes encode transcription factors thought to control segmental identity by regulating expression of largely unknown target genes. The formation of the second midgut constriction requires the Ultrabithorax (Ubx) and abdominal-A (abd-A) homeotic genes and decapentaplegic (dpp), a gene encoding a member of the TGF beta family of proteins. We identified a 674 bp enhancer of dpp controlling its expression in the second constriction domain of the visceral mesoderm (parasegment 7). Normal enhancer function requires positive regulation by Ubx and negative regulation by abd-A. This enhancer contains UBX- and ABD-A-binding sites defined in vitro. By generating complementary alterations of the binding sites and the binding specificity of UBX, we show that Ubx directly regulates dpp expression. These regulatory interactions are relevant to normal development, because a transgene made with this enhancer driving a dpp transcription unit rescues the second midgut constriction and larval lethality phenotypes of dpp(s) mutations.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	CAPOVILLA, M (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.		Capovilla, Maria/O-8483-2016	Capovilla, Maria/0000-0002-1308-7964				AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; APPEL B, 1993, EMBO J, V12, P1099, DOI 10.1002/j.1460-2075.1993.tb05751.x; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOFFMANN FM, 1987, GENE DEV, V1, P615, DOI 10.1101/gad.1.6.615; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JONES B, 1993, GENE DEV, V7, P229, DOI 10.1101/gad.7.2.229; Kaufman T C, 1990, Adv Genet, V27, P309; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MALLCKI J, 1990, CELL, V63, P961; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; OHARA E, 1993, DEVELOPMENT, V117, P847; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1990, EMBO J, V11, P382; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1990, DEVELOPMENT, V110, P1031; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHLER AF, 1992, NATURE, V356, P804; SCHMID P, 1991, DEVELOPMENT, V111, P117; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TREISMAN J, 1989, CELL, V59, P553; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	71	167	168	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					461	475		10.1016/0092-8674(94)90111-2	http://dx.doi.org/10.1016/0092-8674(94)90111-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	7906203				2022-12-01	WOS:A1994MX20700008
J	NIEHRS, C; STEINBEISSER, H; DEROBERTIS, EM				NIEHRS, C; STEINBEISSER, H; DEROBERTIS, EM			MESODERMAL PATTERNING BY A GRADIENT OF THE VERTEBRATE HOMEOBOX GENE GOOSECOID	SCIENCE			English	Article							XENOPUS-LAEVIS; EMBRYOS; EXPRESSION; TRANSCRIPTION; ORGANIZER; ACTIVIN; HOMOLOG; ACTIVATION; INDUCTION; DOMAIN	Amphibian mesoderm arises from the marginal zone of the early gastrula and generates various tissues such as notochord, muscle, kidney, and blood. Small changes (twofold) in the amount of microinjected messenger RNA encoding the goosecoid (gsc) homeodomain protein resulted in marked changes in the differentiation of mesoderm in Xenopus laevis. At least three thresholds were observed, which were sufficient to specify four mesodermal cell states. Endogenous gsc messenger RNA was expressed in the marginal zone in a graded fashion that is congruent with a role for this gene in dorso-ventral patterning of mesoderm at the early gastrula stage.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD21502-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1987, DEVELOPMENT, V100, P279; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; NIEHRS C, UNPUB; NUSSLEINVOLHARD C, 1901, DEVELOPMENT S, V1, P1; PATIENT RK, 1982, NUCLEIC ACIDS RES, V10, P7935, DOI 10.1093/nar/10.24.7935; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SCHULTEMERKER S, IN PRESS DEVELOPMENT; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	27	149	149	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					817	820		10.1126/science.7905664	http://dx.doi.org/10.1126/science.7905664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	7905664				2022-12-01	WOS:A1994MV86600038
J	GRAVES, BJ; CROWTHER, RL; CHANDRAN, C; RUMBERGER, JM; LI, S; HUANG, KS; PRESKY, DH; FAMILLETTI, PC; WOLITZKY, BA; BURNS, DK				GRAVES, BJ; CROWTHER, RL; CHANDRAN, C; RUMBERGER, JM; LI, S; HUANG, KS; PRESKY, DH; FAMILLETTI, PC; WOLITZKY, BA; BURNS, DK			INSIGHT INTO E-SELECTIN LIGAND INTERACTION FROM THE CRYSTAL-STRUCTURE AND MUTAGENESIS OF THE LEC EGF DOMAINS	NATURE			English	Article							LEUKOCYTE-ADHESION MOLECULE-1; GROWTH FACTOR-ALPHA; MANNOSE-BINDING PROTEIN; NODE HOMING RECEPTOR; CARBOHYDRATE-RECOGNITION; EVOLUTIONARY CONSERVATION; FUNCTIONAL INTERACTIONS; NMR-SPECTROSCOPY; CELL-ADHESION; P-SELECTIN	The three-dimensional structure of the ligand-binding region of human E-selectin has been determined at 2.0 angstrom resolution. The structure reveals limited contact between the two domains and a coordination of Ca2+ not predicted from other C-type lectins. Structure/function analysis indicates a defined region and specific amino-acid side chains that may be involved in ligand binding. These features of the E-selectin/ligand interaction have important implications for understanding the recruitment of leukocytes to sites of inflammation.			GRAVES, BJ (corresponding author), HOFFMANN LA ROCHE INC,ROCHE RES CTR,NUTLEY,NJ 07110, USA.							BARON M, 1992, PROTEIN SCI, V1, P81; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BVALL GE, 1992, J AM CHEM SOC, V114, P5449; DEFREES SA, 1993, J AM CHEM SOC, V115, P7549, DOI 10.1021/ja00069a083; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARIGAN JD, 1992, DNA CELL BIOL, V11, P149, DOI 10.1089/dna.1992.11.149; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LI SH, IN PRESS J BIOL CHEM; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PIGOTT R, 1991, J IMMUNOL, V147, P130; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SCALLON BJ, 1992, BIO-TECHNOL, V10, P550, DOI 10.1038/nbt0592-550; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STRUBEL NA, 1993, BIOCHEM BIOPH RES CO, V192, P338, DOI 10.1006/bbrc.1993.1420; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WELLER A, 1992, J BIOL CHEM, V267, P15176; WORMALD MR, 1991, BIOCHEM BIOPH RES CO, V180, P1214, DOI 10.1016/S0006-291X(05)81325-7; 1992, SYBYL MOL MODELING S	52	403	418	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					532	538		10.1038/367532a0	http://dx.doi.org/10.1038/367532a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509040				2022-12-01	WOS:A1994MV86300050
J	LEE, HS; HUANG, SS; KAO, TH				LEE, HS; HUANG, SS; KAO, TH			S-PROTEINS CONTROL REJECTION OF INCOMPATIBLE POLLEN IN PETUNIA-INFLATA	NATURE			English	Article							SELF-INCOMPATIBILITY; NICOTIANA-ALATA; RIBONUCLEASE-ACTIVITY; ALLELES; EXPRESSION; HYBRIDA	FLOWERING plants have evolved various stratagems to prevent inbreeding and promote outcrosses1. One such mechanism, gametophytic self-incompatibility, provides a genetic barrier to self-fertilization, and in the simplest cases is controlled by the highly polymorphic S locus2. Growth of a pollen tube in the style is arrested when the S allele carried by the pollen matches one of the two S alleles carried by the pistil. Putative S allele proteins of the pistil have been identified in several solanaceous species based on their co-segregation with S alleles3-12, and they have been shown to be ribonucleases13-15. So far. there has been only correlative or indirect evidence for the claim that these S allele-associated proteins (S proteins) are involved in recognition and rejection of self pollen16,17. Here we show that inhibition of synthesis of S3 and S2 proteins in Petunia inflata plants of S2S3 genotype by the antisense S3 gene resulted in failure of the transgenic plants to reject S3 and S2 pollen. We further show that expression of the transgene encoding S3 protein in P. inflata plants of S1S2 genotype confers on the transgenic plants the ability to reject S3 pollen. The self-incompatibility behaviour of the pollen was not affected by the transgene in either set of experiments. Taken together, these findings provide direct in vivo evidence that S proteins control the self-incompatibility behaviour of the pistil.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIV PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University								AI YJ, 1991, MOL GEN GENET, V230, P353, DOI 10.1007/BF00280291; AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; BREDEMEIJER GMM, 1981, THEOR APPL GENET, V59, P185, DOI 10.1007/BF00264974; BROOTHAERTS W, 1991, SEX PLANT REPROD, V4, P258, DOI 10.1007/BF00200545; BROOTHAERTS WJ, 1989, PLANT MOL BIOL, V14, P93; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; COLEMAN CE, 1992, PLANT MOL BIOL, V18, P725, DOI 10.1007/BF00020014; De Nettancourt D., 1977, MONOGRAPHS THEORETIC, P28; FRANKEL R, 1977, MONOGRAPHS THEORETIC, P5; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; IOERGER TR, 1991, SEX PLANT REPROD, V4, P81; KAMBOJ RK, 1986, THEOR APPL GENET, V71, P815, DOI 10.1007/BF00276423; KHEYRPOUR A, 1990, SEX PLANT REPROD, V3, P88, DOI 10.1007/BF00198851; KIRCH HH, 1989, THEOR APPL GENET, V78, P581, DOI 10.1007/BF00290845; LEE HS, 1992, PLANT MOL BIOL, V20, P1131, DOI 10.1007/BF00028899; LEWIS D, 1949, HEREDITY, V3, P339, DOI 10.1038/hdy.1949.25; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; MAU SL, 1986, PLANTA, V169, P184, DOI 10.1007/BF00392312; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; SIMS TL, 1993, CRIT REV PLANT SCI, V12, P129, DOI 10.1080/07352689309382359; SINGH A, 1991, PLANT PHYSIOL, V96, P61, DOI 10.1104/pp.96.1.61; SINGH A, 1992, SEXUAL REPRODUCTION, P449; XU B, 1990, SEX PLANT REPROD, V3, P54, DOI 10.1007/BF00189952	25	333	374	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					560	563		10.1038/367560a0	http://dx.doi.org/10.1038/367560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509041				2022-12-01	WOS:A1994MV86300059
J	OCONNOR, JJ; ROWAN, MJ; ANWYL, R				OCONNOR, JJ; ROWAN, MJ; ANWYL, R			LONG-LASTING ENHANCEMENT OF NMDA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION BY METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION	NATURE			English	Article							TERM POTENTIATION; TRANS-ACPD; TRANS-1-AMINOCYCLOPENTANE-1,3-DICARBOXYLIC ACID; RAT HIPPOCAMPUS; CURRENTS; SLICES; CELLS; RESPONSES; AGONIST	SYNAPTIC transmission mediated by the N-methyl-D-aspartate (NMDA) glutamate receptor plays a key role in a range of plastic processes in the nervous system. These include long-term potentiation of synaptic transmission mediated by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor, neuronal development, excitotoxicity and certain learning tasks1,2. Recently, long-term potentiation of NMDA receptor-mediated synaptic transmission was found to occur following high-frequency (tetanic) stimulation via an unknown mechanism3-7. We show here that activation of metabotropic glutamate (mGlu) receptors by neurally released transmitter underlies this type of long-term potentiation. The whole-cell patch-clamp technique in the 'thick' slice of the rat dentate gyrus was used to measure NMDA receptor-mediated excitatory postsynaptic currents. We have found that mGlu receptor activation by a selective agonist produced a long-lasting enhancement which was mutually exclusive with long-term potentiation of these NMDA currents. Moreover, both forms of potentiation were greatly reduced by the mGlu receptor antagonists L-2-amino-3-phosphonopropionate and (R,S)-alpha-methyl-4-carboxyphenylglycine.	UNIV DUBLIN TRINITY COLL, DEPT PHARMACOL & THERAPEUT, DUBLIN 2, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT PHYSIOL, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin				O'Connor, John/0000-0001-8229-8602; Rowan, Michael Joseph/0000-0002-3867-9536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BEHNISCH T, 1991, NEUROREPORT, V2, P386, DOI 10.1097/00001756-199107000-00008; BERETTA N, 1991, EUR J NEUROSCI, V3, P850; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; CERNE R, 1992, NEUROSCI LETT, V144, P180, DOI 10.1016/0304-3940(92)90745-S; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1992, INT ACAD B, V2, P41; COLLINS GGS, 1993, BRIT J PHARMACOL, V108, P422, DOI 10.1111/j.1476-5381.1993.tb12820.x; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LOVINGER DM, 1991, NEUROSCI LETT, V129, P17, DOI 10.1016/0304-3940(91)90710-B; MCGUINNESS N, 1991, NEUROREPORT, V2, P688, DOI 10.1097/00001756-199111000-00014; MCGUINNESS N, 1991, EUR J PHARMACOL, V197, P231, DOI 10.1016/0014-2999(91)90529-Y; MULLER D, 1992, HIPPOCAMPUS, V2, P29, DOI 10.1002/hipo.450020105; MUSGRAVE MA, 1993, NEUROREPORT, V4, P171, DOI 10.1097/00001756-199302000-00014; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; XIE X, 1992, NEUROPHYSIOL, V67, P1009	24	160	162	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					557	559		10.1038/367557a0	http://dx.doi.org/10.1038/367557a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7906392				2022-12-01	WOS:A1994MV86300058
J	UMEMORI, H; SATO, S; YAGI, T; AIZAWA, S; YAMAMOTO, T				UMEMORI, H; SATO, S; YAGI, T; AIZAWA, S; YAMAMOTO, T			INITIAL EVENTS OF MYELINATION INVOLVE FYN TYROSINE KINASE SIGNALING	NATURE			English	Article							CELL ANTIGEN RECEPTOR; SRC PROTEIN; TERMINAL REGION; GLYCOPROTEIN; ASSOCIATION; FAMILY; ADHESION; BRAIN; EXPRESSION; EFFICIENT	MYELIN is the lipoprotein multimembrane that functions as an insulator preventing the flow of ion currents across the axonal membrane and facilitating the conduction of nerve impulses. It is synthesized by oligodendrocytes in the central nervous system at about the time of birth in mammals1. During the initial stages of myelination, several proteins are phosphorylated on tyrosine. Among these proteins, we identified Fyn tyrosine kinase, one of the non-receptor-type tyrosine kinases of the Src family. Here we report that Fyn tyrosine kinase is activated during the initial stages of myelination and that it is associated with the large myelin-associated glycoprotein (MAG), an adhesion molecule that has been implicated in myelinogenesis2. The Fyn-large MAG association requires amino-terminal domains of Fyn that include SH2 and SH3 (Src homology domains 2 and 3). Crosslinking of large MAG with antibody induces a rapid increase in the specific activity of Fyn kinase. These results indicate that Fyn participates in the initial events of myelination as a signalling molecule downstream of large MAG; indeed, we find that fyn-deficient mice exhibit impaired myelination.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROL,NIIGATA 951,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Niigata University; RIKEN			Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Umemori, Hisashi/0000-0001-7198-2062				Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DUNCAN ID, 1990, MYELINATION DYSMYELI; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; EISEMAN E, 1992, NATURE, V355, P78; FUJITA N, 1989, BIOCHEM BIOPH RES CO, V165, P1162, DOI 10.1016/0006-291X(89)92724-1; FUJITA N, 1990, J NEUROCHEM, V55, P1056, DOI 10.1111/j.1471-4159.1990.tb04596.x; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STERNBERGER NH, 1979, P NATL ACAD SCI USA, V76, P1510, DOI 10.1073/pnas.76.3.1510; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; SUKEGAWA J, 1990, ONCOGENE, V5, P611; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	30	341	348	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					572	576		10.1038/367572a0	http://dx.doi.org/10.1038/367572a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509042				2022-12-01	WOS:A1994MV86300063
J	BARR, CS; NAAS, A; FREEMAN, M; LANG, CC; STRUTHERS, AD				BARR, CS; NAAS, A; FREEMAN, M; LANG, CC; STRUTHERS, AD			QT DISPERSION AND SUDDEN UNEXPECTED DEATH IN CHRONIC HEART-FAILURE	LANCET			English	Article							PLASMA NOREPINEPHRINE; INTERVAL PROLONGATION; PROGNOSTIC IMPORTANCE; MORTALITY; PREDICTORS; RISK	Death in chronic heart failure (CHF) can be from progression of disease or sudden and unexpected. We have attempted to identify factors that predict sudden death in CHF. We followed up 44 patients with CHF for 12-50 (mean 36) months. 4 patients died of non-cardiovascular causes and were excluded from analysis. There were 7 sudden deaths (symptoms for less than 1 h in a previously stable patient) and 12 from progressive CHF. Patients who died of progressive CHF had lower left-ventricular ejection fractions and higher concentrations of atrial natriuretic factor than the 21 survivors, but there were no differences in these variables between survivors and those who died suddenly. However, the sudden death group had significantly (p<0.05) greater inter-lead variability in the QT interval on the electrocardiogram (QT dispersion; 98.6 [95% CI 79.1-118] ms1/2) than survivors (53.1 [41.9-64.3] ms1/2) or the group who died from progressive CHF (66.7 [51.8-81.6] ms%). QT dispersion is a marker of myocardial electrical instability. The association of increased QT dispersion with sudden death suggests that patients at high risk of such death could be identified by means of this simple, reproducible test. This group might benefit from more intensive treatment.			BARR, CS (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.			Lang, Chim/0000-0002-4530-3078; Struthers, Allan/0000-0002-2926-2528				ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; CLELAND JGF, 1987, BRIT HEART J, V58, P572; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; DAY CP, 1990, BRIT HEART J, V63, P342; DAY CP, 1993, LANCET, V341, P1423; FRANCIS GS, 1990, CARDIOSCIENCE, V1, P29; GOTTLIEB SS, 1990, J AM COLL CARDIOL, V16, P827, DOI 10.1016/S0735-1097(10)80329-8; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V13, P1534, DOI 10.1016/0735-1097(89)90344-6; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; Higham P. D., 1993, European Heart Journal, V14, P86; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; MERX W, 1977, AM HEART J, V94, P603, DOI 10.1016/S0002-8703(77)80130-0; PACKER M, 1987, AM J MED, V82, P4, DOI 10.1016/0002-9343(87)90126-4; Potratz J., 1993, European Heart Journal, V14, P254; PUDDU PE, 1986, J ELECTROCARDIOL, V19, P203, DOI 10.1016/S0022-0736(86)80030-9; PUDDU PE, 1982, J ELECTROCARDIOL, V15, P15, DOI 10.1016/S0022-0736(82)80040-X; SCHOUTEN EG, 1991, CIRCULATION, V84, P1516, DOI 10.1161/01.CIR.84.4.1516; STEVENSON WG, 1988, AM HEART J, V116, P1447, DOI 10.1016/0002-8703(88)90727-2	21	641	646	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					327	329		10.1016/S0140-6736(94)91164-9	http://dx.doi.org/10.1016/S0140-6736(94)91164-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905146				2022-12-01	WOS:A1994MU98500010
J	GOODEVE, AC; PRESTON, FE; PEAKE, IR				GOODEVE, AC; PRESTON, FE; PEAKE, IR			FACTOR-VIII GENE REARRANGEMENTS IN PATIENTS WITH SEVERE HEMOPHILIA-A	LANCET			English	Note							HEMOPHILIA-A	Sequences within intron 22 of the factor VIII (FVIII) gene have been implicated in the cause of haemophilia in almost 50% of severely affected patients. The changes result from intrachromosomal rearrangements of the tip of the long arm of the X chromosome, one break-point being within intron 22 of the FVIII gene. The rearrangements can be identified by Southern blot and we report use of this procedure to detect rearrangements in 11 of 23 unrelated families with severe haemophilia A. Of 22 patients studied, none of the 10 with the gene rearrangement had at any time developed inhibitors to FVIII, compared with 7 of 12 lacking the rearrangement.	ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,HAEMATOL SECT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,MOLEC GENET SECT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield				Goodeve, Anne/0000-0002-6177-7062				HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; MILLAR DS, 1990, HUM GENET, V86, P219; NAYLOR J, 1993, HUM MOL GENET, V2, P1773, DOI 10.1093/hmg/2.11.1773; NAYLOR JA, 1993, HUM MOL GENET, V2, P11, DOI 10.1093/hmg/2.1.11; PEAKE IR, 1993, BLOOD COAGUL FIBRIN, V4, P313, DOI 10.1097/00001721-199304000-00013; WION KL, 1986, NUCLEIC ACIDS RES, V14, P4553	7	66	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					329	330		10.1016/S0140-6736(94)91165-7	http://dx.doi.org/10.1016/S0140-6736(94)91165-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905147				2022-12-01	WOS:A1994MU98500011
J	HEAGERTY, AM				HEAGERTY, AM			WINNING RHYTHM	LANCET			English	Editorial Material											HEAGERTY, AM (corresponding author), UNIV HOSP S MANCHESTER,DEPT MED,MANCHESTER M20 8LR,LANCS,ENGLAND.			Heagerty, Anthony/0000-0002-9043-2119				BENNET WC, 1935, TARAHUMARA INDIAN TR, P113; EDWARDS RG, 1972, J APPL PHYSIOL, V32, P386, DOI 10.1152/jappl.1972.32.3.386; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P270; OROURKE M, 1993, AUST NZ J MED, V23, P703; PALATINI P, 1989, J APPL PHYSIOL, V67, P52, DOI 10.1152/jappl.1989.67.1.52; ROST R, 1983, MUNCHEN MED WOCHEN, V125, P1025; ROWE WJ, 1992, LANCET, V340, P712, DOI 10.1016/0140-6736(92)92243-9; ROWELL LB, 1968, CIRCULATION, V37, P954, DOI 10.1161/01.CIR.37.6.954; VANCITTERS RL, 1969, CIRC RES, V24, P33, DOI 10.1161/01.RES.24.1.33	9	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					310	310		10.1016/S0140-6736(94)91160-6	http://dx.doi.org/10.1016/S0140-6736(94)91160-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905142				2022-12-01	WOS:A1994MU98500006
J	LISSAU, I; SORENSEN, TIA				LISSAU, I; SORENSEN, TIA			PARENTAL NEGLECT DURING CHILDHOOD AND INCREASED RISK OF OBESITY IN YOUNG ADULTHOOD	LANCET			English	Article							BODY-MASS INDEX; ADOPTION	The association of various features of family life with obesity in childhood is well established, but less is known about the effect of these influences on the risk of later obesity. In this prospective, population-based study, we examined the influence of parental care in childhood on the risk of obesity in the offspring in young adulthood. In 1974, 1258 pupils aged 9-10 years were randomly selected from the third grade of Copenhagen schools. Information on 987 pupils was obtained from the form teachers on family structure and the perceived support from the parents; school medical services reported on the child's general hygiene. 756 (86%) of the 881 eligible participants were followed up 10 years later. The influence of family factors in childhood on the risk of obesity (body-mass index > 95th centile) in young adulthood was estimated by odds ratios with control for age and body-mass index in 1974, sex, and social background. Family structure (biological or other parents and number of siblings) did not significantly affect the risk of adult obesity. Parental neglect greatly increased the risk in comparison with harmonious support (odds ratio 7.1 [95% CI 2.6-19.3]). Dirty and neglected children had a much greater risk of adult obesity than averagely groomed children (9.8 [3.5-28.2]). However, being an only child, receiving overprotective parental support, or being well-groomed had no effect. Parental neglect during childhood predicts a great risk of obesity in young adulthood, independent of age and body-mass index in childhood, sex, and social background.	UNIV COPENHAGEN, RIGSHOSP, DEPT PAEDIAT, DK-2100 COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen	LISSAU, I (corresponding author), KOMMUNE HOSP COPENHAGEN, INST PREVENT MED, COPENHAGEN HLTH SERV, DK-1399 COPENHAGEN, DENMARK.		Lissau, Inge/AAJ-3971-2020	Lissau, Inge/0000-0002-2225-9975				BRUCH H, 1957, IMPORTANCE OVERWEIGH; DIETZ WH, 1984, AM J CLIN NUTR, V39, P619, DOI 10.1093/ajcn/39.4.619; DIETZ WH, 1986, PEDIATR CLIN N AM, V33, P823; FRIISASCHE E, 1981, THESIS COPENHAGEN; GARROW JS, 1992, INT J OBESITY, V16, pS59; GARROW JS, 1988, MANAGEMENT PREVENTIO; HERTZEL BS, 1987, CARDIOVASCULAR RISK; JOHNSTON FE, 1985, ANN INTERN MED, V103, P1068, DOI 10.7326/0003-4819-103-6-1068; KINSTON W, 1988, J PSYCHOSOM RES, V32, P513, DOI 10.1016/0022-3999(88)90036-0; LISSAU I, 1993, INT J OBESITY, V17, P125; LISSAU I, 1993, INT J OBESITY, V17, P169; LISSAU I, 1993, THESIS U COPENHAGEN; LISSAULUNDSORENSEN I, 1992, INT J OBESITY, V16, P169; LOADER PJ, 1985, INT J EAT DISORDER, V4, P211, DOI 10.1002/1098-108X(198505)4:2<211::AID-EAT2260040208>3.0.CO;2-P; POWER C, 1988, INT J OBESITY, V12, P445; QUAADE F, 1955, OBESE CHILDREN ANTHR; SILVERMAN WK, 1987, BEHAV THERAPIST, V10, P197; SORENSEN TIA, 1992, INT J OBESITY, V16, P705; SORENSEN TIA, 1992, INT J OBESITY, V16, P227; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; 1985, SAS USERS GUIDE STAT	21	316	320	1	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					324	327		10.1016/S0140-6736(94)91163-0	http://dx.doi.org/10.1016/S0140-6736(94)91163-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905145				2022-12-01	WOS:A1994MU98500009
J	LOUTAN, L; BOVIER, P; ALTHAUS, B; GLUCK, R				LOUTAN, L; BOVIER, P; ALTHAUS, B; GLUCK, R			INACTIVATED VIROSOME HEPATITIS-A VACCINE	LANCET			English	Article							SUPPRESSION	Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and tolerability of an IRIV-HAV vaccine and the effectiveness of a booster by immunising 104 healthy HAV seronegative volunteers. A single dose was highly immunogenic, since 98% of volunteers had seroconverted after 2 weeks. Anti-HAV titres remained high, with 100% seroconversion rate 1 year later, when the booster was given. The vaccine was effective, with a 22-fold increase in geometric mean titres 1 month later. No serious adverse reactions were observed.	SWISS SERUM & VACCINE INST, DEPT MED & VIROL, BERN, SWITZERLAND		LOUTAN, L (corresponding author), UNIV GENEVA, HOP CANTONAL, DEPT MED, MED POLICLIN, COMMUNITY MED UNIT, CH-1211 GENEVA 14, SWITZERLAND.							AMBROSCH F, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P98; ANDRE FE, 1990, PROG MED VIROL, V37, P72; ANDRE FE, 1992, VACCINE, V10, pS160, DOI 10.1016/0264-410X(92)90576-6; ETLINGER HM, 1990, SCIENCE, V249, P423, DOI 10.1126/science.1696030; GLUCK R, 1992, J CLIN INVEST, V90, P2491, DOI 10.1172/JCI116141; GLUCK R, 1993, 3RD C INT TRAV MED P; GUPTA RK, 1993, VACCINE, V11, P293, DOI 10.1016/0264-410X(93)90190-9; HERZENBERG LA, 1982, J EXP MED, V155, P1730, DOI 10.1084/jem.155.6.1730; MILLINER DS, 1985, NEW ENGL J MED, V312, P165, DOI 10.1056/NEJM198501173120307; POOVORAWAN Y, IN PRESS J INFECT DI; SCHUTZE MP, 1989, J IMMUNOL, V142, P2635; 1992, LANCET, V339, P1198	12	75	77	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 5	1994	343	8893					322	324		10.1016/S0140-6736(94)91162-2	http://dx.doi.org/10.1016/S0140-6736(94)91162-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905144				2022-12-01	WOS:A1994MU98500008
J	ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH				ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH			INTENSIVE CHEMOTHERAPY FOR PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Note							LEUKEMIA	Childhood acute lymphoblastic leukaemia with the classic Philadelphia chromosome translocation is fatal in patients treated with chemotherapy alone. We report probable cures in three adolescents and one child who received extensively reinforced, early chemotherapy followed by rotational treatment with pairs of non-cross-resistant drugs. The median duration of leukaemia-free survival in this subgroup is 6.5 years (range 6-8 years). The two patients with long-term bone marrow surveillance for residual disease showed no evidence of the Philadelphia chromosome at 31 and 53 months post-remission. Such intensive chemotherapy is a reasonable option for patients who are not able to undergo bone marrow transplantation.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	ROBERTS, WM (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Pui, Ching-Hon/N-8076-2018; Raimondi, Susana C/N-8166-2018	Pui, Ching-Hon/0000-0003-0303-5658; 	NCI NIH HHS [P01 CA20180, P30 CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT AJ, 1992, BLOOD, V79, P3067; CRIST W, 1990, BLOOD, V76, P489; DOW LW, 1989, BLOOD, V73, P1291; FLETCHER JA, 1992, LEUKEMIA LYMPHOMA, V8, P75, DOI 10.3109/10428199209049820; MIYAMURA K, 1993, BLOOD, V81, P1089; PRIEST JR, 1980, BLOOD, V56, P15; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RIBEIRO RC, 1993, HEMATOL PATHOL, V7, P121; RIBEIRO RC, 1987, BLOOD, V70, P948; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SURYANARAYAN K, 1991, BLOOD, V77, P324	11	48	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					331	332		10.1016/S0140-6736(94)91166-5	http://dx.doi.org/10.1016/S0140-6736(94)91166-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905148				2022-12-01	WOS:A1994MU98500012
J	THOMPSON, C				THOMPSON, C			IGE DECLARES WAR ON PARASITES	LANCET			English	Editorial Material							SCHISTOSOMIASIS; REINFECTION; RESISTANCE											BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; CAPRON A, 1992, MEM I OSWALDO CRUZ, V87, P19, DOI [10.1590/S0074-02761992000800003, 10.1016/S0171-2985(11)80480-8]; CAPRON M, 1986, Parasitology Today, V2, P69, DOI 10.1016/0169-4758(86)90158-4; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; GUONNI AS, 1994, NATURE, V67, P183; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; 1993, WHO TECH REP SER, V830, P86	7	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					309	310		10.1016/S0140-6736(94)91159-2	http://dx.doi.org/10.1016/S0140-6736(94)91159-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905141				2022-12-01	WOS:A1994MU98500005
J	WALD, NJ; BOWER, C				WALD, NJ; BOWER, C			FOLIC-ACID, PERNICIOUS-ANEMIA, AND PREVENTION OF NEURAL-TUBE DEFECTS	LANCET			English	Editorial Material											WALD, NJ (corresponding author), MED COLL ST BARTHOLOMEWS HOSP,WOLFSON INST PREVENT MED,LONDON,ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; WALD NJ, 1994, CIBA F SYMP, V181, P192; 1992, MMWR, V41, P1; 1994, BRIT MED J, V208, P223; 1991, LANCET, V338, P132; 1992, FOLIC ACID PREVENTIO	6	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					307	307		10.1016/S0140-6736(94)91156-8	http://dx.doi.org/10.1016/S0140-6736(94)91156-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905138				2022-12-01	WOS:A1994MU98500002
J	JACOBS, RE; FRASER, SE				JACOBS, RE; FRASER, SE			MAGNETIC-RESONANCE MICROSCOPY OF EMBRYONIC-CELL LINEAGES AND MOVEMENTS	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; XENOPUS-LAEVIS; NMR MICROSCOPY; INTRACELLULAR INJECTION; MOUSE EMBRYOS; FATE MAP; RESOLUTION; RETINA; RETROVIRUS; BLASTOMERE	Key events in vertebrate embryogenesis are difficult to observe in many species. High-resolution magnetic resonance imaging was used to follow cell movements and lineages in developing frog embryos. A single cell was injected at the 16-cell stage with a contrast agent, based on the gadolinium chelate gadolinium-diethylenetriamine pentaacetic acid-dextran. The labeled progeny cells could be followed uniquely in three-dimensional magnetic resonance images, acquired from the embryo over several days. The results show that external ectodermal and internal mesodermal tissues extend at different rates during amphibian gastrulation and neurulation.			JACOBS, RE (corresponding author), CALTECH,BECKMAN INST 13974,DIV BIOL,PASADENA,CA 91125, USA.		Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223	NICHD NIH HHS [HD 25390] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025390] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUAYO JB, 1986, NATURE, V322, P190, DOI 10.1038/322190a0; AHN CB, 1989, MED PHYS, V16, P22, DOI 10.1118/1.596393; AKERS RM, 1986, SCIENCE, V231, P613, DOI 10.1126/science.3945801; BALAKIER H, 1982, DEV BIOL, V90, P352, DOI 10.1016/0012-1606(82)90384-0; BEHLING RW, 1989, NATURE, V341, P321, DOI 10.1038/341321a0; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CALLAGHAN PT, 1988, J MAGN RESON, V78, P1, DOI 10.1016/0022-2364(88)90151-5; CALLAGHAN PT, 1991, PRINCIPLES NUCLEAR M; CAMERON RA, 1987, GENE DEV, V1, P75, DOI 10.1101/gad.1.1.75; CHO ZH, 1988, MED PHYS, V15, P815, DOI 10.1118/1.596287; CONNER WE, 1988, EXPERIENTIA, V44, P11, DOI 10.1007/BF01960223; DALE L, 1987, DEVELOPMENT, V99, P527; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; ECCLES CD, 1986, J MAGN RESON, V68, P393, DOI 10.1016/0022-2364(86)90261-1; EFFMANN EL, 1988, TERATOLOGY, V38, P59, DOI 10.1002/tera.1420380109; GIBBY WA, 1989, INVEST RADIOL, V24, P302, DOI 10.1097/00004424-198904000-00009; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GLOVER P, 1989, 8TH ANN M SOC MAGN R, P285; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEDGECOCK EM, 1985, TRENDS NEUROSCI, V8, P288, DOI 10.1016/0166-2236(85)90104-3; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; JACKSON GE, 1990, MAGNET RESON MED, V16, P57, DOI 10.1002/mrm.1910160107; JACOBS RR, COMMUNICATION; JENNER CF, 1988, NATURE, V336, P399, DOI 10.1038/336399a0; JOHNSON GA, 1986, J MAGN RESON, V68, P129, DOI 10.1016/0022-2364(86)90322-7; KELLER R, 1991, GASTRULATION MOVEMEN; KELLER RE, 1985, NEW SERIES, V31; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KUHN W, 1990, ANGEW CHEM INT EDIT, V29, P1, DOI 10.1002/anie.199000013; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; LEE DH, 1991, J CAN ASSOC RADIOL, V42, P6; MAKI JH, 1988, J MAGN RESON, V80, P482, DOI 10.1016/0022-2364(88)90243-0; Mansfield P., 1982, NMR IMAGING BIOMEDIC; Mathews WW., 1986, ATLAS DESCRIPTIVE EM; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SLACK JMW, 1992, DEVELOPMENT, V114, P285; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WANG SC, 1990, RADIOLOGY, V175, P483, DOI 10.1148/radiology.175.2.1691513; WEISBLAT DA, 1980, SCIENCE, V209, P1538, DOI 10.1126/science.6159680; WEISBLAT DA, 1978, SCIENCE, V202, P1295, DOI 10.1126/science.725606; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WETTS R, 1989, DEVELOPMENT, V105, P9; WILSON PA, 1989, DEVELOPMENT, V105, P155; ZHOU X, 1989, 8TH ANN M SOC MAGN R, P286; [No title captured]	52	144	158	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					681	684		10.1126/science.7508143	http://dx.doi.org/10.1126/science.7508143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	7508143				2022-12-01	WOS:A1994MU96400049
J	BRAIG, HR; GUZMAN, H; TESH, RB; ONEILL, SL				BRAIG, HR; GUZMAN, H; TESH, RB; ONEILL, SL			REPLACEMENT OF THE NATURAL WOLBACHIA SYMBIONT OF DROSOPHILA-SIMULANS WITH A MOSQUITO COUNTERPART	NATURE			English	Article							CYTOPLASMIC INCOMPATIBILITY; REPRODUCTIVE ISOLATION; POPULATIONS	INHERITED rickettsial symbionts of the genus Wolbachia occur commonly in arthropods and have been implicated in the expression of parthenogenesis1,2, feminization2,3 and cytoplasmic incompatibility phenomena in their respective hosts4-7. Here we use purified Wolbachia from the Asian tiger mosquito, Aedes albopictus, to replace the natural infection of Drosophila simulans by means of embryonic microinjection techniques. The transferred Wolbachia infection behaves like a natural Drosophila infection with regard to its inheritance, cytoskeleton interactions and ability to induce incompatibility when crossed with uninfected flies. The trans-infected flies are bidirectionally incompatible with all other naturally infected strains of Drosophila simulans, however, and as such represent a unique crossing type. The successful transfer of this symbiont between distantly related hosts suggests that it may be possible to introduce this agent experimentally into arthropod species of medical and agricultural importance in order to manipulate natural populations genetically.			BRAIG, HR (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 3333,NEW HAVEN,CT 06510, USA.		O'Neill, Scott/R-9560-2019; O'Neill, Scott L/B-3568-2009; Braig, Henk/I-5477-2013	O'Neill, Scott/0000-0002-4131-3615; O'Neill, Scott L/0000-0002-4131-3615; Braig, Henk/0000-0001-9592-1141				BEARD CB, 1993, PARASITOL TODAY, V9, P179, DOI 10.1016/0169-4758(93)90142-3; BOYLE L, 1993, SCIENCE, V260, P1796, DOI 10.1126/science.8511587; Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BREEUWER JAJ, 1993, GENETICS, V135, P565; CURTIS CF, 1992, NATURE, V357, P450, DOI 10.1038/357450b0; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HSIAO C, 1985, J INVERTEBR PATHOL, V45, P244, DOI 10.1016/0022-2011(85)90016-3; JOST E, 1970, THEOR APPL GENET, V40, P251, DOI 10.1007/BF00282034; LAVEN H, 1959, COLD SPRING HARB SYM, V24, P166, DOI 10.1101/SQB.1959.024.01.017; MONTCHAMPMOREAU C, 1991, GENETICS, V129, P399; NIGRO L, 1991, HEREDITY, V66, P41, DOI 10.1038/hdy.1991.5; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; RIGAUD T, 1993, GENETICS, V133, P247; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V250, P91, DOI 10.1098/rspb.1992.0135; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V247, P163, DOI 10.1098/rspb.1992.0023; RYAN SL, 1968, MOL GEN GENET, V103, P29, DOI 10.1007/BF00271154; Simon C., 1991, MOL TECHNIQUES TAXON, P329; SOUTHAMER R, 1993, NATURE, V361, P66; TURELLI M, 1991, NATURE, V353, P440, DOI 10.1038/353440a0; WADE MJ, 1985, SCIENCE, V227, P527, DOI 10.1126/science.3966160; YEN JH, 1971, NATURE, V232, P657, DOI 10.1038/232657a0	24	127	143	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					453	455		10.1038/367453a0	http://dx.doi.org/10.1038/367453a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7906391				2022-12-01	WOS:A1994MU67900052
J	HUANG, MX; CHALFIE, M				HUANG, MX; CHALFIE, M			GENE INTERACTIONS AFFECTING MECHANOSENSORY TRANSDUCTION IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							SODIUM-CHANNEL; EXPRESSION; NEURONS; PROTEIN	GENETIC screening has identified a group of mec (mechanosensory) genes that are required for the function of a set of six touch-receptor neurons in the nematode Caenorhabditis elegans1,2. Such genes potentially encode components of the mechanosensory apparatus. We have cloned one of these genes, mec-10, which is a member of the degenerin gene family (genes such as mec-4 and deg-1 (refs 3, 4) that can be mutated to cause neurodegeneration). Because components of an amiloride-sensitive sodium channel (alpha, beta and gammarENaC) from rat6-8 share considerable sequence similarity with the C. elegans genes, it is likely that degenerins may function as channel proteins. Here we show that two degenerin homologues (mec-4 and mec-10) are expressed in the same cells, although each provides a unique function. Based on genetic data of mutations affecting mec-10-induced degeneration, we propose that the products of three genes (mec-4, mec-10 and mec-6) form a complex needed for mechanosensation, and that several other mec genes may be important in regulating the putative channel complex.			HUANG, MX (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,1012 FAIRCHILD CTR,NEW YORK,NY 10027, USA.							BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MITANI S, 1993, DEVELOPMENT, V119, P373; PALOZZOLO MJ, 1990, GENE, V88, P25; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; SULSTON J, 1988, CAENORHABDITIS ELEGA; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	24	337	362	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					467	470		10.1038/367467a0	http://dx.doi.org/10.1038/367467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7509039				2022-12-01	WOS:A1994MU67900056
J	KOKUBO, T; GONG, DW; WOOTTON, JC; HORIKOSHI, M; ROEDER, RG; NAKATANI, Y				KOKUBO, T; GONG, DW; WOOTTON, JC; HORIKOSHI, M; ROEDER, RG; NAKATANI, Y			MOLECULAR-CLONING OF DROSOPHILA TFIID SUBUNITS	NATURE			English	Article							MAJOR LATE PROMOTER; RNA POLYMERASE-II; TATA BOX-BINDING; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; PROTEIN; NUCLEOSOME; COACTIVATORS; INITIATION	TRANSCRIPTION initiation factor TFIID is a multisubunit complex containing a TATA-box-binding factor (TFIIDtau/TBP) and associated polypeptide factors (TAFs) with sizes ranging from M(r) approximately 20,000 to >200,000 (refs 1-7). As a result of direct promoter interactions8,9, TFIID nucleates the assembly of RNA polymerase II and other initiation factors into a functional preinitiation complex10. Although the native TFIID complex mediates both basal and activator-dependent transcription in reconstituted systems, TBP itself is competent for only basal transcription. Thus, TAFs are essential cofactors for regulated transcription. The complementary DNAs encoding the p230 (M(r) 230,000), p110 and p85 subunits of TFIID have recently been cloned11-18. Here we report the molecular cloning and characterization of the p62, p42, p28 and p22 subunits. These participate in a network of heterogeneous protein-protein interactions within TFIID. Sequence similarities between p62/p42 and the histones H4/H3, respectively, suggest that these subunits have a functional relationship with chromatin.	NICHHD,BETHESDA,MD 20892; NINCDS,BETHESDA,MD 20892; NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20892; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Rockefeller University; University of Tokyo								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GASH A, 1990, NATURE, V346, P390; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TABASSUM R, 1992, J BACTERIOL, V174, P7890, DOI 10.1128/JB.174.24.7890-7895.1992; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; Wolffe Alan P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P167; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	30	105	109	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					484	487		10.1038/367484a0	http://dx.doi.org/10.1038/367484a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7545910				2022-12-01	WOS:A1994MU67900061
J	OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M				OBRIEN, S; KANTARJIAN, H; ESTEY, E; KOLLER, C; ROBERTSON, B; BERAN, M; ANDREEFF, M; PIERCE, S; KEATING, M			LACK OF EFFECT OF 2-CHLORODEOXYADENOSINE THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA REFRACTORY TO FLUDARABINE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HAIRY-CELL LEUKEMIA; PLASMA; AGENT	Background. Fludarabine and 2-chlorodeoxyadenosine are nucleoside analogues that have proved effective in patients with chronic lymphocytic leukemia (CLL). Although their mechanism of action is thought to be similar, a small number of patients who do not respond to fludarabine do respond to 2-chlorodeoxyadenosine. The extent to which 2-chlorodeoxyadenosine is effective in patients who do not respond to fludarabine is not known, however. Methods. We treated 28 patients with CLL refractory to fludarabine therapy with a continuous infusion of 2-chlorodeoxyadenosine at a daily dose of 4 mg per square meter of body-surface area for seven days. The treatment could be repeated monthly. The number of treatments ranged from one to five; patients who responded continued to receive treatment until the maximal response was achieved. Results. Two patients (7 percent) had partial remissions, but no patients had complete remissions. One other patient had a substantial response but had residual thrombocytopenia. The rate of response in most affected organs was 20 percent, but anemia or thrombocytopenia rarely improved. Myelosuppression was frequent, and 65 percent of the courses of 2-chlorodeoxyadenosine therapy were accompanied by febrile episodes or infections. Ten patients died within 60 days of starting therapy with 2-chlorodeoxyadenosine; eight deaths were related to infection. The median platelet count at the start of 2-chlorodeoxyadenosine therapy in these 10 patients was 24,000 per cubic millimeter, as compared with 109,000 per cubic millimeter in the other 18 patients. Five patients were alive after a median follow-up of 24 months. Conclusions. Patients with advanced CLL refractory to fludarabine therapy are unlikely to benefit from treatment with 2-chlorodeoxyadenosine. Although 20 percent of the patients have some response, thrombocytopenia and anemia are rarely corrected and may be made worse by 2-chlorodeoxyadenosine therapy.			OBRIEN, S (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 61,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145; DELANNOY A, 1993, NEW ENGL J MED, V328, P812; ESTEY EH, 1992, BLOOD, V79, P882; GANDHI V, 1993, LEUKEMIA LYMPHOMA, V10, P49, DOI 10.3109/10428199309147356; JULIUSSON G, 1993, J CLIN ONCOL, V11, P679, DOI 10.1200/JCO.1993.11.4.679; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; KEATING MJ, 1989, BLOOD, V74, P19; LILIEMARK J, 1991, BLOOD S, V78, pA33; LILIEMARK JO, 1985, CANCER RES, V45, P5952; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; PIRO LD, 1988, BLOOD, V72, P1069; PLUNKETT W, 1993, CHRONIC LYMPHOCYTIC, V1, P197; ROBERTSON LE, 1993, BLOOD, V81, P143; SAVEN A, 1991, LEUKEMIA LYMPHOMA, V5, P133, DOI 10.3109/10428199109103394	15	82	84	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					319	322		10.1056/NEJM199402033300504	http://dx.doi.org/10.1056/NEJM199402033300504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	7904047				2022-12-01	WOS:A1994MU48900004
J	EPSTEIN, JI; WALSH, PC; CARMICHAEL, M; BRENDLER, CB				EPSTEIN, JI; WALSH, PC; CARMICHAEL, M; BRENDLER, CB			PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; TRANSRECTAL ULTRASOUND; ANTIGEN; ADENOCARCINOMA; VOLUME; DIFFERENTIATION; PROGNOSIS; DISEASE	Objectives.-We examined preoperative clinical and pathologic parameters in men with clinical stage T1c disease who underwent radical prostatectomy and correlated these findings with the pathologic extent of disease in the surgical specimen in an attempt to identify a subset of patients with potentially biologically insignificant tumor who might be followed up without immediate treatment. Design and Patients.-A case series of 157 consecutive men who underwent radical prostatectomy for clinical stage T1c disease compared with 64 similarly treated clinical stage T1a cancers (incidental minimal cancers found on transurethral resection of prostate) and 439 clinical stage T2 (palpable) cancers. Main Outcome Measures.-Pathologic stage, grade, and margins; tumor volume; and tumor location. Results.-Sixteen percent of tumors were insignificant (<0.2 cm3 and confined to the prostate, with a Gleason score <7); 10% were minimal (0.2 to 0.5 cm3 and confined to the prostate, with a Gleason score <7); 37% were moderate (>0.5 cm3 or capsular penetration, with a Gleason score <7); and 37% were advanced (capsular penetration, with a Gleason score greater-than-or-equal-to 7 or positive margins, seminal vesicles, or lymph nodes). These findings are intermediate between those found in clinical stage T1a and stage T2 disease. The following parameters were not predictive of tumor extent: age, reason for evaluation, method of detection, and transrectal ultrasound. The best model predicting insignificant tumor was prostate-specific antigen (PSA) density less than 0.1 ng/mL per gram and no adverse pathologic findings on needle biopsy, or PSA density of 0.1 to 0.15 ng/mL per gram, with a low- to intermediate-grade cancer smaller than 3 mm found in only one needle biopsy core specimen. The positive predictive value of the model was 95%, with a negative predictive value of 66%. We accurately predicted 73% of cases with insignificant tumor. Conclusions.-Eighty-four percent of nonpalpable prostate cancers diagnosed by screening techniques are significant tumors and warrant definitive therapy. However, 16% are insignificant. Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent. lt may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies.	JOHNS HOPKINS UNIV HOSP,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University								BASTACKY SS, 1991, J UROLOGY, V145, P1003, DOI 10.1016/S0022-5347(17)38513-0; BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CARTER HB, 1989, J UROLOGY, V142, P1008, DOI 10.1016/S0022-5347(17)38971-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; EPSTEIN JI, 1993, CANCER-AM CANCER SOC, V71, P3582, DOI 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; EPSTEIN JI, 1993, J UROLOGY, V149, P1478, DOI 10.1016/S0022-5347(17)36421-2; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LARSEN MP, 1991, J UROLOGY, V146, P1059, DOI 10.1016/S0022-5347(17)38000-X; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PALKEN M, 1991, J UROLOGY, V145, P86, DOI 10.1016/S0022-5347(17)38254-X; PARTIN AW, 1989, J UROLOGY, V141, P341, DOI 10.1016/S0022-5347(17)40761-0; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; Stamey TA, 1992, CAMPBELLS UROLOGY, P1200; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; TERRIS MK, 1992, J UROLOGY, V148, P829, DOI 10.1016/S0022-5347(17)36735-6; WHITMORE WF, 1990, UROL CLIN N AM, V17, P689	23	1461	1495	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					368	374		10.1001/jama.271.5.368	http://dx.doi.org/10.1001/jama.271.5.368			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	7506797				2022-12-01	WOS:A1994MR98300032
J	SCHECHTER, M; HARRISON, LH; HALSEY, NA; TRADE, G; SANTINO, M; MOULTON, LH; QUINN, TC				SCHECHTER, M; HARRISON, LH; HALSEY, NA; TRADE, G; SANTINO, M; MOULTON, LH; QUINN, TC			COINFECTION WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I AND HIV IN BRAZIL - IMPACT ON MARKERS OF HIV DISEASE PROGRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS-DRUG-USERS; HTLV-II; HOMOSEXUAL MEN; LEUKEMIA; INFECTION; RETROVIRUS; AIDS; LYMPHOCYTES; LYMPHOMA; CLINICS	Objectives.-To study the effect of human T-cell lymphtropic virus type I (HTLV-1) on markers of human immunodeficiency virus (HIV) disease progression. Design.-A retrospective, nested case-control study. Setting.-A university hospital outpatient HIV clinic in Rio de Janeiro, Brazil. Participants.-Human immunodeficiency virus-seropositive adults participating in a prospective HIV cohort study. Main Outcome Measures.-The HIV clinical stage, CD4+ lymphocyte counts, and other laboratory parameters in 27 individuals infected with HIV and HTLV-1 (coinfection) and 99 age-matched, HIV-seropositive, HTLV-seronegative controls (single infection). Results.-Variables independently associated with coinfection included higher CD4+ lymphocyte count (odds ratio [OR], 2.3; 95% confidence limits [CL], 1.3, 4.1), higher CD4+ percentage (OR, 2.0; 95% CL, 1.3, 3.2), beta2-Microglobulin level of 254 nmol/L or more (OR, 6.8; 95% CL, 1.3, 35.4), World Health Organization stages 3 and 4 (OR, 4.4; 95% CL, 1.1, 18.0), and reporting a parenteral risk factor (OR, 7.4; 95% CL, 1.4, 38.9). When stratified by p24 antigenemia, coinfection was associated with an estimated 82% higher CD4+ lymphocyte count (P<.05). Conclusion.-Coinfection was associated with higher CD4+ lymphocyte counts, more advanced clinical disease, and higher beta2-MiCroglobulin levels than HIV infection alone. The higher mean CD4+ lymphocyte count does not appear to offer immunologic benefit. Caution should be exercised when using CD4+ lymphocytes as a surrogate marker in studies of HIV infection in-populations where HTLV-I is prevalent. Further studies are needed to address whether current CD4+ lymphocyte values for the initiation of antiretroviral therapy and chemoprophylaxis against opportunistic infections in HIV infection are appropriate in coinfection.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,ROOM 5515,615 N WOLFE ST,BALTIMORE,MD 21205; UNIV FED RIO DE JANEIRO,HOSP UNIV CLEMENTINO FRAGA FILHO,DEPT PREVENT MED,INFECT DIS SERV,RIO JANEIRO,BRAZIL; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NIAID,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Universidade Federal do Rio de Janeiro; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University				Moulton, Lawrence/0000-0001-7041-7387				[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BARTHOLOMEW C, 1987, LANCET, V2, P1469; BARTHOLOMEW C, 1990, 6TH INT C AIDS SAN F; BOLLINGER RC, 1992, J INFECT DIS, V165, P913, DOI 10.1093/infdis/165.5.913; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; CLEGHORN FR, 1992, ARCH INTERN MED, V152, P1372, DOI 10.1001/archinte.152.7.1372; DESORMEAUX J, 1991, 7TH INT C AIDS FLOR; GALLO RC, 1991, J INFECT DIS, V164, P235, DOI 10.1093/infdis/164.2.235; HERSHOW RC, 1993, 9TH INT C AIDS BERL; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HJELLE B, 1991, J INFECT DIS, V163, P435, DOI 10.1093/infdis/163.3.435; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HORTA B L, 1992, Boletin de la Oficina Sanitaria Panamericana, V113, P131; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KRIMER A, 1990, HUMAN RETROVIROLOGY, P79; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LIMA LAA, 1993, AIDS, V7, P295, DOI 10.1097/00002030-199302000-00031; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MOREIRA ED, 1993, J ACQ IMMUN DEF SYND, V6, P959; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAGLIUCA A, 1990, LANCET, V336, P383, DOI 10.1016/0140-6736(90)91931-Y; PARK LP, 1992, J ACQ IMMUN DEF SYND, V5, P1124; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUINN TC, 1989, NEW ENGL J MED, V320, P1005, DOI 10.1056/NEJM198904133201509; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROSENBLATT JD, 1987, LEUKEMIA, V1, P397; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; SCHECHTER M, 1992, 8TH INT C AIDS AMST; VILLIGER PM, 1991, J IMMUNOL, V146, P550; WEISS SH, 1989, 5 INT C AIDS MONTR; WEISS SH, 1992, 1992 ANN M SPONS LAB; WELLES SL, 1992, 5TH P INT C HUM RETR; WIKTOR SZ, 1992, J INFECT DIS, V165, P920, DOI 10.1093/infdis/165.5.920; WIKTOR SZ, 1991, LANCET, V337, P327, DOI 10.1016/0140-6736(91)90947-N; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P2110, DOI 10.1073/pnas.89.6.2110; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; 1989, MMWR MORB MORTAL WKL, V38, P845	40	83	86	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					353	357		10.1001/jama.271.5.353	http://dx.doi.org/10.1001/jama.271.5.353			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	7904317				2022-12-01	WOS:A1994MR98300029
J	CLAES, G; DROTT, C				CLAES, G; DROTT, C			HYPERHIDROSIS	LANCET			English	Editorial Material											CLAES, G (corresponding author), BORAS HOSP,DEPT SURG,BORAS,SWEDEN.							BYRNE J, 1990, BRIT J SURG, V77, P1046, DOI 10.1002/bjs.1800770931; CLAES G, 1993, SCAND J PLAST RECONS, V27, P29, DOI 10.3109/02844319309080288; EDMONDSON RA, 1992, ANN SURG, V215, P289, DOI 10.1097/00000658-199203000-00015; Hughes J, 1942, Proc R Soc Med, V35, P585; Kotzareff A, 1920, REV MED SUISSE ROM, V40, P111; KUX E, 1954, THORAKOSKOPISCHE EIN	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					247	248		10.1016/S0140-6736(94)91105-3	http://dx.doi.org/10.1016/S0140-6736(94)91105-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905089				2022-12-01	WOS:A1994MT44000003
J	CROSS, AS				CROSS, AS			INDUCING AN ABSCESS	LANCET			English	Editorial Material							POLYSACCHARIDE; BACTEROIDES				CROSS, AS (corresponding author), WALTER REED ARMY INST RES,DEPT SOCIOL,WASHINGTON,DC 20307, USA.							BYCROFT BW, 1989, ANTIMICROB AGENTS CH, V33, P1516, DOI 10.1128/AAC.33.9.1516; DOMENICO P, 1993, J INFECT DIS, V168, P766, DOI 10.1093/infdis/168.3.766; ONDERDONK AB, 1977, J INFECT DIS, V136, P82, DOI 10.1093/infdis/136.1.82; RANNEY DF, 1985, SCIENCE, V227, P182, DOI 10.1126/science.3966151; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SHAPIRO ME, 1982, J EXP MED, V154, P1188; TAKAHASHI T, 1991, INFECT IMMUN, V59, P18, DOI 10.1128/IAI.59.1.18-23.1991; TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161; VERINGA EM, 1989, J ANTIMICROB CHEMOTH, V23, P577, DOI 10.1093/jac/23.4.577; WEINSTEIN WM, 1975, J INFECT DIS, V132, P282, DOI 10.1093/infdis/132.3.282	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					248	249		10.1016/S0140-6736(94)91106-1	http://dx.doi.org/10.1016/S0140-6736(94)91106-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905090				2022-12-01	WOS:A1994MT44000004
J	DOCKE, WD; PROSCH, S; FIETZE, E; KIMEL, V; ZUCKERMANN, H; KLUG, C; SYRBE, U; KRUGER, DH; VONBAEHR, R; VOLK, HD				DOCKE, WD; PROSCH, S; FIETZE, E; KIMEL, V; ZUCKERMANN, H; KLUG, C; SYRBE, U; KRUGER, DH; VONBAEHR, R; VOLK, HD			CYTOMEGALOVIRUS REACTIVATION AND TUMOR-NECROSIS-FACTOR	LANCET			English	Note							FACTOR-ALPHA; IMMUNODEFICIENCY; CELLS	Tumour necrosis factor-alpha (TNF) stimulates cytomegalovirus (CMV) activity in a transfected human monocytic cell line. We assessed whether this finding is relevant in vivo by evaluating the frequency of active CMV infection in patients with diseases that enhance plasma TNF. In septic disease, peripheral blood mononuclear cells of almost all patients studied were positive for CMV. Furthermore, CMV antigenaemia and enhanced plasma TNF occurred in many patients with liver cirrhosis, common variable immunodeficiency, and B-cell chronic lymphocytic leukaemia. Thus, TNF may have a central role in CMV reactivation.	HUMBOLDT UNIV BERLIN,MED SCH CHARITE,INST VIROL,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,MED SCH CHARITE,DEPT SURG,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,MED SCH CHARITE,DEPT ANAESTHESIOL & INTENS CARE,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	DOCKE, WD (corresponding author), HUMBOLDT UNIV BERLIN,MED SCH CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY.		volk, hans-dieter/AAV-8053-2021; Syrbe, Uta/T-7557-2017	volk, hans-dieter/0000-0002-7743-6668; Syrbe, Uta/0000-0001-8463-7890				CORDONNIER C, 1990, Revue de Pneumologie Clinique, V46, P244; DOCKE WD, 1991, LANCET, V338, P1597, DOI 10.1016/0140-6736(91)92422-X; FOA R, 1990, BLOOD, V76, P393; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; PROSCH S, 1992, J MED VIROL, V38, P246, DOI 10.1002/jmv.1890380404; RUBIN RH, 1990, REV INFECT DIS    S7, V12, P5754; STEIN J, 1993, J GEN VIROL, V74, P2333, DOI 10.1099/0022-1317-74-11-2333; TANAKA S, 1992, HEPATOLOGY, V16, P1409, DOI 10.1002/hep.1840160617; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; TLG H, 1992, GASTROENTEROLOGY, V103, P264	10	216	218	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					268	269		10.1016/S0140-6736(94)91116-9	http://dx.doi.org/10.1016/S0140-6736(94)91116-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905100				2022-12-01	WOS:A1994MT44000014
J	HEAGERTY, AHM; FITZGERALD, D; SMITH, A; BOWERS, B; JONES, P; FRYER, AA; ZHAO, L; ALLDERSEA, J; STRANGE, RC				HEAGERTY, AHM; FITZGERALD, D; SMITH, A; BOWERS, B; JONES, P; FRYER, AA; ZHAO, L; ALLDERSEA, J; STRANGE, RC			GLUTATHIONE-S-TRANSFERASE GSTM1 PHENOTYPES AND PROTECTION AGAINST CUTANEOUS TUMORS	LANCET			English	Note							SQUAMOUS-CELL CARCINOMA; CANCER SUSCEPTIBILITY; RISK; SKIN	Multiple allelism at loci encoding detoxicating enzymes is associated with cancer risk. We have studied genetic variation at the glutathione S-transferase GSTM1 locus to see whether phenotypes confer altered susceptibility to basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), or multiple skin tumours of different histological types. The frequency of GSTM1 null in cases and controls (52%) was similar, except for patients with two or more tumours of different types (71%, p = 0.033). GSTM1 A/B was reduced in frequency (p < 0.05) in patients with single or multiple BCC. Thus GSTM1 A/B may be protective, and effectiveness of detoxication may be a factor determining susceptibility to skin cancer.	ROYAL CORNWALL HOSP,DEPT DERMATOL,TRURO,CORNWALL,ENGLAND; UNIV KEELE,DEPT MATH,KEELE ST5 5BG,STAFFS,ENGLAND; KEELE UNIV,N STAFFORDSHIRE HOSP,SCH POSTGRAD MED,CTR PATHOL & MOLEC MED,STOKE ON TRENT,STAFFS,ENGLAND	Royal Cornwall Hospital; Keele University; Keele University; University Hospital of North Staffordshire NHS Trust	HEAGERTY, AHM (corresponding author), N STAFFORDSHIRE HOSP,DEPT DERMATOL,STOKE ON TRENT ST4 7BQ,STAFFS,ENGLAND.			Fryer, Anthony/0000-0001-8678-0404				AUBRY F, 1985, CANCER-AM CANCER SOC, V55, P907, DOI 10.1002/1097-0142(19850215)55:4<907::AID-CNCR2820550433>3.0.CO;2-5; FRYER AA, 1993, BIOCHEM J, V295, P313, DOI 10.1042/bj2950313; KARAGAS MR, 1992, JAMA-J AM MED ASSOC, V267, P3305, DOI 10.1001/jama.267.24.3305; KETTERER B, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P97; MUKHTAR H, 1993, CANCER RES, V53, P3439; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; STRANGE RC, 1991, CARCINOGENESIS, V12, P25, DOI 10.1093/carcin/12.1.25; STRANGE RC, 1993, STRUCTURE FUNCTION G, P160; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533	10	161	163	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					266	268		10.1016/S0140-6736(94)91115-0	http://dx.doi.org/10.1016/S0140-6736(94)91115-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905099				2022-12-01	WOS:A1994MT44000013
J	HENG, MCY; HENG, SY; ALLEN, SG				HENG, MCY; HENG, SY; ALLEN, SG			COINFECTION AND SYNERGY OF HUMAN IMMUNODEFICIENCY VIRUS-1 AND HERPES-SIMPLEX VIRUS-1	LANCET			English	Article							LYMPHOCYTES-T; HUMAN CYTOMEGALOVIRUS; LANGERHANS CELLS; HIV-1; TYPE-1; MACROPHAGES; REPLICATION; EXPRESSION; GENE; TRANSACTIVATION	The human immunodeficiency virus (HIV-1) uses the CD4 molecule, expressed by T helper cells and activated macrophages, as a receptor for entry into host cells. In tissues co-infected with herpes simplex type 1 (HSV-1), HIV-1 virions were observed to infect keratinocytes, which, because they lack the CD4 molecule, are normally incapable of being infected by HIV-1. Although a number of other viruses have been reported to enhance HIV-1 viral transcription in vitro, this is the first in-vivo report to our knowledge of reciprocal enhancement of viral replication associated with co-infection of keratinocytes and macrophages by HIV-1 and HSV-1 in patients with AIDS and non-genital herpes simplex lesions. The virions in the coinfected cells were larger, morphologically atypical, and appear to be hybrids; most contain the HIV-1 envelope necessary for infectivity. The increased viral load and the proximity of the virions to the cutaneous surface may lead to increased risk of transcutaneous transmission of both viruses. These findings point to the need for incorporation of suppressive treatment for herpes simplex in the treatment of AIDS.			HENG, MCY (corresponding author), VET AFFAIRS MED CTR,UCLA SAN FERNANDO VALLEY INTERNAL MED PROGRAM,DEPT MED,DIV DERMATOL,SEPULVEDA,CA 91343, USA.							COOPER DA, 1993, AIDS, V7, P197, DOI 10.1097/00002030-199302000-00007; CROWE S, 1987, AIDS RES HUM RETROV, V3, P135, DOI 10.1089/aid.1987.3.135; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; HO WZ, 1991, J ACQ IMMUN DEF SYND, V4, P1098; HO WZ, 1990, J GEN VIROL, V71, P97, DOI 10.1099/0022-1317-71-1-97; KEET IPM, 1990, GENITOURIN MED, V66, P330; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NELSON JA, 1988, VIROLOGY, V165, P280; POPOVIC M, 1987, LANCET, V2, P916; RANDO RF, 1987, ONCOGENE, V1, P13; RAPPERSBERGER K, 1988, INTERVIROLOGY, V29, P185; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988	20	152	155	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					255	258		10.1016/S0140-6736(94)91110-X	http://dx.doi.org/10.1016/S0140-6736(94)91110-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905094				2022-12-01	WOS:A1994MT44000008
J	LUYAO, GL; GREENBERG, ER				LUYAO, GL; GREENBERG, ER			CHANGES IN PROSTATE-CANCER INCIDENCE AND TREATMENT IN USA	LANCET			English	Article							UNITED-STATES; SURVIVAL	We examined time trends and geographical variations in the detection and treatment of prostate cancer in USA, based on information from white men aged 50 to 79 who resided in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program of the United States National Cancer Institute. Prostate-cancer incidence and treatment rates were determined for the 9 population-based cancer registries which participate in the SEER program. Prostate-cancer mortality rates were assessed from data compiled by the National Center for Health Statistics. Prostate cancer incidence rates increased by 6.4% per year between 1983 and 1989. The increase appeared to be due to detection of early-stage disease; there was no increase in the incidence rate of metastatic cancer. Incidence rates varied widely among the SEER program areas: in 1989 from 267.9 per 100 000 in Connecticut to 606.8 in Seattle. Radical prostatectomy rates more than tripled between 1983 and 1989 in the SEER areas as a whole. Among men aged 70-79, the rate of prostatectomy increased by nearly 35% per year. There was a five-fold variation among SEER areas in radical prostatectomy rates in 1989, with a low of 43.4 per 100 000 in Connecticut and a high of 224.4 in Seattle. Prostate cancer mortality rates did not increase during the period of study; there was little variation among areas in prostate-cancer mortality rates, and no apparent correlation between the incidence and mortality rates for an area. Increases in rates of prostate cancer incidence and prostate surgery have occurred in the United States without clear evidence that screening and prostectomy are effective in reducing mortality. Moreover, much of the growth in incidence and radical prostatectomy rates has occurred among older men, who appear least likely to benefit from early detection and surgery of occult prostate cancer.	DARTMOUTH COLL, SCH MED, CTR EVALUAT CLIN SCI, 7251 STRASENBURGH HALL, HANOVER, NH 03755 USA; DARTMOUTH COLL, NORRIS COTTON CANC CTR, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center				Lu-Yao, Grace/0000-0002-6017-9175	NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; AHRQ HHS [HS06336] Funding Source: Medline; NCI NIH HHS [CA 23108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKNER M, 1985, J CHRON DIS, V38, P225, DOI 10.1016/0021-9681(85)90065-7; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; DEVESA SS, 1987, J NATL CANCER I, V79, P701; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GOLDBLOOM R, 1991, CAN MED ASSOC J, V145, P413; GREENBERG ER, 1982, J NATL CANCER I, V68, P743; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LANGE PH, 1993, JAMA-J AM MED ASSOC, V269, P95, DOI 10.1001/jama.269.1.95; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; MILLER BA, 1992, CANCER STATISTICS RE; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; WALSH PC, 1987, J UROLOGY, V138, P823, DOI 10.1016/S0022-5347(17)43385-4; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; WHITMORE WF, 1993, CANCER-AM CANCER SOC, V71, P970, DOI 10.1002/1097-0142(19930201)71:3+<970::AID-CNCR2820711412>3.0.CO;2-6; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P642; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P110; 1989, GUIDE CLIN PREVENTIV, P63; 1987, JAMA-J AM MED ASSOC, V258, P2727; 1993, J NATL CANCER I, V85, P947	28	207	207	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	1994	343	8892					251	254		10.1016/S0140-6736(94)91109-6	http://dx.doi.org/10.1016/S0140-6736(94)91109-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905093	hybrid			2022-12-01	WOS:A1994MT44000007
J	OGRADY, J; STEWART, S; ELTON, RA; KRAJEWSKI, AS				OGRADY, J; STEWART, S; ELTON, RA; KRAJEWSKI, AS			EPSTEIN-BARR-VIRUS IN HODGKINS-DISEASE AND SITE OF ORIGIN OF TUMOR	LANCET			English	Note							PERSISTENCE; CELLS	Epstein-Barr virus (EBV) may be involved in the pathogenesis of Hodgkin's disease. We investigated whether EBV in Hodgkin's disease is related to the site of origin of the tumour. In 40 patients with stage I disease, there was a significant association between EBV latent membrane protein (LMP-1) expression and presentation in neck lymph nodes. There was no association in stage II-IV disease (57 cases). Nodular sclerosing subtype was rarely associated with LMP-1 expression. In some cases of Hodgkin's disease of mixed cellularity or lymphocyte predominant subtype originating in the neck, EBV may be an important aetiological co-factor.	UNIV EDINBURGH,MED STAT UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	OGRADY, J (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ALLDAY MJ, 1988, LANCET, V1, P855; ARMSTRONG AA, 1992, LEUKEMIA, V6, P869; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; CHAN MKM, 1989, ACTA CYTOL, V33, P351; COATES PJ, 1991, J PATHOL, V164, P291, DOI 10.1002/path.1711640404; HO SC, 1990, HAEMATOL ONCOL, V8, P271; ISAACSON PG, 1992, J PATHOL, V2, P267; JARRETT RF, 1991, J CLIN PATHOL, V44, P844, DOI 10.1136/jcp.44.10.844; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107	10	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					265	266		10.1016/S0140-6736(94)91114-2	http://dx.doi.org/10.1016/S0140-6736(94)91114-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905098				2022-12-01	WOS:A1994MT44000012
J	REES, M				REES, M			ON MENSTRUAL BLEEDING WITH HORMONE REPLACEMENT THERAPY	LANCET			English	Editorial Material							PROGESTOGEN; WOMEN				REES, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.							ANDERSSON K, 1992, OBSTET GYNECOL, V79, P963; CHRISTIANSEN C, 1990, BRIT J OBSTET GYNAEC, V97, P1087, DOI 10.1111/j.1471-0528.1990.tb02495.x; COOPE J, 1992, MATURITAS, V15, P151, DOI 10.1016/0378-5122(92)90249-4; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HAWTHORN RJS, 1991, BRIT J OBSTET GYNAEC, V98, P939, DOI 10.1111/j.1471-0528.1991.tb13519.x; MACLENNAN AH, 1993, MED J AUSTRALIA, V159, P102, DOI 10.5694/j.1326-5377.1993.tb137744.x; REES MCP, 1991, BRIT J OBSTET GYNAEC, V98, P106, DOI 10.1111/j.1471-0528.1991.tb10322.x; REES MCP, 1993, WOMENS PROBLEMS GENE, P171; SPORRONG T, 1992, BRIT J OBSTET GYNAEC, V99, P399, DOI 10.1111/j.1471-0528.1992.tb13757.x; STALAND B, 1981, MATURITAS, V3, P14	10	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 29	1994	343	8892					250	250		10.1016/S0140-6736(94)91108-8	http://dx.doi.org/10.1016/S0140-6736(94)91108-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905092				2022-12-01	WOS:A1994MT44000006
J	VAGERO, D; LEON, D				VAGERO, D; LEON, D			ISCHEMIC-HEART-DISEASE AND LOW-BIRTH-WEIGHT - A TEST OF THE FETAL-ORIGINS HYPOTHESIS FROM THE SWEDISH-TWIN-REGISTRY	LANCET			English	Article							ADULT LIFE; HEIGHT; MORTALITY; GROWTH; INFANCY; COHORT; DEATH	Twins constitute a population with lower than average birth weight for reasons that are not a consequence of social disadvantage. The hypothesis that ischaemic heart disease (IHD) is linked to low birth weight was tested by analysing whether or not 8174 female and 6612 male Swedish twins had a higher mortality compared to the general Swedish population. The association between adult body height and IHD mortality was also analysed in a nested case-control study among monozygotic and dizygotic twins. Ischaemic heart disease mortality was not higher among twins (women: relative risk [RR] 0.99; 95% confidence limits [CL] 0.89-1.10; men: RR 0.85; CL 0.79-0.92). However, the shorter twin in a twin pair was more likely to die of heart disease than the taller (odds ratio [OR] 1.15, CL 1.03-1.25). We suggest that postnatal influences may well be as important as prenatal influences in producing any effect on ischaemic heart disease mortality and that the type of growth retardation in utero experienced by twins may not constitute a risk for ischaemic heart disease in adulthood.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	VAGERO, D (corresponding author), UNIV STOCKHOLM, SWEDISH INST SOCIAL RES, S-10691 STOCKHOLM, SWEDEN.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Vagero, Denny/0000-0002-1854-2292				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; CAMPELL D, 1988, TWINNING TWINS; CEDERLOF R, 1966, TWIN METHOD EPIDEMIO; CEDERLOF R, 1977, ACTA MED SCAND, V202, pS49; FISCHBEIN S, 1990, 29 U STOCKH DEP SOC; FLEIGNER JR, 1984, AUSTR NZ J OBS GYNEC, V24, P192; ILLSLEY R, 1955, BRIT MED J, V2, P1520, DOI 10.1136/bmj.2.4955.1520; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; MACINTYRE S, 1988, SOC SCI MED, V27, P327, DOI 10.1016/0277-9536(88)90266-3; MARMOT MG, 1984, LANCET, V1, P1003; MOILANEN I, 1989, GROWTH DEVELOP AGING, V53, P145; NAEYE RL, 1964, PEDIATRICS, V33, P546; NOTKOLA V, 1985, LIVING CONDITIONS CH; PECK AMN, 1989, J EPIDEMIOL COMMUN H, V43, P380, DOI 10.1136/jech.43.4.380; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; VAGERO D, 1994, IN PRESS PREMATURE A; WILSON R, 1986, HUMAN GROWTH COMPREH, V3; WILSON RS, 1974, ANN HUM BIOL, V1, P57, DOI 10.1080/03014467400000061; WILSON RS, 1979, ANN HUM BIOL, V6, P205, DOI 10.1080/03014467900007212; WILSON RS, 1974, ANN HUM BIOL, V1, P175, DOI 10.1080/03014467400000191; [No title captured]	26	122	122	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 29	1994	343	8892					260	263		10.1016/S0140-6736(94)91112-6	http://dx.doi.org/10.1016/S0140-6736(94)91112-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT440	7905096				2022-12-01	WOS:A1994MT44000010
J	GUO, YJ; WU, MC; CHEN, H; WANG, XN; LIU, GL; LI, GL; MA, J; SY, MS				GUO, YJ; WU, MC; CHEN, H; WANG, XN; LIU, GL; LI, GL; MA, J; SY, MS			EFFECTIVE TUMOR VACCINE GENERATED BY FUSION OF HEPATOMA-CELLS WITH ACTIVATED B-CELLS	SCIENCE			English	Article							RECEPTOR	Fusion of BERH-2 rat hepatocellular carcinoma cells with activated B cells produced hybrid cells that lost their tumorigenicity and became immunogenic. Syngeneic rats injected with BERH-2-B hybrid cells became resistant to challenge with parental BERH-2 cells, and rats with established BERH-2 hepatomas were cured by subsequent injection of BERH-2-B cells. Both CD4+ and CD8+ cells were essential for the induction of protective immunity; however, only CD8+ cells were required for the eradication of BERH-2 tumors. The generation of hybrid tumor cells that elicit antitumor immune responses may be a useful strategy for cancer immunotherapy.	CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University	GUO, YJ (corresponding author), EASTERN INST HEPATOBILIARY SURG,CTR TUMOR IMMUNOL & BIOTHERAPY,SHANGHAI 200433,PEOPLES R CHINA.							ALAN J, 1988, IMMUNOCHEMISTRY PRAC, pCH2; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHESTNUT RW, 1981, J IMMUNOL, V128, P1075; ELIOT BE, 1989, ADV CANCER RES, V53, P181; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GEORGE JT, 1993, CANCER RES, V53, P2374; Guo Y., UNPUB; GUO YJ, 1988, J MIL MED COLL PEOPL, V3, P272; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MUUL LM, 1987, J IMMUNOL, V138, P989; OSBAND ME, 1990, IMMUNOL TODAY, V11, P193, DOI 10.1016/0167-5699(90)90080-S; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9459	18	143	184	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					518	520		10.1126/science.7507262	http://dx.doi.org/10.1126/science.7507262			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	7507262				2022-12-01	WOS:A1994MT96600032
J	MURPHY, TH; BARABAN, JM; WIER, WG; BLATTER, LA				MURPHY, TH; BARABAN, JM; WIER, WG; BLATTER, LA			VISUALIZATION OF QUANTAL SYNAPTIC TRANSMISSION BY DENDRITIC CALCIUM IMAGING	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPAL SLICES; PHORBOL ESTERS; CURRENTS; NEURONS; VARIABILITY; RESPONSES; SPINES; NMDA; CA2+	As changes in synaptic strength are thought to be critical for learning and memory, it would be useful to monitor the activity of individual identified synapses on mammalian central neurons. Calcium imaging of cortical neurons grown in primary culture was used to visualize the activation of individual postsynaptic elements by miniature excitatory synaptic currents elicited by spontaneous quantal release. This approach revealed that the probability of spontaneous activity differed among synapses on the same dendrite. Furthermore, synapses that undergo changes in activity induced by glutamate or phorbol ester treatment were identified.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	MURPHY, TH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.		Murphy, Timothy/AAW-1975-2021; Wier, Withrow/AAE-2451-2020; Murphy, Timothy H/I-4982-2014; Blatter, Lothar/AAC-8431-2020	Murphy, Timothy/0000-0002-0093-4490; Murphy, Timothy H/0000-0002-0093-4490; Baraban, Jay/0000-0002-8165-2638				AMARAL DG, 1990, PROG BRAIN RES, V83, P1; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLATTER LA, 1992, AM J PHYSIOL, V263, pH576, DOI 10.1152/ajpheart.1992.263.2.H576; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; KOCH C, 1993, J NEUROSCI, V13, P413; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TF, UNPUB; MURPHY TH, 1992, J NEUROSCI, V12, P4834; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; ROBITAILLE R, 1991, NEUROSCIENCE, V40, P571, DOI 10.1016/0306-4522(91)90142-B; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YOSHIKAMI D, 1984, NATURE, V310, P53, DOI 10.1038/310053a0	30	72	73	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	1994	263	5146					529	532		10.1126/science.7904774	http://dx.doi.org/10.1126/science.7904774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	7904774				2022-12-01	WOS:A1994MT96600036
J	GILLESPIE, DH; CUDDY, KK; KOLBE, T; MARKS, DI				GILLESPIE, DH; CUDDY, KK; KOLBE, T; MARKS, DI			DISSOLVE AND CAPTURE - A STRATEGY FOR ANALYZING MESSENGER-RNA IN BLOOD	NATURE			English	Article							THIOCYANATE; DNA		RNA LAB INC,EAGLE,PA 19480		GILLESPIE, DH (corresponding author), HAHNEMANN UNIV,DEPT NEOPLAST DIS,ROAD & VINE,PHILADELPHIA,PA 19102, USA.							CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUDDY K, 1993, NUCLEIC ACIDS RES, V21, P2281, DOI 10.1093/nar/21.9.2281; CUDDY KK, 1993, IN PRESS NOV EDGW RE; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; THOMPSON J, 1987, ANAL BIOCHEM, V163, P281, DOI 10.1016/0003-2697(87)90225-9; THOMPSON JD, 1992, BLOOD, V79, P1629; VOGELSTEIN B, 1977, BIOCHEM BIOPH RES CO, V75, P1127, DOI 10.1016/0006-291X(77)91500-5	9	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					390	391		10.1038/367390a0	http://dx.doi.org/10.1038/367390a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	7509457				2022-12-01	WOS:A1994MT54000075
J	HOFSTRA, RMW; LANDSVATER, RM; CECCHERINI, I; STULP, RP; STELWAGEN, T; LUO, Y; PASINI, B; HOPPENER, JWM; VANAMSTEL, HKP; ROMEO, G; LIPS, CJM; BUYS, CHCM				HOFSTRA, RMW; LANDSVATER, RM; CECCHERINI, I; STULP, RP; STELWAGEN, T; LUO, Y; PASINI, B; HOPPENER, JWM; VANAMSTEL, HKP; ROMEO, G; LIPS, CJM; BUYS, CHCM			A MUTATION IN THE RET PROTOONCOGENE ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE-2B AND SPORADIC MEDULLARY-THYROID CARCINOMA	NATURE			English	Article							CHROMOSOME-10; LINKAGE; DOMAINS; KINASE	MULTIPLE endocrine neoplasia type 2 (MEN 2) comprises three clinically distinct, dominantly inherited cancer syndromes. MEN 2A patients develop medullary thyroid carcinoma (MTC) and phaeochromocytoma. MEN 2B patients show in addition ganglioneuromas of the gastrointestinal tract and skeletal abnormalities. In familial MTC, only the thyroid is affected. Germ-line mutations of the RET proto-oncogene have recently been reported in association with MEN 2A and familial MTC1,2. All mutations occurred within codons specifying cysteine residues in the transition point between the RET protein extracellular and transmembrane domains. We now show that MEN 2B is also associated with mutation of the RET proto-oncogene. A mutation in codon 664, causing the substitution of a threonine for a methionine in the tyrosine kinase domain of the protein, was found in all nine unrelated MEN 2B patients studied. The same mutation was found in six out of 18 sporadic tumours.	UNIV GRONINGEN,DEPT MED GENET,ANT DEUSINGLAAN 4,9713 AW GRONINGEN,NETHERLANDS; UNIV UTRECHT HOSP,CTR CLIN GENET,DEPT INTERNAL MED & PATHOL,3584 CX UTRECHT,NETHERLANDS; INST G GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY	University of Groningen; Utrecht University; Utrecht University Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini			Ceccherini, Isabella/P-8195-2014; Pasini, Barbara/AHI-2004-2022	Ceccherini, Isabella/0000-0001-8732-1955; Pasini, Barbara/0000-0002-4373-1212; Hofstra, Robert/0000-0001-7498-3829				CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JACKSON CE, 1979, AM J HUM GENET, V101, P704; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NELKIN BD, 1989, CANCER RES, V49, P4114; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; ORITA M, 1989, GENOMICS, V5, P873; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1992, COLD SPRING HARBOR M; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571	14	954	979	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					375	376		10.1038/367375a0	http://dx.doi.org/10.1038/367375a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	7906866				2022-12-01	WOS:A1994MT54000069
J	BRISCO, MJ; CONDON, J; HUGHES, E; NEOH, SH; SYKES, PJ; SESHADRI, R; TOOGOOD, I; WATERS, K; TAURO, G; EKERT, H; MORLEY, AA				BRISCO, MJ; CONDON, J; HUGHES, E; NEOH, SH; SYKES, PJ; SESHADRI, R; TOOGOOD, I; WATERS, K; TAURO, G; EKERT, H; MORLEY, AA			OUTCOME PREDICTION IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA BY MOLECULAR QUANTIFICATION OF RESIDUAL DISEASE AT THE END OF INDUCTION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; LYMPHOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDE PROBES; INVITRO AMPLIFICATION; GENE REARRANGEMENTS; LEUKEMIA; LINEAGE; RELAPSE; CELLS; PCR	Methods to detect and quantify minimal residual disease (MRD) after chemotherapy for acute lymphoblastic leukaemic (ALL) could improve treatment by identifying patients who need more or less intensive therapy. We have used a clone-specific polymerase chain reaction to detect rearranged immunoglobulin heavy-chain gene from the leukaemic clone, and quantified the clone by limiting dilution analysis. MRD was successfully quantified, by extracting DNA from marrow slides, from 88 of 181 children with ALL, who had total leucocyte counts below 100 x 10(9)/L at presentation and were enrolled in two clinical trials, in 1980-84 and 1985-89, Leukaemia was detected in the first remission marrow of 38 patients, in amounts between 6.7 x 10(2) and 9.9 x 10(-7) cells; 26 of these patients relapsed. Of 50 patients with no MRD detected, despite study of 522-496 000 genomes, only 6 relapsed. The association between MRD detection and outcome was significant for patients in each trial. In the first trial, patients relapsed at all levels of detected MRD, whereas in the later trial, in which treatment was more intensive and results were better, the extent of MRD was closely related to the probability of relapse (5 of 5 patients with >10(-3) MRD, 4 of 10 with 10(-3)to 2 x 10(-5), 0 of 3 with levels below 2 x 10(-5), and 2 of 26 with no MRD detected). Early quantification of leukaemic cells after chemotherapy may be a successful strategy for predicting outcome and hence individualising treatment in childhood ALL, because the results indicate both in-vivo drug sensitivity of the leukaemia and the number of leukaemic cells that remain to be killed by post-induction therapy.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT HAEMATOL,BEDFORD PK,SA 5042,AUSTRALIA; WOMENS & CHILDRENS HOSP,ADELAIDE,SA,AUSTRALIA	Flinders University South Australia; Womens & Childrens Hospital Australia				Sykes, Pam/0000-0001-9239-7639				BEISHUIZEN A, 1991, NEW ENGL J MED, V324, P772; BIONDI A, 1992, LEUKEMIA, V6, P282; BOURGUIN A, 1990, P NATL ACAD SCI USA, V87, P8536, DOI 10.1073/pnas.87.21.8536; BRISCO MJ, 1991, BRIT J HAEMATOL, V79, P211, DOI 10.1111/j.1365-2141.1991.tb04524.x; BRISCO MJ, 1993, LEUKEMIA, V7, P1514; BRISCO MJ, 1990, BRIT J HAEMATOL, V75, P163, DOI 10.1111/j.1365-2141.1990.tb02643.x; DAURIOL L, 1989, LEUKEMIA, V3, P155; DEANE M, 1991, BRIT J HAEMATOL, V77, P274, DOI 10.1111/j.1365-2141.1991.tb08570.x; EKERT H, 1990, CANCER THERAPY CONTR, V1, P87; HANSENHAGGE TE, 1989, BLOOD, V74, P1762; JONSSON OG, 1990, BLOOD, V76, P2072; KIYOI H, 1991, BONE MARROW TRANSPL, V8, P59; MACINTYRE EA, 1990, J CLIN INVEST, V86, P2125, DOI 10.1172/JCI114951; MCCARTHY KP, 1990, J CLIN PATHOL, V43, P429, DOI 10.1136/jcp.43.5.429; NEALE GAM, 1991, BLOOD, V78, P739, DOI 10.1182/blood.V78.3.739.bloodjournal783739; NIZET Y, 1991, BRIT J HAEMATOL, V79, P205, DOI 10.1111/j.1365-2141.1991.tb04523.x; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; RALPH QM, 1993, BLOOD, V82, P202, DOI 10.1182/blood.V82.1.202.bloodjournal821202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SYKES PJ, 1992, BIOTECHNIQUES, V13, P444; TRAINOR KJ, 1991, BLOOD, V78, P192; TRAINOR KJ, 1990, BLOOD, V75, P2220; VANDENVELDE C, 1991, NOUV REV FR HEMATOL, V33, P25; VEELKEN H, 1991, BLOOD, V78, P1318; WASSERMAN R, 1992, BLOOD, V79, P223; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YOKOTA S, 1991, BLOOD, V77, P331	29	257	297	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					196	200		10.1016/S0140-6736(94)90988-1	http://dx.doi.org/10.1016/S0140-6736(94)90988-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904666				2022-12-01	WOS:A1994MT33200007
J	CATASSI, C; RATSCH, IM; FABIANI, E; ROSSINI, M; BORDICCHIA, F; CANDELA, F; COPPA, GV; GIORGI, PL				CATASSI, C; RATSCH, IM; FABIANI, E; ROSSINI, M; BORDICCHIA, F; CANDELA, F; COPPA, GV; GIORGI, PL			CELIAC-DISEASE IN THE YEAR 2000 - EXPLORING THE ICEBERG	LANCET			English	Article							SELECTIVE IGA DEFICIENCY; CELIAC-DISEASE; ANTIGLIADIN ANTIBODIES; CHILDREN; MALIGNANCY	lt is now generally believed that subclinical coeliac disease is common in the general population. We have undertaken screening for this disorder in a school district in central Italy. Screening was divided into three levels: first, IgG and IgA antigliadin antibody (AGA) assay on capillary blood obtained by finger prick; second. AGA plus IgA anti-endomysium antibody (AEA) test and measurement of serum immunoglobulins in venous blood: and third, intestinal biopsy. 3351 students (66% of the eligible population) aged 11-15 years attended first level screening. 71 (2%) were recalled because of AGA positivity; 18 of these satisfied second-level criteria and underwent intestinal biopsy. Coeliac disease was diagnosed in 11 subjects, most of whom had no serious symptoms. Selective IgA deficiency was found in 4 subjects, 1 of whom also had coeliac disease. The prevalence of subclinical coeliac disease in the study group was 3.28 per 1000. Coeliac disease screening is feasible and involves only slight discomfort to the general population. Such screening can detect large numbers of cases of coeliac disease, which can be treated with a gluten-free diet. Many subclinical cases of coeliac disease would not be detected by screening only a selected group of at-risk patients.	G SALESI CHILDRENS HOSP, DEPT CLIN CHEM, ANCONA, ITALY		CATASSI, C (corresponding author), UNIV ANCONA, DEPT PEDIAT, VIA CORRIDONI 11, I-60123 ANCONA, ITALY.							BARERA G, 1991, ARCH DIS CHILD, V66, P491, DOI 10.1136/adc.66.4.491; BURGINWOLFF A, 1989, EUR J PEDIATR, V148, P496, DOI 10.1007/BF00441541; BURGINWOLFF A, 1991, ARCH DIS CHILD, V66, P941, DOI 10.1136/adc.66.8.941; CACCIARI E, 1985, LANCET, V1, P1469; COLLIN P, 1992, SCAND J GASTROENTERO, V27, P367, DOI 10.3109/00365529209000089; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; CUNNINGHAMRUNDLES C, 1981, CLIN EXP IMMUNOL, V45, P299; FERGUSON MM, 1980, GUT, V21, P223, DOI 10.1136/gut.21.3.223; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Greco L., 1992, COMMON FOOD INTOLERA, P25; GRODZINSKY E, 1992, ANN ALLERGY, V69, P66; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOLMES GKT, 1992, COMMON FOOD INTOLERA, V1, P105; KOISTINEN J, 1975, VOX SANG, V29, P192, DOI 10.1111/j.1423-0410.1975.tb00494.x; Logan R. F. A., 1992, COMMON FOOD INTOLERA, P14; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; MAKI M, 1992, COMMON FOOD INTOLERA, V1, P93; MAZZETTI DP, 1992, ITAL J GASTROENTEROL, V24, P352; SAVILAHTI E, 1983, LANCET, V1, P320; SWINSON CM, 1983, LANCET, V1, P111; TRONCONE R, 1991, J PEDIATR GASTR NUTR, V12, P150, DOI 10.1097/00005176-199102000-00002; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909	22	618	641	0	45	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	1994	343	8891					200	203		10.1016/S0140-6736(94)90989-X	http://dx.doi.org/10.1016/S0140-6736(94)90989-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904667				2022-12-01	WOS:A1994MT33200008
J	LEFRERE, JJ; MARIOTTI, M; THAUVIN, M				LEFRERE, JJ; MARIOTTI, M; THAUVIN, M			B19 PARVOVIRUS DNA IN SOLVENT DETERGENT-TREATED ANTI-HEMOPHILIA CONCENTRATES	LANCET			English	Note							INFECTION	A transfusional B19 parvovirus infection may have severe consequences in immunocompromised hosts. The presence of B19 DNA was investigated with a polymerase chain reaction (PCR) assay in 30 batches of solvent/detergent-treated clotting factor concentrates (12 batches of factor VIII, 16 batches of factor IX, 1 batch of factor VII, and 1 batch of PPSB). B19 DNA was detected in 6 (20%) batches, including 3 factor VIII and 3 factor IX concentrates. Because of the frequency of B19 DNA in batches of clotting factors, measures to prevent transfusional risk of B19 infection via these blood products are justified, especially in recipients immunocompromised by HIV infection.			LEFRERE, JJ (corresponding author), HOP ST ANTOINE,INST NATL TRANSFUS SANGUINE,53 BLVD DIDEROT,F-75571 PARIS 12,FRANCE.							AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; CORSI OB, 1988, J MED VIROL, V25, P165, DOI 10.1002/jmv.1890250206; LEFRERE JJ, 1992, BRIT J HAEMATOL, V82, P467, DOI 10.1111/j.1365-2141.1992.tb06446.x; LEFRERE JJ, 1986, BRIT J HAEMATOL, V62, P653, DOI 10.1111/j.1365-2141.1986.tb04088.x; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORFINI M, 1992, AM J HEMATOL, V39, P149, DOI 10.1002/ajh.2830390217; MORTIMER PP, 1983, LANCET, V2, P482; NAIDES SJ, 1993, J INFECT DIS, V168, P101, DOI 10.1093/infdis/168.1.101; SOL N, 1993, J GEN VIROL, V74, P2011, DOI 10.1099/0022-1317-74-9-2011; ZAKRZEWSKA K, 1992, BRIT J HAEMATOL, V81, P407, DOI 10.1111/j.1365-2141.1992.tb08248.x	10	81	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					211	212		10.1016/S0140-6736(94)90993-8	http://dx.doi.org/10.1016/S0140-6736(94)90993-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904670				2022-12-01	WOS:A1994MT33200012
J	MASTRO, TD; SATTEN, GA; NOPKESORN, T; SANGKHAROMYA, S; LOGINI, IM				MASTRO, TD; SATTEN, GA; NOPKESORN, T; SANGKHAROMYA, S; LOGINI, IM			PROBABILITY OF FEMALE-TO-MALE TRANSMISSION OF HIV-1 IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; INFECTION; PARTNERS; CHILDREN; VIREMIA; TYPE-1; ADULTS; AIDS	The epidemic of human immunodeficiency virus type 1 (HIV-1) infection in Thailand has allowed an estimate to be made of the probability of female-to-male HIV-1 transmission per sexual contact. In a study of 1115 21 year-old male military conscripts, of whom 77 (6.9%) were HIV-1 seropositive, sex with female prostitutes was identified as the principal mode of HIV-1. transmission. With a mathematical model including data on conscript's age at first sexual contact, frequency of sex with female prostitutes, and province of origin; as well as province-specific HIV-1 seroprevalence of prostitutes, we estimated the probability of HIV-1 transmission per sexual contact to be 0.031 (95% confidence limits [CL] 0.025-0.040). Allowing for random error in the self-reported frequency of contacts, the estimate was 0.056 (95% CL 0.041-0.075). The transmission probability was significantly greater among men with a history of sexually-transmitted diseases. These estimates are substantially higher than analogous estimates made in North America. This high per-act probability of heterosexual transmission helps to explain the rapid spread of HIV-1 in the emerging epidermic in Thailand and perhaps in other countries where HIV-1 transmission is predominately heterosexual.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA; SOMDEJ PRANARESUAN MAHARAJ HOSP,PHITSANULOKE,THAILAND; EMORY UNIV,SCH PUBL HLTH,DIV BIOSTAT,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Emory University	MASTRO, TD (corresponding author), HIV AIDS COLLABORAT,88-7 SOI BAMRASNARADURA,TIVANON RD,NONTHABURI 11000,THAILAND.			Satten, Glen/0000-0001-7275-5371				CAMERON DW, 1989, LANCET, V2, P403; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; EISENBERG B, 1989, STAT MED, V8, P83, DOI 10.1002/sim.4780080109; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; HAVERKOS HW, 1992, JAMA-J AM MED ASSOC, V268, P1855, DOI 10.1001/jama.1992.03490140063023; HORSBURGH CR, 1989, LANCET, V2, P637; JEWELL NP, 1990, BIOMETRICS, V46, P1133, DOI 10.2307/2532454; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1199, DOI 10.1093/oxfordjournals.aje.a115832; LIMPAKARNJANARA.K, 1993, 9 INT C AIDS BERL; MYERS G, 1992, HUMAN RETROVIRUSES A; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SATTEN GA, IN PRESS STAT MED; SIRAYSIRISOPANA N, 1992, 8 INT C AIDS AMST; SIRISOPANA N, 1993, 9 INT C AIDS BERL; TAYLOR DN, 1984, SEX TRANSM DIS, V11, P148, DOI 10.1097/00007435-198407000-00005; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; [No title captured]; 1993, WHOGPACNPEVA931 PUBL	25	177	179	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					204	207		10.1016/S0140-6736(94)90990-3	http://dx.doi.org/10.1016/S0140-6736(94)90990-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7904668				2022-12-01	WOS:A1994MT33200009
J	PATTISON, J; NELSON, PJ; HUIE, P; VONLEUTTICHAU, I; FARSHID, G; SIBLEY, RK; KRENSKY, AM				PATTISON, J; NELSON, PJ; HUIE, P; VONLEUTTICHAU, I; FARSHID, G; SIBLEY, RK; KRENSKY, AM			RANTES CHEMOKINE EXPRESSION IN CELL-MEDIATED TRANSPLANT REJECTION OF THE KIDNEY	LANCET			English	Note							MONOCLONAL-ANTIBODIES; FAMILY	RANTES (regulated upon activation, normal T cell expressed and secreted) is a chemotactic cytokine (a chemokine) for memory T lymphocytes, monocytes, and eosinophils. RANTES expression was studied in renal allograft biopsy specimens. Although RANTES was not expressed in samples,taken one hour after transplantation, or in native renal biopsy specimens from patients with cyclosporin nephrotoxicity, it was expressed during cell-mediated transplant rejection. RANTES mRNA was detected in infiltrating mononuclear cells and renal tubular epithelium, and RANTES protein was localised to mononuclear cells, tubular epithelium, and vascular endothelium. This suggests RANTES has a role in allograft rejection.	STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305	Stanford University	PATTISON, J (corresponding author), STANFORD UNIV,MED CTR,DEPT PEDIAT,STANFORD,CA 94305, USA.		Krensky, Alan/F-7956-2011					BISHOP GA, 1986, KIDNEY INT, V29, P708, DOI 10.1038/ki.1986.56; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; MCCAUGHAN GW, 1990, HEPATOLOGY, V12, P1305, DOI 10.1002/hep.1840120610; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337	10	255	267	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					209	211		10.1016/S0140-6736(94)90992-X	http://dx.doi.org/10.1016/S0140-6736(94)90992-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7507196				2022-12-01	WOS:A1994MT33200011
J	PARKER, MW; BUCKLEY, JT; POSTMA, JPM; TUCKER, AD; LEONARD, K; PATTUS, F; TSERNOGLOU, D				PARKER, MW; BUCKLEY, JT; POSTMA, JPM; TUCKER, AD; LEONARD, K; PATTUS, F; TSERNOGLOU, D			STRUCTURE OF THE AEROMONAS TOXIN PROAEROLYSIN IN ITS WATER-SOLUBLE AND MEMBRANE-CHANNEL STATES	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; HOLE-FORMING TOXIN; AEROLYSIN; HYDROPHILA; OLIGOMERIZATION; HISTIDINES; MONOMER; VIRUS	AEROLYSIN is chiefly responsible for the pathogenicity of Aeromonas hydrophila, a bacterium associated with diarrhoeal diseases and deep wound infections1. Like many other microbial toxins, the protein changes in a multistep process from a completely water-soluble form to produce a transmembrane channel that destroys sensitive cells by breaking their permeability barriers2. Here we describe the structure of proaerolysin determined by X-ray crystallography at 2.8 angstrom resolution. The protoxin (M(r) 52,000) adopts a novel protein fold. Images of an aerolysin oligomer derived from electron microscopy have assisted in constructing a model of the membrane channel and have led to the proposal of a scheme to account for insertion of the protein into lipid bilayers to form ion channels.	UNIV VICTORIA,DEPT BIOCHEM & MOLEC BIOL,VICTORIA V8W 2Y2,BC,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Victoria; European Molecular Biology Laboratory (EMBL)	PARKER, MW (corresponding author), ST VINCENTS INST MED RES,41 VICTORIA PARADE,FITZROY,VIC 3065,AUSTRALIA.		Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTWEGG M, 1989, CRC CR REV MICROBIOL, V16, P253, DOI 10.3109/10408418909105478; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAKDI S, 1987, REV PHYSL BIOCH PHAR, V107, P148; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; TUCKER AD, 1990, J MOL BIOL, V212, P561, DOI 10.1016/0022-2836(90)90222-8; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; VANGUNSTEREN WF, 1988, PROTEIN ENG, V2, P5, DOI 10.1093/protein/2.1.5; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; WILMSEN HU, 1991, MOL MICROBIOL, V5, P2745, DOI 10.1111/j.1365-2958.1991.tb01983.x; 1979, CCP4 DAR LAB	27	366	375	3	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					292	295		10.1038/367292a0	http://dx.doi.org/10.1038/367292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	7510043				2022-12-01	WOS:A1994MR49400062
J	CHAZOUILLERES, O; MAMISH, D; KIM, M; CAREY, K; FERRELL, L; ROBERTS, JP; ASCHER, NL; WRIGHT, TL				CHAZOUILLERES, O; MAMISH, D; KIM, M; CAREY, K; FERRELL, L; ROBERTS, JP; ASCHER, NL; WRIGHT, TL			OCCULT HEPATITIS-B VIRUS AS SOURCE OF INFECTION IN LIVER-TRANSPLANT RECIPIENTS	LANCET			English	Article							CLINICAL IMPLICATIONS; VIRAL-INFECTION; NON-A; DNA; SEQUENCES; DISEASE; SERUM	Hepatitis B virus (HBV) infection almost always recurs after liver transplantation in patients who were surface antigen (HBsAg) positive before surgery but apparent de novo acquisition of infection in a transplant setting has not previously been reported. We have used sensitive techniques to elucidate the origin of such infections in patients in a Californian transplantation programme. We tested post-transplant serum from 207 patients who had been HBsAg negative and found 20 to be HBsAg positive. The origin of infection was identified in 7 patients, being occult pre-transplant infection in 5 and occult infection in the donor in 2. No pre-transplant patient nor donor with demonstrable HBV DNA had serological markers of hepatitis B. Post-transplant HBV DNA was present in serum from 19 patients. Analysis of the variable pre-S region of HBV demonstrated 100% sequence homology between recipient liver and post-transplant serum (2 patients) and between donor serum and recipient post-transplant serum (2). There was only 84% homology between the 2 different patients infected with subtype adw. 19 patients are alive, 9 without histological evidence of hepatitis (mean follow-up 33 months), and survival was significantly greater than that of a group with recurrent HBV infection. Apparent acquisition of HBV infection with liver transplantation is not rare, and may be due to occult pre-transplant infection or occult infection in the donor. The post-transplant outcome of this infection tends to be benign but our findings do underscore the clinical relevance of HBV infection in the absence of serological markers.	DEPT VET AFFAIRS MED CTR,DEPT MED,4150 CLEMENT ST,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [R29AI32242-01] Funding Source: Medline; NIDDK NIH HHS [P30DK26743] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUM HE, 1991, HEPATOLOGY, V14, P56, DOI 10.1002/hep.1840140110; BRECHOT C, 1991, J HEPATOL, V13, pS49, DOI 10.1016/0168-8278(91)90023-5; BROWN J L, 1992, Hepatology, V15, P144, DOI 10.1002/hep.1840150124; CADRANEL JF, 1991, TRANSPLANTATION, V52, P645, DOI 10.1097/00007890-199110000-00013; DEGOS F, 1988, GASTROENTEROLOGY, V94, P151, DOI 10.1016/0016-5085(88)90623-3; DEMETRIS AJ, 1990, AM J PATHOL, V137, P667; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; HOOFNAGLE JH, 1978, NEW ENGL J MED, V298, P1379, DOI 10.1056/NEJM197806222982502; LAVINE JE, 1991, GASTROENTEROLOGY, V100, P263, DOI 10.1016/0016-5085(91)90611-N; LIANG TJ, 1991, HEPATOLOGY, V13, P1044, DOI 10.1002/hep.1840130607; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; MALTER JM, 1991, HEPATOLOGY, V13, P188, DOI 10.1002/hep.1840130127; OGRADY JG, 1992, J HEPATOL, V14, P104, DOI 10.1016/0168-8278(92)90138-F; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1016/0270-9139(91)90273-X; Sambrook J., 1989, MOL CLONING LAB MANU; THIERS V, 1988, LANCET, V2, P1273; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YOFFE B, 1990, HEPATOLOGY, V12, P187, DOI 10.1002/hep.1840120202; ZELDIS JB, 1989, J CLIN INVEST, V84, P1503, DOI 10.1172/JCI114326	21	266	275	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					142	146		10.1016/S0140-6736(94)90934-2	http://dx.doi.org/10.1016/S0140-6736(94)90934-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904004				2022-12-01	WOS:A1994MQ86900010
J	DEBONO, D				DEBONO, D			DIGOXIN IN EURHYTHMIC HEART-FAILURE - PROVED OR NOT PROVEN	LANCET			English	Editorial Material											DEBONO, D (corresponding author), UNIV LEICESTER,DEPT MED,DIV CARDIOL,LEICESTER LE1 7RH,ENGLAND.							NOBLE D, 1980, CARDIOVASC RES, V14, P495, DOI 10.1093/cvr/14.9.495; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PUGH SE, 1989, BRIT HEART J, V61, P529; SMITH T W, 1988, New England Journal of Medicine, V318, P358; SMITH TW, 1993, NEW ENGL J MED, V329, P51, DOI 10.1056/NEJM199307013290111; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; YUSUF S, 1992, AM J CARDIOL, V69, pG64, DOI 10.1016/0002-9149(92)91255-3; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1429	9	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					128	129		10.1016/S0140-6736(94)90926-1	http://dx.doi.org/10.1016/S0140-6736(94)90926-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903996				2022-12-01	WOS:A1994MQ86900002
J	EASTWOOD, R; SCHNEIDERMAN, G				EASTWOOD, R; SCHNEIDERMAN, G			COUCH FELLOWS	LANCET			English	Editorial Material											EASTWOOD, R (corresponding author), CLARKE INST PSYCHIAT, TORONTO M5T 1R8, ONTARIO, CANADA.							ANDREWS G, 1989, AM J PSYCHIAT, V146, P881; CAILLARD VF, 1992, INT PSYCHIATRY TODAY, V2, P1; KUPFER DJ, 1993, J CLIN PSYCHIAT, V54, P29; PAYKEL ES, 1993, INT ACAD B, V5, P62; REYNOLDS CF, 1992, AM J PSYCHIAT, V149, P1687; RODENHAUSER P, 1993, INT J GROUP PSYCHOTH, V43, P11, DOI 10.1080/00207284.1994.11491203	6	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					131	132		10.1016/S0140-6736(94)90929-6	http://dx.doi.org/10.1016/S0140-6736(94)90929-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903999				2022-12-01	WOS:A1994MQ86900005
J	KHARITONOV, SA; YATES, D; ROBBINS, RA; LOGANSINCLAIR, R; SHINEBOURNE, EA; BARNES, PJ				KHARITONOV, SA; YATES, D; ROBBINS, RA; LOGANSINCLAIR, R; SHINEBOURNE, EA; BARNES, PJ			INCREASED NITRIC-OXIDE IN EXHALED AIR OF ASTHMATIC-PATIENTS	LANCET			English	Article							HUMANS	Nitric oxide (NO) gas is produced by various cells within the lower respiratory tract, including inflammatory and epithelial cells, and is detectable in the exhaled air of normal human subjects. We have measured exhaled NO in patients with asthma, since several cell types that are activated in asthma can produce NO after induction. NO was measured reproducibly by a slow vital capacity manoeuvre and an adapted chemiluminescence analyser. NO was detectable in exhaled air of 67 control subjects (mean peak concentration 80.2 [SE 4.1] ppb) and was significantly reduced by inhalation of the specific NO synthase inhibitor N(G)-monomethyl-L-arginine. 61 non-steroid-treated asthmatic subjects had significantly higher peak expired NO concentrations than controls (283 [16] ppb, p < 0.001) but 52 asthmatic patients receiving inhaled corticosteroids had levels similar to controls (101 [71 ppb). High exhaled NO concentrations in asthmatic patients may reflect induction of NO synthase, which is known to be inhibited by steroids. Measurement of exhaled NO concentrations may be clinically useful in detection and management of cytokine-mediated inflammatory lung disorders.	NATL HEART & LUNG INST, DEPT THORAC MED, LONDON SW3 6HP, ENGLAND; ROYAL BROMPTON HOSP, DEPT BIOMED ENGN, LONDON SW3 6HP, ENGLAND; ROYAL BROMPTON HOSP, DEPT PAEDIAT, LONDON SW3 6HP, ENGLAND	Imperial College London; Royal Brompton Hospital; Royal Brompton Hospital				Barnes, Peter/0000-0002-5122-4018				ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; BARNES PJ, 1993, EUR RESPIR J, V6, P163; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; DINHXUAN AT, 1992, EUR RESPIR J, V5, P757; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; JORENS PG, 1991, EUR J PHARMACOL, V200, P205, DOI 10.1016/0014-2999(91)90573-9; KOBZIK L, 1993, AM REV RESPIR DIS, V147, pA515; KUO HP, 1992, EUR J PHARMACOL, V221, P385; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; NAKAYAMA DK, 1992, AM J RESP CELL MOL, V7, P471, DOI 10.1165/ajrcmb/7.5.471; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROBBINS RA, 1993, LIFE SCI, V52, P709, DOI 10.1016/0024-3205(93)90232-R; SPRINGALL DR, 1993, AM REV RESPIR DIS, V147, pA515; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0	16	1217	1245	1	68	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					133	135		10.1016/S0140-6736(94)90931-8	http://dx.doi.org/10.1016/S0140-6736(94)90931-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904001				2022-12-01	WOS:A1994MQ86900007
J	MACPHERSON, AJS; KHOO, UY; BJARNASON, I				MACPHERSON, AJS; KHOO, UY; BJARNASON, I			INFLAMMATORY BOWEL-DISEASE OF MICE - AND MEN	LANCET			English	Editorial Material							CYTOKINE PRODUCTION				MACPHERSON, AJS (corresponding author), UNIV LONDON KINGS COLL, SCH MED, DEPT MED, LONDON WC2R 2LS, ENGLAND.							FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; MACDERMOTT RP, 1988, ADV IMMUNOL, V42, P285, DOI 10.1016/S0065-2776(08)60848-2; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5	8	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 15	1994	343	8890					130	131		10.1016/S0140-6736(94)90928-8	http://dx.doi.org/10.1016/S0140-6736(94)90928-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903998				2022-12-01	WOS:A1994MQ86900004
J	NEAL, KR; BRIJ, SO; SLACK, RCB; HAWKEY, CJ; LOGAN, RFA				NEAL, KR; BRIJ, SO; SLACK, RCB; HAWKEY, CJ; LOGAN, RFA			RECENT TREATMENT WITH H(2) ANTAGONISTS AND ANTIBIOTICS AND GASTRIC-SURGERY AS RISK-FACTORS FOR SALMONELLA INFECTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,DIV GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND; NOTTINGHAM HLTH AUTHOR,DIV GASTROENTEROL,NOTTINGHAM NG3 5AF,ENGLAND	University of Nottingham	NEAL, KR (corresponding author), UNIV NOTTINGHAM,DEPT HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND.							GIANNELLA RA, 1972, GUT, V13, P251, DOI 10.1136/gut.13.4.251; HOLT P, 1985, PRACTITIONER, V229, P1027; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; NORDBRING F, 1962, ACTA MED SCAND, V171, P783; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255	5	74	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					176	176						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	7906170				2022-12-01	WOS:A1994MR97400020
J	PERSSON, MG; ZETTERSTROM, O; AGRENIUS, V; IHRE, E; GUSTAFSSON, LE				PERSSON, MG; ZETTERSTROM, O; AGRENIUS, V; IHRE, E; GUSTAFSSON, LE			SINGLE-BREATH NITRIC-OXIDE MEASUREMENTS IN ASTHMATIC-PATIENTS AND SMOKERS	LANCET			English	Note							GUINEA-PIGS; HUMANS	Exhaled nitric oxide (NO) concentrations were measured in asthmatic outpatients and in non-smoking and smoking healthy controls. In single exhalations, NO showed a peak suggestive of airway origin in both controls and asthmatic patients. The peak NO concentration was higher in asthmatic patients and lower in smokers than in non-smoking controls (p<0.05). The findings support a role for NO in the host defence response in asthma and suggest that NO measurements can discriminate between different types of lung disorders.	KAROLINSKA INST,DEPT PHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,INST ENVIRONM SCI,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA HOSP,DEPT THORAC MED,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital			Gustafsson, Lars E/E-6950-2013					BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BOUSQUET J, 1992, ALLERGY, V47, P129, DOI 10.1111/j.1398-9995.1992.tb00952.x; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; JORENS PG, 1993, EUR RESPIR J, V6, P258; NORMAN V, 1965, NATURE, V205, P915, DOI 10.1038/205915b0; PERSSON MG, 1993, AM REV RESPIR DIS, V148, P1210, DOI 10.1164/ajrccm/148.5.1210; PERSSON MG, 1993, ACTA PHYSIOL SCAND, V149, P461, DOI 10.1111/j.1748-1716.1993.tb09643.x; PERSSON MG, 1993, EUR J PHARMACOL, V249, P7	9	413	425	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					146	147		10.1016/S0140-6736(94)90935-0	http://dx.doi.org/10.1016/S0140-6736(94)90935-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904005				2022-12-01	WOS:A1994MQ86900011
J	SILVA, JM; SILVA, PS				SILVA, JM; SILVA, PS			SEXLESS HDL	LANCET			English	Editorial Material											SILVA, JM (corresponding author), UNIV HOSP COIMBRA,DEPT MED 2,COIMBRA,PORTUGAL.							AILHAUD G, 1993, ANN BIOL CLIN-PARIS, V51, P267; ASSMANN G, 1993, CIRCULATION, V87, P28; DEMIROVIC J, 1992, AM J EPIDEMIOL, V136, P155, DOI 10.1093/oxfordjournals.aje.a116482; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; KUSHWAHA RS, 1992, CURR OPIN LIPIDOL, V3, P167; WALLDIUS G, 1992, CURR OPIN LIPIDOL, V3, P34; WILSON PWF, 1990, AM J CARDIOL, V66, pA7, DOI 10.1016/0002-9149(90)90562-F; 1992, NUTR META CARDIOVASC, V2, P113; 1988, EUROPEAN HEART J, V9, P571	9	1	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					129	130		10.1016/S0140-6736(94)90927-X	http://dx.doi.org/10.1016/S0140-6736(94)90927-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7903997				2022-12-01	WOS:A1994MQ86900003
J	SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE				SOLOMON, T; FELIX, JM; SAMUEL, M; DENGO, GA; SALDANHA, RA; SCHAPIRA, A; PHILLIPS, RE			HYPOGLYCEMIA IN PEDIATRIC ADMISSIONS IN MOZAMBIQUE	LANCET			English	Note							SEVERE FALCIPARUM-MALARIA; HYPOGLYCEMIA; CHILDREN; CHILDHOOD	We studied the incidence and clinical associations of hypoglycaemia in an acute medical paediatric service in Maputo, Mozambique. Of 603 children, 43 (7.1%) were hypoglycaemic. 16 of these with Plasmodium falciparum malaria had a shorter illness, and a higher incidence of convulsions and focal neurological signs than those with other diagnoses, but were less likely to die. Hypoglycaemia also complicated protein energy malnutrition, pneumonia, encephalitis, intestinal parasite infection, and nephrotic syndrome. 25 of the 603 children died: 7 (16.3%) of 43 with hypoglycaemia and 18 (3.2%) of 560 who were normoglycaemic, (relative risk of death 5.8 [95% confidence interval 2.25 to 14.93]). Hypoglycaemia is common in children in hospital in Mozambique, and should be suspected in any acutely-ill child regardless of the primary disease.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; UNIV EDUARDO MONDLANE,FAC MED,MAPUTO,MOZAMBIQUE; HOSP CENT MAPUTO,MAPUTO,MOZAMBIQUE; UNIV OXFORD,DEPT STAT,OXFORD,ENGLAND	University of Oxford; Eduardo Mondlane University; University of Oxford			Schapira, Allan/AAZ-8116-2020	Solomon, Tom/0000-0001-7266-6547; Saldanha, Richard/0000-0002-4137-3917	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNISH ML, 1990, NEW ENGL J MED, V322, P1357, DOI 10.1056/NEJM199005103221905; FILKINS JP, 1974, AM J PHYSIOL, V227, P778, DOI 10.1152/ajplegacy.1974.227.4.778; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; MOLYNEUX ME, 1989, AM J TROP MED HYG, V40, P470, DOI 10.4269/ajtmh.1989.40.470; PAGLIARA AS, 1973, J PEDIATR-US, V82, P558, DOI 10.1016/S0022-3476(73)80581-5; PAGLIARA AS, 1973, J PEDIATR-US, V82, P365, DOI 10.1016/S0022-3476(73)80109-X; TAYLOR TE, 1988, NEW ENGL J MED, V319, P1040, DOI 10.1056/NEJM198810203191602; WHARTON B, 1970, LANCET, V1, P171; WHITE NJ, 1987, LANCET, V1, P708; 1990, T R SOC TROP MED H S, P1; 1972, LANCET, V2, P143	11	33	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					149	150		10.1016/S0140-6736(94)90937-7	http://dx.doi.org/10.1016/S0140-6736(94)90937-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904007				2022-12-01	WOS:A1994MQ86900013
J	WEST, LJ; MORRIS, PJ; WOOD, KJ				WEST, LJ; MORRIS, PJ; WOOD, KJ			FETAL LIVER HEMATOPOIETIC-CELLS AND TOLERANCE TO ORGAN ALLOGRAFTS	LANCET			English	Note							TRANSPLANTATION	Fetal liver haematopoietic cells were used to induce neonatal tolerance to cardiac allografts. Newborn mice were injected with fetal or newborn haematopoietic liver cells in two fully allogeneic strain combinations. There was no clinical evidence of graft-versus-host disease. Long-term survival of subsequent cardiac allografts occurred in both strains without immunosuppressants. Unresponsiveness was found not to be donor-specific with prolongation of third-party allografts as well as donor-type grafts. These findings have important implications for inducing tolerance in paediatric organ transplantation.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford				West, Lori/0000-0002-1990-3651				BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; FLAKE AW, 1986, SCIENCE, V233, P76; HARRISON MR, 1989, LANCET, V2, P1425; ROYO C, 1987, THYMUS, V10, P57; SANHADJI K, 1992, BONE MARROW TRANSPL, V9, P77; STREILEIN JW, 1991, TRANSPLANTATION, V252, P1; SUPERINA RA, 1986, TRANSPLANTATION, V42, P227; TOURAINE JL, 1992, BONE MARROW TRANSPL, V9, P121; TOURAINE JL, 1989, TRANSPLANT P, V21, P3112	9	30	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 15	1994	343	8890					148	149		10.1016/S0140-6736(94)90936-9	http://dx.doi.org/10.1016/S0140-6736(94)90936-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ869	7904006				2022-12-01	WOS:A1994MQ86900012
J	AFONSO, LCC; SCHARTON, TM; VIEIRA, LQ; WYSOCKA, M; TRINCHIERI, G; SCOTT, P				AFONSO, LCC; SCHARTON, TM; VIEIRA, LQ; WYSOCKA, M; TRINCHIERI, G; SCOTT, P			THE ADJUVANT EFFECT OF INTERLEUKIN-12 IN A VACCINE AGAINST LEISHMANIA-MAJOR	SCIENCE			English	Article							CELL STIMULATORY FACTOR; CUTANEOUS LEISHMANIASIS; PROTECTIVE IMMUNITY; INTERFERON-GAMMA; MURINE MODEL; INDUCTION; SUBSETS	Protection induced by vaccination depends on the capacity of the vaccine to elicit an appropriate immune response. In leishmaniasis, protection requires leishmanial-specific CD4+ T helper (T(H)) cells. Vaccination of BAL-B/c mice with leishmanial antigens and interleukin-12 (IL-12) promoted the development of leishmanial-specific CD4+ T(H)1 cells These mice were resistant to subsequent infection with Leishmania major. Thus, IL-12 is an effective adjuvant for the initiation of protective cell-mediated immunity against leishmaniasis and may be an important component in other vaccines that need tc induce cell-mediated immunity.	UNIV PENN,SCH VET MED,DEPT PATHOBIOL,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute			Afonso, Luis C C/G-5436-2012; Trinchieri, Giorgio/F-9369-2015; Vieira, Leda Q/G-7487-2014; Vieira, Leda Quercia/AAD-3424-2019; Afonso, Luis C C/C-2224-2013	Afonso, Luis C C/0000-0003-2498-4086; Trinchieri, Giorgio/0000-0001-5892-7464; Vieira, Leda Quercia/0000-0001-5481-9618; Afonso, Luis C C/0000-0003-2498-4086	NCI NIH HHS [CA-20833] Funding Source: Medline; NIAID NIH HHS [AI-30073] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020833, R37CA020833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFONSO LCC, UNPUB; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; MACATONIA SE, 1993, INT IMMUNOL, V5, P1119, DOI 10.1093/intimm/5.9.1119; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCOTT P, 1987, J IMMUNOL, V139, P221; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, J IMMUNOL, V147, P3149; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; WARREN HS, 1986, ANNU REV IMMUNOL, V4, P369, DOI 10.1146/annurev.iy.04.040186.002101	18	660	706	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					235	237		10.1126/science.7904381	http://dx.doi.org/10.1126/science.7904381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	7904381				2022-12-01	WOS:A1994MQ87900038
J	GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF				GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF			REGULATION OF THE ARABIDOPSIS FLORAL HOMEOTIC GENE APETALA1	CELL			English	Article							FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; TRANSCRIPTION FACTOR; DNA-BINDING; MADS-BOX; LEAFY; INTERACTS; DEFICIENS; THALIANA	The Arabidopsis floral homeotic gene APETALA1 (AP1) encodes a putative transcription factor that acts locally to specify the identity of the floral meristem and to determine sepal and petal development. RNA tissue in situ hybridization studies show that AP1 RNA accumulates uniformly throughout young floral primordia, but is absent from the inflorescence meristem. Later in development, AP1 RNA is excluded from cells that will give rise to the two inner whorls of organs. Here we show that AP1 expression is under the control of two negative regulators: the meristem identity gene TERMINAL FLOWER represses AP1 RNA accumulation in the inflorescence meristem, and the organ identity gene AGAMOUS prevents AP1 RNA accumulation in the two inner whorls of wild-type flowers. These and other data presented here lead to a revised model for the regulatory interactions among the genes specifying floral organ identity in Arabidopsis.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	GUSTAFSONBROWN, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GMO7313] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	24	320	344	1	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					131	143		10.1016/0092-8674(94)90178-3	http://dx.doi.org/10.1016/0092-8674(94)90178-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	7506995				2022-12-01	WOS:A1994MR49500012
J	YOUNG, ACM; ZHANG, WG; SACCHETTINI, JC; NATHENSON, SG				YOUNG, ACM; ZHANG, WG; SACCHETTINI, JC; NATHENSON, SG			THE 3-DIMENSIONAL STRUCTURE OF H-2D(B) AT 2.4 ANGSTROM RESOLUTION - IMPLICATIONS FOR ANTIGEN-DETERMINANT SELECTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; INFLUENZA NUCLEOPROTEIN; SELF-PEPTIDES; TRANSPLANTATION ANTIGENS; SYNTHETIC PEPTIDES; BINDING MOTIF; SIDE-CHAINS; MHC	Solution at 2.4 angstrom resolution of the structure of H-2D(b) with the influenza virus peptide NP366-374 (ASNENMETM) and comparison with the H-2K(b)-VSV (RGYVYQGL) structure allow description of the molecular details of MHC class I peptide binding interactions for mice of the H-2b haplotype, revealing a strategy that maximizes the repertoire of peptides that can be presented. The H-2D(b) cleft has a mouse-specific hydrophobic ridge that causes a compensatory arch in the backbone of the peptide, exposing the arch residues to TCR contact and requiring the peptide to be at least 9 residues. This ridge occurs in about 40% of the known murine D and L allelic molecules, classifying them as a structural subgroup.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI007289, R37AI007289, R01AI007289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-10792, AI-07289] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOYD LF, 1992, IMMUNOLOGY, V89, P2242; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARYANSKI JL, 1989, COLD SH Q B, V54, P545; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NATHENSON SG, 1981, ANNU REV BIOCHEM, V50, P1025, DOI 10.1146/annurev.bi.50.070181.005113; OTTEN GR, 1992, J IMMUNOL, V148, P3723; POTTEN JK, 1992, I IMMUNOLOGY, V148, P953; PULLEN JK, 1992, J IMMUNOL, V148, P953; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAPER MA, 1991, J MOL BIOL, V219, P227; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROWSDALE J, 1992, EUR J IMMUNOGENET, V19, P45; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VANBLEEK GM, 1990, NATURE, V348, P213; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	39	244	249	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					39	50		10.1016/0092-8674(94)90171-6	http://dx.doi.org/10.1016/0092-8674(94)90171-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	7506996				2022-12-01	WOS:A1994MR49500005
J	BLADIN, CF; ALEXANDROV, AV; SMURAWSKA, LT				BLADIN, CF; ALEXANDROV, AV; SMURAWSKA, LT			SHOULD PATIENTS WITH STROKE SEE A NEUROLOGIST	LANCET			English	Editorial Material											BLADIN, CF (corresponding author), UNIV TORONTO,STROKE RES UNIT,TORONTO M5S 1A1,ONTARIO,CANADA.		bladin, chris/B-9136-2013	Alexandrov, Andrei V/0000-0001-8871-1023				ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; HEWER RL, 1992, J NEUROL NEUROSUR PS, V55, P8; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; NORRIS JW, 1982, LANCET, V1, P328; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; 1991, LANCET, V337, P1235; 1993, GUIDELINES CARE PATI; 1993, LANCET, V342, P1255; 1991, NEW ENGL J MED, V325, P445	10	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					69	70		10.1016/S0140-6736(94)90811-7	http://dx.doi.org/10.1016/S0140-6736(94)90811-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903774				2022-12-01	WOS:A1994MQ09200006
J	CALNE, R; DAVIES, H				CALNE, R; DAVIES, H			ORGAN GRAFT TOLERANCE - THE LIVER EFFECT	LANCET			English	Editorial Material							TRANSPLANTATION; RECIPIENTS; CHIMERISM; ANTIGENS				CALNE, R (corresponding author), ADDENBROOKES HOSP,DEPT SURG,CAMBRIDGE CB2 2QQ,ENGLAND.							DAVIES HFS, 1989, TRANSPLANTATION, V47, P524; GONWA TA, 1988, TRANSPLANTATION, V46, P690, DOI 10.1097/00007890-198811000-00013; JAMIESON NV, 1991, TRANSPLANT INT, V4, P67, DOI 10.1007/BF00336399; KAMADA N, 1980, TRANSPLANTATION, V29, P429, DOI 10.1097/00007890-198005000-00021; MARGREITER R, 1988, TRANSPLANT P, V20, P522; RASMUSSEN A, 1993, 6TH C EUR SOC ORG TR; SRIWATANAWONGA V, 1993, THESIS U CAMBRIDGE; SRIWATANAWONGSA V, 1993, TRANSPLANT P, V25, P371; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; 1969, LANCET, V2, P940	12	75	75	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					67	68		10.1016/S0140-6736(94)90809-5	http://dx.doi.org/10.1016/S0140-6736(94)90809-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903772				2022-12-01	WOS:A1994MQ09200004
J	CUI, KH; WARNES, GM; JEFFREY, R; MATTHEWS, CD				CUI, KH; WARNES, GM; JEFFREY, R; MATTHEWS, CD			SEX DETERMINATION OF PREIMPLANTATION EMBRYOS BY HUMAN TESTIS-DETERMINING-GENE AMPLIFICATION	LANCET			English	Article							DNA AMPLIFICATION; SPERM RECEPTOR; INVITRO; FERTILIZATION; PROTEIN; BIOPSY; ZP3	When there is a risk of inherited disease, preimplantation diagnosis gives couples an opportunity to avoid having a child with the disease. Sex determination can be used to exclude the likelihood of a sex-linked disorder. Accuracy of the diagnosis is important. We have tested the reliability of sex determination based on the recognition of a testis-determining gene (SRY) sequence. DNA from the blood of 120 men and women and from 38 single lymphocytes was amplified by polymerase chain reaction (PCR) with the SRY and control (ZP3) gene primers. All results confirmed the correct sex of origin (100%). The test was then used to determine the sex of 21 single embryo cells biopsied from 21 (4-8 cell) human polyspermic embryos. 2 embryo cells recognised at biopsy to have degenerated produced negative results. The other 19 single embryo cells showed 100% PCR amplification. 11 (58%) of the embryos were judged to be ''male'' and 8 (42%) ''female''. The SRY and ZP3 gene primers selected are highly specific and give accurate results in sex determination and their use provides a new reliable method for routine preimplantation and general prenatal sex determination in man.			CUI, KH (corresponding author), UNIV ADELAIDE,QUEEN ELIZABETH HOSP,DEPT OBSTET & GYNAECOL,WOODVILLE,SA 5011,AUSTRALIA.							BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BRADBURY MW, 1990, P NATL ACAD SCI USA, V87, P4053, DOI 10.1073/pnas.87.11.4053; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; CUI KH, 1993, HUM REPROD, V8, P621, DOI 10.1093/oxfordjournals.humrep.a138107; CUI KH, 1993, NATURE, V366, P117, DOI 10.1038/366117b0; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; Kawasaki E.S., 1990, PCR PROTOCOLS GUIDE, P146; LO YMD, 1989, LANCET, V2, P1363; NAKAGOME Y, 1990, LANCET, V335, P291, DOI 10.1016/0140-6736(90)90109-I; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; PAYNE D, 1991, HUM REPROD, V6, P423, DOI 10.1093/oxfordjournals.humrep.a137352; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; TROUNSON AL, 1992, HUM REPROD, V7, P583; VANDUIN M, 1991, CYTOGENET CELL GENET, V58, P1927; WINSTON RML, 1991, HUM REPROD, V6, P281	20	54	53	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					79	82		10.1016/S0140-6736(94)90815-X	http://dx.doi.org/10.1016/S0140-6736(94)90815-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903778				2022-12-01	WOS:A1994MQ09200010
J	EVAINBRION, D; PORQUET, D; THEROND, P; FJELLESTADPAULSEN, A; GRENECHE, MO; FRANCOIS, L; CZERNICHOW, P				EVAINBRION, D; PORQUET, D; THEROND, P; FJELLESTADPAULSEN, A; GRENECHE, MO; FRANCOIS, L; CZERNICHOW, P			VITAMIN-A-DEFICIENCY AND NOCTURNAL GROWTH-HORMONE SECRETION IN SHORT CHILDREN	LANCET			English	Note							ALPHA-TOCOPHEROL; RETINOL	In the growth hormone (GH) neurosecretory dysfunction syndrome affecting slowly growing children with delayed bone age, low nocturnal GH secretion is accompanied by normal responses to pharmacological stimuli. We compared plasma vitamin A with physiological nocturnal and stimulated GH secretion in 68 short prepubertal children. Fasting plasma vitamin A correlated with nocturnal GH secretion but not with stimulated GH secretion. Total dietary vitamin A intake was significantly lower in short children with abnormal nocturnal GH secretion than in normal children and in endocrinologically-normal short children. 9 of 12 children with low nocturnal GH secretion and normal stimulated GH peaks who were supplemented with vitamin A 3000 mug for 3 months had increased nocturnal GH secretion.	HOP ROBERT DEBRE,SERV BIOCHIM HORMONOL,F-75019 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT DIETET,F-75019 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	EVAINBRION, D (corresponding author), HOP ROBERT DEBRE,SERV ENDOCRINOL & DIABETOL INFANTILE,48 BLVD SERURIER,F-75019 PARIS,FRANCE.							AMEDEEMANESME O, 1985, HEPATOLOGY, V5, P1143, DOI 10.1002/hep.1840050614; DELEENHEER AP, 1979, J CHROMATOGR, V162, P408, DOI 10.1016/S0378-4347(00)81528-5; MALVY JMD, 1989, INT J VITAM NUTR RES, V59, P29; MERRIAM GR, 1982, AM J PHYSIOL, V243, pE310, DOI 10.1152/ajpendo.1982.243.4.E310; PORQUET D, 1992, CLIN CHEM, V38, P1717; PORQUET D, 1993, HORM RES, V39, P19; SOUCI SW, 1989, COMPOSITION ALIMENTS; SPILIOTIS BE, 1984, JAMA-J AM MED ASSOC, V251, P2223, DOI 10.1001/jama.251.17.2223; ZADIK Z, 1985, PEDIATRICS, V76, P355	9	35	37	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					87	88		10.1016/S0140-6736(94)90819-2	http://dx.doi.org/10.1016/S0140-6736(94)90819-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903782				2022-12-01	WOS:A1994MQ09200014
J	HOOTON, TM; ROBERTS, MC; KENNY, GE				HOOTON, TM; ROBERTS, MC; KENNY, GE			MYCOPLASMA-GENITALIUM AND NONGONOCOCCAL URETHRITIS	LANCET			English	Editorial Material											HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,MADISON CLIN,SEATTLE,WA 98104, USA.							BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; BOWIE WR, 1989, SEXUALLY TRANSMITTED, P627; HANDSFIELD H H, 1976, Journal of the American Venereal Disease Association, V2, P5; HOERNER PJ, 1993, LANCET, V342, P582; Hooton T M, 1987, Infect Dis Clin North Am, V1, P165; HOOTON TM, 1988, LANCET, V1, P266; TAYLORROBINSON D, 1985, BRIT J EXP PATHOL, V66, P95	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					69	69		10.1016/S0140-6736(94)90810-9	http://dx.doi.org/10.1016/S0140-6736(94)90810-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903773				2022-12-01	WOS:A1994MQ09200005
J	OFFERHAUS, GJA				OFFERHAUS, GJA			GASTRIC STUMP CANCER - LESSONS FROM OLD SPECIMENS	LANCET			English	Editorial Material											OFFERHAUS, GJA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS.							ALEXANDERWILLIAMS J, 1991, BRIT MED J, V302, P547, DOI 10.1136/bmj.302.6776.547; CORREA P, 1992, CANCER RES, V52, P6735; DUBROW R, 1993, J NATL CANCER I, V85, P1268, DOI 10.1093/jnci/85.16.1268; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER SG, 1993, JNCI-J NATL CANCER I, V85, P1303, DOI 10.1093/jnci/85.16.1303; LEE S, 1990, SCAND J GASTROENTERO, V25, P1223, DOI 10.3109/00365529008998557; OFFERHAUS GJA, 1985, EUR J CANCER CLIN ON, V21, P73, DOI 10.1016/0277-5379(85)90203-2; OFFERHAUS GJA, 1992, LANCET, V340, P33, DOI 10.1016/0140-6736(92)92433-G; VONHOLSTEIN CS, 1993, CANCER, V72, P1532; WRIGHT PA, 1993, GUT, V34, P145, DOI 10.1136/gut.34.2.145	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					66	67		10.1016/S0140-6736(94)90807-9	http://dx.doi.org/10.1016/S0140-6736(94)90807-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903770				2022-12-01	WOS:A1994MQ09200002
J	PAGE, C				PAGE, C			SODIUM CROMOGLYCATE, A TACHYKININ ANTAGONIST	LANCET			English	Editorial Material											PAGE, C (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED,SACKLER INST PULM PHARMACOL,LONDON SE5 8RX,ENGLAND.							BASRAN G S, 1983, European Journal of Pharmacology, V86, P143; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CROSSMAN DC, 1993, J APPL PHYSIOL, V75, P167, DOI 10.1152/jappl.1993.75.1.167; DIXON M, 1979, BRIT J PHARMACOL, V67, P567; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1150; SPINA D, 1991, BRIT J PHARMACOL, V103, P1268, DOI 10.1111/j.1476-5381.1991.tb12335.x; STOKES TC, 1981, BR J DIS CHEST, V75, P11	7	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					70	70		10.1016/S0140-6736(94)90812-5	http://dx.doi.org/10.1016/S0140-6736(94)90812-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903775				2022-12-01	WOS:A1994MQ09200007
J	TAYLOR, JA; WATSON, MA; DEVEREUX, TR; MICHELS, RY; SACCOMANNO, G; ANDERSON, M				TAYLOR, JA; WATSON, MA; DEVEREUX, TR; MICHELS, RY; SACCOMANNO, G; ANDERSON, M			P53 MUTATION HOTSPOT IN RADON-ASSOCIATED LUNG-CANCER	LANCET			English	Note							TUMOR SUPPRESSOR GENE; JAPAN	Mutations in gene p53 are the most common defects in lung cancer and may be a pathway through which environmental carcinogens initiate cancer. We investigated p53 mutations in lung cancers from uranium miners with high radon exposure. 16 (31%) of 52 large-cell and squamous-cell cancers from miners contained the same AGG to ATG transversion at codon 249, including cancers from 3 or 5 miners who had never smoked. This specific mutation has been reported in only 1 of 241 published p53 mutations from lung cancers. The codon 249 mutation may be a marker for radon-induced lung cancer.	NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; ST MARYS HOSP,GRAND JCT,CO	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	TAYLOR, JA (corresponding author), NIEHS,EPIDEMIOL BRANCH,POB 12233,RES TRIANGLE PK,NC 27709, USA.		taylor, jack a/C-7154-2019	taylor, jack a/0000-0001-5303-6398				DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; JABERABOANSARI A, 1991, RADIAT RES, V127, P202, DOI 10.2307/3577966; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KONDO K, 1992, BIOCHEM BIOPH RES CO, V183, P1139, DOI 10.1016/S0006-291X(05)80309-2; MITSUDOMI T, 1992, ONCOGENE, V7, P171; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SOZZI G, 1992, CANCER RES, V52, P6079; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	10	139	149	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 8	1994	343	8889					86	87		10.1016/S0140-6736(94)90818-4	http://dx.doi.org/10.1016/S0140-6736(94)90818-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903781				2022-12-01	WOS:A1994MQ09200013
J	WALD, NJ; LAW, M; WATT, HC; WU, TS; BAILEY, A; JOHNSON, AM; CRAIG, WY; LEDUE, TB; HADDOW, JE				WALD, NJ; LAW, M; WATT, HC; WU, TS; BAILEY, A; JOHNSON, AM; CRAIG, WY; LEDUE, TB; HADDOW, JE			APOLIPOPROTEINS AND ISCHEMIC-HEART-DISEASE - IMPLICATIONS FOR SCREENING	LANCET			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; SERUM; RISK; CHOLESTEROL; MEN	Apolipoproteins and lipids are established risk factors of ischaemic heart disease (IHD) but their efficacy as screening tests is not known. We therefore examined the mortality from IHD and serum concentrations of lipids and apolipoproteins in a prospective study of 21 520 men aged 35-64 years. Serum apo B was the apolipoprotein most strongly associated with IHD risk; a decrease in apo B of 10% was associated with 22% lower risk of IHD. However, measurement of apo B alone detected only 17% of all IHD deaths at the cost of a 5% false-positive rate. Combining apo B with apo Al and apo (a) increased the detection rate to 19%. With systolic blood pressure, smoking, and family history of IHD the detection rate increased to 28%. We conclude that screening for IHD by measuring apo B alone or with apo Al and apo (a) is too poor to discriminate between recommending drug therapy or lifestyle change for some and not others. It is not advisable to screen for IHD by measuring any combination of cholesterol, apo B, apo Al, apo (a) and the other risk factors. The primary aim in prevention of ischaemic heart disease should be to lower the risk factors in the population.	BUPA MED RES, LONDON WC2, ENGLAND; FDN BLOOD RES, SCARBOROUGH, ME USA	Foundation for Blood Research (FBR)	WALD, NJ (corresponding author), ST BARTHOLOMEWS HOSP, MED COLL, DEPT ENVIRONM & PREVENT MED, WOLFSON INST PREVENT MED, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; H, V/M-5550-2014; Wald, Nicholas/AAY-8924-2021					BUCOLO G, 1973, CLIN CHEM, V19, P476; CREMER P, 1988, KLIN WOCHENSCHR, V66, P42; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; IRISH GR, 1987, CLIN CHEM, V33, P1267; IRISH GR, 1987, CLIN CHEM, V33, P1266; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; LAW MR, IN PRESS BMJ; MACIEJKO JJ, 1987, CLIN CHEM, V33, P2065; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, CORONARY HEART DIS E, P358; WARNICK GR, 1982, CLIN CHEM, V28, P1379; ZHAO SP, 1991, CLIN CHEM, V37, P1139	18	235	239	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	1994	343	8889					75	79		10.1016/S0140-6736(94)90814-1	http://dx.doi.org/10.1016/S0140-6736(94)90814-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ092	7903777				2022-12-01	WOS:A1994MQ09200009
J	TSARFATY, I; RONG, S; RESAU, JH; SHEN, RL; DASILVA, PP; VANDEWOUDE, GF				TSARFATY, I; RONG, S; RESAU, JH; SHEN, RL; DASILVA, PP; VANDEWOUDE, GF			THE MET PROTOONCOGENE MESENCHYMAL TO EPITHELIAL-CELL CONVERSION	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; LIVER-REGENERATION; FACTOR HGF; C-MET; PROTOONCOGENE; VIMENTIN; CYTOKERATINS; EXPRESSION; RECEPTOR	Coexpression of the human Met receptor and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), in NIH 3T3 fibroblasts causes the cells to become tumorigenic in nude mice. The resultant tumors display lumen-like morphology, contain carcinoma-like focal areas with intercellular junctions resembling desmosomes, and coexpress epithelial (cytokeratin) and mesenchymal (vimentin) cytoskeletal markers. The tumor cells also display enhanced expression of desmosomal and tight-junction proteins. The apparent mesenchymal to epithelial conversion of the tumor cells mimics the conversion that occurs during embryonic kidney development, suggesting that Met-HGF/SF signaling plays a role in this process as well as in tumors that express both epithelial and mesenchymal markers.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,FREDERICK,MD 21702; NCI,DIV CANC BIOL DIAG & CTR,INTRAMURAL RES PROGRAM,MATH BIOL LAB,MEMBRANE BIOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Shen, Rulong/E-4079-2011	Tsarfaty, Ilan/0000-0002-5230-7093	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACALLAO R, 1989, AM J PHYSIOL, V257, P913; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEJFEC G, 1991, ULTRASTRUCT PATHOL, V15, P131, DOI 10.3109/01913129109016231; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; DOMAGALA W, 1990, AM J PATHOL, V137, P1059; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GOULD VE, 1990, AM J PATHOL, V137, P1143; GRONE HJ, 1987, AM J PATHOL, V129, P1; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NAKAMURA T, 1989, SEIKAGAKU, V61, P1243; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, UNPUB; WARD JM, 1992, AM J PATHOL, V141, P955	29	198	210	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					98	101		10.1126/science.7505952	http://dx.doi.org/10.1126/science.7505952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	7505952				2022-12-01	WOS:A1994MQ30100040
J	DILWORTH, SM; BREWSTER, CEP; JONES, MD; LANFRANCONE, L; PELICCI, G; PELICCI, PG				DILWORTH, SM; BREWSTER, CEP; JONES, MD; LANFRANCONE, L; PELICCI, G; PELICCI, PG			TRANSFORMATION BY POLYOMA-VIRUS MIDDLE T-ANTIGEN INVOLVES THE BINDING AND TYROSINE PHOSPHORYLATION OF SHC	NATURE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; SITE-DIRECTED MUTAGENESIS; PROTEIN; INVITRO; PP60C-SRC; 3-KINASE; DOMAIN; CELLS	POLYOMA virus middle T-antigen converts normal fibroblasts to a fully transformed, tumorigenic phenotype1. It achieves this, at least in part, by binding and activating one of the non-receptor tyrosine kinases, pp60c-src, pp62c-yes or pp59c-fyn (reviewed in refs 2 and 3). As a result, middle T-antigen itself is phosphorylated on tyrosine residues4,5, one of which (Tyr 315) acts as a binding site for the SH2 domains of phosphatidylinositol-3'OH kinase 85K sub-unit6-8. Here we show that another tyrosine phosphorylation site in middle T-antigen (Tyr 250; refs 4, 5) acts as a binding region for the SH2 domain of the transforming protein Shc9. This results in Shc also becoming tyrosine-phosphorylated and binding to the SH2 domain of Grb2 (ref. 10). This probably stimulates p21ras activity through the mammalian homologue of the Drosophila guanine-nucleotide-exchange factor Sos (reviewed in ref. 11). We suggest that middle T-antigen transforms cells by acting as a functional homologue of an activated tyrosine kinase-associated growth-factor receptor.	ROYAL POSTGRAD MED SCH, DEPT VIROL, LONDON W12 0NN, ENGLAND; UNIV PERUGIA, IST CLIN MED 1, I-06100 PERUGIA, ITALY	Imperial College London; University of Perugia	DILWORTH, SM (corresponding author), ROYAL POSTGRAD MED SCH, DEPT CHEM PATHOL, DU CANE RD, LONDON W12 0NN, ENGLAND.		Pelicci, Pier Giuseppe/AAL-6572-2020; Pelicci, Giuliana/AAA-8921-2022; Lanfrancone, Luisa/AAC-8671-2019	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815				AUGER KR, 1992, J BIOL CHEM, V267, P5408; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1982, EMBO J, V1, P1319, DOI 10.1002/j.1460-2075.1982.tb01317.x; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; GRIFFIN BE, 1979, COLD SPRING HARB SYM, V44, P271; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	199	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					87	90		10.1038/367087a0	http://dx.doi.org/10.1038/367087a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7509037				2022-12-01	WOS:A1994MP86500066
J	LI, XL; NOLL, M				LI, XL; NOLL, M			EVOLUTION OF DISTINCT DEVELOPMENTAL FUNCTIONS OF 3 DROSOPHILA GENES BY ACQUISITION OF DIFFERENT CIS-REGULATORY REGIONS	NATURE			English	Article							SEGMENT POLARITY GENES; EVEN-SKIPPED PROTEIN; INT-1 PROTOONCOGENE; SPATIAL EXPRESSION; PAIRED GENE; POX-NEURO; EMBRYOS; PATTERN; DNA; EMBRYOGENESIS	IT is generally accepted that the specific function of a gene depends on its coding sequence. The three paired-box and homeobox genes paired (prd), gooseberry (gsb) and gooseberry neuro (gsbn) have distinct developmental functions in Drosophila embryogenesis1-5. During the syncytial blastoderm stage, the pair-rule gene prd4,6 activates segment-polarity genes, such as gsb7, wingless (wg), and engrailed (en), in segmentally repeated stripes8. After germ-band extension, gsb maintains the expression of wg, which in turn specifies the denticle pattern by repressing a default state of ubiquitous denticle formation in the ventral epidermis9. In addition, gsb activates gsbn5, which is expressed mainly in the central nervous system2,3, suggesting that gsbn is involved in neural development. Here we show that, despite the functional difference and the considerably diverged coding sequence of these genes, their proteins have conserved the same function. The finding that the essential difference between genes may reside in their cis-regulatory regions exemplifies an important evolutionary mechanism of how function diversifies after gene duplication.			LI, XL (corresponding author), UNIV ZURICH,INST MOLEC BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.							BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DAMBLYCHAUDIERE C, 1992, CELL, V69, P159, DOI 10.1016/0092-8674(92)90127-X; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GUTJAHR T, 1993, DEVELOPMENT, V117, P609; GUTJAHR T, 1993, DEVELOPMENT, V118, P21; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MANOUKIAN AS, 1993, DEVELOPMENT, V118, P785; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRISSEY D, 1991, GENE DEV, V5, P1684, DOI 10.1101/gad.5.9.1684; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wieschaus E., 1986, P199	36	123	129	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					83	87		10.1038/367083a0	http://dx.doi.org/10.1038/367083a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7906390				2022-12-01	WOS:A1994MP86500065
J	NOORDERMEER, J; KLINGENSMITH, J; PERRIMON, N; NUSSE, R				NOORDERMEER, J; KLINGENSMITH, J; PERRIMON, N; NUSSE, R			DISHEVELLED AND ARMADILLO ACT IN THE WINGLESS SIGNALING PATHWAY IN DROSOPHILA	NATURE			English	Article							POLARITY GENE ARMADILLO; PROTEIN; EXPRESSION; PRODUCT; ENCODES; EMBRYOGENESIS; REQUIREMENTS; SECRETION; EPIDERMIS; HEDGEHOG	THE Wnt genes encode conserved secreted proteins that play a role in normal development and tumorigenesis1,2. Little is known about the signal transduction pathways of Wnt gene products. One of the best characterized Wnt family members is the Drosophila segment polarity gene wingless3-6. We have investigated whether segment polarity genes with a wingless-like phenotype mediate the wingless signal. We used a wingless transgene controlled by a heat-shock promoter for genetic epistasis experiments. We show that wingless acts through dishevelled and armadillo to affect the expression of the homeobox gene engrailed and cuticle differentiation.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT DEV BIOL, STANFORD, CA 94305 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School				Perrimon, Norbert/0000-0001-7542-472X				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CHOU TB, 1992, GENETICS, V131, P643; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; EBERL DF, 1992, GENETICS, V130, P569; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KLINGENSMITH J, IN PRESS GENES DEV; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MOHLER J, 1988, GENETICS, V120, P1061; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDENHEUVEL M, IN PRESS EMBO J; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; Wieschaus E., 1986, DROSOPHILA PRACTICAL	33	332	335	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					80	83		10.1038/367080a0	http://dx.doi.org/10.1038/367080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7906389				2022-12-01	WOS:A1994MP86500064
J	GALE, JL; THAPA, PB; WASSILAK, SGF; BOBO, JK; MENDELMAN, PM; FOY, HM				GALE, JL; THAPA, PB; WASSILAK, SGF; BOBO, JK; MENDELMAN, PM; FOY, HM			RISK OF SERIOUS ACUTE NEUROLOGICAL ILLNESS AFTER IMMUNIZATION WITH DIPHTHERIA-TETANUS-PERTUSSIS VACCINE - A POPULATION-BASED CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE REACTIONS; DISORDERS; CHILDREN	Objective.-To evaluate the association between serious acute neurological illness and receipt of whole-cell pertussis vaccine, given as diphtheria-tetanus-pertussis (DTP) vaccine. Design.-Population-based case-control study. Setting.-Outpatient and inpatient hospital settings, physician practices, and the general population in Washington and Oregon states. Subjects.-A total of 424 confirmed cases of neurological illness were identified prospectively during a 12-month period by statewide active surveillance from the population of 218 000 children 1 to 24 months of age living in Washington and Oregon (estimated 368 000 DTP immunizations given). Each case child was matched to two population control children by birth date (+/-5 days), gender, and county of birth. Written immunization records were used to determine whether illness occurred within 7 days of immunization in case children, or within 7 days of the same reference date in control children, thus qualifying as exposed. Main Outcome Measures.-Outpatient and inpatient cases of complex febrile seizures, seizures without fever, infantile spasms, and acute encephalitis/encephalopathy confirmed by an expert panel masked to immunization history. Results.-The estimated odds ratio (OR) for onset of serious acute neurological illness within 7 days for young children exposed to DTP vaccine was 1.1 (95% confidence interval [CI], 0.6 to 2.0). When the analysis was restricted to children with encephalopathy or complicated seizures and adjusted for factors possibly affecting vaccine administration, the OR was 3.6 (95% Cl, 0.8 to 15.2). Odds ratios for specific study diagnoses varied, but all CIs included 1. No elevated risk was observed for the largest group of illnesses studied, nonfebrile seizures (OR, 0.5; 95% CI, 0.2 to 1.5). Conclusions.-This study did not find any statistically significant increased risk of onset of serious acute neurological illness in the 7 days after DTP vaccine exposure for young children.	UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; CTR DIS CONTROL,ATLANTA,GA 30333	University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA	GALE, JL (corresponding author), UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195, USA.				PHS HHS [200-87-0506] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELLMAN MH, 1983, LANCET, V1, P1031; BOBO JK, 1993, PEDIATRICS, V91, P308; BRESLOW NE, 1980, STAT METHODS CANC RE, P176; BYERS RK, 1948, PEDIATRICS, V1, P437; CHERRY JD, 1988, PEDIATRICS S, V81, P959; CODY CL, 1981, PEDIATRICS, V68, P650; CORSELLIS JAN, 1983, NEUROPATH APPL NEURO, V9, P261, DOI 10.1111/j.1365-2990.1983.tb00113.x; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GLOBUS JH, 1949, JAMA-J AM MED ASSOC, V141, P507, DOI 10.1001/jama.1949.02910080007003; GRIFFIN MR, 1990, JAMA-J AM MED ASSOC, V263, P1641, DOI 10.1001/jama.263.12.1641; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; Madsen T, 1933, J AMER MED ASSOC, V101, P187, DOI 10.1001/jama.1933.02740280007003; MARCUSE EK, 1990, VACCINE, V8, P531, DOI 10.1016/0264-410X(90)90003-5; Miller D, 1985, Dev Biol Stand, V61, P389; MILLER D, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P145; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; NICOLL A, 1989, MANUAL INFECTIONS IM, P207; POLLOCK TM, 1983, LANCET, V1, P753; SHIELDS WD, 1988, J PEDIATR-US, V113, P801, DOI 10.1016/S0022-3476(88)80004-0; SUTHERLAND JM, 1953, ARCH DIS CHILD, V28, P149, DOI 10.1136/adc.28.138.149; WALKER AM, 1988, PEDIATRICS, V81, P345; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1990, BRIT JOINT COMMITTEE, P20; 1989, CANADIAN IMMUNIZATIO, P78; 1991, ADVERSE EFFECTS PERT; 1991, PEDIATRICS, V88, P397	26	64	69	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					37	41		10.1001/jama.271.1.37	http://dx.doi.org/10.1001/jama.271.1.37			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	7903109				2022-12-01	WOS:A1994MN72500028
J	AMIEL, SA				AMIEL, SA			GLUCAGON-LIKE PEPTIDE - A THERAPEUTIC GLIMMER	LANCET			English	Editorial Material											AMIEL, SA (corresponding author), GUYS HOSP,DIV MED,LONDON SE1 9RT,ENGLAND.							GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HIROTA M, 1990, DIABETES RES CLIN PR, V9, P179, DOI 10.1016/0168-8227(90)90110-F; KREYMANN B, 1987, LANCET, V2, P1300; NAUCK MA, 1993, DIABETOLOGIA, V36, P741, DOI 10.1007/BF00401145; NAUCK MA, 1993, J CLIN ENDOCR METAB, V76, P912, DOI 10.1210/jc.76.4.912; ORSKOV C, 1991, J CLIN INVEST, V87, P415, DOI 10.1172/JCI115012	7	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					4	5		10.1016/S0140-6736(94)90869-9	http://dx.doi.org/10.1016/S0140-6736(94)90869-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905051				2022-12-01	WOS:A1994MN93700005
J	BIGRIGG, A; HAFFENDEN, DK; SHEEHAN, AL; CODLING, BW; READ, MD				BIGRIGG, A; HAFFENDEN, DK; SHEEHAN, AL; CODLING, BW; READ, MD			EFFICACY AND SAFETY OF LARGE-LOOP EXCISION OF THE TRANSFORMATION ZONE	LANCET			English	Article							DIATHERMY EXCISION	Large-loop excision of the transformation zone (LLETZ) has become a popular treatment for women with cervical intraepithelial neoplasia (CIN) before long-term effectiveness and safety have been fully evaluated. Women who took part in a 1990 study of the procedure have been followed-up by cervical cytology for longer than 2 years. The rate of recurrences and residual lesions was 5.0% in the first year and 0.6% in the second year. LLETZ was also effective when used as a repeat procedure, although the negative histology rate was much higher (4.7% for initial procedures and 20% for repeat procedures). 250 women from the original study group of 1000 answered a questionnaire on fertility and menstrual symptoms 3 years after LLETZ. We found no differences between these women and controls of the same age, living in the same geographical area, with a history of negative cervical smears. LLETZ is a safe and effective procedure with no effect on menstruation or fertility.	GLOUCESTERSHIRE ROYAL HOSP,DEPT OBSTET & GYNAECOL,GLOUCESTER,ENGLAND; ST MICHAELS HOSP,DEPT HISTOPATHOL,BRISTOL,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,DEPT HISTOPATHOL,GLOUCESTER,ENGLAND	Gloucestershire Royal Hospital; Gloucestershire Royal Hospital	BIGRIGG, A (corresponding author), UNIV BRISTOL,SOUTHMEAD HOSP,DEPT OBSTET & GYNAECOL,BRISTOL BS10 5NB,AVON,ENGLAND.							Altman DG, 1991, PRACTICAL STAT MED R, P403, DOI [DOI 10.1002/SIM.4780101015, 10.1002/sim.4780101015]; BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; BIGRIGG MA, 1991, BRIT MED J, V302, P577, DOI 10.1136/bmj.302.6776.577; COPPLESON M, 1981, GYNAECOLOGIC ONCOLOG, P428; HAMMOND RH, 1990, BRIT MED J, V301, P1344, DOI 10.1136/bmj.301.6765.1344; KITCHENER HC, 1991, BRIT J OBSTET GYNAEC, V98, P1112, DOI 10.1111/j.1471-0528.1991.tb15363.x; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MACINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MURDOCH JB, 1991, INT J GYNECOL CANCER, V1, P105, DOI 10.1111/j.1525-1438.1991.tb00024.x	9	112	116	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					32	34		10.1016/S0140-6736(94)90881-8	http://dx.doi.org/10.1016/S0140-6736(94)90881-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905048				2022-12-01	WOS:A1994MN93700017
J	CHILD, J				CHILD, J			BATS IN MY BELFRY	LANCET			English	Editorial Material											CHILD, J (corresponding author), DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							AJELLO L, 1962, AM J TROP MED HYG, V11, P249, DOI 10.4269/ajtmh.1962.11.249; KING AA, 1993, J COMP PATHOL, V108, P1, DOI 10.1016/S0021-9975(08)80224-1; KLITE PD, 1965, AM J TROP MED HYG, V14, P433, DOI 10.4269/ajtmh.1965.14.433; LAFON M, 1986, LANCET, V2, P515; MEREDITH C D, 1971, South African Medical Journal, V45, P767; TAYLOR RL, 1962, AM J TROP MED HYG, V11, P790, DOI 10.4269/ajtmh.1962.11.790; 1990, RABIES B EUR, V14	7	4	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					5	6		10.1016/S0140-6736(94)90870-2	http://dx.doi.org/10.1016/S0140-6736(94)90870-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905056				2022-12-01	WOS:A1994MN93700006
J	GREWE, M; GYUFKO, K; SCHOPF, E; KRUTMANN, J				GREWE, M; GYUFKO, K; SCHOPF, E; KRUTMANN, J			LESIONAL EXPRESSION OF INTERFERON-GAMMA IN ATOPIC ECZEMA	LANCET			English	Note							DERMATITIS	Atopic eczema is thought to be caused by skin-infiltrating CD4 T cells of the Th1-like and/or Th2-like subtype. We assessed expression of the Th1-like cytokine, interferon-gamma, and the Th2-like cytokine, interleukin-4, in lesional atopic skin. Compared with that in normal skin, interferon-gamma and interleukin-4 mRNA expression were increased in eczematous skin lesions in 13 and 4 of 15 patients, respectively. After successful therapy of atopic dermatitis, the increased interferon-gamma mRNA expression but not the increased interleukin-4 mRNA expression was significantly down-regulated. These data indicate that in-situ expression of interferon-gamma is linked to the clinical course of atopic dermatitis.			KRUTMANN, J (corresponding author), UNIV FREIBURG,DEPT DERMATOL,PHOTODERMATOL SECT,D-79104 FREIBURG,GERMANY.							BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; HENNINGER HP, 1991, BIOCH BIOPHYS HOPPE, V374, P625; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; KRUTMANN J, 1994, EPIDERMAL CYTOKINES, P4415; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SZER N, 1992, J ALLERGY CLIN IMMUN, V89, P801	9	345	354	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					25	26		10.1016/S0140-6736(94)90879-6	http://dx.doi.org/10.1016/S0140-6736(94)90879-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905045				2022-12-01	WOS:A1994MN93700015
J	LADWIG, KH; ROLL, G; BREITHARDT, G; BUDDE, T; BORGGREFE, M				LADWIG, KH; ROLL, G; BREITHARDT, G; BUDDE, T; BORGGREFE, M			POSTINFARCTION DEPRESSION AND INCOMPLETE RECOVERY 6 MONTHS AFTER ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							CORONARY-ARTERY DISEASE; MORTALITY; LIFE	Patients who suffer from post-infarction depression are a high risk group with an increased mortality risk. The reasons for this are not known although it may be because such patients cannot cope with the chronic condition of cardiac disease. We designed a profile of clinical and behavioural outcome measurements representing recovery after myocardial infarction. 552 male survivors of acute myocardial infarction (29-65 years; mean=53) were grouped at study entry according to their depression status. 377 patients were reassessed after 6 months and were divided into the following subgroups: 50 (13.3%) patients had severe depression; 85 (22.5%) moderate depression and 242 (64.2%) low degrees of depression in the initial study. There were no substantial differences in baseline characteristics between the index group and the drop-out group. The unadjusted relative risk for follow-up angina pectoris among patients with depression (severe versus low) was 3.12 (95% CI 1.58 to 6.16) and was 5.55 (CI 2.87 to 10.71) for emotional instability. The relative risk for maintenance of smoking habits was 2.63 (CI 1.23 to 5.60) and was for work resumption 0.39 (CI 0.18 to 0.88). There was no association between depression and the occurrence of late potentials. After adjustment for univariate variables (age, social class, recurrent infarction, helplessness) only small and nonsignificant changes in the relative risks were found. However the inverse association of depression and work resumption was lost after adjustment. The investigation revealed that persistent postinfarction depression is an independent and important source of subsequent morbidity and long-acting reduced quality of life. Depression has adverse effects on illness behaviour and pain perception.	TECH UNIV MUNICH,PSYCHOSOMAT MED PSYCHOTHERAPIE & MED PSYCHOL POLIKLIN,MUNICH,GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST MED INFORMAT & SYST FORSCH,MUNICH,GERMANY; UNIV MUNSTER,MED KLIN & POLIKLIN,W-4400 MUNSTER,GERMANY	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munster	LADWIG, KH (corresponding author), TECH UNIV MUNICH,INST PSYCHOSOMAT MED PSYCHOTHERAPIE & MED PSYCHOL,LANGER STR 3,D-81675 MUNICH,GERMANY.		Ladwig, Karl-Heinz/B-5351-2014	Ladwig, Karl-Heinz/0000-0003-0710-1720				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; AHNVE J, 1988, AM HEART J, V117, P925; BORGGREFE M, 1990, European Heart Journal, V11, P403; BREITHARDT G, 1987, CIRCULATION, V75, P1091, DOI 10.1161/01.CIR.75.6.1091; BRESLOW N. E., 1980, STATISTICAL METHODS; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; CARNEY RM, 1988, J PSYCHOSOM RES, V32, P159, DOI 10.1016/0022-3999(88)90050-5; DALY LE, 1983, BMJ-BRIT MED J, V287, P324, DOI 10.1136/bmj.287.6388.324; DEMUYNCK RU, 1980, DIAGNOSE THERAPIE SO; FLETCHER AE, 1987, J CHRON DIS, V40, P557, DOI 10.1016/0021-9681(87)90014-2; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GILPIN E, 1989, CIRCULATION, V80, P457; HAWIK OE, 1990, J PSYCHOSOM RES, V34, P271; KENNEDY GJ, 1987, PSYCHOSOM MED, V49, P410, DOI 10.1097/00006842-198707000-00010; LADWIG KH, 1992, J PSYCHOSOM RES, V36, P723, DOI 10.1016/0022-3999(92)90130-T; LADWIG KH, 1986, KARDIOVASKULARE HYPE; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; PYSZCZYNSKI T, 1987, PSYCHOL BULL, V102, P122, DOI 10.1037/0033-2909.102.1.122; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; SILVERSTONE PH, 1990, J PSYCHOSOM RES, V34, P659, DOI 10.1016/0022-3999(90)90110-P; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; YOUNG LD, 1988, CARDIOLOGY, V75, P10, DOI 10.1159/000174344; ZUNG WWK, 1984, J CLIN PSYCHIAT, V45, P26; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3	24	185	187	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					20	23		10.1016/S0140-6736(94)90877-X	http://dx.doi.org/10.1016/S0140-6736(94)90877-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MN937	7905043				2022-12-01	WOS:A1994MN93700013
J	MANNUCCI, PM; GDOVIN, S; GRINGERI, A; COLOMBO, M; MELE, A; SCHINAIA, N; CIAVARELLA, N; EMERSON, SU; PURCELL, RH				MANNUCCI, PM; GDOVIN, S; GRINGERI, A; COLOMBO, M; MELE, A; SCHINAIA, N; CIAVARELLA, N; EMERSON, SU; PURCELL, RH			TRANSMISSION OF HEPATITIS-A TO PATIENTS WITH HEMOPHILIA BY FACTOR-VIII CONCENTRATES TREATED WITH ORGANIC-SOLVENT AND DETERGENT TO INACTIVATE VIRUSES	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; EPIDEMIOLOGY; STRAINS; RNA; PCR	Objective: To determine whether an outbreak of hepatitis A virus (HAV) infection that occurred in 52 patients with hemophilia in Italy was acquired through infusion of contaminated factor VIII or through environmental enteric transmission. Design: A case-control study and a molecular analysis of HAV sequences from implicated lots of factor VIII and from infected patients. Patients: The first 29 patients with hemophilia and jaundice in whom hepatitis A developed were compared with one to three matched controls with hemophilia but no jaundice. Measurements: Type of concentrate and batches infused, number of doses, contacts with persons who had jaundice or hepatitis A, travel abroad to countries reported to have a high attack rate for hepatitis A, and consumption of raw shellfish. Hepatitis A viral sequences sought by polymerase chain reaction in lots of factor VIII and in serial serum samples from two patients with hemophilia in whom hepatitis A developed. Amplification by polymerase chain reaction of cDNA transcribed with reverse transcriptase from matched sets of factor VIII and recipient serum samples. Determination of nucleotide sequence of amplified hepatitis A virus genome. Main Results: Case patients were neither more nor less likely than controls to have traveled to high-risk countries, consumed raw shellfish, or had contact with persons with jaundice. Case patients were more likely than controls to have received a factor VIII concentrate treated with a solvent-detergent mixture to inactivate viruses (odds ratio, infinity; 95% CI, 4.5 to infinity) and to have had larger infusions of the concentrate during the presumed HAV incubation period (odds ratio, 8.54; CI, 2.78 to 27.5). Hepatitis A viral sequences were found in 5 of 12 tested lots of factor VIII. Genomic sequences of HAV obtained for two matched sets of factor VIII and recipient serum samples were identical within each set but different for the two sets. Conclusion: Hepatitis A was transmitted by a factor VIII concentrate treated by a virucidal method (solvent-detergent) that ineffectively inactivates nonenveloped viruses.							NIAID NIH HHS [N01-AI-05069] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JI, 1987, P NATL ACAD SCI USA, V84, P2497, DOI 10.1073/pnas.84.8.2497; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; FROSNER GG, 1979, AM J EPIDEMIOL, V110, P63; GERRITZEN A, 1992, LANCET, V340, P1231, DOI 10.1016/0140-6736(92)92937-B; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; JANSEN RW, 1990, P NATL ACAD SCI USA, V87, P2867, DOI 10.1073/pnas.87.8.2867; KREUZ W, 1993, LANCET, V341, P446, DOI 10.1016/0140-6736(93)93050-B; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MANNUCCI PM, 1992, LANCET, V339, P819, DOI 10.1016/0140-6736(92)91955-8; MELE A, 1991, ITAL J GASTROENTEROL, V23, P341; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H; PURCELL RH, 1984, VIRAL HEPATITIS LIVE, P9; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWINN H, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1302; SHERERTZ RJ, 1984, ARCH INTERN MED, V144, P1579, DOI 10.1001/archinte.144.8.1579; TEMPERLEY IJ, 1992, LANCET, V340, P1466; THOMAS DG, 1975, COMPUT BIOMED RES, V8, P423, DOI 10.1016/0010-4809(75)90048-8; TSAREV SA, 1993, J INFECT DIS, V168, P369, DOI 10.1093/infdis/168.2.369; TSAREV SA, 1991, J GEN VIROL, V72, P1677, DOI 10.1099/0022-1317-72-7-1677; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; 1992, LANCET, V339, P1198	25	176	180	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					1	7		10.7326/0003-4819-120-1-199401010-00001	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	7504424				2022-12-01	WOS:A1994MP28000001
J	MCPHERSON, MA; DORMER, RL				MCPHERSON, MA; DORMER, RL			CYSTIC-FIBROSIS GENE AND MUCIN SECRETION	LANCET			English	Editorial Material							CELLS; CFTR				MCPHERSON, MA (corresponding author), UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES.							BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; DRUMM ML, 1993, PEDIATR PULMONOL, V250; KUVER R, 1993, PEDIATR PULMONOL S9, V254; MCPHERSON MA, 1986, LANCET, V2, P1007; MILLS CL, 1992, BIOCHEM BIOPH RES CO, V188, P1146, DOI 10.1016/0006-291X(92)91351-P; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; TSENG HC, 1993, 7TH ANN N AM CF C DA	7	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					7	7		10.1016/S0140-6736(94)90872-9	http://dx.doi.org/10.1016/S0140-6736(94)90872-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905085				2022-12-01	WOS:A1994MN93700008
J	OZONOFF, D				OZONOFF, D			LEAD ON THE RANGE	LANCET			English	Editorial Material							INDOOR FIRING RANGE; EXPOSURE; INSTRUCTORS; ABSORPTION				OZONOFF, D (corresponding author), BOSTON UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02215 USA.			Ozonoff, David/0000-0002-4281-4171				BICKIS U, 1988, AM J PUBLIC HEALTH, V78, P95, DOI 10.2105/AJPH.78.1.95; BREWER F, 1989, J OCCUP ENVIRON MED, V31, P409; FISCHBEIN A, 1992, ISRAEL J MED SCI, V28, P560; FISCHBEIN A, 1993, CLIN IMMUNOL IMMUNOP, V66, P163, DOI 10.1006/clin.1993.1020; FISHERFISCHBEIN J, 1987, JAMA-J AM MED ASSOC, V257, P803, DOI 10.1001/jama.257.6.803; GEORGE PM, 1993, NEW ZEAL MED J, V106, P422; GOLDBERG RL, 1991, J OCCUP ENVIRON MED, V33, P718, DOI 10.1097/00043764-199106000-00013; LANDRIGAN PJ, 1975, JAMA-J AM MED ASSOC, V234, P394, DOI 10.1001/jama.234.4.394; MAIZLISH N, 1990, AM J PUBLIC HEALTH, V80, P931, DOI 10.2105/AJPH.80.8.931; MILLER CH, 1984, OCCUP HLTH, V36, P8; MUSKETT CJ, 1980, ANN OCCUP HYG, V23, P283, DOI 10.1093/annhyg/23.3.283; NOVOTNY T, 1987, AM J PUBLIC HEALTH, V77, P1225, DOI 10.2105/AJPH.77.9.1225; Smith D L, 1976, J Soc Occup Med, V26, P139, DOI 10.1093/occmed/26.4.139; SVENSSON BG, 1992, INT ARCH OCC ENV HEA, V64, P219, DOI 10.1007/BF00378278; TRIPATHI RK, 1991, AM J PUBLIC HEALTH, V81, P753, DOI 10.2105/AJPH.81.6.753; TRIPATHI RK, 1990, AM IND HYG ASSOC J, V51, P28, DOI 10.1080/15298669091369286; VALWAY SE, 1989, AM J PUBLIC HEALTH, V79, P1029, DOI 10.2105/AJPH.79.8.1029	17	12	12	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					6	7		10.1016/S0140-6736(94)90871-0	http://dx.doi.org/10.1016/S0140-6736(94)90871-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905076				2022-12-01	WOS:A1994MN93700007
J	RIFAT, SL				RIFAT, SL			ALUMINUM HYPOTHESIS LIVES	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE				RIFAT, SL (corresponding author), NIAGARA HLTH SERV DEPT, DIV EPIDEMIOL, ST CATHARINES, ON, CANADA.							BIRCHALL JD, 1989, NATURE, V338, P146, DOI 10.1038/338146a0; BIRCHALL JD, 1988, LANCET, V2, P1008, DOI 10.1016/S0140-6736(88)90754-4; BIRCHALL JD, 1991, ALZHEIMERS DISEASE E, P70; COMMENGES D, 1992, NEUROBIOL AGING S1, V13, pS116; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; DRISCOLL CT, 1988, J ENVIRON ENG-ASCE, V114, P21, DOI 10.1061/(ASCE)0733-9372(1988)114:1(21); EDWARDSON JA, 1993, LANCET, V342, P211, DOI 10.1016/0140-6736(93)92301-9; JACQMIN H, IN PRESS AM J EPIDEM; KRAUS AS, 1992, CAN J PUBLIC HEALTH, V83, P97; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; MCLACHLAN DRC, 1991, CAN MED ASSOC J, V145, P793; MICHEL P, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P387	12	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 1	1994	343	8888					3	4		10.1016/S0140-6736(94)90868-0	http://dx.doi.org/10.1016/S0140-6736(94)90868-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905047				2022-12-01	WOS:A1994MN93700004
J	SANDLE, GI; MCNICHOLAS, CM; LOMAX, RB				SANDLE, GI; MCNICHOLAS, CM; LOMAX, RB			POTASSIUM CHANNELS IN COLONIC CRYPTS	LANCET			English	Note							EPITHELIAL-CELL LINE; MEMBRANE; TRANSPORT; CA-2+; CAMP	A characteristic feature of intestinal epithelia is their ability to secrete chloride (Cl-), a process that occurs mainly in intestinal crypts and is the critical transport event in secretory diarrhoea. Increased potassium (K+) channel activity in the basolateral membrane has an important role in the Cl-secretory process by hyperpolarising the cell and maintaining a favourable electrochemical driving force for Cl- exit at the apical membrane. We have shown, using patch-clamp techniques, that the basolateral membrane of human colonic crypt cells contains low conductance K+ channels that are voltage and calcium (Ca2+) sensitive and blocked by barium (Ba2+). These K+ channels are regulated by cytosolic cyclic adenosine monophosphate (cAMP) and Ca2+, intracellular second messengers that also stimulate Cl- secretion. This population of human intestinal K+ channels may be a target for the pharmacological control of Cl- secretory diarrhoea.			SANDLE, GI (corresponding author), UNIV MANCHESTER,HOPE HOSP,SCH MED,DEPT MED,SALFORD M6 8HD,LANCS,ENGLAND.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; McNicholas-Bevensee, Carmel/0000-0002-7013-8764	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRETT KE, 1993, ADV COMP ENV PHYSL, V16, P215; Binder HJ, 1987, PHYSL GASTROINTESTIN, P1389; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWKER PC, 1978, GASTROENTEROLOGY, V74, P1241; LOO DDF, 1989, J MEMBRANE BIOL, V110, P19, DOI 10.1007/BF01870989; MANDEL KG, 1986, J BIOL CHEM, V261, P704; RAMBAUD JC, 1986, CLIN GASTROENTEROL, V15, P603; WEYER A, 1985, J CLIN INVEST, V76, P1828	10	60	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					23	25		10.1016/S0140-6736(94)90878-8	http://dx.doi.org/10.1016/S0140-6736(94)90878-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905044				2022-12-01	WOS:A1994MN93700014
J	SUZUKI, S; NAKATOMI, Y; SATO, H; TSUKADA, H; ARAKAWA, M				SUZUKI, S; NAKATOMI, Y; SATO, H; TSUKADA, H; ARAKAWA, M			HAEMOPHILUS-PARAINFLUENZAE ANTIGEN AND ANTIBODY IN RENAL BIOPSY SAMPLES AND SERUM OF PATIENTS WITH IGA NEPHROPATHY	LANCET			English	Article							FC-RECEPTOR; VIRUS; DEPOSITION; PROTEINS	IgA nephropathy may be associated with colonisation with Haemophilus parainfluenzae. In patients with glomerular diseases, we examined renal-biopsy specimens for presence of bacterial antigen by immunofluorescence microscopy with rabbit antiserum against H parainfluenzae, and by enzyme-linked immunosorbent assay looked for IgA antibody against H parainfluenzae in patient sera. The rabbit antiserum recognised by immunoblotting four components of H parainfluenzae outer membranes (OMHP) of molecular weights 19.5, 30, 33, and 40 5 kDa. All 44 patients with IgA nephropathy and 2 of 3 9 patients with other glomerular diseases showed mesangial deposition of OMHP antigens (p<0.001). Patients with IgA nephropathy had significantly more IgA antibody against H parainfluenzae than did patients with other glomerular diseases. IgA antibody in the sera of patients with IgA nephropathy recognised by immunoblotting the same four components of OMHP as recognised by rabbit antiserum. Glomerular deposition of OMHP antigens and the presence of IgA antibody against OMHP in patients with IgA nephropathy suggest that H parainfluenzae has a role in the aetiology of this disease.	DENKA SELKEN CO LTD,DIV RES & DEV,NIIGATA,JAPAN		SUZUKI, S (corresponding author), NIIGATA UNIV,SCH MED,DEPT MED 2,ASAHIMACHI DORI,NIIGATA 951,JAPAN.							ANDRE PM, 1990, NEPHRON, V54, P185, DOI 10.1159/000185845; BERGER J, 1969, TRANSPL P, V1, P939; BORRADORI L, 1990, NEPHRON, V56, P35, DOI 10.1159/000186097; CLARKSON AR, 1984, CLIN NEPHROL, V21, P7; COPPO R, 1990, CLIN NEPHROL, V33, P72; DAMICO G, 1985, NEPHRON, V41, P1, DOI 10.1159/000183538; DAVIN JC, 1987, KIDNEY INT, V31, P1132, DOI 10.1038/ki.1987.119; GREGORY MC, 1988, LANCET, V1, P11; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI KN, 1988, CLIN NEPHROL, V29, P229; LAWRENCE S, 1983, CLIN NEPHROL, V16, P280; MORTON DJ, 1989, J GEN MICROBIOL, V135, P445; NICHOLLS K, 1984, AM J KIDNEY DIS, V4, P128, DOI 10.1016/S0272-6386(84)80060-8; ROCCATELLO D, 1985, CLIN NEPHROL, V23, P159; SATO M, 1988, CLIN EXP IMMUNOL, V73, P295; SUZUKI S, 1992, AM J NEPHROL, V12, P22, DOI 10.1159/000168413; TOMINO Y, 1987, NEPHRON, V47, P258, DOI 10.1159/000184520; WOODROFFE AJ, 1980, KIDNEY INT, V18, P366, DOI 10.1038/ki.1980.147	18	111	120	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 1	1994	343	8888					12	16		10.1016/S0140-6736(94)90875-3	http://dx.doi.org/10.1016/S0140-6736(94)90875-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN937	7905040				2022-12-01	WOS:A1994MN93700011
J	GENDRONMAGUIRE, M; MALLO, M; ZHANG, M; GRIDLEY, T				GENDRONMAGUIRE, M; MALLO, M; ZHANG, M; GRIDLEY, T			HOXA-2 MUTANT MICE EXHIBIT HOMEOTIC TRANSFORMATION OF SKELETAL ELEMENTS DERIVED FROM CRANIAL NEURAL CREST	CELL			English	Article							HOMEOBOX GENE; RETINOIC ACID; TARGETED DISRUPTION; DEVELOPMENTAL DEFECTS; DROSOPHILA EMBRYO; EXPRESSION; CELLS; HINDBRAIN; PATTERN; HOX-1.6	Mice homozygous for a targeted mutation of the Hoxa-2 (Hox 1.11) gene are born with cleft palates and die within 24 hr of birth. Analysis of stained skeletons revealed that homozygous mutant animals contained multiple cranial skeletal defects, including a duplication of the ossification centers of the bones of the middle ear. Histological analysis suggested that this duplication resulted from the transformation of skeletal elements derived from the second branchial arch into more anterior structures, resulting in a duplication of Meckel's cartilage adjacent to the otic capsule. Skeletal elements normally derived from the second arch were absent in the mutants. These data provide direct experimental evidence for the existence of a branchial Hox code.	HOFFMANN LA ROCHE INC, DEPT TOXICOL & PATHOL, NUTLEY, NJ 07110 USA	Roche Holding	GENDRONMAGUIRE, M (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA.		Mallo, Moises/D-5907-2016	Mallo, Moises/0000-0002-9744-0912				AKAM M, 1987, DEVELOPMENT, V101, P1; ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; COULY GF, 1993, DEVELOPMENT, V117, P409; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HOGAN B, 1992, NATURE, V355, P494, DOI 10.1038/355494a0; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOORE KL, 1993, DEV HUMAN CLIN ORIEN, P186; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1993, J NEUROBIOL, V24, P248, DOI 10.1002/neu.480240210; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; Paxinos G., 1991, ATLAS DEV RAT BRAIN; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; Sambrook J., 1989, MOL CLONING LAB MANU; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SMITH DE, 1992, DEVELOPMENT, V116, P555; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STJOHNSTON D, 1992, CELL, V68, P201; STONER CM, 1989, CANCER RES, V49, P1497; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; Van de Water T R, 1980, Birth Defects Orig Artic Ser, V16, P147	51	460	465	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1317	1331		10.1016/0092-8674(93)90619-2	http://dx.doi.org/10.1016/0092-8674(93)90619-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7903600				2022-12-01	WOS:A1993MP86900011
J	HUANG, PL; DAWSON, TM; BREDT, DS; SNYDER, SH; FISHMAN, MC				HUANG, PL; DAWSON, TM; BREDT, DS; SNYDER, SH; FISHMAN, MC			TARGETED DISRUPTION OF THE NEURONAL NITRIC-OXIDE SYNTHASE GENE	CELL			English	Article							LONG-TERM POTENTIATION; HYPERTROPHIC PYLORIC-STENOSIS; RAT ANOCOCCYGEUS MUSCLE; MONOMETHYL-L-ARGININE; NADPH-DIAPHORASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HUNTINGTONS-DISEASE; ADP-RIBOSYLATION; STRIATAL NEURONS; PENILE ERECTION	By homologous recombination, we have generated mice that lack the neuronal nitric oxide synthase (NOS) gene. Neuronal NOS expression and NADPH-diaphorase (NDP) staining are absent in the mutant mice. Very low level residual catalytic activity suggests that other enzymes in the brain may generate nitric oxide. The neurons normally expressing NOS appear intact, and the mutant NOS mice are viable, fertile, and without evident histopathological abnormalities in the central nervous system. The most evident effect of disrupting the neuronal NOS gene is the development of grossly enlarged stomachs, with hypertrophy of the pyloric sphincter and the circular muscle layer. This phenotype resembles the human disorder infantile pyloric stenosis, in which gastric outlet obstruction is associated with the lack of NDP neurons in the pylorus.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	HUANG, PL (corresponding author), MASSACHUSETTS GEN HOSP, CARDIOVASC RES CTR, BOSTON, MA 02129 USA.				NHLBI NIH HHS [HL-02792-02] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NINDS NIH HHS [CIDA NS-01578] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001578] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BOECKXSTAENS GE, 1991, BRIT J PHARMACOL, V102, P434, DOI 10.1111/j.1476-5381.1991.tb12191.x; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRESLOW MJ, 1987, AM J PHYSIOL, V252, pH521, DOI 10.1152/ajpheart.1987.252.3.H521; BRESLOW MJ, 1992, EUR J PHARMACOL, V87, P682; BULT H, 1990, NATURE, V345, P3469; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DICKIE BGM, 1992, NEUROSCI LETT, V138, P145, DOI 10.1016/0304-3940(92)90492-P; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; EDELMAN GM, 1992, P NATL ACAD SCI USA, V89, P11651, DOI 10.1073/pnas.89.24.11651; FARACI FM, 1992, PHARMACOL THERAPEUT, V56, P1, DOI 10.1016/0163-7258(92)90035-X; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIRSCH DP, 1993, IN PRESS CURR BIOL; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; KOH JY, 1986, SCIENCE, V234, P73, DOI 10.1126/science.2875522; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LE E, 1992, CELL, V69, P915; LI CG, 1990, EUR J PHARMACOL, V191, P303; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P88; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P70, DOI 10.1038/jcbfm.1993.9; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POLAK JM, 1981, LANCET, V2, P217; PRADO R, 1992, STROKE, V23, P1118, DOI 10.1161/01.STR.23.8.1118; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SPICER RD, 1982, BRIT J SURG, V69, P128, DOI 10.1002/bjs.1800690304; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; THOMAS E, 1961, HISTOCHEMISTRY, V2, P266, DOI 10.1007/BF00736504; THOMAS E., 1964, ACTA NEUROPATHOL, V3, P238; TODA N, 1990, BIOCHEM BIOPH RES CO, V170, P308, DOI 10.1016/0006-291X(90)91275-W; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UEMURA Y, 1990, ANN NEUROL, V27, P620, DOI 10.1002/ana.410270606; VANDERWINDEN JM, 1992, NEW ENGL J MED, V327, P511, DOI 10.1056/NEJM199208203270802; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; WHITTLE BJR, 1992, ANN NY ACAD SCI, V664, P126, DOI 10.1111/j.1749-6632.1992.tb39755.x; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; WILLIS EA, 1983, LIFE SCI, V33, P383, DOI 10.1016/S0024-3205(83)80013-7; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZHU XZ, 1992, J NEUROCHEM, V59, P932, DOI 10.1111/j.1471-4159.1992.tb08332.x; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	71	1132	1154	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 31	1993	75	7					1273	1286		10.1016/0092-8674(93)90615-W	http://dx.doi.org/10.1016/0092-8674(93)90615-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7505721				2022-12-01	WOS:A1993MP86900007
J	RIJLI, FM; MARK, M; LAKKARAJU, S; DIERICH, A; DOLLE, P; CHAMBON, P				RIJLI, FM; MARK, M; LAKKARAJU, S; DIERICH, A; DOLLE, P; CHAMBON, P			A HOMEOTIC TRANSFORMATION IS GENERATED IN THE ROSTRAL BRANCHIAL REGION OF THE HEAD BY DISRUPTION OF HOXA-2, WHICH ACTS AS A SELECTOR GENE	CELL			English	Article							HOMEOBOX GENE; NEURAL CREST; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; CHICK-EMBRYO; EXPRESSION; HINDBRAIN; SEGMENTATION; ORIGIN; MORPHOGENESIS	The Hoxa-2 gene was disrupted by homologous recombination. Homozygous mutant mice died at birth. Defects were found in the branchial region of the head, which corresponds to the Hoxa-2 rostral expression domain. While rhombomeric and neural crest cell (NCC) segmentation was not affected, mesenchymal NCC derivatives of the second arch were lacking, and second arch mesenchymal NCC identity was changed to first arch identity, resulting in homeotic transformation of second to first arch skeletal elements. These results reveal the existence of a skeletogenic ground pattern program common to at least the mesenchymal NCC that originated from rhombomeres 2 and 4. The appearance of an atavistic reptilian pterygoquadrate element in Hoxa-2 mutants suggests that this ground pattern is intermediate between reptiles and mammals. The ground pattern program appears to be modified in the mouse first arch by a Hox-independent process, whereas Hoxa-2 acts as a selector gene in the second arch.			RIJLI, FM (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL, GENET MOLEC EUCARYOTES LAB, CNRS, F-67085 STRASBOURG, FRANCE.		Dolle, Pascal/A-8037-2010; RIJLI, Filippo/AAP-2516-2020	Dolle, Pascal/0000-0002-9294-9090; RIJLI, Filippo/0000-0003-0515-0182				ALLIN EF, 1975, J MORPHOL, V147, P403, DOI 10.1002/jmor.1051470404; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CLARKE JDW, 1993, DEVELOPMENT, V118, P151; de Beer G.R, 1971, DEV VERTEBRATE SKULL; DEDOUARIN N, 1993, DEV BIOL, V159, P24; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GAUNT SJ, 1993, DEVELOPMENT, V117, P769; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; Hall B.K., 1992, EVOLUTIONARY DEV BIO; HALL BK, 1982, J CRAN GENET DEV BIO, V2, P309; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KEYNES R, 1990, NEURON, V4, P1, DOI 10.1016/0896-6273(90)90438-L; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LANGILLE RM, 1989, BIOL REV, V64, P73, DOI 10.1111/j.1469-185X.1989.tb00672.x; Lawrence P. A., 1992, MAKING FLY GENETICS; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MARK M, 1993, DEVELOPMENT, V119, P319; MORRISSKAY G, 1991, J CRAN GENET DEV BIO, V11, P181; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; OLSON EC, 1959, EVOLUTION, V13, P344, DOI 10.2307/2406111; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; Stadtmuller F., 1936, HDB VERGLEICHENDEN A, V4, P839; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; VERSLUYS VJ, 1936, HDB VERGLEICHENDEN A, V4, P699; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802	44	516	522	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1333	1349		10.1016/0092-8674(93)90620-6	http://dx.doi.org/10.1016/0092-8674(93)90620-6			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7903601				2022-12-01	WOS:A1993MP86900012
J	CALLEBAUT, C; KRUST, B; JACOTOT, E; HOVANESSIAN, AG				CALLEBAUT, C; KRUST, B; JACOTOT, E; HOVANESSIAN, AG			T-CELL ACTIVATION ANTIGEN, CD26, AS A COFACTOR FOR ENTRY OF HIV IN CD4+ CELLS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DIPEPTIDYL PEPTIDASE-IV; PRINCIPAL NEUTRALIZING DETERMINANT; HUMAN LYMPHOCYTES-T; ENVELOPE GLYCOPROTEIN; V3 DOMAIN; MONOCLONAL-ANTIBODIES; CD4-MEDIATED FUSION; SYNTHETIC PEPTIDES; AMINOPEPTIDASE-IV	The CD4 molecule is essential for binding HIV particles, but is not sufficient for efficient viral entry and infection. The cofactor was shown to be dipeptidyl peptidase IV (DPP IV), also known as CD26. This serine protease cleaves its substrates at specific motifs; such motifs are also highly conserved in the V3 loops of HIV-1, HIV-2, and related simian isolates. Entry of HIV-1 or HIV-2 into T lymphoblastoid and monocytoid cell lines was inhibited by a specific monoclonal antibody against DPP IV or specific peptide inhibitors of this protease. Co-expression of human CD4 and CD26 in murine NIH 3T3 cells rendered them permissive to infection by HIV-1 and HIV-2. These observations could provide the basis for developing simple and specific inhibitors of HIV and open a possibility for vaccine development.	INST PASTEUR, CNRS, UA 1157, UNITE VIROL & IMMUNOL CELLULAIRE, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite				/0000-0002-5301-1569				ARDMAN B, 1990, J ACQ IMMUN DEF SYND, V3, P206; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BAUVOIS B, 1992, EUR J IMMUNOL, V22, P923, DOI 10.1002/eji.1830220407; BAUVOIS B, 1991, LYMPHATIC TISSUES IN; BLAZQUEZ MV, 1992, J IMMUNOL, V149, P3073; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; Brown A J, 1991, AIDS, V5 Suppl 2, pS35, DOI 10.1097/00002030-199101001-00005; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CHOU SH, 1992, AIDS RES HUM RETROV, V8, P1611, DOI 10.1089/aid.1992.8.1611; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANG NH, 1990, J IMMUNOL, V145, P3963; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; DEMEESTER I, 1992, CLIN CHIM ACTA, V210, P23, DOI 10.1016/0009-8981(92)90042-O; DEPASQUALE A, 1989, ACTA HAEMATOL-BASEL, V81, P19; DEROSSI A, 1991, VIROLOGY, V184, P187; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; EBENBICHLER CF, 1993, AIDS, V7, P489, DOI 10.1097/00002030-199304000-00006; EIDEN LE, 1992, IMMUNOL TODAY, V13, P201, DOI 10.1016/0167-5699(92)90154-Y; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; GOWDA SD, 1989, J IMMUNOL, V142, P773; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HAFLER DA, 1989, J IMMUNOL, V142, P2590; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HEGEN M, 1990, J IMMUNOL, V144, P2908; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HENDERSON LA, 1993, J BIOL CHEM, V268, P15291; HOLMBACK K, 1993, J VIROL, V67, P1612; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIDO H, 1988, J BIOL CHEM, V263, P18104; KINNEYTHOMAS E, 1988, AIDS, V2, P25; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Koito A, 1989, Int Immunol, V1, P613, DOI 10.1093/intimm/1.6.613; KREUTZ R, 1992, AIDS RES HUM RETROV, V8, P1619, DOI 10.1089/aid.1992.8.1619; KUDO M, 1985, J BIOCHEM, V97, P1211, DOI 10.1093/oxfordjournals.jbchem.a135166; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MASUDA T, 1990, J IMMUNOL, V145, P3240; MATTERN T, 1991, SCAND J IMMUNOL, V33, P737, DOI 10.1111/j.1365-3083.1991.tb02548.x; MCKEATING JA, 1992, VIROLOGY, V191, P732, DOI 10.1016/0042-6822(92)90249-O; MILICH L, 1993, J VIROL, V67, P5623, DOI 10.1128/JVI.67.9.5623-5634.1993; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; MUNOZ E, 1992, IMMUNOLOGY, V77, P43; MYERS G, 1992, HUMAN RETROVIRUSES A; NEHETE PN, 1993, J VIROL, V67, P6841, DOI 10.1128/JVI.67.11.6841-6846.1993; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; QURESHI NM, 1990, AIDS, V4, P553, DOI 10.1097/00002030-199006000-00009; RAO PE, 1983, CELL IMMUNOL, V80, P310, DOI 10.1016/0008-8749(83)90119-3; REY MA, 1989, VIROLOGY, V173, P258, DOI 10.1016/0042-6822(89)90242-0; REYCUILLE MA, UNPUB; REYCUILLE MA, IN PRESS; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SCHON E, 1989, SCAND J IMMUNOL, V29, P127, DOI 10.1111/j.1365-3083.1989.tb01108.x; STEPHENS PE, 1990, NATURE, V343, P219, DOI 10.1038/343219b0; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; UMEZAWA H, 1984, J ANTIBIOT, V37, P422, DOI 10.7164/antibiotics.37.422; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; WEISS RA, 1992, SCIENCE CHALLENGING AIDS, P107; WERNER A, 1993, J VIROL, V67, P2566, DOI 10.1128/JVI.67.5.2566-2574.1993; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	79	234	241	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					2045	2050		10.1126/science.7903479	http://dx.doi.org/10.1126/science.7903479			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	7903479				2022-12-01	WOS:A1993MN10800042
J	CULOTTA, E; KOSHLAND, DE				CULOTTA, E; KOSHLAND, DE			P53 SWEEPS THROUGH CANCER-RESEARCH	SCIENCE			English	Editorial Material																			0	89	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					1958	1961		10.1126/science.7903477	http://dx.doi.org/10.1126/science.7903477			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	7903477				2022-12-01	WOS:A1993MN10800012
J	FLEMING, DM; CROSS, KW				FLEMING, DM; CROSS, KW			RESPIRATORY SYNCYTIAL VIRUS OR INFLUENZA	LANCET			English	Article							INFECTION; OUTBREAK	We compared data from clinical surveillance of acute respiratory infections in elderly people reported by a network of sentinel general practitioners, virus isolate data for respiratory syncytial virus (RSV) and influenza A and B viruses, and registered deaths, during the past four winters. Cases of acute respiratory disease (ARD) and deaths (3-week moving averages) showed strong similarity in timing. Periods of high incidence of ARD and numbers of deaths were followed within 2-3 weeks by reports of high numbers of RSV or influenza virus isolates. The epidemic period in December, 1989, was followed by high numbers of both virus isolates, but in all other epidemic periods one virus predominated. The lethality of epidemics due to RSV or influenza A or B varied both within and between years. These analyses suggest that RSV is as important as influenza viruses in causing morbidity and excess deaths among elderly people. RSV was prevalent at the end of each of the past four years in the UK; its importance as a cause of excess deaths would therefore be concealed in any analysis based on several years' experience. By contrast, the inconsistency of epidemics due to influenza viruses makes excess deaths due to these viruses easily recognisable. Integrated clinical and viriological surveillance is essential if epidemics due to RSV, influenza virus, or any other virus are to be correctly interpreted.			FLEMING, DM (corresponding author), RCGP,BIRMINGHAM RES UNIT,LORDSWOOD HOUSE,54 LORDSWOOD RD,BIRMINGHAM B17 9DB,ENGLAND.							ADAMS F, 1849, GENUINE WORKS HIPPOC, P203; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; ALDERSON MR, 1988, MORTALITY MORBIDITY, P122; ANDERSON TW, 1970, LANCET, V1, P291; Curwen M, 1990, POPUL TRENDS, P31; Curwen M., 1990, HLTH TRENDS, V22, P169; DAB W, 1991, EUR J EPIDEMIOL, V7, P579, DOI 10.1007/BF00218667; FLEMING DM, IN PRESS EUR J EPIDE; Fleming DM, 1991, 53 ROYAL COLL GEN PR; GARVIE DG, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253-a; Graman P S, 1989, Semin Respir Infect, V4, P253; JOSEPH CA, 1992, COMMUN DIS REV, V2, P149; KUNST AE, 1990, INT J EPIDEMIOL, V20, P971; MARTIN AJ, 1978, LANCET, V1, P1035; NOAH ND, 1989, EPIDEMIOL INFECT, V102, P175, DOI 10.1017/S0950268800029848; OSTERWEIL D, 1990, J AM GERIATR SOC, V38, P659, DOI 10.1111/j.1532-5415.1990.tb01425.x; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; 1988, MORTALITY STATISTICS	18	137	139	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1507	1510		10.1016/S0140-6736(05)80082-0	http://dx.doi.org/10.1016/S0140-6736(05)80082-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902899				2022-12-01	WOS:A1993MM40200009
J	HAMID, Q; SPRINGALL, DR; RIVEROSMORENO, V; CHANEZ, P; HOWARTH, P; REDINGTON, A; BOUSQUET, J; GODARD, P; HOLGATE, S; POLAK, JM				HAMID, Q; SPRINGALL, DR; RIVEROSMORENO, V; CHANEZ, P; HOWARTH, P; REDINGTON, A; BOUSQUET, J; GODARD, P; HOLGATE, S; POLAK, JM			INDUCTION OF NITRIC-OXIDE SYNTHASE IN ASTHMA	LANCET			English	Article							NECROSIS-FACTOR-ALPHA; MAST-CELLS; BRONCHIAL HYPERRESPONSIVENESS; PULMONARY VASODILATOR; GUINEA-PIGS; L-ARGININE; EXPRESSION; MACROPHAGES; EOSINOPHILS; EPITHELIUM	Nitric oxide (NO) is a mediator of vasodilatation and bronchodilatation synthesised from L-arginine by the enzyme NO synthase, which is either constitutive or induced by lipopolysaccharides and/or cytokines. The presence and function of NO synthase in normal or diseased lung is not yet clear. Asthma is characterised by bronchial hyperresponsiveness, epithelial damage, inflammation, and increased cytokine production. To investigate the presence of NO synthase in asthma, we immunostained bronchial biopsies from non-steroid-treated people with asthma and non-asthmatic controls with specific polyvalent antisera to purified inducible NO synthase and to a selected peptide sequence of the same enzyme. Immunoreactivity was seen in the epithelium and some inflammatory cells in 22 of 23 biopsies from people with asthma, but in only 2 of 20 controls. To assess the relation of cytokines to NO synthase induction, bronchial epithelial cells in culture were stimulated with tumour necrosis factor (TNFalpha). Inducible enzyme immunoreactivity was found only in the treated cells. The existence of inducible NO synthase in human lungs suggests that increased production of NO, probably induced by cytokines, may be relevant to the pathology of asthma.	ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,DU CANE RD,LONDON W12 0NN,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND; HOP ARNAUD VILLENEUVE,SERV MALAD RESP,F-34059 MONTPELLIER,FRANCE; SOUTHAMPTON GEN HOSP,DEPT MED,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	Imperial College London; GlaxoSmithKline; Wellcome Research Laboratories; Imperial College London; Universite de Montpellier; CHU de Montpellier; University of Southampton				Howarth, Peter/0000-0003-0619-7927; chanez, pascal/0000-0003-4059-0917				BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CRAWLEY DE, 1992, J APPL PHYSIOL, V72, P1425, DOI 10.1152/jappl.1992.72.4.1425; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MASON DY, 1985, TECH IMMUNOCYTOCHEM, V3, P25; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTEFORT S, 1992, CLIN EXP ALLERGY, V22, P511, DOI 10.1111/j.1365-2222.1992.tb00159.x; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; OGUCHI S, 1992, FEBS LETT, V308, P22, DOI 10.1016/0014-5793(92)81041-J; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RIVEROSMORENO V, 1993, IN PRESS EUR J BIOCH; ROCHE WR, 1989, LANCET, V1, P520; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; SPRINGALL DR, 1992, HISTOCHEMISTRY, V98, P259, DOI 10.1007/BF00271040; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x	31	719	740	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1510	1513		10.1016/S0140-6736(05)80083-2	http://dx.doi.org/10.1016/S0140-6736(05)80083-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7504773				2022-12-01	WOS:A1993MM40200010
J	JOHNSTON, SRD; HAYNES, BP; SMITH, IE; JARMAN, M; SACKS, NPM; EBBS, SR; DOWSETT, M				JOHNSTON, SRD; HAYNES, BP; SMITH, IE; JARMAN, M; SACKS, NPM; EBBS, SR; DOWSETT, M			ACQUIRED TAMOXIFEN RESISTANCE IN HUMAN BREAST-CANCER AND REDUCED INTRA-TUMORAL DRUG CONCENTRATION	LANCET			English	Note								Reduced intra-tumoral drug concentrations have been investigated as a mechanism of tamoxifen resistance in 51 patients with locally recurrent breast cancer. Serum tamoxifen was similar in patients with acquired and de-novo resistance, but intra-tumoral concentrations were significantly lower in patients with acquired resistance. Tumour oestrogen-receptor concentrations at relapse did not support the hypothesis that selective outgrowth of oestrogen-receptor-negative cells is a major mechanism for acquired tamoxifen resistance. Reduced intra-tumoral tamoxifen levels during prolonged therapy may be an important mechanism for acquired resistance in breast cancer.	ROYAL MARSDEN HOSP,BREAST UNIT,LONDON SW3 6JJ,ENGLAND; INST CANC RES,DRUG DEV SECT,SUTTON SM2 5PX,SURREY,ENGLAND; MAYDAY UNIV HOSP,DEPT SURG,CROYDON,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Croydon University Hospital	JOHNSTON, SRD (corresponding author), ROYAL MARSDEN HOSP,ACAD DEPT BIOCHEM,LONDON SW3 6JJ,ENGLAND.							JENSEN EV, 1982, RECENT PROG HORM RES, V38, P1; JOHNSTON SRD, 1992, ANN ONCOL, V3, P503, DOI 10.1093/oxfordjournals.annonc.a058251; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LANGANFAHEY SM, 1990, EUR J CANCER, V26, P883, DOI 10.1016/0277-5379(90)90191-U; MCCAGUE R, 1989, J MED CHEM, V32, P2527, DOI 10.1021/jm00132a006; OSBORNE CK, 1992, J CLIN ONCOL, V10, P304, DOI 10.1200/JCO.1992.10.2.304; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; SMITH IE, 1982, CANCER RES, V42, P3430	8	78	79	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1521	1522		10.1016/S0140-6736(05)80088-1	http://dx.doi.org/10.1016/S0140-6736(05)80088-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902904				2022-12-01	WOS:A1993MM40200015
J	KOSTER, T; ROSENDAAL, FR; DERONDE, H; BRIET, E; VANDENBROUCKE, JP; BERTINA, RM				KOSTER, T; ROSENDAAL, FR; DERONDE, H; BRIET, E; VANDENBROUCKE, JP; BERTINA, RM			VENOUS THROMBOSIS DUE TO POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - LEIDEN THROMBOPHILIA STUDY	LANCET			English	Article							INACTIVATION	We undertook a population-based case-control study to test the clinical importance of a hereditary abnormality in the coagulation system, characterised by poor anticoagulant response to activated protein C (APC), which is associated with familial thrombophilia. The abnormality was detected in 64 (21%) of 301 unselected consecutive patients younger than 70 years,with a first, objectively confirmed episode of deep-vein thrombosis and without underlying malignant disease. Among 301 healthy control subjects matched for age and sex, the frequency was 5% (14 subjects). Thus, there is a seven-fold increase in risk of deep-vein thrombosis in subjects with a poor response to APC (matched odds ratio 6.6 [95% CI 3.6-12.0]). In addition, there was a clear inverse relation between the degree of response to APC and thrombosis risk. In the families of the patients an autosomal dominant mode of transmission of the abnormality was confirmed. 9 of 10 thrombosis patients with a poor response to APC had 1 parent with a similar poor response, whereas 9 of 10 patients with normal tests had parents with equally normal tests. The abnormality was found in both parents of 1 patient with an extremely poor response to APC; this patient is probably homozygous for the abnormality. We conclude that the poor response to APC is the most important hereditary cause of venous thrombosis. Its high prevalence in a series of unselected patients will make testing of all thrombosis patients for this abnormality worth while.	UNIV HOSP LEIDEN, HEMOSTASIS & THROMBOSIS RES CTR, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	KOSTER, T (corresponding author), UNIV HOSP LEIDEN, DEPT CLIN EPIDEMIOL, BLDG 1, CO-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BOYERNEUMANN C, IN PRESS THROMB HAEM; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1993, THROMB HAEMOSTASIS, V69, P529; DEUTZTERLOUW PP, 1990, CLIN CHIM ACTA, V186, P321, DOI 10.1016/0009-8981(90)90318-M; ESMON CT, 1983, BLOOD, V62, P1155; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB104, DOI 10.1016/S0735-1097(86)80012-2; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LOELIGER EA, 1984, ANTICOAGULANTS MYOCA, P157; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILETICH J, 1987, NEW ENGL J MED, V317, P919; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; SVENSSON PJ, 1993, THROMB HAEMOSTASIS, V69, P1252; SVENSSON PJ, 1993, THROMB HAEMOSTASIS, V69, P999; VANHINSBERGH VWM, 1985, BLOOD, V65, P444	18	1276	1296	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1503	1506		10.1016/S0140-6736(05)80081-9	http://dx.doi.org/10.1016/S0140-6736(05)80081-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902898				2022-12-01	WOS:A1993MM40200008
J	SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E				SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E			INDIVIDUAL RISK ASSESSMENT FOR INTRACRANIAL HEMORRHAGE DURING THROMBOLYTIC THERAPY	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; INTRAVENOUS STREPTOKINASE; INTRACEREBRAL HEMORRHAGE; RANDOMIZED TRIAL; PHASE-II; STROKE; EPIDEMIOLOGY; NETHERLANDS; ANGIOPLASTY	Thrombolytic therapy improves outcome in patients with myocardial infarction but is associated with an increased risk of intracranial haemorrhage. For some patients, this risk may outweigh the potential benefits of thrombolytic treatment. Using data from other studies, we developed a model for the assessment of an individual's risk of intracranial haemorrhage during thrombolysis. Data were available from 150 patients with documented intracranial haemorrhage and 294 matched controls. 49 patients with intracranial haemorrhage and 122 controls had been treated with streptokinase, whereas 88 cases and 148 controls had received alteplase. By multivariate analysis, four factors were identified as independent predictors of intracranial haemorrhage; age over 65 years (odds ratio 2.2 [95% CI 1.4-3.5]), bodyweight below 70 kg (2.1 [1.3-3.2]), hypertension on hospital admission (2.0 [1.2-3.2]), and administration of alteplase (1.6 [1.0-2.5]). If the overall incidence of intracranial haemorrhage is assumed to be 0.75%, patients without risk factors who receive streptokinase have a 0.26% probability of intracranial haemorrhage. The risk is 0.96%, 1.32%, and 2.17% in patients with one, two, or three risk factors, respectively. We present a model for individual risk assessment that can be used easily in clinical practice.	ERASMUS UNIV ROTTERDAM, THORAXCTR, 3000 DR ROTTERDAM, NETHERLANDS; MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY; DUKE UNIV, DEPT CARDIOL, DURHAM, NC 27706 USA; FREE UNIV BERLIN, W-1000 BERLIN 33, GERMANY; MARYLAND MED RES INST, BALTIMORE, MD USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Erasmus University Rotterdam; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Duke University; Free University of Berlin; Harvard University; Brigham & Women's Hospital	SIMOONS, ML (corresponding author), UNIV HOSP ROTTERDAM, THORAXCTR, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BOSSUYT PMM, 1990, KLINISCHE BESLISKUND, P127; BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CAPLAN LR, 1992, LANCET, V339, P656, DOI 10.1016/0140-6736(92)90804-C; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; KASE CS, 1992, AM J MED, V92, P384, DOI 10.1016/0002-9343(92)90268-G; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; VERMEER F, 1986, CIRCULATION, V74, P1379, DOI 10.1161/01.CIR.74.6.1379; VERMEER F, 1988, BRIT HEART J, V59, P527; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; WALL TC, 1992, J AM COLL CARDIOL, V19, P482, DOI 10.1016/S0735-1097(10)80259-1; WILCOX RG, 1988, LANCET, V2, P525	33	231	236	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1523	1528		10.1016/S0140-6736(05)80089-3	http://dx.doi.org/10.1016/S0140-6736(05)80089-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902905	Green Submitted			2022-12-01	WOS:A1993MM40200016
J	TAKESHIMA, Y; SEYAMA, T; BENNETT, WP; AKIYAMA, M; TOKUOKA, S; INAI, K; MABUCHI, K; LAND, CE; HARRIS, CC				TAKESHIMA, Y; SEYAMA, T; BENNETT, WP; AKIYAMA, M; TOKUOKA, S; INAI, K; MABUCHI, K; LAND, CE; HARRIS, CC			P53 MUTATIONS IN LUNG CANCERS FROM NONSMOKING ATOMIC-BOMB SURVIVORS	LANCET			English	Note							GENE	Tobacco smoke contains many carcinogens and has been linked with the development of lung cancer. We sequenced the conserved regions of the p53 tumour suppressor gene in lung cancers from 17 non-smokers from Hiroshima, Japan; 9 were atomic-bomb survivors. The mutations were predominantly transitions (all G:C to A:T); there were no G:C to T:A transversions. By contrast, lung cancers from 77 Japanese smokers have a predominance of G:C to T:A transversions in which the guanine residues occur on the non-transcribed DNA strand. These findings further implicate tobacco smoke carcinogens in the molecular pathogenesis of lung cancer.	NCI,BLDG 37,ROOM 2C05,BETHESDA,MD 20892; HIROSHIMA UNIV,SCH MED,HIROSHIMA 730,JAPAN; RADIAT EFFECTS RES FDN,HIROSHIMA 730,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hiroshima University; Radiation Effects Research Foundation - Japan					NCI NIH HHS [NCI N01-CP-71128] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP071128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		EVANS MK, IN PRESS CANCER RES; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; MILLER CW, 1992, CANCER RES, V52, P1695; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	10	108	109	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1520	1521		10.1016/S0140-6736(05)80087-X	http://dx.doi.org/10.1016/S0140-6736(05)80087-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902903				2022-12-01	WOS:A1993MM40200014
J	THOMPSON, C				THOMPSON, C			A SLIPPERY DEFENSE AGAINST HIV	LANCET			English	Editorial Material																		LEHNER T, 1993, P NATL ACAD SCI USA, V90, P8638, DOI 10.1073/pnas.90.18.8638; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; LEHNER T, IN PRESS J VIROL	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1500	1500		10.1016/S0140-6736(05)80077-7	http://dx.doi.org/10.1016/S0140-6736(05)80077-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902894				2022-12-01	WOS:A1993MM40200004
J	WOOD, N; STANDEN, G; HOWS, J; BRADLEY, B; BIDWELL, J				WOOD, N; STANDEN, G; HOWS, J; BRADLEY, B; BIDWELL, J			DIAGNOSIS OF SICKLE-CELL DISEASE WITH A UNIVERSAL HETERODUPLEX GENERATOR	LANCET			English	Note							ENZYMATIC AMPLIFICATION; GENOMIC DNA; ANEMIA	A new diagnostic technique, universal heteroduplex generator screening, has been developed to detect homozygosity and heterozygosity for sickle-cell disease. Since it is a polymerase chain reaction-based technique, it may be used to detect haemoglobin S and haemoglobin C genotypes in adults, neonates, or from coelocentesis during the first 10 weeks of pregnancy. Beta-globin gene nucleotide sequences are amplified by the polymerase chain reaction, and are heteroduplexed with a beta-globulin universal heteroduplex generator. Haemoglobins S and C mutations are identified by characteristic polyacrylamide minigel banding patterns. The technique is simple and rapid to do, even by nonspecialist laboratories, and is applicable to large-scale screening for haemoglobin S and C mutations as well as prenatal diagnosis of sickle cell disease.	UNIV BRISTOL, HOMOEOPATH HOSP, DEPT TRANSPLANTAT SCI, BRISTOL BS6 6JU, ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP, DEPT HAEMATOL, BRISTOL BS2 8HW, AVON, ENGLAND; SOUTHMEAD HLTH SERV, DEPT HAEMATOL, BRISTOL, ENGLAND	University of Bristol; Bristol Royal Infirmary								BIDWELL JL, 1993, HDB HLA TYPING TECHN, P99; CHEHAB FF, 1990, LANCET, V335, P15, DOI 10.1016/0140-6736(90)90138-U; HUISMAN THJ, 1993, BAILLIERE CLIN HAEM, V6, P1, DOI 10.1016/S0950-3536(05)80064-2; JURKOVIC D, 1993, LANCET, V341, P1623, DOI 10.1016/0140-6736(93)90761-5; LOSEKOOT M, 1990, BRIT J HAEMATOL, V76, P269, DOI 10.1111/j.1365-2141.1990.tb07883.x; RIGHETTI PG, 1986, METHODS HEMATOLOGY S, V15, P47; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; STEINBERG MH, 1993, AM J HEMATOL, V43, P110, DOI 10.1002/ajh.2830430208; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	10	20	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1519	1520		10.1016/S0140-6736(05)80086-8	http://dx.doi.org/10.1016/S0140-6736(05)80086-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902902				2022-12-01	WOS:A1993MM40200013
J	ORLANDO, V; PARO, R				ORLANDO, V; PARO, R			MAPPING POLYCOMB-REPRESSED DOMAINS IN THE BITHORAX COMPLEX USING IN-VIVO FORMALDEHYDE CROSS-LINKED CHROMATIN	CELL			English	Article							POSITION-EFFECT VARIEGATION; HOMEOTIC GENE ULTRABITHORAX; ABDOMINAL-B DOMAIN; DROSOPHILA-MELANOGASTER; MOLECULAR-GENETICS; ANTENNAPEDIA GENE; CONTROL REGION; DNA-SEQUENCES; PROTEIN; EXPRESSION	The Polycomb group (Pc-G) proteins are responsible for keeping developmental regulators, like homeotic genes, stably and inheritably repressed during Drosophila development. Several similarities to a protein class involved in heterochromatin formation suggest that the Pc-G exerts its function at the higher order chromatin level. Here we have mapped the distribution of the Pc protein in the homeotic bithorax complex (BX-C) of Drosophila tissue culture cells. We have elaborated a method, based on the in vivo formaldehyde cross-linking technique, that allows a substantial enrichment for Pc-interacting sites by immunoprecipitation of the cross-linked chromatin with anti-Pc antibodies. We find that the Pc protein quantitatively covers large regulatory regions of repressed BX-C genes. Conversely, we find that the Abdominal-B gene is active in these cells and the region devoid of any bound Pc protein.			ORLANDO, V (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,IM NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BIENZ M, 1988, CELL, V53, P567, DOI 10.1016/0092-8674(88)90573-9; BLANCO J, 1985, BIOCHEMISTRY-US, V24, P8021, DOI 10.1021/bi00348a028; BOULET AM, 1988, GENE DEV, V2, P1600, DOI 10.1101/gad.2.12a.1600; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; CASANOVA J, 1986, CELL, V47, P627, DOI 10.1016/0092-8674(86)90627-6; CASTELLIGAIR J, 1992, DEVELOPMENT, V114, P877; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; DELORENZI M, 1988, EMBO J, V7, P3223, DOI 10.1002/j.1460-2075.1988.tb03189.x; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; ENGSTROM Y, 1992, ROUX ARCH DEV BIOL, V201, P65, DOI 10.1007/BF00420417; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GOLDSCHMIDTCLERMONT M, 1980, NUCLEIC ACIDS RES, V8, P235, DOI 10.1093/nar/8.2.235; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; IRVINE KD, 1991, DEVELOPMENT, V111, P407; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; JOHNSON DH, 1991, PCR PRACTICAL APPROA; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KUZIORA MA, 1988, EMBO J, V7, P3233, DOI 10.1002/j.1460-2075.1988.tb03190.x; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LOCKE J, 1988, GENETICS, V120, P181; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PARO R, 1983, EMBO J, V2, P853, DOI 10.1002/j.1460-2075.1983.tb01513.x; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SAKONJU S, 1984, GENETICS, V107, P593; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SAUNDERS RDC, 1989, NUCLEIC ACIDS RES, V17, P9027, DOI 10.1093/nar/17.22.9027; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SCHOUTEN JP, 1985, J BIOL CHEM, V260, P9929; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SIMON J, 1992, DEVELOPMENT, V114, P493; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; ZAVORTINK M, 1989, GENE DEV, V3, P1969, DOI 10.1101/gad.3.12a.1969; ZHANG CC, 1991, DEVELOPMENT, V113, P1171; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	71	305	316	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1187	1198		10.1016/0092-8674(93)90328-N	http://dx.doi.org/10.1016/0092-8674(93)90328-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903220				2022-12-01	WOS:A1993MM89300017
J	RASTINEJAD, F; CONBOY, MJ; RANDO, TA; BLAU, HM				RASTINEJAD, F; CONBOY, MJ; RANDO, TA; BLAU, HM			TUMOR SUPPRESSION BY RNA FROM THE 3' UNTRANSLATED REGION OF ALPHA-TROPOMYOSIN	CELL			English	Article							TRANSFORMED-CELLS; MOLECULAR-CLONING; EPITHELIAL-CELLS; GENE-EXPRESSION; PROTEIN-KINASE; GROWTH-FACTOR; CANCER-CELLS; BHK CELLS; RETINOBLASTOMA; ONCOGENE	NMU2, a nondifferentiating mutant myogenic cell line, gives rise to rhabdomyosarcomas in mice. We show that constitutive expression of RNA from 0.2 kb of the alpha-tropomyosin (Tm) 3' untranslated region (UTR), but not control 3'UTRs, suppresses anchorage-independent growth and tumor formation by NMU2 cells. When beta-galactosidase (beta-gal)-labeled cells were implanted into muscles of adult mouse hindlimbs, Tm 3'UTR expression suppressed the proliferation, invasion, and destruction of muscle tissues characteristic of NMU2. In the rare tumors that developed from Tm 3'UTR transfectants, RNA expression was extinguished. These results suggest that suppression of tumorigenicity is dependent on the continued expression of Tm transcripts lacking a coding region. We conclude that untranslated RNAs can function as regulators (riboregulators) that suppress tumor formation.			RASTINEJAD, F (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.				NICHD NIH HHS [HD 20203, HD 07249-11] Funding Source: Medline; NIGMS NIH HHS [GM 14588] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014588] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOUCK N, 1982, MOL CELL BIOL, V2, P97, DOI 10.1128/MCB.2.2.97; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO M, 1993, J CELL BIOL, V121, P795, DOI 10.1083/jcb.121.4.795; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P448; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOINTOURA BMA, 1992, MOL CELL BIOL, V12, P5145; FUKUI T, 1982, J BIOCHEM-TOKYO, V91, P331, DOI 10.1093/oxfordjournals.jbchem.a133692; GABBIANI G, 1976, AM J PATHOL, V83, P457; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRAHAM F, 1973, VIROLOGY, V52, P452; HARRIS H, 1985, J CELL SCI, V79, P83; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEAVITT J, 1982, CELL, V28, P259, DOI 10.1016/0092-8674(82)90344-0; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIU DG, 1992, SCI CHINA SER B, V35, P822; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARTINZANCA D, 1986, COLD SPRING HARB SYM, V51, P983, DOI 10.1101/SQB.1986.051.01.112; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Mintz B, 1981, Adv Cancer Res, V34, P211, DOI 10.1016/S0065-230X(08)60243-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SACHS L, 1981, BLOOD CELLS, V7, P31; Sachs L, 1984, Symp Fundam Cancer Res, V37, P341; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; VANDERIJN M, 1993, IN PRESS APPL IMMUNO; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314; ZELENETZ AD, 1993, GENE CHROMOSOME CANC, V6, P140, DOI 10.1002/gcc.2870060303	61	200	203	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1107	1117		10.1016/0092-8674(93)90320-P	http://dx.doi.org/10.1016/0092-8674(93)90320-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505203				2022-12-01	WOS:A1993MM89300009
J	SAATCIOGLU, F; DENG, TL; KARIN, M				SAATCIOGLU, F; DENG, TL; KARIN, M			A NOVEL CIS-ELEMENT MEDIATING LIGAND-INDEPENDENT ACTIVATION BY C-ERBA - IMPLICATIONS FOR HORMONAL-REGULATION	CELL			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; DNA-BINDING; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; RESPONSE ELEMENTS; AP-1-RESPONSIVE GENES; TRANSCRIPTION FACTOR; TRANS-ACTIVATION	A novel type of hormone-responsive element (HRE) is described. Unlike classical HREs, this element, RSV-T3RE (found in Rous sarcoma virus-long terminal repeat), mediates strong activation by the c-ErbAalpha thyroid hormone (T3) receptor in the absence of T3, and addition of T3 reverses this response. Whereas both c-ErbAalpha and v-ErbA are potent ligand-independent activators through the RSV-T3RE, c-ErbAbeta is not. The RSV-T3RE is recognized and activated by either c-ErbAalpha homodimers or c-ErbAalpha/retinoid X receptor (RXR) heterodimers. Ligand-independent activation by c-ErbAalpha depends on a unique N-terminal activation domain, while the C-terminal activation domain is not absolutely required. Ligand-dependent activation, on the other hand, requires the C-terminal but not the N-terminal activation domain. Upon binding to the RSV-T3RE, c-ErbAalpha assumes a different conformation than when bound to a classical T3RE. c-ErbAalpha is therefore capable of selective deployment of activation domains, dictated both by the HRE with which it interacts and by T3 binding.	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	SAATCIOGLU, F (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.				NCI NIH HHS [CA50528] Funding Source: Medline; NHLBI NIH HHS [HL35018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBOIS C, 1991, CELL, V67, P731; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P597; GLASS CK, 1991, MOL ASPECTS CELLULAR, V6, P229; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Ivarie R D, 1980, Recent Prog Horm Res, V36, P195; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAKAI DD, 1988, GENE DEV, V2, P114; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	121	121	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1095	1105		10.1016/0092-8674(93)90319-L	http://dx.doi.org/10.1016/0092-8674(93)90319-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903219				2022-12-01	WOS:A1993MM89300008
J	SAKO, D; CHANG, XJ; BARONE, KM; VACHINO, G; WHITE, HM; SHAW, G; VELDMAN, GM; BEAN, KM; AHERN, TJ; FURIE, B; CUMMING, DA; LARSEN, GR				SAKO, D; CHANG, XJ; BARONE, KM; VACHINO, G; WHITE, HM; SHAW, G; VELDMAN, GM; BEAN, KM; AHERN, TJ; FURIE, B; CUMMING, DA; LARSEN, GR			EXPRESSION CLONING OF A FUNCTIONAL GLYCOPROTEIN LIGAND FOR P-SELECTIN	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; PLASMA-MEMBRANE; ADHESION; GMP-140; NEUTROPHILS; PLATELETS; CELLS; CARBOHYDRATE; SEQUENCE; RECEPTOR	The initial adhesive interactions between circulating leukocytes and endothelia are mediated, in part, by P-selectin. We now report the expression cloning of a functional ligand for P-selectin from an HL-60 cDNA library. The predicted amino acid sequence reveals a novel mucin-like transmembrane protein. Significant binding of transfected COS cells to P-selectin requires coexpression of both the protein ligand and a fucosyltransferase. This binding is calcium dependent and can be inhibited by a neutralizing monoclonal antibody to P-selectin. Cotransfected COS cells express the ligand as a homodimer of 220 kd. A soluble ligand construct, when coexpressed with fucosyltransferase in COS cells, also mediates P-selectin binding and is immunocrossreactive with the major HL-60 glycoprotein that specifically binds P-selectin.	TUFTS UNIV NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL & ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	SAKO, D (corresponding author), SMALL MOLEC DRUG DISCOVERY GRP,INST GENET,87 CAMBRIDGE PK DR,CAMBRIDGE,MA 02140, USA.			Vachino, Gloria/0000-0002-9193-9990				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRENAN M, 1984, J IMMUNOL METHODS, V74, P31, DOI 10.1016/0022-1759(84)90364-8; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; GROBER JS, 1993, J CLIN INVEST, V91, P2609, DOI 10.1172/JCI116500; HAMBURGER SA, 1990, BLOOD, V75, P550; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; Sambrook J., 1989, MOL CLONING LAB MANU; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WELLER A, 1992, J BIOL CHEM, V267, P15176; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; [No title captured]	41	659	698	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1179	1186		10.1016/0092-8674(93)90327-M	http://dx.doi.org/10.1016/0092-8674(93)90327-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505206				2022-12-01	WOS:A1993MM89300016
J	SCHNEIDERMAUNOURY, S; TOPILKO, P; SEITANIDOU, T; LEVI, G; COHENTANNOUDJI, M; POURNIN, S; BABINET, C; CHARNAY, P				SCHNEIDERMAUNOURY, S; TOPILKO, P; SEITANIDOU, T; LEVI, G; COHENTANNOUDJI, M; POURNIN, S; BABINET, C; CHARNAY, P			DISRUPTION OF KROX-20 RESULTS IN ALTERATION OF RHOMBOMERE-3 AND RHOMBOMERE-5 IN THE DEVELOPING HINDBRAIN	CELL			English	Article							SEGMENT-SPECIFIC EXPRESSION; DEVELOPING MOUSE HINDBRAIN; DEVELOPING CHICK HINDBRAIN; CRANIAL NEURAL CREST; ZINC-FINGER GENE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; EMBRYO HINDBRAIN; VERTEBRATE HEAD; REGION	The zinc finger gene Krox-20 is transcribed in two alternate segments (rhombomeres) of the developing hindbrain. To investigate its function, we have used homologous recombination to generate mice carrying an in-frame insertion of the E. coli lacZ gene within Krox-20. Analysis of the beta-galactosidase pattern in heterozygous embryos confirmed the known profile with expression restricted to rhombomeres (r) 3 and 5. Mice homozygous for the mutation die during the first two weeks after birth. Anatomical analysis of the hindbrain and of the cranial nerves during embryogenesis, combined with the determination of the expression patterns of rhombomere-specific genes, demonstrated that Krox-20 inactivation results in a marked reduction or elimination of r3 and r5. We conclude that Krox-20, although not required for the initial delimitation of r3 and r5, plays an important role in the process of segmentation governing hindbrain development.	ECOLE NORMALE SUPER, CNRS, UNITE RECH ASSOCIEE 1337, F-75230 PARIS 05, FRANCE; INST SCI TUMORI, CTR BIOTECNOL AVANZATE, I-16132 GENOA, ITALY; INST PASTEUR, CNRS, UNITE RECH ASSOCIEE 361, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	SCHNEIDERMAUNOURY, S (corresponding author), ECOLE NORMALE SUPER, INSERM, UNITE 368, F-75230 PARIS 05, FRANCE.		Schneider-Maunoury, Sylvie/K-6795-2017; Levi, Giovanni/B-4416-2013	Schneider-Maunoury, Sylvie/0000-0002-0797-4735; Charnay, Patrick/0000-0002-3847-6042; Levi, Giovanni/0000-0002-7041-6787; Cohen-Tannoudji, Michel/0000-0002-6405-2657	NICHD NIH HHS [N01-HD-6-2915] Funding Source: Medline; Telethon [94] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD062915] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1991, J NEUROBIOL, V22, P742, DOI 10.1002/neu.480220709; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KALLEN B, 1956, KLUNG FYSIOGRAF SALL, V26, P1; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LEDOUARIN N, 1982, DEV CELL BIOL, V12; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P319; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1983, DEV BIOL, V96, P144, DOI 10.1016/0012-1606(83)90318-4; NODEN DM, 1988, DEVELOPMENT, V103, P121; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SOFRONIEW MV, 1985, RAT NERVOUS SYSTEM, V1, P471; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Vaage S., 1969, ERG ANAT ENTWICKLU, V41, P1; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILKINSON DG, 1990, SEMINARS DEV BIOL, V1, P127	50	381	384	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1199	1214		10.1016/0092-8674(93)90329-O	http://dx.doi.org/10.1016/0092-8674(93)90329-O			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7903221				2022-12-01	WOS:A1993MM89300018
J	WANG, H; LAMBOWITZ, AM				WANG, H; LAMBOWITZ, AM			THE MAURICEVILLE PLASMID REVERSE-TRANSCRIPTASE CAN INITIATE CDNA SYNTHESIS DE-NOVO AND MAY BE RELATED TO REVERSE-TRANSCRIPTASE AND DNA-POLYMERASE PROGENITOR	CELL			English	Article							RNA-LIKE STRUCTURES; MITOCHONDRIAL PLASMIDS; VIRUS RNA; 3' END; NEUROSPORA; ORIGIN; REPLICATION; EVOLUTION; SEQUENCE; ELEMENTS	We show that the reverse transcriptase (RT) encoded by the Mauriceville mitochondrial plasmid of Neurospora closely resembles viral RNA-dependent RNA polymerases in initiating cDNA synthesis opposite the penultimate C residue of a 3' tRNA-like structure and has the unprecedented ability for a DNA polymerase to initiate DNA synthesis at a specific site in a natural template without a primer. The Mauriceville plasmid enzyme can also use DNA or RNA primers in a manner suggesting how a primitive RT could have evolved from an RNA-dependent RNA polymerase into retroviral and other types of RTs. The characteristics of the Mauriceville plasmid RT suggest that it may be related to the progenitor of present-day RTs and DNA polymerases.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	WANG, H (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1988, J MOL BIOL, V204, P1, DOI 10.1016/0022-2836(88)90594-3; AKINS RA, 1989, MOL CELL BIOL, V9, P678, DOI 10.1128/MCB.9.2.678; AKINS RA, 1986, CELL, V47, P505, DOI 10.1016/0092-8674(86)90615-X; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COLLINS RA, 1981, CELL, V24, P443, DOI 10.1016/0092-8674(81)90335-4; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Deininger PL, 1989, MOBILE DNA, P619; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Eickbush Thomas H., 1994, P121; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; KUIPER MTR, 1990, J BIOL CHEM, V265, P6936; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MAIZELS N, 1993, IN PRESS RNA WORLD; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; NARGANG FE, 1984, CELL, V38, P441, DOI 10.1016/0092-8674(84)90499-9; PANET A, 1975, P NATL ACAD SCI USA, V72, P2535, DOI 10.1073/pnas.72.7.2535; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; TEMIN HM, 1989, NATURE, V339, P254, DOI 10.1038/339254a0; TEMIN HM, 1980, CELL, V21, P599, DOI 10.1016/0092-8674(80)90420-1; TEMIN HM, 1970, PERSPECT BIOL MED, V14, P11; TESSIER DC, 1986, ANAL BIOCHEM, V158, P171, DOI 10.1016/0003-2697(86)90606-8; VARMUS H, 1989, MOBILE DNA, P53; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WANG H, 1993, J BIOL CHEM, V268, P18951; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WINTERSBERGER U, 1987, TRENDS GENET, V3, P198, DOI 10.1016/0168-9525(87)90233-2; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	45	82	84	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1071	1081		10.1016/0092-8674(93)90317-J	http://dx.doi.org/10.1016/0092-8674(93)90317-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505202				2022-12-01	WOS:A1993MM89300006
J	BERG, EL; MCEVOY, LM; BERLIN, C; BARGATZE, RF; BUTCHER, EC				BERG, EL; MCEVOY, LM; BERLIN, C; BARGATZE, RF; BUTCHER, EC			L-SELECTIN-MEDIATED LYMPHOCYTE ROLLING ON MADCAM-1	NATURE			English	Article							ENDOTHELIAL CELL RECOGNITION; NODE HOMING RECEPTOR; VASCULAR ADDRESSIN; LIGAND; MOLECULE; IDENTIFICATION; MIGRATION; ADHESION; VENULES; SPECIFICITY	THE L-selectin, a cell surface C-type lectin, directs lymphocyte traffic to lymph nodes1, and contributes to lymphocyte homing to Peyer's patches2,3 and to leukocyte interactions with inflamed venules4,5. Here we report that the mucosal vascular addressin MAdCAM-1, a mucosal endothelial adhesion molecule with immunoglobulin- and mucin-like domains6, is a facultative ligand for L-selectin. MAdCAM-1 isolated from mesenteric lymph nodes, but not from cultured endothelioma cells, bears N-glycanase-resistant sialic acid-containing carbohydrate which supports adhesion of L-selectin-transfected lymphoid cells under shear. Interacting lymphoid cells display a 'rolling' behaviour similar to the selectin-dependent rolling of neutrophils observed in inflamed venules. MAdCAM-1 is also a ligand for the lymphocyte integrin homing receptor for Peyer's patches, alpha4beta7 (ref. 7), and may be uniquely adapted to support both selectin-mediated lymphocyte rolling and integrin-mediated adhesion and arrest in vivo.	STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305; VET ADM MED CTR,FOOTHILL RES CTR,CTR MOLEC BIOL & MED,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 				BARGATZE RF, 1990, J CELL BIOCHEM, V42, P219, DOI 10.1002/jcb.240420405; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG E L, 1991, P111; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BJERKNES M, 1986, SCIENCE, V231, P402, DOI 10.1126/science.3941903; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HOLTZMANN B, 1989, CELL, V56, P37; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; NAKACHE M, 1988, NATURE, V304, P32; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SIMMONS DL, 1992, J IMMUNOL, V148, P267; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	30	487	502	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					695	698		10.1038/366695a0	http://dx.doi.org/10.1038/366695a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	7505053				2022-12-01	WOS:A1993MM26500072
J	HAYASHI, Y; MOMIYAMA, A; TAKAHASHI, T; OHISHI, H; OGAWAMEGURO, R; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				HAYASHI, Y; MOMIYAMA, A; TAKAHASHI, T; OHISHI, H; OGAWAMEGURO, R; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			ROLE OF A METABOTROPIC GLUTAMATE-RECEPTOR IN SYNAPTIC MODULATION IN THE ACCESSORY OLFACTORY-BULB	NATURE			English	Article							NERVOUS-SYSTEM; NEURONS; EXPRESSION; CLONING; BRAIN	VARIOUS functions of glutamate transmission are mediated by both ionotropic and metabotropic glutamate receptors1. The metabotropic glutamate receptors (mGluRs) consist of at least six different subtypes that are classified into three subgroups, mGluR1/mGluR5, mGluR2/mGluR3, and mGluR4/mGluR6 (refs 1-5), but their physiological roles are largely unknown. Here we report the identification of a very potent agonist for mGluR2/mGluR3, DCG-IV, and the specific localization of mGluR2 in granule cell dendrites that form dendrodendritic synapses with mitral cells in the accessory olfactory bulb. Using the DCG-IV agonist for mGluR2 in combination with slice patch-recording, we demonstrate that the granule cell mGluR2 presynaptically suppresses inhibitory GABA (gamma-aminobutyrate) transmission to the mitral cell. Our results indicate that mGluR2 in granule cells plays an important role in the persistent excitation of olfactory sensory transmission in the accessory olfactory bulb by relieving mitral cells from the GABA inhibition.	KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University; Kyoto University; Kyoto University; Kyoto University			Takahashi, Tomoyuki/G-5951-2015; Shigemoto, Ryuichi/E-3628-2013; Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Takahashi, Tomoyuki/0000-0002-8771-7666; Shigemoto, Ryuichi/0000-0001-8761-9444; Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004				ABE T, 1992, J BIOL CHEM, V267, P13361; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HAYASHI Y, 1992, BRIT J PHARMACOL, V107, P539, DOI 10.1111/j.1476-5381.1992.tb12780.x; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; ISHIDA M, 1993, BRIT J PHARMACOL, V109, P1169, DOI 10.1111/j.1476-5381.1993.tb13745.x; ITO S, 1991, J PHYSIOL-LONDON, V440, P67, DOI 10.1113/jphysiol.1991.sp018696; KAWAI M, 1992, EUR J PHARMACOL, V211, P195; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHFUNE Y, 1993, BIOORG MED CHEM LETT, V3, P15, DOI 10.1016/S0960-894X(00)80083-9; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; RALL W, 1968, J NEUROPHYSIOL, V31, P884, DOI 10.1152/jn.1968.31.6.884; SHEPHERD GM, 1978, SCI AM, V238, P92, DOI 10.1038/scientificamerican0278-92; SHIGEMOTO R, 1993, NEUROSCI LETT, V153, P157, DOI 10.1016/0304-3940(93)90311-8; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V450, P593, DOI 10.1113/jphysiol.1992.sp019145; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W	20	348	353	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					687	690		10.1038/366687a0	http://dx.doi.org/10.1038/366687a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	7903116				2022-12-01	WOS:A1993MM26500070
J	ADAMSON, BB; GALLACHER, SJ; BYARS, J; RALSTON, SH; BOYLE, IT; BOYCE, BF				ADAMSON, BB; GALLACHER, SJ; BYARS, J; RALSTON, SH; BOYLE, IT; BOYCE, BF			MINERALIZATION DEFECTS WITH PAMIDRONATE THERAPY FOR PAGETS-DISEASE	LANCET			English	Note							BONE	Bone biopsy samples were taken from 20 patients with Paget's disease before and after intravenous pamidronate therapy. In 10 patients given 180 or 360 mg during 6 or 9 weeks, bone turnover decreased as measured biochemically and histologically, but osteomalacia developed in 1 patient and mineralisation defects in 3. 10 other patients received 45 mg every 3 months for 1 year. Bone turnover decreased biochemically but not histologically, and osteoid thickness increased, suggesting impaired mineralisation. Despite overall efficacy, pamidronate has a narrow therapeutic range between resorption inhibition and mineralisation defects. Short courses given to achieve biochemical remission should be administered with caution.	UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW,SCOTLAND; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	University of Glasgow; University of Texas System; University of Texas Health San Antonio	BOYCE, BF (corresponding author), UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW,SCOTLAND.							ANDERSON DC, 1987, BRIT MED J, V294, P1486, DOI 10.1136/bmj.294.6585.1486; BOYCE BF, 1984, LANCET, V1, P821; BYCE BF, 1992, J CLIN PATHOL, V45, P502; CANTRILL JA, 1990, CLIN ENDOCRINOL, V32, P507, DOI 10.1111/j.1365-2265.1990.tb00892.x; FENTON AJ, 1991, CLIN ENDOCRINOL, V34, P197, DOI 10.1111/j.1365-2265.1991.tb00294.x; FLEISCH H, 1987, CLIN ORTHOP RELAT R, V217, P72; GALLACHER SJ, 1991, ANN RHEUM DIS, V50, P930, DOI 10.1136/ard.50.12.930; HARINCK HIJ, 1987, CLIN ORTHOP RELAT R, V217, P79	8	107	108	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1459	1460		10.1016/0140-6736(93)92935-M	http://dx.doi.org/10.1016/0140-6736(93)92935-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902484				2022-12-01	WOS:A1993ML21700011
J	BEDARIDA, GV; KIM, D; BLASCHKE, TF; HOFFMAN, BB				BEDARIDA, GV; KIM, D; BLASCHKE, TF; HOFFMAN, BB			VENODILATION IN RAYNAUDS-DISEASE	LANCET			English	Article							SUPERFICIAL HAND VEINS; NITRIC-OXIDE; L-ARGININE; SYSTEMIC-SCLEROSIS; ENDOTHELIUM; RESPONSIVENESS; PHENYLEPHRINE; RELAXATION; RESPONSES; THERAPY	The pathogenesis of Raynaud's disease is unclear; an enhanced reponse to catecholamines has been hypothesised to contribute to this vasospastic disorder. Impaired endothelium-dependent dilation occurs in other diseases associated with vasospasm, such as coronary atherosclerosis. We investigated both endothelium-dependent and endothelium-independent venodilatory function in Raynaud's disease using the hand-vein compliance technique. Full dose-response curves to noradrenaline were constructed in 10 subjects with primary Raynaud's disease and 10 age and sex matched control subjects. The two groups did not have a different response to noradrenaline. Mean (SD) log values of ED50s (the dose producing half maximum response) were 1.00 (0.59) (geometric mean 10 ng/min) in Raynaud's disease compared with 1.29 (0.66) (20 ng/min) in control subjects (p = 0.16). The efficacy of noradrenaline as a venoconstrictor was similar in the two groups: mean maximum dilation (E(max)) to noradrenaline was 81 (14)% in the Raynaud's group and 89 (8)% in the control group (p = 0.08). Full dose-response curves to the endothelium-dependent dilator bradykinin were constructed. E(max) to bradykinin was significantly lower in the Raynaud's group than in the control group (65 [21] vs 91 [29%], p = 0.02). ED50 values (doses producing half maximum response) for bradykinin were similar in the two groups. Maximum dilation with nitroprusside, a direct releaser of the vasodilator nitric oxide, was not diminished in the Raynaud's group (94 [23] vs 102 [15]% in controls, p = 0.26). These results suggest that endothelium-dependent venodilation is impaired in peripheral vessels in Raynaud's disease, possibly due to diminished release of nitric oxide, and may contribute to the pathogenesis of the disorder.	STANFORD UNIV, MED CTR, DIV CLIN PHARMACOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR GERIATR RES EDUC & CLIN, PALO ALTO, CA 94304 USA	Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Blaschke, Terrence/0000-0001-5307-2620	NIA NIH HHS [AG 05627] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; AGOSTONI A, 1991, INT J CLIN LAB RES, V21, P202; Allen EV, 1932, AM J MED SCI, V183, P187, DOI 10.1097/00000441-193202000-00004; ARNOLD JMO, 1993, ANN INTERN MED, V118, P619, DOI 10.7326/0003-4819-118-8-199304150-00008; COFFMAN JD, 1991, HYPERTENSION, V17, P593, DOI 10.1161/01.HYP.17.5.593; COLLIER JG, 1972, CLIN SCI, V43, P455, DOI 10.1042/cs0430455; DACHMAN WD, 1993, J CARDIOVASC PHARM, V21, P241, DOI 10.1097/00005344-199302000-00009; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; EDWARDS JM, 1987, J VASC SURG, V5, P38, DOI 10.1067/mva.1987.avs0050038; EICHLER HG, 1989, CLIN SCI, V76, P283, DOI 10.1042/cs0760283; EICHLER HG, 1989, J CLIN INVEST, V83, P108, DOI 10.1172/JCI113845; FLEMING WW, 1972, J PHARMACOL-PARIS, V181, P339; FREEDMAN RR, 1989, ARTHRITIS RHEUM, V32, P61, DOI 10.1002/anr.1780320110; FREEMONT AJ, 1992, BRIT J DERMATOL, V126, P561; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; GRAAFSMA SJ, 1991, CLIN SCI, V80, P325, DOI 10.1042/cs0800325; LIU M-F, 1991, Taiwan yixuehui zazhi, V90, P221; MARASINI B, 1992, INT J MICROCIRC, V11, P375; MATUCCICERINIC M, 1990, CLIN EXP RHEUMATOL, V8, P561; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; OKEEFFE ST, 1992, ANN INTERN MED, V116, P985, DOI 10.7326/0003-4819-116-12-985; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAN HYM, 1986, J PHARMACOL EXP THER, V239, P802; RAYNAUD M, 1888, LOCAL ASPHYXIA SYMME, P99; TERBORG EJ, 1990, SEMIN ARTHRITIS RHEU, V20, P164, DOI 10.1016/0049-0172(90)90057-M; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VINCENT J, 1992, CLIN PHARMACOL THER, V51, P68, DOI 10.1038/clpt.1992.9; WOLLERSHEIM H, 1989, EUR J CLIN INVEST, V19, P535, DOI 10.1111/j.1365-2362.1989.tb00271.x	31	50	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1451	1454		10.1016/0140-6736(93)92932-J	http://dx.doi.org/10.1016/0140-6736(93)92932-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902481				2022-12-01	WOS:A1993ML21700008
J	BONITA, R; BROAD, JB; BEAGLEHOLE, R				BONITA, R; BROAD, JB; BEAGLEHOLE, R			CHANGES IN STROKE INCIDENCE AND CASE-FATALITY IN AUCKLAND, NEW-ZEALAND, 1981-91	LANCET			English	Article							CEREBROVASCULAR-DISEASE; COMMUNITY; DECLINE; PROJECT; TRENDS; RATES	The explanation for the substantial decline in stroke death rates can be investigated only by measuring trends in stroke incidence and case-fatality. Two community-based studies carried out in Auckland, New Zealand, in 1981 and 1991 used comparable methods and definitions, met criteria for well-designed studies, and had the power to detect small changes in incidence and case-fatality rates. 703 events (representing 50% of all strokes) were registered in 1981 and 1735 events in 1991. 521 (74.1%) and 1255 (72.3%) events in 1981 and 1991, respectively, were first-ever (in a lifetime) strokes. Although there was no change in overall stroke incidence between 1981 and 1991, there were changes in age and sex groups. The incidence rate among women younger than 75 years rose by a fifth (rate ratio 1.23 [95% CI 1.04-1.47]), whereas that in men of 75 years and older fell by a third (rate ratio 0.67 [0.54-0.82]). The 28-day case-fatality declined from 27.1 (21.7-32.6)% to 21.9 (18.1-25.7)% in men and from 37.6 (31.8-43.5)%to 25.8 (22.3-29.4)% in women from 1981 to 1991, but the decline was not statistically significant in any age or sex group. These findings suggest that we need to reappraise strategies for the prevention of stroke and assess the implications of improved survival in elderly stroke patients.	UNIV AUCKLAND,SCH MED,DEPT MED,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland; University of Auckland			Broad, Joanna B/D-1194-2010	Broad, Joanna B/0000-0003-0157-7031				ANDERSON CS, 1993, MED J AUSTRALIA, V158, P80, DOI 10.5694/j.1326-5377.1993.tb137528.x; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1983, COMMUNITY HEALTH ST, V7, P111; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BONITA R, 1984, AM J EPIDEMIOL, V120, P236, DOI 10.1093/oxfordjournals.aje.a113885; BONITA R, 1993, LANCET, V341, P1510, DOI 10.1016/0140-6736(93)90640-3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; FRASER GE, 1978, INT J EPIDEMIOL, V7, P277, DOI 10.1093/ije/7.3.277; GARRAWAY WM, 1983, MAYO CLIN PROC, V58, P520; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; MALMGREN R, 1987, LANCET, V2, P1196; MALMGREN R, 1989, BRIT MED J, V298, P656, DOI 10.1136/bmj.298.6674.656; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; TERENT A, 1988, STROKE, V19, P598, DOI 10.1161/01.STR.19.5.598; Waterhouse J., 1976, CANCER INCIDENCE 5 C, V3, P456; 1988, J CLIN EPIDEMIOL, V41, P105	18	148	149	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1470	1473		10.1016/0140-6736(93)92938-P	http://dx.doi.org/10.1016/0140-6736(93)92938-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902487				2022-12-01	WOS:A1993ML21700014
J	KERWIN, R				KERWIN, R			ADVERSE REACTION REPORTING AND NEW ANTIPSYCHOTICS	LANCET			English	Editorial Material							CLOZAPINE				KERWIN, R (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; LARGACTIL, 1993, ABPI DATA SHEET COMP, P1266; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; PETERS NS, 1991, J ROY SOC MED, V84, P1; PILOWSKY LS, 1992, LANCET, V340, P199, DOI 10.1016/0140-6736(92)90467-H; VINCENT PC, 1986, DRUGS, V31, P52, DOI 10.2165/00003495-198631010-00004; 1993, CURR PROB PHARM B, V19, P9	9	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1440	1440		10.1016/0140-6736(93)92929-N	http://dx.doi.org/10.1016/0140-6736(93)92929-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7504153				2022-12-01	WOS:A1993ML21700005
J	LEGUENNO, B				LEGUENNO, B			IDENTIFYING A HANTAVIRUS ASSOCIATED WITH ACUTE RESPIRATORY ILLNESS - A PCR VICTORY	LANCET			English	Editorial Material											LEGUENNO, B (corresponding author), INST PASTEUR,CTR NATL REFERENCE FIEVRES HEMORRAG VIRALES,F-75724 PARIS 15,FRANCE.							CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FRENCH GR, 1981, SCIENCE, V211, P1046, DOI 10.1126/science.6110243; GERDING MN, 1993, LANCET, V342, P495, DOI 10.1016/0140-6736(93)91620-2; KULZER P, 1993, LANCET, V342, P313, DOI 10.1016/0140-6736(93)91865-J; Lee HW., 1976, KOREAN J INTERN MED, V19, P371; LEE HW, 1978, J INFECT DIS, V137, P289; LLOYD G, 1990, CURRENT TOPICS CLIN; NEERURKAER V, 1993, LANCET, V342, P1059; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; 1993, MMWR, V42, P421	10	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1438	1439		10.1016/0140-6736(93)92927-L	http://dx.doi.org/10.1016/0140-6736(93)92927-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902477				2022-12-01	WOS:A1993ML21700003
J	MANNS, A; CLEGHORN, FR; FALK, R; HANCHARD, B; JAFFE, ES; BARTHOLOMEW, C; HARTGE, P; BENICHOU, J; BLATTNER, WA				MANNS, A; CLEGHORN, FR; FALK, R; HANCHARD, B; JAFFE, ES; BARTHOLOMEW, C; HARTGE, P; BENICHOU, J; BLATTNER, WA			ROLE OF HTLV-I IN DEVELOPMENT OF NON-HODGKIN-LYMPHOMA IN JAMAICA AND TRINIDAD-AND-TOBAGO	LANCET			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; RISK-FACTORS; DETERMINANTS; RETROVIRUS; INFECTION; MODEL; AGE	Human T-cell lymphotropic virus type I (HTLV-I) has been implicated in the aetiology of adult T-cell leukaemia/lymphoma in Japan and elsewhere, particularly the Caribbean. We have carried out parallel case-control studies in Jamaica and in Trinidad and Tobago to quantify the role of HTLV-I in the development of non-Hodgkin lymphoma (NHL). 135 cases of NHL were enrolled in Jamaica and 104 in Trinidad and Tobago. Controls were selected from patients treated in the same wards or clinics at the same time as the cases. Overall, patients with NHL were 10 times more likely than were controls to be seropositive for HTLV-I (Jamaica odds ratio 10.3 [95% CI 6.0-18.0], Trinidad and Tobago 14.4 [7.6-27.2]). In both countries the association between NHL and HTLV-I was greatest for T-cell lymphomas (18.3 [9.5-35.6] and 63.3 [25-167]). Among T-cell lymphomas especially, there was no significant difference between men and women in the association between NHL and HTLV-I, but there was a significant inverse relation between age and likelihood of HTLV-I seropositivity. B-cell lymphomas were predominant in the older age groups and were not associated with HTLV-I seropositivity. These findings are consistent with the hypothesis that early life exposure to HTLV-I is important for risk of subsequent ATL. Prevention of vertical transmission of HTLV-I could reduce by 70-80% cases of NHL in people under 60 years in this region.	UNIV W INDIES, DEPT PATHOL, KINGSTON 7, JAMAICA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA; NCI, DIV CANC ETIOL, EPIDEMIOL & BLOSTAT PROGRAM, BETHESDA, MD 20892 USA; DEPT MED, PORT OF SPAIN, TRINIDAD TOBAGO	University West Indies Mona Jamaica; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jaffe, Elaine/G-8981-2014		DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP031006] Funding Source: NIH RePORTER; NCI NIH HHS [NCI N01-CP-61002, NCI N01-CP-31006] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BARTHOLOMEW C, 1985, BMJ-BRIT MED J, V290, P1243, DOI 10.1136/bmj.290.6477.1243; BENICHOU J, 1990, BIOMETRICS, V46, P991, DOI 10.2307/2532443; BLATTNER WA, 1990, J ACQ IMMUN DEF SYND, V3, P1102; BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251; BROOKS SEH, 1991, W INDIAN MED J, V40, P134; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CLEGHORN FR, 1990, HUMAN RETROVIROLOGY : HTLV, P185; DEVESA SS, 1992, CANCER RES, V52, pS5432; Francis D P, 1981, Prog Med Virol, V27, P127; GESSAIN A, 1984, LANCET, V1, P1183; GIBBS WN, 1987, ANN INTERN MED, V106, P361, DOI 10.7326/0003-4819-106-3-361; HANAOKA M, 1982, ACTA PATHOL JPN, V29, P2112; HOOVER EA, 1976, J NATL CANCER I, V57, P365, DOI 10.1093/jnci/57.2.365; JAFFE ES, 1992, MANUAL CLIN LABORATO, P288; KUREC AS, 1988, CLIN LAB MED, V8, P223, DOI 10.1016/S0272-2712(18)30708-X; LEVINE PH, 1992, CANCER EPIDEM BIOMAR, V1, P515; LIU MC, 1993, ONCOLOGY, V7, P66; MANN DL, 1987, SCIENCE, V236, P1103, DOI 10.1126/science.2883731; MILLER GJ, 1986, INT J CANCER, V38, P801, DOI 10.1002/ijc.2910380604; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; PRENTICE R, 1976, BIOMETRICS, V32, P599, DOI 10.2307/2529748; REZANKA LJ, 1992, CANCER INVEST, V10, P371, DOI 10.3109/07357909209024796; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Takatsuki K., 1977, TOPICS HEMATOLOGY, P73; 1988, MMWR, V37, P736; 1982, CANCER, V49, P211	30	61	62	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1447	1450		10.1016/0140-6736(93)92931-I	http://dx.doi.org/10.1016/0140-6736(93)92931-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902480				2022-12-01	WOS:A1993ML21700007
J	POWELL, JT; GREENHALGH, RM; RUCKLEY, CV; FOWKES, FGR				POWELL, JT; GREENHALGH, RM; RUCKLEY, CV; FOWKES, FGR			PROLOGUE TO A SURGICAL TRIAL	LANCET			English	Editorial Material							ABDOMINAL AORTIC-ANEURYSMS		UNIV EDINBURGH,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	POWELL, JT (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; HARRIS PL, 1992, BMJ-BRIT MED J, V305, P697, DOI 10.1136/bmj.305.6855.697; HORTON R, 1993, LANCET, V342, P192, DOI 10.1016/0140-6736(93)92295-5; Naylor A R, 1988, Eur J Vasc Surg, V2, P217, DOI 10.1016/S0950-821X(88)80029-X; 1991, LANCET, V337, P1235	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1473	1474		10.1016/0140-6736(93)92939-Q	http://dx.doi.org/10.1016/0140-6736(93)92939-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902488				2022-12-01	WOS:A1993ML21700015
J	RADER, DJ; IKEWAKI, K; DUVERGER, N; FEUERSTEIN, I; ZECH, L; CONNOR, W; BREWER, HB				RADER, DJ; IKEWAKI, K; DUVERGER, N; FEUERSTEIN, I; ZECH, L; CONNOR, W; BREWER, HB			VERY-LOW HIGH-DENSITY-LIPOPROTEINS WITHOUT CORONARY ATHEROSCLEROSIS	LANCET			English	Article							APOLIPOPROTEIN-A-I; ISCHEMIC HEART-DISEASE; INVIVO METABOLISM; PARTICLES; DEFICIENCY; MUTATION; GENE	Epidemiological studies have established that concentrations of plasma high-density lipoproteins (HDL) are inversely associated with premature atherosclerosis, but the physiological basis of this relationship remains unknown. We investigated 5 probands with very low plasma HDL. None had clinical or biochemical findings typical of the known genetic disorders with low HDL nor had evidence of premature coronary atherosclerosis by sensitive diagnostic methods. All 5 probands and the son of 1 of them had rapid catabolism of the HDL apolipoproteins A-I and A-II. These results indicate that not all people with low HDL are necessarily at risk of premature coronary heart disease and that further investigation is required before decisions can be made about their management.	OREGON HLTH SCI UNIV, DEPT MED, CLIN NUTR & LIPID METAB SECT, PORTLAND, OR 97201 USA	Oregon Health & Science University	RADER, DJ (corresponding author), NHLBI, MOLEC DIS BRANCH, BLDG 10, ROOM 7N117, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040566] Funding Source: NIH RePORTER; NCRR NIH HHS [RR334] Funding Source: Medline; NIDDK NIH HHS [DK40566] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREWER HB, 1988, CLIN CHEM, V34, pB4; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; FRUCHART JC, 1992, CLIN CHEM, V38, P793; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; LIPTON MJ, 1991, CIRCULATION, V84, pI72; MATSUNAGA T, 1991, P NATL ACAD SCI USA, V88, P2793, DOI 10.1073/pnas.88.7.2793; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Norum K, 1989, METABOLIC BASIS INHE, P1181; PARRA HJ, 1990, CLIN CHEM, V36, P1431; RADER DJ, 1992, J LIPID RES, V33, P755; RADER DJ, 1991, J LIPID RES, V32, P1849; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SPRECHER DL, 1984, CLIN CHEM, V30, P2084; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WARNICK GR, 1979, CLIN CHEM, V25, P596	21	56	56	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1455	1458		10.1016/0140-6736(93)92933-K	http://dx.doi.org/10.1016/0140-6736(93)92933-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902482				2022-12-01	WOS:A1993ML21700009
J	URNOVITZ, HB; CLERICI, M; SHEARER, GM; GOTTFRIED, TD; ROBISON, DJ; LUTWICK, LI; MONTAGNIER, L; LANDERS, DV				URNOVITZ, HB; CLERICI, M; SHEARER, GM; GOTTFRIED, TD; ROBISON, DJ; LUTWICK, LI; MONTAGNIER, L; LANDERS, DV			HIV-1 ANTIBODY SERUM NEGATIVITY WITH URINE POSITIVITY	LANCET			English	Note								7 individuals who were negative for HIV-1 antibody in a licensed serum enzyme immunoassay (EIA) were positive in a urine EIA and western blot (WB). Follow-up in individuals by use of a cell-mediated immune response showed 1 positive and 1 negative for HIV-1 peptide reactivity. In a second study, 4 out of 5 subjects positive by urine EIA and indeterminate or negative by serum WB were HIV-1 peptide positive in the cell-mediated immune test. Comparison of cell-mediated responses with urine antibody responses may help to resolve discrepant HIV-1 results.	MAIMONIDES HOSP,BROOKLYN,NY 11219; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; INST PASTEUR,F-75724 PARIS 15,FRANCE; NCI,BETHESDA,MD 20892	Maimonides Medical Center; University of California System; University of California San Francisco; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	URNOVITZ, HB (corresponding author), CALYPTE BIOMED CORP,BERKELEY,CA 94710, USA.			Clerici, Mario/0000-0001-5920-6191				BAUER G, 1992, LANCET, V340, P559, DOI 10.1016/0140-6736(92)91763-X; CAO YZ, 1988, LANCET, V1, P831; CHAMARET S, 1992, 8 INT C AIDS AMST; CHEINGSONGPOPOV R, 1993, LANCET, V341, P1659, DOI 10.1016/0140-6736(93)90789-J; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553	8	24	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1458	1459		10.1016/0140-6736(93)92934-L	http://dx.doi.org/10.1016/0140-6736(93)92934-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902483				2022-12-01	WOS:A1993ML21700010
J	WEBB, DJ; HAYNES, WG				WEBB, DJ; HAYNES, WG			ENDOTHELINS COME OF AGE	LANCET			English	Editorial Material							RECEPTOR; CLONING				WEBB, DJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Haynes, William G/D-5374-2013	Haynes, William G/0000-0003-1004-6136				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CLOZEL M, 1993, CIRCULATION, V88, P316; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; MCMAHON EG, 1991, J CARDIOVASC PHARM, V17, pS29, DOI 10.1097/00005344-199100177-00009; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; ROUX SP, 1993, CIRCULATION, V88, P170; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	10	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1439	1440		10.1016/0140-6736(93)92928-M	http://dx.doi.org/10.1016/0140-6736(93)92928-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902478				2022-12-01	WOS:A1993ML21700004
J	CLERICI, M; LUCEY, DR; BERZOFSKY, JA; PINTO, LA; WYNN, TA; BLATT, SP; DOLAN, MJ; HENDRIX, CW; WOLF, SF; SHEARER, GM				CLERICI, M; LUCEY, DR; BERZOFSKY, JA; PINTO, LA; WYNN, TA; BLATT, SP; DOLAN, MJ; HENDRIX, CW; WOLF, SF; SHEARER, GM			RESTORATION OF HIV-SPECIFIC CELL-MEDIATED IMMUNE-RESPONSES BY INTERLEUKIN-12 IN-VITRO	SCIENCE			English	Article							LYMPHOCYTE MATURATION FACTOR; STIMULATORY FACTOR; RECOMBINANT INTERLEUKIN-2; HETERODIMERIC CYTOKINE; IDENTIFICATION; PURIFICATION; INDUCTION; SYNERGY; PEPTIDE	Peripheral blood mononuclear cells (PBMCs) from many asymptomatic individuals infected with human immunodeficiency virus-type 1 (HIV) are unresponsive as measured by in vitro T cell proliferation and interleukin-2 (IL-2) production to influenza virus and synthetic peptides of HIV envelope (Env). Strong influenza virus- and Env-stimulated IL-2 responses and T cell proliferation were restored when cultures were stimulated in the presence of IL-12. Interferon-gamma production by PBMCs from HIV seropositive (HIV+) patients was also restored with IL-12. Furthermore, in vitro antigen-specific production of IL-2 and proliferation of PBMCs from HIV- donors were suppressed by antibody to IL-12, but were not enhanced by addition of exogenous IL-12. Thus, IL-12 may be limiting in PBMCs from HIV+ but not HIV- individuals. These findings demonstrate that IL-12 can restore HIV-specific cell-mediated immunity in vitro in HIV-infected individuals and suggest a potential use of IL-12 in augmenting the diminished immunologic functions associated with HIV infection.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10,ROOM 4B-17,BETHESDA,MD 20892; GENET INST INC,CAMBRIDGE,MA 02140; NCI,METAB BRANCH,BETHESDA,MD 20892; NIAID,PARASIT DIS LAB,BETHESDA,MD 20892; WILFORD HALL USAF MED CTR,HIV UNIT,LACKLAND AFB,TX 78236	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Air Force			Wynn, Thomas A/C-2797-2011; Wynn, Thomas A/AAO-3523-2021; Hendrix, Craig W/G-4182-2014	Wynn, Thomas A/0000-0002-7244-8731; Hendrix, Craig W/0000-0002-5696-8665; Clerici, Mario/0000-0001-5920-6191				ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CHEHIMI J, 1992, J EXP MED, V175, P789, DOI 10.1084/jem.175.3.789; CHEHIMI J, 1993, 9TH INT C AIDS BERL, P24; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; CLERICI M, IN PRESS J CLIN INVE; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DOLAN MJ, 1993, 9TH INT C AIDS BERL, P45; GATELY MK, 1991, J IMMUNOL, V147, P874; GATELY MK, 1986, J IMMUNOL, V136, P1274; GATELY MK, 1992, CELL IMMUNOL, V143, P127, DOI 10.1016/0008-8749(92)90011-D; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LUCEY DR, 1991, J INFECT DIS, V164, P631, DOI 10.1093/infdis/164.4.631; MACOTONIA SE, 1993, INT IMMUNOL, V5, P1119; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; NAUME B, 1993, CYTOKINE, V5, P38, DOI 10.1016/1043-4666(93)90022-W; PINTO LH, UNPUB; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; WOLF SF, 1991, J IMMUNOL, V146, P3074; WONG HL, 1988, CELL IMMUNOL, V111, P39, DOI 10.1016/0008-8749(88)90049-4	33	409	426	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1721	1724		10.1126/science.7903123	http://dx.doi.org/10.1126/science.7903123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7903123				2022-12-01	WOS:A1993ML22000038
J	FOSS, HM; ROBERTS, CJ; CLAEYS, KM; SELKER, EU				FOSS, HM; ROBERTS, CJ; CLAEYS, KM; SELKER, EU			ABNORMAL CHROMOSOME BEHAVIOR IN NEUROSPORA MUTANTS DEFECTIVE IN DNA METHYLATION	SCIENCE			English	Article							TANDEM DUPLICATION; CRASSA; RECOMBINATION; 5-AZACYTIDINE; SEQUENCES; INDUCTION; SIGNAL; CYCLE	The function and regulation of DNA methylation in eukaryotes remain unclear. Genes affecting methylation were identified in the fungus Neurospora crassa. A mutation in one gene, dim-2, resulted in the loss of all detectable DNA methylation. Abnormal segregation of the methylation defects in crosses led to the discovery that the methylation mutants frequently generate strains with extra chromosomes or chromosomal parts. Starvation for S-adenosylmethionine, the presumed methyl group donor for DNA methylation, also produced aneuploidy. These results suggest that DNA methylation plays a role in the normal control of chromosome behavior.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon					NIGMS NIH HHS [GM-35690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035690, R37GM035690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOND DJ, 1987, MUTAT RES, V181, P257, DOI 10.1016/0027-5107(87)90103-5; BULL JH, 1984, NATURE, V310, P701, DOI 10.1038/310701a0; COCK JM, 1990, J PHYCOL, V26, P361, DOI 10.1111/j.0022-3646.1990.00361.x; CULP LA, 1971, BIOCHIM BIOPHYS ACTA, V247, P220, DOI 10.1016/0005-2787(71)90672-1; Davis RH, 1970, METHODS ENZYMOL A, V17A, P47; FOSS H, 1989, FUNGAL GENET NEWSL, V36, P82; FOSS HM, UNPUB; GOUNARI F, 1987, GENE DEV, V1, P899, DOI 10.1101/gad.1.9.899; GRAYBURN WS, 1989, MOL CELL BIOL, V9, P4416, DOI 10.1128/MCB.9.10.4416; HAACK KJ, UNPUB; HAGEMANN A, UNPUB; HORI T, 1983, MUTAT RES, V121, P47, DOI 10.1016/0165-7992(83)90085-4; JACOBSON ES, 1977, J BACTERIOL, V132, P747, DOI 10.1128/JB.132.2.747-748.1977; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; NEVES N, 1992, GENOME, V35, P650, DOI 10.1139/g92-098; NEWMEYER D, 1967, GENETICS, V56, P771; PERKINS DD, 1975, GENETICS, V80, P87; PERKINS DD, 1986, GENETICS, V114, P791; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PITTENGER TH, 1954, GENETICS, V39, P326; POOT M, 1990, HUM GENET, V84, P258; ROBERTS CJ, UNPUB; RUSSELL PJ, 1987, J BACTERIOL, V169, P2902, DOI 10.1128/jb.169.6.2902-2905.1987; SCHROEDER AL, 1991, MOL GEN GENET, V231, P41, DOI 10.1007/BF00293819; SELKER E, UNPUB; SELKER EU, 1987, SCIENCE, V238, P48, DOI 10.1126/science.2958937; SELKER EU, 1987, MOL CELL BIOL, V7, P1032, DOI 10.1128/MCB.7.3.1032; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHAFER DA, 1984, AM J HUM GENET, V30, P534; SMITH DA, 1974, GENETICS, V76, P1; SMITH DA, 1975, GENETICS, V80, P125; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; THRELKELD SF, 1970, GENET RES, V16, P29, DOI 10.1017/S0016672300002251; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	41	110	115	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1737	1741		10.1126/science.7505062	http://dx.doi.org/10.1126/science.7505062			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7505062				2022-12-01	WOS:A1993ML22000043
J	KLOC, M; SPOHR, G; ETKIN, LD				KLOC, M; SPOHR, G; ETKIN, LD			TRANSLOCATION OF REPETITIVE RNA SEQUENCES WITH THE GERM PLASM IN XENOPUS-OOCYTES	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; DROSOPHILA EMBRYOS; ANIMAL DEVELOPMENT; CELL-FORMATION; XIST GENE; LOCALIZATION; LAEVIS; PATTERN; PRODUCT; NUCLEUS	Xlsirts are a family of interspersed repeat RNAs from Xenopus laevis that contain from 3 to 13 repeat units (each 79 to 81 nucleotides long) flanked by unique sequences. They are homologous to the mammalian Xist gene that is involved in X chromosome inactivation. Xlsirt RNA appears first in the mitochondrial cloud (Balbiani body) in stage 2 oocytes and is then translocated as island-like structures to the vegetal cortex at early stage 3 coincident with the localization of the germ plasm. Exogenous Xlsirt RNA injected into oocytes translocates to the location of the endogenous RNA at that particular stage. The Xlsirt RNA repeat sequences are required for translocation and can cause the translocation of heterologous unique RNAs to the vegetal cortex.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV GENEVA, DEPT CELL BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Texas System; UTMD Anderson Cancer Center; University of Geneva			Kloc, Malgorzata/AAF-6982-2020					BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GERHART J, 1989, DEVELOPMENT S; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HEASMAN J, 1984, DEV BIOL, V105, P458, DOI 10.1016/0012-1606(84)90303-8; JAMRICH M, 1983, P NATL ACAD SCI-BIOL, V80, P3364, DOI 10.1073/pnas.80.11.3364; KLOC M, UNPUB; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MAHOWALD AP, 1992, SCIENCE, V255, P1216, DOI 10.1126/science.1372132; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; REITH W, 1982, EMBRYONIC DEV A, P139; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SMITH LD, 1975, MATERNAL EFFECTS DEV, P167; SPOHR G, 1983, MOL BIOL REP, V9, P33, DOI 10.1007/BF00777471; SPOHR G, 1981, J MOL BIOL, V151, P573, DOI 10.1016/0022-2836(81)90424-1; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WYLIE CC, 1985, J EMBRYOL EXP MORPH, V89, P1	26	127	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1712	1714		10.1126/science.7505061	http://dx.doi.org/10.1126/science.7505061			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7505061				2022-12-01	WOS:A1993ML22000035
J	AMIN, J; WEISS, DS				AMIN, J; WEISS, DS			GABA(A) RECEPTOR NEEDS 2 HOMOLOGOUS DOMAINS OF THE BETA-SUBUNIT FOR ACTIVATION BY GABA BUT NOT BY PENTOBARBITAL	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GLYCINE RECEPTOR; ALPHA-SUBUNIT; BINDING-SITE; ION CHANNELS; AMINO-ACIDS; A RECEPTORS; AGONIST; RAT; NEURONS	THE predominant inhibitory neurotrasmitter of the brain, GABA (gamma-antinobutyric acid), activates chloride-selective ion pores integral to the receptor complex. Subunits comprising the presumed hetero-pentameric GABA channel have been cloned1-4, but little information is available on the domains important for activation. Rat wild-type or mutated alpha1-, beta2- and gamma2-subunits (designated alpha, beta and gamma) were coexpressed in Xenopus oocytes and examined electrophysiologically. We report here the identification of two separate and homologous domains of the beta-subunit, each of which contributes a tyrosine and threonine essential for activation by GABA. Conservative substitution of each of these four amino acids dramatically decreased GABA channel sensitivity to activation by GABA and the GABA agonist muscimol. These substitutions, however, did not impair activation by the barbiturate pentobarbital, indicating these two different classes of agonists activate GABA channels through distinct mechanisms. We also present evidence suggesting that the two identified domains of the beta-subunit contribute a major component of the GABA receptor.	UNIV S FLORIDA,COLL MED,DEPT PHYSIOL & BIOPHYS,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,INST BIOMOLEC SCI,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida			Amin, Jahanshah/I-7174-2012					BARKER JL, 1978, J PHYSIOL-LONDON, V280, P355, DOI 10.1113/jphysiol.1978.sp012388; Branden C., 1999, INTRO PROTEIN STRUCT; CASALOTTI SO, 1986, J BIOL CHEM, V261, P5013; COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912; COLQUHOUN D, 1981, PROC R SOC SER B-BIO, V211, P205, DOI 10.1098/rspb.1981.0003; COLQUHOUN D, 1986, ION CHANNELS NEURAL; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; DENG L, 1986, BIOCHEM BIOPH RES CO, V138, P1308, DOI 10.1016/S0006-291X(86)80425-9; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; FRIEDA S, 1990, P R SOC B, V241, P207; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; NEWLAND CF, 1991, J PHYSIOL-LONDON, V432, P203, DOI 10.1113/jphysiol.1991.sp018382; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; NICOLL RA, 1975, NATURE, V258, P625, DOI 10.1038/258625a0; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SAIKI RK, 1988, SCIENCE, V239, P481; Sakmann B, 1983, J Neural Transm Suppl, V18, P83; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHULZ DW, 1981, BRAIN RES, V209, P177, DOI 10.1016/0006-8993(81)91179-3; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; TWYMAN RE, 1990, J PHYSIOL-LONDON, V423, P193, DOI 10.1113/jphysiol.1990.sp018018; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WEISS DS, 1989, J NEUROSCI, V9, P1314	34	384	386	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					565	569		10.1038/366565a0	http://dx.doi.org/10.1038/366565a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504783				2022-12-01	WOS:A1993ML21800070
J	HESSLER, NA; SHIRKE, AM; MALINOW, R				HESSLER, NA; SHIRKE, AM; MALINOW, R			THE PROBABILITY OF TRANSMITTER RELEASE AT A MAMMALIAN CENTRAL SYNAPSE	NATURE			English	Article							EXCITATORY POSTSYNAPTIC POTENTIALS; GROUP-IA SYNAPSES; TIME COURSE; TRANSMISSION; GLUTAMATE; RECEPTOR; CURRENTS	WHEN an action potential reaches a synaptic terminal, fusion of a transmitter-containing vesicle with the presynaptic membrane occurs with a probability (p(r)) of less than one1. Despite the fundamental importance of this parameter, p(r) has not been directly measured in the central nervous system. Here we describe a novel approach to determine p(r), monitoring the decrement of NMDA (N-methyl-D-aspartate)-receptor mediated synaptic currents in the presence of the use-dependent channel blocker MK-801 (ref. 2). On a single postsynaptic CA1 hippocampal slice neuron, two classes of synapses with a sixfold difference in p(r) are resolved. Synapses with low p(r) contribute to over half of transmission and are more sensitive to drugs enhancing transmitter release. Switching between these two classes of synapses provides the potential for large changes in synaptic efficacy and could underlie forms of activity-dependent plasticity.	UNIV IOWA,NEUROSCI PROGRAM,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa			hessler, neal/A-7328-2010					ATWOOD HL, 1967, NATURE, V215, P57, DOI 10.1038/215057a0; CLAMANN HP, 1989, J NEUROPHYSIOL, V61, P403, DOI 10.1152/jn.1989.61.2.403; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; EDMONDS B, 1992, P ROY SOC B-BIOL SCI, V250, P279, DOI 10.1098/rspb.1992.0160; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HEUTTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P111, DOI 10.1113/jphysiol.1981.sp013974; JAHR CE, 1992, SCIENCE, V255, P470, DOI 10.1126/science.1346477; Katz B., 1969, RELEASE NEURAL TRANS; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIN JW, 1988, J NEUROSCI, V8, P1313; RAHAMIMOFF R, 1968, J PHYSIOL-LONDON, V195, P471, DOI 10.1113/jphysiol.1968.sp008468; REDMAN S, 1983, J PHYSIOL-LONDON, V343, P135, DOI 10.1113/jphysiol.1983.sp014885; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; ROSENMUND C, 1993, BIOPH SOC ABSTR, pA327; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889	20	471	473	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					569	572		10.1038/366569a0	http://dx.doi.org/10.1038/366569a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7902955				2022-12-01	WOS:A1993ML21800071
J	SHUAL, K; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; SADOWSKI, HB; GILMAN, MZ; DARNELL, JE				SHUAL, K; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; SADOWSKI, HB; GILMAN, MZ; DARNELL, JE			POLYPEPTIDE SIGNALING TO THE NUCLEUS THROUGH TYROSINE PHOSPHORYLATION OF JAK AND STAT PROTEINS	NATURE			English	Article								BINDING of interferons IFN-alpha and IFN-gamma to their cell surface receptors promptly induces tyrosine phosphorylation of latent cytoplasmic transcriptional activators1-4 (or Stat proteins, for signal transducers and activators of transcription). Interferon-alpha activates both Stat91 (M(r) 91,000; ref. 1) and Stat113 (M(r) 113,000; ref. 2) whereas IFN-gamma activates only Stat91 (refs 3, 4). The activated proteins then move into the nucleus and directly activate genes induced by IFN-alpha and IFN-gamma. Somatic cell genetics experiments have demonstrated a requirement for tyrosine kinase-2 (Tyk2) in the IFN-alpha response pathway5 and for Jak2 (ref. 6), a kinase with similar sequence7, in the IFN-gamma response pathway. Here we investigate the tyrosine phosphorylation events on Stat and Jak proteins after treatment of cells with IFNs alpha and gamma and with epidermal growth factor (EGF). Stat91 is phosphorylated on Tyr 701 after cells are treated with IFN-alpha and EGF, as it was after treatment with IFN-gamma (ref. 8). We find that Jak1 also becomes phosphorylated on tyrosine after cells are treated with these same three ligands, although each ligand is shown to activate at least one other different kinase. Jak1 may therefore be the enzyme that phosphorylates Tyr 701 in Stat91.	UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, PARKVILLE, VIC 3050, AUSTRALIA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Bern; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Cold Spring Harbor Laboratory	SHUAL, K (corresponding author), ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOWARD OMZ, 1992, ONCOGENE, V7, P895; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; SADOWSKI HB, 1993, Z NATURE, V372, P79; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATING D, 1993, NATURE, V366, P166; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	451	461	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					580	583		10.1038/366580a0	http://dx.doi.org/10.1038/366580a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504784				2022-12-01	WOS:A1993ML21800074
J	SILVENNOINEN, O; IHLE, JN; SCHLESSINGER, J; LEVY, DE				SILVENNOINEN, O; IHLE, JN; SCHLESSINGER, J; LEVY, DE			INTERFERON-INDUCED NUCLEAR SIGNALING BY JAK PROTEIN-TYROSINE KINASES	NATURE			English	Article								INTERFERONS IFN-alpha/beta and IFN-gamma act through independent cell-surface receptors, inducing gene expression through tyrosine phosphorylation of cytoplasmic transcription factors1-5. IFN-alpha stimulates phosphorylation and nuclear localization of the 84/91K and 113K subunits of latent ISGF3 (interferon-stimulated gene factor 3), which combine with the 48K DNA-binding subunit6,7 to bind regulatory elements of IFN-alpha-responsive genes8-10. IFN-gamma activates p91 alone2, inducing IFN-gamma-responsive genes through a distinct DNA element11,12. Genetic complementation studies implicated the tyrosine kinase Tyk2 in IFN-alpha signalling13 and, more recently, the related Jak2 kinase in IFN-gamma signalling14. We now present biochemical evidence for Jak-family kinase involvement in IFN signal transduction. Jak1 was activated in response to IFN-alpha and IFN-gamma; Jak2 responded exclusively to IFN-gamma. Overexpression of either Jak1 or Jak2 stimulated p91 DNA-binding activity and p91-dependent transcription. Overexpression also activated endogenous Jak kinases, suggesting that interactions between Jak kinases are required during interferon signalling.	NYU, SCH MED, KAPLAN COMPREHENS, CANC CTR, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	New York University; New York University; New York University; St Jude Children's Research Hospital			Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 				CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHUAI K, 1992, SCIENCE, V258, P1808; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATING D, 1993, NATURE, V366, P166; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	325	332	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					583	585		10.1038/366583a0	http://dx.doi.org/10.1038/366583a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504785				2022-12-01	WOS:A1993ML21800075
J	ALMENDARES, J; SIERRA, M; ANDERSON, PK; EPSTEIN, PR				ALMENDARES, J; SIERRA, M; ANDERSON, PK; EPSTEIN, PR			CRITICAL REGIONS, A PROFILE OF HONDURAS	LANCET			English	Article									HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138; COMIS NACL MOSCA BLANCA,MANAGUA,NICARAGUA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard University; Harvard T.H. Chan School of Public Health								ANDERSON PK, IN PRESS IN PRESS P; CABALLERO R, 1993, TURRIALBA, P50; KASPERSON JX, CRITICAL ENV REGIONS; KIRCHHOFF LV, 1993, NEW ENGL J MED, V329, P639, DOI 10.1056/NEJM199308263290909; SKOLE D, 1993, SCIENCE, V260, P1905, DOI 10.1126/science.260.5116.1905; Twilley Robert R., 1993, P105; WALSH JF, 1993, PARASITOLOGY, V106, P655; 1993, 1993 WORLD BANK WORL; 1991, TECH REP SER WHO, V811	9	17	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1400	1402		10.1016/0140-6736(93)92758-L	http://dx.doi.org/10.1016/0140-6736(93)92758-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901687				2022-12-01	WOS:A1993MK09500015
J	BERNHARD, JD				BERNHARD, JD			BRINGING ON THE BACON FOR MYIASIS	LANCET			English	Editorial Material											BERNHARD, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA 01605, USA.							BREWER TF, 1993, JAMA-J AM MED ASSOC, V270, P2087, DOI 10.1001/jama.270.17.2087; CANIZARES O, 1992, CLIN TROPICAL DERMAT, P404; JAMES AS, 1992, ARCH EMERG MED, V9, P58; LYELL A, 1983, J AM ACAD DERMATOL, P895; PAMPIGLIONE S, 1992, BRIT J DERMATOL, V126, P418, DOI 10.1111/j.1365-2133.1992.tb00698.x; SANUSI ID, 1989, J AM ACAD DERMATOL, V20, P941, DOI 10.1016/S0190-9622(89)70115-8	6	9	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1377	1378						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901678				2022-12-01	WOS:A1993MK09500006
J	BROWN, MJ				BROWN, MJ			ANGIOTENSIN RECEPTOR BLOCKERS IN ESSENTIAL-HYPERTENSION	LANCET			English	Editorial Material											BROWN, MJ (corresponding author), ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.							BURNIER M, 1991, AM J HYPERTENS, V4, P438, DOI 10.1093/ajh/4.5.438; CHRISTEN Y, 1991, CIRCULATION, V83, P133; DOIG JK, 1993, J CARDIOVASC PHARM, V21, P7323; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; MORICE AH, 1987, LANCET, V2, P1116; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; WEBER MA, 1992, AM J HYPERTENS, V5, pS247, DOI 10.1093/ajh/5.12.247S	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1374	1375		10.1016/0140-6736(93)92745-F	http://dx.doi.org/10.1016/0140-6736(93)92745-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901674				2022-12-01	WOS:A1993MK09500002
J	HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY				HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY			FIELD-TESTS FOR RATIONAL DRUG-USE IN 12 DEVELOPING-COUNTRIES	LANCET			English	Article								Increasing efforts are being made to improve drug-use practices and prescribing behaviour in developing countries. An essential tool for such work is an objective and standard method of assessment. We present here a set of drug-use indicators produced and tested in twelve developing countries. We describe practical applications, which include the use of indicators to increase awareness among prescribers in Malawi and Bangladesh, to identify priorities for action (eg, polypharmacy in Indonesia and Nigeria, overuse of injections in Uganda, Sudan, and Nigeria, and low percentage of patients who understood the dosage schedule in Malawi), and to quantify the impact of interventions in Yemen, Uganda, Sudan, and Zimbabwe.	YAYASAN INDONESIA SEJAHTERA,DIV HLTH,JAKARTA,INDONESIA; HARVARD UNIV,SCH MED,DRUG POLICY GRP,BOSTON,MA 02115; MANAGEMENT SCI HLTH,INT NETWORK RAT USE DRUGS,BOSTON,MA; UNIV GHANA,SCH MED,CTR TROP CLIN PHARMACOL,ACCRA,GHANA; GADJAH MADA UNIV,DEPT CLIN PHARMACOL,YOGYAKARTA,INDONESIA; NATL INST PREVENT & SOCIAL MED,DEPT BIOSTAT,DHAKA,BANGLADESH; UNIV DHAKA,DEPT PHARM,DHAKA,BANGLADESH; TRIBHUVAN UNIV HOSP,DEPT CLIN PHARMACOL,KATMANDU,NEPAL; UNIV LAGOS,COLL MED,DEPT PHARMACOL,LAGOS,NIGERIA; MAHIMBILL MED CTR,DEPT CLIN PHARMACOL,DAR ES SALAAM,TANZANIA	Harvard University; Harvard Medical School; University of Ghana; Gadjah Mada University; University of Dhaka; Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Lagos	HOGERZEIL, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA 27,SWITZERLAND.			Ofori-Adjei, David/0000-0003-1912-4188; Massele, Amos/0000-0003-3816-2040				Bannenberg WJ, 1991, WHODAP9110; BATES JA, 1992, GUATEMALA FIELD TEST; Bimo, 1992, INRUD NEWS, V3, P9; Christensen Rene Flamsholt, 1990, STRATEGY IMPROVEMENT; Gelders S, 1992, MALAWI ESSENTIAL DRU; HOGERZEIL HV, 1989, LANCET, V1, P141; KAFLE KK, 1992, INRUD NEWS, V3, P15; LAING RO, 1990, TROP DOCT, V20, P101, DOI 10.1177/004947559002000303; Ofori-Adjei D, 1992, INRUD NEWS, V3, P9; ROSSDEGNAN D, 1992, SOC SCI MED, V35, P1329, DOI 10.1016/0277-9536(92)90037-Q; SALLET JP, 1992, ECUADOR FIELD TEST P; 1991, FIELD TESTING DRUG I; 1993, WHODAP931, P1; 1993, BASELINE SURVEY DRUG; 1987, 1985 C EXP NAIR; 1991, ESSENTIAL DRUGS SURV	16	162	178	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1408	1410		10.1016/0140-6736(93)92760-Q	http://dx.doi.org/10.1016/0140-6736(93)92760-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901689				2022-12-01	WOS:A1993MK09500017
J	KALKSTEIN, LS				KALKSTEIN, LS			DIRECT IMPACTS IN CITIES	LANCET			English	Article							HUMAN MORTALITY; UNITED-STATES; WEATHER				KALKSTEIN, LS (corresponding author), UNIV DELAWARE,DEPT GEOG,CTR CLIMAT RES,NEWARK,DE 19716, USA.							KAKSTEIN LS, IN PRESS DIFFERENTIA; KALKSTEIN LS, 1989, ANN ASSOC AM GEOGR, V79, P44, DOI 10.1111/j.1467-8306.1989.tb00249.x; KALKSTEIN LS, 1991, ENVIRON HEALTH PERSP, V96, P145, DOI 10.2307/3431223; KALKSTEIN LS, 1993, EXPERIENTIA, V49, P1; KALKSTEIN LS, IN PRESS POTENTIAL I; MCMICHAEL AJ, 1993, INT J EPIDEMIOL, V22, P1, DOI 10.1093/ije/22.1.1; RANGO N, 1984, AM J PUBLIC HEALTH, V74, P1159, DOI 10.2105/AJPH.74.10.1159; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; SCHERAGA JS, IN PRESS PRELIMINARY; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; SMITH J, 1989, POTENTIAL EFFECTS GL, P172; 1990, POTENTIAL HLTH EFFEC	12	118	121	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1397	1399		10.1016/0140-6736(93)92757-K	http://dx.doi.org/10.1016/0140-6736(93)92757-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901686				2022-12-01	WOS:A1993MK09500014
J	KUKS, JBM; COOK, MJ; FISH, DR; STEVENS, JM; SHORVON, SD				KUKS, JBM; COOK, MJ; FISH, DR; STEVENS, JM; SHORVON, SD			HIPPOCAMPAL SCLEROSIS IN EPILEPSY AND CHILDHOOD FEBRILE SEIZURES	LANCET			English	Article							TEMPORAL-LOBE EPILEPSY; CONVULSIONS; RISK	The connection between hippocampal sclerosis and childhood febrile seizures (CFS) is a contentious issue in the study of epilepsy. We investigated 107 patients with drug-resistant epilepsy by high-resolution volumetric magnetic resonance imaging (MRI). 20 had a history of CFS, 45 had focal (26) or diffuse (19) hippocampal volume loss (HVL). The frequency of CFS was significantly (p < 0.001) higher in the patients with HVL, especially of the diffuse pattern, compared to other epileptic patients without HVL and to the general population. Furthermore, the severity of HVL was greatest in those with a history of CFS. No other clinical or demographic features were associated with either a history of CFS or HVL. The frequency of CFS in patients with other structural congenital causes of epilepsy did not differ from that in a general population. Although these findings show that hippocampal sclerosis is strongly associated with a history of CFS, they do not indicate whether this is a causal relationship. If CFS do cause some cases of hippocampal sclerosis, this can not be the only mechanism, as 64% of those with HVL gave no history of CFS. As diffuse HVL is more strongly associated with a history of CFS than focal HVL, it is also possible that CFS convert pre-existing congenital focal abnormalities into diffuse hippocampal sclerosis. Given the possibility that CFS may cause hippocampal damage and epilepsy, they require urgent medical intervention.	UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND; STATE UNIV HOSP GRONINGEN, DEPT NEUROL, GRONINGEN, NETHERLANDS	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Imperial College London; University of Groningen			Cook, Mark J/A-7096-2010; Shorvon, Simon D/A-2019-2009	Cook, Mark J/0000-0002-8875-4135; 				AICARDI J, 1983, DELGADO, P115; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; Brown W., 1987, SURGICAL TREATMENT E, P511; BRUTON CJ, 1988, NEUROPATHOLOGY TEMPO, P1; Cook M. J., 1992, Epilepsia, V33, P72; COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; DAM AM, 1982, ACTA NEUROL SCAND, V66, P601, DOI 10.1111/j.1600-0404.1982.tb04528.x; FALCONER MA, 1971, EPILEPSIA, V12, P13, DOI 10.1111/j.1528-1157.1971.tb03912.x; FISH D, 1991, NEUROLOGY, V41, P1781, DOI 10.1212/WNL.41.11.1781; GASTAUT H, 1959, EPILEPSIA, V1, P56, DOI 10.1111/j.1528-1157.1959.tb04249.x; Hauser WA, 1981, FEBRILE SEIZURES, P5; JACK CR, 1992, ANN NEUROL, V31, P138, DOI 10.1002/ana.410310204; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; RASMUSSEN T, 1979, EPILEPSIA, V20, P395, DOI 10.1111/j.1528-1157.1979.tb04819.x; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; Scheibel A B, 1991, Adv Neurol, V55, P59; VERITY CM, 1993, BMJ-BRIT MED J, V307, P225, DOI 10.1136/bmj.307.6898.225; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373	21	131	135	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1993	342	8884					1391	1394						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901683				2022-12-01	WOS:A1993MK09500011
J	LEUNG, DYM; MEISSNER, HC; FULTON, DR; MURRAY, DL; KOTZIN, BL; SCHLIEVERT, PM				LEUNG, DYM; MEISSNER, HC; FULTON, DR; MURRAY, DL; KOTZIN, BL; SCHLIEVERT, PM			TOXIC SHOCK SYNDROME TOXIN-SECRETING STAPHYLOCOCCUS-AUREUS IN KAWASAKI SYNDROME	LANCET			English	Article							STREPTOCOCCAL PYROGENIC EXOTOXINS; SELECTIVE EXPANSION; GAMMA-GLOBULIN; DISEASE; V-BETA-2; AGR	Kawasaki syndrome (KS), the main cause of acquired heart disease in children, is associated with the selective expansion of Vbeta2+ T cells in peripheral blood. Our study suggests that KS may be caused by a superantigen-a staphylococcal or streptococcal toxin. Bacteria were cultured without knowledge of their origin, from the throat, rectum, axilla, and groin of 16 patients with untreated acute KS and 15 controls. Bacteria producing toxins were isolated from 13 of 16 KS patients but from only 1 of 15 controls (p<0.0001). Toxic shock syndrome toxin (TSST) -secreting Staphylococcus aureus was isolated from 11 of the 13 toxin-positive cultures, and streptococcal pyrogenic exotoxin (SPE) B and C were found in the other 2. These toxins are known to stimulate Vbeta2+ T cells. All TSST-producing KS isolates were tryptophan auxotrophs indicating they were clonally related. S aureus isolates from acute KS patients were unusual because they produced less lipase, haemolysin, and protease compared to other isolates (p<0.01). S aureus colonies from KS patients were white, and could be easily mistaken for coagulase-negative staphylococci, whereas colonies of non-KS isolates were gold. These observations suggest that the expansion of Vbeta2+ T cells in most patients with KS may be caused by a new clone of TSST-producing S aureus, and, in a minority of patients, SPEB-producing or SPEC-producing streptococci.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DENVER, CO 80206 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT PEDIAT, BOSTON, MA 02111 USA; UNIV MINNESOTA, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA	National Jewish Health; Tufts Medical Center; University of Minnesota System; University of Minnesota Twin Cities	LEUNG, DYM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, 1400 JACKSON ST, DENVER, CO 80206 USA.			Schlievert, Patrick/0000-0001-8314-9369	NHLBI NIH HHS [HL36611, HL37260] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036611, R37HL037260, R01HL037260, R55HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE J, 1993, J EXP MED, V177, P791, DOI 10.1084/jem.177.3.791; ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHU MC, 1988, INFECT IMMUN, V56, P2702, DOI 10.1128/IAI.56.10.2702-2708.1988; DRAKE CG, 1992, J CLIN IMMUNOL, V12, P149, DOI 10.1007/BF00918083; HOKONOHARA M, 1987, JPN CIRC J, V51, P1353, DOI 10.1253/jcj.51.1353; HYNES WL, 1985, J MICROBIOL METH, V4, P25, DOI 10.1016/0167-7012(85)90004-1; KASS EH, 1988, J INFECT DIS, V158, P44, DOI 10.1093/infdis/158.1.44; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; LEE PK, 1989, J CLIN MICROBIOL, V27, P1890, DOI 10.1128/JCM.27.8.1890-1892.1989; LEE PK, 1992, J INFECT DIS, V165, P1056, DOI 10.1093/infdis/165.6.1056; Leung D Y, 1993, Curr Opin Rheumatol, V5, P41; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LEUNG DYM, 1983, J IMMUNOL, V130, P2002; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MUSSER JM, 1990, P NATL ACAD SCI USA, V87, P225, DOI 10.1073/pnas.87.1.225; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; RECSEI P, 1986, MOL GEN GENET, V202, P58, DOI 10.1007/BF00330517; RIDER LG, 1991, LANCET, V337, P1100, DOI 10.1016/0140-6736(91)91751-F; SCHLIEVERT PM, 1982, ANN INTERN MED, V96, P937, DOI 10.7326/0003-4819-96-6-937; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P236, DOI 10.1093/infdis/147.2.236; SUZUKI A, 1986, PEDIATR CARDIOL, V7, P3, DOI 10.1007/BF02315475; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; TODD JK, 1984, INFECT IMMUN, V45, P339, DOI 10.1128/IAI.45.2.339-344.1984; TOMAI MA, 1992, INFECT IMMUN, V60, P701, DOI 10.1128/IAI.60.2.701-705.1992; 1990, JAMA-J AM MED ASSOC, V44, P1218	27	310	333	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1993	342	8884					1385	1388		10.1016/0140-6736(93)92752-F	http://dx.doi.org/10.1016/0140-6736(93)92752-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901681				2022-12-01	WOS:A1993MK09500009
J	LUCARELLI, G; ANGELUCCI, E; GIARDINI, C; BARONCIANI, D; GALIMBERTI, M; POLCHI, P; BARTOLUCCI, M; MURETTO, P; ALBERTINI, F				LUCARELLI, G; ANGELUCCI, E; GIARDINI, C; BARONCIANI, D; GALIMBERTI, M; POLCHI, P; BARTOLUCCI, M; MURETTO, P; ALBERTINI, F			FATE OF IRON STORES IN THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION	LANCET			English	Article							THALASSEMIA; CHELATION	After successful bone-marrow transplantation (BMT) in thalassaemia, the individual acquires the pattern of globin synthesis of the donor. We call such an individual ''exthalassaemic after BMT'', a term that underscores the cure of the genetic defect but maintenance of residual signs of organ damage due to iron overload and dysfunction acquired during the pretransplant years. We have analysed the extent and fate of tissue iron overload in 151 ex-thalassaemic patients after BMT, according to the risk factors of hepatomegaly, hepatic portal fibrosis, and inadequate chelation therapy. Serum ferritin concentrations decreased and unbound iron binding capacity (UIBC) increased slowly during the years after the transplant. When analysed according to risk group (assigned at the time of the transplant), ferritin and UIBC returned within the normal ranges in only the low-risk group (without hepatomegaly or portal fibrosis, and with adequate chelation pre-BMT). Ferritin and UIBC were still abnormal 7 years after the transplant in the moderate-risk group (those with one or two risk factors) and highly abnormal in the high-risk group (all three risk factors) indicating persistence of, respectively, moderate and severe iron overload at the time of transplant. In ex-thalassaemic patients who were studied before and yearly after the transplant the extent of haemosiderosis, as judged by staining of liver biopsy samples, decreased during the years after transplant. The degree of iron deposition and rate of post-BMT linear growth seem to influence rate of post-BMT decrease in tissue iron overload in different risk groups at the time of BMT.	OSPED PESARO,CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA,I-61100 PESARO,ITALY; OSPED PESARO,SERV LAB ANAL,I-61100 PESARO,ITALY; OSPED PESARO,SERV ANAT PATOL,I-61100 PESARO,ITALY		LUCARELLI, G (corresponding author), OSPED PESARO,DIV EMATOL,I-61100 PESARO,ITALY.		Angelucci, Emanuele/AAC-1855-2021	Angelucci, Emanuele/0000-0002-6512-6080; Baronciani, Donatella/0000-0001-6087-2431				[Anonymous], 1978, Br J Haematol, V38, P281, DOI 10.1111/j.1365-2141.1978.tb01044.x; BORGNAPIGNATTI C, 1991, HAEMATOLOGICA, V76, P409; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; DEVIRGILIIS S, 1980, ARCH DIS CHILD, V55, P43, DOI 10.1136/adc.55.1.43; FORSBURG MT, 1990, BLOOD, V76, P435; LEY TS, 1982, CCLIN HAEMATOL, V11, P439; LUCARELLI G, 1985, LANCET, V1, P1355; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MURETTO P, IN PRESS LIVER; OVERMOYER BA, 1987, ARCH PATHOL LAB MED, V111, P549; THOMAS ED, 1982, LANCET, V2, P227; 1993, BONE MARROW TRANS S1, V12, pS56	13	62	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1388	1391		10.1016/0140-6736(93)92753-G	http://dx.doi.org/10.1016/0140-6736(93)92753-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901682				2022-12-01	WOS:A1993MK09500010
J	MAHMOUD, HH; HURWITZ, CA; ROBERTS, WM; SANTANA, VM; RIBEIRO, RC; KRANCE, RA				MAHMOUD, HH; HURWITZ, CA; ROBERTS, WM; SANTANA, VM; RIBEIRO, RC; KRANCE, RA			TRETINOIN TOXICITY IN CHILDREN WITH ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Note							TRANS-RETINOIC ACID; DIFFERENTIATION THERAPY; LEUKEMIA; CANCER	Tretinoin is effective in acute promyelocytic leukaemia in adults. Data about its efficacy and safety in children are limited. We have treated 9 children with tretinoin at 45 mg/m2 per day. Pseudotumour cerebri or hyperleucocytosis occurred in 5 patients. Retinoic acid syndrome was seen in 3 cases. 1 of 2 children who developed hyperleucocytosis, pseudotumour cerebri, and retinoic acid syndrome died despite steroids and mechanical ventilation. Complete remissions with tretinoin alone were achieved in 5 patients. All 8 surviving children received consolidation chemotherapy. Our experience with tretinoin therapy suggests that toxicity is frequent in children.	UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	MAHMOUD, HH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 323 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20180] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVVISATI G, 1991, HAEMATOLOGICA S4, V76, P16; CASTAIGNE S, 1990, BLOOD, V76, P1704; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAHN MJ, 1992, J NATL CANCER I, V84, P1669, DOI 10.1093/jnci/84.21.1669; KURZROCK R, 1993, J CLIN ONCOL, V11, P1489, DOI 10.1200/JCO.1993.11.8.1489; SMITH MA, 1992, J CLIN ONCOL, V10, P1666, DOI 10.1200/JCO.1992.10.11.1666; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307	10	77	79	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1394	1395		10.1016/0140-6736(93)92755-I	http://dx.doi.org/10.1016/0140-6736(93)92755-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901684				2022-12-01	WOS:A1993MK09500012
J	REES, M				REES, M			MENARCHE WHEN AND WHY	LANCET			English	Editorial Material											REES, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.							DANN TC, 1993, J BIOSOC SCI, V25, P531, DOI 10.1017/S0021932000021908; FRISCH RE, 1990, BAILLIERE CLIN OB GY, V4, P419, DOI 10.1016/S0950-3552(05)80302-5; KJAER K, 1992, J CLIN ENDOCR METAB, V75, P524, DOI 10.1210/jc.75.2.524; MOISAN J, 1990, AM J EPIDEMIOL, V132, P953, DOI 10.1093/oxfordjournals.aje.a115738; Rosetta L, 1993, Oxf Rev Reprod Biol, V15, P113	5	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1375	1376		10.1016/0140-6736(93)92746-G	http://dx.doi.org/10.1016/0140-6736(93)92746-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK095	7901675				2022-12-01	WOS:A1993MK09500003
J	SCOTT, RAP; WILSON, NM; ASHTON, HA; KAY, DN				SCOTT, RAP; WILSON, NM; ASHTON, HA; KAY, DN			IS SURGERY NECESSARY FOR ABDOMINAL AORTIC-ANEURYSM LESS-THAN 6 CM IN DIAMETER	LANCET			English	Note								During 8 years of an ultrasound screening programme for abdominal aortic aneurysm (AAA), 8944 people aged 65-80 years were scanned. 356 (4%) had AAA of diameter 3 cm or greater. Under our criteria repair was indicated if the aortic diameter reached 6 cm, if expansion reached 1 cm per year, or if the AAA caused symptoms; 124 patients met these criteria. Among the 8820 screened patients who did not meet the criteria, 1 death (0.4%) was attributed to ruptured aneurysm, although the retroperitoneal haematoma had developed within 5 days of surgery for a colon tumour. The risk of aortic rupture in patients with AAA less than 6 cm diameter with these criteria (0.4%) is lower than that for elective surgery (1-8%). Surgical repair is unnecessary and possibly detrimental in such patients, provided that ultrasound surveillance is undertaken.	ST RICHARDS HOSP,DEPT RADIOL,CHICHESTER PO19 4SE,W SUSSEX,ENGLAND		SCOTT, RAP (corresponding author), ST RICHARDS HOSP,SCOTT RES UNIT,SPITALFIELD LANE,CHICHESTER PO19 4SE,W SUSSEX,ENGLAND.							Campbell W B, 1991, Eur J Vasc Surg, V5, P111; COLLIN J, 1987, LANCET, V1, P909; COOLEY DA, 1984, CIRCULATION, V70, P1; DARLING RC, 1977, CIRCULATION, V56, P161; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; Johansson G, 1990, Eur J Vasc Surg, V4, P497, DOI 10.1016/S0950-821X(05)80791-1; SCOTT A, 1992, ANN ROY COLL SURG, V74, P205; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; TURK KAD, 1965, P ROY SOC MED, V58, P869, DOI 10.1177/003591576505811P109	10	64	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1395	1396		10.1016/0140-6736(93)92756-J	http://dx.doi.org/10.1016/0140-6736(93)92756-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901685				2022-12-01	WOS:A1993MK09500013
J	SPENCER, K; MALLARD, AS; COOMBES, EJ; MACRI, JN				SPENCER, K; MALLARD, AS; COOMBES, EJ; MACRI, JN			PRENATAL SCREENING FOR TRISOMY-18 WITH FREE BETA-HUMAN CHORIONIC-GONADOTROPIN AS A MARKER	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; MATERNAL SERUM; DOWNS-SYNDROME; CHROMOSOME-ABNORMALITIES; UNCONJUGATED ESTRIOL; HUMAN CHORIOGONADOTROPIN; PREGNANCY; AGE; RATES; RISK	Objective-To determine the relation between maternal serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations in pregnancies complicated by trisomy 18 and establish whether prenatal biochemical screening for this condition could be developed in a way similar to that proposed for trisomy 21. Design-Serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations in women with singleton pregnancies affected by cytogenetically confirmed trisomy 18, uncomplicated by neural tube defect or ventral wall defect, were identified from prospective trisomy 21 screening programmes. Additionally, stored maternal serum from similar pregnancies was analysed retrospectively. Analyte concentrations from singleton unaffected pregnancies were identified from a prospective screening programme as controls. Statistical parameters of the affected and unaffected populations were compiled. Setting-Biochemical screening laboratories in Britain and the United States. Subjects-52 women with singleton pregnancies complicated by trisomy 18; control population of 6661 women with unaffected singleton pregnancies. Main outcome measures-Median values of each analyte and their distribution in the affected and unaffected populations; detection rate of trisomy 18 and the false positive rate. Results-Maternal serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations were significantly lower in pregnancies complicated by trisomy 18 (median values 0.71 and 0.37 respectively). By using a multivariate risk algorithm incorporating maternal age risk of trisomy 18 and the concentration of the two biochemical markers it was predicted that 50% of trisomy 18 cases (unaffected by neural tube defect or ventral wall defect) could be detected with a 1% false positive rate. Conclusion-Second trimester biochemical screening for trisomy 18 could be a valuable addition to trisomy 21 screening programmes.	ROYAL CORNWALL HOSP,DEPT CLIN BIOCHEM,TRURO,CORNWALL,ENGLAND; QUEEN ALEXANDRA HOSP,DEPT CHEM PATHOL,PORTSMOUTH,HANTS,ENGLAND; NTD LABS INC,DIV RES,NEW YORK,NY 11514	Royal Cornwall Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	SPENCER, K (corresponding author), OLDCHURCH HOSP,DEPT CLIN BIOCHEM,ENDOCRINE UNIT,ROMFORD RM7 0BE,ESSEX,ENGLAND.							Aitken D. A., 1993, Clinical Chemistry, V39, P1170; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1990, PRENATAL DIAG, V10, P546, DOI 10.1002/pd.1970100813; CROSSLEY JA, 1991, PRENATAL DIAG, V11, P83, DOI 10.1002/pd.1970110204; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; DARNULE A, 1990, AM J HUM GENET S, V47, pA272; FERGUSONSMITH MA, 1984, PRENATAL DIAG, V4, P5, DOI 10.1002/pd.1970040704; GREENBERG F, 1992, AM J OBSTET GYNECOL, V166, P1388, DOI 10.1016/0002-9378(92)91610-M; HEYL PS, 1990, OBSTET GYNECOL, V76, P1025; HOOK EB, 1981, OBSTET GYNECOL, V58, P282; HOOK EB, 1983, AM J HUM GENET, V35, P110; LINDENBAUM RH, 1987, PRENATAL DIAG, V7, P511, DOI 10.1002/pd.1970070707; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, 1993, PRENATAL DIAG, V13, P557, DOI 10.1002/pd.1970130704; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; NORGAARDPEDERSEN B, 1990, CLIN GENET, V37, P35; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SPENCER K, 1985, BRIT MED J, V290, P1940, DOI 10.1136/bmj.290.6486.1940; SPENCER K, 1993, BRIT MED J, V307, P764, DOI 10.1136/bmj.307.6907.764; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1992, LANCET, V339, P1480, DOI 10.1016/0140-6736(92)92073-O; SPENCER K, 1992, BRIT MED J, V305, P769, DOI 10.1136/bmj.305.6856.769; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P349, DOI 10.1177/000456329202900319; STAPLES AJ, 1991, AM J HUM GENET, V49, P1025; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883	28	39	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1455	1458		10.1136/bmj.307.6917.1455	http://dx.doi.org/10.1136/bmj.307.6917.1455			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	7506599	Bronze, Green Published			2022-12-01	WOS:A1993MK79700021
J	WILDEN, JN				WILDEN, JN			RAPID RESUSCITATION IN SEVERE HEAD-INJURY	LANCET			English	Editorial Material											WILDEN, JN (corresponding author), ROYAL LONDON HOSP,DEPT NEUROSURG,LONDON,ENGLAND.							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KONG DL, 1991, CRIT CARE MED, V19, P532, DOI 10.1097/00003246-199104000-00013; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1378	1378		10.1016/0140-6736(93)92750-N	http://dx.doi.org/10.1016/0140-6736(93)92750-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901679				2022-12-01	WOS:A1993MK09500007
J	ARIDOR, M; RAJMILEVICH, G; BEAVEN, MA; SAGIEISENBERG, R				ARIDOR, M; RAJMILEVICH, G; BEAVEN, MA; SAGIEISENBERG, R			ACTIVATION OF EXOCYTOSIS BY THE HETEROTRIMERIC-G PROTEIN-G(I3)	SCIENCE			English	Article							RAT MAST-CELLS; GTP-BINDING PROTEINS; SYNTHETIC PEPTIDES; ALPHA-SUBUNIT; SUBSTANCE-P; MASTOPARAN; IDENTIFICATION; NUCLEOTIDE; SECRETION; MEMBRANES	Secretagogues of rat peritoneal mast cells, such as mastoparan and compound 48/80, induce mast cell exocytosis by activating directly the guanosine triphosphate-binding proteins that are required for exocytosis. The introduction of a synthetic peptide that corresponds to the carboxyl-terminal end sequence of Galpha(i3) into the cells specifically blocked this secretion. Similar results were obtained when antibodies to this peptide were introduced. The Galpha(i3) was located in both the Golgi and the plasma membrane, but only the latter source of Galpha(i3) appeared to be essential for secretion. These results indicate that Galpha(i3) functions to control regulated exocytosis in mast cells.	NHLBI,CHEM PHARMACOL LAB,BLDG 10,ROOM 8H108,BETHESDA,MD 20892; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Weizmann Institute of Science								ARIDOR M, 1990, J CELL BIOL, V111, P2885, DOI 10.1083/jcb.111.6.2885; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; ARIDOR M, UNPUB; BARSAGI D, 1988, ONCOGENE, V3, P463; BUEB JL, 1990, MOL PHARMACOL, V38, P816; CERIONE RA, 1988, J BIOL CHEM, V262, P14683; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; KAHN RA, 1991, J BIOL CHEM, V266, P15595; LILLIE THW, 1992, BIOCHEM J, V288, P181, DOI 10.1042/bj2880181; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; MOUSLI M, 1990, IMMUNOL LETT, V25, P355, DOI 10.1016/0165-2478(90)90207-7; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; ORTNER MJ, 1981, BIOCHEM PHARMACOL, V30, P283, DOI 10.1016/0006-2952(81)90055-1; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P113; TRAUB LM, 1991, J BIOL CHEM, V266, P24642	27	230	236	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1569	1572		10.1126/science.7504324	http://dx.doi.org/10.1126/science.7504324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	7504324				2022-12-01	WOS:A1993MK32900040
J	BONNI, A; FRANK, DA; SCHINDLER, C; GREENBERG, ME				BONNI, A; FRANK, DA; SCHINDLER, C; GREENBERG, ME			CHARACTERIZATION OF A PATHWAY FOR CILIARY NEUROTROPHIC FACTOR SIGNALING TO THE NUCLEUS	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; PROTEIN-TYROSINE KINASES; C-FOS PROMOTER; TRANSCRIPTION FACTOR; CYTOPLASMIC ACTIVATION; BINDING PROTEIN; FACTOR PREVENTS; FACTOR RECEPTOR; MOTOR NEURONS; IFN-GAMMA	Components of a signaling pathway that couples the ciliary neurotrophic factor (CNTF) receptor to induction of transcription were identified. CNTF stimulated the tyrosine phosphorylation of p91, a protein implicated in interferon signaling pathways, and of two proteins that are distinct but related to p91. Tyrosine-phosphorylated p91 translocated to the nucleus, where p91 and p91-related proteins bound to a DNA sequence found in promoters of genes responsive to CNTF. This DNA sequence, when inserted upstream of a reporter gene, conferred a transcriptional response to CNTF. A pathway that transduces interferon signals may therefore have a more general function in the propagation of responses to certain neurotrophic factors.	HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Columbia University					NCI NIH HHS [R01 CA43855] Funding Source: Medline; NHLBI NIH HHS [HL21006-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BONNI A, UNPUB; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LARNER AC, 1993, IN PRESS SCIENCE, V261, P1730; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PINE R, IN PRESS TRENDS BIOC; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, IN PRESS SCIENCE; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	57	178	181	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1575	1579		10.1126/science.7504325	http://dx.doi.org/10.1126/science.7504325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	7504325				2022-12-01	WOS:A1993MK32900042
J	KAMOGAWA, Y; MINASI, LAE; CARDING, SR; BOTTOMLY, K; FLAVELL, RA				KAMOGAWA, Y; MINASI, LAE; CARDING, SR; BOTTOMLY, K; FLAVELL, RA			THE RELATIONSHIP OF IL-4-PRODUCING AND IFN-GAMMA-PRODUCING T-CELLS STUDIED BY LINEAGE ABLATION OF IL-4-PRODUCING CELLS	CELL			English	Article							STIMULATORY FACTOR-I; SIMPLEX VIRUS TYPE-1; EXPRESSES B-CELL; MONOCLONAL-ANTIBODY; THYMIDINE KINASE; MESSENGER-RNA; TH2 CLONES; IL-4; INTERLEUKIN-4; MICE	Subsets of CD4 T cells are defined by the cytokines that they produce; these cytokines determine the effector function of these cells. Cloned CD4 T cells fall into two subsets, producing either interferon-gamma (IFNgamma) or interleukin-4 (IL-4) in combination with other cytokines, and are called Th1 and Th2 cells, respectively. The lineage relationship between naive T cells and effector Th1- and Th2-type cells is unclear. We generated transgenic mice in which IL-4-producing cells express herpes simplex virus 1 thymidine kinase and are eliminated by ganciclovir (GANC). Activation of transgenic T cells in the presence of GANC eliminates IL-4 and IFNgamma production, showing that IL-4- and IFNgamma-producing cells express or have expressed IL-4. These results show that effector cells producing either IL-4 or IFNgamma have a common precursor, which expresses the IL-4 gene.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19106; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19106	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	KAMOGAWA, Y (corresponding author), YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510, USA.			Carding, Simon/0000-0002-2383-9701				ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BETZ M, 1990, J IMMUNOL, V145, P1046; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P1; Bottomly K, 1989, Semin Immunol, V1, P21; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CARDING SR, 1989, EUR J IMMUNOL, V19, P231, DOI 10.1002/eji.1830190203; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HENKEL G, 1992, J IMMUNOL, V149, P3239; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JONES B, 1983, EUR J IMMUNOL, V13, P678, DOI 10.1002/eji.1830130813; KILLAR L, 1987, J IMMUNOL, V138, P1674; KIM J, 1985, J EXP MED, V162, P188, DOI 10.1084/jem.162.1.188; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MINASI LAE, 1993, J EXP MED, V177, P1451, DOI 10.1084/jem.177.5.1451; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OTSUKA T, 1987, NUCLEIC ACIDS RES, V15, P333, DOI 10.1093/nar/15.1.333; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; POWERS GD, 1988, J IMMUNOL, V140, P3352; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SIDERAS P, 1988, P NATL ACAD SCI USA, V85, P218, DOI 10.1073/pnas.85.1.218; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; STOUT RD, 1989, J IMMUNOL, V142, P760; STREET NE, 1990, J IMMUNOL, V144, P1629; SUMMERS WC, 1977, J VIROL, V24, P314, DOI 10.1128/JVI.24.1.314-318.1977; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1988, J IMMUNOL, V141, P3445; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TITE JP, 1985, J IMMUNOL, V135, P25; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441	48	269	273	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					985	995		10.1016/0092-8674(93)90542-X	http://dx.doi.org/10.1016/0092-8674(93)90542-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	7902780	Bronze			2022-12-01	WOS:A1993MK96600018
J	RASSOULZADEGAN, M; PAQUISFLUCKLINGER, V; BERTINO, B; SAGE, J; JASIN, M; MIYAGAWA, K; VANHEYNINGEN, V; BESMER, P; CUZIN, F				RASSOULZADEGAN, M; PAQUISFLUCKLINGER, V; BERTINO, B; SAGE, J; JASIN, M; MIYAGAWA, K; VANHEYNINGEN, V; BESMER, P; CUZIN, F			TRANSMEIOTIC DIFFERENTIATION OF MALE GERM-CELLS IN CULTURE	CELL			English	Article							SEMINIFEROUS EPITHELIAL CYCLE; CYTOMETRIC DNA ANALYSIS; TUMOR GENE WT1; SERTOLI-CELL; TRANSGENIC MICE; MESSENGER-RNA; C-KIT; FLOW-CYTOMETRY; EXPRESSION; MOUSE	A cell culture system that supports the differentiation of male germ cells through meiosis is described. It takes advantage of the properties of a cell line, 15P-1, established from testicular cells of transgenic mice that express the large T protein of polyoma virus in the seminiferous epithelium. This line exhibits features characteristic of Sertoli cells, including transcription of the Wilms' tumor (WT1) and Steel genes. Cells of the 15P-1 type support the meiotic and postmeiotic differentiation in cocultures of diploid premeiotic germ cells into haploid spermatids expressing the protamine (Prm-1) gene. When cocultured with P-15-1 cells, testicular cells explanted from immature 9-day-old animals, before the onset of the first meiosis, generated tetrads of haploid cells with the morphology of round spermatids and initiated protamine transcription.	SLOAN KETTERING INST CANC RES, NEW YORK, NY 10021 USA; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2X4, SCOTLAND	Memorial Sloan Kettering Cancer Center; University of Edinburgh	RASSOULZADEGAN, M (corresponding author), UNIV NICE, INSERM, U273, F-06108 NICE 2, FRANCE.		van Heyningen, Veronica/B-8039-2008; Rassoulzadegan, Minoo/O-7939-2016; VAN HEYNINGEN, Veronica/GYE-0531-2022	van Heyningen, Veronica/0000-0003-0359-0141; 	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAUER TW, 1990, AM J CLIN PATHOL, V93, P322, DOI 10.1093/ajcp/93.3.322; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CASTELLON E, 1989, MOL CELL ENDOCRINOL, V64, P169, DOI 10.1016/0303-7207(89)90143-3; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; DJAKIEW D, 1988, BIOL REPROD, V39, P1193, DOI 10.1095/biolreprod39.5.1193; ERICKSONLAWRENCE M, 1991, MOL ENDOCRINOL, V5, P1789, DOI 10.1210/mend-5-12-1789; Fritz I. B., 1990, Biology of mammalian germ cell mutagenesis.., P19; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOETZ P, 1984, J CELL SCI, V65, P249; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; JASIN M, 1992, P NATL ACAD SCI USA, V89, P10681, DOI 10.1073/pnas.89.22.10681; JEGOU B, 1991, ANN NY ACAD SCI, V637, P340; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LACROIX M, 1981, BIOL REPROD, V25, P143, DOI 10.1095/biolreprod25.1.143; LEMAGUERESSE B, 1988, J ENDOCRINOL, V118, pR13, DOI 10.1677/joe.0.118R013; Leonard Davis G., 1986, BASIC METHODS MOL BI; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MURTI JR, 1992, MOL CELL BIOL, V12, P2545, DOI 10.1128/MCB.12.6.2545; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; PARVINEN M, 1986, INT REV CYTOL, V104, P115, DOI 10.1016/S0074-7696(08)61925-7; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; ROSSI P, 1991, BIOCHEM BIOPH RES CO, V176, P910, DOI 10.1016/S0006-291X(05)80272-4; Russell L, 1990, HISTOLOGICAL HISTOPA; RUSSELL LD, 1983, AM J ANAT, V167, P181, DOI 10.1002/aja.1001670204; SHULDINER AR, 1991, P NATL ACAD SCI USA, V88, P7679, DOI 10.1073/pnas.88.17.7679; SKINNER MK, 1985, P NATL ACAD SCI USA, V82, P114, DOI 10.1073/pnas.82.1.114; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; Steinberger A, 1975, Methods Enzymol, V39, P283; TOKUDA N, 1992, J UROLOGY, V147, P278, DOI 10.1016/S0022-5347(17)37213-0; TOPPARI J, 1985, J ANDROL, V6, P325; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702	36	140	145	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					997	1006		10.1016/0092-8674(93)90543-Y	http://dx.doi.org/10.1016/0092-8674(93)90543-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	7504588				2022-12-01	WOS:A1993MK96600019
J	PLOWMAN, GD; GREEN, JM; CULOUSCOU, JM; CARLTON, GW; ROTHWELL, VM; BUCKLEY, S				PLOWMAN, GD; GREEN, JM; CULOUSCOU, JM; CARLTON, GW; ROTHWELL, VM; BUCKLEY, S			HEREGULIN INDUCES TYROSINE PHOSPHORYLATION OF HER4/P180(ERBB4)	NATURE			English	Article							GROWTH-FACTOR; EGF RECEPTOR; P185ERBB2; CLONING	THE HER4/ERBB4 gene encodes a 180K transmembrane protein (HER4/p180erbB4) that is structurally related to the 185K product (HER2/p185erbB2) of the HER2/ERBB2 proto-oncogene1. A 45K heparin-binding glycoprotein (p45) has been characterized that specifically activates the intrinsic tyrosine kinase activity of HER4 (ref. 2). This HER4 ligand shares several features with the heregulin family of proteins, including molecular mass, ability to induce differentiation of breast cancer cells, activation of tyrosine phosphorylation in MDA-MB453 cells, and amino-terminal protein sequence. Heregulin exists as multiple isoforms and all are presumed to interact directly with HER2 (refs 3-6). We have used binding and phosphorylation studies with recombinant ligand on cell lines expressing recombinant receptors, and report here that heregulin, like p45, is a specific ligand for HER4. Furthermore, heregulin fails to induce phosphorylation of HER2 in the absence of HER4. These findings suggest that activation of the HER4 receptor is involved in signal transduction by heregulin.			PLOWMAN, GD (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		PLOWMAN, Greg D/E-2012-2011					CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	13	466	519	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					473	475		10.1038/366473a0	http://dx.doi.org/10.1038/366473a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	7902537				2022-12-01	WOS:A1993MK09800067
J	BURACK, JH; BARRETT, DC; STALL, RD; CHESNEY, MA; EKSTRAND, ML; COATES, TJ				BURACK, JH; BARRETT, DC; STALL, RD; CHESNEY, MA; EKSTRAND, ML; COATES, TJ			DEPRESSIVE SYMPTOMS AND CD4 LYMPHOCYTE DECLINE AMONG HIV-INFECTED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLOW-UP; AIDS; COHORT; HEALTH; RISK; MARKERS	Objective.-To investigate whether high levels of depressive symptomatology. at baseline predict more rapid decline of CD4 lymphocyte counts and progression of clinical disease in persons infected with the human immunodeficiency virus (HIV). Design.-Prospective cohort study with semiannual data collection waves and up to 66 months of follow-up. Setting.-Population-based probability sample of single men in areas of San Francisco with high case rates of the acquired immunodeficiency syndrome (AIDS). Subjects.-All 330 homosexual or bisexual men who by January 1985 had serological evidence of HIV infection but had not had an AIDS diagnosis. Analysis of CD4 lymphocyte change was performed for 277 subjects (83.9%) who had three or more CD4 lymphocyte counts recorded during the study period January 1985 through July 1990. Outcome Measures.-Depressive symptoms were assessed using the Center for Epidemiologic Studies-Depression scale (CES-D). All subjects were classified according to two indicators of depression: (1) as overall depressed using a cut point of 16 or higher on the complete CES-D, and (2) as affectively depressed using a cut point of more than 1 SD above the mean on a subscale of the CES-D measuring affective depression. Laboratory and symptom measures, antiretroviral use, demographics, and behavioral measures were also used. The primary outcome measure was the rate of change of the CD4 lymphocyte count. Secondary outcomes were AIDS-free survival and mortality. Results.-At baseline 65 subjects (19.7%) were classified as depressed on the overall scale and 53 (16.1%) were classified as depressed on the affective scale. The unadjusted mean rate of CD4 change was 38% greater for overall depressed subjects than for the overall nondepressed (-0.0812 vs -0.0588 x 10(9)/L [-81.2 vs -58.8/muL per year; P=.07) and 34% greater for affectively depressed subjects than for the affectively nondepressed (-0.0804 vs -0.0598 x 10(9)/L per year; P=.06). In hierarchical multivariate analysis controlling for antiretroviral use, symptoms, and other predictors, baseline overall depression was associated with an excess decline in CD4 count of -0.0285 x 10(9)/L per year (95% confidence interval, -0.0496 to -0.0073), and baseline affective depression was associated with an excess decline in CD4 count of -0.0236 x 10(9)/L per year (95% confidence interval, -0.0464 to -0.0008). Neither overall depression nor affective depression was significantly associated with earlier AIDS diagnosis or earlier mortality. Conclusions.-Overall depression and affective depression predicted a more rapid decline in CD4 lymphocyte counts; this association was not attributable to baseline physiological differences. While the mechanism of the association remains unknown and cannot be addressed directly by this study, the data suggest that it can be explained neither as simply a reflection of perceived somatic symptoms nor as the result of differences in recreational drug and alcohol use. Further study is necessary to determine whether treating depression can alter the course of HIV infection.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY ST,SUITE 600,SAN FRANCISCO,CA 94105; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline; PHS HHS [N01-A1-82515, N01-A1-32519] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASCHER MS, 1993, NATURE, V362, P103, DOI 10.1038/362103a0; BORNSTEIN RA, 1991, ARCH NEUROL-CHICAGO, V48, P704, DOI 10.1001/archneur.1991.00530190050015; COOKE M, 1991, APR C ADH AIDS CLIN; DEGRUTTOLA V, 1991, J AM STAT ASSOC, V86, P569, DOI 10.2307/2290384; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GLASER R, 1987, Brain Behavior and Immunity, V1, P107, DOI 10.1016/0889-1591(87)90013-4; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; HAYS RB, 1992, J CONSULT CLIN PSYCH, V60, P463, DOI 10.1037/0022-006X.60.3.463; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; HOPKINS A, 1990, BMDP STATISTICAL SOF, P769; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; KATZ MH, 1992, ANN INTERN MED, V117, P797, DOI 10.7326/0003-4819-117-9-797_1; KEMENY ME, IN PRESS NEUROPSYCHI; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PERSKY VW, 1987, PSYCHOSOM MED, V49, P435, DOI 10.1097/00006842-198709000-00001; PIAZZA T, 1989, 3 U CAL CAL SURV RES; RABKIN JG, 1993, HOSP COMMUNITY PSYCH, V44, P162; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; Solomon G F, 1989, Psychiatr Med, V7, P47; VALENTINE F T, 1990, AIDS (London), V4, pS201; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P1037; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1987, MMWR MORB MORTAL S2S, V36, P1	30	268	270	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2568	2573		10.1001/jama.270.21.2568	http://dx.doi.org/10.1001/jama.270.21.2568			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	7901433				2022-12-01	WOS:A1993MJ26600023
J	DURRINGTON, PN				DURRINGTON, PN			HOW HDL PROTECTS AGAINST ATHEROMA	LANCET			English	Editorial Material							CHOLESTERYL-ESTER TRANSFER; DENSITY-LIPOPROTEIN; MUTATION				DURRINGTON, PN (corresponding author), UNIV MANCHESTER, DEPT MED, MANCHESTER M13 9PL, LANCS, ENGLAND.							[Anonymous], 1991, LANCET, V338, P666; ASSMANN G, 1989, INT CONGR SER, V826, P51; BAGDADE JD, 1991, EUR J CLIN INVEST, V21, P161, DOI 10.1111/j.1365-2362.1991.tb01805.x; BHATNAGAR D, 1992, ATHEROSCLEROSIS, V92, P49, DOI 10.1016/0021-9150(92)90009-6; BREWER HB, 1984, CLIN METABOLIC ASPEC, P273; DEEB SS, 1990, AM J HUM GENET, V46, P822; FAGER G, 1981, ARTERIOSCLEROSIS, V1, P273, DOI 10.1161/01.ATV.1.4.273; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; NEARY R, 1991, ATHEROSCLEROSIS, V89, P35, DOI 10.1016/0021-9150(91)90005-N; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912	14	26	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1993	342	8883					1315	1316		10.1016/0140-6736(93)92243-M	http://dx.doi.org/10.1016/0140-6736(93)92243-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901633				2022-12-01	WOS:A1993MJ03900006
J	ETSUDA, H; MIZUNO, K; ARAKAWA, K; SATOMURA, K; SHIBUYA, T; ISOJIMA, K				ETSUDA, H; MIZUNO, K; ARAKAWA, K; SATOMURA, K; SHIBUYA, T; ISOJIMA, K			ANGIOSCOPY IN VARIANT ANGINA - CORONARY-ARTERY SPASM AND INTIMAL INJURY	LANCET			English	Article							ACETYLCHOLINE; INVIVO; PIGS; PATHOGENESIS; VASOSPASM	Studies in pigs and dogs show that intimal injury is related to coronary artery spasm; it is not known whether intimal injury is related to coronary artery spasm in human beings. We examined intima at the site of coronary artery spasm by percutaneous transluminal coronary angioscopy in 10 of 13 consecutive patients with variant angina. Coronary artery spasms occurred spontaneously or were induced by intracoronary acetylcholine (10-100 mug). Angioscopy showed intimal injuries (haemorrhage, flap, thrombus, or ulcer) in 4 of the 10. We suggest that intimal injury is related to coronary artery spasm in human beings.	NATL DEF MED COLL,DEPT INTERNAL MED 1,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN	National Defense Medical College - Japan								EGASHIRA K, 1986, CIRCULATION, V74, P826, DOI 10.1161/01.CIR.74.4.826; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GANZ P, 1985, AM J CARDIOL, V56, P11; GERRITY RG, 1977, AM J PATHOL, V89, P313; GERTZ SD, 1981, CIRCULATION, V63, P476, DOI 10.1161/01.CIR.63.3.476; KASKI JC, 1989, J AM COLL CARDIOL, V14, P1456, DOI 10.1016/0735-1097(89)90382-3; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MACALPIN RN, 1980, AM J CARDIOL, V46, P143, DOI 10.1016/0002-9149(80)90616-5; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5; MIZUNO K, 1991, LANCET, V337, P809, DOI 10.1016/0140-6736(91)92514-3; NAGASAWA K, 1989, CIRC RES, V65, P272, DOI 10.1161/01.RES.65.2.272; OKAMOTO Y, 1991, Japanese Circulation Journal, V55, P95; SHIMOKAWA H, 1983, SCIENCE, V221, P560, DOI 10.1126/science.6408736; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; YASUE H, 1986, CIRCULATION, V74, P955, DOI 10.1161/01.CIR.74.5.955	19	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1322	1324		10.1016/0140-6736(93)92245-O	http://dx.doi.org/10.1016/0140-6736(93)92245-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901635				2022-12-01	WOS:A1993MJ03900008
J	PARRY, ML; ROSENZWEIG, C				PARRY, ML; ROSENZWEIG, C			FOOD-SUPPLY AND RISK OF HUNGER	LANCET			English	Article									COLUMBIA UNIV,NEW YORK,NY 10027; GODDARD INST SPACE STUDIES,NEW YORK,NY 10025	Columbia University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	PARRY, ML (corresponding author), UNIV OXFORD,ENVIRONM CHANGE UNIT,1A MANSFIELD RD,OXFORD OX1 3TB,ENGLAND.							[Anonymous], 1992, CLIMATE CHANGE SUPPL; Peart R.M., 1989, POTENTIAL EFFECTS GL; ROSENZWEIG C, 1993, 3 ENV CHANG UN ENV C; ROSENZWEIG C, IN PRESS IMPLICATION; 1989, DECISION SUPPORT SYS	5	24	26	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1345	1347		10.1016/0140-6736(93)92251-N	http://dx.doi.org/10.1016/0140-6736(93)92251-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901640				2022-12-01	WOS:A1993MJ03900014
J	RITTER, K; KUHLENCORD, A; THOMSSEN, R; BOMMER, W				RITTER, K; KUHLENCORD, A; THOMSSEN, R; BOMMER, W			PROLONGED HEMOLYTIC-ANEMIA IN MALARIA AND AUTOANTIBODIES AGAINST TRIOSEPHOSPHATE ISOMERASE	LANCET			English	Note							PLASMODIUM-FALCIPARUM MALARIA; IGM ANTIBODIES; ANEMIA	Prolonged haemolysis may accompany infection with Plasmodium falciparum. We observed prolonged haemolysis in 4 of 10 patients with this type of malaria after parasitological cure. IgM antibodies specific for the glycolytic enzyme triosephosphate isomerase were detected in these patients' sera. Clinical recovery and a decrease in haemolysis coincided with a fall in these autoantibodies. In vitro, affinity purified autoantibodies isolated from the sera directed against triosephosphate isomerase induced lysis of erythrocytes and activation of complement as shown by the Cr-51 release assay. We assume that autoantibodies against triosephosphate isomerase contribute to the development of prolonged haemolysis and anaemia in P. falciparum malaria.	UNIV GOTTINGEN,DEPT TROP MED,D-37075 GOTTINGEN,GERMANY	University of Gottingen	RITTER, K (corresponding author), UNIV GOTTINGEN,ZENTRUM HYG & HUMANGENET,MED MIKROBIOL ABT,D-37075 GOTTINGEN,GERMANY.							Brown I. N., 1969, Adv. Immunol., V11, P267, DOI 10.1016/S0065-2776(08)60481-2; GEURS F, 1992, ACTA HAEMATOL-BASEL, V88, P142; RITTER K, 1991, J IMMUNOL METHODS, V137, P209, DOI 10.1016/0022-1759(91)90026-C; RITTER K, 1990, J EXP MED, V171, P565, DOI 10.1084/jem.171.2.565; ROSENBERG EB, 1973, AM J TROP MED HYG, V22, P146, DOI 10.4269/ajtmh.1973.22.146; ROSENBERG YJ, 1978, NATURE, V274, P170, DOI 10.1038/274170a0; ROSSI F, 1990, EUR J IMMUNOL, V20, P2089, DOI 10.1002/eji.1830200930; WEATHERALL DJ, 1982, BRIT MED BULL, V38, P147, DOI 10.1093/oxfordjournals.bmb.a071751; WEATHERALL DJ, 1983, CIBA F SYMP, V94, P74; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6	10	40	40	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1333	1334		10.1016/0140-6736(93)92248-R	http://dx.doi.org/10.1016/0140-6736(93)92248-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901638				2022-12-01	WOS:A1993MJ03900011
J	SHERMAN, DIN; WARD, RJ; WARRENPERRY, M; WILLIAMS, R; PETERS, TJ				SHERMAN, DIN; WARD, RJ; WARRENPERRY, M; WILLIAMS, R; PETERS, TJ			ASSOCIATION OF RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM IN ALCOHOL DEHYDROGENASE-2 GENE WITH ALCOHOL-INDUCED LIVER-DAMAGE	BRITISH MEDICAL JOURNAL			English	Article							ALDEHYDE DEHYDROGENASE; DISEASE; PREDISPOSITION; SENSITIVITY; CIRRHOSIS; GENOTYPES; WOMEN	Objective-To investigate the role of genetically determined differences in the enzymes of alcohol metabolism in susceptibility to liver damage from misusing alcohol. Design-Use of pADH36 probe to study PVU II restriction length fragment polymorphism in alcohol dehydrogenase 2 gene in white alcohol misusers and controls. Setting-Teaching hospital referral centres for fiver disease and alcohol misuse. Subjects-45 white alcohol misusers (38 with alcoholic liver disease) and 23 healthy controls. Main outcome measures-Alcohol misuse, the presence and severity of alcoholic liver disease, alcohol dependency, and family history of alcohol misuse. Results-A two allele polymorphism (A and B) was identified. In control subjects the allele frequencies were 85% for A and 15% for B compared with 37% and 63% respectively in alcohol misusers (p < 0.001). B allele was significantly associated with severe liver damage (p < 0.05) as well as alcohol dependency and family history of alcohol misuse compared with controls. Conclusion-Inherited variation in enzymes of ethanol metabolism may contribute to the pathogenesis of alcohol induced liver damage. This supports the presence of a genetic component in alcohol misuse.	KINGS COLL,SCH MED & DENT,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	SHERMAN, DIN (corresponding author), KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND.			Ward, Roberta J/0000-0002-5671-784X; opoku, anita/0000-0001-7243-8157				AGARWAL D, PHARMACOL THERAPEUT, V45, P69; BOHMAN M, 1981, ARCH GEN PSYCHIAT, V38, P965; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; CLONINGER CR, 1990, BANB REPORT, V33, P105; COLLINS MA, 1979, SCIENCE, V206, P1184, DOI 10.1126/science.505002; COUZIGOU P, 1990, ALCOHOL ALCOHOLISM, V25, P623, DOI 10.1093/oxfordjournals.alcalc.a045058; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; DAY CP, 1991, HEPATOLOGY, V14, P798, DOI 10.1002/hep.1840140509; DUESTER G, 1986, J BIOL CHEM, V261, P2027; ENOMOTO N, 1991, HEPATOLOGY, V13, P1071, DOI 10.1002/hep.1840130611; GOEDDE HW, 1987, ENZYME, V37, P29, DOI 10.1159/000469239; HITTLE JB, 1988, J LAB CLIN MED, V112, P7; HRUBEC Z, 1981, ALCOHOL CLIN EXP RES, V5, P207, DOI 10.1111/j.1530-0277.1981.tb04890.x; Lelbach W K, 1976, Prog Liver Dis, V5, P494; MARTIN NG, 1985, BEHAV GENET, V15, P93, DOI 10.1007/BF01065891; Peters T J, 1987, Prog Clin Biol Res, V241, P215; SAUNDERS JB, 1981, BMJ-BRIT MED J, V282, P1140, DOI 10.1136/bmj.282.6270.1140; SHIBUYA A, 1988, AM J HUM GENET, V43, P744; SMITH M, 1986, ADV HUM GENET, V15, P249; SORRELL MF, 1985, ALCOHOL CLIN EXP RES, V9, P306, DOI 10.1111/j.1530-0277.1985.tb05549.x; 1987, GREAT GROWING EVIL M	22	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1388	1390		10.1136/bmj.307.6916.1388	http://dx.doi.org/10.1136/bmj.307.6916.1388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	7903883	Green Published, Bronze			2022-12-01	WOS:A1993MK42000019
J	ZIEGLER, JL				ZIEGLER, JL			ENDEMIC KAPOSIS-SARCOMA IN AFRICA AND LOCAL VOLCANIC SOILS	LANCET			English	Article							ELEPHANTIASIS; PATHOGENESIS; UGANDA; AIDS	Endemic Kaposi's sarcoma (KS) in Africa has been attributed to a geographically-determined environmental factor. Endemic KS, a chronic nodular condition predominantly affecting the feet and legs, is believed to arise in the lymphatic endothelium and is associated with chronic lymphoedema. As such, KS bears a resemblance to podoconiosis (non-filarial elephantiasis). The prevalence of both conditions in highland areas close to volcanoes suggests a shared pathogenetic relationship to exposure to volcanic soils. The lymphatics and lymph nodes of patients with podoconiosis contain particulate alumino-silicates in macrophages consistent with the theory that ultrafine clay minerals are absorbed through the feet. The resulting chronic lymphatic irritation, inflammation, and collagenosis causes obstruction and lymphoedema. The geographical proximity of endemic KS to areas containing volcanic clay minerals, its lympho-endothelial origin, predilection for the feet and legs, and its prevalence among rural peasants and cultivators, suggest a common aetiology. Other features point to the participation of a low-grade, possibly sexually-transmitted, infective agent that becomes more pathogenic in the presence of immunosuppression. Damage to the dermal lymphatics of the feet and legs by absorbed clays could impair local immunity to such an agent. Endemic KS would then occur in exposed individuals who harbour the KS infective agent and are susceptible to the KS phenotype (males).	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								ALLISON AC, 1966, J EXP MED, V124, P141, DOI 10.1084/jem.124.2.141; BAYLEY AC, 1991, CANCER SURV, V10, P53; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BLAND JM, 1977, E AFR J MED RES, V4, P47; BRONSON DM, 1988, KAPOSIS SARCOMA TEXT, P24; BRYCESON AD, 1970, T ROY SOC TROP MED H, V64, P380, DOI 10.1016/0035-9203(70)90174-4; COLLEY MH, 1989, AM J SURG PATHOL, V13, P803, DOI 10.1097/00000478-198909000-00011; DESMONDHELLMANN SD, 1991, J ACQ IMMUN DEF SYND, V4, P647; DIGIOVANNA JJ, 1981, AM J MED, V71, P779, DOI 10.1016/0002-9343(81)90364-8; DORFMAN RF, 1988, KAPOSIS SARCOMA PATH, P71; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; FYFE NCM, 1985, T ROY SOC TROP MED H, V79, P645, DOI 10.1016/0035-9203(85)90180-4; GAAFAR S, 1969, J PATHOL, V100, P9; GIGASE PL, 1986, VIRUS ASS CANCERS AF, P549; HUTT MSR, 1984, BRIT MED BULL, V40, P355, DOI 10.1093/oxfordjournals.bmb.a072004; KALENGAYI NMR, 1986, VIRUS ASS CANCERS AF, P559; KENNEDY TP, 1989, ARCH BIOCHEM BIOPHYS, V269, P359, DOI 10.1016/0003-9861(89)90118-5; KESTENS L, 1985, INT J CANCER, V36, P49, DOI 10.1002/ijc.2910360109; Kungu A, 1981, Antibiot Chemother (1971), V29, P38; OTU AA, 1986, J ROY SOC MED, V79, P510, DOI 10.1177/014107688607900905; PETERMAN TA, 1991, CANCER SURV, V10, P23; PRICE EW, 1972, T ROY SOC TROP MED H, V66, P150, DOI 10.1016/0035-9203(72)90063-6; PRICE EW, 1976, T ROY SOC TROP MED H, V70, P288, DOI 10.1016/0035-9203(76)90078-X; Price EW, 1990, PODOCONIOSIS NONFILA; SCHMID H, 1973, TROP GEOGR MED, V25, P266; TAYLOR JF, 1972, BRIT J CANCER, V26, P483, DOI 10.1038/bjc.1972.66; TAYLOR JF, 1971, INT J CANCER, V8, P122, DOI 10.1002/ijc.2910080116; Templeton A C, 1981, Pathol Annu, V16, P315; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WILSON M, 1993, IGNEOUS PETROGENESIS, P549	31	111	112	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1348	1351		10.1016/0140-6736(93)92252-O	http://dx.doi.org/10.1016/0140-6736(93)92252-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901641				2022-12-01	WOS:A1993MJ03900015
J	ASCH, AS; LIU, I; BRICCETTI, FM; BARNWELL, JW; KWAKYEBERKO, F; DOKUN, A; GOLDBERGER, J; PERNAMBUCO, M				ASCH, AS; LIU, I; BRICCETTI, FM; BARNWELL, JW; KWAKYEBERKO, F; DOKUN, A; GOLDBERGER, J; PERNAMBUCO, M			ANALYSIS OF CD36 BINDING DOMAINS - LIGAND SPECIFICITY CONTROLLED BY DEPHOSPHORYLATION OF AN ECTODOMAIN	SCIENCE			English	Article							PLATELET MEMBRANE GLYCOPROTEIN; FALCIPARUM-INFECTED ERYTHROCYTES; CIRCUMSPOROZOITE PROTEIN; IIB-IIIA; IV CD36; THROMBOSPONDIN; RECEPTOR; COLLAGEN; PHOSPHORYLATION; ADHESION	The protein CD36 is a membrane receptor for thrombospondin (TSP), malaria-infected erythrocytes, and collagen. Three functional sequences were identified within a single disulfide loop of CD36: one that mediates TSP binding (amino acids 87 to 99) and two that support malarial cytoadhesion (amino acids 8 to 21 and 97 to 110). One of these peptides (p87-99) is a consensus protein kinase C (PKC) phosphorylation site. Dephosphorylation of constitutively phosphorylated CD36 in resting platelets and a megakaryocytic cell line led to the loss of collagen adhesion and platelet reactivity to collagen, with a reciprocal increase in TSP binding. PKC-mediated phosphorylation of this ectodomain resulted in a loss of TSP binding and the reciprocal acquisition of collagen binding. In site-directed mutagenesis studies, when the threonine phosphorylation site was changed to alanine, CD36 was expressed in a dephosphorylated state and bound to TSP constitutively.	NYU,SCH MED,DEPT MOLEC PARASITOL,NEW YORK,NY 10010	New York University	ASCH, AS (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL44389, HL02541, HL18828] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018828, R01HL044389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH A, UNPUB; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; ERDODI F, 1992, ARCH BIOCHEM BIOPHYS, V298, P682, DOI 10.1016/0003-9861(92)90466-A; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GREENBERG SM, 1988, BLOOD, V72, P1968; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KEHREL B, 1988, BLOOD, V71, P1074; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; Legrand C, 1991, Platelets, V2, P99, DOI 10.3109/09537109109113695; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; MARCUS AJ, 1966, J CLIN INVEST, V45, P14, DOI 10.1172/JCI105318; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; STOMSKI FC, 1992, EXP CELL RES, V198, P85, DOI 10.1016/0014-4827(92)90152-X; TANDON NN, 1989, J BIOL CHEM, V264, P7576; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	31	182	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1436	1440		10.1126/science.7504322	http://dx.doi.org/10.1126/science.7504322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	7504322				2022-12-01	WOS:A1993MJ04600038
J	MARTIN, GB; BROMMONSCHENKEL, SH; CHUNWONGSE, J; FRARY, A; GANAL, MW; SPIVEY, R; WU, TY; EARLE, ED; TANKSLEY, SD				MARTIN, GB; BROMMONSCHENKEL, SH; CHUNWONGSE, J; FRARY, A; GANAL, MW; SPIVEY, R; WU, TY; EARLE, ED; TANKSLEY, SD			MAP-BASED CLONING OF A PROTEIN-KINASE GENE CONFERRING DISEASE RESISTANCE IN TOMATO	SCIENCE			English	Article							CLONED AVIRULENCE GENES; SYRINGAE PV GLYCINEA; VIRULENCE DETERMINANT; CONSERVED FEATURES; BRASSICA-OLERACEA; RAF ONCOGENE; IDENTIFICATION; LOCUS; SEQUENCE; INCOMPATIBILITY	The Pto gene in tomato confers resistance to races of Pseudomonas syringae pv. tomato that carry the avirulence gene avrPto. A yeast artificial chromosome clone that spans the Pto region was identified and used to probe a leaf complementary DNA (cDNA) library. A cDNA clone was isolated that represents a gene family, at least six members of which genetically cosegregate with Pto. When susceptible tomato plants were transformed with a cDNA from this family, they were resistant to the pathogen. Analysis of the amino acid sequence revealed similarity to serine-threonine protein kinases, suggesting a role for Pto in a signal transduction pathway.	CORNELL UNIV, DEPT PLANT BREEDING & BIOMETRY, ITHACA, NY 14853 USA	Cornell University			Frary, Anne/A-5417-2015; Brommonschenkel, Sergio/C-5748-2013; Martin, Gregory B/F-6262-2011	Frary, Anne/0000-0002-8973-0100; Martin, Gregory B/0000-0003-0044-6830				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arumuganathan K., 1991, PLANT MOL BIOL REP, V9, P229, DOI [10.1007/BF02672073, DOI 10.1007/BF02672073]; BENNETZEN JL, 1992, PLANT MOL BIOL, V20, P575, DOI 10.1007/BF00046442; BERNATZKY R, 1986, GENETICS, V112, P887; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CHUNWONGSE J, UNPUB; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DICKINSON MJ, 1993, MOL PLANT MICROBE IN, V6, P341, DOI 10.1094/MPMI-6-341; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FRARY A, UNPUB; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GABRIEL DW, 1986, P NATL ACAD SCI USA, V83, P6415, DOI 10.1073/pnas.83.17.6415; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HULBERT SH, 1985, THEOR APPL GENET, V70, P520, DOI 10.1007/BF00305985; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KING EO, 1954, J LAB CLIN MED, V44, P301; KOBAYASHI DY, 1989, P NATL ACAD SCI USA, V86, P157, DOI 10.1073/pnas.86.1.157; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MARTIN G, UNPUB; MARTIN GB, 1991, P NATL ACAD SCI USA, V88, P2336, DOI 10.1073/pnas.88.6.2336; MARTIN GB, 1992, MOL GEN GENET, V233, P25, DOI 10.1007/BF00587557; MARTIN GB, 1993, MOL PLANT MICROBE IN, V6, P26, DOI 10.1094/MPMI-6-026; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MESHI T, 1989, PLANT CELL, V1, P515, DOI 10.1105/tpc.1.5.515; MESSEGUER R, 1991, THEOR APPL GENET, V82, P529, DOI 10.1007/BF00226787; OCHMAN H, 1988, GENETICS, V120, P621; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SARFATTI M, 1989, THEOR APPL GENET, V78, P755, DOI 10.1007/BF00262574; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; TANKSLEY SD, 1992, GENETICS, V132, P1141; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; Watterson J.C., 1986, TOMATO CROP SCI BASI, P443; ZAMIR D, 1988, MOL GEN GENET, V213, P254, DOI 10.1007/BF00339589	55	1080	1261	5	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1993	262	5138					1432	1436		10.1126/science.7902614	http://dx.doi.org/10.1126/science.7902614			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	7902614				2022-12-01	WOS:A1993MJ04600037
J	BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA				BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA			REVERSAL BY SHORT-CHAIN FATTY-ACIDS OF COLONIC FLUID SECRETION INDUCED BY ENTERAL FEEDING	LANCET			English	Article							ABSORPTION; DIET; NUTRITION; INTESTINE; DIARRHEA; RAT	Diarrhoea complicates enteral feeding in up to 25% of patients. In-vivo perfusion studies in healthy subjects have shown secretion of salt and water in the ascending colon in response to enteral feeding. This study investigated the effect of short-chain fatty acids (SCFA) on this secretory response. Six healthy volunteers underwent segmental in-vivo colonic perfusion. First, baseline fasting colonic water and electrolyte movement was established, then a standard polymeric enteral diet was infused into the stomach while the colon was perfused with either a control electrolyte solution or a test solution containing SCFA. The electrolyte concentrations and osmolality of the two perfusates were identical. In the fasting state water was absorbed throughout the colon. During the control infusion there was significant (p < 0.05) secretion of water in the ascending colon (median rate 1.0 mL per min [95% CI 2.8 mL per min secretion to 0.8 mL per min absorption]). During the SCFA infusion the secretion was significantly reversed (p < 0.05) and there was net absorption (1.6 [0.8-3.7] mL per min). In the distal colon water absorption was significantly greater during the control infusion than during fasting (3.7 [2.5-4.6] vs 1.3 [0.3-2.2] mL per min); during the test infusion this absorption persisted (2.8 [1.3-3.6] mL per min). Movement of sodium, chloride, and potassium ions was similar to that of water in all stages of the study. Bicarbonate movement did not significantly change at any stage. Infusion of SCFA directly into the caecum reverses the fluid secretion seen in the ascending colon during enteral feeding. This finding could have implications for the management of diarrhoea related to enteral feeding.			SILK, DBA (corresponding author), CENT MIDDLESEX HOSP TRUST,DEPT GASTROENTEROL & NUTR,LONDON NW10 7NS,ENGLAND.							BINDER HJ, 1989, GASTROENTEROLOGY, V96, P989, DOI 10.1016/0016-5085(89)91614-4; BOWLING TE, 1993, EUR J GASTROEN HEPAT, V5, P809; BOWLING TE, 1993, GUT               S1, V34, pA54; BOWLING TE, 1993, CLIN NUTR S2, V12, P23; CUMMINGS JH, 1984, SCAND J GASTROENTERO, V19, P89; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DEVROEDE GJ, 1969, GASTROENTEROLOGY, V56, P92; DOBB GJ, 1986, INTENS CARE MED, V12, P113; FORD EG, 1987, J PEDIATR SURG, V22, P597, DOI 10.1016/S0022-3468(87)80106-9; JACOBS LR, 1983, AM J CLIN NUTR, V37, P954, DOI 10.1093/ajcn/37.6.954; JONES BJM, 1983, GUT, V24, P78, DOI 10.1136/gut.24.1.78; KEOHANE PP, 1984, BMJ-BRIT MED J, V288, P678, DOI 10.1136/bmj.288.6418.678; Kritchevsky D., 1986, DIETARY FIBER, P131, DOI DOI 10.1007/978-1-4613-2111-8_10; LEVITAN R, 1962, J CLIN INVEST, V41, P1754, DOI 10.1172/JCI104634; MACFARLANE GT, 1992, J APPL BACTERIOL, V72, P57, DOI 10.1111/j.1365-2672.1992.tb04882.x; OKEEFE SJD, 1984, GUT, V25, P942, DOI 10.1136/gut.25.9.942; PHILLIPS SF, 1973, J LAB CLIN MED, V81, P733; RAIMUNDO AH, 1988, GUT, V29, pA1469; RAIMUNDO AH, 1990, GUT, V31, pA1195; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; SILK DBA, 1987, CLIN NUTR, V6, P61, DOI 10.1016/0261-5614(87)90023-9; WAITZBERG D, 1988, CLIN NUTR S1, V7, P58; WHALEN GE, 1966, GASTROENTEROLOGY, V51, P975	24	97	99	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1266	1268		10.1016/0140-6736(93)92360-6	http://dx.doi.org/10.1016/0140-6736(93)92360-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901584				2022-12-01	WOS:A1993MH56600010
J	EKBOM, A; HSIEH, CC; YUEN, J; TRICHOPOULOS, D; MCLAUGHLIN, J; LAN, SJ; ADAMI, HO				EKBOM, A; HSIEH, CC; YUEN, J; TRICHOPOULOS, D; MCLAUGHLIN, J; LAN, SJ; ADAMI, HO			RISK OF EXTRAHEPATIC BILEDUCT CANCER AFTER CHOLECYSTECTOMY	LANCET			English	Article							SCLEROSING CHOLANGITIS; ULCERATIVE-COLITIS; CARCINOMA; CHOLANGIOCARCINOMA; CYSTS	The aetiology of cancer of the extrahepatic bile duct is unknown. Gallstones have been proposed to be a risk factor on the basis of ecological and epidemiological evidence. As gallstones are formed in the gallbladder, the occurrence of extrahepatic bileduct cancer in patients after cholecystectomy is of interest. All patients (62 734) who had had a cholecystectomy during 1965-1983 within the Uppsala Health Care Region, Sweden, were followed up to the end of 1987. Excluding the first year of follow-up, 23 cancers of the extrahepatic bileduct occurred vs 26.3 expected for a standardised incidence ratio (SIR) of 0.88 (95% confidence interval [CI] 0.56-1.31). 10 years or more after operation there was a greater reduction of risk (SIR = 0.27; 95% CI 0.06-0.80). Similar patterns were observed for men and women, and among patients who had undergone cholecystectomy only compared with those who had had their common bileducts explored. To assess surveillance bias the incidence of primary liver cancer was also analysed: SIR = 1.15; 95% CI 0.91-1.44 overall, and 10 years or more after cholecystectomy SIR = 0.98; 95% CI 0.66-1.40. This study shows a reduced risk of extrahepatic bileduct cancer 10 or more years after cholecystectomy, indicating that gallstones may be a cause of this cancer.	NCI,BIOSTAT BRANCH,BETHESDA,MD 20892; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	EKBOM, A (corresponding author), UNIV HOSP UPPSALA,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN.		Yuen, Jonathan/AAI-2035-2021	Yuen, Jonathan/0000-0003-2944-9226	NATIONAL CANCER INSTITUTE [R01CA044683] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1CA44683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILAR JC, 1964, BIOMETRICS, V20, P639; BRETT M, 1976, INT J EPIDEMIOL, V5, P335, DOI 10.1093/ije/5.4.335; CARBONI M, 1986, SCAND J GASTROENTERO, V21, P461, DOI 10.3109/00365528609015163; CETTA F, 1991, ANN SURG, V213, P315, DOI 10.1097/00000658-199104000-00006; DAY NE, 1984, IARC SCI PUBL, V56, P339; DONALDSON DR, 1975, BR J CLIN PRACT, V33, P297; Drinka P, 1985, Wis Med J, V84, P16; EKBOM A, 1993, GASTROENTEROLOGY, V105, P142, DOI 10.1016/0016-5085(93)90019-9; FLANIGAN DP, 1977, CANCER-AM CANCER SOC, V40, P880, DOI 10.1002/1097-0142(197708)40:2<880::AID-CNCR2820400242>3.0.CO;2-X; FRAUMENI JF, 1982, CANCER EPIDEMIOL, P683; GLENN F, 1974, ANN SURG, V179, P528, DOI 10.1097/00000658-197405000-00003; HERBA MJ, 1986, AM J ROENTGENOL, V147, P513, DOI 10.2214/ajr.147.3.513; JARHULT J, 1981, ACTA CHIR SCAND, V147, P147; KATO K, 1989, JPN J CANCER RES, V80, P932, DOI 10.1111/j.1349-7006.1989.tb01629.x; LEBORGNE J, 1984, ANN CHIR, V38, P369; MIRMADJLESSI SH, 1987, DIGEST DIS SCI, V32, P145, DOI 10.1007/BF01297102; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; ROBBINS S, 1988, AM J GASTROENTEROL, V83, P675; ROSSI RL, 1987, ANN SURG, V205, P377, DOI 10.1097/00000658-198704000-00006; SCHWARTZ DA, 1986, AM J GASTROENTEROL, V81, P76; SRIVATANAKUL P, 1991, INT J CANCER, V48, P821, DOI 10.1002/ijc.2910480606; TODANI T, 1979, CANCER-AM CANCER SOC, V44, P1134, DOI 10.1002/1097-0142(197909)44:3<1134::AID-CNCR2820440350>3.0.CO;2-T; WARREN KW, 1987, DISEASES LIVER, P1289; WEE A, 1985, HUM PATHOL, V16, P719, DOI 10.1016/S0046-8177(85)80158-1; WELTON JC, 1979, LANCET, V1, P791; YEN S, 1987, CANCER, V59, P2112, DOI 10.1002/1097-0142(19870615)59:12<2112::AID-CNCR2820591226>3.0.CO;2-H; 1991, CANCER INCIDENCE SWE	27	45	47	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1262	1265		10.1016/0140-6736(93)92359-2	http://dx.doi.org/10.1016/0140-6736(93)92359-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901583				2022-12-01	WOS:A1993MH56600009
J	FREIER, JE				FREIER, JE			EASTERN EQUINE ENCEPHALOMYELITIS	LANCET			English	Article											FREIER, JE (corresponding author), USDA,CTR EPIDEMIOL & ANIM HLTH,ANIM & PLANT HLTH INSPECT SERV,VET SERV,555 S HOWES ST,FT COLLINS,CO 80525, USA.							CRANS WJ, 1977, MOSQ NEWS, V37, P85; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; SCHWARZ D, 1985, SURVEILLANT SCI REMO, P53; TSAI TF, 1987, TXB PEDIATRIC INFECT, V2, P1417	4	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1281	1282		10.1016/0140-6736(93)92366-2	http://dx.doi.org/10.1016/0140-6736(93)92366-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7695660				2022-12-01	WOS:A1993MH56600016
J	GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH				GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH			GENERATION OF ACTIVATED PROTEIN-C DURING THROMBOLYSIS	LANCET			English	Note								The observation that urokinase infusion increases circulating levels of the anticoagulant activated protein C (APC) in baboons implies that APC might be elevated during thrombolytic therapy. Patients undergoing coronary thrombolysis showed an 11-fold increase (means from 6 to 69 mug/L) in APC during infusion of streptokinase. Thrombolytic therapy thus generates at least two potent antithrombotic factors in the circulation-the fibrinolytic enzyme, plasmin, and the anticoagulant enzyme, APC. APC may help prevent reocclusion during or after thrombolysis.	Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY	Scripps Research Institute				Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANSON HE, 1983, LANCET, V2, P1165; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; EISENBERG PR, 1987, J AM COLL CARDIOL, V10, P527, DOI 10.1016/S0735-1097(87)80194-8; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESPANA F, 1991, BLOOD, V77, P1754; GEIGER M, 1989, THROMB HAEMOSTASIS, V61, P86; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; VARADI K, 1992, CIRCULATION, V86, pA736	10	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1275	1276		10.1016/0140-6736(93)92364-Y	http://dx.doi.org/10.1016/0140-6736(93)92364-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901587				2022-12-01	WOS:A1993MH56600014
J	HOHMANN, AW; BOOTH, K; PETERS, V; GORDON, DL; COMACCHIO, RM				HOHMANN, AW; BOOTH, K; PETERS, V; GORDON, DL; COMACCHIO, RM			COMMON EPITOPE ON HIV P24 AND HUMAN PLATELETS	LANCET			English	Note							IMMUNE THROMBOCYTOPENIC PURPURA; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; GLYCOPROTEINS; DISEASE	Mimicry of human antigen by HIV may underlie the autoreactivity seen in AIDS. A mouse monoclonal antibody (VIC8) raised against HIV p24 cross-reacted with human platelets; binding could be abolished by recombinant p24 antigen. VIC8 bound less well to platelets from patients with HIV than to those from healthy individuals. In the HIV group, binding was not related to p24 antigenaemia, disease stage, or platelet counts. This cross-reactivity is another example of antigenic mimicry by HIV and may be mechanistically important in HIV-associated autoimmune-like thrombocytopenia.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT CLIN IMMUNOL,BEDFORD PK,SA 5042,AUSTRALIA; FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT MICROBIOL & INFECT DIS,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia; Flinders University South Australia				Gordon, David/0000-0003-3276-9685				BALLEM PJ, 1992, NEW ENGL J MED, V327, P1779, DOI 10.1056/NEJM199212173272503; BETTAIEB A, 1992, BLOOD, V80, P162; DEKEYSER F, 1992, CLIN IMMUNOL IMMUNOP, V62, P285, DOI 10.1016/0090-1229(92)90104-V; LOUACHE F, 1991, BLOOD, V78, P1697; MORROW WJW, 1991, CLIN IMMUNOL IMMUNOP, V58, P163, DOI 10.1016/0090-1229(91)90134-V; QUADRI MI, 1992, CLIN LAB HAEMATOL, V14, P109; STRICKER RB, 1991, HEMATOL ONCOL CLIN N, V5, P249, DOI 10.1016/S0889-8588(18)30439-8; ZAULI G, 1991, AIDS, V5, P1345, DOI 10.1097/00002030-199111000-00010	8	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1274	1275		10.1016/0140-6736(93)92363-X	http://dx.doi.org/10.1016/0140-6736(93)92363-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7694021				2022-12-01	WOS:A1993MH56600013
J	MCCARTHY, M				MCCARTHY, M			UNLOCKING THE DATASETS	LANCET			English	Editorial Material											MCCARTHY, M (corresponding author), CAMDEN & ISLINGTON HLTH AUTHOR,DEPT PUBL HLTH,LONDON,ENGLAND.							[Anonymous], HIGH TECHNOLOGY MED; CHALMERS I, 1991, NEW ENGL J MED, V325, P1514; COX TM, 1993, LANCET, V342, P694, DOI 10.1016/0140-6736(93)91703-O; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; 1989, LANCET, V2, P195; 1993, ASSESSING EFFECTS HL	6	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1252	1253		10.1016/0140-6736(93)92355-W	http://dx.doi.org/10.1016/0140-6736(93)92355-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901579				2022-12-01	WOS:A1993MH56600005
J	MOSSEL, DAA; STRUIJK, CB				MOSSEL, DAA; STRUIJK, CB			FOOD-BORNE ILLNESS 1993 - UPDATING WILSON TRIAD	LANCET			English	Editorial Material											MOSSEL, DAA (corresponding author), UNIV UTRECHT,EIJKMAN FDN,UTRECHT,NETHERLANDS.							CHRISTIAN JHB, 1980, FOOD RES Q, V40, P13; Lund B. M., 1993, Food Technology International, Europe, P196; Mossel D. A. A., 1988, Animal & Human Health, V1, P13; Mossel D. A. A., 1987, Elimination of pathogenic organisms from meat and poultry., P305; MOSSEL DAA, 1989, LETT APPL MICROBIOL, V9, P207, DOI 10.1111/j.1472-765X.1989.tb00327.x; MOSSEL DAA, 1992, INT J FOOD MICROBIOL, V15, P1, DOI 10.1016/0168-1605(92)90131-L; MOSSEL DAA, 1990, FOOD TECHNOL-CHICAGO, V44, P63; POTTER ME, 1984, JAMA-J AM MED ASSOC, V252, P2048, DOI 10.1001/jama.252.15.2048; RAMPLING A, 1993, LANCET, V342, P317, DOI 10.1016/0140-6736(93)91466-Y; VANNETTEN P, 1992, PREDICTIVE MICROBIOL, P181; Wilson GS, 1933, LANCET, V2, P829; WILSON GS, 1935, MRC SPEC REP SER, V206	12	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1254	1254		10.1016/0140-6736(93)92357-Y	http://dx.doi.org/10.1016/0140-6736(93)92357-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901581				2022-12-01	WOS:A1993MH56600007
J	NICHOLLS, N				NICHOLLS, N			EL-NINO-SOUTHERN OSCILLATION AND VECTOR-BORNE DISEASE	LANCET			English	Article											NICHOLLS, N (corresponding author), BUR METEOROL RES CTR,POB 1289K,MELBOURNE 3001,AUSTRALIA.		Nicholls, Neville/A-1240-2008	Nicholls, Neville/0000-0002-1298-4356				LIEHNE PFS, 1988, GREENHOUSE PLANNING, P752; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; NICHOLLS N, 1986, AUST J EXP BIOL MED, V64, P587, DOI 10.1038/icb.1986.62; Nicholls N., 1991, TELECONNECTIONS LINK, P493; 1990, CLIMATE CHANGE IPCC	5	105	110	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1284	1285		10.1016/0140-6736(93)92368-4	http://dx.doi.org/10.1016/0140-6736(93)92368-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901589				2022-12-01	WOS:A1993MH56600018
J	ROGERS, DJ; PACKER, MJ				ROGERS, DJ; PACKER, MJ			VECTOR-BORNE DISEASES, MODELS, AND GLOBAL CHANGE	LANCET			English	Article											ROGERS, DJ (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.							Anderson RM, 1982, POPULATION DYNAMICS, V368, DOI [10.1007/978-1-4899-2901-3, DOI 10.1007/978-1-4899-2901-3]; MAURICE J, 1993, NEW SCI         1016; RAI KS, 1991, ANNU REV ENTOMOL, V36, P459, DOI 10.1146/annurev.en.36.010191.002331; ROGERS DJ, 1988, PARASITOLOGY, V97, P193, DOI 10.1017/S0031182000066853; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; 1990, WHO TDRCTDHH901	6	73	76	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1282	1284		10.1016/0140-6736(93)92367-3	http://dx.doi.org/10.1016/0140-6736(93)92367-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7695661				2022-12-01	WOS:A1993MH56600017
J	SACKS, SH; ZHOU, WD; ANDREWS, PA; HARTLEY, B				SACKS, SH; ZHOU, WD; ANDREWS, PA; HARTLEY, B			ENDOGENOUS COMPLEMENT C3 SYNTHESIS IN IMMUNE-COMPLEX NEPHRITIS	LANCET			English	Note							BIOSYNTHESIS; C-4	Human renal epithelial and mesangial cells have been shown to synthesise complement C3 in culture, but the relevance of this finding to the development of complement-mediated nephritis is uncertain. We investigated C3 gene expression in tissue biopsies that showed three main categories of renal injury. By semiquantitative polymerase chain reaction, biopsies from patients with immune-complex glomerulonephritis and those with cell-mediated interstitial nephritis showed increased C3 expression (p < 0.05), but biopsies from patients with non-immune glomerular injury did not. These findings suggest that local C3 production is enhanced in immune-mediated nephritis and are consistent with the hypothesis that locally synthesised complement components are involved in the pathogenesis of tissue injury.			SACKS, SH (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,RENAL LAB,3RD FLOOR GUYS TOWER,LONDON SE1 9RT,ENGLAND.			Sacks, Steven/0000-0001-6361-9095	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; Colten H R, 1979, Ann N Y Acad Sci, V332, P482, DOI 10.1111/j.1749-6632.1979.tb47142.x; COUSER WG, 1985, KIDNEY INT, V28, P879, DOI 10.1038/ki.1985.214; FEUCHT HE, 1989, NEPHRON, V53, P338, DOI 10.1159/000185778; FEY G, 1981, FED PROC, V40, P2099; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; SACKS SH, 1993, IMMUNOLOGY, V79, P348; SACKS SH, IN PRESS CLIN EXP IM; ZHOU W, IN PRESS EUR J IMMUN	10	68	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1273	1274		10.1016/0140-6736(93)92362-W	http://dx.doi.org/10.1016/0140-6736(93)92362-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901586				2022-12-01	WOS:A1993MH56600012
J	WALLACE, CJ				WALLACE, CJ			MAGNETIC-RESONANCE FOR DETECTION OF ABNORMALITIES IN PARTIAL EPILEPSY	LANCET			English	Editorial Material							HIPPOCAMPAL				WALLACE, CJ (corresponding author), FOOTHILLS PROV GEN HOSP,DEPT RADIOL SCI,CALGARY,AB,CANADA.							COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; CROSS JH, 1993, ARCH DIS CHILD, V69, P104, DOI 10.1136/adc.69.1.104; DUCHOWNY M, 1992, EPILEPSIA, V33, P298, DOI 10.1111/j.1528-1157.1992.tb02319.x; HIRSCHORN K A, 1991, Neurology, V41, P170; JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282; JACKSON GD, 1990, NEUROLOGY, V40, P1869, DOI 10.1212/WNL.40.12.1869; TSURUDA JS, 1992, ASNR M NOTES VANCOUV, P174	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1252	1252		10.1016/0140-6736(93)92354-V	http://dx.doi.org/10.1016/0140-6736(93)92354-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901578				2022-12-01	WOS:A1993MH56600004
J	BLONDELGUINDI, S; CWIRLA, SE; DOWER, WJ; LIPSHUTZ, RJ; SPRANG, SR; SAMBROOK, JF; GETHING, MJH				BLONDELGUINDI, S; CWIRLA, SE; DOWER, WJ; LIPSHUTZ, RJ; SPRANG, SR; SAMBROOK, JF; GETHING, MJH			AFFINITY PANNING OF A LIBRARY OF PEPTIDES DISPLAYED ON BACTERIOPHAGES REVEALS THE BINDING-SPECIFICITY OF BIP	CELL			English	Article							MHC CLASS-I; SECRETORY PROTEINS; TRANSLOCATION; POLYPEPTIDE; LIGANDS; RESOLUTION; MOLECULES; PHAGE; GROEL; DNAK	We have used affinity panning of libraries of bacteriophages that display random octapeptide or dodecapeptide sequences at the N-terminus of the adsorption protein (pIII) to characterize peptides that bind to the endoplasmic reticulum chaperone BiP and to develop a scoring system that predicts potential BiP-binding sequences in naturally occurring polypeptides. BiP preferentially binds peptides containing a subset of aromatic and hydrophobic amino acids in alternating positions, suggesting that peptides bind in an extended conformation, with the side chains of alternating residues pointing into a cleft on the BiP molecule. Synthetic peptides with sequences corresponding to those displayed by BiP-binding bacteriophages bind to BiP and stimulate its ATPase activity, with a half-maximal concentration in the range 10-60 muM.	UNIV TEXAS,DALLAS,TX 75235; AFFYMAX RES INST,PALO ALTO,CA 94304	University of Texas System; University of Texas Dallas	BLONDELGUINDI, S (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED,DALLAS,TX 75235, USA.							BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOWER W J, 1992, Current Biology, V2, P251, DOI 10.1016/0960-9822(92)90368-K; Efron B., 1982, MONOGRAPH SOC IND AP; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; KOZUTSUMI Y, 1989, J CELL SCI S, V11, P115; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; OBLAS B, 1990, BIOCHEM BIOPH RES CO, V166, P978, DOI 10.1016/0006-291X(90)90907-5; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHONBERGER O, 1991, MOL MICROBIOL, V11, P2663; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	34	561	595	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					717	728		10.1016/0092-8674(93)90492-9	http://dx.doi.org/10.1016/0092-8674(93)90492-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7902213	Bronze			2022-12-01	WOS:A1993MH74900017
J	KOTANIDES, H; REICH, NC				KOTANIDES, H; REICH, NC			REQUIREMENT OF TYROSINE PHOSPHORYLATION FOR RAPID ACTIVATION OF A DNA-BINDING FACTOR BY IL-4	SCIENCE			English	Article							STIMULATORY FACTOR-I; RECOMBINANT INTERLEUKIN-4; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; INTERFERON-ALPHA; IFN-GAMMA; PROTEIN; RECEPTOR; EXPRESSION; PROMOTER	Interleukin-4 (IL-4) is an immunoregulatory cytokine produced by activated T lymphocytes to promote the growth and differentiation of cells that participate in immune defense. This study demonstrates the rapid activation of a specific DNA binding factor by IL-4. The IL-4 nuclear-activated factor (IL-4 NAF) appeared within minutes of IL-4 stimulation and recognized a specific DNA sequence found in the promoters of IL-4-responsive genes. Activation of this putative transcription factor required tyrosine phosphorylation, and antibodies specific for phosphotyrosine recognize the IL-4 NAF-DNA complex. Thus, IL-4 appears to transduce a signal to the nucleus through tyrosine phosphorylation of a latent DNA binding factor.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,GRAD PROGRAM MOLEC & CELLULAR BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook					NCI NIH HHS [R29CA50773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; CAO H, 1989, J IMMUNOL, V143, P3524; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GILMOUR KC, UNPUB; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; GUTCH MJ, UNPUB; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOTANIDES H, UNPUB; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MCGARVIE GM, 1989, IMMUNOL LETT, V22, P221, DOI 10.1016/0165-2478(89)90195-8; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MOND JJ, 1986, J IMMUNOL, V137, P353; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAUL WE, 1991, BLOOD, V77, P1859; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SARFATI M, 1992, IMMUNOL RES, V11, P260, DOI 10.1007/BF02919132; SHINDLER C, 1992, SCIENCE, V257, P809; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STUART PM, 1988, J IMMUNOL, V140, P1542; SUTER U, 1989, J IMMUNOL, V143, P3087; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANG Q, 1993, J BIOL CHEM, V268, P6622; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	40	261	267	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1265	1267		10.1126/science.7694370	http://dx.doi.org/10.1126/science.7694370			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7694370				2022-12-01	WOS:A1993MH32400039
J	KUEHN, MJ; OGG, DJ; KIHLBERG, J; SLONIM, LN; FLEMMER, K; BERGFORS, T; HULTGREN, SJ				KUEHN, MJ; OGG, DJ; KIHLBERG, J; SLONIM, LN; FLEMMER, K; BERGFORS, T; HULTGREN, SJ			STRUCTURAL BASIS OF PILUS SUBUNIT RECOGNITION BY THE PAPD CHAPERONE	SCIENCE			English	Article							TOXIGENIC ESCHERICHIA-COLI; AREA-DETECTOR DIFFRACTOMETER; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; PEPTIDE-BINDING; PROTEIN SUBUNIT; GENE; EXPRESSION; FIMBRIAE; CELL	The assembly of different types of virulence-associated surface fibers called pili in Gram-negative bacteria requires periplasmic chaperones. PapD is the prototype member of the periplasmic chaperone family, and the structural basis of its interactions with pilus subunits was investigated. Peptides corresponding to the carboxyl terminus of pilus subunits bound PapD and blocked the ability of PapD to bind to the pilus adhesin PapG in vitro. The crystal structure of PapD complexed to the PapG carboxyl-terminal peptide was determined to 3.0 angstrom resolution. The peptide bound in an extended conformation with its carboxyl terminus anchored in the interdomain cleft of the chaperone via hydrogen bonds to invariant chaperone residues Arg8 and Lys112. Main chain hydrogen bonds and contacts between hydrophobic residues in the peptide and the chaperone stabilized the complex and may play a role in determining binding specificity. Site-directed mutations in Arg8 and Lys112 abolished the ability of PapD to bind pilus subunits and mediate pilus assembly in vivo, an indication that the PapD-peptide crystal structure is a reflection of at least part of the PapD-subunit interaction.	WASHINGTON UNIV,DEPT MOLEC MICROBIOL,BOX 8230,ST LOUIS,MO 63110; SYMBICOM AB,PROT STRUCT LAB,S-75183 UPPSALA,SWEDEN; LUND UNIV,DEPT ORGAN CHEM,S-22100 LUND,SWEDEN; UNIV UPPSALA,DEPT MICROBIOL,S-75105 UPPSALA,SWEDEN	Washington University (WUSTL); Lund University; Uppsala University			Kuehn, Meta/AAL-2950-2021; Kihlberg, Jan/S-4739-2019	Kuehn, Meta/0000-0003-0519-3019; 	NIAID NIH HHS [AI07172, R01AI29549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172, R01AI029549] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN BL, 1991, J BACTERIOL, V173, P916, DOI 10.1128/jb.173.2.916-920.1991; BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BRUNGER A, 1992, X PLOR MANUAL; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CLOUTHIER SC, 1993, J BACTERIOL, V175, P2523, DOI 10.1128/JB.175.9.2523-2533.1993; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DERRICK JP, 1992, NATURE, V359, P752, DOI 10.1038/359752a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAASTRA W, 1981, FEMS MICROBIOL LETT, V12, P41; GAASTRA W, 1984, FEMS MICROBIOL LETT, V22, P253; GALYOV EE, 1991, FEBS LETT, V286, P79, DOI 10.1016/0014-5793(91)80945-Y; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILSDORF JR, 1990, INFECT IMMUN, V58, P1065, DOI 10.1128/IAI.58.4.1065-1072.1990; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HOLMGREN A, UNPUB; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; Jacob-Dubuisson Francoise, 1993, Trends in Microbiology, V1, P50, DOI 10.1016/0966-842X(93)90032-M; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JALAJAKUMARI MB, 1989, MOL MICROBIOL, V3, P1685, DOI 10.1111/j.1365-2958.1989.tb00154.x; JONES AT, 1992, VERSION 5 6; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LINTERMANS P, 1988, INFECT IMMUN, V56, P1475, DOI 10.1128/IAI.56.6.1475-1484.1988; LINTERMANS P, 1990, THESIS RIJKSUNIVERSI; LIVEY I, 1987, MOL MICROBIOL, V1, P203, DOI 10.1111/j.1365-2958.1987.tb00513.x; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MOOI FR, 1990, FEMS MICROBIOL LETT, V54, P327; Normark S., 1986, Microbial lectins and agglutinins, P113; ORNDORFF PE, 1985, J BACTERIOL, V162, P454, DOI 10.1128/JB.162.1.454-457.1985; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; ROOSENDAAL B, 1989, J BACTERIOL, V171, P1262; SCHMOLL T, 1987, FEMS MICROBIOL LETT, V41, P229; SCHMOLL T, 1989, MOL MICROBIOL, V3, P1735, DOI 10.1111/j.1365-2958.1989.tb00159.x; SIMONS BL, 1990, FEMS MICROBIOL LETT, V67, P107, DOI 10.1111/j.1574-6968.1990.tb13845.x; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; 1979, WA44AD DAR LAB	51	195	199	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1234	1241		10.1126/science.7901913	http://dx.doi.org/10.1126/science.7901913			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7901913				2022-12-01	WOS:A1993MH32400030
J	MADDEN, DR; GARBOCZI, DN; WILEY, DC				MADDEN, DR; GARBOCZI, DN; WILEY, DC			THE ANTIGENIC IDENTITY OF PEPTIDE-MHC COMPLEXES - A COMPARISON OF THE CONFORMATIONS OF 5 VIRAL PEPTIDES PRESENTED BY HLA-A2	CELL			English	Article							T-CELL RECOGNITION; CRYSTAL-STRUCTURES; VIRUS PEPTIDE; MOLECULES; PROTEIN; RESOLUTION; EPITOPE; HLA-B27; BINDING; CHAINS	Complexes of five peptides (from HIV-1, influenza A virus, HTLV-1, and hepatitis B virus proteins) bound to the human class I MHC molecule HLA-A2 have been studied by X-ray crystallography. While the peptide termini and their second and C-terminal anchor side chains are bound similarly in all five cases, the main chain and side chain conformations of each peptide are strikingly different in the center of the binding site, and these differences are accessible to direct TCR recognition. Each of the central peptide residues is seen to point up for some bound peptides, but down or sideways for others. Thus, although fixed at its ends, the structure of an MHC-bound peptide appears to be a highly complex function of its entire sequence, potentially sensitive to even small sequence differences. In contrast, MHC structural variation is relatively limited. These results offer a structural framework for understanding the role of nonanchor peptide side chains in both peptide-MHC binding affinity and TCR recognition.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute								ALEXANDER J, 1993, J IMMUNOL, V150, P1; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, XPLOR MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; JAMES MNG, 1983, J APPL CRYSTALLOGR, V11, P268; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KOENIG S, 1993, J IMMUNOL, V156, P3874; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; NAYERSINA R, 1993, J IMMUNOL, V150, P4659; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARKER KC, 1992, J IMMUNOL, V149, P3580; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; UTZ U, 1992, J IMMUNOL, V149, P214; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	46	663	696	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					693	708		10.1016/0092-8674(93)90490-H	http://dx.doi.org/10.1016/0092-8674(93)90490-H			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7694806				2022-12-01	WOS:A1993MH74900015
J	ROSAHL, TW; GEPPERT, M; SPILLANE, D; HERZ, J; HAMMER, RE; MALENKA, RC; SUDHOF, TC				ROSAHL, TW; GEPPERT, M; SPILLANE, D; HERZ, J; HAMMER, RE; MALENKA, RC; SUDHOF, TC			SHORT-TERM SYNAPTIC PLASTICITY IS ALTERED IN MICE LACKING SYNAPSIN-I	CELL			English	Article							SQUID GIANT SYNAPSE; PROTEIN-KINASE-II; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; PHOSPHORYLATION; VESICLES; CALMODULIN; GENE; POTENTIATION; HIPPOCAMPUS	Synapsin I, the major phosphoprotein of synaptic vesicles, is thought to play a central role in neurotransmitter release. Here we introduce a null mutation into the murine synapsin I gene by homologous recombination. Mice with no detectable synapsin I manifest no apparent changes in well-being or gross nervous system function. Thus, synapsin I is not essential for neurotransmitter release. Electrophysiology reveals that mice lacking synapsin I exhibit a selective increase in paired pulse facilitation, with no major alterations in other synaptic parameters such as long-term potentiation. In addition to potential redundant functions shared with other proteins, synapsin I in normal mice may function to limit increases in neurotransmitter release elicited by residual Ca2+ after an initial stimulus.	UNIV TEXAS, HLTH SCI CTR, SW MED SCH, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ROSAHL, TW (corresponding author), UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT MOLEC GENET, DALLAS, TX 75235 USA.							BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENNETT AF, 1991, BIOCHEM J, V276, P793, DOI 10.1042/bj2760793; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; FYKSE EM, 1993, IN PRESS J NEUROSCI; GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HAYES NVL, 1991, BIOCHEM J, V275, P93, DOI 10.1042/bj2750093; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KAHLE JS, 1989, BRAIN RES, V482, P159, DOI 10.1016/0006-8993(89)90554-4; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MCGUINNESS TL, 1989, J NEUROSCI, V9, P4138; MCNAUGHTON BL, 1980, BRAIN RES, V199, P1, DOI 10.1016/0006-8993(80)90226-7; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; PRINCE DA, 1992, P NATL ACAD SCI USA, V89, P8586, DOI 10.1073/pnas.89.18.8586; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sambrook J., 1989, MOL CLONING LAB MANU; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SIKORSKI AF, 1991, BRAIN RES BULL, V27, P195, DOI 10.1016/0361-9230(91)90067-T; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1991, NEUROSCI YEAR, V2, P146; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P2238; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P213, DOI 10.1085/jgp.76.2.213; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	46	279	290	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					661	670		10.1016/0092-8674(93)90487-B	http://dx.doi.org/10.1016/0092-8674(93)90487-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7902212	Bronze			2022-12-01	WOS:A1993MH74900012
J	WILLIS, MC; HICKE, BJ; UHLENBECK, OC; CECH, TR; KOCH, TH				WILLIS, MC; HICKE, BJ; UHLENBECK, OC; CECH, TR; KOCH, TH			PHOTO-CROSS-LINKING OF 5-IODOURACIL SUBSTITUTED RNA AND DNA TO PROTEINS	SCIENCE			English	Article							PHOTOCHEMICAL CROSS-LINKING; LAC REPRESSOR PROTEIN; 5-BROMOURACIL-SUBSTITUTED DNA; RIBONUCLEIC-ACID; OPERATOR DNA; BROMODEOXYURIDINE; IDENTIFICATION; COMPLEX; REGION; SITE	5-Iodouracil-substituted RNA and DNA were crosslinked regiospecifically to associated proteins in yields of 70 to 94% of bound nucleic acid. Irradiation of the iodouracil chromophore with monochromatic, long-wavelength ultraviolet radiation (325 nanometers) eliminates excitation of other nucleic acid and protein chromophores. The combination of high crosslinking yields, excellent specificity, and elimination of photodamage to other chromophores represents an important advance toward the precise identification of contacts in nucleoprotein complexes.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,HOWARD HUGHES MED INST,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM-36944, GM-28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM036944, R01GM028039, R37GM036944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BARBIER B, 1984, BIOCHEMISTRY-US, V23, P2933, DOI 10.1021/bi00308a013; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; DIETZ TM, 1987, J AM CHEM SOC, V109, P1793, DOI 10.1021/ja00240a032; DIETZ TM, 1987, PHOTOCHEM PHOTOBIOL, V46, P971, DOI 10.1111/j.1751-1097.1987.tb04879.x; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; HICKE BJ, UNPUB; Hutchinson F., 1980, PROG MOL SUBCELL BIO, V7, P1; KATOUZIANSAFADI M, 1991, PHOTOCHEM PHOTOBIOL, V53, P611, DOI 10.1111/j.1751-1097.1991.tb08487.x; KATOUZIANSAFADI M, 1991, NUCLEIC ACIDS RES, V19, P4937, DOI 10.1093/nar/19.18.4937; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; SAITO I, 1990, BIOORGANIC PHOTOCHEM, V1, P317; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; UHLENBECK C, 1988, NUCLEIC ACIDS, V16, P11725; WEINTRAUB H, 1973, COLD SPRING HARB SYM, V38, P247, DOI 10.1101/SQB.1974.038.01.028; WICK KL, 1991, J BIOL CHEM, V266, P6106; WILLIS M, UNPUB; WOLFES H, 1986, EUR J BIOCHEM, V159, P267, DOI 10.1111/j.1432-1033.1986.tb09863.x	25	175	197	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1255	1257		10.1126/science.7694369	http://dx.doi.org/10.1126/science.7694369			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7694369				2022-12-01	WOS:A1993MH32400036
J	MARTIN, J; MAYHEW, M; LANGER, T; HARTL, FU				MARTIN, J; MAYHEW, M; LANGER, T; HARTL, FU			THE REACTION CYCLE OF GROEL AND GROES IN CHAPERONIN-ASSISTED PROTEIN-FOLDING	NATURE			English	Article							ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; MOLECULAR CHAPERONE; ATP HYDROLYSIS; PURIFICATION; COOPERATIVITY; SURFACE	The reaction mechanism of protein folding by the chaperonin GroEL and its regulator GroES has been defined. GroES and substrate protein counteract each other's effects on GroEL: whereas GroES stabilizes GroEL in the ADP-bound state, binding of unfolded polypeptide within the cavity of the GroEL cylinder triggers ADP and GroES release. Upon ADP-ATP exchange, GroES reassociates with GroEL and ATP hydrolysis discharges the bound protein for folding. Partially folded protein rebinds to the chaperonin, thus perpetuating the cycle until folding is complete.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	Langer, Thomas/0000-0003-1250-1462				BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522	31	265	268	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					228	233		10.1038/366228a0	http://dx.doi.org/10.1038/366228a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	7901770				2022-12-01	WOS:A1993MH32500052
J	MARTIN, J; GEROMANOS, S; TEMPST, P; HARTL, FU				MARTIN, J; GEROMANOS, S; TEMPST, P; HARTL, FU			IDENTIFICATION OF NUCLEOTIDE-BINDING REGIONS IN THE CHAPERONIN PROTEINS GROEL AND GROES	NATURE			English	Article							ESCHERICHIA-COLI; ATP HYDROLYSIS; COOPERATIVITY; PURIFICATION; F1-ATPASE; GENES; SITE	THE chaperonin GroEL, a tetradecameric cylinder consisting of subunits of M(r) approximately 60,000 (60K), and its cofactor GroES, a heptameric ring of 10K subunits, mediate protein folding in the cytosol of Escherichia coli1-3. In the presence of nucleotide, GroES forms a 1:1 complex with GroEL which binds unfolded protein in its central cavity and releases it to allow folding upon ATP hydrolysis4-7. Using labelling with azido-ATP, we have identified a protease-stable nucleotide-binding domain of M(r) 40K in the GroEL subunits (residues 153-531). Azido-ATP is crosslinked to the highly conserved Tyr 477, indicating that this residue is close to the purine ring of the bound nucleotide. Surprisingly, GroES also binds ATP cooperatively and with an affinity comparable to that of GroEL. Azido-nucleotide labelling of GroES subunits occurs at the conserved Tyr 71 in a protease-stable 6.5K domain (starting at residue 33). Proteinase K cleavage at residue 32 is prevented when GroES is bound to GroEL. ATP binding to GroES may be important in charging the seven subunits of the interacting GroEL ring with ATP to facilitate cooperative ATP binding and hydrolysis for substrate protein release.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019					Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEROMANOS S, IN PRESS TECHNIQUES, V5; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	29	94	99	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					279	282		10.1038/366279a0	http://dx.doi.org/10.1038/366279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	7901771				2022-12-01	WOS:A1993MH32500068
J	EPSTEIN, PR; FORD, TE; COLWELL, RR				EPSTEIN, PR; FORD, TE; COLWELL, RR			MARINE ECOSYSTEMS	LANCET			English	Article							TEMPERATURE; CHOLERA; WATER		HARVARD UNIV,DEPT ENVIRONM BIOL,CAMBRIDGE,MA 02138; UNIV MARYLAND,INST BIOTECHNOL,COLL PK,MD 20742	Harvard University; University System of Maryland; University of Maryland College Park	EPSTEIN, PR (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DIV SOCIAL & COMMUNITY MED,CAMBRIDGE,MA 02139, USA.			Ford, Timothy/0000-0001-5194-5459				[Anonymous], TOXIC PHYTOPLANKTON; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; BYRD JJ, 1991, APPL ENVIRON MICROB, V57, P875, DOI 10.1128/AEM.57.3.875-878.1991; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Glantz M.H., 1991, TELECONNECTIONS LINK; Hayes R.L., 1991, WORLD RES REV, V3, P306; Houghton J.T., 1990, CLIMATE CHANGE IPCC; HUQ A, 1984, APPL ENVIRON MICROB, V48, P420, DOI 10.1128/AEM.48.2.420-424.1984; ISLAM S, 1990, J TROP MED HYG, V93, P133; MACKENZIE D, 1988, NEW SCI         0128, P30; MANABE S, 1993, NATURE, V364, P215, DOI 10.1038/364215a0; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; SAMADI AR, 1983, T ROY SOC TROP MED H, V77, P853, DOI 10.1016/0035-9203(83)90306-1; SHERMAN L, 1993, LARGE MARINE ECOSYST, P301; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; YAN XH, 1992, SCIENCE, V258, P1643, DOI 10.1126/science.258.5088.1643	17	74	74	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1216	1219		10.1016/0140-6736(93)92191-U	http://dx.doi.org/10.1016/0140-6736(93)92191-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901535				2022-12-01	WOS:A1993MG27400015
J	FIORETTO, P; MAUER, SM; BILOUS, RW; GOETZ, FC; SUTHERLAND, DER; STEFFES, MW				FIORETTO, P; MAUER, SM; BILOUS, RW; GOETZ, FC; SUTHERLAND, DER; STEFFES, MW			EFFECTS OF PANCREAS TRANSPLANTATION ON GLOMERULAR STRUCTURE IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH THEIR OWN KIDNEYS	LANCET			English	Article							ISLET TRANSPLANTATION; NEPHROPATHY; MELLITUS; SURFACE; VOLUME; RATS	Pancreas transplantation prevents or retards development of earlY diabetic glomerular lesions in renal allografts transplanted to patients with insulin-dependent diabetes mellitus (IDDM), but its effect on established renal lesions in native kidneys of such patients is unknown. Renal biopsy samples were taken before and 5 years after pancreas transplantation from 13 non-uraemic IDDM patients and compared with baseline and 5-year biopsy samples from 10 persistently hyperglycaemic IDDM patients who did not undergo transplantation. The two groups were similar in age, duration of diabetes, metabolic control, renal function, and blood pressure. Glomerular structures were measured by standard morphometric techniques. Haemoglobin A1 concentrations fell to within the normal range after pancreas transplantation but did not change in the comparison group. Glomerular basement membrane width did not significantly change in either group. Glomerular volume decreased and mesangial fractional volume increased in the pancreas transplant recipients but there was no significant change in total mesangial volume over 5 years. By contrast, both glomerular volume and mesangial fractional volume increased in the comparison patients, resulting in increased total mesangial volume. Diabetic glomerular lesions in patients with their own kidneys were not ameliorated by pancreas transplantation, despite 5 years of normoglycaemia. Pancreas transplantation can correct severe metabolic instability and thus improve quality of life, but it cannot yet be recommended for the treatment of established lesions of diabetic nephropathy.	UNIV MINNESOTA,SCH MED,DEPT PEDIAT,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT MED,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT SURG,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,DULUTH,MN 55812; MIDDLESBROUGH GEN HOSP,DEPT MED,MIDDLESBROUGH,ENGLAND	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth			fioretto, paola/AHD-4415-2022	FIORETTO, PAOLA/0000-0003-3445-0387	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017697, P01DK013083, R01DK043605] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17697, DK-43605, DK-13083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBOSA J, 1992, DIABETES S1, V41; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; BOHMAN SO, 1985, DIABETES, V34, P306, DOI 10.2337/diabetes.34.3.306; De Francisco A M, 1987, J Diabet Complications, V1, P128, DOI 10.1016/S0891-6632(87)80070-3; ELLIS EN, 1986, KIDNEY INT, V29, P889, DOI 10.1038/ki.1986.82; ELLIS EN, 1986, METHODS DIABETES RES, V2, P633; FUETREN G, 1992, NEW ENGL J MED, V326, P1654; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; ORLOFF MJ, 1986, DIABETES, V35, P347, DOI 10.2337/diabetes.35.3.347; OSTERBY R, 1980, DIABETOLOGIA, V18, P493; PEREJDA AJ, 1982, COLLAGEN REL RES, V2, P83; RAMSAY RC, 1988, NEW ENGL J MED, V318, P208, DOI 10.1056/NEJM198801283180403; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; STEFFES MW, 1980, DIABETES, V29, P509, DOI 10.2337/diab.29.7.509; STEFFES MW, 1979, LAB INVEST, V41, P116; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; SUTHERLAND DER, 1989, ANN SURG, V210, P274, DOI 10.1097/00000658-198909000-00003; SUTHERLAND DER, 1988, SURGERY, V104, P453; ZEHRER CL, 1991, DIABETOLOGIA S1, V34, P145	25	131	132	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1193	1196		10.1016/0140-6736(93)92183-T	http://dx.doi.org/10.1016/0140-6736(93)92183-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901527				2022-12-01	WOS:A1993MG27400007
J	GARATTINI, S; GARATTINI, L				GARATTINI, S; GARATTINI, L			PHARMACEUTICAL PRESCRIPTIONS IN 4 EUROPEAN COUNTRIES	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), MARIO NEGRI INST PHARMACOL RES,CTR ECON SANIT A VALENTI,I-20157 MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297					0	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1191	1192		10.1016/0140-6736(93)92181-R	http://dx.doi.org/10.1016/0140-6736(93)92181-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901525				2022-12-01	WOS:A1993MG27400005
J	JENSEN, GB; PAKKENBERG, B				JENSEN, GB; PAKKENBERG, B			DO ALCOHOLICS DRINK THEIR NEURONS AWAY	LANCET			English	Article							BRAIN; ATROPHY; DENDRITES; ETHANOL; NUMBER	Although it is commonly believed that chronic alcohol abuse results in loss of neocortical neurons, this assumption has not been properly tested. We used new stereological techniques to make a precise and unbiased estimate of the total number of neurons in the neocortex of brains obtained at necropsy from 11 chronic alcoholic men and 11 control men. The groups were matched with respect to age and height. Total mean neocortical neuron numbers in the two groups did not differ (alcoholics 23.4 x 10(9), controls 23.2 x 10(9)). Estimation of macroscopic brain volumes showed significant reductions in alcoholics compared with controls of the volume/weight ratios of white matter (11%, p = 0.013) and of archicortex (30%, p = 0.028). The volume of the ventricles in the alcoholic group was enlarged by 26%, but this was not statistically significant. There was no difference in the volumes of the neocortices. Our study confirms that chronic alcoholics lose white matter, and this could provide the basis for their functional impairment. However, the results also suggest that the observed brain damage in the alcoholic group is potentially reversible since preserved nerve-cell bodies might allow lost or malfunctioning axons to be re-established and restored to function after prolonged abstinence and/or treatment. By contrast, lost neocortical neurons cannot be replaced.	KOMMUNE HOSP COPENHAGEN, BARTHOLIN INST, NEUROL RES LAB, DK-1399 COPENHAGEN K, DENMARK; AARHUS UNIV, BARTHOLIN BYGNINGEN, STEREOL RES LAB, DK-8000 AARHUS, DENMARK	Aarhus University				pakkenberg, bente/0000-0003-3851-6494				BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; CARLEN PL, 1987, ACTA MED SCAND, P19; CARLEN PL, 1981, NEUROLOGY, V31, P377; CHARNESS ME, 1989, NEW ENGL J MED, V321, P442, DOI 10.1056/NEJM198908173210706; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; DELAMONTE SM, 1988, ARCH NEUROL-CHICAGO, V45, P990, DOI 10.1001/archneur.1988.00520330076013; FERRER I, 1986, NEUROSCI LETT, V69, P115, DOI 10.1016/0304-3940(86)90425-8; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HANSEN LA, 1991, ARCH NEUROL-CHICAGO, V48, P939, DOI 10.1001/archneur.1991.00530210065025; HARPER C, 1987, BRIT MED J, V294, P534, DOI 10.1136/bmj.294.6571.534; HARPER C, 1985, J NEUROL NEUROSUR PS, V48, P211, DOI 10.1136/jnnp.48.3.211; HARPER C, 1990, J NEUROL NEUROSUR PS, V53, P856, DOI 10.1136/jnnp.53.10.856; HARPER CG, 1982, J NEUROL NEUROSUR PS, V45, P838, DOI 10.1136/jnnp.45.9.838; HARPER CG, 1990, ALCOHOL ALCOHOLISM, V25, P445; HARPER CG, 1990, ALCOHOL ALCOHOLISM, V25, P207, DOI 10.1093/oxfordjournals.alcalc.a044994; HARPER CG, 1985, BRIT MED J, V290, P501, DOI 10.1136/bmj.290.6467.501; HILL SY, 1979, SCIENCE, V204, P1237, DOI 10.1126/science.451571; ISHII T, 1983, ACTA PSYCHIAT SCAND, V309, P7; KJELLSTROM C, 1993, ACTA NEUROPATHOL, V85, P117; LEE K, 1979, LANCET, V2, P759; LISHMAN WA, 1987, ACTA MED SCAND, P5; MCMULLEN PA, 1984, J COMP NEUROL, V225, P111, DOI 10.1002/cne.902250112; Pakkenberg B, 1989, ACTA STEREOL, V8, P251; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; TAVARES MA, 1983, J NEUROCYTOL, V12, P939, DOI 10.1007/BF01153343; THOMSON AD, 1982, BRIT MED BULL, V38, P87, DOI 10.1093/oxfordjournals.bmb.a071740; TORVIK A, 1987, ACTA MED SCAND, P47; 1987, DIAGNOSTIC STATISTIC	29	80	83	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1201	1204						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901529				2022-12-01	WOS:A1993MG27400009
J	LEE, HS; CROSS, SJ; RAWLES, JM; JENNINGS, KP				LEE, HS; CROSS, SJ; RAWLES, JM; JENNINGS, KP			PATIENTS WITH SUSPECTED MYOCARDIAL-INFARCTION WHO PRESENT WITH ST DEPRESSION	LANCET			English	Article							NON-Q-WAVE; NATURAL-HISTORY; UNSTABLE ANGINA; CHEST PAIN; SEGMENT; THROMBOLYSIS; ELECTROCARDIOGRAM; MYOGLOBIN	Patients with suspected myocardial infarction who present with ST depression have a high mortality which is not reduced by thrombolytic therapy. Despite this, there are few data on these patients. We studied the electrocardiographic and clinical characteristics of these patients, the diagnostic and prognostic value of the presenting electrocardiogram (ECG), and the reasons for the high mortality and apparent lack of thrombolytic efficacy. We studied all patients with suspected infarction admitted during 1990 with ST depression. Of the 136 patients (84 men, mean [SD] age 68 [11] years), 74 (54%) had confirmed infarction and 73 (54%) had previous infarction. 1-year mortality was 26% for all patients, 31% for those with confirmed infarcts, and 19% for those in whom infarction was subsequently excluded. Patients with infarction had more severe ST depression (mean 2.5 mm [SD 1.5]) and more ECG leads with ST depression (mean 4.7 leads [1.81]) compared with patients without infarction (1.4 mm [0.8], p < 0.001; 3.6 leads [1.7], p < 0.001). Sensitivity and specificity for the subsequent diagnosis of infarction with ST depression were 20% and 97%, respectively, for at least 4 mm; and 21% and 95%, respectively, for at least 7 leads. 1-year mortality was low in patients with 1 mm ST depression (14%) or no more than 2 leads (11%), but high in patients with at least 2 mm ST depression (39%, p < 0.001) and at least 3 leads (30%, p = 0.08). Patients with suspected infarction and ST depression had a high mean age, high incidence of previous infarction, and poor prognosis. The presenting ECG is helpful in predicting prognosis, and ST depression of at least 4 mm or involving at least 7 leads is highly specific for diagnosis of infarction.	UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 1FX, SCOTLAND; ABERDEEN ROYAL INFIRM, DEPT CARDIOL, ABERDEEN AB9 2ZB, SCOTLAND	University of Aberdeen; University of Aberdeen								ABBOTT JA, 1973, AM J MED, V55, P608, DOI 10.1016/0002-9343(73)90182-4; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BERLAND J, 1986, AM HEART J, V111, P481, DOI 10.1016/0002-8703(86)90052-9; BOSSAERT L, 1991, EUR HEART J, V12, P965; CHOUHAN L, 1991, AM J CARDIOL, V68, P446, DOI 10.1016/0002-9149(91)90776-H; GHEORGHIADE M, 1991, AM HEART J, V122, P1548, DOI 10.1016/0002-8703(91)90270-R; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; KAGEN LJ, 1978, CRC CR REV CL LAB SC, V9, P273, DOI 10.3109/10408367809150922; LEE HS, 1992, BRIT HEART J, V68, P145; MAIR J, 1992, BRIT HEART J, V68, P462; METCALFE MJ, 1990, BRIT HEART J, V63, P267; MIRANDA CP, 1991, CIRCULATION, V84, P2357, DOI 10.1161/01.CIR.84.6.2357; ODEMUYIWA O, 1985, BRIT HEART J, V54, P479; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; PRUITT RD, 1963, PROG CARDIOVASC DIS, V6, P85, DOI 10.1016/S0033-0620(63)80023-7; RAUNIO H, 1979, AM HEART J, V98, P176, DOI 10.1016/0002-8703(79)90219-9; SCHECHTMAN KB, 1989, CIRCULATION, V80, P1148, DOI 10.1161/01.CIR.80.5.1148; SCRUTINIO D, 1991, AM J CARDIOL, V68, pB99, DOI 10.1016/0002-9149(91)90391-W; SERNERI GGN, 1990, LANCET, V335, P615; SUGIURA M, 1969, JPN HEART J, V10, P203; WILLICH SN, 1987, AM HEART J, V114, P1110, DOI 10.1016/0002-8703(87)90186-4	22	71	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1204	1207		10.1016/0140-6736(93)92186-W	http://dx.doi.org/10.1016/0140-6736(93)92186-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901530				2022-12-01	WOS:A1993MG27400010
J	MUERS, M				MUERS, M			UNDERSTANDING BREATHLESSNESS	LANCET			English	Editorial Material							AIR HUNGER				MUERS, M (corresponding author), KILLINGBECK HOSP,RESP UNIT,LEEDS,ENGLAND.							BANZETT RB, 1990, RESP PHYSIOL, V81, P1, DOI 10.1016/0034-5687(90)90065-7; BANZETT RB, 1989, RESP PHYSIOL, V76, P53, DOI 10.1016/0034-5687(89)90017-0; CAMPBELL EJ, 1969, CLIN SCI, V36, P323; DAVIS JN, 1967, CLIN SCI, V33, P249; FOWLER WS, 1954, J APPL PHYSIOL, V6, P539, DOI 10.1152/jappl.1954.6.9.539; GANDEVIA SC, 1993, J PHYSIOL-LONDON, V470, P85, DOI 10.1113/jphysiol.1993.sp019849; HOWELL JBL, 1990, THORAX, V45, P287, DOI 10.1136/thx.45.4.287; HOWELL JBL, 1970, HERRINGBREUER CENTEN, P287; HOWELL JBL, 1990, BREATHLESSNESS, P221; MCCLOSKEY DI, 1981, HDB PHYSL NERVOUS SY, V2, P1415; Merton P A, 1964, Symp Soc Exp Biol, V18, P387	11	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1190	1191		10.1016/0140-6736(93)92180-2	http://dx.doi.org/10.1016/0140-6736(93)92180-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901524				2022-12-01	WOS:A1993MG27400004
J	MURPHY, DGM; DECARLI, C; DALY, E; HAXBY, JV; ALLEN, G; WHITE, BJ; MCINTOSH, AR; POWELL, CM; HORWITZ, B; RAPOPORT, SI; SCHAPIRO, MB				MURPHY, DGM; DECARLI, C; DALY, E; HAXBY, JV; ALLEN, G; WHITE, BJ; MCINTOSH, AR; POWELL, CM; HORWITZ, B; RAPOPORT, SI; SCHAPIRO, MB			X-CHROMOSOME EFFECTS ON FEMALE BRAIN - A MAGNETIC-RESONANCE-IMAGING STUDY OF TURNERS-SYNDROME	LANCET			English	Article							INACTIVATION; MEMORY	Many neuropsychiatric disorders differ between the sexes in incidence, symptoms, and age at onset. To investigate the effects of X-chromosome aneuploidy and of sex steroid deficiency during childhood on brain structure and function, we used neuropsychological tests and quantitative magnetic resonance imaging (MRI) to study the brains of eighteen women with Turner's syndrome (TS) and nineteen healthy control women of similar age. Nine TS subjects had mosaic 45,X karyotypes, and 9 had non-mosaic 45,X. The TS group had significantly lower scores than the controls for all the Wechsler adult intelligence scale tests, except verbal comprehension and reading level. The greatest difference was in visuospatial construction (mean 90 [SD 12] vs 118 [13], p < 0.0001). The TS subjects also had a greater discrepancy than controls between verbal and performance intelligence quotients (9 [8] vs -5 [9], p<0.001). We found that TS subjects had significantly smaller values than controls in MRI-measured volumes of hippocampus, caudate, lenticular, and thalamic nuclei, and parieto-occipital brain matter, on both sides. Women with mosaic TS had values between the full TS and control groups for cerebral hemisphere and lenticular and thalamic nuclei volume and for verbal ability. Within the mosaic TS group, visuospatial ability was significantly correlated with the percentage of lymphocytes that had the 45,X karyotype. Hippocampal volume and memory test scores were significantly lower in mosaic and non-mosaic 45,X TS subjects than in controls. We postulate that in human beings the X chromosome plays an important part in the development and ageing of grey matter in striatum, diencephalon, and cerebral hemispheres.	NIDDKD,CHEM BIOL LAB,CYTOGENET UNIT,BETHESDA,MD; NIH,MED GENET PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA	MURPHY, DGM (corresponding author), NIA,NEUROSCI LAB,BLDG 10,ROOM 6C-414,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		DeCarli, Charles/B-5541-2009; McIntosh, Anthony R/G-4955-2011; daly, eileen m/B-6716-2011	Daly, Eileen/0000-0003-3625-3467; McIntosh, Anthony/0000-0002-1784-5662				BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; HARNDEN DG, 1985, ISCN 1985 INT SYSTEM; Jastak J., 1978, WIDE RANGE ACHIEVEME; LYON MF, 1988, AM J HUM GENET, V42, P8; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; MONEY JOHN, 1966, J MED GENET, V3, P47, DOI 10.1136/jmg.3.1.47; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; RESKENIELSEN E, 1982, CORTEX, V18, P181, DOI 10.1016/S0010-9452(82)80001-4; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; TELLEGEN A, 1967, J CONSULT PSYCHOL, V31, P499, DOI 10.1037/h0024963; TORANALLERAND CD, 1991, PSYCHONEUROENDOCRINO, V16, P7, DOI 10.1016/0306-4530(91)90068-5; Verma RS, 1989, HUMAN CHROMOSOMES MA, p[5, 47]; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Wechsler, 2012, WECHSLER ADULT INTEL, DOI 10.1037/t15169-000; 1985, SAS USERS GUIDE BASI	17	156	156	1	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1197	1200		10.1016/0140-6736(93)92184-U	http://dx.doi.org/10.1016/0140-6736(93)92184-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901528				2022-12-01	WOS:A1993MG27400008
J	SPORN, MB				SPORN, MB			CHEMOPREVENTION OF CANCER	LANCET			English	Editorial Material							RECEPTOR SUPERFAMILY; PREVENTION; CARCINOGENESIS; TAMOXIFEN; DISEASE; EFFICACY; TRIALS; TUMORS				SPORN, MB (corresponding author), NCI, CHEMOPREVENT LAB, BLDG 41, ROOM C629, BETHESDA, MD 20892 USA.							ABE O, 1992, LANCET, V339, P71; [Anonymous], 1992, Lancet, V339, P1; BOONE CW, 1992, CANCER RES, V52, P1651; CHIESA F, 1992, ORAL ONCOL, V28B, P97; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; CONNEY AH, 1977, FED PROC, V36, P1647; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUGHBERMAN A, 1992, LANCET, V340, P1143, DOI 10.1016/0140-6736(92)93161-F; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KOHN EC, 1992, CANCER RES, V52, P3208; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; RATKO TA, 1989, CANCER RES, V49, P4472; ROBERTS AB, 1992, CANCER SURV, V14, P205; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SPORN MB, 1976, FED PROC, V35, P1332; SPORN MB, 1991, CANCER RES, V51, P6215; SPORN MB, 1980, NATURE, V287, P107, DOI 10.1038/287107a0; WATTENBERG LW, 1983, CANCER RES, V43, P2448; WATTENBERG LW, 1985, CANCER RES, V45, P1; Yoshizawa S., 1987, PHYTOTHER RES, V1, P44, DOI [10.1002/ptr.2650010110, DOI 10.1002/PTR.2650010110]; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; 1976, CANCER RES, V36, P2475	29	69	70	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1211	1213						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901533				2022-12-01	WOS:A1993MG27400013
J	SUNDNES, KO; HAIMANOT, AT				SUNDNES, KO; HAIMANOT, AT			EPIDEMIC OF LOUSE-BORNE RELAPSING FEVER IN ETHIOPIA	LANCET			English	Article							TETRACYCLINE; PENICILLIN	During summer 1991 an outbreak of louse-borne relapsing fever occurred simultaneously in two transit camps established for prisoners of war being returned from Eritrea at the end of the Ethiopian civil war. Only antibiotic treatment was given at the Bahr Dar camp where the frequency of cases increased for 20 days. Vector control by delousing in addition to antibiotics was given at Mekele camp where the frequency of cases fell over a similar period. This difference was significant (p < 0.001). Furthermore, there was a significant correlation between the decreasing proportion of camp inhabitants that had not been deloused at Mekele camp each day and the numbers of patients with fever (r = 0.89, p < 0.001). Taken together, these results confirm that effective control of an epidemic of louse-borne relapsing fever is dependent on efficient vector control in addition to antibiotic treatment.	INT COMM RED CROSS,MEKELE DELEGAT,ADDIS ABABA,ETHIOPIA; WHO,MALARIA UNIT,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization								BRYCESON AD, 1970, Q J MED, V39, P129; GEBREHIWOT T, 1992, ETHIOPIAN MED J, V30, P175; MEKASHA A, 1992, J TROP MED HYG, V95, P206; PERINE PL, 1983, AM J TROP MED HYG, V32, P1096, DOI 10.4269/ajtmh.1983.32.1096; RIJKELS DF, 1971, TROP GEOGR MED, V23, P335; WARRELL DA, 1983, J INFECT DIS, V147, P898, DOI 10.1093/infdis/147.5.898	6	42	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1213	1215		10.1016/0140-6736(93)92190-5	http://dx.doi.org/10.1016/0140-6736(93)92190-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901534				2022-12-01	WOS:A1993MG27400014
J	BELFORT, M				BELFORT, M			AN EXPANDING UNIVERSE OF INTRONS	SCIENCE			English	Editorial Material							GROUP-I INTRON; TETRAHYMENA				BELFORT, M (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DAVID AXELROD INST PUBL HLTH,ALBANY,NY 12201, USA.			Belfort, Marlene/0000-0002-1592-5618				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MORI M, 1990, CELL, V60, P629; MORI M, 1992, CELL, V70, P803; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	14	29	31	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1009	1010		10.1126/science.7694364	http://dx.doi.org/10.1126/science.7694364			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694364				2022-12-01	WOS:A1993MG18700023
J	COOK, SJ; MCCORMICK, F				COOK, SJ; MCCORMICK, F			INHIBITION BY CAMP OF RAS-DEPENDENT ACTIVATION OF RAF	SCIENCE			English	Article							CYCLIC-AMP; PROTEIN-KINASE; TYROSINE KINASES; CHOLERA-TOXIN; MAP KINASE; CELL-PROLIFERATION; GROWTH; PATHWAY; SHC; EXPRESSION	Activation of the Raf and extracellular signal-regulated kinases (ERKs) (or mitogen-activated protein kinases) are key events in mitogenic signaling, but little is known about interactions with other signaling pathways. Agents that raise levels of intracellular cyclic adenosine 3',5'-monophosphate (cAMP) blocked DNA synthesis and signal transduction in Rat1 cells exposed to epidermal growth factor (EGF) or lysophosphatidic acid. In the case of EGF, receptor tyrosine kinase activity and association with the signaling molecules Grb2 and Shc were unaffected by cAMP. Likewise, EGF-dependent accumulation of the guanosine 5'-triphosphate-bound form of Ras was unaffected. In contrast, activation of Raf-1 and ERK kinases was inhibited. Thus, cAMP appears to inhibit signal transmission from Ras by preventing Ras-dependent activation of Raf-1.			COOK, SJ (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.				NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA51992-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOK S, UNPUB; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOTTESMAN MM, 1986, CANCER SURV, V5, P291; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAUR G, 1992, CANCER RES, V52, P3340; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P88; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, IN PRESS MOL CELL BI; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; NODA N, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RALL TW, 1957, J BIOL CHEM, V224, P463; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAKODA T, 1992, ONCOGENE, V7, P1705; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDOP C, 1984, J BIOL CHEM, V259, P696; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	46	932	948	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1069	1072		10.1126/science.7694367	http://dx.doi.org/10.1126/science.7694367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694367				2022-12-01	WOS:A1993MG18700040
J	MURPHY, CJ; ARKIN, MR; JENKINS, Y; GHATLIA, ND; BOSSMANN, SH; TURRO, NJ; BARTON, JK				MURPHY, CJ; ARKIN, MR; JENKINS, Y; GHATLIA, ND; BOSSMANN, SH; TURRO, NJ; BARTON, JK			LONG-RANGE PHOTOINDUCED ELECTRON-TRANSFER THROUGH A DNA HELIX	SCIENCE			English	Article							MARCUS INVERTED REGION; MOLECULAR LIGHT SWITCH; METAL-COMPLEXES; EXCITED-STATE; DIIMINE COMPLEXES; RUTHENIUM(II); DISTANCE; RHODIUM(III); RECOGNITION; SEQUENCE	Rapid photoinduced electron transfer is demonstrated over a distance of greater than 40 angstroms between metallointercalators that are tethered to the 5' termini of a 15-base pair DNA duplex. An oligomeric assembly was synthesized in which the donor is Ru(phen)2dppz2+ (phen, phenanthroline, and dppz, dipyridophenazine) and the acceptor is Rh(phi)2phen3+ (phi, phenanthrenequinone diimine). These metal complexes are intercalated either one or two base steps in from the helix termini. Although the ruthenium-modified oligonucleotide hybridized to an unmodified complement luminesces intensely, the ruthenium-modified oligomer hybridized to the rhodium-modified oligomer shows no detectable luminescence. Time-resolved studies point to a lower limit of 10(9) per second for the quenching rate. No quenching was observed upon metallation of two complementary octamers by Ru(phen)3(2+) and Rh(phen)3(3+) under conditions where the phen complexes do not intercalate. The stacked aromatic heterocycles of the DNA duplex therefore serve as an efficient medium for coupling electron donors and acceptors over very long distances.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; COLUMBIA UNIV, DEPT CHEM, NEW YORK, NY 10027 USA	California Institute of Technology; Columbia University			Bossmann, Stefan/AAG-9881-2020	Murphy, Catherine/0000-0001-7066-5575	NIGMS NIH HHS [GM49216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL E, 1990, J CHEM SOC DALTON, P1841, DOI 10.1039/dt9900001841; BANNWARTH W, 1988, HELV CHIM ACTA, V71, P2085, DOI 10.1002/hlca.19880710826; BARTON JK, 1986, J AM CHEM SOC, V108, P6391, DOI 10.1021/ja00280a047; BARTON JK, 1986, J AM CHEM SOC, V108, P2081, DOI 10.1021/ja00268a057; BERATAN DN, 1991, ADV CHEM SER, P71; BOWLER BE, 1990, PROG INORG CHEM, V38, P259; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CHAMBRON JC, 1985, NOUV J CHIM, V9, P527; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHOW CS, 1990, J AM CHEM SOC, V112, P2839, DOI 10.1021/ja00163a076; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P972, DOI 10.1021/bi00119a005; CLEMENTI E, 1982, INT J QUANTUM CHEM, P213; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; CLOSS GL, 1986, J PHYS CHEM-US, V90, P3673, DOI 10.1021/j100407a039; DAVID SS, 1993, J AM CHEM SOC, V115, P2984, DOI 10.1021/ja00060a060; FRIEDMAN AE, 1990, J AM CHEM SOC, V112, P4960, DOI 10.1021/ja00168a052; FROMHERZ P, 1986, J AM CHEM SOC, V108, P5361, DOI 10.1021/ja00277a060; FURUE M, 1990, CHEM LETT, P2065, DOI 10.1246/cl.1990.2065; GUPTA N, 1992, ANGEW CHEM INT EDIT, V31, P1048, DOI 10.1002/anie.199210481; HARTSHORN RM, 1992, J AM CHEM SOC, V114, P5919, DOI 10.1021/ja00041a002; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOFFMANN TA, 1964, ADV CHEM PHYS, V7, P84; JENKINS Y, 1992, BIOCHEMISTRY-US, V31, P10809, DOI 10.1021/bi00159a023; JENKINS Y, 1992, J AM CHEM SOC, V114, P8736, DOI 10.1021/ja00048a077; JORAN AD, 1987, NATURE, V327, P508, DOI 10.1038/327508a0; JORAN AD, 1984, J AM CHEM SOC, V106, P6090, DOI 10.1021/ja00332a062; KALYANASUNDARAM K, 1992, J PHYS CHEM-US, V96, P5865, DOI 10.1021/j100193a041; KROTZ AH, 1993, J AM CHEM SOC, V115, P3877, DOI 10.1021/ja00063a004; KROTZ AH, 1990, IN PRESS INORG CHEM, V29; KUMAR CV, 1985, J AM CHEM SOC, V107, P5518, DOI 10.1021/ja00305a032; LARSSON S, 1982, CHEM PHYS LETT, V90, P136, DOI 10.1016/0009-2614(82)83627-0; LINDBERG O, 1954, METHODS BIOCH ANAL, V3; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; MARKS TJ, 1985, SCIENCE, V227, P881, DOI 10.1126/science.227.4689.881; MCLENDON G, 1988, ACCOUNTS CHEM RES, V21, P160, DOI 10.1021/ar00148a005; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MURPHY CF, UNPUB; NALEWAY CA, 1991, J PHYS CHEM-US, V95, P8434, DOI 10.1021/j100175a005; NOZAKI K, 1992, J PHYS CHEM-US, V96, P10880, DOI 10.1021/j100205a051; PURUGGANAN MD, 1988, SCIENCE, V241, P1645, DOI 10.1126/science.3420416; PYLE AM, 1990, J AM CHEM SOC, V112, P9432, DOI 10.1021/ja00181a077; PYLE AM, 1990, INORG CHEM, V29, P4487, DOI 10.1021/ic00347a031; PYLE AM, 1989, J AM CHEM SOC, V111, P4520, DOI 10.1021/ja00194a070; RATNER MA, 1990, J PHYS CHEM-US, V94, P4877, DOI 10.1021/j100375a024; SCHOUTEN PG, 1991, NATURE, V353, P736, DOI 10.1038/353736a0; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; TANAKA M, 1991, J PHYS CHEM-US, V95, P955, DOI 10.1021/j100155a084; TELSER J, 1989, J AM CHEM SOC, V111, P7221, DOI 10.1021/ja00200a049; Turro NJ., 1991, MODERN MOL PHOTOCHEM; UCHIDA K, 1989, NUCLEIC ACIDS RES, V17, P10259, DOI 10.1093/nar/17.24.10259; WASIELEWSKI MR, 1992, CHEM REV, V92, P435, DOI 10.1021/cr00011a005; WOITELLIER S, 1989, INORG CHEM, V28, P758, DOI 10.1021/ic00303a029	53	891	933	3	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1025	1029		10.1126/science.7802858	http://dx.doi.org/10.1126/science.7802858			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7802858				2022-12-01	WOS:A1993MG18700026
J	SPENCER, DM; WANDLESS, TJ; SCHREIBER, SL; CRABTREE, GR				SPENCER, DM; WANDLESS, TJ; SCHREIBER, SL; CRABTREE, GR			CONTROLLING SIGNAL-TRANSDUCTION WITH SYNTHETIC LIGANDS	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; LYMPHOCYTE-T ACTIVATION; CYCLOSPORINE-A; ZETA-CHAIN; MATHEMATICAL THEORY; MOLECULAR-CLONING; ATOMIC-STRUCTURE; BINDING SYSTEMS; KINASE-ACTIVITY; PROTEIN	Dimerization and oligomerization are general biological control mechanisms contributing to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. Cell permeable, synthetic ligands were devised that can be used to control the intracellular oligomerization of specific proteins. To demonstrate their utility, these ligands were used to induce intracellular oligomerization of cell surface receptors that lacked their transmembrane and extracellular regions but contained intracellular signaling domains. Addition of these ligands to cells in culture resulted in signal transmission and specific target gene activation. Monomeric forms of the ligands blocked the pathway. This method of ligand-regulated activation and termination of signaling pathways has the potential to be applied wherever precise control of a signal transduction pathway is desired.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Harvard University; Howard Hughes Medical Institute; Stanford University								BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FELDMAN H, 1972, ANAL BIOCHEM, V45, P530, DOI 10.1016/0003-2697(72)90216-3; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LYSON T, 1993, CIRC RES, V73, P596, DOI 10.1161/01.RES.73.3.596; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ORGAN HM, 1993, BIOORG MED CHEM LETT, V3, P657, DOI 10.1016/S0960-894X(01)81248-8; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROSEN MK, 1992, ANGEW CHEM INT EDIT, V31, P384, DOI 10.1002/anie.199203841; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SPENCER DJE, UNPUB; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WAQNDLESS TJ, UNPUB; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; YU LM, 1992, J IMMUNOL, V148, P633	53	665	774	3	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1019	1024		10.1126/science.7694365	http://dx.doi.org/10.1126/science.7694365			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694365				2022-12-01	WOS:A1993MG18700025
J	WU, J; DENT, P; JELINEK, T; WOLFMAN, A; WEBER, MJ; STURGILL, TW				WU, J; DENT, P; JELINEK, T; WOLFMAN, A; WEBER, MJ; STURGILL, TW			INHIBITION OF THE EGF-ACTIVATED MAP KINASE SIGNALING PATHWAY BY ADENOSINE-3',5'-MONOPHOSPHATE	SCIENCE			English	Article							PROTEIN-KINASE; CORONARY-ARTERIES; RECEPTOR; CELLS; RAF	Mitogen-activated protein (MAP) kinases P42mapk and p44mapk are activated in cells stimulated with epidermal growth factor (EGF) and other agents. A principal pathway for MAP kinase (MAPK) activation by EGF consists of sequential activations of the guanine nucleotide exchange factor Sos, the guanosine triphosphate binding protein Ras, and the protein kinases Raf-1, MAPK kinase (MKK), and MAPK. Because adenosine 3',5'-monophosphate (cAMP) does not activate MAPK and has some opposing physiologic effects, the effect of increasing intracellular concentrations of cAMP with forskolin and 3-isobutyl-1-methylxanthine on the EGF-stimulated MAPK pathway was studied. Increased concentrations of cAMP blocked activation of Raf-1, MKK, and MAPK in Rat1hER fibroblasts, accompanied by a threefold increase in Raf-1 phosphorylation on serine 43 in the regulatory domain. Phosphorylation of Raf-1 in vitro and in vivo reduces the apparent affinity with which it binds to Ras and may contribute to the blockade by cAMP.	UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; CLEVELAND CLIN EDUC FDN, DEPT CELL BIOL, CLEVELAND, OH 44106 USA	University of Virginia; University of Virginia; University of Virginia; Cleveland Clinic Foundation			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606	NATIONAL CANCER INSTITUTE [R01CA039076, R37CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NCI NIH HHS [CA39076] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHOW YL, UNPUB; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CONRAD KE, 1992, ONCOGENE, V7, P1279; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JIANG H, 1992, J BIOL CHEM, V267, P1015; JOHNSON GS, 1972, NATURE, V263, P247; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; ODA A, 1988, Hokkaido Journal of Medical Science, V63, P747; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1505; RHEE SG, 1993, ADV SEC MESS PHOSPH, V28, P57; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEBER MJ, 1974, P C MECHANISMS VIRUS, P327; WELLS JN, 1975, MOL PHARMACOL, V11, P775; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Wu J.-Y., UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	46	905	924	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1065	1069		10.1126/science.7694366	http://dx.doi.org/10.1126/science.7694366			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694366				2022-12-01	WOS:A1993MG18700039
J	TAKAHASHI, T; MOMIYAMA, A				TAKAHASHI, T; MOMIYAMA, A			DIFFERENT TYPES OF CALCIUM CHANNELS MEDIATE CENTRAL SYNAPTIC TRANSMISSION	NATURE			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; OMEGA-AGA-IVA; SELECTIVE MODULATION; NERVE-TERMINALS; NEURONS; CONOTOXIN; HIPPOCAMPUS; RELEASE; INVITRO	SYNAPTIC transmission is mediated by calcium entry through voltage-dependent calcium channels in presynaptic nerve terminals1,2. Various types of calcium channel have been characterized in neuronal somata3-6, but it is not clear which subtypes induce transmitter release at central synapses. The N-type Ca2+ channel blocker omega-conotoxin GVIA (omega-CgTx) suppresses the excitatory postsynaptic responses only partially7,8, whereas potassium-induced release of glutamate from brain synaptosomes can be blocked by omega-Aga-VIA (ref. 9), a blocker of P-type calcium channels5,10 and possibly of other types of calcium channels11,12. Here we test type-specific calcium-channel blockers on postsynaptic currents recorded from neurons in thin slices of rat central nervous system13. Inhibitory postsynaptic currents in cerebellar and spinal neurons and excitatory postsynaptic currents in hippocampal neurons are markedly suppressed by omega-Aga-IVA and reduced to a lesser extent by omega-CgTx. The L-type calcium channel blocker nicardipine had no effect. Our results indicate that at least two types of calcium channel mediate synaptic transmission in the mammalian central nervous system.	KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN	Kyoto University			Takahashi, Tomoyuki/G-5951-2015	Takahashi, Tomoyuki/0000-0002-8771-7666				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; AUGUSTINE GJ, 1986, J PHYSIOL-LONDON, V381, P619, DOI 10.1113/jphysiol.1986.sp016347; COX DH, 1992, J NEUROSCI, V12, P906; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; Katz B., 1969, RELEASE NEURAL TRANS; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Sather W. A., 1992, Society for Neuroscience Abstracts, V18, P10; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V450, P593, DOI 10.1113/jphysiol.1992.sp019145; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P	25	643	657	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					156	158		10.1038/366156a0	http://dx.doi.org/10.1038/366156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	7901765				2022-12-01	WOS:A1993MG21600057
J	WATLING, D; GUSCHIN, D; MULLER, M; SILVENNOINEN, O; WITTHUHN, BA; QUELLE, FW; ROGERS, NC; SCHINDLER, C; STARK, GR; IHLE, JN; KERR, IM				WATLING, D; GUSCHIN, D; MULLER, M; SILVENNOINEN, O; WITTHUHN, BA; QUELLE, FW; ROGERS, NC; SCHINDLER, C; STARK, GR; IHLE, JN; KERR, IM			COMPLEMENTATION BY THE PROTEIN-TYROSINE KINASE JAK2 OF A MUTANT-CELL LINE DEFECTIVE IN THE INTERFERON-GAMMA SIGNAL-TRANSDUCTION PATHWAY	NATURE			English	Article							IFN-GAMMA; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; RECEPTOR; ANTIGEN; DOMAIN	INTERFERONS (IFNs) alpha/beta (type I) and gamma (type II) bind to distinct cell surface receptors1, inducing transcription of overlapping sets of genes by intracellular pathways that have recently attracted much attention2,3. Previous studies using cell lines selected for their inability to respond to IFN-alpha (ref. 4) have shown that the protein kinase Tyk2 plays a central role in the IFN alpha/beta response5. Here we report the isolation of the cell line gamma1A, selected for its inability to express IFN-gamma-inducible cell-surface markers, that is deficient in all aspects of the IFN-gamma response tested, but responds normally to IFNs alpha and beta. The mutant cells can be complemented by the expression of another member of the JAK family of protein tyrosine kinases, JAK2 (refs 6-9). Unlike IFNs alpha and beta, IFN-gamma induces rapid tyrosine phosphorylation of JAK2 in wild-type cells, and JAK2 immunoprecipitates from these cells show tyrosine kinase activity. These responses are absent in gamma1A cells. JAK2 is therefore required for the response to IFN-gamma but not to IFNs alpha and beta.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; COLUMBIA UNIV, MED CTR, DEPT MOLEC MED, NEW YORK, NY 10032 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	New York University; St Jude Children's Research Hospital; Columbia University; Cleveland Clinic Foundation	WATLING, D (corresponding author), IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Guschin, Dmitry/U-3731-2019; witthuhn, bruce/GSE-3193-2022; Guschin, Dmitry/O-7594-2018	Guschin, Dmitry/0000-0002-4184-0001; Guschin, Dmitry/0000-0002-4184-0001; Muller, Mathias/0000-0002-7879-3552; Rogers, Neil/0000-0001-8977-7585; Quelle, Frederick/0000-0002-1184-6170				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1328; HARPUR AG, 1992, ONCOGENE, V7, P1347; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEWELL WA, 1986, P NATL ACAD SCI USA, V83, P8718, DOI 10.1073/pnas.83.22.8718; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STASHL N, 1993, CELL, V74, P587; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	27	478	486	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					166	170		10.1038/366166a0	http://dx.doi.org/10.1038/366166a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	7901766				2022-12-01	WOS:A1993MG21600060
J	ARTHUR, RR; ELSHARKAWY, MS; COPE, SE; BOTROS, BA; OUN, S; MORRILL, JC; SHOPE, RE; HIBBS, RG; DARWISH, MA; IMAM, IZE				ARTHUR, RR; ELSHARKAWY, MS; COPE, SE; BOTROS, BA; OUN, S; MORRILL, JC; SHOPE, RE; HIBBS, RG; DARWISH, MA; IMAM, IZE			RECURRENCE OF RIFT-VALLEY FEVER IN EGYPT	LANCET			English	Note								Rift Valley fever (RVF) has been recorded in man and in domestic animals in Egypt after a 12-year absence. Human infections were first noted in the Aswan Governorate in late May, 1993. Only cases of ocular disease, an infrequent and late manifestation, were reported. Of 41 cases, 35 were tested serologically and 27 (77%) had RVF virus-specific IgM antibodies. An estimated 600-1500 infections occurred in the region. Abortions in cattle and buffalo were seen concurrently and antibodies to RVFV were present in 39% of domestic livestock, presumably unvaccinated. RVFV was isolated from an aborted water buffalo fetus.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD 21218; MINIST HLTH CAIRO,CAIRO,EGYPT; USA,INFECT DIS RES INST,FT DETRICK,MD; YALE UNIV,YALE ARBOVIRUS RES UNIT,NEW HAVEN,CT 06520; AIN SHAMS UNIV,FAC MED,CAIRO,EGYPT	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt; Yale University; Egyptian Knowledge Bank (EKB); Ain Shams University	ARTHUR, RR (corresponding author), USN,MED RES UNIT 3,CODE 307,PSC 452,BOX 5000,FPO AE 09835 000,CAIRO,EGYPT.				NIAID NIH HHS [AI 10984] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI010984, R37AI010984, R01AI010984] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		IMAM IZE, 1981, J EGYPT PUBL HLTH AS, V56, P435; NIKLASSON B, 1984, J CLIN MICROBIOL, V19, P225, DOI 10.1128/JCM.19.2.225-229.1984; SIAM AL, 1980, T ROY SOC TROP MED H, V74, P539, DOI 10.1016/0035-9203(80)90074-7; 1985, INT CATALOGUE ARBOVI, P857	4	78	81	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1149	1150		10.1016/0140-6736(93)92128-G	http://dx.doi.org/10.1016/0140-6736(93)92128-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901480				2022-12-01	WOS:A1993MF19800014
J	BOYLE, P; MACFARLANE, GJ; SCULLY, C				BOYLE, P; MACFARLANE, GJ; SCULLY, C			ORAL-CANCER - NECESSITY FOR PREVENTION STRATEGIES	LANCET			English	Editorial Material									BRISTOL DENT HOSP & SCH, CTR STUDY ORAL DIS, BRISTOL, ENGLAND	University of Bristol	BOYLE, P (corresponding author), EUROPEAN INST ONCOL, DIV EPIDEMIOL & BIOSTAT, MILAN, ITALY.		Macfarlane, Gary J/I-9521-2014; Boyle, Peter/A-4380-2014	Macfarlane, Gary J/0000-0003-2322-3314; Boyle, Peter/0000-0001-6251-0610				BOYLE P, 1990, J ROY SOC MED, V83, P724, DOI 10.1177/014107689008301116; DAVIS S, 1987, LANCET, V2, P910; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JENSEN OM, 1990, EUR J CANCER, V26, P1167; LAVECCHIA C, 1992, EUR J CANCER, V28A, P132; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; MACFARLANE GJ, 1992, BRIT MED J, V305, P1121, DOI 10.1136/bmj.305.6862.1121; MACFARLANE GJ, 1987, LANCET, V2, P912; MALAOWALLA AM, 1976, CANCER-AM CANCER SOC, V37, P1882, DOI 10.1002/1097-0142(197604)37:4<1882::AID-CNCR2820370437>3.0.CO;2-2; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SCULLY C, 1992, ORAL ONCOL, V28B, P87, DOI 10.1016/0964-1955(92)90033-W	11	32	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1993	342	8880					1129	1129		10.1016/0140-6736(93)92119-E	http://dx.doi.org/10.1016/0140-6736(93)92119-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901471				2022-12-01	WOS:A1993MF19800005
J	BRENNER, MK; RILL, DR; HOLLADAY, MS; HESLOP, HE; MOEN, RC; BUSCHLE, M; KRANCE, RA; SANTANA, VM; ANDERSON, WF; IHLE, JN				BRENNER, MK; RILL, DR; HOLLADAY, MS; HESLOP, HE; MOEN, RC; BUSCHLE, M; KRANCE, RA; SANTANA, VM; ANDERSON, WF; IHLE, JN			GENE MARKING TO DETERMINE WHETHER AUTOLOGOUS MARROW INFUSION RESTORES LONG-TERM HEMATOPOIESIS IN CANCER-PATIENTS	LANCET			English	Article							HEMATOPOIETIC STEM-CELLS; HIGH-DOSE CHEMOTHERAPY; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; BONE-MARROW; TRANSPLANTATION; EXPRESSION; PROGENITORS; RECOVERY; RECONSTITUTION	The contribution of infused bone marrow cells to long-term haemopoietic recovery in patients undergoing autologous bone marrow transplantation is unknown. Such information would help to clarify the role of this procedure in cancer therapy and would aid in the development of strategies to reduce the risk of subsequent aplasia. By transferring a neomycin resistance marker gene into the marrow cells of 20 patients before transplantation, we were able to trace the pattern of haemopoietic reconstitution postinfusion. The marker gene was present and expressed in all haemopoietic lineages in vivo in 15 of 18 evaluable patients at 1 month post-transplantation, in 8 of 9 patients at 6 months, and in 5 of 5 at 1 year. The marker has remained detectable for up to 18 months-the duration of our study. Our findings indicate that harvested bone marrow consistently contributes to long-term multilineage recovery of haemopoiesis after autologous marrow transplantation in cancer patients. These results, provide a rationale for the continued exploration of more ablative preparative regimens with single or sequential autologous marrow transplants.	UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT MED, MEMPHIS, TN 38163 USA; GENET THERAPY INC, GAITHERSBURG, MD 20878 USA; USC, SCH MED, LOS ANGELES, CA 90033 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Novartis; University of Southern California; St Jude Children's Research Hospital	BRENNER, MK (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA.		Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P30CA021765, U01CA058211] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58211, CA 21765, CA 59479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BODINE DM, 1991, EXP HEMATOL, V19, P206; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; CHOPRA R, 1991, J CLIN ONCOL, V9, P1840, DOI 10.1200/JCO.1991.9.10.1840; EKHTERAE D, 1990, BLOOD, V75, P365; GALE RP, 1989, LANCET, V2, P315; GIANNI AM, 1989, LANCET, V2, P580; GRAHAMPOLE J, 1991, BLOOD, V78, P1607; LAPORTE JP, 1991, LANCET, V338, P601, DOI 10.1016/0140-6736(91)90609-S; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; LOTHROP CD, 1991, BLOOD, V78, P237; MCMILLAN AK, 1990, BLOOD, V76, P480; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1990, BLOOD, V76, P271; RILL DR, 1992, BLOOD, V79, P2694; RILL DR, 1992, HUM GENE THER, V3, P129, DOI 10.1089/hum.1992.3.2-129; SCHUENING FG, 1991, BLOOD, V78, P2568; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SIENA S, 1991, BLOOD, V77, P400; STEWART FM, 1989, EXP HEMATOL, V17, P974; VANBEUSECHEM VW, 1992, P NATL ACAD SCI USA, V89, P7640, DOI 10.1073/pnas.89.16.7640; WIEDER R, 1991, BLOOD, V77, P448; 1989, LANCET, V2, P317	25	384	395	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1134	1137		10.1016/0140-6736(93)92122-A	http://dx.doi.org/10.1016/0140-6736(93)92122-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901474				2022-12-01	WOS:A1993MF19800008
J	CLARKE, IMC				CLARKE, IMC			PEPPERING PAIN	LANCET			English	Editorial Material							CAPSAICIN				CLARKE, IMC (corresponding author), UNIV CALGARY,CALGARY T2N 1N4,ALBERTA,CANADA.							CARPENTER SE, 1983, ADV PAIN RES THER, V5, P83; DRAY A, 1992, LIFE SCI, V51, P1759, DOI 10.1016/0024-3205(92)90045-Q; GEPPETTI P, 1992, REGUL PEPTIDES, V41, P83, DOI 10.1016/0167-0115(92)90516-W; LAMOTTE RH, 1992, J PHYSIOL-LONDON, V448, P749, DOI 10.1113/jphysiol.1992.sp019068; LEVINE JD, 1988, 5TH P WORLD C PAIN, P33	5	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1130	1130		10.1016/0140-6736(93)92120-I	http://dx.doi.org/10.1016/0140-6736(93)92120-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901472				2022-12-01	WOS:A1993MF19800006
J	HOWARD, R				HOWARD, R			SCHIZOPHRENIA AND THE GUT, AGAIN	LANCET			English	Editorial Material							LIPID-PEROXIDATION; PERMEABILITY				HOWARD, R (corresponding author), INST PSYCHIAT,LONDON SE5,ENGLAND.			Howard, Robert/0000-0002-3071-2338				BEAUCHAMP RO, 1983, CRC CR REV TOXICOL, V11, P169, DOI 10.3109/10408448309128255; HUMAD S, 1988, FREE RADICAL RES COM, V5, P101, DOI 10.3109/10715768809066917; KOVALEVA ES, 1989, ZH NEVROPATOL PSIKH, V89, P108; Kretschmer Ernst, 1925, PHYSIQUE CHARACTER; LAMBERT MT, 1989, BRIT J PSYCHIAT, V155, P619; PHILLIPS M, 1993, J CLIN PATHOL, V46, P861, DOI 10.1136/jcp.46.9.861; SMYTHIES JR, 1963, SCHIZOPHRENIA CHEM M; VANGOSSUM A, 1989, EUR RESPIR J, V2, P787; WEITZ ZW, 1991, LANCET, V337, P933, DOI 10.1016/0140-6736(91)91569-G; WOOD NC, 1987, BRIT J PSYCHIAT, V150, P853, DOI 10.1192/bjp.150.6.853	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1128	1129		10.1016/0140-6736(93)92118-D	http://dx.doi.org/10.1016/0140-6736(93)92118-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901470				2022-12-01	WOS:A1993MF19800004
J	JEEVAN, A; KRIPKE, ML				JEEVAN, A; KRIPKE, ML			OZONE DEPLETION AND THE IMMUNE-SYSTEM	LANCET			English	Article							HUMANS; RADIATION; INDUCTION; SKIN		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; JEEVAN A, 1992, BIOL EFFECTS LIGHT, P83; KRIPKE ML, 1990, J NATL CANCER I, V82, P1392, DOI 10.1093/jnci/82.17.1392; VERMEER M, 1991, J INVEST DERMATOL, V97, P729, DOI 10.1111/1523-1747.ep12484259; YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877	5	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1159	1160		10.1016/0140-6736(93)92131-C	http://dx.doi.org/10.1016/0140-6736(93)92131-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901483				2022-12-01	WOS:A1993MF19800017
J	LLOYD, SA				LLOYD, SA			STRATOSPHERIC OZONE DEPLETION	LANCET			English	Article							ANTARCTIC VORTEX; SUNLIGHT; EXPOSURE; RISK		HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								ANDERSON DE, 1990, J GEOPHYS RES-ATMOS, V95, P7429, DOI 10.1029/JD095iD06p07429; ANDERSON JG, 1989, J GEOPHYS RES-ATMOS, V94, P11480, DOI 10.1029/JD094iD09p11480; ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; EMMETT EA, 1986, EFFECTS CHANGES STRA, V1, P129; GLEASON JF, 1993, SCIENCE, V260, P523, DOI 10.1126/science.260.5107.523; KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366; ROWLAND FS, 1974, NATURE, V249, P810; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1481, DOI 10.1001/archopht.1989.01070020555039; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; TUCKER MA, 1985, NEW ENGL J MED, V313, P789, DOI 10.1056/NEJM198509263131305; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; 1986, NASA16 WORLD MET ORG, V1; 1991, REPORT INT OZONE TRE; [No title captured]	16	42	44	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1156	1158		10.1016/0140-6736(93)92130-L	http://dx.doi.org/10.1016/0140-6736(93)92130-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901482				2022-12-01	WOS:A1993MF19800016
J	MILLER, D; MADGE, N; DIAMOND, J; WADSWORTH, J; ROSS, E				MILLER, D; MADGE, N; DIAMOND, J; WADSWORTH, J; ROSS, E			PERTUSSIS IMMUNIZATION AND SERIOUS ACUTE NEUROLOGICAL ILLNESSES IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							VACCINE; IMMUNIZATION	Objective-To determine long term outcome in children who had a severe acute neurological illness in early childhood associated with pertussis immunisation. Design-Follow up study of cases and matched controls. Setting-Assessment of children at home and at school throughout Britain. Subjects-Children recruited into the national childhood encephalopathy study in 1976-9 were followed up, with one of their two original matched controls, in 1986-9. Main outcome measures-Performance in educational attainment tests; behaviour problems reported by teachers and parents; continuing convulsions; evidence of other neurological or physical dysfunction. Results-Over 80% of cases and controls were traced. Case children were significantly more likely than controls to have died or to have some form of educational, behavioural, neurological, or physical dysfunction a decade after their illness. The prevalence of one or more of these adverse outcomes in case children who had been immunised with diphtheria, tetanus, and pertussis vaccine within seven days before onset of their original illness was similar to that in case children who had not been immunised recently. The relative risk for recent diphtheria, tetanus, and pertussis immunisation in children who had died or had any dysfunction in comparison with controls was 5.5 (95% confidence interval 1.6 to 23.7). However, the number of cases associated with vaccine (12) was extremely small and statistically vulnerable, and other possible agents or predisposing factors could not be excluded. Conclusions-Diphtheria, tetanus, and pertussis vaccine may on rare occasions be associated with the development of severe acute neurological illnesses that can have serious sequelae. Some cases may occur by chance or have other causes. The role of pertussis vaccine as a prime or concomitant factor in the aetiology of these illnesses cannot be determined in any individual case. The balance of possible risk against known benefits from pertussis immunisation supports continued use of the vaccine.	UNIV LONDON,KINGS COLL HOSP,SCH MED & DENT,DEPT COMMUNITY PAEDIAT,LONDON,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London	MILLER, D (corresponding author), UNIV LONDON,SCH MED,ST MARYS HOSP,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND.			Madge, Nicola/0000-0003-3028-7690				ALDERSLADE R, 1981, WHOOPING COUGH, P79; [Anonymous], 1983, MANUAL RAVENS PROGR; BELLMAN MH, 1985, CHILD CARE HLTH DEV, V11, P309, DOI 10.1111/j.1365-2214.1985.tb00472.x; BELLMAN MH, 1983, LANCET, V1, P1031; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BRIMER A, 1984, WIDE SPAN READING TE; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GALE JL, 1990, DHSS FDA901162 DEP H, P228; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HOWSON CP, 1991, ADVERSE EFFECTS PERT, P65; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; Madge N, 1993, Dev Med Child Neurol Suppl, V68, P1; MARCUSE EK, 1990, VACCINE, V8, P531, DOI 10.1016/0264-410X(90)90003-5; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; MILLER D, 1990, LANCET, V335, P655, DOI 10.1016/0140-6736(90)90438-B; MILLER D, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P145; MILLER DL, 1982, EPIDEMIOL REV, V4, P1; MILLER DL, 1989, VACCINE, V7, P487, DOI 10.1016/0264-410X(89)90268-5; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; MILLER DL, 1985, DEV BIOL STAND, V16, P389; RAVEN JC, 1982, MANUAL RAVENS PROGR; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; RUTTER M, 1970, ED HLTH BEHAVIOR; STEWART GT, 1977, LANCET, V1, P234; VERNON PE, 1906, GRADED ARITHMETIC MA; VERNON PE, 1977, GRADED WORD SPELLING; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1981, WHOOPING COUGH REPOR, P170	28	65	72	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1171	1176		10.1136/bmj.307.6913.1171	http://dx.doi.org/10.1136/bmj.307.6913.1171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	7504540	Green Published, Bronze			2022-12-01	WOS:A1993MF82400020
J	NAKAMURA, T; EBIHARA, I; SHIRATO, I; FUKUI, M; TOMINO, Y; KOIDE, H				NAKAMURA, T; EBIHARA, I; SHIRATO, I; FUKUI, M; TOMINO, Y; KOIDE, H			ENDOTHELIN-1 MESSENGER-RNA EXPRESSION BY PERIPHERAL-BLOOD MONOCYTES IN IGA NEPHROPATHY	LANCET			English	Note							CELLS	We investigated endothelin-1 mRNA expression in peripheral blood monocytes from 40 patients with IgA nephropathy, 40 with other glomerulonephritides and 10 with essential hypertension without renal diseases, and from 30 healthy age-matched controls. 95% of patients with IgA nephropathy had increased endothelin-1 mRNA expression in monocytes but little was detected from the other groups. Endothelin-1 mRNA was positively correlated with urinary protein excretion (95% CI 0.835-0.952) and histopathological findings (0.796-0.939). In. 15 patients with IgA nephropathy endothelin-1 mRNA values and proteinuria decreased gradually after treatment Endathelin-1 mRNA-expressing activated monocytes may be associated with the progression of IgA nephropathy.	JUNTENDO UNIV,SCH MED,DEPT MED,DIV NEPHROL,TOKYO 113,JAPAN	Juntendo University								BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; ISHIMURA E, 1989, AM J PATHOL, V134, P843; LEE SMK, 1982, HUM PATHOL, V13, P314, DOI 10.1016/S0046-8177(82)80221-9; NAKAMURA T, 1992, AM J NEPHROL, V12, P292, DOI 10.1159/000168463; NAKAMURA T, 1992, J LAB CLIN MED, V120, P212	6	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1147	1148		10.1016/0140-6736(93)92126-E	http://dx.doi.org/10.1016/0140-6736(93)92126-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901478				2022-12-01	WOS:A1993MF19800012
J	SHERLOCK, S				SHERLOCK, S			EUROPEAN LIVERS	LANCET			English	Editorial Material											SHERLOCK, S (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT SURG,LONDON,ENGLAND.								0	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1127	1128		10.1016/0140-6736(93)92117-C	http://dx.doi.org/10.1016/0140-6736(93)92117-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901469				2022-12-01	WOS:A1993MF19800003
J	TANG, WZ; LUO, HY; ENG, B; WAYE, JS; CHUI, DHK				TANG, WZ; LUO, HY; ENG, B; WAYE, JS; CHUI, DHK			IMMUNOCYTOLOGICAL TEST TO DETECT ADULT CARRIERS OF (--SEA/) DELETIONAL ALPHA-THALASSEMIA	LANCET			English	Note							GLOBIN; THALASSEMIA	The gene frequency for (--SEA/) deletional alpha-thalassaemia is high in Southeast Asian populations. We report a simple immunocytological test that is highly sensitive and specific for the detection of adult carriers of the (--SEA/) deletion. We prospectively studied 296 consecutive adult blood samples. All 41 with the (--SEA/) deletion had a positive test; all but 1 of the 165 non-carriers were negative. This test, whose major requirement is a fluorescence microscope, should be useful to identify couples at risk of conceiving fetuses with homozygous alpha-thalassaemia.	MCMASTER UNIV,SCH MED,DEPT PATHOL,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University				Chui, David/0000-0002-1475-7309				BOWDEN DK, 1992, BRIT J HAEMATOL, V81, P104, DOI 10.1111/j.1365-2141.1992.tb08180.x; CHUI DHK, 1986, NEW ENGL J MED, V314, P76, DOI 10.1056/NEJM198601093140203; FUCHAROEN S, 1991, BLOOD, V78, pA198; HIGGS DR, 1989, BLOOD, V73, P1081; TANG WZ, 1992, BLOOD, V80, P517; WAYE JS, 1993, CLIN INVEST MED, V16, P358; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2315; ZENG YT, 1985, LANCET, V1, P304	8	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1145	1147		10.1016/0140-6736(93)92125-D	http://dx.doi.org/10.1016/0140-6736(93)92125-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901477				2022-12-01	WOS:A1993MF19800011
J	FREEMAN, GJ; BORRIELLO, F; HODES, RJ; REISER, H; HATHCOCK, KS; LASZLO, G; MCKNIGHT, AJ; KIM, J; DU, LN; LOMBARD, DB; GRAY, GS; NADLER, LM; SHARPE, AH				FREEMAN, GJ; BORRIELLO, F; HODES, RJ; REISER, H; HATHCOCK, KS; LASZLO, G; MCKNIGHT, AJ; KIM, J; DU, LN; LOMBARD, DB; GRAY, GS; NADLER, LM; SHARPE, AH			UNCOVERING OF FUNCTIONAL ALTERNATIVE CTLA-4 COUNTER-RECEPTOR IN B7-DEFICIENT MICE	SCIENCE			English	Article							T-CELL ACTIVATION; INVIVO; EXPRESSION; MOLECULE; ANTIGEN; CLONES	B7 delivers a costimulatory signal through CD28, resulting in interleukin-2 secretion and T cell proliferation. Blockade of this pathway results in T cell anergy. The in vivo role of B7 was evaluated with B7-deficient mice. These mice had a 70 percent decrease in costimulation of the response to alloantigen. Despite lacking B7 expression, activated B cells from these mice bound CTLA-4 and GL1 monoclonal antibody, demonstrating that alternative CTLA-4 ligand or ligands exist. These receptors are functionally important because the residual allogenic mixed lymphocyte responses were blocked by CTLA4Ig. Characterization of these CTLA-4 ligands should lead to strategies for manipulating the immune response.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,IMMUNOL RES DIV,BOSTON,MA 02115; REPLIGEN CORP,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NIA,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Borriello, Frank/0000-0003-3957-3685; Lombard, David/0000-0002-4292-0185; Sharpe, Arlene/0000-0002-9736-2109	NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORRIELLO F, UNPUB; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; FREEMAN G, UNPUB; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; RAZIWOLF Z, IN PRESS P NATL ACAD; REISER H, 1989, P NATL ACAD SCI USA, V86, P10069, DOI 10.1073/pnas.86.24.10069; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WILLIAMS IR, 1990, J IMMUNOL, V145, P85; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	21	396	434	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					907	909		10.1126/science.7694362	http://dx.doi.org/10.1126/science.7694362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694362				2022-12-01	WOS:A1993MF43800038
J	FREEMAN, GJ; GRIBBEN, JG; BOUSSIOTIS, VA; NG, JW; RESTIVO, VA; LOMBARD, LA; GRAY, GS; NADLER, LM				FREEMAN, GJ; GRIBBEN, JG; BOUSSIOTIS, VA; NG, JW; RESTIVO, VA; LOMBARD, LA; GRAY, GS; NADLER, LM			CLONING OF B7-2 - A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T-CELL PROLIFERATION	SCIENCE			English	Article							ACTIVATION; INTERLEUKIN-2; ANTIGEN-B7; INDUCTION; ANERGY	Although presentation of antigen to the T cell receptor is necessary for the initiation of an immune response, additional molecules expressed on antigen-presenting cells deliver essential costimulatory signals. T cell activation, in the absence of costimulation, results in T cell anergy. The B7-1 protein is a costimulator molecule that regulates interleukin-2 (IL-2) secretion by signaling through the pathway that uses CD28 and CTLA-4 (hereafter referred to as the CD28 pathway). We have cloned a counter-receptor of CD28 and CTLA-4, termed B7-2. Although only 26 percent identical to B7-1, B7-2 also costimulates IL-2 production and T cell proliferation. Unlike B7-1, B7-2 messenger RNA is constitutively expressed in unstimulated B cells. It is likely that B7-2 provides a critical early costimulatory signal determining if the T cell will contribute to an immune response or become anergic.	REPLIGEN CORP,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	FREEMAN, GJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616	NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUSSIOTIS VA, IN PRESS J EXP MED; BOUSSIOTIS VA, IN PRESS P NATL ACAD; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN G, UNPUB; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; NICKOLOFF BJ, 1993, AM J PATHOL, V142, P1029; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; YOKOCHI T, 1982, J IMMUNOL, V128, P823	18	898	1006	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					909	911		10.1126/science.7694363	http://dx.doi.org/10.1126/science.7694363			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694363				2022-12-01	WOS:A1993MF43800039
J	HATHCOCK, KS; LASZLO, G; DICKLER, HB; BRADSHAW, J; LINSLEY, P; HODES, RJ				HATHCOCK, KS; LASZLO, G; DICKLER, HB; BRADSHAW, J; LINSLEY, P; HODES, RJ			IDENTIFICATION OF AN ALTERNATIVE CTLA-4 LIGAND COSTIMULATORY FOR T-CELL ACTIVATION	SCIENCE			English	Article							EXPRESSION; PROLIFERATION; ANTIGEN-B7; MOLECULE; INVIVO; B7	Stimulation of T cell proliferation generally requires two signals: The first signal is provided by the T cell receptor binding to antigen, and the second signal or costimulus is provided by a different receptor-ligand interaction. In mouse and human, the CD28-B7 interaction has been identified as a source of costimulatory signals. We have identified a cell surface molecule (GL1) that is distinct from B7 and abundantly expressed on activated B cells. On activated B cells GL1, rather than B7, is the predominant ligand for the T cell-activation molecule CTLA-4. GL1 provides a critical signal for T cell-dependent responses in vitro and in vivo.	NIA,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Bristol-Myers Squibb	HATHCOCK, KS (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.							CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; HATHCOCK KS, UNPUB; LASZLO G, 1993, J IMMUNOL, V150, P5252; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; STEINMAN R, UNPUB; TAN RS, 1992, J IMMUNOL, V149, P3217; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102	16	524	555	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					905	907		10.1126/science.7694361	http://dx.doi.org/10.1126/science.7694361			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694361				2022-12-01	WOS:A1993MF43800037
J	AZUMA, M; ITO, D; YAGITA, H; OKUMURA, K; PHILLIPS, JH; LANIER, LL; SOMOZA, C				AZUMA, M; ITO, D; YAGITA, H; OKUMURA, K; PHILLIPS, JH; LANIER, LL; SOMOZA, C			B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28	NATURE			English	Article							T-CELL ACTIVATION; COSTIMULATORY SIGNAL; LYMPHOCYTES-T; B-CELLS; EXPRESSION; AMPLIFICATION; SUPERFAMILY; MECHANISM; RECEPTOR; B7/BB-1	THE membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes3. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex4,5. Discrepancies between results with anti-CD28 and anti-B7 antibodies have suggested the existence of a second ligand for CD28 and CTLA-4 (refs 3, 6-8). We have generated a monoclonal antibody, IT2, that reacts with a 70K glycoprotein (B70). B70 complementary DNA was cloned from a B-lymphoblastoid cell line library and encodes a new protein of the immunoglobulin superfamily with limited homology to B7. B70 is expressed on resting monocytes and dendritic cells and on activated, but not resting, T, NK and B lymphocytes. IT2 substantially inhibited the binding of a CTLA4-immunoglobulin fusion protein to human B-lymphoblastoid cell lines and, together with anti-B7 antibody, completely blocked CTLA-4 binding. Further IT2 efficiently inhibited primary allogeneic mixed lymphocyte responses. These findings indicate that B70 is a second ligand for CD28 and CTLA-4 and may play an important role for costimulation of T cells in a primary immune response.	UNIV TOKYO,FAC MED,DEPT ORAL & MAXILLOFACIAL SURG,BUNKYO KU,TOKYO 113,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	AZUMA, M (corresponding author), JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,HONGO 2-1-1,BUNKYO KU,TOKYO 113,JAPAN.		Azuma, Miyuki/AAT-8928-2021; Lanier, Lewis L/E-2139-2014	Azuma, Miyuki/0000-0002-3529-4585; Lanier, Lewis L/0000-0003-1308-3952				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1992, J IMMUNOL, V149, P1115; AZUMA M, 1993, J IMMUNOL, V150, P2091; AZUMA M, 1993, J EXP MED, V177, P845, DOI 10.1084/jem.177.3.845; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DOMLO NK, 1991, EUR J IMMUNOL, V21, P1277; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; LANIER LL, 1988, J IMMUNOL, V141, P3478; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; NORTON SD, 1992, J IMMUNOL, V149, P1556; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; YOKOCHI T, 1982, J IMMUNOL, V128, P823; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840	24	910	981	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					76	79		10.1038/366076a0	http://dx.doi.org/10.1038/366076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694153				2022-12-01	WOS:A1993MF00700058
J	KAUFMAN, DL; CLARESALZLER, M; TIAN, JD; FORSTHUBER, T; TING, GSP; ROBINSON, P; ATKINSON, MA; SERCARZ, EE; TOBIN, AJ; LEHMANN, PV				KAUFMAN, DL; CLARESALZLER, M; TIAN, JD; FORSTHUBER, T; TING, GSP; ROBINSON, P; ATKINSON, MA; SERCARZ, EE; TOBIN, AJ; LEHMANN, PV			SPONTANEOUS LOSS OF T-CELL TOLERANCE TO GLUTAMIC-ACID DECARBOXYLASE IN MURINE INSULIN-DEPENDENT DIABETES	NATURE			English	Article							HEAT-SHOCK PROTEIN; AUTOANTIGEN; MOUSE; GAMMA; CD4+; ENCEPHALOMYELITIS; AUTOANTIBODIES; IDENTIFICATION; AUTOIMMUNITY; INDUCTION	INSULIN-DEPENDENT diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice results from the T-lymphocyte-mediated destruction of the insulin-producing pancreatic beta-cells and serves as a model for human IDDM1. Whereas a number of autoantibodies are associated with IDDM2, it is unclear when and to what beta-cell antigens pathogenic T cells become activated during the disease process. We report here that a T-helper-1 (Th1) response to glutamate decarboxylase develops in NOD mice at the same time as the onset of insulitis. This response is initially limited to a confined region of glutamate decarboxylase, but later spreads intramolecularly to additional determinants. Subsequently, T-cell reactivity arises to other beta-cell antigens, consistent with intermolecular diversification of the response. Prevention of the spontaneous anti-glutamate decarboxylase response, by tolerization of glutamate decarboxylase-reactive T cells, blocks the development of T-cell autoimmunity to other beta-cell antigens, as well as insulitis and diabetes. Our data suggest that (1) glutamate decarboxylase is a key target antigen in the induction of murine IDDM; (2) autoimmunity to glutamate decarboxylase triggers T-cell responses to other beta-cell antigens, and (3) spontaneous autoimmune disease can be prevented by tolerization to the initiating target antigen.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of Florida	KAUFMAN, DL (corresponding author), UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024, USA.		Forsthuber, Thomas/AID-8080-2022; Kaufman, Daniel/AAU-1228-2021	Kaufman, Daniel/0000-0002-9844-5918; /0000-0003-0692-7125	NINDS NIH HHS [R01 NS022256] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CASTANO L, 1991, J CLIN ENDOCR METAB, V73, P1197, DOI 10.1210/jcem-73-6-1197; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, TRENDS PHARMACOL SCI, V14, P107, DOI 10.1016/0165-6147(93)90079-Y; LEE DS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P157, DOI 10.1016/0167-4781(93)90056-J; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; PALMER JP, 1993, DIABETES REV, V1, P104; QIN HY, 1993, J IMMUNOL, V150, P2072; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; TAGUCHI T, 1990, J IMMUNOL, V145, P68; WATANABE R, 1983, NATURE, V305, P150, DOI 10.1038/305150a0; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	29	1038	1079	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					69	72		10.1038/366069a0	http://dx.doi.org/10.1038/366069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694152	Green Accepted			2022-12-01	WOS:A1993MF00700056
J	MARTENSON, C; STONE, K; REEDY, M; SHEETZ, M				MARTENSON, C; STONE, K; REEDY, M; SHEETZ, M			FAST AXONAL-TRANSPORT IS REQUIRED FOR GROWTH CONE ADVANCE	NATURE			English	Article							NERVE-CELLS; CYTOSKELETON; DYNAMICS; MEMBRANE; TUBULIN; TENSION	GROWTH cones are capable of advancing despite linkage to a stationary axonal cytoskeleton in chick and murine dorsal root ganglion neurites1,2. Several lines of evidence point to the growth cone as the site of cytoskeletal elongation3,4. Fast axonal transport is probably the means by which cytoskeletal elements5 or cofactors are rapidly moved through the axon. We report that direct, but reversible, inhibition of fast axonal transport with laser optical tweezers inhibits growth cone motility if cytoskeletal attachment to the cell body is maintained. Advancement ceases after a distance-dependent lag period which correlates with the rate of fast axonal transport. But severing the axonal cytoskeleton with the laser tweezers allows growth cones to advance considerably further. We suggest that axon elongation requires fast axonal transport but growth cone motility does not.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University								ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BAMBURG JR, 1986, NATURE, V321, P788, DOI 10.1038/321788a0; BRAY D, 1979, J CELL SCI, V37, P391; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; HOLLENBECK PJ, 1987, J CELL BIOL, V105, P2827, DOI 10.1083/jcb.105.6.2827; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; SHAW G, 1977, EXP CELL RES, V104, P55, DOI 10.1016/0014-4827(77)90068-4	14	44	45	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					66	69		10.1038/366066a0	http://dx.doi.org/10.1038/366066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694151				2022-12-01	WOS:A1993MF00700055
J	TABCHARANI, JA; ROMMENS, JM; HOU, YX; CHANG, XB; TSUI, LC; RIORDAN, JR; HANRAHAN, JW				TABCHARANI, JA; ROMMENS, JM; HOU, YX; CHANG, XB; TSUI, LC; RIORDAN, JR; HANRAHAN, JW			MULTIION PORE BEHAVIOR IN THE CFTR CHLORIDE CHANNEL	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CALCIUM CHANNELS; CONDUCTANCE; CELLS; SELECTIVITY; MUTAGENESIS; EXPRESSION; INVITRO	CYSTIC fibrosis transmembrane conductance regulator (CFTR) is a non-rectifying, low-conductance channel1,2 regulated by ATP3 and phosphorylation, which mediates apical chloride conductance in secretory epithelia5,6 and malfunctions in cystic fibrosis (CF)7,8. Mutations at Lys 335 and Arg 347 in the sixth predicted transmembrane helix of CFTR alter its halide selectivity in whole-cell studies9 and its single channel conductance10, but the physical basis of these alterations is unknown and permeation in CFTR is poorly understood. Here we present evidence that wild-type CFTR can contain more than one anion simultaneously. The conductance of CFTR passes through a minimum when channels are bathed in mixtures of two permeant anions. This anomalous mole fraction effect can be abolished by replacing Arg 347 with an aspartate and can be toggled on or off by varying the pH after the same residue is replaced with a histidine. Thus the CFTR channel should provide a convenient model in which to study multi-ion pore behaviour and conduction. The loss of multiple occupancy may explain how naturally occurring CF mutations at this site cause disease.	MCGILL UNIV,DEPT PHYSIOL,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM & CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	McGill University; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Hanrahan, John/AGG-1926-2022; Tsui, Lap-chee/A-1081-2010	Hanrahan, John/0000-0001-9080-2039; 				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Cremonesi Laura, 1992, Human Mutation, V1, P314, DOI 10.1002/humu.1380010409; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hille B., 1992, IONIC CHANNELS EXCIT; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1989, J MEMBRANE BIOL, V112, P109, DOI 10.1007/BF01871272; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	21	209	209	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					79	82		10.1038/366079a0	http://dx.doi.org/10.1038/366079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694154				2022-12-01	WOS:A1993MF00700059
J	MCGAVOCK, H; WEBB, CH; JOHNSTON, GD; MILLIGAN, E				MCGAVOCK, H; WEBB, CH; JOHNSTON, GD; MILLIGAN, E			MARKET PENETRATION OF NEW DRUGS IN ONE UNITED-KINGDOM REGION - IMPLICATIONS FOR GENERAL-PRACTITIONERS AND ADMINISTRATORS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the use of new drugs in one United Kingdom region. Design-Examination of data on prescribing of angiotensin converting enzyme inhibitors, new broad spectrum antibiotics, and H-2 receptor antagonists. Calculation of number of defined daily doses prescribed each month. Setting-All general practices in Northern Ireland. Main outcome measures-Drug use index and market share of each drug. Results-During 1988-91 prescribing of angiotensin converting enzyme inhibitors increased by 126%, of H-2 receptor antagonists by 46%, and of new antibiotics by 207%. The first drug on the market usually retained the largest market share. Use of oral antibiotics increased threefold irrespective of the reporting policy of the general practitioners' local laboratory. Conclusions-The increase in prescribing of these drugs seems to be greater than can be accounted for by an increase in patients with specific indications for these drugs. This suggests that the profession has not instituted effective checks to ensure that the legitimate promotion of new products does not lead to inappropriate and wasteful use.	ROYAL VICTORIA HOSP,DEPT BACTERIOL,BELFAST BT12 6BA,NORTH IRELAND		MCGAVOCK, H (corresponding author), QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,DRUG UTILIZAT RES UNIT,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							Elmes P C, 1978, Ulster Med J, V47, P79; GRIFFITHS K, 1985, EUR J CLIN PHARMACOL, V29, P1; HAWKEY PM, 1989, J ANTIMICROB CHEMOTH, V24, P477, DOI 10.1093/jac/24.4.477; HOOD H, 1968, LANCET, V2, P96; MARSHALL BJ, 1988, LANCET, V2, P1437; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; WADE OL, 1972, BRIT J PREV SOC MED, V26, P121; 1992, BMJ, V304, P405; 1985, BMJ, V291, P97; 1993, ANATOMICAL THERAPEUT, P1; 1993, BRIT NATIONAL FORMUL, V25, P203; 1987, DRUG THERAPEUTICS B, V25, P69	12	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1118	1120		10.1136/bmj.307.6912.1118	http://dx.doi.org/10.1136/bmj.307.6912.1118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	7902744	Green Published, Bronze			2022-12-01	WOS:A1993ME91800021
J	MACKINNON, R; ALDRICH, RW; LEE, AW				MACKINNON, R; ALDRICH, RW; LEE, AW			FUNCTIONAL STOICHIOMETRY OF SHAKER POTASSIUM CHANNEL INACTIVATION	SCIENCE			English	Article								Shaker potassium channels from Drosophila are composed of four identical subunits. The contribution of a single subunit to the inactivation gating transition was investigated. Channels carrying a specific mutation in a single subunit can be labeled in a heterogeneous population and studied quantitatively with scorpion toxin sensitivity as a selection tag. Linkage within a single subunit of a mutation that removes the inactivation gate to a second mutation that affects scorpion toxin sensitivity demonstrates that only a single gate is necessary to produce inactivation. The inactivation rate constant for channels with a single gate was one-fourth that of channels with four gates. In contrast, the rate of recovery from inactivation was independent of the number of gates. It appears that each of the four open inactivation gates in a Shaker potassium channel is independent, but only one of the four gates closes in a mutually exclusive manner.	STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	MACKINNON, R (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.				NINDS NIH HHS [NS23294] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023294] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	8	162	168	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					757	759		10.1126/science.7694359	http://dx.doi.org/10.1126/science.7694359			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	7694359				2022-12-01	WOS:A1993MD95200047
J	ROSENMUND, C; CLEMENTS, JD; WESTBROOK, GL				ROSENMUND, C; CLEMENTS, JD; WESTBROOK, GL			NONUNIFORM PROBABILITY OF GLUTAMATE RELEASE AT A HIPPOCAMPAL SYNAPSE	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; QUANTAL ANALYSIS; CELL-CULTURE; TIME COURSE; CURRENTS; NEURONS; SLICES; TRANSMISSION; CHANNELS	A change in the probability of neurotransmitter release (P(r)) is an important mechanism underlying synaptic plasticity. Although P(r) is often assumed to be the same for all terminals at a single synapse, this assumption is difficult to reconcile with the nonuniform size and structure of synaptic terminals in the central nervous system. Release probability was measured at excitatory synapses on cultured hippocampal neurons by analysis of the progressive block of N-methyl-D-aspartate receptor-mediated synaptic currents by the irreversible open channel blocker MK-801. Release probability was nonuniform (range of 0.09 to 0.54) for terminals arising from a single axon, the majority of which had a low P(r). However, terminals with high P(r) are more likely to be affected by the activity-dependent modulation that occurs in long-term potentiation.	OREGON HLTH SCI UNIV,VOLLUM 1ST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444	NIMH NIH HHS [MH46613] Funding Source: Medline; NINDS NIH HHS [NS26494] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046613, R37MH046613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026494, R01NS026494] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BROWN TH, 1976, P NATL ACAD SCI USA, V73, P2913, DOI 10.1073/pnas.73.8.2913; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; CLEMENTS JD, 1993, PRESYNAPTIC RECEPTOR, P180; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1986, NEUROSCIENCE, V19, P857, DOI 10.1016/0306-4522(86)90304-0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JAHR CE, 1992, SCIENCE, V255, P470, DOI 10.1126/science.1346477; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McLachlan E M, 1978, Int Rev Physiol, V17, P49; POTIER B, 1993, EUR J PHARMACOL, V231, P427, DOI 10.1016/0014-2999(93)90120-7; PUN RYK, 1986, J NEUROPHYSIOL, V56, P1242, DOI 10.1152/jn.1986.56.5.1242; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; REDMAN S, 1983, J PHYSIOL-LONDON, V343, P135, DOI 10.1113/jphysiol.1983.sp014885; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; TONG G, 1993, SOC NEUR ABSTR, V19; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889	30	497	500	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					754	757		10.1126/science.7901909	http://dx.doi.org/10.1126/science.7901909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	7901909				2022-12-01	WOS:A1993MD95200046
J	MAYER, B; JAUCH, KW; GUNTHERT, U; FIGDOR, CG; SCHILDBERG, FW; FUNKE, I; JOHNSON, JP				MAYER, B; JAUCH, KW; GUNTHERT, U; FIGDOR, CG; SCHILDBERG, FW; FUNKE, I; JOHNSON, JP			DE-NOVO EXPRESSION OF CD44 AND SURVIVAL IN GASTRIC-CANCER	LANCET			English	Article							LYMPHOCYTE HOMING RECEPTOR; GLYCOPROTEIN; CARCINOMA; MOLECULE; VARIANT; CELLS	We have examined the cell surface molecule CD44, which is attracting interest because of reports that isoforms are associated with metastasis. The prognostic value of CD44 expression has yet to be assessed for a solid tumour. Benign (59) and malignant (primary 61, metastatic 59) gastric tissues were examined with antibodies directed at epitopes common to known CD44 isoforms. Normal mucosa was CD44 negative. In atrophic gastritis and intestinal metaplasia expression was restricted to the epithelial cells of the basal glands and was positively correlated with an increased leucocyte infiltrate and with the expression of HLA DR by mucosal cells. These observations suggest a role for chronic inflammation in the induction of CD44 expression on benign mucosa. No such association was observed between inflammatory infiltrate and CD44 expression on gastric tumours. CD44 expression, observed in only 49% of primary tumours, was associated with distant metastases at time of diagnosis and, among 31 curatively resected patients, with tumour recurrence (p=0.0014) and increased mortality (p=0.001) during follow-up averaging 17 months. When we used an antibody directed against the CD44 variant exon 9v, we found a good correlation between the expression of total CD44 and of exon 9v containing isoforms, and 9v expression in primary tumours was significantly and positively associated with tumour recurrence and mortality.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; UNIV MUNICH,INST IMMUNOL,D-81366 MUNICH,GERMANY	Netherlands Cancer Institute; University of Munich	MAYER, B (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT SURG,D-81366 MUNICH,GERMANY.		Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CAMP RL, 1991, J EXP MED, V173, P763, DOI 10.1084/jem.173.3.763; CREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160; DUARTE I, 1981, HUM PATHOL, V12, P237, DOI 10.1016/S0046-8177(81)80124-4; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUNTHERT U, IN PRESS CURR TOP MI; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; HORST E, 1990, LEUKEMIA, V4, P595; JACKSOND G, 1993, LANCET, V341, P252; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MACKAY CR, 1988, IMMUNOLOGY, V65, P93; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MAYER B, 1993, CANCER RES, V53, P1690; PALS ST, 1989, J IMMUNOL, V143, P851; SCHMITZMOORMANN P, 1979, GASTRIC CANCER, P172; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; WAHAB ZA, 1985, INT J CANCER, V36, P677, DOI 10.1002/ijc.2910360610	22	229	245	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1019	1022		10.1016/0140-6736(93)92879-X	http://dx.doi.org/10.1016/0140-6736(93)92879-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	7692200	Green Submitted			2022-12-01	WOS:A1993MD06600010
J	ASHLEY, CT; WILKINSON, KD; REINES, D; WARREN, ST				ASHLEY, CT; WILKINSON, KD; REINES, D; WARREN, ST			FMR1 PROTEIN - CONSERVED RNP FAMILY DOMAINS AND SELECTIVE RNA-BINDING	SCIENCE			English	Article							FRAGILE-X-SYNDROME; ESCHERICHIA-COLI; GENE; DNA; INSTABILITY; SEQUENCE; METHYLATION; REPEAT; SITE	Fragile X syndrome is the result of transcriptional suppression of the gene FMR1 as a result of a trinucleotide repeat expansion mutation. The normal function of the FMR1 protein (FMRP) and the mechanism by which its absence leads to mental retardation are unknown. Ribonucleoprotein particle (RNP) domains were identified within FMRP, and RNA was shown to bind in stoichiometric ratios, which suggests that there are two RNA binding sites per FMRP molecule. FMRP was able to bind to its own message with high affinity (dissociation constant = 5.7 nM) and interacted with approximately 4 percent of human fetal brain messages. The absence of the normal interaction of FMRP with a X syndrome.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Howard Hughes Medical Institute; Emory University; Emory University			excellency, Your/R-2357-2019; Warren, Stephen T/A-2498-2012	excellency, Your/0000-0003-0832-6243; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRAUER D, 1979, FEBS LETT, V106, P352, DOI 10.1016/0014-5793(79)80531-1; BROWN WT, 1990, AM J HUM GENET, V47, P175; BUTLER MG, 1991, CLIN GENET, V39, P347; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DELAHODDE A, 1986, NUCLEIC ACIDS RES, V14, P9213, DOI 10.1093/nar/14.22.9213; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIDEON AK, 1992, NAT GENET, V1, P341; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; KAO CC, 1992, J VIROL, V66, P6322, DOI 10.1128/JVI.66.11.6322-6329.1992; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Price D, UNPUB; REGNIER P, 1987, J BIOL CHEM, V262, P63; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WOHRLE D, 1992, AM J HUM GENET, V51, P299; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZHANG XT, 1990, NUCLEIC ACIDS RES, V18, P6689, DOI 10.1093/nar/18.22.6689	31	599	612	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 22	1993	262	5133					563	566		10.1126/science.7692601	http://dx.doi.org/10.1126/science.7692601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	7692601				2022-12-01	WOS:A1993MC93500039
J	EGELHOFF, TT; LEE, RJ; SPUDICH, JA				EGELHOFF, TT; LEE, RJ; SPUDICH, JA			DICTYOSTELIUM MYOSIN HEAVY-CHAIN PHOSPHORYLATION SITES REGULATE MYOSIN FILAMENT ASSEMBLY AND LOCALIZATION IN-VIVO	CELL			English	Article							PROTEIN-KINASE-C; NULL MUTANTS; CYCLIC-GMP; DISCOIDEUM; CELLS; CYTOSKELETON; PURIFICATION; TAIL; GENE; COMPLEMENTATION	Three threonine residues in the tall region of Dictyostelium myosin II heavy chain have been implicated previously in control of myosin filament formation. Here we report the in vitro and in vivo consequences of converting these sites to alanine residues, which eliminates phosphorylation at these positions, or to aspartate residues, which mimics the negative charge state of the phosphorylated molecule. Alanine substitution allows in vitro assembly and in vivo contractile activity, although this myosin shows substantial over-assembly in vivo. Aspartate substitution eliminates filament assembly in vitro and renders the myosin unable to drive any tested contractile event in vivo. These results demonstrate that heavy chain phosphorylation plays a key modulatory role in controlling myosin function in vivo.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University					NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046551, R37GM046551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09151] Funding Source: Medline; NIAMS NIH HHS [AR01829] Funding Source: Medline; NIGMS NIH HHS [GM46551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1987, J BIOL CHEM, V262, P3918; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COTE GP, 1987, J BIOL CHEM, V262, P1065; COTE GP, 1987, J BIOL CHEM, V262, P13033; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; KUCZMARSKI ER, 1987, J CELL BIOL, V105, P2989, DOI 10.1083/jcb.105.6.2989; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LIU G, 1988, J CELL SCI, V90, P123; LIU G, 1991, J CELL SCI, V98, P483; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MALCHOW D, 1981, EUR J BIOCHEM, V17, P213; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MARUTA H, 1983, EMBO J, V2, P535, DOI 10.1002/j.1460-2075.1983.tb01459.x; OLIVER JM, 1988, PROG ALLERGY, V42, P185; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PELTZ G, 1985, J CELL BIOL, V100, P1016, DOI 10.1083/jcb.100.4.1016; RAHMSDORF HJ, 1978, FEBS LETT, V88, P322, DOI 10.1016/0014-5793(78)80203-8; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; RUPPEL KM, 1990, ANN NY ACAD SCI, V582, P147; Sambrook J., 1989, MOL CLONING LAB MANU; SPUDICH A, 1987, METHOD CELL BIOL, V28, P209; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	42	241	244	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					363	371		10.1016/0092-8674(93)80077-R	http://dx.doi.org/10.1016/0092-8674(93)80077-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7691416				2022-12-01	WOS:A1993MD88500017
J	HOCKENBERY, DM; OLTVAI, ZN; YIN, XM; MILLIMAN, CL; KORSMEYER, SJ				HOCKENBERY, DM; OLTVAI, ZN; YIN, XM; MILLIMAN, CL; KORSMEYER, SJ			BCL-2 FUNCTIONS IN AN ANTIOXIDANT PATHWAY TO PREVENT APOPTOSIS	CELL			English	Article							PROGRAMMED CELL-DEATH; MOUSE EPIDERMAL-CELLS; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; MEMBRANE PROTEIN; OXIDANT STRESS; PARINARIC ACID; CIS-FOS	Bcl-2 inhibits most types of apoptotic cell death, implying a common mechanism of lethality. Bcl-2 is localized to intracellular sites of oxygen free radical generation including mitochondria, endoplasmic reticula, and nuclear membranes. Antioxidants that scavenge peroxides, N-acetylcysteine and glutathione peroxidase, countered apoptotic death, while manganese superoxide dismutase did not. Bcl-2 protected cells from H2O2- and menadione-induced oxidative deaths. Bcl-2 did not prevent the cyanide-resistant oxidative burst generated by menadione. Two model systems of apoptosis showed no increment in cyanide-resistant respiration, and generation of endogenous peroxides continued at an inherent rate that was unaltered by Bcl-2. Following an apoptotic signal, cells sustained progressive lipid peroxidation. Overexpression of Bcl-2 functioned suppress lipid peroxidation completely. We propose a model in which Bcl-2 regulates an antioxidant pathway at sites of free radical generation.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA	Washington University (WUSTL); Washington University (WUSTL); Fred Hutchinson Cancer Center	HOCKENBERY, DM (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA.				PHS HHS [49712-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; APPLEGATE LA, 1991, CANCER RES, V51, P974; BASS DA, 1983, J IMMUNOL, V130, P1910; BLOK J, 1986, MECHANISMS DNA DAMAG, P75; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CRAWFORD D, 1988, ONCOGENE, V3, P27; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DEWEY DL, 1960, NATURE, V186, P780, DOI 10.1038/186780a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ERNSTER L, 1986, CHEM SCRIPTA, V26, P525; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; Gutteridge J M, 1986, Free Radic Res Commun, V1, P173, DOI 10.3109/10715768609083149; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUYPERS FA, 1987, BIOCHIM BIOPHYS ACTA, V921, P266, DOI 10.1016/0005-2760(87)90027-0; LEBRUN DP, 1993, AM J PATHOL, V142, P743; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NGUYEN M, 1993, IN PRESS J BIOL CHEM; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERLEY LW, 1985, HDB METHODS OXYGEN R, P219; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; THOR H, 1982, J BIOL CHEM, V257, P2419; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALTON MI, 1993, CANCER RES, V53, P1853; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	67	3304	3470	4	214	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					241	251		10.1016/0092-8674(93)80066-N	http://dx.doi.org/10.1016/0092-8674(93)80066-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7503812				2022-12-01	WOS:A1993MD88500006
J	KANAAR, R; ROCHE, SE; BEALL, EL; GREEN, MR; RIO, DC				KANAAR, R; ROCHE, SE; BEALL, EL; GREEN, MR; RIO, DC			THE CONSERVED PREMESSENGER RNA SPLICING FACTOR-U2AF FROM DROSOPHILA - REQUIREMENT FOR VIABILITY	SCIENCE			English	Article							AUXILIARY FACTOR; CLONING; YEAST; HOMOLOG; GENE; RIBONUCLEOPROTEIN; REGULATORS; PROTEINS; ACCURATE; DOMAIN	The large subunit of the human pre-messenger RNA splicing factor U2 small nuclear ribonucleoprotein auxiliary factor (hU2AF65) is required for spliceosome assembly in vitro. A complementary DNA clone encoding the large subunit of Drosophila U2AF (dU2AF50) has been isolated. The dU2AF50 protein is closely related to its mammalian counterpart and contains three carboxyl-terminal ribonucleoprotein consensus sequence RNA binding domains and an amino-terminal arginine- and serine-rich (R/S) domain. Recombinant dU2AF50 protein complements mammalian splicing extracts depleted of U2AF activity. Germline transformation of Drosophila with the dU2AF50 complementary DNA rescues a lethal mutation, establishing that the dU2AF50 gene is essential for viability. R/S domains have been found in numerous metazoan splicing factors, but their function is unknown. The mutation in Drosophila U2AF will allow in vivo analysis of a conserved R/S domain-containing general splicing factor.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Massachusetts System; University of Massachusetts Worcester					NICHD NIH HHS [R01-HD28063] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028063] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P1333, DOI 10.1093/nar/21.5.1333; BIRNEY E, 1992, NUCLEIC ACIDS RES, V20, P4663, DOI 10.1093/nar/20.17.4663; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARLOW E, 1989, ANTIBODIES LABORATOR; JONES KR, 1990, NEURON, V4, P711, DOI 10.1016/0896-6273(90)90197-N; KANAAR R, UNPUB; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MORE M, 1993, RNA WORLD, P303; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; RIO DC, 1988, P NATL ACAD SCI USA, V85, P2904, DOI 10.1073/pnas.85.9.2904; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, IN PRESS MOL CELLULA; SAILER A, 1992, NUCLEIC ACIDS RES, V20, P2374, DOI 10.1093/nar/20.9.2374; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	41	80	84	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					569	573		10.1126/science.7692602	http://dx.doi.org/10.1126/science.7692602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	7692602				2022-12-01	WOS:A1993MC93500041
J	ZABNER, J; COUTURE, LA; GREGORY, RJ; GRAHAM, SM; SMITH, AE; WELSH, MJ				ZABNER, J; COUTURE, LA; GREGORY, RJ; GRAHAM, SM; SMITH, AE; WELSH, MJ			ADENOVIRUS-MEDIATED GENE-TRANSFER TRANSIENTLY CORRECTS THE CHLORIDE TRANSPORT DEFECT IN NASAL EPITHELIA OF PATIENTS WITH CYSTIC-FIBROSIS	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ELECTROLYTE TRANSPORT; EXPRESSION; PATHOGENESIS; PERMEABILITY; CHANNEL; CELLS	To evaluate the potential of direct transfer of cystic fibrosis transmembrane conductance regulator (CFTR) cDNA for the treatment of cystic fibrosis (CF), we administered an E1-deficient adenovirus, encoding CFTR, to a defined area of nasal airway epithelium of three individuals with CF. This treatment corrected the Cl- transport defect that is characteristic of CF-affected epithelia. After treatment, there was a decrease in the elevated basal transepithelial voltage, and the normal response to a cAMP agonist was restored. We found no evidence of viral replication or virus-associated adverse effects, even at the highest dose tested (25 MOI). These data represent a small step in achieving long-term improvement of CF lung function by gene therapy.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT OTOLARYNGOL,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Sanofi-Aventis; Genzyme Corporation	ZABNER, J (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Zabner, Joseph/0000-0002-9606-1339; Welsh, Michael/0000-0002-1646-6206; Graham, Scott/0000-0003-2969-2998				ALTON EWF, 1987, THORAX, V342, P815; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHASSE JF, 1989, M S-MED SCI, V5, P331, DOI 10.4267/10608/3974; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DICKSON D, 1993, NATURE, V365, P4; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GRAHAM FL, 1992, VACCINES NEW APPROAC, P363; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; MARIASSY AT, 1992, COMP BIOL NORMAL LUN, P63; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177, DOI 10.1164/ajrccm/146.1.177; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; TAUSSIG LM, 1973, J PEDIATR-US, V82, P380, DOI 10.1016/S0022-3476(73)80110-6; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; Weibel E. R., 1963, MORPHOMETRY HUMAN LU; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; ZABNER J, 1993, IN PRESS NATURE GENE	32	582	663	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					207	216		10.1016/0092-8674(93)80063-K	http://dx.doi.org/10.1016/0092-8674(93)80063-K			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7691415				2022-12-01	WOS:A1993MD88500003
J	HAO, Y; CRENSHAW, T; MOULTON, T; NEWCOMB, E; TYCKO, B				HAO, Y; CRENSHAW, T; MOULTON, T; NEWCOMB, E; TYCKO, B			TUMOR-SUPPRESSOR ACTIVITY OF H19 RNA	NATURE			English	Article							NORMAL HUMAN CHROMOSOME-11; WILMS-TUMOR; CELL-DIFFERENTIATION; GENE; EXPRESSION; MOUSE; TUMORIGENICITY; ALLELES	Loss of heterozygosity in certain human embryonal tumours implicates a tumour-suppressor gene at chromosome 11p15.5 and selective loss of maternal alleles suggests that this gene is paternally imprinted1-4. The human H19 gene maps to 11p15.5, is expressed in differentiating fetal cells5-11 and is paternally imprinted12-16. We report here that two embryonal tumour cell lines, RD and G401, showed growth retardation and morphological changes when transfected with an H19 expression construct. More importantly, clonogenicity in soft agar and tumorigenicity in nude mice were abrogated in the G401-H19 transfectants. In addition to demonstrating its tumour-suppressor potential, this transfection system should help structural and functional studies of the enigmatic H19 gene.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV NEUROPATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,NEW YORK,NY 10032; NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016	Columbia University; Columbia University; Columbia University; New York University								BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; GARVIN AJ, 1992, AM J PATHOL, V142, P375; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAL N, 1990, ONCOGENE, V5, P1665; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; REINER S, 1993, NATURE, V362, P747; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WILES MV, 1988, DEVELOPMENT, V104, P403; WILLIAMS JC, 1989, LANCET, V1, P283; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	24	584	600	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					764	767		10.1038/365764a0	http://dx.doi.org/10.1038/365764a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	7692308				2022-12-01	WOS:A1993MC81200067
J	LERNBECHER, T; MULLER, U; WIRTH, T				LERNBECHER, T; MULLER, U; WIRTH, T			DISTINCT NF-KAPPA-B REL TRANSCRIPTION FACTORS ARE RESPONSIBLE FOR TISSUE-SPECIFIC AND INDUCIBLE GENE ACTIVATION	NATURE			English	Article							DNA-BINDING ACTIVITY; KAPPA-B; PROTO-ONCOGENE; P65 SUBUNIT; C-REL; ENHANCER; INTERACT; CLONING; SEQUENCES; PROMOTER	THE NF-kappaB/Rel family is a growing class of transcriptional regulators1-11 whose members share the conserved Rel-homology domain, involved in specific DNA binding and dimerization. They interact with the regulatory elements of many different genes and are involved in the regulation of lymphoid-specific and inducible transcription12. We tested whether these factors could alone activate a gene in transgenic mice. We report here that a minimal promoter containing three copies of a binding site for these proteins allows tissue-specific and inducible transgene activation. In lymphoid tissues constitutive transgene expression correlates with the presence of a constitutively active p50/RelB heterodimer. Other organs that only contain the p50 homodimer do not express the transgene. In contrast to this constitutive activity mediated by p50/RelB, the p50/p65 heterodimer (which is NF-kappaB) could confer inducible transgene activation in embryo fibroblasts. Thus two different members of the NF-kappaB/Rel family of transcriptional activators are involved in tissue-specific and inducible gene activation in transgenic mice.	ZENTRUM MOLEK BIOL HEIDELBERG,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1992, NUCLEIC ACIDS RES, V20, P1503, DOI 10.1093/nar/20.7.1503; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P423; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOSH S, 1990, CELL, V62, P1019; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	29	195	198	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					767	770		10.1038/365767a0	http://dx.doi.org/10.1038/365767a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	7692309				2022-12-01	WOS:A1993MC81200068
J	ROBBINS, FC				ROBBINS, FC			ERADICATION OF POLIO IN THE AMERICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									PAN AMER HLTH ORG,INT COMMISS CERTIFICAT ERADICAT POLIO AMER,WASHINGTON,DC	Pan American Health Organization	ROBBINS, FC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							CHEN R, 1992, 32ND INT C ANT AG CH; RIORDAN JT, 1961, YALE J BIOL MED, V34, P512; SHALALA DE, 1993, JAMA-J AM MED ASSOC, V269, P144; 1992, MMWR MORB MORTAL WKL, V41, P917; 1993, MMWR MORB MORTAL WKL, V42, P337; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1993, JAMA-J AM MED ASSOC, V269, P1817	7	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1857	1859		10.1001/jama.270.15.1857	http://dx.doi.org/10.1001/jama.270.15.1857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	7692114				2022-12-01	WOS:A1993MB46400031
J	BAUMHUETER, S; SINGER, MS; HENZEL, W; HEMMERICH, S; RENZ, M; ROSEN, SD; LASKY, LA				BAUMHUETER, S; SINGER, MS; HENZEL, W; HEMMERICH, S; RENZ, M; ROSEN, SD; LASKY, LA			BINDING OF L-SELECTIN TO THE VASCULAR SIALOMUCIN CD34	SCIENCE			English	Article							LYMPHOCYTE HOMING RECEPTOR; ENDOTHELIAL LIGAND; IGG CHIMERA; CELLS; ADHESION; ANTIGEN; INFLAMMATION; VENULES; LECAM-1; INVIVO	The adhesive interactions between leukocyte L-selectin and the endothelium are involved in the migration of lymphocytes through peripheral lymph nodes and of neutrophils to sites of inflammation. A recombinant L-selectin stains high endothelial venules (HEVs) in lymph nodes and recognizes sulfated carbohydrates found on two endothelial glycoproteins, Sgp50 and Sgp90. Amino acid sequencing of purified Sgp90 revealed a protein core identical to that of CD34, a sialomucin expressed on hematopoietic stem cells and endothelium. A polyclonal antiserum to recombinant murine CD34 stains peripheral lymph node endothelium and recognizes Sgp90 that is functionally bound by L-selectin. Thus, an HEV glycoform of CD34 can function as a ligand for L-selectin.	GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM IMMUNOL, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Henzel, William/0000-0003-2940-3797	NIGMS NIH HHS [GM 23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMHUETER S, UNPUB; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BRADY HR, 1992, J IMMUNOL, V149, P2437; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CIVIN CI, 1984, J IMMUNOL, V133, P157; DELIA D, 1993, BLOOD, V81, P1001; FINA L, 1990, BLOOD, V75, P2417; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KATZ RC, 1986, J BEHAV MED, V9, P191, DOI 10.1007/BF00848477; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEY K, 1991, BLOOD, V77, P2553; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUTHERLAND DR, 1988, LEUKEMIA, V2, P793; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0	27	594	616	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1993	262	5132					436	438		10.1126/science.7692600	http://dx.doi.org/10.1126/science.7692600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692600				2022-12-01	WOS:A1993MB85900063
J	BERENDES, R; VOGES, D; DEMANGE, P; HUBER, R; BURGER, A				BERENDES, R; VOGES, D; DEMANGE, P; HUBER, R; BURGER, A			STRUCTURE-FUNCTION ANALYSIS OF THE ION-CHANNEL SELECTIVITY FILTER IN HUMAN ANNEXIN-V	SCIENCE			English	Article							MOLECULAR-STRUCTURE; BILAYER-MEMBRANES; RECEPTOR CHANNELS; CALCIUM; CRYSTAL; RESOLUTION; PROTEINS; BINDING; FAMILY	Electrophysiology and structural studies were performed on an annexin V variant c containing a mutation of glutamic acid-95 to serine in the center of the pore region. The mutation resulted in a lower single channel conductance for calcium and a strongly increased conductance for sodium and potassium, indicating that glutamic acid-95 is a crucial constituent of the ion selectivity filter. There were only minor differences in the crystal structures of mutant and wild-type annexin V around the mutation site; however, the mutant showed structural differences elsewhere, including the presence of a calcium binding site in domain III unrelated to the mutation. Analysis of the membrane-bound form of annexin V by electron microscopy revealed no differences between the wild type and mutant.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society			demange, pascal JP/U-3561-2018	demange, pascal JP/0000-0002-9572-9990				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BERENDES R, UNPUB; BRUNGER AT, 1990, X PLOR MANUAL; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; Burger A., UNPUB; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CONCHA NO, 1993, SCIENCE, V2261, P1321; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; EGJEBERG J, 1993, P NATL ACAD SCI USA, V90, P755; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; FERRERMONTIEL AV, 1993, FEBS LETT, V324, P185, DOI 10.1016/0014-5793(93)81390-L; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HOPPE W, 1957, Z ELEKTROCHEM, V61, P1076; HUBER R, 1965, ACTA CRYSTALLOGR, V19, P353, DOI 10.1107/S0365110X65003444; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARSHIKOV A, 1992, EUR BIOPHYS J BIOPHY, V20, P337, DOI 10.1007/BF00196592; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; MEALY T, 1993, BIOCHEMISTRY-US, V32, P5411; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; Moss S. E, 1992, ANNEXINS; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SOPKOVA J, IN PRESS J MOL BIOL; Steigemann W., 1974, THESIS TU MUNCHEN GE; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0	37	102	103	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					427	430		10.1126/science.7692599	http://dx.doi.org/10.1126/science.7692599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692599				2022-12-01	WOS:A1993MB85900060
J	TAN, YH				TAN, YH			YIN AND YANG OF PHOSPHORYLATION IN CYTOKINE SIGNALING	SCIENCE			English	Editorial Material							OKADAIC ACID MIMICS; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; PROTEIN; TYROSINE; PHOSPHATASE; ACTIVATION; KINASE; CALCINEURIN; EXPRESSION				TAN, YH (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P12991; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVIDSON WF, 1979, J IMMUNOL, V122, P884; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUESDON F, 1993, J BIOL CHEM, V261, P358; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HIGUCHI T, 1990, J INTERFERON RES, V10, P413, DOI 10.1089/jir.1990.10.413; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KORETZKY GA, 1990, NATURE, V346, P2037; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MENSON SD, IN PRESS J BIOL CHEM; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; THOMAS JD, 1993, J BIOL CHEM, V261, P355; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	31	28	32	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					376	377		10.1126/science.7692598	http://dx.doi.org/10.1126/science.7692598			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692598				2022-12-01	WOS:A1993MB85900043
J	BROCKE, S; GAUR, A; PIERCY, C; GAUTAM, A; GIJBELS, K; FATHMAN, CG; STEINMAN, L				BROCKE, S; GAUR, A; PIERCY, C; GAUTAM, A; GIJBELS, K; FATHMAN, CG; STEINMAN, L			INDUCTION OF RELAPSING PARALYSIS IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY BACTERIAL SUPERANTIGEN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; STAPHYLOCOCCAL ENTEROTOXIN-B; MYELIN BASIC-PROTEIN; T-CELLS; MICE; ANERGY; INVIVO	THE role of infection in the pathogenesis of clinical relapses that occur in most autoimmune diseases, including multiple sclerosis, remains to be established1,2. Experimental autoimmune encephalomyelitis (EAE) serves as a model for multiple sclerosis, with episodes of relapsing paralysis3-9. In certain strains of mice, T-lymphocytes expressing the Vbeta8 T-cell receptor (TCR)6-8 engage the amino-terminal epitope Ac1-11 of myelin basic protein, leading to EAE. The bacterial superantigen staphylococcal enterotoxin B (SEB) activates Vbeta8-expressing T cells. Here we show that after immunization with Ac1-11, or after transfer of encephalitogenic T-cell lines or clones reactive to Ac1-11, SEB induces exacerbation or relapses of paralytic disease in mice that are in clinical remission following an initial episode of paralysis, and triggers paralysis in mice with subclinical disease. Tumour necrosis factor has a critical role in the mechanism underlying SEB-induced exacerbation of disease, because anti-tumour necrosis factor antibody given in vivo delays the onset of paralysis triggered by SEB. On reactivation of autoaggressive cells through their T-cell receptor, superantigens may induce clinical relapses of autoimmune disease.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Stanford University	BROCKE, S (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305, USA.			Steinman, Lawrence/0000-0002-2437-2250				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEN I, 1991, MCALPINES MULTIPLE S; Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BEHIKE MA, 1986, P NATL ACAD SCI USA, V83, P767; BELL RB, 1993, J IMMUNOL, V150, P4085; BROCKE S, 1991, INFECT IMMUN, V59, P4531, DOI 10.1128/IAI.59.12.4531-4539.1991; GAUR A, 1993, J IMMUNOL, V150, P3062; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; POSER CM, 1992, J NEUROL SCI, V107, P127, DOI 10.1016/0022-510X(92)90280-X; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; ROTT O, 1992, INT IMMUNOL, V4, P347, DOI 10.1093/intimm/4.3.347; SOOS JM, 1993, J NEUROIMMUNOL, V43, P39, DOI 10.1016/0165-5728(93)90073-8; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	23	234	244	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					642	644		10.1038/365642a0	http://dx.doi.org/10.1038/365642a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	7692305				2022-12-01	WOS:A1993MB84600057
J	SHENKER, A; LAUE, L; KOSUGI, S; MERENDINO, JJ; MINEGISHI, T; CUTLER, GB				SHENKER, A; LAUE, L; KOSUGI, S; MERENDINO, JJ; MINEGISHI, T; CUTLER, GB			A CONSTITUTIVELY ACTIVATING MUTATION OF THE LUTEINIZING-HORMONE RECEPTOR IN FAMILIAL MALE PRECOCIOUS PUBERTY	NATURE			English	Article							ALPHA-1B-ADRENERGIC RECEPTOR; CHORIONIC-GONADOTROPIN; SEXUAL PRECOCITY; GENE; SUBSTITUTIONS; RHODOPSIN; RAT; LH	FAMILIAL male precocious puberty (FMP) is a gonadotropin-independent disorder that is inherited in an autosomal dominant, male-limited pattern1-5. Affected males generally exhibit signs of puberty by age 4. Testosterone production and Leydig cell hyperplasia occur in the context of prepubertal levels of luteinizing hormone (LH)3-5. The LH receptor is a member of the family of G-protein-coupled receptors6,7, and we hypothesized that FMPP might be due to a mutant receptor that is activated in the presence of little or no agonist8-12 . A single A --> G base change that results in substitution of glycine for aspartate at position 578 in the sixth transmembrane helix of the LH receptor was found in affected individuals from eight different families. Linkage of the mutation to FMPP was supported by restriction-digest analysis. COS-7 cells expressing the mutant LH receptor exhibited markedly increased cyclic AMP production in the absence of agonist, suggesting that autonomous Leydig cell activity in FMPP is caused by a constitutively activated LH receptor.	NIDDK,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892; KYOTO UNIV,SCH MED,DEPT LAB MED,KYOTO 606,JAPAN; GUNMA UNIV,SCH MED,DEPT OBSTET & GYNECOL,MAEBASHI,GUNMA 371,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kyoto University; Gunma University	SHENKER, A (corresponding author), NIDDK,MOLEC PATHOPHYSIOL BRANCH,BLDG 10,ROOM 8C-101,BETHESDA,MD 20892, USA.		KOSUGI, Shinji/GYR-2946-2022					ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; HOLLAND FJ, 1991, ENDOCRIN METAB CLIN, V20, P191, DOI 10.1016/S0889-8529(18)30288-3; HUNZICKERDUNN M, 1985, LUTEINIZING HORMONE, P57; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; LAUE L, 1993, J CLIN ENDOCR METAB, V76, P151, DOI 10.1210/jc.76.1.151; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; Myers R, 1989, PCR TECHNOLOGY PRINC, P71; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OERTER KE, 1990, J CLIN ENDOCR METAB, V71, P1251, DOI 10.1210/jcem-71-5-1251; REN Q, 1993, J BIOL CHEM, V268, P16483; RIESNER D, 1989, ELECTROPHORESIS, V10, P377, DOI 10.1002/elps.1150100516; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROSENTHAL SM, 1983, J CLIN ENDOCR METAB, V57, P571, DOI 10.1210/jcem-57-3-571; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHEDEWIE HK, 1981, J CLIN ENDOCR METAB, V52, P271, DOI 10.1210/jcem-52-2-271; SKLAR CA, 1981, J CLIN ENDOCR METAB, V53, P656, DOI 10.1210/jcem-53-3-656; STONE RK, 1852, AM J M SC, V24, P561; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WALKER SH, 1952, J PEDIATR-US, V41, P251, DOI 10.1016/S0022-3476(52)80001-0; YAGHMAI R, 1992, P NATL ACAD SCI USA, V89, P7890, DOI 10.1073/pnas.89.17.7890	30	597	624	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					652	654		10.1038/365652a0	http://dx.doi.org/10.1038/365652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	7692306	Green Published			2022-12-01	WOS:A1993MB84600060
J	EGHOLM, M; BUCHARDT, O; CHRISTENSEN, L; BEHRENS, C; FREIER, SM; DRIVER, DA; BERG, RH; KIM, SK; NORDEN, B; NIELSEN, PE				EGHOLM, M; BUCHARDT, O; CHRISTENSEN, L; BEHRENS, C; FREIER, SM; DRIVER, DA; BERG, RH; KIM, SK; NORDEN, B; NIELSEN, PE			PNA HYBRIDIZES TO COMPLEMENTARY OLIGONUCLEOTIDES OBEYING THE WATSON-CRICK HYDROGEN-BONDING RULES	NATURE			English	Article							PEPTIDE NUCLEIC-ACIDS; DNA; RECOGNITION; REPLICATION; ANTISENSE; STABILITY; THYMINE; HELICES	DNA ANALOGUES are currently being intensely investigated owing to their potential as gene-targeted drugs1-3. Furthermore, their properties and interaction with DNA and RNA could provide a better understanding of the structural features of natural DNA that determine its unique chemical, biological and genetic properties3,4. We recently designed a DNA analogue, PNA, in which the backbone is structurally homomorphous with the deoxyribose backbone and consists of N-(2-aminoethyl)glycine units to which the nucleobases are attached5-9. We showed that PNA oligomers containing solely thymine and cytosine can hybridize to complementary oligonucleotides, presumably by forming Watson-Crick-Hoogsteen (PNA)2-DNA triplexes, which are much more stable than the corresponding DNA-DNA duplexes5-7, and bind to double-stranded DNA by strand displacement5,8. We report here that PNA containing all four natural nucleobases hybridizes to complementary oligonucleotides obeying the Watson-Crick base-pairing rules, and thus is a true DNA mimic in terms of base-pair recognition.	PANUM INST,MED BIOTECHNOL RES CTR,DEPT BIOCHEM B,BLEGDAMSVEJ 3C,DK-2200 COPENHAGEN N,DENMARK; HC ORSTED INST,DEPT ORGAN CHEM,DK-2100 COPENHAGEN 0,DENMARK; ISIS PHARMACEUT,CARLSBAD,CA 92008; RISO NATL LAB,DEPT MAT,POLYMER GRP,DK-4000 ROSKILDE,DENMARK; CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN	University of Copenhagen; Isis Pharmaceuticals Inc; Technical University of Denmark; Chalmers University of Technology			Berg, Rolf H/C-6339-2009; Norden, Bengt/ABE-3675-2020	Norden, Bengt/0000-0002-7946-200X; /0000-0001-8771-330X				BORER PN, 1974, J MOL BIOL, V86, P843, DOI 10.1016/0022-2836(74)90357-X; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; Crooke Stanley T., 1992, Current Opinion in Biotechnology, V3, P656, DOI 10.1016/0958-1669(92)90012-8; EGHOLM M, 1993, J CHEM SOC CHEM COMM, P800, DOI 10.1039/c39930000800; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; FREIER SM, 1983, BIOCHEMISTRY-US, V22, P6198, DOI 10.1021/bi00295a025; FREIER SM, 1983, BIOPOLYMERS, V22, P1107, DOI 10.1002/bip.360220408; Goodchild J, 1990, BIOCONJUGATE CHEM, V1, P165, DOI 10.1021/bc00003a001; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Maniatis T., 1982, MOL CLONING; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; ORO J, 1960, BIOCHEM BIOPH RES CO, V2, P407, DOI 10.1016/0006-291X(60)90138-8; UHLMANN E, 1990, CHEM REV, V90, P544; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569	21	1699	2208	4	252	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					566	568		10.1038/365566a0	http://dx.doi.org/10.1038/365566a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	7692304				2022-12-01	WOS:A1993MA66100061
J	TSUCHIHASHI, Z; KHOSLA, M; HERSCHLAG, D				TSUCHIHASHI, Z; KHOSLA, M; HERSCHLAG, D			PROTEIN ENHANCEMENT OF HAMMERHEAD RIBOZYME CATALYSIS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; TETRAHYMENA-THERMOPHILA RIBOZYME; RNA ANNEALING ACTIVITIES; PRIMER TRANSFER-RNA; NUCLEOCAPSID PROTEIN; RIBONUCLEASE-P; NUCLEIC-ACIDS; VIRAL-RNA; KINETIC DESCRIPTION	When the recognition sequence of a ribozyme is extended beyond a certain length, turnover is slowed and specificity is decreased. Here, it is shown that a protein can help a ribozyme overcome these general limitations on ribozyme activity. Cleavage of an RNA oligonucleotide by a hammerhead ribozyme is enhanced 10- to 20-fold upon addition of a protein derived from the p7 nucleocapsid (NC) protein of human immunodeficiency virus-type 1. The NC protein also enhances the ability of the ribozyme to discriminate between cleavage of RNA oligonucleotides with differing sequences. These catalytic improvements can be attributed to the strand exchange activity of this RNA binding protein. It is conceivable that endogenous or added proteins may provide analogous increases in ribozyme activity and specificity in vivo.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University								ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FERSHT A, 1985, ENZYME STRUCTURE MEC, P111; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HERSCHLAG D, UNPUB; HERTEL KJ, UNPUB; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; JOYCE G, COMMUNICATION; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LEIS JP, 1978, VIROLOGY, V84, P87, DOI 10.1016/0042-6822(78)90220-9; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; NISSENMEYER J, 1980, J MOL BIOL, V142, P19, DOI 10.1016/0022-2836(80)90203-X; OERTLE S, 1990, J VIROL, V64, P5757, DOI 10.1128/JVI.64.12.5757-5763.1990; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; SMITH D, 1992, J BIOL CHEM, V267, P2429; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; TALLSJO A, 1993, NUCLEIC ACIDS RES, V21, P51, DOI 10.1093/nar/21.1.51; TSUCHIHASHI Z, UNPUB	44	196	201	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					99	102		10.1126/science.7692597	http://dx.doi.org/10.1126/science.7692597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	7692597				2022-12-01	WOS:A1993LZ63500031
J	BRUGGEMANN, A; PARDO, LA; STUHMER, W; PONGS, O				BRUGGEMANN, A; PARDO, LA; STUHMER, W; PONGS, O			ETHER-A-GO-GO ENCODES A VOLTAGE-GATED CHANNEL PERMEABLE TO K+ AND CA2+ AND MODULATED BY CAMP	NATURE			English	Article							POTASSIUM CHANNEL; XENOPUS OOCYTES; DROSOPHILA-EAG; ION CHANNELS; EXPRESSION; MUTATIONS; CURRENTS; SYSTEM	THE Drosophila ether-a-go-go (eag) mutant is responsible for altered potassium currents in excitable tissue1. These mutants exhibit spontaneous, repetitive firing of action potentials in the motor axons of larval neuromuscular junctions2. The eag gene encodes a polypeptide3 that shares sequence similarities with several different ionic channel proteins, including voltage-gated potassium channels-, an inward rectifier4,5 as well as cyclic-nucleotide-gated channels6. These formal similarities in the derived primary sequences indicate that eag polypeptides might express a new type of ion channel. Here we report the expression by eag RNA in Xenopus oocytes of such a channel which incorporates properties of both voltage- and ligand-gated channels. The permeability of these eag channels to potassium and calcium is dependent on voltage and cyclic AMP. The ability to mediate potassium-outward and calcium-inward currents endows this channel with properties likely to be important in the modulation of synaptic efficiency in both central and peripheral nervous systems.	MAX PLANCK INST EXPTL MED, HERMANN REIN STR 3, D-37075 GOTTINGEN, GERMANY; ZMNH, INST NEURONALE SIGNALVERARBEITUNG, D-20246 HAMBURG, GERMANY; UNIV OVIEDO, DEPT BIOL FUNCT, E-33006 OVIEDO, SPAIN	Max Planck Society; University of Oviedo			Pardo, Luis/C-5066-2013; Stuehmer, Walter/A-2176-2009	Pardo, Luis/0000-0003-1375-4349; Stuehmer, Walter/0000-0002-0642-7764; Bruggemann, Andrea/0000-0002-7325-6715				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; EISENMAN G, 1962, Biophys J, V2, P259; GANETZKY B, 1986, ANNU REV GENET, V20, P13; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TORO L, 1993, BIOPHYS J, V64, pA2; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WHITE MM, 1990, MOL PHARMACOL, V37, P720; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZAGOTTA WN, 1989, NEURON, V3, P773, DOI 10.1016/0896-6273(89)90246-8; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	23	196	202	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1993	365	6445					445	448		10.1038/365445a0	http://dx.doi.org/10.1038/365445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692301				2022-12-01	WOS:A1993LZ63300057
J	GALIONE, A; WHITE, A; WILLMOTT, N; TURNER, M; POTTER, BVL; WATSON, SP				GALIONE, A; WHITE, A; WILLMOTT, N; TURNER, M; POTTER, BVL; WATSON, SP			CGMP MOBILIZES INTRACELLULAR CA2+ IN SEA-URCHIN EGGS BY STIMULATING CYCLIC ADP-RIBOSE SYNTHESIS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CALCIUM; ACTIVATION; RELEASE; ENZYME	MANY hormones or neurotransmitters act at cell surface receptors to increase the intracellular free calcium concentration, triggering a wide range of cellular responses1. As the source of this Ca2+ is often internal stores, additional messengers are required to convey the hormonal message from the plasma membrane. Cyclic ADP-ribose (cADPR) has been proposed as the endogenous activator of Ca2+-induced Ca2+ release by the ryanodine receptor in sea urchin eggs and in several mammalian cell types2-8,22. A second messenger role for cADPR requires that its intracellular levels be under the control of extracellular stimuli. Here we demonstrate a novel action of 3',5'-cyclic guanosine monophosphate (cGMP) in stimulating the synthesis of cADPR from beta-NAD+ by activating its synthetic enzyme ADP-ribosyl cyclase9-11 in sea urchin eggs and egg homogenates. We suggest that cADPR may transduce signals generated by cell surface receptors or gaseous transmitters linked to cGMP production.	UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND; UNIV BATH,INST LIFE SCI,BATH BA2 7AY,AVON,ENGLAND	University of Bath; University of Bath	GALIONE, A (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Watson, Stephen P/Q-6292-2016; Galione, Antony/E-5884-2011; Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012	Watson, Stephen P/0000-0002-7846-7423; Galione, Antony/0000-0002-4132-7646				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P504; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOFMANN F, 1985, EUR J BIOCHEM, V150, P85, DOI 10.1111/j.1432-1033.1985.tb08991.x; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, J BIOL CHEM, V268, P293; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; POTTER BVL, 1992, INTRACELLULAR MESSEN, V20, P273; RUSKINO N, 1989, J BIOL CHEM, V264, P11725; SWANN K, 1987, MOL BIOL INVERTEBRAT, P45; TAKESAWA S, 1993, SCIENCE, V259, P370; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Whitaker M.J., 1989, MECHANISMS EGG ACTIV, P159; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X	22	272	276	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					456	459		10.1038/365456a0	http://dx.doi.org/10.1038/365456a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692303				2022-12-01	WOS:A1993LZ63300061
J	LARDER, BA; KELLAM, P; KEMP, SD				LARDER, BA; KELLAM, P; KEMP, SD			CONVERGENT COMBINATION THERAPY CAN SELECT VIABLE MULTIDRUG-RESISTANT HIV-1 IN-VITRO	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; HIGH-LEVEL RESISTANCE; NONNUCLEOSIDE INHIBITORS; ZIDOVUDINE AZT; TYPE-1; SENSITIVITY; REPLICATION; MUTATION; SUSCEPTIBILITIES	THE reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1) is the target for many inhibitors1. Amino-acid substitutions in functional regions of the enzyme that abolish reverse transcriptase activity also prevent HIV-1 replication2,3. But selection pressure by drugs such as AZT (3'-azido-3'-deoxythymidine, zidovudine)4-6, ddI(2',3'-dideoxyinosine)7,8 and non-nucleoside reverse transcriptase inhibitors (NNRTIs)9-14 causes outgrowth of resistant variants due to non-lethal mutations in the enzyme7,9-16. Reports of synergy17-19 and lack of cross-resistance between reverse transcriptase inhibitors (refs 7, 9, 10, 12-14, 17, 18, 20, 21), plus the reversal of AZT resistance by mutations induced by ddI7 and NNRTIs14, have indicated that specific drug combinations directed at reverse transcriptase might curtail resistance. Chow et al.22 extended this concept in a report that specific multiple combinations of resistance mutations in the reverse transcriptase can significantly impair HIV-1 replication. They concluded that evolutionary limitations may exist to prevent the emergence of multidrug resistance to inhibitors of reverse transcriptase22. We report here that HIV-1 co-resistant to AZT, ddI and the NNRTI nevirapine23 can be readily selected in cell culture starting with dual AZT- and ddI-resistant virus. We found no evidence for 'replication incompatible' combinations of resistance mutations, although a mutation (M184-->V) conferring oxathiolane-cytosine nucleoside resistance in reverse transcriptase24,25 completely suppressed AZT resistance in a triple-resistant background. These in vitro observations suggest that triple drug combination therapy might ultimately result in co-resistant HIV-1, although they do not preclude assessment of such combinations for treatment of HIV-1 disease.			LARDER, BA (corresponding author), WELLCOME RES LABS,ANTIVIRAL THERAPEUT RES UNIT,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.		Larder, Brendan/AAB-3106-2020	Kellam, Paul/0000-0003-3166-4734				BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CHOW YK, 1993, NATURE, V364, P679, DOI 10.1038/364679a0; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Larder Brendan A., 1993, P527; MCLEOD GX, 1992, ANTIMICROB AGENTS CH, V36, P920, DOI 10.1128/AAC.36.5.920; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653	29	145	155	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					451	453		10.1038/365451a0	http://dx.doi.org/10.1038/365451a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692302				2022-12-01	WOS:A1993LZ63300059
J	QUILL, TE				QUILL, TE			THE AMBIGUITY OF CLINICAL INTENTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											QUILL, TE (corresponding author), UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14607 USA.							ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BRODY H, 1993, J CLIN ETHIC, V4, P112; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; VANDERMAAS PJ, 1992, HLTH POLICY MONOGRAP, V2; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1992, JAMA-J AM MED ASSOC, V267, P2229	9	137	138	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1039	1040		10.1056/NEJM199309303291414	http://dx.doi.org/10.1056/NEJM199309303291414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	7690111				2022-12-01	WOS:A1993LY58700014
J	SPENCER, K; CARPENTER, P				SPENCER, K; CARPENTER, P			PROSPECTIVE-STUDY OF PRENATAL SCREENING FOR DOWNS-SYNDROME WITH FREE BETA-HUMAN CHORIONIC-GONADOTROPIN	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; UNCONJUGATED ESTRIOL; HUMAN CHORIOGONADOTROPIN; PREGNANCY; RISK; AGE; ABNORMALITIES; MARKERS; ASSAY; HCG	Objective-To assess the value and impact of a screening programme for Down's syndrome that uses the two maternal serum markers: alpha fetoprotein and free beta human chorionic gonadotrophin. Design-All women booked into clinics were screened. Further tests were offered to women with a risk of one in 300 or greater of having an affected baby. Follow up of outcome of all pregnancies. Setting-Biochemical screening laboratory serving two health districts. Subjects-8179 women of all ages with singleton pregnancies screened between 15 and 22 weeks' gestation from 1 April 1991 to 31 March 1992. Main outcome measures-Detection rate of Down's syndrome, false positive rate, uptake of screening, uptake of amniocentesis in women identified as at increased risk, prevalence of Down's syndrome at birth. Results-Overall 89% (8317/9345) of women underwent screening. The rate of detection of Down's syndrome was 69% (11/16; 95% confidence interval 41 to 89%) with a 5.2% false positive rate (426/8179; 4.7 to 5.7%). In women under 30 the detection rate was 50% (four out of eight; 32 to 86%) Uptake of amniocentesis was 89% (389/437), resulting in a reduction of prevalence of Down's syndrome at birth from 1.1 per 1000 in previous years (66/59 696) to 0.4 per 1000 during the screening year (4/9345). Additionally, several other abnormalities were identified. Conclusion-The benefit of a high detection rate with this approach and the additional anomalies identified should encourage others to introduce screening programmes for Down's syndrome that use free beta human chorionic gonadotrophin and alpha fetoprotein.			SPENCER, K (corresponding author), OLDCHURCH HOSP,DEPT CLIN BIOCHEM,ENDOCRINE UNIT,ROMFORD RM7 0BE,ESSEX,ENGLAND.							AITKEN DA, IN PRESS PRENAT DIAG; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; CROSSLEY JA, 1993, PRENATAL DIAG, V13, P271, DOI 10.1002/pd.1970130406; CUCKLE H, 1993, BRIT MED J, V306, P1199, DOI 10.1136/bmj.306.6886.1199; CUCKLE H, 1992, BRIT MED J, V305, P1017, DOI 10.1136/bmj.305.6860.1017; CUCKLE HS, 1984, LANCET, V1, P926; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; LAUNDON C, 1993, J MED GENET, V30, P340; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, IN PRESS PRENAT DIAG; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; PARSONS L, 1992, BRIT MED J, V305, P1228, DOI 10.1136/bmj.305.6863.1228-a; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; REYNOLDS T, 1992, CLIN CHEM, V38, P1888; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SPENCER K, 1985, BRIT MED J, V290, P1940, DOI 10.1136/bmj.290.6486.1940; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1992, LANCET, V339, P1480, DOI 10.1016/0140-6736(92)92073-O; SPENCER K, 1993, ANN CLIN BIOCHEM, V30, P394, DOI 10.1177/000456329303000408; SPENCER K, 1993, BRIT MED J, V306, P1616, DOI 10.1136/bmj.306.6892.1616; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P349, DOI 10.1177/000456329202900319; SPENCER K, 1993, IN PRESS MEASUREMENT; SPENCER K, 1993, IN PRESS BMJ; WALD N, 1993, BRIT MED J, V306, P1198, DOI 10.1136/bmj.306.6886.1198-c; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; 1991, BIRTH STATISTICS 199	34	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					764	769		10.1136/bmj.307.6907.764	http://dx.doi.org/10.1136/bmj.307.6907.764			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	7693095	Bronze, Green Published			2022-12-01	WOS:A1993LZ47800021
J	FUKUNAGA, R; ISHIZAKAIKEDA, E; NAGATA, S				FUKUNAGA, R; ISHIZAKAIKEDA, E; NAGATA, S			GROWTH AND DIFFERENTIATION SIGNALS MEDIATED BY DIFFERENT REGIONS IN THE CYTOPLASMIC DOMAIN OF GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR	CELL			English	Article							HEMATOPOIETIC-CELLS; HUMAN MYELOPEROXIDASE; MOLECULAR-CLONING; MYELOID-LEUKEMIA; CHROMOSOMAL GENE; EXPRESSION; MACROPHAGE; CDNA; IDENTIFICATION; PROLIFERATION	Granulocyte colony-stimulating factor (G-CSF) is a cytokine that regulates the proliferation and differentiation of neutrophils. The G-CSF receptor (G-CSFR) is a member of the hemopoietic growth factor receptor family. A G-CSFR expression plasmid was introduced into interleukin-3 (IL-3)-dependent mouse myeloid precursor FDC-P1 cells that normally do not respond to G-CSF. G-CSF stimulated proliferation of the transformants, down-regulated Thy-1 and F4/80 antigens on the cell surface, and induced expression of neutrophil-specific genes such as myeloperoxidase (MPO) and leukocyte elastase. On the other hand, neither granulocyte/macrophage colony-stimulating factor (GM-CSF) nor IL-3 induced MPO gene expression, but they inhibited G-CSFR-mediated MPO gene expression. These results suggested that the G-CSFR, but not the IL-3/GM-CSF receptors, transduced the neutrophilic differentiation signal into cells. Mutational analysis of the G-CSFR indicated that the N-terminal region of its cytoplasmic domain is sufficient to transduce the proliferation signal into cells, while the C-terminal region plays an essential role in transducing the differentiation signal.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN				Nagata, Shigekazu/AAG-3203-2019; Fukunaga, Rikiro/CAG-2891-2022	Nagata, Shigekazu/0000-0001-9758-8426; 				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAINTON DF, 1990, HEMATOLOGY, P761; BASCH RS, 1982, EUR J IMMUNOL, V12, P359, DOI 10.1002/eji.1830120502; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P1556; DEMETRI GD, 1991, BLOOD, V78, P2791; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HOLMES KL, 1988, IMMUNOL TODAY, V9, P344, DOI 10.1016/0167-5699(88)91335-7; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P1232; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; METCALF D, 1992, P NATL ACAD SCI USA, V89, P2819, DOI 10.1073/pnas.89.7.2819; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.iy.10.040192.001455; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAGATA S, 1993, GROWTH FACTORS, V8, P99, DOI 10.3109/08977199309046930; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NAGATA S, 1990, HDB EXPT PHARM, V95, P699; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; OKANO K, 1987, J BIOCHEM-TOKYO, V102, P13, DOI 10.1093/oxfordjournals.jbchem.a122024; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TESHIMA T, 1990, EXP HEMATOL, V18, P316; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VENTURELLI D, 1989, NUCLEIC ACIDS RES, V17, P5852, DOI 10.1093/nar/17.14.5852; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	45	254	257	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1079	1087		10.1016/0092-8674(93)90729-A	http://dx.doi.org/10.1016/0092-8674(93)90729-A			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691413				2022-12-01	WOS:A1993LY49300014
J	MUSIL, LS; GOODENOUGH, DA				MUSIL, LS; GOODENOUGH, DA			MULTISUBUNIT ASSEMBLY OF AN INTEGRAL PLASMA-MEMBRANE CHANNEL PROTEIN, GAP JUNCTION CONNEXIN43, OCCURS AFTER EXIT FROM THE ER	CELL			English	Article							TRANS-GOLGI NETWORK; VIRUS G-PROTEIN; BREFELDIN-A; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; INFLUENZA HEMAGGLUTININ; PRE-GOLGI; ORGANELLE STRUCTURE; LIGAND-BINDING; CELL-SURFACE	Connexin43 (Cx43) is an integral plasma membrane protein that forms gap junctions between vertebrate cells. We have used sucrose gradient fractionation and chemical cross-linking to study the first step in gap junction assembly, oligomerization of Cx43 monomers into connexon channels. In contrast with other plasma membrane proteins, multisubunit assembly of Cx43 was specifically and completely blocked when endoplasmic reticulum (ER)-to-Golgi transport was inhibited by 15-degrees-C incubation, carbonyl cyanide m-chlorophenylhydrazone, or brefeldin A or in CHO cell mutants with temperature-sensitive defects in secretion. Additional experiments indicated that connexon assembly occurred intracellularly, most likely in the trans-Golgi network. These results describe a post-ER assembly pathway for integral membrane proteins and have implications for the relationship between membrane protein oligomerization and intracellular transport.			MUSIL, LS (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.				NATIONAL EYE INSTITUTE [R01EY002430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018974, R37GM018974] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02430] Funding Source: Medline; NIGMS NIH HHS [GM-18974] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Caspar DLD, 1988, GAP JUNCTIONS, P117; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; COLLINS PL, 1991, J GEN VIROL, V72, P3095, DOI 10.1099/0022-1317-72-12-3095; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMELLO W, 1987, INTERCELLULAR COMMUN, P29; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DORAN JE, 1981, INFECT IMMUN, V33, P683, DOI 10.1128/IAI.33.3.683-689.1981; FISHER AS, 1992, THESIS MIT CAMBRIDGE; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; HENDRIX EM, 1992, MOL REPROD DEV, V33, P27, DOI 10.1002/mrd.1080330105; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kumar N M, 1992, Semin Cell Biol, V3, P3; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MATTER K, 1991, BIOCHEMISTRY-US, V30, P1916, DOI 10.1021/bi00221a026; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POTTER TA, 1985, P NATL ACAD SCI USA, V82, P2950, DOI 10.1073/pnas.82.9.2950; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RICKWOOD D, 1984, CENTRIFUGATION PRACT, P95; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHITE S, 1990, J BIOL CHEM, V265, P17385; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cb.06.110190.001245; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YAMADA A, 1988, VIROLOGY, V165, P268, DOI 10.1016/0042-6822(88)90681-2; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	73	405	411	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1065	1077		10.1016/0092-8674(93)90728-9	http://dx.doi.org/10.1016/0092-8674(93)90728-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691412				2022-12-01	WOS:A1993LY49300013
J	NEUHOLD, LA; WOLD, B				NEUHOLD, LA; WOLD, B			HLH FORCED DIMERS - TETHERING MYOD TO E47 GENERATES A DOMINANT POSITIVE MYOGENIC FACTOR INSULATED FROM NEGATIVE REGULATION BY ID	CELL			English	Article							HELIX-LOOP-HELIX; CREATINE-KINASE ENHANCER; MUSCLE-SPECIFIC ENHANCER; LIGATION-MEDIATED PCR; PAN-NEURAL GENE; DNA-BINDING; TRANSCRIPTION FACTORS; CYCLIC AMPLIFICATION; SEX DETERMINATION; NUCLEAR FACTOR	Basic-helix-loop-helix (bHLH) class transcription factors bind DNA as hetero- and homodimers. In murine myogenic cells the HLH network includes multiple members of the E protein, MyoD, and Id families; changes in the network characterize muscle determination and differentiation and have been proposed as causal for these developmental transitions. To test the importance of HLH partner choice in these cellular decisions, we have designed a strategy in which the identity of a bHLH dimer is specified by joining two monomers via a flexible polypeptide linker. A MyoD is similar to E47 polyprotein avidly bound the same DNA target as its unlinked counterpart, but, unlike intermolecular dimers that are very sensitive to inhibition by Id, MyoD is similar E47 was resistant to Id challenge. In cells MyoD is similar to E47 acted as a dominant positive myogenic factor, capable of initiating myogenic determination and also substantially bypassing negative regulation of differentiation by serum growth factors.			NEUHOLD, LA (corresponding author), CALTECH,DIV BIOL,156-29,PASADENA,CA 91125, USA.							ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARMER K, 1992, J BIOL CHEM, V267, P5631; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MINER JH, 1992, DEVELOPMENT, V114, P853; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J., 1989, MOL CLONING LAB MANU; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, CELL, V66, P423, DOI 10.1016/0092-8674(81)90003-9; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTSEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105	65	134	136	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1033	1042		10.1016/0092-8674(93)90725-6	http://dx.doi.org/10.1016/0092-8674(93)90725-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691411				2022-12-01	WOS:A1993LY49300010
J	SHUAI, K; STARK, GR; KERR, IM; DARNELL, JE				SHUAI, K; STARK, GR; KERR, IM; DARNELL, JE			A SINGLE PHOSPHOTYROSINE RESIDUE OF STAT91 REQUIRED FOR GENE ACTIVATION BY INTERFERON-GAMMA	SCIENCE			English	Article							ALPHA-INTERFERON; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; BINDING PROTEIN; MUTANT	Interferon-gamma (IFN-gamma) stimulates transcription of specific genes by inducing tyrosine phosphorylation of a 91-kilodalton cytoplasmic protein (termed STAT for signal transducer and activator of transcription). Stat91 was phosphorylated on a single site (Tyr701), and phosphorylation of this site was required for nuclear translocation, DNA binding, and gene activation. Stat84, a differentially spliced product of the same gene that lacks the 38 carboxyl-terminal amino acids of Stat91, did not activate transcription, although it was phosphorylated and translocated to the nucleus and bound DNA. Thus, Stat91 mediates activation of transcription in response to IFN-gamma.	ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA; CLEVELAND CLIN FDN, RES INST, CLEVELAND, OH 44195 USA; IMPERIAL CANC RES FDN, LONDON, ENGLAND	Rockefeller University; Cleveland Clinic Foundation					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; IMPROTA T, UNPUB; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, IN PRESS EMBO J; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, UNPUB; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897	17	718	738	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1993	261	5129					1744	1746		10.1126/science.7690989	http://dx.doi.org/10.1126/science.7690989			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	7690989				2022-12-01	WOS:A1993LY58400029
J	GAUCHAT, JF; HENCHOZ, S; MAZZEI, G; AUBRY, JP; BRUNNER, T; BLASEY, H; LIFE, P; TALABOT, D; FLORESROMO, L; THOMPSON, J; KISHI, K; BUTTERFIELD, J; DAHINDEN, C; BONNEFOY, JY				GAUCHAT, JF; HENCHOZ, S; MAZZEI, G; AUBRY, JP; BRUNNER, T; BLASEY, H; LIFE, P; TALABOT, D; FLORESROMO, L; THOMPSON, J; KISHI, K; BUTTERFIELD, J; DAHINDEN, C; BONNEFOY, JY			INDUCTION OF HUMAN IGE SYNTHESIS IN B-CELLS BY MAST-CELLS AND BASOPHILS	NATURE			English	Article							MESSENGER-RNA; INTERLEUKIN-4; LIGAND; CD40; IDENTIFICATION; CYCLOSPORINE; LEUKEMIA; LINE	IMMUNOGLOBULIN E (IgE) is central to the induction of allergic diseases through its binding to the high-affinity receptor (FcepsilonR1) on mast cells and basophils. Crosslinking by allergens of the bound IgE leads to the release of various inflammatory mediators. IgE production by B cells requires a physical interaction with T cells1, involving a number of surface adhesion molecules1,2, as well as the soluble factors interleukin-4 (IL-4)3,4 and IL-13 (ref. 5) produced by T cells6,7, basophils8 and mast cells9. Here we report that, in the presence of IL-4, mast and basophilic cell lines can provide the cell contact signals that are required for IgE synthesis. The human cell lines HMC-1 (mast) and KU812 (basophilic) both express the ligand for CD40 (CD40L) which is shown to be responsible for the IgE production. Moreover, freshly isolated purified human lung mast cells and blood basophils are also shown to express CD40L and to induce IgE production. This evidence suggests that mast cells and basophils may therefore play a key role in allergy not only by producing inflammatory mediators, but also by directly regulating IgE production independently of T cells.	GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND; INSELSPITAL BERN,CH-3010 BERN,SWITZERLAND; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND; NIIGATA UNIV,NIIGATA 951,JAPAN; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	GlaxoSmithKline; GlaxoSmithKline; Niigata University; Mayo Clinic								ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1989, EUR J IMMUNOL, V19, P1079, DOI 10.1002/eji.1830190618; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P8166; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295	29	569	580	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					340	343		10.1038/365340a0	http://dx.doi.org/10.1038/365340a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	7690905				2022-12-01	WOS:A1993LY49600052
J	BERBERIAN, L; GOODGLICK, L; KIPPS, TJ; BRAUN, J				BERBERIAN, L; GOODGLICK, L; KIPPS, TJ; BRAUN, J			IMMUNOGLOBULIN-V(H)3 GENE-PRODUCTS - NATURAL LIGANDS FOR HIV GP120	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CROSS-REACTIVE IDIOTYPE; B-CELL ACTIVATION; STAPHYLOCOCCAL PROTEIN; T-CELLS; CD4 RECEPTOR; INFECTION; ANTIGEN; ANTIBODY; AUTOANTIBODIES	Infection with human immunodeficiency virus-type 1 (HIV-1) depletes T cells expressing CD4 and B cells expressing immunoglobulin (Ig) V(H)3 gene products. A subpopulation of normal B cells from non-HIV-infected individuals was shown to bind to HIV gp120 by means of membrane Ig; most of these B cells expressed V(H)3 family Ig. Serum V(H)3 IgM from uninfected individuals also avidly bound gp120. Finally, gp120 selectively induced Ig secretion by V(H)3 B cells, indicating that the binding of gp120 functionally activated these cells. These results indicate that naturally occurring V(H)3 Ig is a second ligand for gp120 and a candidate superantigen for V(H)3 B cells.	UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego				Braun, Jonathan/0000-0003-1646-2974	NCI NIH HHS [CA12800] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; NIGMS NIH HHS [GM08375] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; AULT KA, 1977, J IMMUNOL, V119, P327; AXELROD O, 1991, BLOOD, V77, P1484; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BASS HZ, 1992, CLIN IMMUNOL IMMUNOP, V64, P63, DOI 10.1016/0090-1229(92)90060-2; BERBERIAN L, 1991, BLOOD, V78, P175; BRAUN J, 1992, J CLIN INVEST, V89, P1395, DOI 10.1172/JCI115728; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; CASALI P, 1989, IMMUNOL TODAY, V10, P364, DOI 10.1016/0167-5699(89)90268-5; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CROWLEY JJ, 1990, MOL IMMUNOL, V27, P87, DOI 10.1016/0161-5890(90)90063-6; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GOODGLICK L, UNPUB; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HAIGWOOD NL, 1990, VACCINES 90, P313; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; JEFFERIES LC, 1992, CLIN IMMUNOL IMMUNOP, V65, P119, DOI 10.1016/0090-1229(92)90214-9; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; KIRKHAM PM, 1992, EMBO J, V11, P603, DOI 10.1002/j.1460-2075.1992.tb05092.x; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LYDYARD PM, 1990, SCAND J IMMUNOL, V32, P709, DOI 10.1111/j.1365-3083.1990.tb03214.x; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARTIN T, 1992, J EXP MED, V175, P983, DOI 10.1084/jem.175.4.983; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; OLEE T, 1991, J CLIN INVEST, V88, P193, DOI 10.1172/JCI115277; PASCUAL V, 1991, Current Biology, V1, P315, DOI 10.1016/0960-9822(91)90097-G; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SASSO EH, 1989, J IMMUNOL, V142, P2778; SASSO EH, 1991, J IMMUNOL, V147, P1877; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; SHOKRI F, 1991, J IMMUNOL, V146, P936; STEIMER KS, 1988, VACCINES, V88, P347; SUTOR GC, 1992, J IMMUNOL, V149, P1452; VALLESAYOUB Y, 1990, BLOOD, V76, P17; WALTER MA, 1991, J EXP MED, V174, P335, DOI 10.1084/jem.174.2.335; YOUNG F, 1990, J IMMUNOL, V145, P2545	45	261	271	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1588	1591		10.1126/science.7690497	http://dx.doi.org/10.1126/science.7690497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	7690497				2022-12-01	WOS:A1993LX47400033
J	WEEKS, KM; CROTHERS, DM				WEEKS, KM; CROTHERS, DM			MAJOR GROOVE ACCESSIBILITY OF RNA	SCIENCE			English	Article							INTERNAL LOOPS; NUCLEIC-ACIDS; BINDING-SITE; FREE-ENERGY; RECOGNITION; SYNTHETASE; OLIGORIBONUCLEOTIDES; MISMATCHES	Chemical acylation experiments showed that the RNA major groove, often assumed to be too deep and narrow to permit recognition interactions, is accessible at duplex termini. Reactivity extended further into the helix in the 5' than in the 3' direction. Asymmetric and large loops between helices uncoupled them, which yielded both enhanced reactivity at terminal base pairs and weaker stabilization enthalpy compared to that in small loops or symmetric loops of the same size. Uncoupled helices have effective helix ends with accessible major grooves; such motifs are attractive contributors to protein recognition, tertiary folding, and catalysis.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University					NIGMS NIH HHS [GM21966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021966, R01GM021966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDEN CJ, 1979, J MOL BIOL, V132, P411, DOI 10.1016/0022-2836(79)90268-7; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; CANTOR CR, 1980, BIOPHYSICAL CHEM, P1205; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P3534, DOI 10.1021/bi00128a030; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRALLA J, 1973, J MOL BIOL, V78, P301, DOI 10.1016/0022-2836(73)90118-6; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HOLBROOK SR, 1983, BIOPOLYMERS, V22, P1145, DOI 10.1002/bip.360220410; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; Kim S H, 1976, Prog Nucleic Acid Res Mol Biol, V17, P181, DOI 10.1016/S0079-6603(08)60070-7; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERITZ AE, 1991, BIOCHEMISTRY-US, V30, P6428, DOI 10.1021/bi00240a013; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; VINCZE A, 1973, J AM CHEM SOC, V95, P2677, DOI 10.1021/ja00789a045; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1992, CELL, V70, P1069; WEEKS KM, UNPUB; YARUS M, 1991, NUCLEIC ACIDS RES, V19, P1297, DOI 10.1093/nar/19.6.1297	28	191	197	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1574	1577		10.1126/science.7690496	http://dx.doi.org/10.1126/science.7690496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	7690496				2022-12-01	WOS:A1993LX47400029
J	NGUYEN, M; STRUBEL, NA; BISCHOFF, J				NGUYEN, M; STRUBEL, NA; BISCHOFF, J			A ROLE FOR SIALYL LEWIS-X/A GLYCOCONJUGATES IN CAPILLARY MORPHOGENESIS	NATURE			English	Article							LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; ACTIVATION ANTIGEN; E-SELECTIN; ELAM-1; ENDOTHELIUM; RECOGNITION; INDUCTION; INVITRO	To identify cell adhesion molecules required for angiogenesis, we used an in vitro model in which bovine capillary endothelial cells can be induced to form capillary-like tubes. Monoclonal antibodies directed against the carbohydrate epitopes sialyl Lewis-X and sialyl Lewis-A inhibited capillary formation. We postulated that a member of the selectin family of adhesion molecules may be involved in capillary formation because these proteins bind to sialyl Lewis-X/A-containing ligands. We isolated a 2.8-kilobase complementary DNA from a bovine capillary endothelial cell cDNA library which encodes a polypeptide with 71% identity to human E-selectin. We report here that antibody directed against the bovine E-selectin inhibited capillary formation, suggesting that in addition to its role in leukocyte adhesion to endothelium, a form of E-selectin is involved in capillary morphogenesis.	CHILDRENS HOSP MED CTR,SURG RES LAB,300 LONGWOOD AVE,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974; Strubel, Naomi/0000-0002-4394-2108				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; Heusser C H, 1981, Methods Enzymol, V73, P406; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MESSADI DV, 1987, J IMMUNOL, V139, P1557; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STRUBEL NA, 1993, BIOCHEM BIOPH RES CO, V192, P338, DOI 10.1006/bbrc.1993.1420; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	27	207	214	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					267	269		10.1038/365267a0	http://dx.doi.org/10.1038/365267a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	7690465				2022-12-01	WOS:A1993LX47100059
J	QIAN, XQ; JEON, CJ; YOON, HS; AGARWAL, K; WEISS, MA				QIAN, XQ; JEON, CJ; YOON, HS; AGARWAL, K; WEISS, MA			STRUCTURE OF A NEW NUCLEIC-ACID-BINDING MOTIF IN EUKARYOTIC TRANSCRIPTIONAL ELONGATION-FACTOR TFIIS	NATURE			English	Article							RNA POLYMERASE-II; ZINC FINGER; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; DNA RECOGNITION; DOMAINS; PROTEIN; COMPLEX; SUBUNIT; BLOCK	TRANSCRIPTIONAL elongation involves dynamic interactions among RNA polymerase and single-stranded and double-stranded nucleic acids in the ternary complex1-4. In prokaryotes its regulation provides an important mechanism of genetic control1. Analogous eukaryotic mechanisms are not well understood5, but may control expression of proto-oncogenes6,7 and viruses, including the human immunodeficiency virus HIV-1 (ref. 8). The highly conserved eukaryotic transcriptional elongation factor TFIIS9 enables RNA polymerase II (RNAPII) to read though pause or termination sites, nucleosomes and sequence-specific DNA-binding proteins10-14 . Two distinct domains of human TFIIS, which bind RNAPII and nucleic acids, regulate read-through10 and possibly nascent transcript cleavage11-15. Here we describe the three-dimensional NMR16 structure of a Cys4 nucleic-acid-binding domain from human TFIIS9,10. Unlike previously characterized zinc modules17-21, which contain an alpha-helix, this structure consists of a three-stranded beta-sheet. Analogous Cys4, structural motifs may occur in other proteins involved in DNA or RNA transactions22-24, including RNAPII itself25. This new structure, designated the Zn ribbon, extends the repertoire of Zn-mediated peptide architectures26 and highlights the growing recognition of the beta-sheet as a motif of nucleic-acid recognition27,28.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114	University of Chicago; University of Chicago; Harvard University; Massachusetts General Hospital	QIAN, XQ (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.		Yoon, Ho Sup/A-2193-2011	Yoon, Ho Sup/0000-0002-8243-3904				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAMORSTEIN R, 1992, NATURE, V356, P408; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN X, IN PRESS BIOCHEMISTR; QIAN XQ, 1992, BIOCHEMISTRY-US, V31, P7463, DOI 10.1021/bi00148a006; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RENIES D, 1992, J BIOL CHEM, V267, P3795; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	30	111	118	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					277	279		10.1038/365277a0	http://dx.doi.org/10.1038/365277a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	7626141	Green Accepted			2022-12-01	WOS:A1993LX47100062
J	WOOD, D; HALFON, N; SCARLATA, D; NEWACHECK, P; NESSIM, S				WOOD, D; HALFON, N; SCARLATA, D; NEWACHECK, P; NESSIM, S			IMPACT OF FAMILY RELOCATION ON CHILDRENS GROWTH, DEVELOPMENT, SCHOOL FUNCTION, AND BEHAVIOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIDIMENSIONAL ASSESSMENT; LIFE EVENTS; FOSTER-CARE; HEALTH; MORBIDITY; HOMELESS; POOR	Objective.-The United States is a highly mobile society, with family relocation rates double those of Great Britain and Germany. The objective of this study was to describe the impact of frequent family moves on reported rates of delay in growth or development, learning disorders, school failure, and frequent behavioral problems in US school-age children. Design and Setting.-We analyzed data on 9915 six- to 17-year-old children of families responding to the 1988 National Health Interview Survey, a nationally representative sample of families and children. Outcome Measures.-Parents were asked to report the total number of moves the index child had experienced during his or her lifetime. Total moves were adjusted for the child's age in years. Children were divided into two groups: never moved/infrequent relocation (below the 90th percentile for age-adjusted moves) and frequent relocation (above the 90th percentile for age-adjusted moves). The parent was asked if the child had ever had a learning disability or a delay in growth or development, had ever failed a grade, or had four or more frequently occurring behavioral problems as described by a behavioral problems checklist. Results.-The measures of both child dysfunction and family relocation were independently associated with multiple sociodemographic characteristics such as poverty, race, and family structure. Frequent relocation was associated with higher rates of all measures of child dysfunction; 23% of children who moved frequently had repeated a grade vs 12% of children who never or infrequently moved. Eighteen percent of children who moved frequently had four or more behavioral problems vs 7% of children who never or infrequently moved. Use of logistic regression to control for potential confounding covariates demonstrated that children who moved frequently were 77% more likely to be reported to have four or more behavioral problems (odds ratio, 1.77; 95% confidence interval, 1.37 to 2.29) and were 35% more likely to have failed a grade (odds ratio, 1.35; 95% confidence interval, 1.06 to 1.72), but no more likely to have had delays in growth or development or a learning disorder. Conclusions.-After adjusting for other covariates, frequent family relocation was associated with an increased risk of children failing a grade in school and four or more frequently occurring behavioral problems.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA USA; UCSF, SCH MED, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DIV BIOSTAT, SCI & CLIN COMP SERV, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; University of California System; University of California Los Angeles	WOOD, D (corresponding author), CEDARS SINAI MED CTR, AHAMANSON DEPT PEDIAT, DIV PRIMARY CARE PEDIAT, 310 N SAN VICENTE D, LOS ANGELES, CA 90048 USA.							ACHENBACH TM, 1981, MONOGR SOC RES CHILD, V46, P1, DOI 10.2307/1165983; ADAMS PF, 1989, VITAL HLTH STAT 10, V173, P1; ADAMS PF, 1989, VITAL HLTH STAT, V173, P133; BASSUK EL, 1988, YALE LAW POLICY REV, V6, P309; BEAUTRAIS AL, 1982, PEDIATRICS, V70, P774; CAMPBELL SB, 1982, J ABNORM CHILD PSYCH, V10, P569, DOI 10.1007/BF00920755; CHAMBERLAIN P, 1987, BEHAV ASSESS, V9, P97; DIAZ C, 1986, MED CARE, V24, P848, DOI 10.1097/00005650-198609000-00006; Eisen M., 1980, R2313HEW RAND; EMERY RF, 1988, MARRIAGE DIVORCE CHI, P14; GOULD MS, 1981, J AM ACAD CHILD PSY, V20, P462, DOI 10.1016/S0002-7138(09)61640-X; Haggerty RJ, 1975, CHILD HLTH COMMUNITY; HOCHSTADT NJ, 1987, CHILD ABUSE NEGLECT, V11, P53, DOI 10.1016/0145-2134(87)90033-0; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Jones Jacqueline, 1992, DISPOSSESSED AM UNDE; LEVINE M, 1966, COMMUNITY MENT HLT J, V2, P61, DOI 10.1007/BF01420324; Levy J. E., 1992, FUTURE CHILD, V2, P44; LOCHMAN JE, 1986, J CHILD ADOL PSYCHOL, V3, P91; MCGAUHEY PJ, 1991, PEDIATRICS, V88, P943; MCLANAHAN S, 1988, FOCUS, V2, P16; MCMAHON RC, 1979, J CLIN PSYCHOL, V35, P757, DOI 10.1002/1097-4679(197910)35:4<757::AID-JCLP2270350413>3.0.CO;2-B; NEWACHECK PW, 1988, AM J PUBLIC HEALTH, V78, P927, DOI 10.2105/AJPH.78.8.927; NEWCOMB MD, 1981, J HEALTH SOC BEHAV, V22, P400, DOI 10.2307/2136681; PAVENSTEDT E, 1967, DRIFTERS CHILDREN DI; REYNOLDS AJ, 1989, J EDUC PSYCHOL, V81, P594, DOI 10.1037/0022-0663.81.4.594; REYNOLDS AJ, 1991, ED334019; ROSSI PH, 1980, WHY FAMILIES MOVE, P32; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; SCHOR EL, 1982, PEDIATRICS, V69, P521; SHAF BV, 1992, SUDAAN USERS MANUAL; STANTON WR, 1991, PEDIATRICS, V88, P954; STOKOLS D, 1982, J SOC ISSUES, V38, P149, DOI 10.1111/j.1540-4560.1982.tb01776.x; STUBBLEFIELD RL, 1955, AM J ORTHOPSYCHIAT, V25, P12; Tyack D., 1992, FUTURE CHILD, V2, P19, DOI DOI 10.2307/1602459; WHALEN TE, 1973, J EDUC RES, V67, P163, DOI 10.1080/00220671.1973.10884593; WHITE KR, 1982, PSYCHOL BULL, V91, P461, DOI 10.1037/0033-2909.91.3.461; WOOD D, 1990, AM J PUBLIC HEALTH, V80, P1049, DOI 10.2105/AJPH.80.9.1049; WOOD DL, 1990, PEDIATRICS, V86, P858; 1989, US CHILDREN THEIR FA; 1992, FUTURE CHILD, V2, P6; 1989, CURRENT POPULATI P60, V166; 1990, 19R01 NAT ASS ED PRO; 1985, SAS USERS GUIDE BASI; 1989, CURRENT POPULATI P20, V430; [No title captured]	45	203	204	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1334	1338		10.1001/jama.270.11.1334	http://dx.doi.org/10.1001/jama.270.11.1334			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	7689659				2022-12-01	WOS:A1993LW34500031
J	FAIRBAIRN, LJ; COWLING, GJ; REIPERT, BM; DEXTER, TM				FAIRBAIRN, LJ; COWLING, GJ; REIPERT, BM; DEXTER, TM			SUPPRESSION OF APOPTOSIS ALLOWS DIFFERENTIATION AND DEVELOPMENT OF A MULTIPOTENT HEMATOPOIETIC-CELL LINE IN THE ABSENCE OF ADDED GROWTH-FACTORS	CELL			English	Article							COLONY-STIMULATING FACTORS; HEMATOPOIETIC PROGENITOR CELLS; SELF-RENEWAL; STEM-CELLS; GENE-EXPRESSION; NA+/H+ EXCHANGE; SURVIVAL; DEATH; BCL-2; PROTEIN	In the absence of growth factors, hemopoietic cells die rapidly by the process of apoptosis. Transfection of the human bcl-2 gene into an interleukin-3 (IL-3)-dependent, multipotent hemopoietic cell line allowed these cells to survive in the absence of IL-3, both in serum-containing and serum-deprived conditions, and this survival was accompanied by multilineage differentiation. Moreover, single cell experiments showed that differentiation could occur in the absence of cell division. While these data do not rule out the possibility that growth factors can influence the lineage choice of multipotent cells, they suggest that exposure to growth factors may not be obligatory for the differentiation of stem cells. The data also support the hypothesis that differentiation is intrinsically determined and that the role of the hemopoietic growth factors is enabling rather than inductive.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT BIOPHYS,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	FAIRBAIRN, LJ (corresponding author), CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT EXPTL HAEMATOL,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND.							BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BEGLEY CG, 1986, BLOOD, V68, P162; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BROXMEYER HE, 1992, AM J PEDIAT HEMATOL, V14, P22; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CURRY JL, 1967, SCIENCE, V236, P1229; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAIRBAIRN LJ, 1993, HAEMOPOIESIS PRACTIC, P175; FORD AM, 1992, P NATL ACAD SCI USA, V89, P3424, DOI 10.1073/pnas.89.8.3424; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; Heyworth C M, 1991, Growth Factors, V5, P87, DOI 10.3109/08977199109000274; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KAN O, 1993, HAEMOPOIESIS PRACTIC, P123; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; Maniatis T, 1989, DECONTAMINATION DILU; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1984, COLONY STIMULATING F; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; TESTA NG, 1993, HAEMOPOIESIS PRACTIC; TESTA NG, 1991, CYTOKINES PRACTICAL, P229; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHETTON AD, 1988, BIOCHEM J, V256, P585, DOI 10.1042/bj2560585; WHETTON AD, 1988, BIOCHEM BIOPH RES CO, V152, P1173, DOI 10.1016/S0006-291X(88)80408-X; WHETTON AD, 1989, BIOCHIM BIOPHYS ACTA, V989, P11; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	57	357	359	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					823	832		10.1016/0092-8674(93)90462-Y	http://dx.doi.org/10.1016/0092-8674(93)90462-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	7690686				2022-12-01	WOS:A1993LX29200008
J	KARUPIAH, G; XIE, QW; BULLER, RML; NATHAN, C; DUARTE, C; MACMICKING, JD				KARUPIAH, G; XIE, QW; BULLER, RML; NATHAN, C; DUARTE, C; MACMICKING, JD			INHIBITION OF VIRAL REPLICATION BY INTERFERON-GAMMA-INDUCED NITRIC-OXIDE SYNTHASE	SCIENCE			English	Article							VACCINIA VIRUS; RIBONUCLEOTIDE REDUCTASE; PROTEIN-KINASE; CELLS; MACROPHAGES; BIOCHEMISTRY; MECHANISM; ARGINASE; PRODUCT; SYSTEM	Interferons (IFNs) induce antiviral activity in many cell types. The ability of IFN-gamma to inhibit replication of ectromelia, vaccinia, and herpes simplex-1 viruses in mouse macrophages correlated with the cells' production of nitric oxide (NO). Viral replication was restored in IFN-gamma-treated macrophages exposed to inhibitors of NO synthase. Conversely, epithelial cells with no detectable NO synthesis restricted viral replication when transfected with a complementary DNA encoding inducible NO synthase or treated with organic compounds that generate NO. In mice, an inhibitor of NO synthase converted resolving ectromelia virus infection into fulminant mousepox. Thus, induction of NO synthase can be necessary and sufficient for a substantial antiviral effect of IFN-gamma.	CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, BEATRICE & SAMUEL A SEAVER LAB, NEW YORK, NY 10021 USA	Cornell University	KARUPIAH, G (corresponding author), NIAID, VIRAL DIS LAB, BETHESDA, MD 20892 USA.		Karupiah, Gunasegaran/J-4707-2013	Karupiah, Gunasegaran/0000-0001-6306-4405	NCI NIH HHS [CA43610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CONSTANTOULAKIS P, 1993, SCIENCE, V259, P1314, DOI 10.1126/science.7680491; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DING AH, 1988, J IMMUNOL, V141, P2407; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; HECK DE, 1992, J BIOL CHEM, V267, P21277; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1990, INT CONGR SER, V897, P189; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KARUPIAH G, 1990, J EXP MED, V172, P1495, DOI 10.1084/jem.172.5.1495; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, UNPUB; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1992, INFLAMMATION BASIC P, P265; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1992, J BIOL CHEM, V267, P5017; SETHI KK, 1983, IMMUNOBIOLOGY, V165, P459, DOI 10.1016/S0171-2985(83)80069-2; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WILDY P, 1982, INFECT IMMUN, V37, P40, DOI 10.1128/IAI.37.1.40-45.1982; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; XIE Q, UNPUB; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	40	757	782	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1993	261	5127					1445	1448		10.1126/science.7690156	http://dx.doi.org/10.1126/science.7690156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690156				2022-12-01	WOS:A1993LW54900032
J	KETCHEM, RR; HU, W; CROSS, TA				KETCHEM, RR; HU, W; CROSS, TA			HIGH-RESOLUTION CONFORMATION OF GRAMICIDIN-A IN A LIPID BILAYER BY SOLID-STATE NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSMEMBRANE ION-CHANNEL; PHASE PEPTIDE-SYNTHESIS; C-13 CHEMICAL-SHIFT; RIGHT-HANDED HELIX; PHOSPHOLIPID-BILAYERS; MEMBRANE-PROTEINS; SIDE-CHAINS; TRYPTOPHAN; SPECTROSCOPY	Solid-state nuclear magnetic resonance spectroscopy of uniformly aligned preparations of gramicidin A in lipid bilayers has been used to elucidate a high-resolution dimeric structure of the cation channel conformation solely on the basis of the amino acid sequence and 144 orientational constraints. This initial structure defines the helical pitch as single-stranded, fixes the number of residues per turn at six to seven, specifies the helix sense as right-handed, and identifies the hydrogen bonds. Refinement of this initial structure yields reasonable hydrogen-bonding distances with only minimal changes in the torsion angles.	FLORIDA STATE UNIV,INST MOLEC BIOPHYS,NATL HIGH MAGNET FIELD LAB,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University			Ketchem, Randal/AAB-4372-2020; Ketchem, Randal R/K-2258-2017	Ketchem, Randal/0000-0002-7821-2682; Ketchem, Randal R/0000-0002-7821-2682; Cross, Timothy/0000-0002-9413-0505	NIAID NIH HHS [AI-23007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023007] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER MD, 1991, BIOCHEMISTRY-US, V30, P8830, DOI 10.1021/bi00100a015; BOUCHARD M, 1993, BIOPHYS J, V64, pA61; BYSTROV VF, 1987, B MAGN RESON, V8, P84; CHIU SW, 1993, BIOPHYS J, V64, P98, DOI 10.1016/S0006-3495(93)81344-4; CORNELL BA, 1988, BIOPHYS J, V53, P67, DOI 10.1016/S0006-3495(88)83066-2; Deisenhofer, 1990, CURRENT TOPICS MEMBR, V36, P53; FIELDS CG, 1989, INT J PEPT PROT RES, V33, P298; FIELDS CG, 1989, THESIS FLORIDA STATE; FIELDS GB, 1988, P NATL ACAD SCI USA, V85, P1384, DOI 10.1073/pnas.85.5.1384; GARBOW JR, 1993, J AM CHEM SOC, V115, P238, DOI 10.1021/ja00054a034; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HING AW, 1990, BIOCHEMISTRY-US, V29, P4144, DOI 10.1021/bi00469a018; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; KATSARAS J, 1992, BIOPHYS J, V61, P827, DOI 10.1016/S0006-3495(92)81888-X; KILLIAN JA, 1992, BIOCHEMISTRY-US, V31, P11283, DOI 10.1021/bi00161a004; KINSEY RA, 1981, J BIOL CHEM, V256, P9028; KVICK A, 1977, ACTA CRYSTALLOGR B, V33, P3796, DOI 10.1107/S0567740877012102; LANGS DA, 1991, P NATL ACAD SCI USA, V88, P5345, DOI 10.1073/pnas.88.12.5345; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LEE KC, IN PRESS BIOPHYS J; LOGRASSO PV, 1989, J AM CHEM SOC, V111, P1910, DOI 10.1021/ja00187a072; LOMIZE AL, 1992, BIOORG KHIM+, V18, P182; MAI W, 1993, PROTEIN SCI, V2, P532; NICHOLSON LK, 1989, BIOCHEMISTRY-US, V28, P9379, DOI 10.1021/bi00450a019; PROSSER RS, 1991, BIOCHEMISTRY-US, V30, P4687, DOI 10.1021/bi00233a008; ROUX B, 1988, BIOPHYS J, V53, P297, DOI 10.1016/S0006-3495(88)83107-2; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; SEPAROVIC F, 1991, CHEM PHYS LETT, V181, P157, DOI 10.1016/0009-2614(91)90348-D; SMITH R, 1989, BIOPHYS J, V56, P307, DOI 10.1016/S0006-3495(89)82677-3; TAKEUCHI H, 1990, BIOCHEMISTRY-US, V29, P1572, DOI 10.1021/bi00458a031; TENG Q, 1992, J AM CHEM SOC, V114, P5312, DOI 10.1021/ja00039a048; TENG Q, 1991, J MOL BIOL, V218, P607, DOI 10.1016/0022-2836(91)90705-B; THOMPSON LK, 1992, BIOCHEMISTRY-US, V31, P7931, DOI 10.1021/bi00149a026; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WEINSTEIN S, 1979, P NATL ACAD SCI USA, V76, P4230, DOI 10.1073/pnas.76.9.4230; ZHANG ZL, 1992, BIOCHEMISTRY-US, V31, P8822, DOI 10.1021/bi00152a019	37	625	628	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1457	1460		10.1126/science.7690158	http://dx.doi.org/10.1126/science.7690158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690158				2022-12-01	WOS:A1993LW54900036
J	SUSEK, RE; AUSUBEL, FM; CHORY, J				SUSEK, RE; AUSUBEL, FM; CHORY, J			SIGNAL-TRANSDUCTION MUTANTS OF ARABIDOPSIS UNCOUPLE NUCLEAR CAB AND RBCS GENE-EXPRESSION FROM CHLOROPLAST DEVELOPMENT	CELL			English	Article							MESSENGER-RNA ACCUMULATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PLANT-CELLS; LIGHT; THALIANA; CHLOROPHYLL; PROTEIN; BINDING; MAIZE	Chloroplast development requires coordinate nuclear and chloroplast gene expression. A putative signal from the chloroplast couples the transcription of certain nuclear genes encoding photosynthesis-related proteins with chloroplast function. We have identified at least three Arabidopsis nuclear genes (GUN1, GUN2, and GUN3) necessary for coupling the expression of some nuclear genes to the functional state of the chloroplast. Homozygous recessive gun mutations allow nuclear gene expression in the absence of chloroplast development and furthermore may interfere with the switch from dark-grown to light-grown development. Other reports suggest this intracellular cross-stalk also involves mitochondrial interactions. The GUN genes thus define steps in one specific branch of a complex interorganellar regulatory network.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT EXTRATERR PHYS,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	SUSEK, RE (corresponding author), SALK INST BIOL STUDIES,PLANT BIOL LAB,SAN DIEGO,CA 92186, USA.				NCRR NIH HHS [RR05595] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AN G, 1987, MOL GEN GENET, V270, P210; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BATSCHAUER A, 1986, EUR J BIOCHEM, V154, P625, DOI 10.1111/j.1432-1033.1986.tb09444.x; BURGESS DG, 1987, PLANTA, V170, P520, DOI 10.1007/BF00402986; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P967, DOI 10.1007/BF00016069; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1991, NEW BIOL, V3, P538; CHORY J, 1990, P NATL ACAD SCI USA, V87, P8776, DOI 10.1073/pnas.87.22.8776; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DATTA N, 1989, PLANT CELL, V1, P1069, DOI 10.1105/tpc.1.11.1069; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1987, CELL, V49, P379, DOI 10.1016/0092-8674(87)90290-X; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GOODWIN TW, 1985, INTRO PLANT BIOCH; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HA SB, 1988, P NATL ACAD SCI USA, V85, P8017, DOI 10.1073/pnas.85.21.8017; HARPSTER MH, 1984, PLANT MOL BIOL, V3, P59, DOI 10.1007/BF00040030; HERRERAESTRELLA L, 1983, EMBO J, V2, P987, DOI 10.1002/j.1460-2075.1983.tb01532.x; HOWE CJ, 1991, NATURE, V349, P109, DOI 10.1038/349109c0; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; Kendrick RE., 2012, PHOTOMORPHOGENESIS P, P333; Kirk J.T.O., 1978, PLASTIDS THEIR CHEM; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; LAUER M, 1990, New Biologist, V2, P179; LEAVER CJ, 1980, GENOME ORG EXPRESSIO; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MARTINEAU B, 1986, PLANT PHYSIOL, V78, P399; MARTINEZZAPATER JM, 1992, PLANT CELL, V4, P889, DOI 10.1105/tpc.4.8.889; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MAYFIELD SP, 1984, EUR J BIOCHEM, V144, P79, DOI 10.1111/j.1432-1033.1984.tb08433.x; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; MITRA A, 1989, PLANT MOL BIOL, V12, P169, DOI 10.1007/BF00020502; NGERNPRASIRTSIRI J, 1990, CELL STRUCT FUNCT, V15, P273, DOI 10.1247/csf.15.273; OELMULLER R, 1990, PLANT PHYSIOL, V92, P434, DOI 10.1104/pp.92.2.434; OELMULLER R, 1986, PLANTA, V168, P482, DOI 10.1007/BF00392267; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; OWEN J, 1987, PLANT MITOCHONDRIA S, P211; PLUMLEY FG, 1989, P NATL ACAD SCI USA, V86, P2678, DOI 10.1073/pnas.86.8.2678; RAPP JC, 1991, PLANT MOL BIOL, V17, P813, DOI 10.1007/BF00037063; RAPP JC, 1992, J BIOL CHEM, V267, P21404; REDEI G P, 1973, Mutation Research, V18, P149, DOI 10.1016/0027-5107(73)90031-6; ROUSSELL DL, 1991, PLANT PHYSIOL, V96, P232, DOI 10.1104/pp.96.1.232; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; SCHWARTZ B W, 1991, Plant Physiology (Rockville), V96, P120; SIMPSON J, 1986, SCIENCE, V233, P34, DOI 10.1126/science.233.4759.34; STUMPF P, 1980, BIOCH PLANTS LIPIDS; SUSEK RE, 1992, AUST J PLANT PHYSIOL, V19, P387, DOI 10.1071/PP9920387; TAYLOR WC, 1987, DEV GENET, V8, P305, DOI 10.1002/dvg.1020080503; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; Taylor WC, 1986, CURRENT TOPICS PLANT, V5, P117; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WELLBURN A, 1984, CHLOROPLAST BIOGENES; WHITTAKER PA, 1978, MITOCHONDRIA STRUCTU	62	467	486	3	73	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					787	799		10.1016/0092-8674(93)90459-4	http://dx.doi.org/10.1016/0092-8674(93)90459-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	7690685				2022-12-01	WOS:A1993LX29200005
J	GIRALT, S; ESCUDIER, S; KANTARJIAN, H; DEISSEROTH, A; FREIREICH, EJ; ANDERSSON, BS; OBRIEN, S; ANDREEFF, M; FISHER, H; CORK, A; HIRSCHGINSBERG, C; TRUJILLO, J; STASS, S; CHAMPLIN, RE				GIRALT, S; ESCUDIER, S; KANTARJIAN, H; DEISSEROTH, A; FREIREICH, EJ; ANDERSSON, BS; OBRIEN, S; ANDREEFF, M; FISHER, H; CORK, A; HIRSCHGINSBERG, C; TRUJILLO, J; STASS, S; CHAMPLIN, RE			PRELIMINARY-RESULTS OF TREATMENT WITH FILGRASTIM FOR RELAPSE OF LEUKEMIA AND MYELODYSPLASIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; TOTAL-BODY IRRADIATION; HEMATOLOGICAL MALIGNANCIES; HOST DISEASE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; METHOTREXATE; BUSULFAN; REGIMEN	Background. Patients whose leukemia relapses after allogeneic bone marrow transplantation have a poor prognosis; few respond to further chemotherapy, and almost none survive over the long term. We present preliminary observations on the use of filgrastim (granulocyte colony-stimulating factor) for relapse after transplantation. Methods. Seven female patients with leukemia (one with chronic myelogenous leukemia, five with acute myelogenous leukemia, and one with a myelodysplastic syndrome that transformed into.acute myelogenous leukemia) whose disease relapsed within 360 days after allogeneic bone marrow transplantation received filgrastim (5 mug per kilogram of body weight per day by subcutaneous injection) to reinduce remission by stimulating residual donor marrow cells. Cytogenetic analysis of bone marrow, fluorescence in situ hybridization, and determination of restriction-fragment-length polymorphisms were used to assess response and chimerism. Results. Three of the seven patients had a complete hematologic and cytogenetic remission, with reestablishment of hematopoiesis of donor origin. Mild chronic graft-versus-host disease developed in one patient, and acute graft-versus-host disease in none. One patient had a relapse 12 months after treatment, and two others remained in remission after 10 and 11 months. In two of the patients with a response, fluorescence in situ hybridization demonstrated stimulation of donor cells without differentiation of the leukemic clone. Conclusions. Filgrastim may be effective in selected cases of leukemic relapse after allogeneic bone marrow transplantation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								ARCESE W, 1990, BONE MARROW TRANSPL, V5, P309; BOSTROM B, 1987, J CLIN ONCOL, V5, P376, DOI 10.1200/JCO.1987.5.3.376; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; FRASSONI F, 1988, BRIT J HAEMATOL, V70, P317, DOI 10.1111/j.1365-2141.1988.tb02488.x; GABRILOVE JL, 1989, HEMATOL ONCOL CLIN N, V3, P427, DOI 10.1016/S0889-8588(18)30539-2; GIRALT S, 1991, BLOOD S1, V78, pA503; HIGANO CS, 1990, TRANSPLANTATION, V50, P175; HOROWITZ MM, 1990, BLOOD, V75, P555; ISCN An international system for human cytogenetic nomen-clature, 1978, CYTOGENET CELL GENET, V21, P309; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; METCALF D, 1980, INT J CANCER, V25, P225, DOI 10.1002/ijc.2910250210; MORTIMER J, 1989, J CLIN ONCOL, V7, P50, DOI 10.1200/JCO.1989.7.1.50; Mortimer J, 1989, J CLIN ONCOL, V7, P5451; PETERSEN FB, 1989, BONE MARROW TRANSPL, V4, P617; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRZEPIORKA D, 1992, BLOOD S1, V80, pA337; Sambrook J., 1989, MOL CLONING LAB MANU; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRUJILLO JM, 1979, BLOOD, V53, P695; TUTSCHKA PJ, 1987, BLOOD, V70, P1382; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501; WAGNER JE, 1989, BONE MARROW TRANSPL, V4, P115; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; YAU JC, 1990, BONE MARROW TRANSPL, V5, P269; YAU JC, 1992, AM J HEMATOL, V41, P40, DOI 10.1002/ajh.2830410108; 1989, BONE MARROW TRANSPL, V4, P221	26	100	101	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					757	761		10.1056/NEJM199309093291103	http://dx.doi.org/10.1056/NEJM199309093291103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	7688862				2022-12-01	WOS:A1993LV64200003
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			EFFICIENT CATALYSIS OF DISULFIDE BOND REARRANGEMENTS BY PROTEIN DISULFIDE-ISOMERASE	NATURE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DISULFIDE ISOMERASE; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; KINETIC ROLE; INTERMEDIATE; RESONANCE; BPTI	PROTEIN disulphide isomerase (PDI)1,2 is a highly abundant and ubiquitous eukaryotic protein that is essential for viability in yeast3,4. Although PDI is thought to catalyse disulphide bond formation and isomerization during protein biosynthesis, PDI has been found previously to have only moderate effects (approximately 25-fold) on the rate of oxidative folding of proteins in vitro. In addition, PDI has been implicated in several apparently unrelated cellular functions3. For example, PDI is the beta-subunit of prolyl 4-hydroxylase 5 and is part of the trigylceride transfer complex6. The oxidative folding of bovine pancreatic trypsin inhibitor (BPTI) is slow and inefficient in vitro7-11. Here we report that PDI increases by a factor of 3,000-6,000 the rates of folding of kinetically trapped BPTI folding intermediates, in which native structure impedes disulphide bond formation. By contrast, PDI has only small effects on the rate of disulphide bond formation in intermediates that are oxidized readily in the absence of PDI. These results suggest that an important function of PDI is to catalyse disulphide bond formation and rearrangements within kinetically trapped, structured folding intermediates.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), MIT,DEPT PHYS,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02139, USA.							CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1992, PROTEIN FOLDING, P481; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAJI EH, IN PRESS J BIOL CHEM; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; VENETIANER P, 1963, BIOCHIM BIOPHYS ACTA, V67, P166; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	28	191	195	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					185	188		10.1038/365185a0	http://dx.doi.org/10.1038/365185a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	7690463				2022-12-01	WOS:A1993LW44200055
J	WJST, M; REITMEIR, P; DOLD, S; WULFF, A; NICOLAI, T; VONLOEFFELHOLZCOLBERG, EF; VONMUTIUS, E				WJST, M; REITMEIR, P; DOLD, S; WULFF, A; NICOLAI, T; VONLOEFFELHOLZCOLBERG, EF; VONMUTIUS, E			ROAD TRAFFIC AND ADVERSE-EFFECTS ON RESPIRATORY HEALTH IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION; LUNG-FUNCTION; PULMONARY-FUNCTION; PASSIVE SMOKING; SYMPTOMS; ENVIRONMENT; CHILDHOOD; EXPOSURE	Objectives-To examine whether road traffic in a big city has a direct effect on pulmonary function and respiratory symptoms in children. Design-Cross sectional study. Setting-Of all 7445 fourth grade children (aged 9-11 years) in Munich, 6537 were examined. Of the children with German nationality and the same residence during the past five years and known exposure data, 4678 questionnaires and 4320 pulmonary function tests could be analysed. Main outcome measures-Variables of pulmonary function by forced expiration and respiratory symptoms reported in a questionnaire; census data on car traffic collected in the school district. Results-Density of car traffic ranged from 7000 to 125000 cars per 24 hours. Multiple regression analysis of peak expiratory flow showed a significant decrease of 0.71% (95% confidence interval 1.08% to 0.33%) per increase of 25000 cars daily passing through the school district on the main road. Maximum expiratory flow when 25% vital capacity had been expired was decreased by 0.68% (1.11% to 0.25%). In contrast, response to cold air challenge was not increased. The adjusted odds ratio for the cumulative prevalence of recurrent wheezing with the same exposure was 1.08 (1.01 to 1.16). Cumulative prevalence of recurrent dyspnoea was increased, with an odds ratio of 1.10 (1.00 to 1.20). Lifetime prevalence of asthma (odds ratio 1.04; 0.89 to 1.21) and recurrent bronchitis (1.05; 0.98 to 1.12) were not significantly increased. Conclusions-High rates of road traffic diminish forced expiratory flow and increase respiratory symptoms in children.	TECH UNIV MUNICH,INST UMWELTHYG & TOXIKOL,D-80636 MUNICH,GERMANY; UNIV MUNICH,DR VON HAUNERSCHE KINDERKLIN,D-80337 MUNICH,GERMANY; STADT GESUNDHEITSBEHORDE,D-80335 MUNICH,GERMANY	Technical University of Munich; University of Munich	WJST, M (corresponding author), GSF,FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST MED INFORMAT & SYST FORSCH,POB 1129,D-85758 OBERSCHLEISSHEIM,GERMANY.							AMES RG, 1984, ARCH ENVIRON HEALTH, V39, P389, DOI 10.1080/00039896.1984.10545870; AROSSA W, 1987, ARCH ENVIRON HEALTH, V42, P170, DOI 10.1080/00039896.1987.9935817; Atkinson R., 1988, AIR POLLUTION AUTOMO, P99; BROMBERG PA, 1988, AIR POLLUTION AUTOMO, P465; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; CHARPIN D, 1988, ARCH ENVIRON HEALTH, V43, P22, DOI 10.1080/00039896.1988.9934369; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; DOLD S, 1992, MONATSSCHR KINDERH, V140, P763; EVANS RG, 1988, AM J IND MED, V14, P25, DOI 10.1002/ajim.4700140105; FARLEY JM, 1992, ANNU REV PHARMACOL, V32, P67, DOI 10.1146/annurev.pharmtox.32.1.67; GAMBLE J, 1987, ENVIRON RES, V42, P201, DOI 10.1016/S0013-9351(87)80022-1; GODLEE F, 1991, BRIT MED J, V303, P1539, DOI 10.1136/bmj.303.6816.1539; GOREN AI, 1988, ENVIRON RES, V46, P107, DOI 10.1016/S0013-9351(88)80025-2; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136, DOI 10.1164/ajrccm/141.5_Pt_1.1136; HOPPENBROUWERS T, 1990, LUNG S, V68, P35; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P1055, DOI 10.1016/0091-6749(88)90180-7; MURAKAMI M, 1990, Journal of Human Ergology, V19, P101; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; NGANGA LW, 1992, AM REV RESPIR DIS, V145, P48, DOI 10.1164/ajrccm/145.1.48; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53, DOI 10.1080/00039896.1993.9938393; ROMIEU I, 1992, AM J EPIDEMIOL, V136, P1524, DOI 10.1093/oxfordjournals.aje.a116474; SAMET JM, 1933, TOXICOLOGY LUNG, P311; SAMSON PJ, 1988, POLLUTION AUTOMOBILE, P77; SCHWARTZ J, 1992, ARCH ENVIRON HEALTH, V47, P116, DOI 10.1080/00039896.1992.10118764; SPEIZER FE, 1973, ARCH ENVIRON HEALTH, V26, P313, DOI 10.1080/00039896.1973.10666289; ULFVARSON U, 1990, AM J IND MED, V17, P341, DOI 10.1002/ajim.4700170306; VEDAL S, 1987, AM J PUBLIC HEALTH, V77, P694, DOI 10.2105/AJPH.77.6.694; VONMUTIUS E, 1991, MUNCHEN MED WOCHEN, V133, P675; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Yokoyama Y, 1985, Tokai J Exp Clin Med, V10, P379; 1989, SAS USERS GUIDE STAT; 1987, AIR QUALITY GUIDELIN; 1990, UMWELTATLAS MUNCHEN; 1990, BELASTUNGSBEBIET MUN; 1988, BERICHT IMMISSIONSME; 1985, AM REV RESPIR DIS, V131, P666; 1990, STATISCHE TASCHENBUC	40	325	330	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					596	600		10.1136/bmj.307.6904.596	http://dx.doi.org/10.1136/bmj.307.6904.596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	7691304	Green Published, Bronze			2022-12-01	WOS:A1993LW14900016
J	CHO, CY; MORAN, EJ; CHERRY, SR; STEPHANS, JC; FODOR, SPA; ADAMS, CL; SUNDARAM, A; JACOBS, JW; SCHULTZ, PG				CHO, CY; MORAN, EJ; CHERRY, SR; STEPHANS, JC; FODOR, SPA; ADAMS, CL; SUNDARAM, A; JACOBS, JW; SCHULTZ, PG			AN UNNATURAL BIOPOLYMER	SCIENCE			English	Article							SOLID-PHASE SYNTHESIS; PROTECTED PEPTIDE-FRAGMENTS; DRUG DISCOVERY; NUCLEIC-ACIDS; ALCOHOL RESIN; LIBRARIES; ANTISENSE; ANALOGS	A highly efficient method has been developed for the solid-phase synthesis of an ''unnatural biopolymer'' consisting of chiral aminocarbonate monomers linked via a carbamate backbone. Oligocarbamates were synthesized from N-protected p-nitrophenyl carbonate monomers, substituted with a variety of side chains, with greater than 99 percent overall coupling efficiencies per step. A spatially defined library of oligocarbamates was generated by using photochemical methods and screened for binding affinity to a monoclonal antibody. A number of high-affinity ligands were then synthesized and analyzed in solution with respect to their inhibition concentration values, water/octanol partitioning coefficients, and proteolytic stability. These and other unnatural polymers may provide new frameworks for drug development and for testing theories of protein and peptide folding and structure.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,PALO ALTO,CA 94304	University of California System; University of California Berkeley				cherry, sara/0000-0003-3956-6610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014681] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 F32 GM14681] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BR, 1965, J PHARM SCI, V54, P987, DOI 10.1002/jps.2600540708; BLAKE J, 1992, BIOCONJUGATE CHEM, V3, P510, DOI 10.1021/bc00018a008; BRAY AM, 1990, TETRAHEDRON LETT, V31, P5811, DOI 10.1016/S0040-4039(00)97966-8; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; COULL JM, 1987, TETRAHEDRON LETT, V28, P745, DOI 10.1016/S0040-4039(01)80978-3; ESCHENMOSER A, 1992, HELV CHIM ACTA, V75, P218, DOI 10.1002/hlca.19920750120; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE CM, 1961, J AM CHEM SOC, V83, P4596, DOI 10.1021/ja01483a022; LU G, 1981, J ORG CHEM, V46, P3433, DOI 10.1021/jo00330a009; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MUNGALL WS, 1977, J ORG CHEM, V42, P703, DOI 10.1021/jo00424a028; NEEDELS MC, IN PRESS P NATL ACAD; NIKAWA J, 1979, CHEM LETT, P981, DOI 10.1246/cl.1979.981; OKI M, 1971, B CHEM SOC JPN, V44, P3148, DOI 10.1246/bcsj.44.3148; PATCHORNIK CA, 1970, J AM CHEM SOC, V92, P6333; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; SMITH AB, 1992, J AM CHEM SOC, V114, P10672, DOI 10.1021/ja00052a093; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VANDERWERF S, 1967, TETRAHEDRON LETT, P689; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; WELLER DD, 1991, J ORG CHEM, V56, P6000, DOI 10.1021/jo00021a009	32	293	634	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1303	1305		10.1126/science.7689747	http://dx.doi.org/10.1126/science.7689747			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	7689747				2022-12-01	WOS:A1993LV65600021
J	DURIE, FH; FAVA, RA; FOY, TM; ARUFFO, A; LEDBETTER, JA; NOELLE, RJ				DURIE, FH; FAVA, RA; FOY, TM; ARUFFO, A; LEDBETTER, JA; NOELLE, RJ			PREVENTION OF COLLAGEN-INDUCED ARTHRITIS WITH AN ANTIBODY TO GP39, THE LIGAND FOR CD40	SCIENCE			English	Article							B-CELL ACTIVATION; II COLLAGEN; T-CELLS; PROTEIN; PROLIFERATION; INDUCTION	The ligand for the CD40 antigen is a 39-kilodalton protein, gp39, expressed on the surface of activated CD4+ T cells and is essential for thymus-dependent humoral immunity. The role of gp39-CD40 interactions in autoimmune disease was investigated in vivo with the use of an antibody that blocks their interactions (anti-gp39). Arthritis induced in mice by immunization with type II collagen was inhibited by anti-gp39. Anti-gp39 blocked the development of joint inflammation, serum antibody titers to collagen, the infiltration of inflammatory cells into the subsynovial tissue, and the erosion of cartilage and bone. Thus, interference with gp39-CD40 interactions may have therapeutic potential in the treatment of autoimmune disease.	DARTMOUTH COLL,SCH MED,DEPT MICROBIOL,LEBANON,NH 03756; DEPT VET ADM MED CTR,WHITE RIVER JCT,VT 05009; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; DARTMOUTH COLL,SCH MED,DEPT MED,WHITE RIVER JCT,VT 05009	Dartmouth College; Bristol-Myers Squibb; Dartmouth College					NIAID NIH HHS [AI26296] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI026296, R01AI026296] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; CATHCART ES, 1986, LAB INVEST, V54, P26; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; COOPER WO, 1992, CLIN EXP IMMUNOL, V89, P244; COURTENAY JS, 1980, NATURE, V283, P665; CREMER MA, 1992, J IMMUNOL, V149, P1045; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURIE FH, UNPUB; FOY TM, UNPUB; FOY TM, IN PRESS J EXP MED; HOLMDAHL R, 1986, AGENTS ACTIONS, V19, P295, DOI 10.1007/BF01971231; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOELLE RJ, UNPUB; SEKI N, 1992, J IMMUNOL, V148, P3093; SHIZURU JA, 1992, IMMUNOL REV, V129, P105, DOI 10.1111/j.1600-065X.1992.tb01421.x; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857	23	443	502	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1328	1330		10.1126/science.7689748	http://dx.doi.org/10.1126/science.7689748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	7689748				2022-12-01	WOS:A1993LV65600030
J	MUNRO, S; THOMAS, KL; ABUSHAAR, M				MUNRO, S; THOMAS, KL; ABUSHAAR, M			MOLECULAR CHARACTERIZATION OF A PERIPHERAL RECEPTOR FOR CANNABINOIDS	NATURE			English	Article							RAT-BRAIN; INSITU HYBRIDIZATION; CLONING; INVITRO; CDNA	THE major active ingredient of marijuana, DELTA9-tetrahydrocannabinol (DELTA9-THC), has been used as a psychoactive agent for thousands of years. Marijuana, and DELTA9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting1. The clinical application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochemical bases of their action. Progress stemmed initially from the synthesis of potent derivatives of DELTA9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids6. This receptor is expressed in the brain but not in the periphery, except for a low level in testes. It has been proposed that the non-psychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins1,7,8. Here we report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.			MUNRO, S (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Thomas, Kerrie L/A-6509-2010	Thomas, Kerrie L/0000-0003-3355-9583; Munro, Sean/0000-0001-6160-5773				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; COLLINS SJ, 1987, BLOOD, V70, P1233; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DALLMAN MJ, 1982, EUR J IMMUNOL, V12, P511, DOI 10.1002/eji.1830120612; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S; HUMPHREY JH, 1981, EUR J IMMUNOL, V11, P221, DOI 10.1002/eji.1830110311; JANSEN EM, 1992, BRAIN RES, V575, P93, DOI 10.1016/0006-8993(92)90428-C; KESHAV S, 1991, J EXP MED, V174, P1049, DOI 10.1084/jem.174.5.1049; KRAAL G, 1992, INT REV CYTOL, V132, P31, DOI 10.1016/S0074-7696(08)62453-5; LEE J, 1992, J BIOL CHEM, V267, P16283; LOPEZCEPERO M, 1986, J LEUKOCYTE BIOL, V39, P679, DOI 10.1002/jlb.39.6.679; MAILLEUX P, 1992, NEUROSCIENCE, V48, P655, DOI 10.1016/0306-4522(92)90409-U; MARTIN BR, 1986, PHARMACOL REV, V38, P45; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNSON AE, 1983, ADVERSE HLTH BEHAVIO, P257; RAZDAN RK, 1986, PHARMACOL REV, V38, P75; REICHMAN M, 1991, MOL PHARMACOL, V40, P547; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; SCHATZ AR, 1992, LIFE SCI, V51, P25; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIRASAWA T, 1992, NUCLEIC ACIDS RES, V20, P909, DOI 10.1093/nar/20.4.909; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	34	3801	4002	6	245	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					61	65		10.1038/365061a0	http://dx.doi.org/10.1038/365061a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	7689702				2022-12-01	WOS:A1993LV64600054
J	HORUK, R; CHITNIS, CE; DARBONNE, WC; COLBY, TJ; RYBICKI, A; HADLEY, TJ; MILLER, LH				HORUK, R; CHITNIS, CE; DARBONNE, WC; COLBY, TJ; RYBICKI, A; HADLEY, TJ; MILLER, LH			A RECEPTOR FOR THE MALARIAL PARASITE PLASMODIUM-VIVAX - THE ERYTHROCYTE CHEMOKINE RECEPTOR	SCIENCE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; KNOWLESI MALARIA; CYTOKINE FAMILY; SPECIFICITY; ANTIGEN; PROTEIN	Plasmodium vivax and P. falciparum are the major causes of human malaria, except in sub-Saharan Africa where people lack the Duffy blood group antigen, the erythrocyte receptor for P. vivax. Duffy negative human erythrocytes are resistant to invasion by P. vivax and the related monkey malaria, P. knowlesi. Several lines of evidence in the present study indicate that the Duffy blood group antigen is the erythrocyte receptor for the chemokines interleukin-8 (IL-8) and melanoma growth stimulatory activity (MGSA). First, IL-8 binds minimally to Duffy negative erythrocytes. Second, a monoclonal antibody to the Duffy blood group antigen blocked binding of IL-8 and other chemokines to Duffy positive erythrocytes. Third, both MGSA and IL-8 blocked the binding of the parasite ligand and the invasion of human erythrocytes by P. knowlesi, suggesting the possibility of receptor blockade for anti-malarial therapy.	NIH,MALARIA RES LAB,BETHESDA,MD 20892; MONTEFIORE MED CTR,BRONX,NY 10467; JG BROWN CANC CTR,DIV MED ONCOL HEMATOL,LOUISVILLE,KY 40292	National Institutes of Health (NIH) - USA; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	HORUK, R (corresponding author), GENENTECH INC,S SAN FRANCISCO,CA 94080, USA.			Chitnis, Chetan/0000-0002-8773-9865	NHLBI NIH HHS [HL 41382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARINAGA M, 1992, SCIENCE, V258, P1730, DOI 10.1126/science.1334571; BRADLEY DJ, 1987, OXFORD TXB MED, V1, pCH5; BROUN GO, 1966, NEW ENGL J MED, V275, P1410, DOI 10.1056/NEJM196612222752504; CHAUDHURI A, 1989, J BIOL CHEM, V264, P13770; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DARBONNE WC, UNPUB; GOODING LR, 1992, CELL, V71, P5; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HADLEY TJ, 1984, SCIENCE, V223, P597, DOI 10.1126/science.6695171; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1993, J BIOL CHEM, V268, P541; HORUK R, UNPUB; LEE J, 1992, J BIOL CHEM, V267, P16283; MARSH W L, 1975, Critical Reviews in Clinical Laboratory Sciences, V5, P387, DOI 10.3109/10408367509107049; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; WASNIOWSKA K, 1993, BIOCHEM BIOPH RES CO, V192, P366, DOI 10.1006/bbrc.1993.1424	27	478	496	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1182	1184		10.1126/science.7689250	http://dx.doi.org/10.1126/science.7689250			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	7689250	Green Submitted			2022-12-01	WOS:A1993LU58600036
J	DEMATTEIS, MA; SANTINI, G; KAHN, RA; DITULLIO, G; LUINI, A				DEMATTEIS, MA; SANTINI, G; KAHN, RA; DITULLIO, G; LUINI, A			RECEPTOR AND PROTEIN KINASE-C-MEDIATED REGULATION OF ARF BINDING TO THE GOLGI-COMPLEX	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; GUANINE-NUCLEOTIDE; COATED VESICLES; CELL-SURFACE; BETA-COP; SECRETION; INHIBITION; TRANSPORT; MEMBRANES	THE formation of constitutive transport vesicles involves the association of non-clathrin coat proteins to transport organelles1,2 . Here we report that IgE receptors and protein kinase C (PKC) regulate the GTP-dependent binding of the two coat proteins ADP-ribosylation factor (ARF) and beta-COP3-5 to Golgi membranes in rat basophilic leukaemia cells. Activation of IgE receptors and PKC prevented the ARF and beta-COP dissociation from Golgi membranes that occurs in permeabilized cells in the absence of GTP and potentiated the association-promoting effects of GTP and the G protein activator fluoroaluminate. In contrast, PKC downregulation and PKC inhibition abolished the activity of GTP and fluoro-luminate in promoting ARF binding to the Golgi complex. Studies of ARF binding to isolated Golgi membranes gave similiar results. These findings suggest that coat assembly on Golgi membranes, and thus possibly constitutive secretory traffic, is modulated by membrane receptors and second messengers.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,MOLEC NEUROBIOL LAB,I-66030 SANTA MARIA IMBAR,ITALY; NCI,DIV CANC TREATMENT,BIOL CHEM LAB,BETHESDA,MD 20892	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DEMATTEIS, MA (corresponding author), IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,PHYSIOPATHOL SECRET UNIT,I-66030 SANTA MARIA IMBAR,ITALY.		Kahn, Richard/ABD-2666-2020; Luini, Alberto/L-1372-2013; De Matteis, Maria Antonietta/AHE-5161-2022	Kahn, Richard/0000-0002-0259-0601; Luini, Alberto/0000-0002-8729-2549; De Matteis, Maria Antonietta/0000-0003-0053-3061				ALI H, 1989, J IMMUNOL, V143, P2626; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LOW SH, 1991, J BIOL CHEM, V266, P17729; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Melancon P, 1991, Trends Cell Biol, V1, P165, DOI 10.1016/0962-8924(91)90018-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; ORCI L, 1991, CELL, V64, P1183; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STROUS GJ, 1993, J BIOL CHEM, V268, P2341	36	140	143	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					818	821		10.1038/364818a0	http://dx.doi.org/10.1038/364818a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689177				2022-12-01	WOS:A1993LU58100060
J	MURPHY, JG; GERSH, BJ; MAIR, DD; FUSTER, V; MCGOON, MD; ILSTRUP, DM; MCGOON, DC; KIRKLIN, JW; DANIELSON, GK				MURPHY, JG; GERSH, BJ; MAIR, DD; FUSTER, V; MCGOON, MD; ILSTRUP, DM; MCGOON, DC; KIRKLIN, JW; DANIELSON, GK			LONG-TERM OUTCOME IN PATIENTS UNDERGOING SURGICAL REPAIR OF TETRALOGY OF FALLOT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN-DEATH; FOLLOW-UP; VENTRICULAR ARRHYTHMIAS; SURVIVAL; AGE	Background. Although corrective surgery for tetralogy of Fallot has been available for more than 30 years, the occurrence of late sudden death in patients in whom surgery was apparently successful remains worrisome. Methods. We studied long-term survival among 163 patients who survived 30 days after complete repair of tetralogy of Fallot, examining follow-up hospital records and death certificates when relevant. Results. The overall 32-year actuarial survival rate among all patients who survived surgery was 86 percent, as compared with an expected rate of 96 percent in a control population matched for age and sex (P<0.01). Thirty-year actuarial survival rates were calculated for the patient subgroups. The survival rates among patients less than 5 years old, 5 to 7 years old, and 8 to 11 years old were 90, 93, and 91 percent, respectively - slightly less than the expected rates (P<0.001, P = 0.06, and P = 0.02). Among patients 12 years old or older at the time of surgery, the survival rate was 76 percent, as compared with an expected rate of 93 percent (P<0.001). The performance of a palliative Blalock-Taussig shunt procedure before repair, unlike the performance of a Waterston or Potts shunt procedure, was not associated with reduced long-term survival, nor was the need for a trans-annular patch at the time of surgery. Independent predictors of long-term survival were older age at operation (P = 0.02) and a higher ratio of right ventricular to left ventricular systolic pressure after surgery (P = 0.008). Late sudden death from cardiac causes occurred in 10 patients during the 32-year period. Conclusions. Among patients with surgically repaired tetralogy of Fallot, the rate of long-term survival after the postoperative period is excellent but remains lower than that in the general population. The risk of late sudden death is small.	MAYO CLIN & MAYO FDN, PEDIAT CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT BIOSTAT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV THORAC & CARDIOVASC SURG, ROCHESTER, MN 55905 USA; MASSACHUSETTS GEN HOSP, DIV CARDIOL, BOSTON, MA 02114 USA; UNIV ALABAMA, MED CTR, DEPT SURG, BIRMINGHAM, AL 35233 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Massachusetts General Hospital; University of Alabama System; University of Alabama Birmingham	MURPHY, JG (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				AZAR H, 1969, ARCH SURG-CHICAGO, V99, P281; BERGSTRALH EJ, 1988, TECHNICAL REPORT SER, V37; COLE RB, 1971, CIRCULATION, V43, P263, DOI 10.1161/01.CIR.43.2.263; COX DR, 1972, J R STAT SOC B, V34, P187; DEANFIELD JE, 1991, INT J CARDIOL, V30, P143, DOI 10.1016/0167-5273(91)90088-7; DEANFIELD JE, 1984, BRIT HEART J, V52, P77; DEANFIELD JE, 1986, PEDIATR CARDIOL, P467; FUSTER V, 1980, AM J CARDIOL, V46, P635, DOI 10.1016/0002-9149(80)90514-7; GARSON A, 1980, AM J CARDIOL, V46, P1006, DOI 10.1016/0002-9149(80)90359-8; GARSON A, 1985, J AM COLL CARDIOL, V6, P221, DOI 10.1016/S0735-1097(85)80279-5; GARSON A, 1987, ADULT CONGENITAL HEA, P493; GILLETTE PC, 1977, CIRCULATION, V56, P566, DOI 10.1161/01.CIR.56.4.566; HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.2307/2335991; HORNEFFER PJ, 1990, ANN THORAC SURG, V50, P179, DOI 10.1016/0003-4975(90)90728-O; HU DCK, 1985, J AM COLL CARDIOL, V5, P40, DOI 10.1016/S0735-1097(85)80083-8; JAMES FW, 1975, CIRCULATION, V52, P691, DOI 10.1161/01.CIR.52.4.691; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ NM, 1982, CIRCULATION, V65, P403, DOI 10.1161/01.CIR.65.2.403; KIRKLIN JK, 1989, ANN THORAC SURG, V48, P783, DOI 10.1016/0003-4975(89)90671-1; KIRKLIN JW, 1955, P STAFF M MAYO CLIN, V30, P201; KLINNER W, 1984, THORAC CARDIOV SURG, V32, P244, DOI 10.1055/s-2007-1023394; LILLEHEI CW, 1986, ANN SURG, V204, P490, DOI 10.1097/00000658-198610000-00017; QUATTLEBAUM TG, 1976, CIRCULATION, V54, P289, DOI 10.1161/01.CIR.54.2.289; SHEN WK, 1990, CIRCULATION, V81, P128, DOI 10.1161/01.CIR.81.1.128; VAKSMANN G, 1990, AM J CARDIOL, V66, P346, DOI 10.1016/0002-9149(90)90847-T; ZHAO HX, 1985, J THORAC CARDIOV SUR, V89, P204	26	668	699	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					593	599		10.1056/NEJM199308263290901	http://dx.doi.org/10.1056/NEJM199308263290901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	7688102				2022-12-01	WOS:A1993LU21700001
J	OGASAWARA, J; WATANABEFUKUNAGA, R; ADACHI, M; MATSUZAWA, A; KASUGAI, T; KITAMURA, Y; ITOH, N; SUDA, T; NAGATA, S				OGASAWARA, J; WATANABEFUKUNAGA, R; ADACHI, M; MATSUZAWA, A; KASUGAI, T; KITAMURA, Y; ITOH, N; SUDA, T; NAGATA, S			LETHAL EFFECT OF THE ANTI-FAS ANTIBODY IN MICE	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; APOPTOSIS; EXPRESSION; RECEPTOR; CACHECTIN; DEATH; CDNA	DURING mammalian development, many cells are programmed to die1,2 most mediated by apoptosis3. The Fas antigen4 coded by the structural gene for mouse lymphoproliferation mutation (lpr)5,6, is a cell surface protein belonging to the tumour necrosis factor/nerve growth factor receptor family7,8, and mediates apoptosis7. The Fas antigen messenger RNA is expressed in the thymus, liver, heart, lung and ovary8. We prepared a monoclonal antibody against mouse Fas antigen, which immunoprecipitated the antigen (M(r) 45K) and had cytolytic activity against cell lines expressing mouse Fas antigen. We report here that staining of mouse thymocytes with the antibody indicated that thymocytes from the wild-type and lpr(cg) mice expressed the Fas antigen, whereas little expression of the Fas antigen was found in lpr mice. Intraperitoneal administration of the anti-Fas antibody into mice rapidly killed the wild-type mice but neither lpr nor lpr(cg) mice. Biochemical, histological and electron microscope analyses indicated severe damage of the liver by apoptosis. These findings suggest that the Fas antigen is important in programmed cell death in the liver, and may be involved in fulminant hepatitis in some cases.	OSAKA BIOSCI INST, 6-2-4 FURUEDAI, SUITA, OSAKA 565, JAPAN; OSAKA CITY INST PUBL HLTH & ENVIRONM SCI, TENNOJI KU, OSAKA 543, JAPAN; UNIV TOKYO, INST MED SCI, LAB ANIM RES CTR, TOKYO 108, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOL, SUITA, OSAKA 565, JAPAN	University of Tokyo; Osaka University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; BENEDETTI A, 1988, J HEPATOL, V7, P319, DOI 10.1016/S0168-8278(88)80004-7; Chisari F V, 1992, Mol Genet Med, V2, P67; CLIGAN JE, 1991, CURRENT PROTOCOLS IM; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; FALK MH, 1992, BLOOD, V79, P3300; HIRATA Y, 1989, J IMMUNOL, V143, P2900; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KIMURA M, 1992, IMMUNOLOGY, V76, P498; KOBAYASHI N, 1990, P NATL ACAD SCI USA, V87, P9620, DOI 10.1073/pnas.87.24.9620; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; OEHM A, 1992, J BIOL CHEM, V267, P10709; POTTEN CS, 1992, CANCER METASTASIS RE, V11, P95; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SANCHEZMADRID F, 1983, J IMMUNOL, V130, P309; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON J, 1977, J IMMUNOL, V120, P422; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	27	1799	1861	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	1993	364	6440					806	809		10.1038/364806a0	http://dx.doi.org/10.1038/364806a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689176				2022-12-01	WOS:A1993LU58100057
J	SCHMID, MF; ROBINSON, JP; DASGUPTA, BR				SCHMID, MF; ROBINSON, JP; DASGUPTA, BR			DIRECT VISUALIZATION OF BOTULINUM NEUROTOXIN-INDUCED CHANNELS IN PHOSPHOLIPID-VESICLES	NATURE			English	Article							TETANUS TOXIN; ELECTRON; MEMBRANES; IMAGES	THE seven botulinum neurotoxin (NT) serotypes produced by strains of Clostridium botulinum inhibit neurotransmitter release from synaptic vesicles. Neurotoxin is synthesized as a roughly 150K single-chain protein. Proteolysis produces two fragments, the 50K L-chain and 100K H-chain, that remain linked by a disulphide bond. Intoxication involves membrane attachment by the C-terminal half of the H-chain, endocytotic/lysosomal internalization, vesicle channel formation mediated by the 50K N-terminal half of the H-chain at low pH, and finally blockade of synaptic vesicle fusion after the L-chain reaches the cytosol1-4 . We report here the visualization of the neurotoxin-membrane complex by electron cryomicroscopy and image processing. Three-dimensional reconstructions show the neurotoxin bound to the exterior of ganglioside/PC lipid vesicles and show channels entirely perforating the vesicle wall. Each channel appears to arise from the interaction of four neurotoxin molecules.	BAYLOR COLL MED,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77030; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706	Baylor College of Medicine; University of Wisconsin System; University of Wisconsin Madison	SCHMID, MF (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030, USA.		Taylor, Graham/A-4027-2012	Schmid, Michael/0000-0003-1077-5750				BINZ T, 1990, J BIOL CHEM, V265, P9153; CHANG CF, 1988, J ULTRA MOL STRUCT R, V100, P166, DOI 10.1016/0889-1605(88)90023-7; DASGUPTA BR, 1990, J PHYSIOL-PARIS, V84, P220; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DOLLY JO, 1990, J PHYSIOL-PARIS, V84, P237; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; GRANT RA, 1986, BIOPHYS J, V49, P251, DOI 10.1016/S0006-3495(86)83638-4; HOCH DH, 1985, ANN NY ACAD SCI, V456, P33, DOI 10.1111/j.1749-6632.1985.tb14841.x; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KORNBERG RD, 1991, CURR OPIN STRUC BIOL, V1, P632; MONTAL MS, 1992, FEBS LETT, V313, P12, DOI 10.1016/0014-5793(92)81173-J; ROBINSON JP, 1988, J MOL BIOL, V200, P367, DOI 10.1016/0022-2836(88)90247-1; SCHMID MF, 1991, J MOL BIOL, V221, P711, DOI 10.1016/0022-2836(91)80082-6; SCHMID MF, 1990, 12TH P INT C EL MICR, P496; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235	16	76	76	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					827	830		10.1038/364827a0	http://dx.doi.org/10.1038/364827a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689178				2022-12-01	WOS:A1993LU58100063
J	OESTERLING, JE; JACOBSEN, SJ; CHUTE, CG; GUESS, HA; GIRMAN, CJ; PANSER, LA; LIEBER, MM				OESTERLING, JE; JACOBSEN, SJ; CHUTE, CG; GUESS, HA; GIRMAN, CJ; PANSER, LA; LIEBER, MM			SERUM PROSTATE-SPECIFIC ANTIGEN IN A COMMUNITY-BASED POPULATION OF HEALTHY-MEN - ESTABLISHMENT OF AGE-SPECIFIC REFERENCE RANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MARKER; ADENOCARCINOMA; HYPERPLASIA; IMMUNOASSAY; DISEASE; DENSITY	Objective.-To define the characteristics of serum prostate-specific antigen (PSA) in a population of healthy men without clinically evident prostate cancer, but who are at risk for developing the malignancy. The influence of patient age and prostatic size on the serum PSA concentration was assessed in order to use PSA more appropriately to detect clinically significant prostate cancer at an early, potentially curable stage. Design.-Prospective, community-based study. Participants.-Between December 1989 and March 1991, 2119 healthy men aged 40 to 79 years from Olmsted County, Minnesota, were entered into a prospective study to assess the natural history of benign prostatic hyperplasia. Of these, 537 (25%) were randomly chosen to participate in a detailed clinical examination that included a serum PSA determination (Tandem-R PSA assay), digital rectal examination, and transrectal ultrasonography. Four hundred seventy-one (88%) completed the prostatic evaluation and had no evidence of prostate cancer by any of these three diagnostic tests; these men formed the study population on which all analyses were performed. Main Outcome Measure.-Serum PSA concentration, prostatic volume, and PSA density (serum PSA level/prostatic volume) as a function of patient age. Results.-The serum PSA concentration is correlated with patient age (r=.43; P<.0001) and prostatic volume (r=.55; P<.0001). Prostatic volume, in turn, is directly correlated with patient age (r=.43; P<.0001), whereas the PSA density value is only weakly correlated with patient age (r=.25; P<.001). For a healthy 60-year-old man with no evidence of prostate cancer, the serum PSA concentration increases by approximately 3.2% per year (0.04 ng/mL per year). The recommended reference range for serum PSA (95th percentile) for men aged 40 to 49 years is 0.0 to 2.5 ng/mL; for 50 to 59 years, 0.0 to 3.5 ng/mL; 60 to 69 years, 0.0 to 4.5 ng/mL; and 70 to 79 years, 0.0 to 6.5 ng/mL. Conclusions.-The serum PSA concentration is directly correlated with patient age and prostatic volume, the latter of which also is directly related to age. Thus, rather than rely on a single reference range for men of all age groups, it is more appropriate to have age-specific reference ranges. These age-specific reference ranges have the potential to make serum PSA a more discriminating tumor marker for detecting clinically significant cancers in older men (increasing specificity) and to find more potentially curable cancers in younger men (increasing sensitivity).	MERCK RES LABS, DEPT EPIDEMIOL, BLUE BELL, PA USA; MAYO CLIN & MAYO FDN, CLIN EPIDEMIOL SECT, ROCHESTER, MN 55905 USA	Merck & Company; Mayo Clinic	OESTERLING, JE (corresponding author), MAYO CLIN & MAYO FDN, DEPT UROL, 200 1ST ST SW, ROCHESTER, MN 55905 USA.			Jacobsen, Steven/0000-0002-8174-8533	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRAWER MK, 1989, UROLOGY, V34, P62; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CHAN DW, 1987, CLIN CHEM, V33, P1916; CHUTE CG, 1993, J UROLOGY, V150, P85, DOI 10.1016/S0022-5347(17)35405-8; COLLINS GN, IN PRESS BR J RADIOL; COONER WH, 1993, CAMPBELLS UROLOGY, P1; ELVEBACK LR, 1970, J AMER MED ASSOC, V211, P69, DOI 10.1001/jama.211.1.69; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; GLENSKI WJ, 1992, MAYO CLIN PROC, V67, P249, DOI 10.1016/S0025-6196(12)60101-3; KLEE GG, IN PRESS J UROL; KLEER E, IN PRESS AM J RADIOL; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OESTERLING JE, 1992, JAMA-J AM MED ASSOC, V267, P2236, DOI 10.1001/jama.267.16.2236; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Oesterling JE, 1991, AM UROLOGICAL ASS UP, V10, P137; PANSER LA, IN PRESS AM J EPIDEM; ROBLES JM, 1988, EUR UROL, V14, P360; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; TERRIS MK, 1991, J UROLOGY, V145, P984, DOI 10.1016/S0022-5347(17)38508-7; VESSELLA RL, 1992, CLIN CHEM, V38, P2044; WEBER JP, 1989, J UROLOGY, V141, P987, DOI 10.1016/S0022-5347(17)41083-4; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; 1992, AM UROLOGICAL ASS 19, V4, P20	29	1027	1064	0	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					860	864		10.1001/jama.270.7.860	http://dx.doi.org/10.1001/jama.270.7.860			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	7688054				2022-12-01	WOS:A1993LR61200033
J	BERRA, E; DIAZMECO, MT; DOMINGUEZ, I; MUNICIO, MM; SANZ, L; LOZANO, J; CHAPKIN, RS; MOSCAT, J				BERRA, E; DIAZMECO, MT; DOMINGUEZ, I; MUNICIO, MM; SANZ, L; LOZANO, J; CHAPKIN, RS; MOSCAT, J			PROTEIN KINASE-C-ZETA ISOFORM IS CRITICAL FOR MITOGENIC SIGNAL-TRANSDUCTION	CELL			English	Article							HYDROLYZING PHOSPHOLIPASE-C; XENOPUS-LAEVIS OOCYTES; T-CELL ACTIVATION; GROWTH-FACTOR; RAS ONCOGENE; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROL; STIMULATION; FIBROBLASTS; EXPRESSION	The requirement of protein kinase C zeta(zetaPKC) for maturation of X. laevis oocytes in response to insulin, p21ras, and phosphatidylcholine-hydrolyzing phospholipase C has recently been shown. Here we present experimental evidence demonstrating that activation of zetaPKC is not only necessary but also sufficient by itself to activate maturation in oocytes and to produce deregulation of growth control in mouse fibroblasts. Furthermore, by using a dominant kinase-defective mutant zetaPKC, we confirm that this kinase is required for mitogenic activation in oocytes and fibroblasts. These results permit us to propose zetaPKC as a critical step downstream of p21ras in mitogenic signal transduction.			BERRA, E (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN.		Berra, Edurne/F-9692-2011; Moscat, Jorge/A-7011-2009; Lozano, José/C-2760-2014	Berra, Edurne/0000-0002-3820-5744; Lozano, José/0000-0002-8187-2833; Chapkin, Robert/0000-0002-6515-3898; /0000-0001-9617-4141; Diaz-Meco, Maria/0000-0003-0147-0998				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KALENIC G, 1992, MOL CELL BIOL, V12, P4687; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONDO T, 1992, J BIOL CHEM, V267, P23609; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; WAYS DK, 1992, J BIOL CHEM, V267, P4799; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	32	387	390	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					555	563		10.1016/0092-8674(93)80056-K	http://dx.doi.org/10.1016/0092-8674(93)80056-K			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	7688666				2022-12-01	WOS:A1993LT73900016
J	LOVE, PE; SHORES, EW; JOHNSON, MD; TREMBLAY, ML; LEE, EJ; GRINBERG, A; HUANG, SP; SINGER, A; WESTPHAL, H				LOVE, PE; SHORES, EW; JOHNSON, MD; TREMBLAY, ML; LEE, EJ; GRINBERG, A; HUANG, SP; SINGER, A; WESTPHAL, H			T-CELL DEVELOPMENT IN MICE THAT LACK THE ZETA-CHAIN OF THE T-CELL ANTIGEN RECEPTOR COMPLEX	SCIENCE			English	Article							ETA-CHAIN; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; EXPRESSION; THYMOCYTES; CD4; MUTATIONS; FAMILY; TCR	The zeta subunit of the T cell antigen receptor complex is required for targeting nascent receptor complexes to the cell surface and for receptor-mediated signal transduction. To examine the significance of the zeta subunit in T cell development, mice deficient for zeta expression were generated by gene targeting. These zeta-/- mice had few CD4+CD8+ thymocytes, and the generation of CD4+ and CD8+ single positive T cells was impaired but not completely abrogated. Peripheral T cells were present but were unusual in that they expressed small amounts of CD5 and few T cell receptors. Thus, zeta chain expression influences thymocyte differentiation but is not absolutely required for the generation of single positive T cells.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LOVE, PE (corresponding author), NICHHD,MAMMALIAN GENES & DEV LAB,BLDG 6B,ROOM 210,BETHESDA,MD 20892, USA.							Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISHI H, 1993, J IMMUNOL, V150, P1263; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LOVE PE, 1992, P NATL ACAD SCI USA, V89, P9929, DOI 10.1073/pnas.89.20.9929; LOVE PJ, UNPUB; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; UNKLESS JC, 1979, J EXP MED, V150, P580; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	33	200	204	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					918	921		10.1126/science.7688481	http://dx.doi.org/10.1126/science.7688481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	7688481				2022-12-01	WOS:A1993LR89700040
J	MAYADAS, TN; JOHNSON, RC; RAYBURN, H; HYNES, RO; WAGNER, DD				MAYADAS, TN; JOHNSON, RC; RAYBURN, H; HYNES, RO; WAGNER, DD			LEUKOCYTE ROLLING AND EXTRAVASATION ARE SEVERELY COMPROMISED IN P-SELECTIN-DEFICIENT MICE	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; HUMAN-ENDOTHELIAL-CELLS; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; VONWILLEBRAND-FACTOR; ADHESION DEFICIENCY; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; LUNG INJURY; STEM-CELLS	P selectin, expressed on surfaces of activated endothelial cells and platelets, is an adhesion receptor for leukocytes. We report that P selectin-deficient mice, generated by gene targeting in embryonic stem cells, exhibit a number of defects in leukocyte behavior, including elevated numbers of circulating neutrophils, virtually total absence of leukocyte rolling in mesenteric venules, and delayed recruitment of neutrophils to the peritoneal cavity upon experimentally induced inflammation. These results clearly demonstrate a role for P selectin in leukocyte interactions with the vessel wall and in the early steps of leukocyte recruitment at sites of inflammation. These mutant mice should prove useful in deciphering the contributions of P selectin in various inflammatory responses as well as in platelet functions.	TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; TUFTS UNIV,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CTR CANC RES,CAMBRIDGE,MA 02139	Tufts Medical Center; Tufts University; Tufts University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NHLBI NIH HHS [P01 HL42443, HL41484, T32HL07437] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007437, P01HL041484, P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.me.38.020187.001135; ARNAOUT MA, 1993, CURR OPIN HEMATOL, V1, P113; ATHERTON A, 1973, J PHYSIOL-LONDON, V233, P157, DOI 10.1113/jphysiol.1973.sp010303; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BONFANTI R, 1989, BLOOD, V73, P1109; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FRIES JWU, 1993, IN PRESS AM J PATHOL; FRYDMAN M, 1993, AM J MED GENET, V44, P297; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KOUTTS J, 1978, J CLIN INVEST, V62, P1255, DOI 10.1172/JCI109246; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, INFLAMMATION BASIC P; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS WE, 1992, BLOOD, V80, P795; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; VONANDRIAN UH, 1993, IN PRESS J CLIN INVE; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Wagner R., 1839, ERLAUTERUNGSTAFELN P; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WELLER A, 1992, J BIOL CHEM, V267, P15176	55	922	954	1	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					541	554		10.1016/0092-8674(93)80055-J	http://dx.doi.org/10.1016/0092-8674(93)80055-J			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	7688665				2022-12-01	WOS:A1993LT73900015
J	TSUBATA, T; WU, J; HONJO, T				TSUBATA, T; WU, J; HONJO, T			B-CELL APOPTOSIS INDUCED BY ANTIGEN RECEPTOR CROSS-LINKING IS BLOCKED BY A T-CELL SIGNAL THROUGH CD40	NATURE			English	Article							INVITRO TOLERANCE INDUCTION; LYMPHOCYTES-B; TRANSGENIC MOUSE; ACTIVATION; IMMUNOGLOBULIN; LIGAND; EXPRESSION; PROTEIN; DEATH; PROLIFERATION	IN mice transgenic for an autoantibody, self-reactive B cells have been shown to be eliminated upon interaction with membrane-bound self-antigens in the periphery1,2 as well as in the bone marrow3,5, suggesting that both immature and mature B cells are eliminated by multimerization of surface immunoglobulins (sIg). Activation of mature B cells by antigens may thus require a second signal that inhibits sIg-mediated apoptosis. Such a second signal is likely to be provided by T helper cells, because B-cell tolerance is more easily induced in the absence of T helper cells6-9. To assess the molecular nature of the signal that inhibits sIg-mediated apoptosis, we used anti-IgM-induced apoptotic death of WEHI-231 B lymphoma cells10,11 as a model system. Here we report that the signal for abrogating sIg-mediated apoptosis is generated by association of the CD40L molecule on T cells with the CD40 molecule on WEHI-231 cells. T-cell help through CD40 may thus determine whether B cells are eliminated or activated upon interaction with antigens.			TSUBATA, T (corresponding author), KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN.		Honjo, Tasuku/N-4470-2016; Tsubata, Takeshi/AAI-7489-2021	Tsubata, Takeshi/0000-0003-0760-1258				ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; METCALF ES, 1977, J IMMUNOL, V118, P2111; METCALF ES, 1976, J EXP MED, V143, P1327, DOI 10.1084/jem.143.6.1327; MOND JJ, 1981, J IMMUNOL, V127, P881; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; ODAKA C, 1990, J IMMUNOL, V144, P2096; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OZAKI S, 1988, J IMMUNOL, V141, P71; PAULIE S, 1989, J IMMUNOL, V142, P590; ROBB RJ, 1986, P NATL ACAD SCI USA, V83, P3992, DOI 10.1073/pnas.83.11.3992; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUBBARAO B, 1983, J IMMUNOL, V130, P2033; SUBBARAO B, 1984, J EXP MED, V159, P1796, DOI 10.1084/jem.159.6.1796; VAN DE VELDE H, 1991, NATURE, V351, P662	35	386	400	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 12	1993	364	6438					645	648		10.1038/364645a0	http://dx.doi.org/10.1038/364645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	7688865				2022-12-01	WOS:A1993LR77100058
J	BOUGHTONSMITH, NK; EVANS, SM; HAWKEY, CJ; COLE, AT; BALSITIS, M; WHITTLE, BJR; MONCADA, S				BOUGHTONSMITH, NK; EVANS, SM; HAWKEY, CJ; COLE, AT; BALSITIS, M; WHITTLE, BJR; MONCADA, S			NITRIC-OXIDE SYNTHASE ACTIVITY IN ULCERATIVE-COLITIS AND CROHNS-DISEASE	LANCET			English	Note								Excessive nitric oxide (NO) production by an isoform of NO synthase that can be induced by inflammatory stimuli leads to changes in vascular permeability and to tissue injury. We measured NO synthase activities in mucosa and muscle from the colons of control patients (n=11) and patients with ulcerative colitis (6) or Crohn's disease (4). NO synthase activity in colonic mucosa of ulcerative colitis patients was 0.55 (median interquartile range 0.32-0.57) nmol/min per g tissue, which was about eightfold higher than the value in control mucosa, with no individual overlap (p<0.001). With colonic muscle there was no difference in NO synthase activity between ulcerative colitis patients and controls. In the patients with Crohn's disease, mucosal NO synthase activity did not differ from control values and activity in the colonic muscle was low. Thus, induction of colonic NO synthase may be involved in the mucosal vasodilation and increased vascular permeability of active ulcerative colitis, and could also contribute to the impaired motility that accompanies toxic dilation.	WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; University of Nottingham								BOUGHTONSMITH NK, 1992, BRIT J PHARMACOL, V107, pP79; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; JENKINS D, 1990, GUT, V31, P426, DOI 10.1136/gut.31.4.426; MAHIDA YR, 1989, GUT, V30, P835, DOI 10.1136/gut.30.6.835; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; WAKEFIELD AJ, 1989, LANCET, V2, P1057	10	413	425	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					338	340		10.1016/0140-6736(93)91476-3	http://dx.doi.org/10.1016/0140-6736(93)91476-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	7687730				2022-12-01	WOS:A1993LQ86800014
J	HAWKEN, M; NUNN, P; GATHUA, S; BRINDLE, R; GODFREYFAUSSETT, P; GITHUI, W; ODHIAMBO, J; BATCHELOR, B; GILKS, C; MORRIS, J; MCADAM, K				HAWKEN, M; NUNN, P; GATHUA, S; BRINDLE, R; GODFREYFAUSSETT, P; GITHUI, W; ODHIAMBO, J; BATCHELOR, B; GILKS, C; MORRIS, J; MCADAM, K			INCREASED RECURRENCE OF TUBERCULOSIS IN HIV-1-INFECTED PATIENTS IN KENYA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; MORTALITY; KINSHASA; ZAIRE	There is evidence that in human immunodeficiency virus 1 (HIV-1) infected patients with tuberculosis the rate of recurrence of tuberculosis is increased in those patients treated with a standard thiacetazone-containing regimen. To assess the impact of HIV-1 on tuberculosis in Kenya, patients with tuberculosis were studied prospectively. After treatment with either a standard thiacetazone plus isoniazid regimen or a short-course thiacetazone-containing regimen, overall recurrence rate of tuberculosis was 34 times greater in 58 HIV-1-positive patients than in 138 HIV-1-negative patients (adjusted rate ratio 33.8, 95% CI 4.3-264). Recurrence in the HIV-1-positive group was strongly associated with a cutaneous hypersensitivity reaction due to thiacetazone during initial treatment (rate ratio 13.2, 95% CI 3.1-56.2). In all patients with a cutaneous hypersensitivity reaction ethambutol was substituted for thiacetazone. No significant association was found between recurrence among HIV-1-positive patients and initial resistance, initial treatment regimen, a diagnosis of AIDS (WHO definition), or poor compliance. DNA fingerprinting suggested that both relapse and new infection may have produced recurrence of tuberculosis. In patients who had a cutaneous hypersensitivity reaction, increased recurrence rate may have been related to interruption of treatment, subsequent poor compliance, or more advanced immunosuppression. Alternatively, a change to the combination of ethambutol and isoniazid in the continuation phase for 11 months only may not be adequate.	KENYA GOVT MED RES CTR,NAIROBI,KENYA; PUBL HLTH LAB,OXFORD,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; KENYATTA NATL HOSP,HOSP INFECT DIS,NAIROBI,KENYA	Kenya Medical Research Institute; University of London; London School of Hygiene & Tropical Medicine; Kenyatta National Hospital	HAWKEN, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CITRON KM, 1983, OXFORD TXB MED, V1; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; GODFREYFAUSSETT P, 1991, LANCET, V337, P176, DOI 10.1016/0140-6736(91)90840-L; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2052; NARAIN JP, IN PRESS TUBERC LUNG; NDINYAACHOLA JO, 1991, 7 INT C AIDS FLOR; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1991, LANCET, V337, P627; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; Slutkin G, 1988, Bull Int Union Tuberc Lung Dis, V63, P21; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SORIANO E, 1988, AIDS, V2, P429, DOI 10.1097/00002030-198812000-00003; 1992, WKLY EPIDEMIOL REC, V67, P1; 1990, NATIONAL LEPROSY TUB	17	125	127	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					332	337		10.1016/0140-6736(93)91474-Z	http://dx.doi.org/10.1016/0140-6736(93)91474-Z			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	7687729				2022-12-01	WOS:A1993LQ86800012
J	COTE, J; RUIZCARRILLO, A				COTE, J; RUIZCARRILLO, A			PRIMERS FOR MITOCHONDRIAL-DNA REPLICATION GENERATED BY ENDONUCLEASE-G	SCIENCE			English	Article							DISPLACEMENT LOOP REGION; CONSERVED SEQUENCE; NUCLEASE; CELLS; GENE; RNA; TRANSCRIPTION; INITIATION; PROTEIN; SITE	Endonuclease G (Endo G) is widely distributed among animals and cleaves DNA at double-stranded (dG)n.(dC)n and at single-stranded (dC)n tracts. Endo G is synthesized as a propeptide with an amino-terminal presequence that targets the nuclease to mitochondria. Endo G can also be detected in extranucleolar chromatin. In addition to deoxyribonuclease activities, Endo G also has ribonuclease (RNase) and RNase H activities and specifically cleaves mouse mitochondrial RNA and DNA-RNA substrates containing the origin of heavy-strand DNA replication (O(H)). The cleavage sites match those found in vivo, indicating that Endo G is capable of generating the RNA primers required by DNA polymerase gamma to initiate replication of mitochondrial DNA.	HOP HOTEL DIEU,LAVAL UNIV,SCH MED,CANC RES CTR,QUEBEC CITY G1R 2J6,QUEBEC,CANADA; HOP HOTEL DIEU,LAVAL UNIV,SCH MED,DEPT BIOCHEM,QUEBEC CITY G1R 2J6,QUEBEC,CANADA	Laval University; Laval University			Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BALL TK, 1987, GENE, V57, P183, DOI 10.1016/0378-1119(87)90121-1; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHOW TYK, 1983, J BIOL CHEM, V258, P2010; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; COTE J, 1989, J BIOL CHEM, V264, P3301; COTE J, UNPUB; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUSWIRTH WW, 1984, CELL, V37, P1001, DOI 10.1016/0092-8674(84)90434-3; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; KING TC, 1987, J BIOL CHEM, V262, P6214; KING TC, 1987, J BIOL CHEM, V262, P6204; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOW RL, 1987, J BIOL CHEM, V262, P16164; LOW RL, 1988, NUCLEIC ACIDS RES, V16, P6427, DOI 10.1093/nar/16.14.6427; MOOS M, 1988, J BIOL CHEM, V263, P6005; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PRATS E, 1989, NUCLEIC ACIDS RES, V17, P10097, DOI 10.1093/nar/17.23.10097; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; TOOPER JN, 1992, CELL, V70, P16; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283	32	189	198	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					765	769		10.1126/science.7688144	http://dx.doi.org/10.1126/science.7688144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688144				2022-12-01	WOS:A1993LQ73000041
J	NOLAN, JM; BURKE, DH; PACE, NR				NOLAN, JM; BURKE, DH; PACE, NR			CIRCULARLY PERMUTED TRANSFER-RNAS AS SPECIFIC PHOTOAFFINITY PROBES OF RIBONUCLEASE-P RNA STRUCTURE	SCIENCE			English	Article							SUBSTRATE; ENZYME; SEQUENCE; CATALYSIS; MOIETY; SITE; DNA	Regions of Escherichia coli ribonuclease P (RNase P) RNA in proximity to a bound transfer RNA (tRNA) substrate were mapped by photoaffinity. A photoaffinity cross-linking reagent was introduced at specific sites in the interior of the native tRNA structure by modification of the 5' ends of circularly permuted tRNAs (cptRNAs). The polymerase chain reaction was used for the production of cptRNA templates. After the amplification of a segment of a tandemly duplicated tRNA gene, the cptRNA gene was transcribed in vitro to produce cptRNA. Modified cptRNAs were cross-linked to RNase P RNA, and the conjugation sites in RNase P RNA were determined by primer extension. These sites occur in phylogenetically conserved structures and sequences and identify regions of the ribozyme that form part of the tRNA binding site. The use of circularly permuted molecules to position specific modifications is applicable to the study of many inter- and intramolecular interactions.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	Indiana University System; Indiana University Bloomington; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM34527] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034527, R37GM034527] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BROWN JW, 1992, NUCLEIC ACIDS RES, V20, P1451, DOI 10.1093/nar/20.7.1451; BROWN JW, 1993, NUCLEIC ACIDS RES, V21, P671, DOI 10.1093/nar/21.3.671; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GAUSS DH, 1979, TRANSFER RNA STRUCTU, P518; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NOLAN JM, UNPUB; PACE NR, 1990, J BIOL CHEM, V265, P3587; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; REICH CI, 1988, THESIS U BUENOS AIRE; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH D, 1992, J BIOL CHEM, V267, P2429; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885; USMAN N, 1992, TRENDS BIOCHEM SCI, V17, P334, DOI 10.1016/0968-0004(92)90306-T; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671	28	113	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					762	765		10.1126/science.7688143	http://dx.doi.org/10.1126/science.7688143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688143				2022-12-01	WOS:A1993LQ73000040
J	LAFONCAZAL, M; PIETRI, S; CULCASI, M; BOCKAERT, J				LAFONCAZAL, M; PIETRI, S; CULCASI, M; BOCKAERT, J			NMDA-DEPENDENT SUPEROXIDE PRODUCTION AND NEUROTOXICITY	NATURE			English	Article							NITRIC-OXIDE SYNTHASE; AMINO-ACID RELEASE; STRIATAL NEURONS; NERVOUS-SYSTEM; GLUTAMATE; RECEPTORS; ISCHEMIA; QUANTIFICATION; CULTURES; INJURY	NEURONAL injury resulting from acute brain insults and some neurodegenerative diseases implicates N-methyl-D-aspartate (NMDA) glutamate receptors1-4. The fact that antioxidants reduce some types of brain damage suggests that oxygen radicals may have a roles5-7. It has been shown that mutations in Cu/Zn-superoxide dismutase (SOD), an enzyme catalysing superoxide (O2.-) detoxification in the cell, are linked to a familial form of amyotrophic lateral sclerosis (ALS)4. Here we report that O2.- is produced upon NMDA receptor stimulation in cultured cerebellar granule cells. Electron paramagnetic resonance was used to assess O2.- production that was due in part to the release of arachidonic acid. Activation of kainic acid receptors, or voltage-sensitive Ca2+ channels, did not produce detectable O2.-. We also find that the nitrone DMPO (5,5-dimethyl pyrroline 1-oxide), used as a spin trap, is more efficient than the nitric oxide synthase inhibitor, L-N(G)-nitroarginine, in reducing NMDA-induced neuronal death in these cultures.	CRIPDOM,F-34172 CASTELNAU LEZ,FRANCE; UNIV AIX MARSEILLE 1,SREP,CNRS,URA 1412,F-13397 MARSEILLE 4,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	LAFONCAZAL, M (corresponding author), CNRS,INSERM,CTR PHARMACOL ENDOCRINOL,RUE DE LA CARDONILLE,F-34094 MONTPELLIER 5,FRANCE.							BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIDIER M, 1990, J NEUROSCI RES, V27, P25, DOI 10.1002/jnr.490270105; DIDIER M, 1993, EUR J PHARMACOL, V224, P57; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FAVARON M, 1990, P NATL ACAD SCI USA, V87, P1983, DOI 10.1073/pnas.87.5.1983; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; LAFONCAZAL M, 1992, BRAIN RES, V593, P63, DOI 10.1016/0006-8993(92)91264-F; LERNERNATOLI M, 1992, J NEUROREPORT, V3, P1109; MARIN P, 1992, EUR J NEUROSCI, V4, P425, DOI 10.1111/j.1460-9568.1992.tb00892.x; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONCADA C, 1992, NEUROREPORT, V3, P530; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OLNEY JW, 1989, DRUG DEVELOP RES, V17, P299, DOI 10.1002/ddr.430170406; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; POU S, 1992, J BIOL CHEM, V267, P24173; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; ROSEN GM, 1988, J MED CHEM, V31, P428, DOI 10.1021/jm00397a028; SAEZ JC, 1987, P NATL ACAD SCI USA, V84, P3056, DOI 10.1073/pnas.84.9.3056; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229	29	1097	1112	0	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					535	537		10.1038/364535a0	http://dx.doi.org/10.1038/364535a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687749				2022-12-01	WOS:A1993LQ66700057
J	SASSANFAR, M; SZOSTAK, JW				SASSANFAR, M; SZOSTAK, JW			AN RNA MOTIF THAT BINDS ATP	NATURE			English	Article							MOLECULAR RECOGNITION; RECEPTOR	RNAs that contain specific high-affinity binding sites for small molecule ligands immobilized on a solid support are present at a frequency of roughly one in 10(10)-10(11) in pools of random sequence RNA molecules1,2. Here we describe a new in vitro selection procedure designed to ensure the isolation of RNAs that bind the ligand of interest in solution as well as on a solid support. We have used this method to isolate a remarkably small RNA motif that binds ATP, a substrate in numerous biological reactions and the universal biological high-energy intermediate. The selected ATP-binding RNAs contain a consensus sequence, embedded in a common secondary structure. The binding properties of ATP analogues and modified RNAs show that the binding interaction is characterized by a large number of close contacts between the ATP and RNA, and by a change in the conformation of the RNA.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	SASSANFAR, M (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BRESLOW R, 1989, J AM CHEM SOC, V111, P8296, DOI 10.1021/ja00203a050; CARCANAGUE DR, 1992, J AM CHEM SOC, V114, P1515, DOI 10.1021/ja00030a077; CHANG SK, 1991, J AM CHEM SOC, V113, P7640, DOI 10.1021/ja00020a027; ECHAVARREN A, 1989, J AM CHEM SOC, V111, P4994, DOI 10.1021/ja00195a071; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAN E, 1993, J AM CHEM SOC, V115, P369, DOI 10.1021/ja00054a066; FERSHT A, 1985, ENZYME STRUCTURE MEC, P186; GOSWAMI S, 1989, J AM CHEM SOC, V111, P3425, DOI 10.1021/ja00191a048; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; REBEK J, 1987, SCIENCE, V235, P1478, DOI 10.1126/science.3823899; ROTELLO VM, 1993, J AM CHEM SOC, V115, P797, DOI 10.1021/ja00055a066; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; YOON SS, 1993, J AM CHEM SOC, V115, P823, DOI 10.1021/ja00055a083	17	499	540	2	74	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					550	553		10.1038/364550a0	http://dx.doi.org/10.1038/364550a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687750				2022-12-01	WOS:A1993LQ66700062
J	WYNICK, D; HAMMOND, PJ; AKINSANYA, KO; BLOOM, SR				WYNICK, D; HAMMOND, PJ; AKINSANYA, KO; BLOOM, SR			GALANIN REGULATES BASAL AND ESTROGEN-STIMULATED LACTOTROPH FUNCTION	NATURE			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; RAT PITUITARY-CELLS; THYROTROPIN-RELEASING-HORMONE; ANTERIOR-PITUITARY; PROLACTIN SECRETION; POSSIBLE INVOLVEMENT; ESTROGEN; IMMUNOREACTIVITY; POLYPEPTIDE; TUMOR	OESTROGEN, an essential physiological regulator of reproductive function1, controls lactotroph proliferation and prolactin release2. The neuropeptide galanin co-localizes to the lactotroph3, but its physiological function is largely unknown. Pituitary galanin expression is extremely sensitive to the oestrogen status of the animal. A marked elevation occurs during pregnancy and lactation 4, and exogenous 17beta-oestradiol can cause a 4,000-fold increase in messenger RNA levels5. Here we report that galanin is secreted by a minority of lactotrophs and is essential for the regulation of basal and vasoactive-intestinal-polypeptide-stimulated prolactin release. Hyperoestrogenization increases the number of galanin-secreting cells and the resulting increase in basal prolactin release is completely abolished by treatment with galanin antiserum. Galanin is a potent lactotroph growth factor and galanin-immunoneutralization completely inhibits the previously reported6-8 mitogenic effects of oestrogen on the lactotroph. These findings represent direct evidence for paracrine regulation of lactotroph function and demonstrate that the effect of oestrogen on lactotroph proliferation and prolactin release are mediated by locally secreted galanin.	HAMMERSMITH HOSP, DEPT MED, DUCANE RD, LONDON W12 0NN, ENGLAND	Imperial College London								AIZAWA T, 1985, ENDOCRINOLOGY, V116, P909, DOI 10.1210/endo-116-3-909; BAUER FE, 1986, GASTROENTEROLOGY, V91, P877, DOI 10.1016/0016-5085(86)90689-X; BJORO T, 1987, MOL CELL ENDOCRINOL, V49, P119, DOI 10.1016/0303-7207(87)90205-X; BJORO T, 1990, BIOSCIENCE REP, V10, P189, DOI 10.1007/BF01116578; CARRILLO AJ, 1992, ENDOCRINOLOGY, V131, P964, DOI 10.1210/en.131.2.964; DENEF C, 1989, METHOD ENZYMOL, V168, P47; FRANKS S, 1983, CLIN SCI, V65, P457, DOI 10.1042/cs0650457; GABRIEL SM, 1990, NEUROENDOCRINOLOGY, V51, P168, DOI 10.1159/000125333; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Inagaki H, 1989, No To Shinkei, V41, P593; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P7408, DOI 10.1073/pnas.85.19.7408; KENDALL ME, 1987, ENDOCRINOLOGY, V121, P2260, DOI 10.1210/endo-121-6-2260; Knobil E, 1980, Recent Prog Horm Res, V36, P53; KOSHIYAMA H, 1987, NEUROSCI LETT, V75, P49, DOI 10.1016/0304-3940(87)90073-5; KROWN KA, 1992, ENDOCRINOLOGY, V131, P595, DOI 10.1210/en.131.2.595; LAM KSL, 1989, ENDOCRINOLOGY, V124, P1077, DOI 10.1210/endo-124-2-1077; MELANDER T, 1987, ACTA PHYSIOL SCAND, V131, P25, DOI 10.1111/j.1748-1716.1987.tb08201.x; MOREL G, 1982, NEUROENDOCRINOLOGY, V34, P85, DOI 10.1159/000123282; OHALLORAN DJ, 1990, ENDOCRINOLOGY, V127, P467, DOI 10.1210/endo-127-1-467; PHELPS C, 1983, NEUROENDOCRINOLOGY, V37, P23, DOI 10.1159/000123511; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROTSZTEJN WH, 1981, P NATL ACAD SCI-BIOL, V78, P7584, DOI 10.1073/pnas.78.12.7584; SHIMATSU A, 1983, NEUROSCI LETT, V43, P259, DOI 10.1016/0304-3940(83)90198-2; STEEL JH, 1989, HISTOCHEMISTRY, V93, P183, DOI 10.1007/BF00315973; TATAR P, 1991, EXP CLIN ENDOCRINOL, V97, P29, DOI 10.1055/s-0029-1211034; TROUILLAS J, 1990, CANCER RES, V50, P4081; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231; WYNICK D, 1990, J ENDOCRINOL, V128, P269	29	122	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1993	364	6437					529	532		10.1038/364529a0	http://dx.doi.org/10.1038/364529a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687748				2022-12-01	WOS:A1993LQ66700055
J	SHAHINIAN, A; PFEFFER, K; LEE, KP; KUNDIG, TM; KISHIHARA, K; WAKEHAM, A; KAWAI, K; OHASHI, PS; THOMPSON, CB; MAK, TW				SHAHINIAN, A; PFEFFER, K; LEE, KP; KUNDIG, TM; KISHIHARA, K; WAKEHAM, A; KAWAI, K; OHASHI, PS; THOMPSON, CB; MAK, TW			DIFFERENTIAL T-CELL COSTIMULATORY REQUIREMENTS IN CD28-DEFICIENT MICE	SCIENCE			English	Article							ACCESSORY MOLECULE CD28; CD4+ LYMPHOCYTES-T; MESSENGER-RNA; SIGNAL TRANSDUCTION; STEM-CELLS; ACTIVATION ANTIGEN-B7; IL-2 PRODUCTION; MURINE HOMOLOG; EXPRESSION; GENE	T cell receptor stimulation without costimulation is insufficient for the induction of an optimal immune response. It is thought that engagement of the CD28 molecule with its ligand B7 provides an essential costimulatory signal without which full activation of T cells cannot occur. A mouse strain with a defective CD28 gene was established. Development of T and B cells in the CD28-deficient mice appeared normal. However, T lymphocytes derived from CD28-/- mutant mice had impaired responses to lectins. Lectin stimulation did not trigger interleukin-2 (IL-2) production, IL-2 receptor alpha expression was significantly decreased, and exogenous IL-2 only partially rescued the CD28 defect. Basal immunoglobulin (Ig) concentrations in CD28-deficient mice were about one-fifth of those found in wild-type controls, with low titers of IgG1 and IgG2b but an increase in IgG2a. In addition, activity of T helper cells in CD28-/- mice was reduced and immunoglobulin class switching was diminished after infection with vesicular stomatitis virus. However, cytotoxic T cells could still be induced and the mice showed delayed-type hypersensitivity after infection with lymphocytic choriomeningitis virus. Thus, CD28 is not required for all T cell responses in vivo, suggesting that alternative costimulatory pathways may exist.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, AMGEN INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Kawai, Kazuhiro/D-4998-2011	Kawai, Kazuhiro/0000-0001-9375-0713; Pfeffer, Klaus/0000-0002-5652-6330; Ohashi, Pamela S./0000-0003-2915-9317				ABE R, 1992, J IMMUNOL, V149, P3429; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; AHMANN GB, 1978, J IMMUNOL, V121, P1981; BRADLEY A, 1986, CURR TOP DEV BIOL, V20, P357, DOI 10.1016/S0070-2153(08)60675-4; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CERDAN C, 1992, J IMMUNOL, V149, P2255; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DAMLE NK, 1992, J IMMUNOL, V149, P2541; DAMLE NK, 1992, J IMMUNOL, V148, P1985; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1992, J IMMUNOL, V149, P3795; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GROSS JA, 1990, J IMMUNOL, V144, P3201; GROSS JA, 1992, J IMMUNOL, V149, P380; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPER K, 1991, J IMMUNOL, V147, P1037; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LEDBETTER JA, 1990, BLOOD, V75, P1531; LEE KP, 1990, J IMMUNOL, V145, P344; LEIST TP, 1987, J IMMUNOL, V138, P2278; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, EUR J IMMUNOL, V22, P2855, DOI 10.1002/eji.1830221115; LIU Y, 1990, P NATL ACAD SCI USA, V87, P5031; LU YL, 1992, J IMMUNOL, V149, P24; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NORTON SD, 1992, J IMMUNOL, V149, P1556; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, UNPUB; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TURKA LA, 1991, J IMMUNOL, V146, P1428; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P; YOUNG JW, 1990, J EXP MED, V171, P1315, DOI 10.1084/jem.171.4.1315; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840	59	1155	1186	3	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					609	612		10.1126/science.7688139	http://dx.doi.org/10.1126/science.7688139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	7688139				2022-12-01	WOS:A1993LP72800039
J	NORGARDSUMNICHT, KE; VARKI, NM; VARKI, A				NORGARDSUMNICHT, KE; VARKI, NM; VARKI, A			CALCIUM-DEPENDENT HEPARIN-LIKE LIGANDS FOR L-SELECTIN IN NONLYMPHOID ENDOTHELIAL-CELLS	SCIENCE			English	Article							LYMPHOCYTE HOMING RECEPTOR; ANTITHROMBIN-BINDING SEQUENCE; ADHESION MOLECULE-1 LAM-1; LEUKOCYTE ADHESION; BASEMENT-MEMBRANE; LINKED OLIGOSACCHARIDES; SULFATE PROTEOGLYCANS; VASCULAR ENDOTHELIUM; HUMAN-NEUTROPHILS; PASTEURELLA-HAEMOLYTICA	L-Selectin is a calcium-dependent mammalian lectin that mediates lymphocyte trafficking by recognizing sialylated ligands on high endothelial venules in lymph nodes. Although L-selectin probably mediates neutrophil extravasation into nonlymphoid tissues, no corresponding ligand has been characterized. Staining of cultured endothelial cells with an L-selectin chimera (LS-Rg) showed an internal pool of ligands. Metabolic labeling with sulfur-35-labeled sulfate revealed heparin lyase-sensitive ligands that bound LS-Rg in a calcium-dependent, sialic acid-independent manner. A fraction of commercial heparin bound to LS-Rg and LS-Rg bound to heparin-agarose, both in a calcium-dependent manner. Thus, L-selectin recognizes endothelial heparin-like chains, which could be physiological ligands mediating leucocyte trafficking.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [R01CA38701] Funding Source: Medline; NHLBI NIH HHS [HL07089] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BHAVANANDAN VP, 1992, GLYCOCONJUGATES COMP, P167; BRADBURY MG, 1991, IMMUNOLOGY, V72, P231; BRADBURY MG, 1989, IMMUNOLOGY, V66, P546; BRAUER PR, 1990, DEVELOPMENT, V110, P805; DAWSON J, 1992, EUR J IMMUNOL, V22, P1647, DOI 10.1002/eji.1830220646; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; FAKUDA M, 1985, J BIOL CHEM, V260, P12957; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HUANG K, 1991, J CLIN INVEST, V88, P1778, DOI 10.1172/JCI115498; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; INOUE S, 1989, J HISTOCHEM CYTOCHEM, V37, P597, DOI 10.1177/37.5.2522961; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; LEY K, 1991, BLOOD, V77, P2553; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; NORGARD KE, UNPUB; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROUX L, 1988, J BIOL CHEM, V263, P8879; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SIMONASSMANN P, 1989, J CELL BIOL, V109, P1837, DOI 10.1083/jcb.109.4.1837; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPERTINI O, 1991, J IMMUNOL, V147, P2565; STOOLMAN LM, 1989, J CLIN INVEST, V84, P1196, DOI 10.1172/JCI114285; STOOLMAN LM, 1992, CELL SURFACE CARBOHY, P71; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TANGELDER GJ, 1991, BLOOD, V77, P1565; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VANDENHEUVEL LPWJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P67, DOI 10.1016/0005-2736(90)90191-P; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WALENGA JM, 1988, THROMB RES, V52, P553, DOI 10.1016/0049-3848(88)90128-4; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	67	179	185	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					480	483		10.1126/science.7687382	http://dx.doi.org/10.1126/science.7687382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	7687382				2022-12-01	WOS:A1993LN62300039
J	FERAT, JL; MICHEL, F				FERAT, JL; MICHEL, F			GROUP-II SELF-SPLICING INTRONS IN BACTERIA	NATURE			English	Article							DNA BINDING-PROTEIN; ESCHERICHIA-COLI; PURPLE BACTERIA; CHLOROPLASTS; SEQUENCES; ORIGINS	LIKE nuclear premessenger introns, group II self-splicing introns are excised from primary transcripts as branched molecules, containing a 2'-5' phosphodiester bond. For this reason, it is widely believed that the ribozyme (catalytic RNA) core of group II introns, or some evolutionarily related molecule, gave rise to the RNA components of the spliceosomal splicing machinery of the eukaryotic nucleus1. One difficulty with this hypothesis has been the restricted distribution of group II introns. Unlike group I self-splicing introns, which interrupt not only organelle primary transcripts, but also some bacterial and nuclear genes2-5, group II introns seemed to be confined to mitochondrial and chloroplast genomes (reviewed in ref. 6). We now report the discovery of group II introns both in cyanobacteria (the ancestors of chloroplasts7) and the gamma subdivision of purple bacteria, or proteobacteria8, whose alpha subdivision probably gave rise to mitochondria9. At least one of these introns actually self-splices in vitro.			FERAT, JL (corresponding author), CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; HERDMAN M, 1973, J GEN MICROBIOL, V79, P233, DOI 10.1099/00221287-79-2-233; HIOM K, 1991, J BACTERIOL, V173, P7368, DOI 10.1128/jb.173.22.7368-7373.1991; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; KUCK U, 1989, MOL GEN GENET, V218, P257, DOI 10.1007/BF00331276; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; PEEBLES CL, 1987, COLD SPRING HARB SYM, V52, P223, DOI 10.1101/SQB.1987.052.01.027; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SKELLY PJ, 1991, CURR GENET, V20, P115, DOI 10.1007/BF00312773; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; WOESE CR, 1985, SYST APPL MICROBIOL, V6, P25, DOI 10.1016/S0723-2020(85)80007-2; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	26	205	209	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					358	361		10.1038/364358a0	http://dx.doi.org/10.1038/364358a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	7687328				2022-12-01	WOS:A1993LN57000064
J	OLIET, SHR; BOURQUE, CW				OLIET, SHR; BOURQUE, CW			MECHANOSENSITIVE CHANNELS TRANSDUCE OSMOSENSITIVITY IN SUPRAOPTIC NEURONS	NATURE			English	Article							ION CHANNELS; RAT; VASOPRESSIN; OXYTOCIN; ACTIVATION; NUCLEUS; STIMULI	VASOPRESSIN is a peptide hormone synthesized by neurons of the supraoptic and paraventricular nuclei, which project axon terminals to the neurohypophysis. Consistent with its antidiuretic properties, vasopressin release rises as a function of plasma osmolality1-3, a response that results from accelerated action potential discharge4-6. Previous studies have shown that increases in fluid osmolality depolarize supraoptic neurons in the absence of synaptic transmission7-9, suggesting that these cells behave as intrinsic osmoreceptors. The mechanism by which changes in osmolality are transduced into an electrical signal is unknown, however. Here we report that changes in cell volume accompany physiological variations in fluid osmolality and that these modulate the activity of mechanosensitive cation channels in a way that is consistent with the macroscopic regulation of membrane voltage and action potential discharge. These findings define a function for stretch-inactivated channels in mammalian central neurons.	MONTREAL GEN HOSP,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University				Oliet, Stephane/0000-0003-0595-9029; Bourque, Charles/0000-0002-1594-742X				BOURQUE CW, 1989, J PHYSIOL-LONDON, V417, P263, DOI 10.1113/jphysiol.1989.sp017800; BRIMBLE MJ, 1977, J PHYSIOL-LONDON, V271, P253, DOI 10.1113/jphysiol.1977.sp011999; BRIMBLE MJ, 1978, J PHYSIOL-LONDON, V278, P69, DOI 10.1113/jphysiol.1978.sp012293; Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; DUNN FL, 1973, J CLIN INVEST, V52, P3212, DOI 10.1172/JCI107521; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; FRIEDMAN JE, 1993, J NEUROSCI, V13, P63; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LAWRENCE D, 1985, BRAIN RES, V341, P176, DOI 10.1016/0006-8993(85)91486-6; LENG G, 1982, NEUROENDOCRINOLOGY, V34, P75, DOI 10.1159/000123280; MASON WT, 1980, NATURE, V287, P154, DOI 10.1038/287154a0; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; MORRIS CE, 1991, SCIENCE, V251, P1246, DOI 10.1126/science.1706535; OLIET SHR, 1992, J PHYSIOL-LONDON, V455, P291, DOI 10.1113/jphysiol.1992.sp019302; POULAIN DA, 1982, NEUROSCIENCE, V7, P773, DOI 10.1016/0306-4522(82)90044-6; ROBERTSON GL, 1976, KIDNEY INT, V10, P25, DOI 10.1038/ki.1976.76; SOKABE M, 1992, ADV COMP ENV PHYSL, V10, P55; VERNEY EB, 1947, PROC R SOC SER B-BIO, V135, P25, DOI 10.1098/rspb.1947.0037	19	271	274	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					341	343		10.1038/364341a0	http://dx.doi.org/10.1038/364341a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	7687327				2022-12-01	WOS:A1993LN57000058
J	GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG				GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG			PHOTODYNAMIC THERAPY OF ORAL-CANCER - PHOTOSENSITIZATION WITH SYSTEMIC AMINOLEVULINIC ACID	LANCET			English	Note								Photodynamic therapy with intravenous photosensitising drugs has been shown to be effective in the ablation of superficial cancers, but long-lasting photosensitivity is a serious disadvantage. Similar photosensitivity is a feature of certain types of porphyria. We present the first report of tumour necrosis brought about by photodynamic activation of a temporary endogenous porphyrin accumulation, after an oral dose of the haem precursor, 5-aminolaevulinic acid. In 4 patients, quantitative fluorescence microscopy showed that accumulation of the photoactive intermediate protoporphyrin IX peaked after 4-6 h in 4 oral cavity squamous cell carcinomas, returning to background in 24 h. Irradiation with non-thermal red laser light caused tumour necrosis in 3 patients.	UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, DIV MAXILLOFACIAL SURG, LONDON WC1E 6JJ, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	GRANT, WE (corresponding author), UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, NATL MED LASER CTR, LONDON WC1E 6JJ, ENGLAND.		Bown, Stephen/AAX-6573-2020; Bown, Stephen G/C-5713-2009					BARR H, 1987, BRIT J CANCER, V56, P111, DOI 10.1038/bjc.1987.166; BEDWELL J, 1992, BRIT J CANCER, V65, P818, DOI 10.1038/bjc.1992.175; DIVARIS DXG, 1990, AM J PATHOL, V136, P891; DOUGHERTY TJ, 1990, LASER SURG MED, V10, P485, DOI 10.1002/lsm.1900100514; DOUGHERTY TJ, 1966, ACTA MED SCAND, V179, P11; KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7; LOH CS, 1993, BRIT J CANCER, V68, P41, DOI 10.1038/bjc.1993.284; LOH CS, 1992, BRIT J CANCER, V66, P452, DOI 10.1038/bjc.1992.295; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; MEYER M, 1991, BRIT J CANCER, V64, P1093, DOI 10.1038/bjc.1991.470	10	228	235	1	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					147	148		10.1016/0140-6736(93)91347-O	http://dx.doi.org/10.1016/0140-6736(93)91347-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	7687318				2022-12-01	WOS:A1993LN04200013
J	BERLIN, C; BERG, EL; BRISKIN, MJ; ANDREW, DP; KILSHAW, PJ; HOLZMANN, B; WEISSMAN, IL; HAMANN, A; BUTCHER, EC				BERLIN, C; BERG, EL; BRISKIN, MJ; ANDREW, DP; KILSHAW, PJ; HOLZMANN, B; WEISSMAN, IL; HAMANN, A; BUTCHER, EC			ALPHA-4-BETA-7-INTEGRIN MEDIATES LYMPHOCYTE BINDING TO THE MUCOSAL VASCULAR ADDRESSIN MADCAM-1	CELL			English	Article							ENDOTHELIAL-CELL RECOGNITION; MONOCLONAL-ANTIBODIES; HOMING RECEPTOR; RECIRCULATING LYMPHOCYTES; ADHESION MOLECULE-1; DIVALENT-CATIONS; INTEGRIN VLA-4; IMMUNE-SYSTEM; FIBRONECTIN; LIGAND	The mucosal vascular addressin, MAdCAM-1, is an immunoglobulin superfamily adhesion molecule for lymphocytes that is expressed by mucosal venules and helps direct lymphocyte traffic into Peyer's patches (PP) and the intestinal lamina propria. We demonstrate that the lymphocyte integrin alpha4beta7, also implicated in homing to PP, is a receptor for MAdCAM-1. Certain antibodies to alpha4 and beta7 integrin chains but not to the beta2 integrin LFA-1 inhibit lymphocyte binding to purified MAdCAM-1 and to MAdCAM-1 transfectants. Lymph node lymphocytes, alpha4beta7+ TK1 lymphoma cells, and a beta7-transfected variant of an alpha4 + B cell line, 38C13, bind constitutively to MAdCAM-1. Binding is enhanced by Mn++-induced integrin activation. The related integrin alpha4beta1 supports efficient binding to VCAM-1 but not to MAdCAM-1, even after integrin activation, indicating that MAdCAM-1 is a preferential ligand for alpha4beta7. alpha4beta7 can also bind VCAM-1, but this requires greater integrin activation than binding to MAdCAM-1. The findings imply a selective role for the interaction of alpha4beta7 and MAdCAM-1 lymphocyte in homing to mucosal sites.	STANFORD UNIV,CTR DIGEST DIS,STANFORD,CA 94305; VET ADM MED CTR,FOOTHILL RES CTR,CTR MOLEC BIOL & MED,PALO ALTO,CA 94304; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT CELL BIOL,CAMBRIDGE CB2 4AT,ENGLAND; TECH UNIV MUNICH,INST MED MICROBIOL,W-8000 MUNICH 80,GERMANY; STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; UNIV HAMBURG,KRANKENHAUS EPPENDORF,MED 1 KLIN,DIV IMMUNOL,W-2000 HAMBURG 20,GERMANY	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Technical University of Munich; Stanford University; Stanford University; University of Hamburg	BERLIN, C (corresponding author), STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.		Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 	NIAID NIH HHS [AI19957] Funding Source: Medline; NIDDK NIH HHS [DK45448] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; BARGATZE RF, 1993, IN PRESS J EXP MED; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, VASCULAR ADHESION MO, V2, P111; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GABRIELMASSON CS, 1992, THESIS PENNSYLVANIA; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAMANN A, 1988, J IMMUNOL, V140, P693; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACKAY CR, 1993, IN PRESS ANN REV IMM; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; ONEILL JK, 1991, IMMUNOLOGY, V72, P520; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YUAN Q, 1992, J BIOL CHEM, V267, P7352; Zatz M M, 1970, Cell Immunol, V1, P3, DOI 10.1016/0008-8749(70)90057-2	61	1241	1301	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					185	195		10.1016/0092-8674(93)90305-A	http://dx.doi.org/10.1016/0092-8674(93)90305-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687523				2022-12-01	WOS:A1993LN62500018
J	HAYMAN, MJ; MEYER, S; MARTIN, F; STEINLEIN, P; BEUG, H				HAYMAN, MJ; MEYER, S; MARTIN, F; STEINLEIN, P; BEUG, H			SELF-RENEWAL AND DIFFERENTIATION OF NORMAL AVIAN ERYTHROID PROGENITOR CELLS - REGULATORY ROLES OF THE TGF-ALPHA/C-ERBB AND SCF/C-KIT RECEPTORS	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; TRANSFORMED ERYTHROBLASTS; MYELOID CELLS; EGF RECEPTOR; TS MUTANTS; VIRUS; ONCOGENE	The c-kit proto-oncogene product is a major regulator of early hematopoiesis in mice. We show here that the avian c-Kit protein, together with the c-erbB proto-oncogene product, regulates self-renewal and differentiation in two types of normal chick erythroid progenitors. A relatively frequent progenitor expressing only c-Kit transiently proliferated in response to avian c-Kit ligand (stem cell factor [SCF]). A second, rare progenitor coexpressed c-Kit and c-ErbB and was induced to long-term self-renewal by SCF or transforming growth factor alpha(TGFalpha), a c-ErbB ligand. In the absence of SFC or TGFalpha, both progenitors underwent erythropoietin (Epo)-dependent terminal differentiation with indistinguishable kinetics. Interestingly, Epo induced differentiation in the SCF progenitors even when SCF was present. In contrast, the c-ErbB-expressing, TGFalpha-induced progenitors continued to self-renew when treated with Epo plus the growth factors SCF, TGFalpha, or both. Expression of c-ErbB thus may be a dominant determinant for the sustained self-renewal of committed erythroid progenitors.	AMGEN CTR,THOUSAND OAKS,CA 91320; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Amgen; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	HAYMAN, MJ (corresponding author), SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BEUG H, 1992, NUCLEAR PROCESSES ON, P53; BEUG H, 1985, MODERN TRENDS HUMAN, V6, P284; BEUG H, 1987, ONCOGENES GROWTH CON, P85; BROXMEYER HE, 1991, BLOOD, V77, P2142; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1977, CANCER RES, V37, P59; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HAUNG E, 1990, CELL, V63, P225; KELLER G, 1992, CURR OPIN IMMUNOL, V4, P133, DOI 10.1016/0952-7915(92)90002-V; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KENNEDY M, 1992, BLOOD, V79, P180; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMAN, V7, P199; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	48	88	91	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					157	169		10.1016/0092-8674(93)90303-8	http://dx.doi.org/10.1016/0092-8674(93)90303-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687522				2022-12-01	WOS:A1993LN62500016
J	JACKSON, RJ				JACKSON, RJ			CYTOPLASMIC REGULATION OF MESSENGER-RNA FUNCTION - THE IMPORTANCE OF THE 3' UNTRANSLATED REGION	CELL			English	Editorial Material							TRANSLATIONAL CONTROL; PICORNAVIRUS RNA; INITIATION; DEADENYLATION; PROTEIN; COMPLEX				JACKSON, RJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND.							BRAUN RE, 1991, ENZYME, V44, P120; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; HARFORD JB, 1991, ENZYME, V44, P28; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MACDONALD PM, 1992, SEMIN DEV BIOL, V3, P413; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SIMON R, 1992, GENE DEV, V6, P2580, DOI 10.1101/gad.6.12b.2580; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STRIPECKE R, 1992, NUCLEIC ACIDS RES, V20, P5555, DOI 10.1093/nar/20.21.5555; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; VARNUM SM, 1992, DEV BIOL, V153, P283, DOI 10.1016/0012-1606(92)90113-U; WICKENS M, 1992, SEM DEV BIOL, V3, P399	24	404	411	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					9	14		10.1016/0092-8674(93)90290-7	http://dx.doi.org/10.1016/0092-8674(93)90290-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687524				2022-12-01	WOS:A1993LN62500003
J	UTZ, U; BIDDISON, WE; MCFARLAND, HF; MCFARLIN, DE; FLERLAGE, M; MARTIN, R				UTZ, U; BIDDISON, WE; MCFARLAND, HF; MCFARLIN, DE; FLERLAGE, M; MARTIN, R			SKEWED T-CELL RECEPTOR REPERTOIRE IN GENETICALLY IDENTICAL-TWINS CORRELATES WITH MULTIPLE-SCLEROSIS	NATURE			English	Article							MYELIN BASIC-PROTEIN; GENES; GLYCOPROTEIN; INDIVIDUALS; DISEASE; CLONES; USAGE; ACID	ALTHOUGH the cause of multiple sclerosis (MS) is unknown, it is thought to involve a T cell-mediated autoimmune mechanism. Susceptibility to the disease is influenced by genetic factors such as genes of the HLA and T-cell receptor (TCR) complex1-6. Other evidence for a genetic influence includes the low incidence in certain ethnic groups7, the increased risk if there are affected family members8 and the increased concordance rate for disease in monozygotic twin pairs (26%)9, compared to dizygotic twins. Epidemiological studies indicate that there may be an additional role for envirommental factors. Although the target antigen(s) are not yet identified, several myelin or myelin-associated proteins have been suspected10-12, among them myelin basic protein. A lack of genetically comparable controls has impaired the analysis of the T-cell response in MS patients and caused disagreement on TCR usage in the disease13-15. Here we analyse the role of TCR genes in MS by comparing TCR usage in discordant versus concordant monozygotic twins in response to-self and foreign antigens. We find that after stimulation with myelin basic protein or tetanus toxoid, control twin sets as well as concordant twin sets select similar Valpha chains. Only the discordant twin sets select different TCRs after stimulation with antigens. Thus exogenous factors or the disease shape the TCR repertoire in MS patients, as seen by comparison with unaffected genetically identical individuals. This skewing of the TCR repertoire could contribute to the pathogenesis of MS and other T-cell-mediated diseases.	UNIV TUBINGEN,SCH MED,DEPT NEUROL,W-7400 TUBINGEN 1,GERMANY	Eberhard Karls University of Tubingen	UTZ, U (corresponding author), NINCDS,NEUROIMMUNOL BRANCH,BLDG 10,RM 5B-16,BETHESDA,MD 20892, USA.			Martin, Roland/0000-0002-0982-1329				ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BEALL SS, 1989, J NEUROIMMUNOL, V21, P59, DOI 10.1016/0165-5728(89)90159-8; BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN D, 1984, P NATL ACAD SCI-BIOL, V81, P1774, DOI 10.1073/pnas.81.6.1774; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; JOHNSON D, 1986, J NEUROIMMUNOL, V13, P99, DOI 10.1016/0165-5728(86)90053-6; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; MARTIN R, 1992, J IMMUNOL, V148, P1359; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SUN JB, 1991, J IMMUNOL, V146, P1490; Tiwari JL, 1985, HLA DIS ASS, P152; VARTDAL F, 1989, HUM IMMUNOL, V25, P103, DOI 10.1016/0198-8859(89)90074-8; WAKSMAN BH, 1984, P SOC EXP BIOL MED, V175, P282; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	22	124	126	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					243	247		10.1038/364243a0	http://dx.doi.org/10.1038/364243a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	7686632				2022-12-01	WOS:A1993LM68300059
J	BUTLER, A; TSUNODA, S; MCCOBB, DP; WEI, A; SALKOFF, L				BUTLER, A; TSUNODA, S; MCCOBB, DP; WEI, A; SALKOFF, L			MSLO, A COMPLEX MOUSE GENE ENCODING MAXI CALCIUM-ACTIVATED POTASSIUM CHANNELS	SCIENCE			English	Article							LIPID BILAYERS; ION CHANNELS; K+ CHANNELS; DROSOPHILA; SHAKER; COMPONENTS; PERMEATION; CURRENTS; BLOCKADE; PROTEIN	Complementary DNAs (cDNAs) from mSlo, a gene encoding calcium-activated potassium channels, were isolated from mouse brain and skeletal muscle, sequenced, and expressed in Xenopus oocytes. The mSlo-encoded channel resembled ''maxi'' or BK (high conductance) channel types; single channel conductance was 272 picosiemens with symmetrical potassium concentrations. Whole cell and single channel currents were blocked by charybdotoxin, iberiotoxin, and tetraethylammonium ion. A large number of variant mSlo cDNAs were isolated, indicating that several diverse mammalian BK channel types are produced by a single gene.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NINDS NIH HHS [R01 NS24785-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024785] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BUTLER AR, UNPUB; CAHALAN MD, 1991, CURR TOP MEMBR, V39, P357; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; ELKINS T, 1986, P NATL ACAD SCI USA, V83, P8415, DOI 10.1073/pnas.83.21.8415; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GHO M, 1992, J EXP BIOL, V170, P93; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1992, NEURON, V8, P483; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MEECH RW, 1978, ANNU REV BIOPHYS BIO, V7, P1, DOI 10.1146/annurev.bb.07.060178.000245; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; SAITO M, 1991, J NEUROSCI, V11, P2135; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SALKOFF L, 1987, SCIENCE, V237, P744, DOI 10.1126/science.2441469; SALKOFF L, 1985, J PHYSIOL-PARIS, V80, P275; SALKOFF L, 1983, NATURE, V302, P249, DOI 10.1038/302249a0; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; TORO L, 1991, AM J PHYSIOL, V260, pH1779, DOI 10.1152/ajpheart.1991.260.6.H1779; TORO L, 1990, J GEN PHYSIOL, V96, P373, DOI 10.1085/jgp.96.2.373; TORO L, 1990, AM J PHYSIOL, V258, P912; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157	35	570	587	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					221	224		10.1126/science.7687074	http://dx.doi.org/10.1126/science.7687074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	7687074				2022-12-01	WOS:A1993LL59600044
J	ZHU, N; LIGGITT, D; LIU, Y; DEBS, R				ZHU, N; LIGGITT, D; LIU, Y; DEBS, R			SYSTEMIC GENE-EXPRESSION AFTER INTRAVENOUS DNA DELIVERY INTO ADULT MICE	SCIENCE			English	Article							TRANSGENIC ANIMALS; HIGHLY EFFICIENT; TRANSFECTION; INVIVO; LIPOFECTION	Direct gene transfer into adult animals resulting in generalized or tissue-specific expression would facilitate rapid analysis of transgene effects and allow precise in vivo manipulation of biologic processes at the molecular level. A single intravenous injection of expression plasmid:cationic liposome complexes into adult mice efficiently transfected virtually all tissues. In addition to vascular endothelial cells, most of the extravascular parenchymal cells present in many tissues including the lung, spleen, lymph nodes, and bone marrow expressed the transgene without any apparent treatment-related toxicity. The transgene was still expressed in large numbers of cells in multiple tissues for at least 9 weeks after a single injection. Expression could be targeted to specific tissues and cell types, depending on the promoter element used.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,SCH MED,DEPT COMPARAT MED,SEATTLE,WA 98195	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle								ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; DEBS R, 1992, AM J RESP CELL MOL, V7, P406, DOI 10.1165/ajrcmb/7.4.406; DEBS RJ, 1987, BIOCHIM BIOPHYS ACTA, V901, P183, DOI 10.1016/0005-2736(87)90114-3; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JARNAGIN WR, 1992, NUCLEIC ACIDS RES, V20, P4205, DOI 10.1093/nar/20.16.4205; JULIANO RL, 1983, LIPOSOMES, P53; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; MERLINO GT, 1991, FASEB J, V5, P2996, DOI 10.1096/fasebj.5.14.1752364; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZHU N, UNPUB	24	683	864	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					209	211		10.1126/science.7687073	http://dx.doi.org/10.1126/science.7687073			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	7687073				2022-12-01	WOS:A1993LL59600040
J	MULLIGAN, MS; PAULSON, JC; DEFREES, S; ZHENG, ZL; LOWE, JB; WARD, PA				MULLIGAN, MS; PAULSON, JC; DEFREES, S; ZHENG, ZL; LOWE, JB; WARD, PA			PROTECTIVE EFFECTS OF OLIGOSACCHARIDES IN P-SELECTIN-DEPENDENT LUNG INJURY	NATURE			English	Article							ADHESION; NEUTROPHILS; GMP-140; ACTIVATION	NEUTROPHIL recruitment into tissues is a multistep process involving sequential engagement of adhesion molecules, including selectins (E,P,L), which are reactive with oligosaccharides, and the family of beta2 integrins which are reactive with endothelial intercellular adhesion molecules1-3. These processes result in the initial rolling of leukocytes along the endothelial surfaces, followed by the firm attachment of leukocytes to the endothelium. The intravenous infusion of cobra venom factor into rats results in acute lung injury that is neutrophil-dependent, oxygen radical mediated and P-selectin-dependent4,5. Here we report that infusion of sialyl-Lewis X, a ligand for P-selectin6-9, dramatically reduced lung injury and diminished the tissue accumulation of neutrophils, whereas irrelevant oligosaccharides had no such effects. These results suggest that sialyl-Lewis X carbohydrates maybe used as a new strategy for anti-inflammatory therapy.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE RD,ANN ARBOR,MI 48109; CYTEL CORP,SAN DIEGO,CA 92121; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Paulson, James/AAG-3565-2019					BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; ICHIKAWA Y, IN PRESS J AM CHEM S; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SPRAGG RG, 1991, LUNG SCI F, P2003; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	14	323	361	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					149	151		10.1038/364149a0	http://dx.doi.org/10.1038/364149a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	7686631	Green Published			2022-12-01	WOS:A1993LL36700050
J	DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D				DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D			EFFECT OF MEDICAL AUDIT ON PRESCRIPTION OF PALLIATIVE RADIOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article											DODWELL, D (corresponding author), COOKRIDGE HOSP,YORKSHIRE REG CTR CANC TREATMENT,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND.							CRELLIN AM, 1990, CLIN ONCOLOGY, V1, P63; Maher E J, 1990, Health Trends, V22, P78; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; Priestman T J, 1989, Clin Oncol (R Coll Radiol), V1, P39, DOI 10.1016/S0936-6555(89)80010-X; 1991, BRIT J CANCER, V63, P265	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					24	25		10.1136/bmj.307.6895.24	http://dx.doi.org/10.1136/bmj.307.6895.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	7688252	Green Published, Bronze			2022-12-01	WOS:A1993LL36900021
J	GOVAN, JRW; BROWN, PH; MADDISON, J; DOHERTY, CJ; NELSON, JW; DODD, M; GREENING, AP; WEBB, AK				GOVAN, JRW; BROWN, PH; MADDISON, J; DOHERTY, CJ; NELSON, JW; DODD, M; GREENING, AP; WEBB, AK			EVIDENCE FOR TRANSMISSION OF PSEUDOMONAS-CEPACIA BY SOCIAL CONTACT IN CYSTIC-FIBROSIS	LANCET			English	Article								Pulmonary colonisation with Pseudomonas cepacia in patients with cystic fibrosis can be associated with increased morbidity and mortality. The modes of transmission of P cepacia are, however, unclear. We used selective media and phenotypic and genomic typing systems to investigate the acquisition of P cepacia by adults with cystic fibrosis. An analysis of isolates from 210 patients attending regional clinics in Edinburgh and Manchester between 1986 and 1992 showed that the main cause of increased isolations of P cepacia from 1989 was the emergence of an epidemic strain that had spread between patients in both clinics. Epidemiological evidence indicated that social contact was important in spread of the epidemic strain within and between clinics. We suggest that guidelines to limit the acquisition of P cepacia should not be restricted to patients in hospital, and that intimate or frequent social contact is associated with a high risk of cross-infection.	MONSAL HOSP,DEPT CHEST DIS,MANCHESTER,ENGLAND; WESTERN GEN HOSP,RESP UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	GOVAN, JRW (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ANDERSON DJ, 1991, J CLIN MICROBIOL, V29, P648, DOI 10.1128/JCM.29.3.648-649.1991; Brown P, 1993, THORAX, V48, P425; BUTLER SL, 1992, 11TH INT CYST FIBR C; Editorial, 1992, LANCET, V339, P1385; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GLADMAN G, 1992, ARCH DIS CHILD, V67, P192, DOI 10.1136/adc.67.2.192; GOVAN JRW, 1985, J CLIN MICROBIOL, V22, P490, DOI 10.1128/JCM.22.4.490-494.1985; GOVAN JRW, 1992, BRIT MED BULL, V48, P912, DOI 10.1093/oxfordjournals.bmb.a072585; ISLES A, 1984, J PEDIATR-US, V104, P206, DOI 10.1016/S0022-3476(84)80993-2; LEWIN C, 1993, ANTIMICROB AGENTS CH, V37, P123, DOI 10.1128/AAC.37.1.123; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; MILLARJONES L, 1992, LANCET, V340, P491, DOI 10.1016/0140-6736(92)91817-R; NELSON JW, 1991, LANCET, V338, P1525, DOI 10.1016/0140-6736(91)92342-Y; NELSON JW, IN PRESS J MED MICRO; SIMMONDS EJ, 1990, ARCH DIS CHILD, V65, P874, DOI 10.1136/adc.65.8.874; SMITH DL, 1992, LANCET, V339, P252, DOI 10.1016/0140-6736(92)90063-9; TABLAN OC, 1987, CHEST, V91, P527, DOI 10.1378/chest.91.4.527; 1992, NEWSLETTER ASS C APR, P2	18	381	385	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					15	19		10.1016/0140-6736(93)91881-L	http://dx.doi.org/10.1016/0140-6736(93)91881-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	7686239				2022-12-01	WOS:A1993LK98500010
J	JUNTTIBERGGREN, L; LARSSON, O; RORSMAN, P; AMMALA, C; BOKVIST, K; WAHLANDER, K; NICOTERA, P; DYPBUKT, J; ORRENIUS, S; HALLBERG, A; BERGGREN, PO				JUNTTIBERGGREN, L; LARSSON, O; RORSMAN, P; AMMALA, C; BOKVIST, K; WAHLANDER, K; NICOTERA, P; DYPBUKT, J; ORRENIUS, S; HALLBERG, A; BERGGREN, PO			INCREASED ACTIVITY OF L-TYPE CA2+ CHANNELS EXPOSED TO SERUM FROM PATIENTS WITH TYPE-I DIABETES	SCIENCE			English	Article							KILLS IMMATURE THYMOCYTES; LIVER NUCLEI; CELL; CA-2+; ENDONUCLEASE; LINE	Type I diabetes [insulin-dependent diabetes mellitus (IDDM)] is an autoimmune disease associated with the destruction of pancreatic beta cells. Serum from patients with IDDM increased L-type calcium channel activity of insulin-producing cells and of GH3 cells derived from a pituitary tumor. The subsequent increase in the concentration of free cytoplasmic Ca2+ ([Ca2+]i) was associated with DNA fragmentation typical of programmed cell death or apoptosis. These effects of the serum were prevented by adding a blocker of voltage-activated L-type Ca2+ channels. When the serum was depleted of immunoglobulin M (IgM), it no longer affected [Ca2+]i. An IgM-mediated increase in Ca2+ influx may thus be part of the autoimmune reaction associated with IDDM and contribute to the destruction of beta cells in vivo.	KAROLINSKA INST,KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES,DEPT ENDOCRINOL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN; GOTHENBURG UNIV,DEPT MED PHYS,S-41390 GOTHENBURG,SWEDEN; KAROLINSKA INST,DEPT TOXICOL,S-10401 STOCKHOLM 60,SWEDEN; UNIV HOSP UPPSALA,DEPT INTERNAL MED,S-75185 UPPSALA,SWEDEN	Karolinska Institutet; Karolinska University Hospital; University of Gothenburg; Karolinska Institutet; Uppsala University; Uppsala University Hospital			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767				ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARKHAMMAR P, 1989, BIOCHEM BIOPH RES CO, V159, P223, DOI 10.1016/0006-291X(89)92426-1; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; ASHCROFT FM, 1990, PFLUG ARCH EUR J PHY, V415, P504, DOI 10.1007/BF00373633; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAEKKESKOV S, 1986, IMMUNOLOGY ENDOCRINE, P73; COOKE A, 1990, CURR TOP MICROBIOL I, V164, P126; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; HALLBERG A, UNPUB; HESS P, 1984, NATURE, V311, P588; JUNTTIBERGGREN L, UNPUB; KAMPE O, 1989, DIABETES, V38, P1326, DOI 10.2337/diabetes.38.10.1326; LARSSON O, UNPUB; LERNMARK A, 1985, DIABETOLOGIA, V28, P195; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RORSMAN P, 1986, AM J PHYSIOL, V251, pC912, DOI 10.1152/ajpcell.1986.251.6.C912; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SARA S, 1990, BIOPHYS J, V58, P567; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J	27	183	187	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					86	90		10.1126/science.7686306	http://dx.doi.org/10.1126/science.7686306			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	7686306				2022-12-01	WOS:A1993LK43400037
J	MUEGGE, K; VILA, MP; DURUM, SK				MUEGGE, K; VILA, MP; DURUM, SK			INTERLEUKIN-7 - A COFACTOR FOR V(D)J REARRANGEMENT OF THE T-CELL RECEPTOR BETA-GENE	SCIENCE			English	Article							MURINE INTERLEUKIN-7; RECOMBINATION; RAG-1; IL-7; THYMOCYTES; REGION	The diversity of the T cell receptor repertoire is generated by rearrangement of gene elements in immature thymocytes. To identify a thymic signal that induces this rearrangement, a variety of agents were tested for their ability to induce rearrangement of the T cell receptor beta gene in suspensions of thymocytes from mouse embryos at day 14 of gestation. Of 16 agents tested, only interleukin-7 (IL-7) induced V(D)J gene rearrangement and sustained expression of the RAG-1 and RAG-2 genes, which are known to control rearrangement. These data implicate IL-7, a cytokine that is abundantly expressed in embryonic thymus, in driving gene rearrangement during early T cell development.	NCI,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MUEGGE, K (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702, USA.							ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BORN W, 1985, P NATL ACAD SCI USA, V82, P2925, DOI 10.1073/pnas.82.9.2925; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; KAVALER J, 1984, NATURE, V310, P421, DOI 10.1038/310421a0; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MUEGGE K, UNPUB; MUEGGE K, IN PRESS P NATL ACAD; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SUDA T, 1991, J IMMUNOL, V146, P3068; WATSON JD, 1989, J IMMUNOL, V143, P1215; WILES MV, 1992, EUR J IMMUNOL, V22, P1037, DOI 10.1002/eji.1830220424; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	25	204	206	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					93	95		10.1126/science.7686307	http://dx.doi.org/10.1126/science.7686307			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	7686307	Green Submitted			2022-12-01	WOS:A1993LK43400039
J	GOULDING, EH; TIBBS, GR; LIU, D; SIEGELBAUM, SA				GOULDING, EH; TIBBS, GR; LIU, D; SIEGELBAUM, SA			ROLE OF H5 DOMAIN IN DETERMINING PORE DIAMETER AND ION PERMEATION THROUGH CYCLIC NUCLEOTIDE-GATED CHANNELS	NATURE			English	Article							K+ CHANNEL; TEA BLOCKADE; CHARYBDOTOXIN; INHIBITOR; RECEPTOR; REGION; MUSCLE; SITE	ION permeation through membrane channels is thought to be governed by a narrow region of the channel pore termed the selectivity filter1, which has been proposed to discriminate among ions by both specific binding and molecular sieving, as determined by pore diameter. Recent evidence suggests that a conserved domain (known as H5, P or SS1-SS2) in voltage-gated potassium2-8, sodium9-13 and calcium12channels contributes to the lining of the pore. Here we investigate whether the H5 domain determines pore diameter and examine the role of pore diameter in controlling ion permeation. These studies rely on differences in single channel conductance, ion selectivity and apparent pore diameter between cyclic nucleotide-gated channels cloned from bovine retina14 and catfish olfactory neurons15. Using chimaeric retinal-olfactory channels, we find that the H5 domain determines these differences in permeation properties, providing structural evidence that the cyclic nucleotide-gated channels are indeed members of the voltage-gated channel family15-17. Moreover, these results show directly that the H5 domain helps form the selectivity filter and that molecular sieving is important in controlling ion permeation.	COLUMBIA UNIV,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute	GOULDING, EH (corresponding author), COLUMBIA UNIV,DEPT PHYSIOL,CTR NEUROBIOL & BEHAV,722 W 168 ST,NEW YORK,NY 10032, USA.							BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEIGENBOTHAM L, 1992, SCIENCE, V258, P1152; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1991, IONIC CHANNELS EXCIT; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; NODDA M, 1989, FEBS LETT, V258, P213; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	22	108	108	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					61	64		10.1038/364061a0	http://dx.doi.org/10.1038/364061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	7686276				2022-12-01	WOS:A1993LK81800057
J	TSUKUMA, H; HIYAMA, T; TANAKA, S; NAKAO, M; YABUUCHI, T; KITAMURA, T; NAKANISHI, K; FUJIMOTO, I; INOUE, A; YAMAZAKI, H; KAWASHIMA, T				TSUKUMA, H; HIYAMA, T; TANAKA, S; NAKAO, M; YABUUCHI, T; KITAMURA, T; NAKANISHI, K; FUJIMOTO, I; INOUE, A; YAMAZAKI, H; KAWASHIMA, T			RISK-FACTORS FOR HEPATOCELLULAR-CARCINOMA AMONG PATIENTS WITH CHRONIC LIVER-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; NON-B HEPATITIS; NON-A; CIGARETTE-SMOKING; ITALIAN PATIENTS; BLOOD-DONORS; ANTIBODIES; PREVALENCE; CIRRHOSIS; CANCER	Background and Methods. To detect potentially curable cases of hepatocellular carcinoma, outpatients with chronic hepatitis or compensated liver cirrhosis who were seen at the Center for Adult Diseases (Osaka, Japan) were examined periodically by means of ultrasonography and measurement of serum alpha-fetoprotein. Risk factors for hepatocellular carcinoma were identified with a Cox proportional-hazards model. Results. A total of 917 patients, 40 to 69 years old, were registered from May 1987 to March 1991. By the end of September 1991, liver cancer had developed in 54. The three-year cumulative risk of liver cancer was 12.5 percent for 240 patients with liver cirrhosis at enrollment and 3.8 percent for 677 patients with chronic hepatitis. Cox regression analysis showed that the risk of liver cancer was increased almost sevenfold in patients with hepatitis B surface antigen (rate ratio, 6.92; 95 percent confidence interval, 2.92 to 16.39) and fourfold in patients with hepatitis C antibody (rate ratio, 4.09; 95 percent confidence interval, 1.30 to 12.85). A high alpha-fetoprotein value at enrollment was also a risk marker for liver cancer. Conclusions. Patients with hepatitis C virus infection have a greatly increased risk of liver cancer. Further studies are required to clarify the roles of other risk factors, including drinking and smoking habits.	CTR ADULT DIS,RES INST,OSAKA 537,JAPAN; CTR CANC DETECT & PREVENT,OSAKA,JAPAN		TSUKUMA, H (corresponding author), CTR ADULT DIS,DEPT FIELD RES,3-3 NAKAMICHI 1 CHOME,HIGASHINARI KU,OSAKA 537,JAPAN.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ADAMI HO, 1992, INT J CANCER, V51, P898, DOI 10.1002/ijc.2910510611; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; COX DR, 1972, J R STAT SOC B, V34, P187; HIRAYAMA T, 1989, CANCER CHEMOTH PHARM, V23, pS114, DOI 10.1007/BF00647254; HIRAYAMA T, 1981, BANBURY REPORT, V7, P409; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HSU HH, 1991, GASTROENTEROLOGY, V101, P1724, DOI 10.1016/0016-5085(91)90413-F; JOHNSON PJ, 1990, J NATL CANCER I, V82, P986, DOI 10.1093/jnci/82.12.986; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASUGAI H, 1985, AM J ROENTGENOL, V144, P243, DOI 10.2214/ajr.144.2.243; KATO N, 1989, P JPN ACAD B-PHYS, V65, P219, DOI 10.2183/pjab.65.219; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P1367; LOK ASF, 1991, HEPATOLOGY, V14, P756, DOI 10.1002/hep.1840140503; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; OSHIMA A, 1984, INT J CANCER, V34, P775, DOI 10.1002/ijc.2910340607; SHIBATA A, 1986, JPN J CANCER RES, V77, P287; TAKEUCHI K, 1990, GENE, V91, P287, DOI 10.1016/0378-1119(90)90102-W; TAKEUCHI K, 1990, NUCLEIC ACIDS RES, V18, P4626, DOI 10.1093/nar/18.15.4626; TANAKA K, 1991, CANCER RES, V51, P2842; TRICHOPOULOS D, 1980, JNCI-J NATL CANCER I, V65, P111; TSUKUMA H, 1990, INT J CANCER, V45, P231, DOI 10.1002/ijc.2910450205; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; YU MW, 1991, CANCER RES, V51, P5621; 1991, KOSEI NO SHIHYO, V38, P43; 1991, 5TH OS CANC REG PREF	30	983	1007	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1797	1801		10.1056/NEJM199306243282501	http://dx.doi.org/10.1056/NEJM199306243282501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	7684822	Green Submitted, Green Published			2022-12-01	WOS:A1993LH21000001
J	IMAMOTO, A				IMAMOTO, A			DISRUPTION OF THE CSK GENE, ENCODING A NEGATIVE REGULATOR OF SRC FAMILY TYROSINE KINASES, LEADS TO NEURAL-TUBE DEFECTS AND EMBRYONIC LETHALITY IN MICE	CELL			English	Article							HUMAN-COLON CARCINOMA; PP60C-SRC EXPRESSION; MOUSE-BRAIN; RAT-BRAIN; C-SRC; PHOSPHORYLATION; PROTEIN; ACTIVATION; P60C-SRC; PROTOONCOGENE	All Src family non-receptor tyrosine kinases are negatively regulated by phosphorylation at a carboxy-terminal tyrosine. To analyze the significance of this regulation during development, we have generated mice deficient in Csk, a kinase that phosphorylates this tyrosine, by gene targeting in embryonic stem cells. Homozygous mutant embryos exhibit a complex phenotype that includes defects in the neural tube and die between day 9 and day 10 of gestation. Cells derived from these embryos exhibit an order of magnitude increase in activity of Src and the related Fyn kinase. Phosphorylation at the carboxy-terminal tyrosine of Src was reduced but not eliminated and was accompanied by increased phosphorylation at another key tyrosine residue. These results demonstrate that Src family kinase activity is critically dependent on phosphorylation by Csk and suggest that the regulation of kinase activity may be essential during embryogenesis.	BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute			Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOULTER CA, 1991, DEVELOPMENT, V111, P357; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P424; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P124; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSTON JG, 1989, P NATL ACAD SCI USA, V86, P1066, DOI 10.1073/pnas.86.3.1066; Kaufman M.H., 1992, ATLAS MOUSE DEV; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LUMSDEN A, 1991, CELL, V64, P471, DOI 10.1016/0092-8674(91)90226-O; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MACAULEY A, 1993, ONCOGENE, V8, P117; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MARIN O, 1991, J BIOL CHEM, V266, P17798; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; OKADA M, 1991, J BIOL CHEM, V266, P24249; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; OUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	62	366	373	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1117	1124		10.1016/0092-8674(93)90641-3	http://dx.doi.org/10.1016/0092-8674(93)90641-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	7685657				2022-12-01	WOS:A1993LH54800008
J	CAPEL, B; SWAIN, A; NICOLIS, S; HACKER, A; WALTER, M; KOOPMAN, P; GOODFELLOW, P; LOVELLBADGE, R				CAPEL, B; SWAIN, A; NICOLIS, S; HACKER, A; WALTER, M; KOOPMAN, P; GOODFELLOW, P; LOVELLBADGE, R			CIRCULAR TRANSCRIPTS OF THE TESTIS-DETERMINING GENE SRY IN ADULT-MOUSE TESTIS	CELL			English	Article							SEX-DETERMINING REGION; MESSENGER-RNA; TRANSLATION; DROSOPHILA; EXPRESSION; ENCODES; PROTEIN; LETHAL; INITIATION; SEQUENCE	Sry is expressed at higher levels in the adult testis, where no function has been determined, than in the genital ridge, its critical site of action. cDNA and 5' RACE clones isolated from testis or from Sry-transfected cell lines have an unusual structure, with 3' sequences located in a 5' position. RNAase protection assays and reverse transcription polymerase chain reactions confirmed that these unusual RNA molecules represent the most abundant transcript in testis. Furthermore, oligonucleotide hybridization and RNAase H digestion proved that these Sry RNA molecules are circular. Similar transcripts were detected in the testes of mice with Mus musculus musculus, Mus musculus domesticus, and Mus spretus Sry genes. The circular RNA is found in the cytoplasm but is not substantially bound to polysomes. We suggest that the circles arise from normal splicing processes as a consequence of the unusual genomic structure surrounding the Sry locus in the mouse.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND	University of Cambridge	CAPEL, B (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND.		Koopman, Peter A/C-9416-2009	Koopman, Peter A/0000-0001-6939-0914; Swain, Amanda/0000-0001-8666-1608; Lovell-Badge, Robin/0000-0001-9364-4179; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808	Medical Research Council [MC_U117562207] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BERTA P, 1990, NATURE, V348, P248; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLD P, 1981, BIOCHEMISTRY-US, V20, P4871; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HAWKINS JR, 1992, AM J HUM GENET, V51, P979; HAYFLICK JS, 1989, NUCLEIC ACIDS RES, V17, P6403, DOI 10.1093/nar/17.15.6403; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAYTON MG, 1984, BRIT J CANCER, V49, P415, DOI 10.1038/bjc.1984.67; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RIO D C, 1992, Current Opinion in Cell Biology, V4, P444, DOI 10.1016/0955-0674(92)90010-A; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAFURI SR, 1993, IN PRESS J CELL BIOC; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	49	807	876	4	77	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					1019	1030		10.1016/0092-8674(93)90279-Y	http://dx.doi.org/10.1016/0092-8674(93)90279-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	7684656	Bronze			2022-12-01	WOS:A1993LF06100017
J	KOBAYASHI, S; AMIKURA, R; OKADA, M				KOBAYASHI, S; AMIKURA, R; OKADA, M			PRESENCE OF MITOCHONDRIAL LARGE RIBOSOMAL-RNA OUTSIDE MITOCHONDRIA IN GERM PLASM OF DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							MATERNAL-EFFECT MUTATIONS; INSITU HYBRIDIZATION; POLAR GRANULES; EMBRYOS; GENE; CELLS; SEGMENTATION; LOCALIZATION; PATTERN; NANOS	Mitochondrial large ribosomal RNA (mtlrRNA) has been identified as a cytoplasmic factor that induces pole cell formation in embryos whose ability to form a germ line has been abolished by treatment with ultraviolet light. In situ hybridization analyses reveal that mtlrRNA is enriched in germ plasm and is tightly associated with polar granules, the distinctive organelles of germ plasm, which supports the idea that mtlrRNA functions in pole cell formation. This suggests that a product from the mitochondrial genome, along with nuclear products, participates in a key event in embryonic development: determination of the germ line.			KOBAYASHI, S (corresponding author), UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN.							BINDER M, 1986, J CELL BIOL, V102, P1646, DOI 10.1083/jcb.102.5.1646; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; CLARY DO, 1985, NUCLEIC ACIDS RES, V13, P4029, DOI 10.1093/nar/13.11.4029; DING DF, COMMUNICATION; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; HAY B, 1988, DEVELOPMENT, V103, P625; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KOBAYASHI S, 1990, NUCLEIC ACIDS RES, V18, P4592, DOI 10.1093/nar/18.15.4592; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; KOBAYASHI S, UNPUB; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1992, SCIENCE, V255, P1216, DOI 10.1126/science.1372132; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; OKADA M, 1974, DEV BIOL, V37, P43, DOI 10.1016/0012-1606(74)90168-7; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; UNDERWOOD EM, 1980, DEV BIOL, V77, P303, DOI 10.1016/0012-1606(80)90476-5; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	24	135	138	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1521	1524		10.1126/science.7684857	http://dx.doi.org/10.1126/science.7684857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	7684857				2022-12-01	WOS:A1993LF05800042
J	TAN, RY; CHEN, L; BUETTNER, JA; HUDSON, D; FRANKEL, AD				TAN, RY; CHEN, L; BUETTNER, JA; HUDSON, D; FRANKEL, AD			RNA RECOGNITION BY AN ISOLATED ALPHA-HELIX	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL NUCLEAR RIBONUCLEOPROTEIN; HIV-1 REV PROTEIN; TAT PROTEIN; CRYSTAL-STRUCTURE; BINDING DOMAIN; CIRCULAR-DICHROISM; DNA-BINDING; AMINO-ACIDS; SYNTHETASE	A 17 amino acid peptide containing the arginine-rich region of the HIV Rev protein binds specifically to Rev response element (RRE) RNA. Even though it is highly charged, the peptide forms an alpha helix in solution, but only when its N- and C-termini are modified to provide favorable electrostatic interactions with the helix macrodipole. Binding affinity for IIB RNA (the primary binding site within the RRE) increases with alpha helix content, whereas nonspecific binding affinity is independent of helix content. Binding of mutant peptides demonstrates that one threonine, one asparagine, and four arginine side chains are important for sequence-specific recognition. Transactivation of the HIV LTR using Tat-Rev peptide hybrids and the RRE IIB site indicates that the peptide adopts an alpha-helical conformation in vivo. The results suggest that interactions with the RNA backbone may help to orient the alpha helix in the major groove of RNA.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; ARRIS PHARMACEUT, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes	TAN, RY (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIAID NIH HHS [AI29135, AI08591] Funding Source: Medline; NIGMS NIH HHS [GM39589] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135, F32AI008591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039589] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BOHNLEIN E, 1991, J VIROL, V65, P7051; BUETTNER JA, 1993, IN PRESS PEPTIDES 19; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; Creighton TE, 1993, PROTEINS STRUCTURES; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PUGLISI JD, 1993, IN PRESS P NATL ACAD, V90; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RIORDAN FA, 1992, J MOL BIOL, V226, P305, DOI 10.1016/0022-2836(92)90947-I; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TAN RY, 1992, BIOCHEMISTRY-US, V31, P10288, DOI 10.1021/bi00157a016; TAO JS, 1993, P NATL ACAD SCI USA, V90, P1571, DOI 10.1073/pnas.90.4.1571; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Turner DH, 1992, CURR OPIN STRUC BIOL, V2, P334; VANDERGRAAF M, 1992, BIOCHEMISTRY-US, V31, P9177, DOI 10.1021/bi00153a009; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	58	252	257	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					1031	1040		10.1016/0092-8674(93)90280-4	http://dx.doi.org/10.1016/0092-8674(93)90280-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	7684657				2022-12-01	WOS:A1993LF06100018
J	WAGNER, RW; MATTEUCCI, MD; LEWIS, JG; GUTIERREZ, AJ; MOULDS, C; FROEHLER, BC				WAGNER, RW; MATTEUCCI, MD; LEWIS, JG; GUTIERREZ, AJ; MOULDS, C; FROEHLER, BC			ANTISENSE GENE INHIBITION BY OLIGONUCLEOTIDES CONTAINING C-5 PROPYNE PYRIMIDINES	SCIENCE			English	Article							EXPRESSION; RNA	Phosphorothioate oligodeoxynucleotides containing the C-5 propyne analogs of uridine and cytidine bind RNA with high affinity and are potent antisense inhibitors of gene expression. In a cellular assay, gene-specific antisense inhibition occurred at nanomolar concentrations of oligonucleotide, was dose-dependent and exquisitely sensitive to sequence mismatches, and was correlated with the melting temperature and length of oligonucleotide. Activity was independent of RNA target site and cell type but was detectable only when the oligonucleotides were microinjected or delivered with cell-permeabilizing agents. These oligonucleotides may have important applications in therapy and in studies of gene function.			WAGNER, RW (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BISCHOFBERGER N, 1992, SEMIN VIROL, V3, P57; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; DRAPER KG, 1991, Patent No. 12811; FISEHR TL, IN PRESS NUCLEIC ACI; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; FROEHLER BC, 1993, PROTOCOLS OLIGONUCLE, P63; GRAESSMANN M, 1991, NUCLEIC ACIDS RES, V19, P53, DOI 10.1093/nar/19.1.53; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; ROSOLEN A, 1990, CANCER RES, V50, P6316; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; TACK LC, 1989, J VIROL, V63, P3962; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463	17	401	456	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1510	1513		10.1126/science.7684856	http://dx.doi.org/10.1126/science.7684856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	7684856				2022-12-01	WOS:A1993LF05800038
J	HIDE, M; FRANCIS, DM; GRATTAN, CEH; HAKIMI, J; KOCHAN, JP; GREAVES, MW				HIDE, M; FRANCIS, DM; GRATTAN, CEH; HAKIMI, J; KOCHAN, JP; GREAVES, MW			AUTOANTIBODIES AGAINST THE HIGH-AFFINITY IGE RECEPTOR AS A CAUSE OF HISTAMINE-RELEASE IN CHRONIC URTICARIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-SUBUNIT; MAST-CELLS; ANTIBODIES	Background. Most urticarias are induced by vasoactive mediators such as histamine released from mast cells. Although mast cells are activated by allergens through cross-linking of cell-surface-bound IgE, this mechanism does not appear to explain most cases of chronic urticaria, which, when allergic, infectious, drug-induced, or physical causes cannot be identified, are classified as idiopathic. Methods. We recruited 26 patients with chronic idiopathic urticaria, in whom intradermal injection of autologous serum caused a wheal-and-flare response. Serum from four patients that induced marked histamine release from basophils from a donor with very low serum IgE levels was studied with respect to the IgE dependence of the histamine release, the activity of the IgG fractions, and the neutralizing effect of a recombinant preparation of the soluble extracellular domain of the a subunit of the high-affinity IgE receptor (sFcepsilonRIalpha). Results. The histamine-releasing activity of the serum was abolished by passive sensitization of basophils with myeloma IgE, enhanced after dissociation of IgE by treatment with lactic acid, and induced by IgG fractions from the serum of all four patients. Preincubation of the serum and isolated IgG with sFcepsilonRIalpha resulted in almost complete neutralization. Conclusions. Histamine-releasing IgG autoantibodies against the a subunit of the high-affinity IgE receptor are present in the circulation of some patients with chronic urticaria. Autoantibody-induced cross-linking of IgE receptors may be an important mechanism in the pathogenesis of chronic urticaria and other diseases mediated by mast cells.	HOFFMANN LA ROCHE INC,DEPT MOLEC GENET,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110	Roche Holding; Roche Holding			Hide, Michihiro/H-2519-2019	Hide, Michihiro/0000-0002-1569-6034				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BENDTZEN K, 1990, IMMUNOL TODAY, V11, P167, DOI 10.1016/0167-5699(90)90068-K; BLANK U, 1991, J BIOL CHEM, V266, P2639; BOROS P, 1991, J EXP MED, V173, P1473, DOI 10.1084/jem.173.6.1473; CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P221, DOI 10.1111/j.1365-2222.1990.tb02671.x; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HOLGATE ST, 1991, INT ARCH ALLER A IMM, V94, P210, DOI 10.1159/000235363; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MACDONALD SM, 1991, INT ARCH ALLER A IMM, V94, P144, DOI 10.1159/000235347; METZGER H, 1991, CLIN EXP ALLERGY, V21, P269, DOI 10.1111/j.1365-2222.1991.tb01658.x; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P57; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROSMAN H, 1962, ACTA ALLERGOL, V17, P168; SCHWARTZ LB, 1991, J AM ACAD DERMATOL, V25, P190, DOI 10.1016/S0190-9622(08)80468-9; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH BR, 1974, LANCET, V2, P427; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	28	696	720	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1599	1604		10.1056/NEJM199306033282204	http://dx.doi.org/10.1056/NEJM199306033282204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	7683772				2022-12-01	WOS:A1993LE28900004
J	MACCHIA, D; ALMERIGOGNA, F; PARRONCHI, P; RAVINA, A; MAGGI, E; ROMAGNANI, S				MACCHIA, D; ALMERIGOGNA, F; PARRONCHI, P; RAVINA, A; MAGGI, E; ROMAGNANI, S			MEMBRANE TUMOR-NECROSIS-FACTOR-ALPHA IS INVOLVED IN THE POLYCLONAL B-CELL ACTIVATION-INDUCED BY HIV-INFECTED HUMAN T-CELLS	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; HOMOSEXUAL MEN; BINDING; CLONES	INFECTION of CD4+ T cells by human immune deficiency virus-1 (HIV-1) causes severe dysfunction of cellular immunity1-3, but paradoxically results in intense polyclonal activation of B cells, possibly accounting for both hypergammaglobulinaemia and frequent development of B-cell malignancies seen in HIV-infected patients4-7. We have reported that human CD4+ T-cell clones infected with HIV in vitro markedly stimulate immunoglobulin synthesis by B cells through a non-cognate, contact-dependent mechanism8. We show here that HIV-infected T-cell clones do not express the CD40 ligand (CD40L), a molecule critical for non-cognate B-cell activation9, but a small proportion of them do express membrane tumour-necrosis factor (TNF)-alpha. The ability of HIV-infected T-cell clones to induce polyclonal B-cell activation appears to be restricted to TNF-alpha-positive T blasts and is inhibited by antibodies against both TNF-alpha and TNF-alpha receptor. Freshly isolated CD4+ T cells from HIV-infected individuals express TNF-alpha on the cell membrane and induce TNF-alpha-mediated immunoglobulin production by B cells. Thus, membrane TNF-alpha seems to be involved in the polyclonal B-cell activation induced by HIV-infected T cells.	UNIV FLORENCE,DIV CLIN IMMUNOL & ALLERGOL,VIALE MORGAGNI 85,I-50134 FLORENCE,ITALY; UNIV PISA,POLICLIN SANTA CHIARA,IST CLIN MED 1,I-56100 PISA,ITALY	University of Florence; University of Pisa			Almerigogna, Fabio/AAL-4583-2020; Almerigogna, Fabio/A-4636-2012; Parronchi, Paola/AAE-5422-2022; Maggi, Enrico/AAA-8045-2019	Parronchi, Paola/0000-0002-9184-5089; Maggi, Enrico/0000-0002-1824-3583; Macchia, Donatella/0000-0001-9143-4186				AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; AMMANN AJ, 1983, CLIN IMMUNOL IMMUNOP, V27, P315, DOI 10.1016/0090-1229(83)90084-3; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EULER HH, 1985, CLIN EXP IMMUNOL, V59, P267; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; KINKHABWALA M, 1990, J EXP MED, V171, P941, DOI 10.1084/jem.171.3.941; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACCHIA D, 1991, J IMMUNOL, V146, P3413; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; TERPSTRA FG, 1989, EUR J IMMUNOL, V19, P667, DOI 10.1002/eji.1830190415	17	158	158	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					464	466		10.1038/363464a0	http://dx.doi.org/10.1038/363464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	7684824				2022-12-01	WOS:A1993LE93800063
J	SIGMAN, DS; CHEN, CB; GORIN, MB				SIGMAN, DS; CHEN, CB; GORIN, MB			SEQUENCE-SPECIFIC SCISSION OF DNA BY RNAS LINKED TO A CHEMICAL NUCLEASE	NATURE			English	Article							1,10-PHENANTHROLINE COPPER-ION; DELTA-1 CRYSTALLIN GENE; CLEAVAGE; CONVERSION; SITE		UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV PITTSBURGH,DEPT OPHTHALMOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT HUMAN GENET,PITTSBURGH,PA 15213; EYE & EAR INST,PITTSBURGH,PA 15213	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SIGMAN, DS (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.							BRUICE TW, 1991, J AM CHEM SOC, V113, P5446, DOI 10.1021/ja00014a042; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; CHEN CHB, 1993, BIOCONJUGATE CHEM, V4, P69, DOI 10.1021/bc00019a010; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GOYNE TE, 1987, J AM CHEM SOC, V109, P2846, DOI 10.1021/ja00243a060; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LONGMIRE JL, 1987, NUCLEIC ACIDS RES, V15, P859, DOI 10.1093/nar/15.2.859; NICKERSON JM, 1985, J BIOL CHEM, V260, P9100; NICKERSON JM, 1986, J BIOL CHEM, V261, P552; PENDERGRAST PS, 1993, J CELL BIOCHEM, V17, P156; Rosbash M, 1979, Methods Enzymol, V68, P454; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; SIGMAN DS, 1979, J BIOL CHEM, V254, P2269; SIGMAN DS, 1990, ANNU REV BIOCHEM, V59, P207, DOI 10.1146/annurev.biochem.59.1.207; SIGMAN DS, 1993, ACCOUNTS CHEM RES, V26, P98, DOI 10.1021/ar00027a004; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; THOMAS M, 1976, P NATL ACAD SCI USA, V73, P2294, DOI 10.1073/pnas.73.7.2294	24	20	21	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					474	475		10.1038/363474a0	http://dx.doi.org/10.1038/363474a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	7684825				2022-12-01	WOS:A1993LE93800067
J	AMMALA, C; ASHCROFT, FM; RORSMAN, P				AMMALA, C; ASHCROFT, FM; RORSMAN, P			CALCIUM-INDEPENDENT POTENTIATION OF INSULIN RELEASE BY CYCLIC-AMP IN SINGLE BETA-CELLS	NATURE			English	Article							SECRETION; CA-2+; CAMP; EXOCYTOSIS; ACTIVATION; INTERPLAY; CURRENTS	How does cyclic AMP potentiate insulin secretion from pancreatic islet beta-cells? This question is fundamental to understanding how hormones such as glucagon, which elevates cAMP1, stimulate insulin secretion and so contribute to the normal secretory response of the islet2,3. It is well established that a rise in the cytoplasmic Ca2+ concentration ([Ca2+]i) is essential for insulin secretion4 and therefore cAMP has been proposed to act by elevating [Ca2+]i. But studies on permeabilized beta-cells indicate that cAMP increases insulin release even when [Ca2+]i is held constant5,6. We have used microfluorimetry and the patch-clamp technique to measure changes simultaneously in Ca2+ currents, [Ca2+]i and exocytosis7-9 in a single beta-cell in response to cAMP. We show here that cAMP, through activation of protein kinase A, increases Ca2+-influx through voltage-dependent L-type Ca2+ channels, thereby elevating [Ca2+]i and accelerating exocytosis. More importantly, cAMP also promotes insulin release by a direct interaction with the secretory machinery, which accounts for as much as 80% of its effect.	DEPT MED BIOPHYS,MEDICINAREGATAN 11,S-41390 GOTHENBURG,SWEDEN; UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND	University of Oxford			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767				AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; AMMALA C, IN PRESS J PHYSL LON; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P1; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P97; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; FIDLERLIM N, 1990, NATURE, V344, P449; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HENQUIN JC, 1985, ARCH INT PHYSIOL BIO, V93, P37, DOI 10.3109/13813458509104514; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUGHES SJ, 1989, MOL CELL ENDOCRINOL, V65, P35, DOI 10.1016/0303-7207(89)90162-7; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; JONES PM, 1988, BIOCHEM J, V254, P397, DOI 10.1042/bj2540397; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; MARTY A, 1982, P NATL ACAD SCI USA, V79, P6712; PERSAUD SJ, 1990, BIOCHEM BIOPH RES CO, V173, P833, DOI 10.1016/S0006-291X(05)80862-9; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; RORSMAN P, 1988, PFLUGERS ARCH, V412, P587; SIKDAR SK, 1990, FEBS LETT, V273, P150, DOI 10.1016/0014-5793(90)81072-V	23	346	351	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					356	358		10.1038/363356a0	http://dx.doi.org/10.1038/363356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	7684514				2022-12-01	WOS:A1993LD91700055
J	CATARSI, S; DRAPEAU, P				CATARSI, S; DRAPEAU, P			TYROSINE KINASE-DEPENDENT SELECTION OF TRANSMITTER RESPONSES INDUCED BY NEURONAL CONTACT	NATURE			English	Article							IDENTIFIED LEECH NEURON; ACETYLCHOLINE-RECEPTOR; CULTURE; REINNERVATION; CONNECTIONS; SEROTONIN	TRANSMITTER receptors are localized to discrete cellular sites1 such that only those responses appropriate for a particular pattern of inputs are activated2-4. How neurons select between synaptic and extrasynaptic responses during development is not understood. We have investigated how contact during synapse formation between identified leech neurons5-7 selectively suppresses the modulation of extrasynaptic channels by protein kinase C8-10. A microelectrode with an isolated membrane patch containing channels from an uninnervated target neuron was 'crammed'11 into a similar cell contacted by a presynaptic partner. We report here that within a few minutes, the crammed channels were rendered insensitive to activation of protein kinase C, demonstrating the action of a cytoplasmic signal. Treatment of the neurons with selective inhibitors of tyrosine kinases12, which are signalling molecules during normal and oncogenic cellular differentiation13,14, prevented the loss of channel modulation. Thus, tyrosine kinases mediate early functional changes during specific synapse formation that are induced by neuronal contact.	MONTREAL GEN HOSP,RES INST,MONTREAL H3G 1A4,QUEBEC,CANADA	McGill University	CATARSI, S (corresponding author), MCGILL UNIV,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,PQ,CANADA.							ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CATARSI S, 1992, NEURON, V8, P275, DOI 10.1016/0896-6273(92)90294-N; COHEN MW, 1987, J NEUROSCI, V7, P2849; DIETZEL ID, 1986, J PHYSIOL-LONDON, V372, P191, DOI 10.1113/jphysiol.1986.sp016004; DRAPEAU P, 1989, J NEUROBIOL, V20, P312, DOI 10.1002/neu.480200505; DRAPEAU P, 1989, J NEUROSCI, V9, P2502; DRAPEAU P, 1988, J NEUROSCI, V8, P4718; DRAPEAU P, 1990, NEURON, V4, P875, DOI 10.1016/0896-6273(90)90140-B; FUCHS PA, 1981, J PHYSIOL-LONDON, V316, P203, DOI 10.1113/jphysiol.1981.sp013783; GERSCHENFELD HM, 1973, PHYSIOL REV, V53, P1, DOI 10.1152/physrev.1973.53.1.1; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KRAMER RH, 1990, NEURON, V2, P335; MERZ DC, 1992, P ROY SOC B-BIOL SCI, V248, P129, DOI 10.1098/rspb.1992.0052; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEHER E, 1976, J PHYSIOL-LONDON, V258, P705, DOI 10.1113/jphysiol.1976.sp011442; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PURVES D, 1985, PRINCIPLES NEURAL DE; QU Z, 1990, NEURON, V2, P367; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125	29	35	35	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					353	355		10.1038/363353a0	http://dx.doi.org/10.1038/363353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	7684513				2022-12-01	WOS:A1993LD91700054
J	MURGATROYD, FD; CAMM, AJ				MURGATROYD, FD; CAMM, AJ			ATRIAL ARRHYTHMIAS	LANCET			English	Article							SINUS RHYTHM; ANTIARRHYTHMIC DRUGS; VENTRICULAR RATE; FIBRILLATION; FLUTTER; FLECAINIDE; THERAPY; CARDIOVERSION; MAINTENANCE; FRAMINGHAM		ST GEORGE HOSP, SCH MED, DEPT CARDIOL SCI, CRANMER TERR, LONDON SW17 0RE, ENGLAND	St Georges University London								Allessie M.A., 1985, CARDIAC ELECTROPHYSI, P265, DOI DOI 10.1016/J.HRTHM.2012.03.008; ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ANTMAN EM, 1990, J AM COLL CARDIOL, V15, P698, DOI 10.1016/0735-1097(90)90649-A; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; BAILY D, 1992, J AM COLL CARDIOL, V19, P41; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COUMEL P, 1978, ARCH MAL COEUR VAISS, V71, P645; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; CRAWFORD W, 1989, AM J MED, V86, P663, DOI 10.1016/0002-9343(89)90440-3; FALK RH, 1991, ANN INTERN MED, V114, P573, DOI 10.7326/0003-4819-114-7-573; FISHER JD, 1990, ATRIAL ARRHYTHMIAS C, P400; FLEG JL, 1982, CHEST, V81, P302, DOI 10.1378/chest.81.3.302; GILLETTE PC, 1985, JAMA-J AM MED ASSOC, V253, P391, DOI 10.1001/jama.253.3.391; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MOE GK, 1962, ARCH INT PHARMACOD T, V140, P183; MURGATROYD FD, 1993, J AM COLL CARDIOL, V21, P380; MURGATROYD FD, 1993, J AM COLL CARDIOL, V21, P478; NATHAN AW, 1987, CLIN CARDIOL, V10, P317, DOI 10.1002/clc.4960100505; OLSHANSKY B, 1990, J AM COLL CARDIOL, V16, P1639, DOI 10.1016/0735-1097(90)90314-F; OLSHANSKY B, 1988, J AM COLL CARDIOL, V11, P359, DOI 10.1016/0735-1097(88)90102-7; PETERSEN P, 1989, LANCET, V1, P175; PRITCHETT ELC, 1991, AM J CARDIOL, V67, P976, DOI 10.1016/0002-9149(91)90170-P; RAWLES JM, 1990, BRIT HEART J, V63, P225; RAWLES JM, 1990, BRIT HEART J, V63, P157; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SUTTORP MJ, 1990, J AM COLL CARDIOL, V16, P1722, DOI 10.1016/0735-1097(90)90326-K; VANGELDER IC, 1991, AM J CARDIOL, V68, P41, DOI 10.1016/0002-9149(91)90707-R; WELLS JL, 1979, CIRCULATION, V60, P665, DOI 10.1161/01.CIR.60.3.665; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973	37	117	120	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1317	1322						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	7684105				2022-12-01	WOS:A1993LD25300012
J	WANG, N; BUTLER, JP; INGBER, DE				WANG, N; BUTLER, JP; INGBER, DE			MECHANOTRANSDUCTION ACROSS THE CELL-SURFACE AND THROUGH THE CYTOSKELETON	SCIENCE			English	Article							VASCULAR ENDOTHELIAL-CELLS; RAT CARDIAC MYOCYTES; MECHANICAL FORCES; PC-12 NEURITES; SHEAR-STRESS; STRETCH; TENSION; MATRIX; ORGANIZATION; STIMULATION	Mechanical stresses were applied directly to cell surface receptors with a magnetic twisting device. The extracellular matrix receptor, integrin beta1, induced focal adhesion formation and supported a force-dependent stiffening response, whereas nonadhesion receptors did not. The cytoskeletal stiffness (ratio of stress to strain) increased in direct proportion to the applied stress and required intact microtubules and intermediate filaments as well as microfilaments. Tensegrity models that incorporate mechanically interdependent struts and strings that reorient globally in response to a localized stress mimicked this response. These results suggest that integrins act as mechanoreceptors and transmit mechanical signals to the cytoskeleton. Mechanotransduction, in turn, may be mediated simultaneously at multiple locations inside the cell through force-induced rearrangements within a tensionally integrated cytoskeleton.	CHILDRENS HOSP MED CTR,DEPT SURG,ENDERS 1007,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,RESP BIOL PROGRAM,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Ingber, Donald E/AAC-5894-2019; Wang, Ning/B-6966-2008		NCI NIH HHS [CA45548] Funding Source: Medline; NHLBI NIH HHS [HL-33009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BIZAL CL, 1991, J LEUKOCYTE BIOL, V50, P240, DOI 10.1002/jlb.50.3.240; BRODLAND GW, 1991, J BIOMECH ENG, V112, P319; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUXBAUM RE, 1988, J THEOR BIOL, V134, P379, DOI 10.1016/S0022-5193(88)80068-7; CIPRIANO LF, 1991, PHYSIOLOGIST, V34, P72; DEGROOT RP, 1990, J CELL SCI, V97, P33; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FOLKMAN J, 1989, CELL, V58, P803; FOLKMAN J, 1989, J CELL BIOL, V109, P317; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; Fuller B., 1961, PORTFOLIO ARTNEWS AN, V4, P112; FUNG YC, 1988, BIOMECHANICS; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532, DOI 10.1152/ajplegacy.1967.213.6.1532; HARRIS RC, 1992, LAB INVEST, V66, P548; HAY M, 1991, CELL MOTIL CYTOSKEL, V18, P63, DOI 10.1002/cm.970180107; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; Ingber D., 1993, PHYSICAL FORCES MAMM, P61; Ingber D. E, 1989, CELL SHAPE DETERMINA, P3; INGBER DE, 1993, J CELL SCI, V104, P613; Ingber DE., 1985, GENE EXPRESSION NORM, P13; INGBER DE, 1972, P NATL ACAD SCI USA, V69, P3579; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; KACAHR B, 1990, HEARING RES, V45, P179; Koch JC, 1917, AM J ANAT, V21, P177, DOI 10.1002/aja.1000210202; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; McMahon TA., 1984, MUSCLES REFLEXES LOC; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NICKOLLS GH, 1992, J CELL SCI, V102, P753; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PETERSEN NO, 1982, P NATL ACAD SCI-BIOL, V79, P5327, DOI 10.1073/pnas.79.17.5327; PIENTA KJ, 1991, MED HYPOTHESES, V34, P88, DOI 10.1016/0306-9877(91)90072-7; PINTO JG, 1973, J BIOMECH, V6, P597, DOI 10.1016/0021-9290(73)90017-1; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SAMUEL JL, 1990, IN VITRO CELL DEV B, V26, P905; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SIMS JR, 1992, J CELL SCI, V103, P1215; Sokolnikoff IS, 1983, THEORY ELASTICITY; STAMENOVIC D, 1990, PHYSIOL REV, V70, P1117, DOI 10.1152/physrev.1990.70.4.1117; SUMPIO BE, 1988, ARCH SURG-CHICAGO, V123, P1233; TERRACIO L, 1988, IN VITRO CELL DEV B, V24, P53; VALBERG PA, 1984, SCIENCE, V224, P513, DOI 10.1126/science.6710153; VALBERG PA, 1985, J CELL BIOL, V101, P130, DOI 10.1083/jcb.101.1.130; VALBERG PA, 1987, BIOPHYS J, V52, P537, DOI 10.1016/S0006-3495(87)83243-5; WAGNER VT, 1992, P NATL ACAD SCI USA, V89, P3644, DOI 10.1073/pnas.89.8.3644; WARD IM, 1983, MECHANICAL PROPERTIE; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WAYNE R, 1992, J CELL SCI, V101, P611; WILSON LJ, 1990, J COMP NEUROL, V296, P343, DOI 10.1002/cne.902960302; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861; WOLOSEWICK JJ, 1979, J CELL BIOL, V82, P114, DOI 10.1083/jcb.82.1.114; YAHARA I, 1972, P NATL ACAD SCI USA, V69, P608, DOI 10.1073/pnas.69.3.608; ZANER KS, 1989, J CELL BIOL, V109, P2233, DOI 10.1083/jcb.109.5.2233; [No title captured]; [No title captured]; [No title captured]	61	2327	2415	22	563	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1124	1127		10.1126/science.7684161	http://dx.doi.org/10.1126/science.7684161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	7684161				2022-12-01	WOS:A1993LC94200029
J	GABRIEL, SE; CLARKE, LL; BOUCHER, RC; STUTTS, MJ				GABRIEL, SE; CLARKE, LL; BOUCHER, RC; STUTTS, MJ			CFTR AND OUTWARD RECTIFYING CHLORIDE CHANNELS ARE DISTINCT PROTEINS WITH A REGULATORY RELATIONSHIP	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CL CHANNELS; KINASE-C; CONDUCTANCE; CELLS; CAMP; EXPRESSION; EPITHELIA; DISEASE	IN cystic fibrosis (CF), numerous epithelial cell functions are abnormal, including Cl- conductance, sodium absorption, mucin sulphation and enzyme secretion1-4. Although the CF gene product, the cystic fibrosis transmembrane conductance regulator (CFTR), functions as a small linear Cl- channel5-8, it is difficult to attribute such pleiotropic disease manifestations solely to a defect in Cl-conductance. This has led to speculation that CFTR regulates the activity of other proteins. One possible example is the protein kinase A activation of outward rectifying Cl- channels (ORCC), which is defective in membrane patches excised from CF cells9-16. Whether CFTR regulates the activity of an independent anion channel is debatable, because ORCC occur exclusively in excised membrane patches and could be an excision-induced molecular derivative of CFTR. 'Knockout' mice that lack CFTR17,18 provide a means to define the relationship between CFTR and ORCC. Here we report that ORCC are present in CFTR(-/-) mouse nasal epithelial cells and thus cannot be a derivative of the CFTR molecule. Also ORCC were regulated by protein kinase A in membrane patches from normal but not CFTR(-/-) cells. These observations are the first, to our knowledge definitive demonstration that CFTR regulates the activity of another protein.			GABRIEL, SE (corresponding author), UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599, USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FISCHER H, IN PRESS PFLUEGERS A; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; HAWS C, 1992, PEDIATR PULM S, V8, P253; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRAUSS RD, 1992, EMBO J, V11, P875, DOI 10.1002/j.1460-2075.1992.tb05125.x; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LUCKACS GL, 1992, J BIOL CHEM, V267, P14568; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; MORRIS AP, 1992, PULMONOL S, V8, P247; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1991, AM J PHYSIOL-GASTR L, V261, P992; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277	32	253	260	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					263	266		10.1038/363263a0	http://dx.doi.org/10.1038/363263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	7683773				2022-12-01	WOS:A1993LC86600053
J	HERWALDT, BL; STOKES, SL; JURANEK, DD				HERWALDT, BL; STOKES, SL; JURANEK, DD			AMERICAN CUTANEOUS LEISHMANIASIS IN UNITED-STATES TRAVELERS	ANNALS OF INTERNAL MEDICINE			English	Article						LEISHMANIASIS, CUTANEOUS; TRAVEL; TREES; MEXICO; CENTRAL AMERICA	DIAGNOSIS; GUATEMALA; WORLD; ULCER	Objective: To characterize the exposures and practices of U.S. travelers who acquired cutaneous leishmaniasis in the Americas and to highlight problems they encountered in seeking medical care from U.S. physicians. Design: A retrospective review of Centers for Disease Control and Prevention Drug Service records and a telephone survey of patients. Patients: Fifty-nine civilian U.S. travelers with American cutaneous leishmaniasis for whom the Drug Service released sodium stibogluconate between 1 January 1985 and 30 April 1990; 58 travelers (98%) were interviewed. Main Measurements: Travel destination, exposure duration, knowledge about leishmaniasis, and time from noticing skin lesions to release of drug. Results: Overall, travelers acquired leishmaniasis in as many as 14 countries; 33 of 59 travelers (56%) were infected in Mexico or Central America. Twenty-seven travelers (46%) were conducting field studies and 23 (39%) were tourists, visitors, or tour guides. At least 15 persons (26% of the 58 interviewed travelers) were in forested areas for 1 week or less; at least 6 of these persons had a maximum exposure of 2 days. Ten persons (17%) were home at least 1 month before they noticed skin lesions. Patients consulted from one to seven physicians (mean, 2.1 physicians) before leishmaniasis was diagnosed. Overall, the median time from noticing lesions to the release of drug was 112 days (range, 13 to 1022 days); however, the median was only 55 days for 13 patients (22%) unusually knowledgeable about leishmaniasis and was a maximum of 60 days for 16 patients (28%) (including 7 of the 13 unusually knowledgeable patients) who generally consulted physicians exceptionally knowledgeable about infectious and tropical diseases. Conclusions: Travelers to forested areas in Central America and Texas and their physicians need to be educated about the risk for acquiring leishmaniasis even during short stays; effective preventive measures; and appropriate medical management.			HERWALDT, BL (corresponding author), CTR DIS CONTROL & PREVENT, PARASIT DIS BRANCH, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA.							ANDRADENARVAEZ FJ, 1990, T ROY SOC TROP MED H, V84, P219, DOI 10.1016/0035-9203(90)90262-D; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BERGER RS, 1987, J AM ACAD DERMATOL, V16, P1096, DOI 10.1016/S0190-9622(87)70142-X; BERMAN JD, 1988, REV INFECT DIS, V10, P560; Chulay J D, 1988, Rev Soc Bras Med Trop, V21, P165, DOI 10.1590/S0037-86821988000400002; COPELAND HW, 1990, AM J TROP MED HYG, V43, P257, DOI 10.4269/ajtmh.1990.43.257; DEDET JP, 1987, T ROY SOC TROP MED H, V81, P748, DOI 10.1016/0035-9203(87)90017-4; Desjeux P, 1991, WHOLEISH9130; GARNHAM P. C. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P12, DOI 10.1016/0035-9203(59)90080-X; GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270; GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; LAINSON R., 1963, TRANS ROY SOC TROP MED AND HYG, V57, P242, DOI 10.1016/0035-9203(63)90182-2; MAGUIRE JH, 1983, AM J MED SCI, V285, P32, DOI 10.1097/00000441-198303000-00005; MELBY PC, 1992, CLIN INFECT DIS, V15, P924, DOI 10.1093/clind/15.6.924; MERMEL LA, 1990, J AM ACAD DERMATOL, V23, P1178, DOI 10.1016/S0190-9622(08)80926-7; MORRISJONES SD, 1990, LANCET, V336, P691, DOI 10.1016/0140-6736(90)92187-M; NAVIN TR, 1990, AM J TROP MED HYG, V42, P36, DOI 10.4269/ajtmh.1990.42.36; PARKS A, 1987, J AM ACAD DERMATOL, V17, P855, DOI 10.1016/S0190-9622(87)80295-5; RODGERS MR, 1990, EXP PARASITOL, V71, P267, DOI 10.1016/0014-4894(90)90031-7; SANCHEZ JL, 1992, AM J TROP MED HYG, V47, P47, DOI 10.4269/ajtmh.1992.47.47; TAKAFUJI ET, 1980, AM J TROP MED HYG, V29, P516, DOI 10.4269/ajtmh.1980.29.516; WALTON BC, 1968, AM J TROP MED HYG, V17, P19, DOI 10.4269/ajtmh.1968.17.19; WEIGLE KA, 1987, AM J TROP MED HYG, V36, P489, DOI 10.4269/ajtmh.1987.36.489; 1989, YB TOURISM STATISTIC, V2; 1992, MMWR, V41, P131; 1991, NEW ENGL J MED, V324, P476; 1990, WHO TECHNICAL REPORT, V793; 1990, YB TOURISM STATISTIC, V2	30	68	71	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					779	784		10.7326/0003-4819-118-10-199305150-00004	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	7682386				2022-12-01	WOS:A1993LB64900004
J	TUVESON, DA; CARTER, RH; SOLTOFF, SP; FEARON, DT				TUVESON, DA; CARTER, RH; SOLTOFF, SP; FEARON, DT			CD19 OF B-CELLS AS A SURROGATE KINASE INSERT REGION TO BIND PHOSPHATIDYLINOSITOL 3-KINASE	SCIENCE			English	Article							FACTOR-I RECEPTOR; PROTEIN TYROSINE PHOSPHORYLATION; GROWTH-FACTOR STIMULATION; LYMPHOCYTES-B; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; COMPLEMENT RECEPTOR; PDGF RECEPTOR; MIDDLE-T; ASSOCIATION	Antigen receptors on B and T lymphocytes transduce signals by activating nonreceptor protein tyrosine kinases (PTKs). A family of receptor PTKs contains kinase insert regions with the sequence tyrosine-X-X-methionine (where X is any amino acid) that when phosphorylated mediate the binding and activation of phosphatidylinositol 3-kinase (PI 3-kinase). The CD19 membrane protein of B cells enhances activation through membrane immunoglobulin M (mIgM) and was found to contain a functional analog of the kinase insert region. Ligation of mIgM induced phosphorylation of CD19 and association with PI 3-kinase. Thus, CD19 serves as a surrogate kinase insert region for mIgM by providing the means for PI 3-kinase activation by nonreceptor PTKs.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA	Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	TUVESON, DA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022833, R01AI028191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28191, AI22833] Funding Source: Medline; NIGMS NIH HHS [5T32GM07309] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; NADLER LM, 1983, J IMMUNOL, V131, P244; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TEDDER TF, 1989, J IMMUNOL, V143, P712; VANNOESEL CJM, 1991, J IMMUNOL, V146, P3881; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	54	292	298	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					986	989		10.1126/science.7684160	http://dx.doi.org/10.1126/science.7684160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	7684160				2022-12-01	WOS:A1993LB79100044
J	HAYGOOD, MG; DISTEL, DL				HAYGOOD, MG; DISTEL, DL			BIOLUMINESCENT SYMBIONTS OF FLASHLIGHT FISHES AND DEEP-SEA ANGLERFISHES FORM UNIQUE LINEAGES RELATED TO THE GENUS VIBRIO	NATURE			English	Article							16S RIBOSOMAL-RNA; LUMINOUS BACTERIA; KRYPTOPHANARON-ALFREDI; EVOLUTION; ANOMALOPIDAE; PHYLOGENY; SEAWATER; GENES	BIOLUMINESCENT symbioses range from facultative associations to highly adapted. apparently obligate ones1. The family Anomalopidae (flashlight fishes) encompasses five genera of tropical reef fishes that have large suborbital light organs2. The suborder Ceratioidei (deep-sea anglerfishes) contains 11 families. In nine of these, females have a bioluminescent lure3,4 that contains bacterial symbionts5. In all other fish light-organ symbioses (occuring in 10 families in 5 orders6), the symbionts belong to three Photobacterium species7; nonsymbiotic luminous bacteria are Vibrio species8. The bacteria are extracellular and tightly packed in tubules that communicate with the exterior7, releasing bacteria into the gut of the host or the surrounding sea water. The released bacteria are usually cultivable and can contribute to planktonic populations9,10. Although anomalopids release bacteria9 and ceratioids have pores that would allow release, the fate of these bacteria is unknown and they cannot be cultured by standard isolation techniques. We report here phylogenetic analysis of 16S ribosomal RNA gene sequences from light organs that show that anomalopid and ceratioid symbionts are not known luminous bacteria, but are new groups related to Vibrio spp. They are characterized by host specificity, deep divergence between symbionts from different genera (anomalopids) or families (ceratioids) and, possibly, parallel divergence of hosts and symbionts.			HAYGOOD, MG (corresponding author), UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, DIV MARINE BIOL RES, 0202, LA JOLLA, CA 92093 USA.		Distel, Daniel/A-8047-2017	Distel, Daniel/0000-0002-3860-194X				Bertelsen E., 1986, P1371; BERTELSEN E, 1984, SPEC PUBL AM SOC ICH, V1, P323; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; DORSCH M, 1992, INT J SYST BACTERIOL, V42, P58, DOI 10.1099/00207713-42-1-58; EDWARDS DB, 1991, APPL ENVIRON MICROB, V57, P1082, DOI 10.1128/AEM.57.4.1082-1088.1991; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; HAYGOOD MG, 1986, GENE, V45, P203, DOI 10.1016/0378-1119(86)90255-6; HAYGOOD MG, 1984, MAR BIOL, V78, P249, DOI 10.1007/BF00393010; HAYGOOD MG, 1992, J MAR BIOL ASSOC UK, V72, P149, DOI 10.1017/S0025315400048852; HAYGOOD MG, 1990, ARCH MICROBIOL, V154, P496, DOI 10.1007/BF00245234; Herring P.J., 1987, Journal of Bioluminescence and Chemiluminescence, V1, P147, DOI 10.1002/bio.1170010303; HERRING PJ, 1982, OCEANOGR MAR BIOL, V20, P415; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; LEISMAN G, 1980, SCIENCE, V208, P1271, DOI 10.1126/science.208.4449.1271; MACDONELL MT, 1985, SYST APPL MICROBIOL, V6, P171, DOI 10.1016/S0723-2020(85)80051-5; NEALSON K, 1981, ANN NY ACAD SCI, V361, P76, DOI 10.1111/j.1749-6632.1981.tb54358.x; NEALSON KH, 1984, MICROBIAL ECOL, V10, P69, DOI 10.1007/BF02011596; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P2017, DOI 10.1093/nar/19.suppl.2017; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; OLSEN GJ, 1992, FASTDNAML; ROSENBLATT RH, 1991, P BIOL SOC WASH, V104, P328; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; Stackebrandt E, 1990, NUCL ACID TECHNIQUES, P115; Swofford D., 1990, B ILL NAT HIST SURV; VALLE O, 1990, SYST APPL MICROBIOL, V13, P257, DOI 10.1016/S0723-2020(11)80195-5; WOLFE CJ, 1991, BIOL BULL, V181, P135, DOI 10.2307/1542496	28	65	67	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1993	363	6425					154	156		10.1038/363154a0	http://dx.doi.org/10.1038/363154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	7683390				2022-12-01	WOS:A1993LB80100045
J	ROSE, J; GERKEN, S; LYNCH, S; PISANI, P; VARVIL, T; OTTERUD, B; LEPPERT, M				ROSE, J; GERKEN, S; LYNCH, S; PISANI, P; VARVIL, T; OTTERUD, B; LEPPERT, M			GENETIC SUSCEPTIBILITY IN FAMILIAL MULTIPLE-SCLEROSIS NOT LINKED TO THE MYELIN BASIC-PROTEIN GENE	LANCET			English	Note								The myelin basic- protein (MBP) gene is a candidate locus for disease susceptibility in familial multiple sclerosis. Amplification of a polymorphic tetranucleotide repeat region immediately 5' to MBP exon 1 demonstrated the presence of eight different alleles among members of 14 multiplex multiple sclerosis families (36 affected individuals). Linkage analysis was performed with autosomal dominant and autosomal recessive models, normal individuals with abnormal magnetic resonance scans being scored as either unknown or affected. Cumulative LOD scores were negative for both models of inheritance. The results do not demonstrate linkage between the MBP gene region and multiple sclerosis.	UNIV UTAH,DEPT NEUROL,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	ROSE, J (corresponding author), VET ADM MED CTR,NEUROVIROL RES LAB 151B,SALT LAKE CITY,UT 84148, USA.							BOYLAN KB, 1990, ANN NEUROL, V27, P291, DOI 10.1002/ana.410270311; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; ELDRIDGE R, 1984, NEW ENGL J MED, V311, P948, DOI 10.1056/NEJM198410113111504; LYNCH SG, 1990, NEUROLOGY, V40, P900, DOI 10.1212/WNL.40.6.900; LYNCH SG, 1992, NEUROLOGY, V42, P839, DOI 10.1212/WNL.42.4.839; MARTIN R, 1990, J IMMUNOL, V145, P540; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; NELSON L M, 1986, Neuroepidemiology, V5, P17, DOI 10.1159/000110809; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A	10	67	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1179	1181		10.1016/0140-6736(93)91003-5	http://dx.doi.org/10.1016/0140-6736(93)91003-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	7683738				2022-12-01	WOS:A1993LB01700005
J	VANDEUREN, M; VANDIJKE, B; KOOPMAN, RJJ; HORREVORTS, AM; MEIS, JFGM; SANTMAN, FW; VANDERMEER, JWM				VANDEUREN, M; VANDIJKE, B; KOOPMAN, RJJ; HORREVORTS, AM; MEIS, JFGM; SANTMAN, FW; VANDERMEER, JWM			RAPID DIAGNOSIS OF ACUTE MENINGOCOCCAL INFECTIONS BY NEEDLE ASPIRATION OR BIOPSY OF SKIN-LESIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BACTERIAL-MENINGITIS; PROGNOSIS; DISEASE; PURPURA; SHOCK	Objectives-To evaluate the usefulness of Gram staining and culture of skin lesions in patients with acute meningococcal infections. Design-Retrospective study. Setting-Community hospital and intensive care unit of a teaching hospital. Subjects-51 patients admitted from 1989 to 1993 with proved meningococcal infections and microbiological examination of specimens from skin lesions. Interventions-Needle aspiration of a skin lesion before start of antibiotic treatment in 26 patients in the community hospital; punch biopsy of skin lesion after start of antibiotic treatment in 25 patients in the teaching hospital. Main outcome measures-Detection of meningococci by Gram staining of specimens from skin lesions according to category of infection (meningococcaemia, meningitis, meningitis with shock, or septic shock without meningitis). Results-Bacteria were detected in the specimen from haemorrhagic skin lesions by culture or Gram staining, or both in 32 (63%) patients. The sensitivity of the Gram stain was 51% and did not differ significantly from its sensitivity in detecting bacteria in cerebrospinal fluid. In meningococcal sepsis, however, a Gram stained skin lesion was significantly more sensitive (72%) than Gram stained cerebrospinal fluid (22%). In patients with meningitis skin lesions gave positive results on staining more often if shock was present. The results for punch biopsy specimens were not affected by antibiotics as Gram staining gave positive results up to 45 hours after the start of treatment and culture gave positive results up to 13 hours. Conclusion-Microbiological examination of skin lesions is informative, especially in patients with sepsis and inconclusive results from cerebrospinal fluid, and may provide a diagnosis in such patients within 45 minutes. It differentiates well between meningitis with and without haemodynamic complications, and the result is not affected by previous antibiotic treatment.	UNIV HOSP NIJMEGEN, DEPT DERMATOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT MED MICROBIOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT INTENS CARE, 6500 HB NIJMEGEN, NETHERLANDS; ST LAURENTIUS HOSP, DEPT MED MICROBIOL, ROERMOND, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	VANDEUREN, M (corresponding author), UNIV HOSP NIJMEGEN, DEPT INTERNAL MED, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		van der Meer, Jos W.M./C-8521-2013; Meis, Jacques F/A-9241-2010	van der Meer, Jos W.M./0000-0001-5120-3690; Meis, Jacques F/0000-0003-3253-6080				[Anonymous], NIPH ANN; APICELLA MA, 1990, PRINCIPLES PRACTICE, P1600; ARGENBRIGHT LW, 1992, J CLIN INVEST, V89, P259, DOI 10.1172/JCI115570; BAXTER P, 1988, LANCET, V1, P1166; BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; Bernhard WG, 1944, J LAB CLIN MED, V29, P273; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BRANDTZAEG P, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P183; CAHALANE SF, 1975, LANCET, V2, P120; DAHLE J S, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P49; DAVIS CE, 1974, J EXP MED, V140, P159, DOI 10.1084/jem.140.1.159; EMPARANZA JI, 1988, CRIT CARE MED, V16, P168, DOI 10.1097/00003246-198802000-00015; GEDDEDAHL TW, 1990, REV INFECT DIS, V12, P359; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; HALSTENSEN A, 1987, SCAND J INFECT DIS, V19, P35, DOI 10.3109/00365548709032375; HILL WR, 1947, JAMA-J AM MED ASSOC, V134, P513, DOI 10.1001/jama.1947.02880230023006; HOALIN NI, 1992, LANCET, V340, P1432; HOYNE AL, 1948, ANN INTERN MED, V28, P248, DOI 10.7326/0003-4819-28-2-248; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; MANIOS S G, 1971, Scandinavian Journal of Infectious Diseases, V3, P127, DOI 10.3109/inf.1971.3.issue-2.06; MCGEJEE WG, 1967, ANN INTERN MED, V67, P250, DOI 10.7326/0003-4819-67-2-250; McLean S, 1931, AM J DIS CHILD, V42, P1053, DOI 10.1001/archpedi.42.5.1053; MERCIER JC, 1988, CRIT CARE MED, V16, P27, DOI 10.1097/00003246-198801000-00006; MOVAT HZ, 1985, HDB ENDOTOXIN, V3, P260; NETTER A, 1917, BRIT J CHILD DIS, V14, P101; NETTER A, 1917, BRIT J CHILD DIS, V14, P264; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; Rubenstein R, 1986, Pediatr Dermatol, V3, P414, DOI 10.1111/j.1525-1470.1986.tb00553.x; SINCLAIR JF, 1987, LANCET, V2, P38; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; TALAN DA, 1988, REV INFECT DIS, V10, P365; TOEWS WH, 1974, AM J DIS CHILD, V127, P173, DOI 10.1001/archpedi.1974.02110210023003; TOMPKINS LS, 1992, NEW ENGL J MED, V327, P1290; TOMPKINS V. N., 1943, Journal of the American Medical Association, V123, P31; TONJUM T, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P175; VANDEUREN M, 1992, CLIN INFECT DIS, V15, P424, DOI 10.1093/clind/15.3.424; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333	37	63	64	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1993	306	6887					1229	1232		10.1136/bmj.306.6887.1229	http://dx.doi.org/10.1136/bmj.306.6887.1229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	7684633	Green Published, Bronze			2022-12-01	WOS:A1993LB80400013
J	LYAMICHEV, V; BROW, MAD; DAHLBERG, JE				LYAMICHEV, V; BROW, MAD; DAHLBERG, JE			STRUCTURE-SPECIFIC ENDONUCLEOLYTIC CLEAVAGE OF NUCLEIC-ACIDS BY EUBACTERIAL DNA-POLYMERASES	SCIENCE			English	Article							SINGLE-STRANDED-DNA; CHAIN-REACTION; THERMUS-AQUATICUS; 5'->3' EXONUCLEASE; AMPLIFICATION; PURIFICATION; GENERATION	Previously known 5' exonucleases of several eubacterial DNA polymerases have now been shown to be structure-specific endonucleases that cleave single-stranded DNA or RNA at the bifurcated end of a base-paired duplex. Cleavage was not coupled to synthesis, although primers accelerated the rate of cleavage considerably. The enzyme appeared to gain access to the cleavage site by moving from the free end of a 5' extension to the bifurcation of the duplex, where cleavage took place. Single-stranded 5' arms up to 200 nucleotides long were cleaved from such a duplex. Essentially any linear single-stranded nucleic acid can be targeted for specific cleavage by the 5' nuclease of DNA polymerase through hybridization with an oligonucleotide that converts the desired cleavage site into a substrate.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,1300 UNIV AVE,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					PHS HHS [30220] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BARGSEID M, 1991, STRATEGIES, V4, P34; CARBALLEIRA N, 1990, BIOTECHNIQUES, V9, P276; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KALEDIN A S, 1981, Biokhimiya, V46, P1576; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEHMAN IR, 1978, ENZYME, V14, P15; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, UNPUB; MATHUR EJ, 1991, NUCLEIC ACIDS RES, V19, P6952, DOI 10.1093/nar/19.24.6952; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEDRINI AM, 1983, J BIOL CHEM, V258, P1536; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SETLOW P, 1972, J BIOL CHEM, V247, P232; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377	31	305	381	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					778	783		10.1126/science.7683443	http://dx.doi.org/10.1126/science.7683443			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	7683443				2022-12-01	WOS:A1993LA74400021
J	MACNICOL, AM; MUSLIN, AJ; WILLIAMS, LT				MACNICOL, AM; MUSLIN, AJ; WILLIAMS, LT			RAF-1 KINASE IS ESSENTIAL FOR EARLY XENOPUS DEVELOPMENT AND MEDIATES THE INDUCTION OF MESODERM BY FGF	CELL			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACTIVIN-A; C-RAF; ACTIVATION; EMBRYOS; RECEPTOR; HOMOLOG	Animal cap explants from Xenopus embryos injected with a dominant negative Raf-1 mutant, termed NAF (not a functional Raf), demonstrated a complete block to basic fibroblast growth factor (FGF)-stimulated mesoderm induction. Activin induction of mesoderm was normal in embryos that expressed NAF. Injection of NAF RNA into 2-cell stage embryos blocked normal development during neurula stages and caused severe posterior truncations in tadpoles. The phenotype induced by NAF could be rescued by coinjection of wild-type raf-I RNA. The NAF mutant functioned by specifically blocking the activation of endogenous Raf kinase activity. These findings suggest that Raf-1 mediates FGF, but not activin, receptor signaling during mesoderm induction and implicate Raf-1 as a key signaling molecule in the development of posterior structure.			MACNICOL, AM (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,PROGRAM EXCELLENCE MOLEC BIOL,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002571, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43821, K11HL02571-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTABA AR, 1989, NATURE, V341, P33; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRUDERJT, 1992, GENE DEV, V6, P545; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COUGHLIN SR, 1988, J BIOL CHEM, V263, P1; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HOPWOOD ND, 1990, BIOESSAYS, V12, P465, DOI 10.1002/bies.950121003; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MATTHEWS LS, 1991, CELL, V65, P973; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAPP UR, 1991, ONCOGENE, V6, P495; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SYMES K, 1987, DEVELOPMENT, V101, P339; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; UENO H, 1992, J BIOL CHEM, V267, P1470; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	62	182	182	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					571	583		10.1016/0092-8674(93)90143-E	http://dx.doi.org/10.1016/0092-8674(93)90143-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	7683975				2022-12-01	WOS:A1993LA74300017
J	RESSLER, KJ; SULLIVAN, SL; BUCK, LB				RESSLER, KJ; SULLIVAN, SL; BUCK, LB			A ZONAL ORGANIZATION OF ODORANT RECEPTOR GENE-EXPRESSION IN THE OLFACTORY EPITHELIUM	CELL			English	Article							2-DEOXYGLUCOSE METHOD; BULB; RAT; PROJECTIONS; PATTERNS; NEURONS; NERVES; MOUSE; MODEL; DIFFERENTIATION	The mechanisms by which mammals discriminate a vast array of diverse odors are poorly understood. To gain insight into the organizational strategies underlying this discriminatory capacity, we have examined the spatial distribution of odorant receptor RNAs in the mouse olfactory epithelium. We have observed topographically distinct patterns of receptor RNAs suggesting that the nasal cavity is divided into a series of expression zones. The zones exhibit bilateral symmetry in the two nasal cavities and are organized along the dorsal-ventral and medial-lateral axes. Within each zone, a neuron may select a gene for expression from a zonal gene set via a stochastic mechanism. The observed zonal patterning may serve as an initial organizing step in olfactory sensory information coding.			RESSLER, KJ (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.		Ressler, Kerry J/N-8741-2018	Ressler, Kerry J/0000-0002-5158-1103	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001662] Funding Source: NIH RePORTER; NIDCD NIH HHS [1-R01-DC01662-01] Funding Source: Medline; NIGMS NIH HHS [2-T32GM07753-14, T32 GM007753] Funding Source: Medline; NINDS NIH HHS [5T32NS07009-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DR, 1972, J MORPHOL, V137, P161, DOI 10.1002/jmor.1051370204; ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ADRIAN ED, 1956, J LARYNGOL OTOL, V70, P1; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; AMOORE JE, 1964, SCI AM, V210, P42, DOI 10.1038/scientificamerican0264-42; [Anonymous], [No title captured]; ASTIC L, 1983, DEV BRAIN RES, V10, P257, DOI 10.1016/0165-3806(83)90142-6; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck L B, 1992, Curr Opin Neurobiol, V2, P282, DOI 10.1016/0959-4388(92)90116-3; Buck LB, 1992, CURR OPIN GENET DEV, V2, P467, DOI 10.1016/S0959-437X(05)80159-5; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CLANCY AN, 1985, CHEM SENSES, V10, P399; CLARK WEL, 1951, J NEUROL NEUROSUR PS, V14, P1, DOI 10.1136/jnnp.14.1.1; COOPERSMITH R, 1986, DEV BRAIN RES, V27, P191, DOI 10.1016/0165-3806(86)90245-2; COSTANZO RM, 1978, BRAIN RES, V139, P327, DOI 10.1016/0006-8993(78)90932-0; CUSCHIERI A, 1975, J ANAT, V119, P277; CUSCHIERI A, 1975, J ANAT, V119, P471; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DASTON MM, 1990, BRAIN RES, V537, P69, DOI 10.1016/0006-8993(90)90340-H; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EDWARDS DA, 1988, EXPERIENTIA, V44, P208, DOI 10.1007/BF01941707; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FREEMAN WJ, 1987, BIOL CYBERN, V56, P139, DOI 10.1007/BF00317988; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; HABERLY LB, 1989, TRENDS NEUROSCI, V12, P258, DOI 10.1016/0166-2236(89)90025-8; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MACKAYSIM A, 1991, EUR J NEUROSCI, V3, P209, DOI 10.1111/j.1460-9568.1991.tb00081.x; MACKAYSIM A, 1991, J NEUROSCI, V11, P979; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MOZELL MM, 1970, J GEN PHYSIOL, V56, P46, DOI 10.1085/jgp.56.1.46; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Sambrook J., 1989, MOL CLONING LAB MANU; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SHARP FR, 1977, J NEUROPHYSIOL, V40, P800, DOI 10.1152/jn.1977.40.4.800; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, V3rd Edn, P133; SKEEN LC, 1977, BRAIN RES, V124, P147, DOI 10.1016/0006-8993(77)90871-X; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STEWART WB, 1987, BRAIN RES, V411, P248, DOI 10.1016/0006-8993(87)91076-6; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	61	847	866	0	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					597	609		10.1016/0092-8674(93)90145-G	http://dx.doi.org/10.1016/0092-8674(93)90145-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	7683976				2022-12-01	WOS:A1993LA74300019
J	KURAHASHI, T; YAU, KW				KURAHASHI, T; YAU, KW			COEXISTENCE OF CATIONIC AND CHLORIDE COMPONENTS IN ODORANT-INDUCED CURRENT OF VERTEBRATE OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							CYCLIC-NUCLEOTIDES; ADENYLATE-CYCLASE; GATED CHANNELS; NEURONS; CILIA; ACTIVATION; MEMBRANE; CONDUCTANCE; NEWT; TRANSDUCTION	ODORANT stimulation leads to a depolarization of olfactory receptor neurons1-3. A mechanism underlying this transduction, which occurs in the sensory cilia3-6, involves a G-protein-mediated increase in adenylyl cyclase activity7-10, and therefore a rise in internal cyclic AMP and consequent opening of a cAMP-gated cation channel on the plasma membrane11-22. Another mechanism, not as well established, involves the opening of an inositol trisphosphate-activated cation channel on the plasma membrane23 as a result of phospholipase C activity24,25. In both cases, an influx of cations is thought to generate the depolarizing receptor potential. We now report, however, that the mechanism is actually more complex. The odorant-induced current appears to contain an inward chloride component also, which is triggered by calcium influx through the cation-selective channel. This newly found chloride component can be as large as the cationic component. The co-existence of cationic and chloride components in the odorant response, possibly unique among sensory transduction mechanisms, may serve to reduce variations in the transduction current resulting from changes in external ionic concentrations around the olfactory cilia. Our finding can explain the long-standing puzzle of why removal of most mucosal cations still does not diminish the amplitude of the olfactory receptor cell response26-28.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University								ALVAREZLEEFMANS FJ, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P109; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; DIONNE VE, 1992, J GEN PHYSIOL, V99, P415, DOI 10.1085/jgp.99.3.415; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GETCHELL TV, 1986, PHYSIOL REV, V66, P772, DOI 10.1152/physrev.1986.66.3.772; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; KLEENE SJ, 1991, J MEMBRANE BIOL, V120, P75, DOI 10.1007/BF01868593; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KOLESNIKOV SS, 1990, FEBS LETT, V266, P96, DOI 10.1016/0014-5793(90)81515-P; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1989, P NATL ACAD SCI USA, V86, P5641, DOI 10.1073/pnas.86.14.5641; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUZUKI N, 1978, COMP BIOCHEM PHYS A, V61, P461; SUZUKI N, 1989, CHEM SENSES, V1, P469; TUCKER D, 1965, COLD SPRING HARB SYM, V30, P207, DOI 10.1101/SQB.1965.030.01.023; YAMASHITA M, 1991, VISUAL NEUROSCI, V6, P399, DOI 10.1017/S0952523800006635; YOSHII K, 1983, BRAIN RES, V274, P239, DOI 10.1016/0006-8993(83)90701-1; ZUFALL F, 1991, J NEUROSCI, V11, P3573	33	264	266	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					71	74		10.1038/363071a0	http://dx.doi.org/10.1038/363071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	7683113				2022-12-01	WOS:A1993LA68200061
J	LU, B; FU, WM; GREENGARD, P; POO, MM				LU, B; FU, WM; GREENGARD, P; POO, MM			CALCITONIN GENE-RELATED PEPTIDE POTENTIATES SYNAPTIC RESPONSES AT DEVELOPING NEUROMUSCULAR-JUNCTION	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CHICK SKELETAL-MUSCLE; EMBRYONIC NEURON; RAPID INDUCTION; INITIAL EVENTS; SPINAL-CORD; PHOSPHORYLATION; MYOTUBES; DESENSITIZATION; CULTURE	PROTEIN phosphorylation is important in synaptic transmission and plasticity1. At the neuromuscular junction, phosphorylation of acetylcholine (ACh) receptor-channels increases the rate of agonist-induced channel desensitization2. In contrast, potentiation of ACh channel activity through protein phosphorylation has not been described. We report here that calcitonin gene-related peptide (CGRP), a neuropeptide present at presynaptic motor nerve terminals3,4, enhances the postsynaptic response at developing neuromuscular junctions by increasing the burst duration of embryonic ACh channels. The effect of CGRP on these ACh channels is mimicked by dibutyryl-cyclic AMP and by cAMP-dependent protein kinase (PKA) and prevented by a specific peptide inhibitor of PKA. Moreover, postsynaptic inhibition of PKA reduced the amplitude and decay time of spontaneous synaptic currents, suggesting that endogenous CGRP may act as a potentiating factor during the early phase of synaptogenesis.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University	LU, B (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021, USA.		Lu, Bai/A-4018-2012	FU, WEN-MEI/0000-0003-4157-8987; Lu, Bai/0000-0001-5418-9759				BREHM P, 1982, DEV BIOL, V91, P93, DOI 10.1016/0012-1606(82)90012-4; BREHM P, 1984, J PHYSIOL-LONDON, V357, P203, DOI 10.1113/jphysiol.1984.sp015497; BREHM P, 1988, ION CHANNEL MODULATO, P345; EUSEBI F, 1985, J CELL BIOL, V100, P1339, DOI 10.1083/jcb.100.4.1339; FERRERMONTIEL AV, 1991, P NATL ACAD SCI USA, V88, P10213, DOI 10.1073/pnas.88.22.10213; FONTAINE B, 1986, NEUROSCI LETT, V71, P59, DOI 10.1016/0304-3940(86)90257-0; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOPFIELD JF, 1988, NATURE, V336, P577; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JENNINGS CGB, 1989, BRAIN RES, V504, P199, DOI 10.1016/0006-8993(89)91357-7; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MASON RT, 1984, NATURE, V308, P653, DOI 10.1038/308653a0; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; PENG HB, 1989, J COMP NEUROL, V290, P533; POPPER P, 1989, BRAIN RES, V496, P180, DOI 10.1016/0006-8993(89)91064-0; ROA M, 1991, NEUROSCIENCE, V41, P563, DOI 10.1016/0306-4522(91)90349-S; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; TABTI N, 1991, CULTURES NERVE CELLS, P37; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V304, P161, DOI 10.1038/304161a0	28	105	105	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					76	79		10.1038/363076a0	http://dx.doi.org/10.1038/363076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	7683114				2022-12-01	WOS:A1993LA68200063
J	KIM, KJ; LI, B; WINER, J; ARMANINI, M; GILLETT, N; PHILLIPS, HS; FERRARA, N				KIM, KJ; LI, B; WINER, J; ARMANINI, M; GILLETT, N; PHILLIPS, HS; FERRARA, N			INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS SUPPRESSES TUMOR-GROWTH INVIVO	NATURE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN	THE development of new blood vessels (angiogenesis) is required for many physiological processes including embryogenesis, wound healing and corpus luteum formation1,2. Blood vessel neoformation is also important in the pathogenesis of many disorders1-5, particularly rapid growth and metastasis of solid tumours3-5. There are several potential mediators of tumour angiogenesis, including basic and acidic fibroblast growth factors, tumour necrosis factor-alpha and transforming factors-alpha and -beta1,2. But it is unclear whether any of these agents actually mediates angiogenesis and tumour growth in vivo. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an angiogenesis inducer released by a variety of tumour cells and expressed in human tumours in situ. To test whether VEGF may be a tumour angiogenesis factor in vivo, we injected human rhabdomyosarcoma, glioblastoma multiforme or leiomyosarcoma cell lines into nude mice. We report here that treatment with a monoclonal antibody specific for VEGF inhibited the growth of the tumours, but had no effect on the growth rate of the tumour cells in vitro. The density of vessels was decreased in the antibody-treated tumours. These findings demonstrate that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.	GENENTECH INC,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERMAN PW, 1989, J VIROL, V63, P3489, DOI 10.1128/JVI.63.8.3489-3498.1989; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIEBERMANN TA, 1987, EMBO J, V6, P1627; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; ROSENTHAL R, 1990, J GROWTH FACTORS, V4, P53; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SENGER DR, 1986, CANCER RES, V46, P5629; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tisher E, 1991, J BIOL CHEM, V266, P11947; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WESTPHAL M, 1987, EXP CELL BIOL, V55, P152	32	3108	3559	4	205	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					841	844		10.1038/362841a0	http://dx.doi.org/10.1038/362841a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	7683111				2022-12-01	WOS:A1993KZ56300057
J	NABEL, EG; YANG, ZY; PLAUTZ, G; FOROUGH, R; ZHAN, X; HAUDENSCHILD, CC; MACIAG, T; NABEL, GJ				NABEL, EG; YANG, ZY; PLAUTZ, G; FOROUGH, R; ZHAN, X; HAUDENSCHILD, CC; MACIAG, T; NABEL, GJ			RECOMBINANT FIBROBLAST GROWTH FACTOR-I PROMOTES INTIMAL HYPERPLASIA AND ANGIOGENESIS IN ARTERIES INVIVO	NATURE			English	Article							GENE-EXPRESSION INVIVO; ENDOTHELIAL-CELLS; PROLIFERATION; SEQUENCE; CORONARY; VESSELS; INJURY; WALL	THE prototype members of the heparin-binding fibroblast growth factor (FGF) family1-6, acidic FGF (FGF-1) and basic FGF (FGF-2), are among the growth factors that act directly on vascular cells to induce endothelial cell growth and angiogenesis. In vivo, the role of the FGF prototypes in vascular pathology has been difficult to determine. We report here the introduction, by direct gene transfer into porcine arteries, of a eukaryotic expression vector encoding a secreted form of FGF-1. This somatic transgenic model defines gene function in the arterial wall in vivo. FGF-1 expression induced intimal thickening in porcine arteries 21 days after gene transfer, in contrast to control arteries transduced with an Escherichia coli beta-galactosidase gene. Where there was substantial intimal hyperplasia, neocapillary formation was detected in the expanded intima. These findings suggest that FGF-1 induces intimal hyperplasia in the arterial wall in vivo and, through its ability to stimulate angiogenesis in the neointima, FGF-1 could stimulate neovascularization of atherosclerotic plaques. Potentially, gene transfer of FGF-1 could also be used as a genetic intervention to improve blood flow to ischaemic tissues in selected clinical settings.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109; AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; AMER RED CROSS,HOLLAND LAB,DEPT EXPTL PATHOL,ROCKVILLE,MD 20855	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; American Red Cross; American Red Cross	NABEL, EG (corresponding author), UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Christian, Haudenschild C/D-1602-2009					ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAPMAN GD, 1992, CIRC RES, V71, P27, DOI 10.1161/01.RES.71.1.27; CLOWES AW, 1986, LAB INVEST, V54, P295; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GAJDUSEK CM, 1989, J CELL PHYSIOL, V139, P570, DOI 10.1002/jcp.1041390317; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LIM CS, 1991, CIRCULATION, V83, P2007, DOI 10.1161/01.CIR.83.6.2007; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; PLAUTZ G, 1991, CIRCULATION, V83, P578, DOI 10.1161/01.CIR.83.2.578; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313	26	335	369	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					844	846		10.1038/362844a0	http://dx.doi.org/10.1038/362844a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	7683112	Green Published			2022-12-01	WOS:A1993KZ56300058
J	TEEM, JL; BERGER, HA; OSTEDGAARD, LS; RICH, DP; TSUI, LC; WELSH, MJ				TEEM, JL; BERGER, HA; OSTEDGAARD, LS; RICH, DP; TSUI, LC; WELSH, MJ			IDENTIFICATION OF REVERTANTS FOR THE CYSTIC-FIBROSIS DELTA-F508 MUTATION USING STE6-CFTR CHIMERAS IN YEAST	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR CHLORIDE CHANNEL; MULTIDRUG RESISTANCE; STRUCTURAL MODEL; GENE; CELLS; EXPRESSION; TRANSPORT; PROTEIN; PHOSPHORYLATION	Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis; the most common mutation is deletion of phenylalanine at position 508 (DELTAF508). We constructed STE6-CFTR chimeras with portions of the first nucleotide-binding domain (NBD1) of the yeast STE6 a-factor transporter replaced by portions of CFTR NBD1. The chimeras were functional in yeast, but mating efficiency decreased when DELTAF508 was introduced into NBD1. We isolated two DELTAF508 revertant mutations (R553M and R553Q) that restored mating; both were located within the CFTR NBD1 sequence. Introduction of these revertant mutations into human CFTR partially corrected the processing and Cl- channel gating defects caused by the DELTAF508 mutation. These results suggest that the NBD1s of CFTR and STE6 share a similar structure and function and that, in CFTR, the regions containing F508 and R553 interact. They also indicate that the abnormal conformation produced by DELTAF508 can be partially corrected by additional alterations in the protein.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA	Howard Hughes Medical Institute; University of Iowa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	TEEM, JL (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Tsui, Lap-chee/A-1081-2010	Berger, Herbert/0000-0003-4383-2643; Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DORK T, 1991, HUM GENET, V87, P441; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	40	151	166	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					335	346		10.1016/0092-8674(93)90233-G	http://dx.doi.org/10.1016/0092-8674(93)90233-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	7682896				2022-12-01	WOS:A1993KY50500014
J	VALIUS, M; KAZLAUSKAS, A				VALIUS, M; KAZLAUSKAS, A			PHOSPHOLIPASE-C-GAMMA-1 AND PHOSPHATIDYLINOSITOL-3 KINASE ARE THE DOWNSTREAM MEDIATORS OF THE PDGF RECEPTORS MITOGENIC SIGNAL	CELL			English	Article							GROWTH-FACTOR RECEPTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; C-GAMMA; DNA-SYNTHESIS; BOVINE BRAIN; RAT-LIVER; ASSOCIATION; 3-KINASE	Upon ligand-induced tyrosine phosphorylation, the platelet-derived growth factor (PDGF) receptor (PDGFR) beta subunit associates with PLC-gamma1, RasGAP, PI3K, and a 64 kd protein. To determine the relative role of each of these associated proteins in PDGFR signaling, we constructed a PDGFR mutant (F5) unable to bind any of them and a panel of ''add-back'' mutants that could bind only one of the receptor-associated proteins. F5 PDGFR failed to activate PLC-gamma1, PI3K, or Ras and was unable to trigger DNA synthesis. Permitting association of F5 PDGFR with either PLC-gamma1 or PI3K restored Ras activation and a mitogenic response. Surprisingly, even though binding of the 64 kd protein almost fully restored Ras activation, it did not rescue the receptor's ability to trigger DNA synthesis. Thus Ras activation is insufficient to trigger PDGF-dependent DNA synthesis, and PLC-gamma1 and PI3K are independent downstream mediators of PDGFs mitogenic signal.	NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	National Jewish Health			Valius, Mindaugas/N-1220-2019; Valius, Mindaugas/F-2734-2012	Valius, Mindaugas/0000-0001-8478-8517; 	NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, IN PRESS MOL CELL BI; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLLOY CJ, 1989, CELL, V58, P649; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VALIUS M, 1993, MOL CELL BIOL, V13, P7266; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	68	625	630	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					321	334		10.1016/0092-8674(93)90232-F	http://dx.doi.org/10.1016/0092-8674(93)90232-F			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	7682895				2022-12-01	WOS:A1993KY50500013
J	WANG, JF; DOWNS, WD; CECH, TR				WANG, JF; DOWNS, WD; CECH, TR			MOVEMENT OF THE GUIDE SEQUENCE DURING RNA CATALYSIS BY A GROUP-I RIBOZYME	SCIENCE			English	Article							SELF-SPLICING RNA; TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; ENDORIBONUCLEASE ACTIVITY; RIBONUCLEASE-P; RIBOSOMAL-RNA; SUBSTRATE; YEAST; CLEAVAGE; INVITRO	Ribozymes derived from the self-splicing pre-ribosomal RNA of Tetrahymena act as sequence-specific endonucleases. The reaction involves binding an RNA or DNA substrate by base pairing to the internal guide sequence (IGS) to form helix P1. Site-specific photo-crosslinking localized the 5' end of the IGS in helix P1 to the vicinity of conserved bases between helices P4 and P5, supporting a major feature of the Michel-Westhof three-dimensional structure model. The crosslinked ribozyme retained catalytic activity. When not base-paired, the IGS was still specifically crosslinked, but the major site was 37 angstrom distant from the reactive site in the experimentally supported three-dimensional model. The data indicate that a substantial induced-fit conformational change accompanies P1 formation, and they provide a physical basis for understanding the transport of oligonucleotides to the catalytic core of the ribozyme. The ability of RNA to orchestrate large-scale conformational changes may help explain why the ribosome and the spliceosome are RNA-based machines.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, COMMUNICATION; HERSCHLAG D, UNPUB; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P4411; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LECUYER KA, IN PRESS BIOCHEMISTR; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCHUSTER GB, 1989, NATO ADV SCI I C-MAT, V272, P31; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; Williams K., COMMUNICATION; WILLIAMS KP, 1992, P NATL ACAD SCI USA, V89, P10400, DOI 10.1073/pnas.89.21.10400; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	48	101	106	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					504	508		10.1126/science.7682726	http://dx.doi.org/10.1126/science.7682726			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	7682726				2022-12-01	WOS:A1993KY50400022
J	CHEN, TY; PENG, YW; DHALLAN, RS; AHAMED, B; REED, RR; YAU, KW				CHEN, TY; PENG, YW; DHALLAN, RS; AHAMED, B; REED, RR; YAU, KW			A NEW SUBUNIT OF THE CYCLIC NUCLEOTIDE-GATED CATION CHANNEL IN RETINAL RODS	NATURE			English	Article							VERTEBRATE PHOTORECEPTORS; ACTIVATED CONDUCTANCE; FUNCTIONAL EXPRESSION; ION CHANNELS; TEA BLOCKADE; K+ CHANNELS; GMP; EXCITATION; SEGMENTS; CALCIUM	RETINAL rods respond to light with a membrane hyperpolarization produced by a G-protein-mediated signalling cascade that leads to cyclic GMP hydrolysis and the consequent closure of a cGMP-gated channel that is open in darkness1-7. A protein that forms this channel has recently been purified from bovine retina8 and molecularly cloned9, suggesting that the native cGMP-gated channel might be a homo-oligomer10. Here we report the cloning of another protein from human retina which has only about 30% overall identity to the rod channel subunit. This protein, immunocytochemically localized to rod outer segments, does not form functional channels by itself. However, when co-expressed with the cloned human rod channel protein'', it introduces rapid flickers to the channel openings that are characteristic of the native channel12-16. The hetero-oligomeric channel is also highly sensitive to the blocker L-CiS-diltiazem, like the native channel15,17,18. This new protein thus seems to be another subunit of the native rod channel. The hetero-oligomeric nature of the rod channel means that it is no exception to a common motif shared by other ligand-gated channels.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOMED ENGN, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								BEAN BP, 1990, J NEUROSCI, V10, P11; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES LW, 1992, J GEN PHYSIOL, V100, P783, DOI 10.1085/jgp.100.5.783; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KAUPP UB, 1992, REV PHYSL, V54, P153; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LUHRING H, 1990, NATO ADV SCI I A-LIF, V194, P169; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATTHEWS G, 1986, J NEUROSCI, V6, P2521; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; QUANDT FN, 1991, NEUROSCIENCE, V42, P629, DOI 10.1016/0306-4522(91)90032-J; SHIELLS RA, 1992, P ROY SOC B-BIOL SCI, V247, P21, DOI 10.1098/rspb.1992.0004; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; STRYER L, 1991, J BIOL CHEM, V266, P10711; TORRE V, 1992, P ROY SOC B-BIOL SCI, V250, P209, DOI 10.1098/rspb.1992.0151; WOHLFART P, 1992, J BIOL CHEM, V267, P644; Yau K W, 1991, Curr Opin Neurobiol, V1, P252, DOI 10.1016/0959-4388(91)90086-M; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289; YAU KW, 1986, MEMBRANE CONTROL CEL, P343; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	38	298	304	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1993	362	6422					764	767		10.1038/362764a0	http://dx.doi.org/10.1038/362764a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	7682292				2022-12-01	WOS:A1993KY45000061
J	FALANGA, V; EAGLSTEIN, WH				FALANGA, V; EAGLSTEIN, WH			THE TRAP HYPOTHESIS OF VENOUS ULCERATION	LANCET			English	Article							PERICAPILLARY FIBRIN; SKIN CAPILLARIES; GROWTH; LIPODERMATOSCLEROSIS; FIBROBLAST; CELLS; LEG	The pathogenesis of venous ulceration is unknown. We propose that macromolecules leaking into the dermis as a result of venous hypertension bind to or ''trap'' growth factors and matrix material, which then become unavailable for tissue repair and for the maintenance of tissue integrity.			FALANGA, V (corresponding author), UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,POB 016250,MIAMI,FL 33101, USA.			Falanga, Vincent/0000-0003-2292-2017	NIA NIH HHS [AG 10998] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG010998] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALSLEV E, 1992, BRIT J DERMATOL, V126, P582; BROWSE NL, 1982, LANCET, V2, P243; BUCALO B, 1989, J INVEST DERMATOL, V92, P539; BURNAND KG, 1982, BRIT J SURG, V69, P41, DOI 10.1002/bjs.1800690114; BURNAND KG, 1982, BMJ-BRIT MED J, V285, P1071, DOI 10.1136/bmj.285.6348.1071; CHRISTOPOULOS D, 1989, SURGERY, V106, P829; CLAUDY AL, DETECTIONUNDERGRADED; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DODD HJ, 1985, J ROY SOC MED, V78, P373, DOI 10.1177/014107688507800505; FALANGA V, 1987, ARCH DERMATOL, V123, P620, DOI 10.1001/archderm.123.5.620; FALANGA V, 1992, J DERMATOL SURG ONC, V18, P409, DOI 10.1111/j.1524-4725.1992.tb03694.x; FALANGA V, 1992, J DERMATOL SURG ONC, V18, P604, DOI 10.1111/j.1524-4725.1992.tb03514.x; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; Higley HR, 1992, WOUNDS, V4, P33; HOPKINS NFG, 1983, BRIT MED J, V286, P333, DOI 10.1136/bmj.286.6362.333; KATZ MH, 1991, J AM ACAD DERMATOL, V25, P1054, DOI 10.1016/0190-9622(91)70306-M; PARDES JB, 1990, J INVEST DERMATOL, V94, P563; PARTSCH H, 1984, BRIT J DERMATOL, V110, P249, DOI 10.1111/j.1365-2133.1984.tb07481.x; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCOTT HJ, 1991, BRIT J SURG, V78, P210, DOI 10.1002/bjs.1800780226	20	208	213	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1006	1008		10.1016/0140-6736(93)91085-Z	http://dx.doi.org/10.1016/0140-6736(93)91085-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	7682272				2022-12-01	WOS:A1993KY36800016
J	TAUB, DD; CONLON, K; LLOYD, AR; OPPENHEIM, JJ; KELVIN, DJ				TAUB, DD; CONLON, K; LLOYD, AR; OPPENHEIM, JJ; KELVIN, DJ			PREFERENTIAL MIGRATION OF ACTIVATED CD4+ AND CD8+ T-CELLS IN RESPONSE TO MIP-1-ALPHA AND MIP-1-BETA	SCIENCE			English	Article							LANGERHANS CELLS; FLUORESCEIN ISOTHIOCYANATE; ADHESION RECEPTORS; CYTOKINE FAMILY; DENDRITIC CELLS; LYMPHOCYTES-T; ANTIGEN; INHIBITION; CHEMOTAXIS; SKIN	Recombinant human macrophage inflammatory protein-1alpha (rhMIP-1alpha) and rhMIP-1beta were potent chemoattractants of human T lymphocytes. These rhMIP-1 cytokines attracted only T cells activated by monoclonal antibody to CD3 and did not attract unstimulated lymphocytes. Phenotypic analysis revealed that CD4+ T cells were capable of migrating in response to rhMIP-1beta, whereas rhMIP-1alpha induced chemotaxis of predominantly CD8+ T lymphocytes. Activated naive and memory T cells also migrated in response to rhMIP-1 cytokines. Furthermore, these cytokines enhanced the ability of T cells to bind to an endothelial cell monolayer. These results suggest that rhMIP-1 cytokines preferentially recruit specific T cell subsets during the evolution of the immune response.	NCI,FCRDC,BIOL RESPONSE MODIFIER PROGRAM,EXPTL IMMUNOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAUB, DD (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIER PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702, USA.		Lloyd, Andrew/AAF-6071-2022; Lloyd, Andrew/E-7334-2017; Lloyd, Andrew/AFJ-8960-2022	Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887	PHS HHS [N01-C0-74102] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIBA S, 1990, J IMMUNOL, V145, P2791; BACON KB, 1989, BIOCHEM BIOPH RES CO, V165, P349, DOI 10.1016/0006-291X(89)91076-0; CENTER DM, 1983, J IMMUNOL, V128, P2563; CONLON KC, 1992, J IMMUNOL, V149, P3278; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HYENS RO, 1992, CELL, V69, P11; KORNFELD H, 1985, J IMMUNOL, V134, P3887; KUDO C, 1991, J IMMUNOL, V147, P2196; LARSEN C, 1990, PROG CLIN BIOL RES, V349, P419; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MACATONIA SE, 1986, IMMUNOLOGY, V59, P509; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MIOSSEC P, 1984, J IMMUNOL, V133, P2007; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAPOLITANO M, 1990, J EXP MED, V173, P285; OH KO, 1991, J IMMUNOL, V147, P2978; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PILARO AM, 1990, J IMMUNOL METHODS, V135, P213, DOI 10.1016/0022-1759(90)90275-Z; RUSSELL RJ, 1975, NATURE, V256, P646, DOI 10.1038/256646a0; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAUB DD, UNPUB; TURKA LA, 1990, J IMMUNOL, V144, P1646	28	742	752	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					355	358		10.1126/science.7682337	http://dx.doi.org/10.1126/science.7682337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	7682337				2022-12-01	WOS:A1993KX80000039
J	DESAI, SA; KROGSTAD, DJ; MCCLESKEY, EW				DESAI, SA; KROGSTAD, DJ; MCCLESKEY, EW			A NUTRIENT-PERMEABLE CHANNEL ON THE INTRAERYTHROCYTIC MALARIA PARASITE	NATURE			English	Article							HOST-CELL MEMBRANE; PLASMODIUM-FALCIPARUM; MITOCHONDRIAL-MEMBRANE; ERYTHROCYTIC STAGES; PRECURSORS; TRANSPORT; PATHWAY; CULTURE	DURING its 48-hour cycle inside the red blood cell, the human malaria parasite, Plasmodium falciparum, increases its volume 25-fold and divides asexually. This rapid growth demands large amounts of nutrients, a problem exacerbated by the lower metabolic rate and relative ionic impermeability of the host red blood cell. Direct passage of small nutrients across the two membranes that separate the parasite from the erythrocyte cytosol may be important for parasite development, and has been demonstrated for radiolabelled glucose2, amino acids3,4 and purine nucleosides4-6. Flux studies on plasmodia are limited, however, to suspensions of erythrocyte-free parasites and so cannot be used to examine the individual transport properties of the two membranes involved. Here we use the cell-attached patch clamp method7 to overcome this limitation. After removing the intervening red blood cell membrane and forming gigaohm seals on the small (3-5 mum) parasite, we studied transport across the parasitophorous vacuole membrane (PVM), the outer of the two membranes that separate the parasite from the erythrocyte cytosol. A 140-pS channel which is permeable to both cations and anions was identified on the PVM. This channel is present at high density, is open more than 98 per cent of the time at the resting potential of the PVM, and is permeable to lysine and glucuronate. The channel can readily transport amino acids and monosaccharides across the PVM and may be essential for fulfilling the parasite's metabolic demands.	WASHINGTON UNIV,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT MECH ENGN,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Desai, Sanjay A/B-7110-2009	Desai, Sanjay/0000-0003-2150-2483				BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; GERO AM, 1991, ADV EXP MED BIOL, V309, P169; GINSBERG H, 1990, COMP BIOCHEM PHYS A, V95, P31, DOI 10.1016/0300-9629(90)90006-E; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN BD, 1980, J PARASITOL, V66, P205, DOI 10.2307/3280805; HUNTER M, 1987, NATURE, V327, P522, DOI 10.1038/327522a0; IZUMO A, 1988, COMP BIOCHEM PHYS B, V91, P735, DOI 10.1016/0305-0491(88)90201-5; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; KANAANI J, 1989, J BIOL CHEM, V264, P3194; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LANGRETH SG, 1977, B WORLD HEALTH ORGAN, V55, P171; LEE P, 1988, AM J TROP MED HYG, V39, P157, DOI 10.4269/ajtmh.1988.39.157; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SHERMAN IW, 1977, B WORLD HEALTH ORGAN, V55, P211; SHERMAN IW, 1988, PARASITOLOGY, V96, pS57, DOI 10.1017/S003118200008598X; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; TANABE K, 1990, PARASITOL TODAY, V6, P225, DOI 10.1016/0169-4758(90)90199-E; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRAGER W, 1971, J PROTOZOOL, V18, P392, DOI 10.1111/j.1550-7408.1971.tb03341.x; WIBO M, 1981, J CELL BIOL, V89, P456, DOI 10.1083/jcb.89.3.456; YAMADA KA, 1981, MOL BIOCHEM PARASIT, V3, P253, DOI 10.1016/0166-6851(81)90056-6	29	172	179	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					643	646		10.1038/362643a0	http://dx.doi.org/10.1038/362643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	7681937				2022-12-01	WOS:A1993KX43800052
J	SPOHR, HL; WILLMS, J; STEINHAUSEN, HC				SPOHR, HL; WILLMS, J; STEINHAUSEN, HC			PRENATAL ALCOHOL EXPOSURE AND LONG-TERM DEVELOPMENTAL CONSEQUENCES	LANCET			English	Article							FOLLOW-UP; MATCHED CONTROLS; FETAL; CHILDREN; MOTHERS; IMPACT; GROWTH	Fetal alcohol syndrome (FAS) is a leading cause of congenital mental retardation but little is known about the long-term development and adolescent outcome of children with FAS. In a 10-year follow-up study of 60 patients diagnosed as having FAS in infancy and childhood, we investigated the long-term sequelae of intrauterine alcohol exposure. We found that the characteristic craniofacial malformations of FAS diminish with time, but microcephaly and, to a lesser degree, short stature and underweight (in boys) persist; in female adolescents body weight normalises. Persistent mental retardation is the major sequela of intrauterine alcohol exposure in many cases, and environmental and educational factors do not have strong compensatory effects on the intellectual development of affected children.	UNIV ZURICH,DEPT CHILD & ADOLESCENT PSYCHIAT,CH-8006 ZURICH,SWITZERLAND	University of Zurich	SPOHR, HL (corresponding author), GERMAN RED CROSS,RITTBERG HOSP,DEPT PEDIAT,CARSTENNSTR 58,W-1000 BERLIN 45,GERMANY.							Abel E. L., 1983, FETAL ALCOHOL SYNDRO; ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; ARONSON M, 1985, ACTA PAEDIATR SCAND, V74, P27, DOI 10.1111/j.1651-2227.1985.tb10916.x; CLARREN SK, 1978, NEW ENGL J MED, V298, P1036; DEHAENE P, 1977, REV ALCOOL, P145; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; KYLLERMAN M, 1985, ACTA PAEDIATR SCAND, V74, P20, DOI 10.1111/j.1651-2227.1985.tb10915.x; LANDESMANDWYER S, 1981, NEUROBEH TOXICOL TER, V3, P187; LARGO RH, 1980, HELV PAEDIATR ACTA, V35, P419; LEMOINE P, 1968, QUEST MED, V8, P476; Majewski F, 1976, MMW Munch Med Wochenschr, V118, P1635; NESTLER V, 1981, ALKOHOLEMBRYOPATHIE; QUELETTE EM, 1977, NEW ENGL J MED, V297, P528; SOKOL RJ, 1989, ALCOHOL CLIN EXP RES, V13, P597, DOI 10.1111/j.1530-0277.1989.tb00384.x; SPOHR HL, 1987, NEUROPEDIATRICS, V18, P13, DOI 10.1055/s-2008-1052428; STEINHAUSEN HC, 1982, J DEV BEHAV PEDIATR, V3, P49, DOI 10.1097/00004703-198206000-00001; STREISSGUTH AP, 1985, LANCET, V2, P85; STREISSGUTH AP, 1991, JAMA-J AM MED ASSOC, V265, P1961, DOI 10.1001/jama.265.15.1961; STREISSGUTH AP, 1991, J AM ACAD CHILD PSY, V30, P584, DOI 10.1097/00004583-199107000-00009	20	201	202	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					907	910		10.1016/0140-6736(93)91207-3	http://dx.doi.org/10.1016/0140-6736(93)91207-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	7681518				2022-12-01	WOS:A1993KW98100001
J	BACSKAI, BJ; HOCHNER, B; MAHAUTSMITH, M; ADAMS, SR; KAANG, BK; KANDEL, ER; TSIEN, RY				BACSKAI, BJ; HOCHNER, B; MAHAUTSMITH, M; ADAMS, SR; KAANG, BK; KANDEL, ER; TSIEN, RY			SPATIALLY RESOLVED DYNAMICS OF CAMP AND PROTEIN KINASE-A SUBUNITS IN APLYSIA SENSORY NEURONS	SCIENCE			English	Article							ACTION-POTENTIAL DURATION; CYCLIC-AMP; BEHAVIORAL SENSITIZATION; ADENOSINE 3'=5'-MONOPHOSPHATE; TRANSMITTER RELEASE; REGULATORY SUBUNIT; WITHDRAWAL REFLEX; CATALYTIC SUBUNIT; FACILITATION; SEROTONIN	Cyclic adenosine monophosphate (cAMP)-dependent protein kinase, labeled with fluorescein and rhodamine on the catalytic and regulatory subunits, respectively, was injected into Aplysia sensory neurons either in culture or in intact cell clusters. Energy transfer between the subunits, a measure of cytosolic cAMP concentration ([cAMP]), and compartmentation of the dissociated subunits were monitored by confocal fluorescence microscopy. Bath application of serotonin produced a much greater elevation of [cAMP] in the processes than in the central bodies of the neurons. The resulting gradients must drive a sizable centripetal flux of cAMP because direct microinjection of cAMP showed that it diffused readily. Perinuclear increases in [cAMP] slowly caused the translocation of the freed catalytic subunit into the nucleus to an extent proportional to the percentage of its dissociation from the regulatory subunit.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Howard Hughes Medical Institute; University of California System; University of California San Diego; Columbia University			Bacskai, Brian/AAE-9583-2021					Adams S.R., 1993, FLUORESCENT PROBES B, P133; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BERNIER L, 1982, J NEUROSCI, V2, P1682; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CASTELLUCCI VF, 1980, P NATL ACAD SCI-BIOL, V77, P7492, DOI 10.1073/pnas.77.12.7492; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; COHEN MH, 1975, BIOPHYS J, V15, P753, DOI 10.1016/S0006-3495(75)85852-8; Crank J., 1980, MATH DIFFUSION; DALE N, 1987, J NEUROSCI, V7, P2232; DWORKIN M, 1977, J BIOL CHEM, V252, P864; FROST WN, 1985, P NATL ACAD SCI USA, V82, P9266; GREENBERG SM, 1987, J NEUROSCI, V7, P291; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAYES JS, 1982, J CYCLIC NUCL PROT, V8, P1; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; HOCHNER B, UNPUB; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUANG RC, 1991, J GEN PHYSIOL, V98, P835, DOI 10.1085/jgp.98.4.835; KAANG BK, IN PRESS NEURON; KUPFERMANN I, 1970, SCIENCE, V167, P1743, DOI 10.1126/science.167.3926.1743; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORIMOTO BH, 1991, P NATL ACAD SCI USA, V88, P10835, DOI 10.1073/pnas.88.23.10835; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OCORR KA, 1985, NEUROSCI LETT, V55, P113, DOI 10.1016/0304-3940(85)90004-7; POTTER RL, 1979, J BIOL CHEM, V254, P2413; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; TERASAKI WL, 1977, J BIOL CHEM, V252, P1041; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1990, P R MICROSCOPICAL SO, V25, pS53	38	389	400	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					222	226		10.1126/science.7682336	http://dx.doi.org/10.1126/science.7682336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	7682336				2022-12-01	WOS:A1993KW45200041
J	KENNELL, JC; MORAN, JV; PERLMAN, PS; BUTOW, RA; LAMBOWITZ, AM				KENNELL, JC; MORAN, JV; PERLMAN, PS; BUTOW, RA; LAMBOWITZ, AM			REVERSE-TRANSCRIPTASE ACTIVITY ASSOCIATED WITH MATURASE-ENCODING GROUP-II INTRONS IN YEAST MITOCHONDRIA	CELL			English	Article							CYTOCHROME-OXIDASE; RNA MATURASE; S-CEREVISIAE; SUBUNIT-I; GENE; DNA; EVOLUTION; PROTEINS; ORIGIN; RIBONUCLEOPROTEIN	Group II introns al1 and al2 of the yeast mtDNA cox1 gene encode reverse transcriptase-like proteins that function in RNA splicing and may play a role in intron mobility and excision. We find that ribonucleoprotein particles from yeast mitochondria contain a reverse transcriptase activity that is likely encoded by al1 and al2 and is highly specific for the introns and their flanking exons. Using a mutant strain with elevated activity, we show that the reverse transcriptase uses either excised intron RNA or cox1 pre-mRNA as template and initiates cDNA synthesis near the 3' end of al2 and immediately downstream in E3. Our results suggest that introns al1 and al2 are retroelements, which encode reverse transcriptases that have adapted to function in RNA splicing.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KENNELL, JC (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035510, R01GM031480, R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31480, GM35510, GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER NJ, 1979, J BIOL CHEM, V254, P2471; ANZIANO PQ, 1990, NUCLEIC ACIDS RES, V18, P3233, DOI 10.1093/nar/18.11.3233; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CARIGNANI G, 1986, CURR GENET, V11, P55, DOI 10.1007/BF00389426; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Dujon B., 1989, MOBILE DNA, P861; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; Gargouri A., 1983, MITOCHONDRIA 1983, P259; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KUCK U, 1985, CURR GENET, V9, P373, DOI 10.1007/BF00421608; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1992, CR ACAD SCI III-VIE, V315, P37; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; PEEBLES CL, 1993, IN PRESS J BIOL CHEM; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J., 1989, MOL CLONING LAB MANU; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHERMAN F, 1986, LABORATORY COURSE MA; SIPICZKI M, 1977, MOL GEN GENET, V151, P77, DOI 10.1007/BF00446915; SKELLY PJ, 1991, CURR GENET, V20, P115, DOI 10.1007/BF00312773; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WENZLAU JM, 1989, THESIS OHIO STATE U; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	46	115	119	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					133	146		10.1016/0092-8674(93)90166-N	http://dx.doi.org/10.1016/0092-8674(93)90166-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	7681727				2022-12-01	WOS:A1993KW75300014
J	LASSOUED, K; NUNEZ, CA; BILLIPS, L; KUBAGAWA, H; MONTEIRO, RC; LEBIEN, TW; COOPER, MD				LASSOUED, K; NUNEZ, CA; BILLIPS, L; KUBAGAWA, H; MONTEIRO, RC; LEBIEN, TW; COOPER, MD			EXPRESSION OF SURROGATE LIGHT CHAIN RECEPTORS IS RESTRICTED TO A LATE STAGE IN PRE-B CELL-DIFFERENTIATION	CELL			English	Article							LAMBDA-LIKE GENES; HEAVY-CHAIN; BONE-MARROW; BINDING-PROTEIN; MU-CHAIN; MONOCLONAL-ANTIBODY; SUPPRESSED MICE; LINEAGE CELLS; VPREB GENE; SURFACE	Surrogate light chain (psiLC) genes are transcriptionally active in progenitor B (pro-B) cells before immunoglobulin genes are rearranged. Current hypothetical models suggest that the psiLC proteins may couple with surrogate or conventional heavy chain proteins to form cell surface receptors that signal the progressive differentiation of pro-B, precursor B (pre-B), and immature B cells. Monoclonal antibodies were produced and used to examine the synthesis, expression, intermolecular interaction, and function of psiLC during B cell differentiation. The results indicate that, while psiLC production spans several developmental stages, cell surface expression is confined to a relatively late stage in normal pre-B cell differentiation, during which receptor cross-linkage does not impede cell growth or B cell differentiation.	UNIV ALABAMA, DEPT PEDIAT, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PATHOL, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MICROBIOL, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, HOWARD HUGHES MED INST, BIRMINGHAM, AL 35294 USA; UNIV MINNESOTA, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; University of Minnesota System; University of Minnesota Twin Cities	LASSOUED, K (corresponding author), UNIV ALABAMA, DEPT MED, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA.		Monteiro, Renato C/U-8633-2017	Monteiro, Renato C/0000-0001-5202-5646; LeBien, Tucker/0000-0001-5011-2199	NCI NIH HHS [CA31685, CA13148] Funding Source: Medline; NIAID NIH HHS [AI30879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031685, P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BAUER SR, 1988, EMBO J, V7, P111, DOI 10.1002/j.1460-2075.1988.tb02789.x; BAUER SR, 1991, BLOOD, V78, P1581; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOSSY D, 1991, INT IMMUNOL, V3, P1081, DOI 10.1093/intimm/3.11.1081; Burrows P D, 1990, Semin Immunol, V2, P189; BURROWS PD, 1978, J IMMUNOL, V120, P1526; CHANG H, 1986, J EXP MED, V163, P425, DOI 10.1084/jem.163.2.425; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CIVIN CI, 1984, J IMMUNOL, V133, P157; COOPER MD, 1980, IMMUNOL REV, V52, P29, DOI 10.1111/j.1600-065X.1980.tb00329.x; COOPER MD, 1990, IMMUNOGLOBULIN GENES, P1; DEFRANCO AL, 1982, B T CELL TUMORS BIOL, P445; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P46; EWERT DL, 1984, J IMMUNOL, V132, P2524; FAHEY JL, 1971, ANN NY ACAD SCI, V190, P221, DOI 10.1111/j.1749-6632.1971.tb13537.x; FINDLEY HW, 1982, BLOOD, V60, P1305; FULOP GM, 1983, CELL IMMUNOL, V75, P91, DOI 10.1016/0008-8749(83)90308-8; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HOLLIS GF, 1989, P NATL ACAD SCI USA, V86, P5552, DOI 10.1073/pnas.86.14.5552; ISHIGAMI T, 1992, J IMMUNOL, V148, P360; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KIM KM, 1992, J IMMUNOL, V148, P29; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KIYOTAKI M, 1987, J IMMUNOL, V138, P4150; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIEN TW, 1990, LEUKEMIA, V4, P354; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; MARUYAMA S, 1985, J IMMUNOL, V135, P192; MASON DY, 1991, J IMMUNOL, V147, P2474; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; PULVERTAFT RJV, 1964, LANCET, V1, P238; RALPH P, 1973, J IMMUNOL, V110, P1470; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHIFF C, 1991, BLOOD, V78, P1516; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SMITH RG, 1981, J IMMUNOL, V126, P596; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; TSUBATA T, 1992, INT IMMUNOL, V4, P637, DOI 10.1093/intimm/4.6.637; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; VILLABLANCA JG, 1990, J EXP MED, V172, P325, DOI 10.1084/jem.172.1.325; WORMANN B, 1989, J IMMUNOL, V142, P110; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	71	156	157	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					73	86		10.1016/0092-8674(93)90161-I	http://dx.doi.org/10.1016/0092-8674(93)90161-I			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	7681728				2022-12-01	WOS:A1993KW75300009
J	DECAMPOSLIMA, PO; GAVIOLI, R; ZHANG, QJ; WALLACE, LE; DOLCETTI, R; ROWE, M; RICKINSON, AB; MASUCCI, MG				DECAMPOSLIMA, PO; GAVIOLI, R; ZHANG, QJ; WALLACE, LE; DOLCETTI, R; ROWE, M; RICKINSON, AB; MASUCCI, MG			HLA-A11 EPITOPE LOSS ISOLATES OF EPSTEIN-BARR-VIRUS FROM A HIGHLY A11+ POPULATION	SCIENCE			English	Article							DETECTED MEMBRANE ANTIGEN; BURKITTS-LYMPHOMA CELLS; EBV LATENT GENES; RESTRICTED EXPRESSION; STRUCTURAL PROTEINS; BACTERIOPHAGE-T4; CLEAVAGE; LINES; HEAD	Cytotoxic T lymphocytes (CTLs) control viral infections by recognizing viral peptides presented by major histocompatibility complex (MHC) class I molecules. Human leukocyte antigen (HLA)-A11-restricted CTLs that recognize peptide residues 416 to 424 of the Epstein-Barr virus (EBV) nuclear antigen-4 frequently dominate EBV-induced responses in A11+ Caucasian donors. This epitope is conserved in type A EBV strains from Caucasians and central African populations, where A11 is relatively infrequent. However, strains from highly A11+ populations in New Guinea carry a lysine-to-threonine mutation at residue 424 that abrogates CTL recognition and binding of the peptide to nascent A11 molecules. The results suggest that evolution of a widespread and genetically stable virus such as EBV is influenced by pressure from MHC-restricted CTL responses.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN; UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	Karolinska Institutet; University of Birmingham			Gavioli, Riccardo/K-7594-2016; Rowe, Martin/B-2880-2009; Dolcetti, Riccardo/O-3832-2015; Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019; de Campos-Lima, Pedro Otavio/I-3495-2013	Gavioli, Riccardo/0000-0002-7805-4290; Rowe, Martin/0000-0003-4139-7326; Dolcetti, Riccardo/0000-0003-1625-9853; Masucci, Maria/0000-0002-5541-2809; de Campos-Lima, Pedro Otavio/0000-0001-8024-8628	NCI NIH HHS [2RO1 CA30264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1989, HUM BIOL, V61, P45; COLOMBANI J, 1982, TISSUE ANTIGENS, V20, P161; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DUMAS B, 1975, CLIN CHEM, V21, P1159; GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HIRS C, 1977, ENZYME STRUCTURE, V47, P501; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; MASUCCI MG, 1992, INT IMMUNOL, V4, P1283, DOI 10.1093/intimm/4.11.1283; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MORRIS PJ, 1973, HISTOCOMPATIBILITY T, P267; MOSS D, 1978, INT J CANCER, V23, P618; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIZZO PA, 1978, NATURE, V272, P629, DOI 10.1038/272629a0; POPE JH, 1968, AUST J EXP BIOL MED, V46, P643, DOI 10.1038/icb.1968.171; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SERJEANTSON S, 1989, COLONIZATION PACIFIC, V7, P120; TORSTEINSDOTTIR S, 1986, P NATL ACAD SCI USA, V83, P5620, DOI 10.1073/pnas.83.15.5620; WALLACE LE, 1982, NATURE, V297, P413, DOI 10.1038/297413a0; ZHANG QJ, 1993, P NATL ACAD SCI USA, V90, P2217, DOI 10.1073/pnas.90.6.2217; ZIMBER U, 1986, VIROLOGY, V154, P56, DOI 10.1016/0042-6822(86)90429-0	31	225	226	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					98	100		10.1126/science.7682013	http://dx.doi.org/10.1126/science.7682013			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682013				2022-12-01	WOS:A1993KV42300037
J	LONG, MY; LANGLEY, CH				LONG, MY; LANGLEY, CH			NATURAL-SELECTION AND THE ORIGIN OF JINGWEI, A CHIMERIC PROCESSED FUNCTIONAL GENE IN DROSOPHILA	SCIENCE			English	Article							MOLECULAR EVOLUTION; DNA; PSEUDOGENES; AMPLIFICATION; DUPLICATION; TRANSCRIPTS; RETROPOSONS; POLYMERASE; PRIMER	The origin of new genes includes both the initial molecular events and subsequent population dynamics. A processed Drosophila alcohol dehydrogenase (Adh) gene, previously thought to be a pseudogene, provided an opportunity to examine the two phases of the origin of a new gene. The sequence of the processed Adh messenger RNA became part of a new functional gene by capturing several upstream exons and introns of an unrelated gene. This novel chimeric gene, jingwei, differs from its parent Adh gene in both its pattern of expression and rate of molecular evolution. Natural selection participated in the origin and subsequent evolution of this gene.	UNIV CALIF DAVIS,EVOLUT & ECOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,CTR POPULAT BIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis	LONG, MY (corresponding author), UNIV CALIF DAVIS,GENET SECT,DAVIS,CA 95616, USA.							ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOLDBERG DA, 1982, CELL, V34, P59; Haldane JBS., 1932, CAUSES EVOLUTION; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOLLIS GF, 1982, NATURE, V296, P321, DOI 10.1038/296321a0; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENETICS, V116, P153; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JUKES T H, 1969, P21; Kimura M., 1983, NEUTRAL THEORY MOL E; KREITMAN M, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P204; LACHAISE D, 1988, EVOL BIOL, V22, P159; LANGLEY CH, 1982, P NATL ACAD SCI-BIOL, V79, P5631, DOI 10.1073/pnas.79.18.5631; LANGLEY CH, 1990, POPULATION BIOL GENE, P75; Li W.-H., 1983, P14; Li W-H., 1991, FUNDAMENTALS MOL EVO; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; LONG MW, UNPUB; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MORIYAMA EN, 1992, GENETICS, V130, P855; NEI M, 1981, GENETICS, V97, P145; NEI M, 1987, MOL EVOLUTIONARY GEN, P276; Ohno S., 1970, EVOLUTION GENE DUPLI, DOI [DOI 10.1007/978-3-642-86659-3, 10.1007/978-3-642-86659-3_11]; OHTA T, 1989, GENOME, V31, P304, DOI 10.1139/g89-048; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SULLIVAN DT, 1990, EVOL BIOL, V24, P107; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631; [No title captured]	43	307	318	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					91	95		10.1126/science.7682012	http://dx.doi.org/10.1126/science.7682012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682012				2022-12-01	WOS:A1993KV42300035
J	NURCOMBE, V; FORD, MD; WILDSCHUT, JA; BARTLETT, PF				NURCOMBE, V; FORD, MD; WILDSCHUT, JA; BARTLETT, PF			DEVELOPMENTAL REGULATION OF NEURAL RESPONSE TO FGF-1 AND FGF-2 BY HEPARAN-SULFATE PROTEOGLYCAN	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; CELL-SURFACE; BASEMENT-MEMBRANE; PRECURSOR CELLS; EXPRESSION; RECEPTOR; DIFFERENTIATION; NEURONS	Murine neural precursor cells and cell lines derived from them are stimulated by members of the heparin-binding fibroblast growth factor (FGF) family. The activity of FGF is regulated by heparan sulfate proteoglycans (HSPGs), and this interaction is an essential prerequisite for the binding of growth factor to the signal transducing receptors. Messenger RNA for FGF-2 was detectable in the neuroepithelium at embryonic day 9, and the HSPGs produced by these cells at this time preferentially bound FGF-2. However, at embryonic day 11, when messenger RNA for FGF-1 was first detectable, there was a switch in the binding specificity of the HSPG to FGF-1. Thus, a single species of HSPG undergoes a rapid, tightly controlled change in growth factor-binding specificity concomitant with the temporal expression of the FGFs.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute	NURCOMBE, V (corresponding author), UNIV MELBOURNE,DEPT ANAT & CELL BIOL,PARKVILLE,VIC 3052,AUSTRALIA.		Bartlett, Perry/F-3813-2012					ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ANY AH, 1990, BIOCHEM J, V265, P461; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BERNFIELD ME, 1992, ANN REV CELL BIOL, V8, P1; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; COLE GJ, 1989, EXP CELL RES, V182, P44, DOI 10.1016/0014-4827(89)90278-4; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FU YM, 1991, NEURON, V114, P1261; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KILPATRICK T, 1993, NEURON, V10, P1; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MATTHEW WD, 1985, J NEUROSCI, V5, P1842; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; NURCOMBE V, 1991, SOC NEUR ABSTR, V105, P553; NURCOMBE V, UNPUB; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHNURCH H, 1991, DEVELOPMENT, V111, P1143; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; THOMAS D, 1991, DEV BRAIN RES, V59, P117, DOI 10.1016/0165-3806(91)90091-V; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	386	406	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					103	106		10.1126/science.7682010	http://dx.doi.org/10.1126/science.7682010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682010				2022-12-01	WOS:A1993KV42300039
J	LUSSO, P; MALNATI, MS; GARZINODEMO, A; CROWLEY, RW; LONG, EO; GALLO, RC				LUSSO, P; MALNATI, MS; GARZINODEMO, A; CROWLEY, RW; LONG, EO; GALLO, RC			INFECTION OF NATURAL-KILLER-CELLS BY HUMAN HERPESVIRUS-6	NATURE			English	Article							CHRONIC FATIGUE SYNDROME; HUMAN-IMMUNODEFICIENCY-VIRUS; INVITRO; AIDS; DEFICIENCY; MECHANISM; ANTIGEN	NATURAL killer (NK) cells are a functionally defined subset of non-T, non-B lymphocytes of bone marrow origin, which induce lysis of selected target cells, including neoplastic and virus-infected cells1-3. The NK cell function provides an important mechanism of primary defence against viruses in vivo, as demonstrated by the occurrence of multiple herpesvirus infections in patients congenitally lacking NK cells4,5. Here we show that functionally competent CD3- NK clones can be productively infected by human herpesvirus 6 (HHV-6)6, a T-lymphotropic DNA virus7 that may play a role in the acquired immunodeficiency syndrome (AIDS)8 and in the chronic fatigue syndrome9, two disorders associated with a defective NK cell activity10-15. The infection is cytopathic and induces de novo expression of CD4, an antigen not expressed within the NK lineage16,17, thereby predisposing NK cells to infection by human immunodeficiency virus type 1 (HIV-1). These results provide evidence that a herpesvirus can directly target and kill NK cells, a potential strategy to suppress the natural anti-viral immunity of the host.	NIAID, IMMUNOGENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LUSSO, P (corresponding author), NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA.		Malnati, Mauro/AAN-4207-2020; Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728; Garzino-Demo, Alfredo/0000-0002-4095-6950; Malnati, mauro/0000-0001-5355-1680				AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BONAVIDA B, 1986, J IMMUNOL, V137, P1157; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CHEHIMI J, 1991, J VIROL, V65, P1812, DOI 10.1128/JVI.65.4.1812-1822.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FLEISHER G, 1982, J PEDIATR-US, V100, P727, DOI 10.1016/S0022-3476(82)80572-6; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; LANIER LL, 1986, LEUKOCYTE TYPING 2, V3, P157; LUSSO P, 1991, J IMMUNOL, V147, P685; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; LUSSO P, 1992, HUMAN HERPESVIRUS, V6, P121; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; MORETTA A, 1990, J EXP MED, V171, P695, DOI 10.1084/jem.171.3.695; OLDSTONE MBA, 1991, J VIROL, V65, P6381, DOI 10.1128/JVI.65.12.6381-6386.1991; RITZ J, 1988, ADV IMMUNOL, V42, P181, DOI 10.1016/S0065-2776(08)60845-7; ROBERTSON MJ, 1990, BLOOD, V76, P2421; ROBINSON WE, 1988, HUM PATHOL, V19, P535, DOI 10.1016/S0046-8177(88)80200-4; ROOK AH, 1983, J CLIN INVEST, V72, P398, DOI 10.1172/JCI110981; RUSCETTI FW, 1986, J IMMUNOL, V136, P3619; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SIRIANNI MC, 1988, J IMMUNOL, V140, P2565; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	29	172	174	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					458	462		10.1038/362458a0	http://dx.doi.org/10.1038/362458a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	7681936				2022-12-01	WOS:A1993KV42400087
J	HERRERO, C; VICENTE, A; BRUGUERA, M; ERCILLA, MG; BARRERA, JM; VIDAL, J; TERES, J; MASCARO, JM; RODES, J				HERRERO, C; VICENTE, A; BRUGUERA, M; ERCILLA, MG; BARRERA, JM; VIDAL, J; TERES, J; MASCARO, JM; RODES, J			IS HEPATITIS-C VIRUS-INFECTION A TRIGGER OF PORPHYRIA-CUTANEA-TARDA	LANCET			English	Note							HEPATOCELLULAR-CARCINOMA; PATHOLOGY; LIVER	The causes of liver disease, ranging from fatty changes to cirrhosis and hepatocellular carcinoma, in prophyria cutanea tarda (PCT) remain unclear. We tested 100 consecutive PCT patients for antibodies to hepatitis C virus (HCV) by enzyme-linked immunosorbent assay and a recombinant immunoblot assay. 75 (79%) patients with sporadic PCT but none of 5 with familial PCT were positive. HCV RNA was found in serum of all 18 anti-HCV-positive patients tested. There were no significant differences in the prevalence of anti-HCV between treated and untreated patients or between those with and without various HCV risk factors. The frequency of anti-HCV increased with the severity of liver histology. These findings implicate HCV in the aetiology of PCT-associated liver disease.	UNIV BARCELONA,HOSP CLIN,LIVER UNIT,VILLARROEL 170,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,SERV IMMUNOL,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,SERV MICROBIOL,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,DEPT DERMATOL,E-08036 BARCELONA,SPAIN	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona								BRUGUERA M, 1986, SEMIN DERMATOL, V5, P178; BRUIX J, 1989, LANCET, V2, P1004; CORTES JM, 1980, HISTOPATHOLOGY, V4, P471, DOI 10.1111/j.1365-2559.1980.tb02942.x; ELDER GH, 1990, RECENT ADV DERMATOLO, P55; LEEVY CM, 1979, DISEASES LIVER BILIA; LEFKOWITCH JH, 1983, LIVER, V3, P19; Lentner C, 1982, GEIGY SCI TABLES; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SALATA H, 1985, J HEPATOL, V1, P477, DOI 10.1016/S0168-8278(85)80746-7; SUAREZ M, 1992, GASTROENTEROL HEPATO, V15, P272	10	198	205	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					788	789		10.1016/0140-6736(93)90562-U	http://dx.doi.org/10.1016/0140-6736(93)90562-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	7681135				2022-12-01	WOS:A1993KU90000005
J	COLEMAN, TR; TANG, ZH; DUNPHY, WG				COLEMAN, TR; TANG, ZH; DUNPHY, WG			NEGATIVE REGULATION OF THE WEE1 PROTEIN-KINASE BY DIRECT ACTION OF THE NIM1/CDR1 MITOTIC INDUCER	CELL			English	Article							XENOPUS CDC2 PROTEIN; FISSION YEAST; TYROSINE PHOSPHORYLATION; CELL-CYCLE; ACTIVATES P34CDC2; DNA-REPLICATION; M-PHASE; MITOSIS; DEPHOSPHORYLATION; PHOSPHATASE	The wee1 protein kinase suppresses the entry into mitosis by mediating the inhibitory tyrosine phosphorylation of p34cdc2. Genetic studies have suggested that the nim1 protein kinase (also known as cdr1) acts as a positive regulator of mitosis by down-regulating the wee1 pathway in yeast cells. We have overexpressed the nim1 protein in both bacteria and insect cells. The recombinant nim1 protein autophosphorylates on both tyrosine and serine residues and can phosphorylate the isolated wee1 protein directly in a cell-free system. The nim1-catalyzed phosphorylation of the wee1 protein occurs in its C-terminal region and leads to a substantial drop in its activity as a cdc2-specific tyrosine kinase. This nim1-dependent inhibition of the wee1 protein kinase can be reversed readily in vitro by treatment with a protein phosphatase. These experiments provide direct biochemical evidence that the wee1 protein is subject to negative regulation by phosphorylation and indicate that the nim1 protein acts as an inhibitory, wee1-specific kinase.			COLEMAN, TR (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; Fleig U N, 1991, Semin Cell Biol, V2, P195; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MILARSKI KL, 1991, COLD SH Q B, V56, P377; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	43	148	150	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					919	929		10.1016/0092-8674(93)90580-J	http://dx.doi.org/10.1016/0092-8674(93)90580-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681363				2022-12-01	WOS:A1993KU17500012
J	KOHDA, D; HATANAKA, H; ODAKA, M; MANDIYAN, V; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F				KOHDA, D; HATANAKA, H; ODAKA, M; MANDIYAN, V; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F			SOLUTION STRUCTURE OF THE SH3 DOMAIN OF PHOSPHOLIPASE C-GAMMA	CELL			English	Article							SIGNAL TRANSDUCTION; PROTEIN-STRUCTURE; TYROSINE KINASE; VIRAL ONCOGENE; PC12 CELLS; GROWTH; DIFFERENTIATION; SPECTROSCOPY; REQUIREMENT; EXCHANGE	SH3 (Src homology 3) domains are found in many signaling proteins and appear to function as binding modules for cytoplasmic target proteins. The solution structure of the SH3 domain of human phospholipase C-gamma (PLC-gamma) was determined by two-dimensional H-1 NMR analysis. This SH3 domain is composed of eight antiparallel beta strands consisting of two successive ''Greek key'' motifs, which form a barrel-like structure. The conserved aliphatic and aromatic residues form a hydrophobic pocket on the molecular surface, and the conserved carboxylic residues are localized to the periphery. The hydrophobic pocket may serve as a binding site for target proteins. Analysis of the slowly exchanging amide protons by NMR measurements indicates that despite containing a high content of beta structure, the SH3 domain of PLC-gamma is flexible.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	New York University; Max Planck Society	KOHDA, D (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYS,18-22 HONKOMAGOME 3-CHOME,BUNKYO KU,TOKYO 113,JAPAN.		Odaka, Masafumi/C-2378-2013; Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				BRUNGER AT, 1990, X PLOR VERSION 2 1 M; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAVANAGH J, 1992, J MAGN RESON, V96, P670, DOI 10.1016/0022-2364(92)90357-D; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	29	116	118	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					953	960		10.1016/0092-8674(93)90583-C	http://dx.doi.org/10.1016/0092-8674(93)90583-C			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681365				2022-12-01	WOS:A1993KU17500015
J	GETHER, U; JOHANSEN, TE; SNIDER, RM; LOWE, JA; NAKANISHI, S; SCHWARTZ, TW				GETHER, U; JOHANSEN, TE; SNIDER, RM; LOWE, JA; NAKANISHI, S; SCHWARTZ, TW			DIFFERENT BINDING EPITOPES ON THE NK1 RECEPTOR FOR SUBSTANCE-P AND A NONPEPTIDE ANTAGONIST	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; LIGAND-BINDING; SPECIFICITY; EXPRESSION; INHIBITORS; AGONIST; SITES; CDNA	NON-PEPTIDE ligands for peptide receptors have been discovered in several systems through file screening programs1-6, but the mechanism of action for these candidate drugs is obscure as they do not chemically resemble the native peptides. The compound CP 96345 is a high-affinity, non-peptide antagonist of the substance P (NK1) receptor4,5,7, which is important in pain perception and neurogenic inflammation8-11. Here we identify epitopes on the NK1 receptor responsible for the specific binding of CP 96345 by systematic exchange of corresponding segments between the NK1 receptor and the homologous NK3 (neurokinin B) receptor, which does not bind the non-peptide ligand. Non-conserved residues, in two epitopes around the top of transmembrane segment V and in one epitope at the top of transmembrane segment VI, are essential for the specific action of CP 96345 on the NK1 receptor, but are surprisingly not important for the binding of the natural peptide ligand, substance P. Susceptibility to the non-peptide antagonists can be conveyed to the previously unresponsive NK3 receptor by mutational transfer of this discontinuous epitope from the NK1 receptor.	PFIZER INC, DIV CENT RES, DEPT EXPLORATORY MED CHEM, GROTON, CT 06340 USA; KYOTO UNIV, FAC MED, INST IMMUNOL, KYOTO 606, JAPAN	Pfizer; Kyoto University	GETHER, U (corresponding author), UNIV COPENHAGEN, DEPT CLIN BIOCHEM, MOLEC ENDOCRINOL LAB, RIGSHOSP 6321, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Schwartz, Thue W./0000-0002-0261-6904; Gether, Ulrik/0000-0002-0020-3807				BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CHANG RSL, 1990, MOL PHARMACOL, V37, P347; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHIMAWN HG, 1991, REV BIOCH, V60, P653; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ENGBERG G, 1981, NATURE, V293, P222, DOI 10.1038/293222a0; FONG TM, 1992, J BIOL CHEM, V267, P25664; FREIDINGER RM, 1990, ALFRED BENZON SYMP S, V29, P389; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; IVERSEN LL, 1990, ALFRED BENZON SYMP S, V29, P363; JOHANSEN TE, 1990, BIOCHEM BIOPH RES CO, V172, P1384, DOI 10.1016/0006-291X(90)91603-P; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAUFER R, 1985, P NATL ACAD SCI USA, V82, P7444, DOI 10.1073/pnas.82.21.7444; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; MIZRAHI J, 1984, EUR J PHARMACOL, V99, P193, DOI 10.1016/0014-2999(84)90241-3; PERNOW B, 1983, PHARMACOL REV, V35, P85; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; SNIDER RM, 1991, P NATL ACAD SCI USA, V88, P10042, DOI 10.1073/pnas.88.22.10042; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1988, J BIOL CHEM, V263, P10267; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1992, MOL PHARMACOL, V41, P369; YAMAMURA Y, 1991, SCIENCE, V252, P572, DOI 10.1126/science.1850553; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	28	235	235	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					345	348		10.1038/362345a0	http://dx.doi.org/10.1038/362345a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	7681152				2022-12-01	WOS:A1993KU17600061
J	BREWSTER, JL; DEVALOIR, T; DWYER, ND; WINTER, E; GUSTIN, MC				BREWSTER, JL; DEVALOIR, T; DWYER, ND; WINTER, E; GUSTIN, MC			AN OSMOSENSING SIGNAL TRANSDUCTION PATHWAY IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; MAP KINASE; PHOSPHORYLATION; PHEROMONE; GENES; DNA; ACCUMULATION; RESISTANCE	Yeast genes were isolated that are required for restoring the osmotic gradient across the cell membrane in response to increased external osmolarity. Two of these genes, HOG1 and PBS2, encode members of the mitogen-activated protein kinase (MAP kinase) and MAP kinase kinase gene families, respectively. MAP kinases are activated by extracellular ligands such as growth factors and function as intermediate kinases in protein phosphorylation cascades. A rapid, PBS2-dependent tyrosine phosphorylation of HOG1 protein occurred in response to increases in extracellular osmolarity. These data define a signal transduction pathway that is activated by changes in the osmolarity of the extracellular environment.	RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA	Rice University; Jefferson University; Jefferson University				Dwyer, Noelle/0000-0002-1995-7203; Gustin, Michael/0000-0003-0097-9194	NIGMS NIH HHS [GM45772] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLARD MJ, 1991, EMBO J, V10, P3753, DOI 10.1002/j.1460-2075.1991.tb04944.x; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, UNPUB; Chamberlin ME, 1989, AM J PHYSIOL, Vl257, P159; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Dayhoff M., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EDGELY M, 1983, J GEN MICROBIOL, V129, P3453; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FRINGS CS, 1966, ANAL CHIM ACTA, V34, P225, DOI 10.1016/S0003-2670(00)89030-3; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; MEIKLE AJ, 1988, J GEN MICROBIOL, V134, P3049; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; REED RH, 1987, APPL ENVIRON MICROB, V53, P2119, DOI 10.1128/AEM.53.9.2119-2123.1987; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; [No title captured]	38	1020	1100	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1760	1763		10.1126/science.7681220	http://dx.doi.org/10.1126/science.7681220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681220				2022-12-01	WOS:A1993KT81000039
J	ZAMBRANO, MM; SIEGELE, DA; ALMIRON, M; TORMO, A; KOLTER, R				ZAMBRANO, MM; SIEGELE, DA; ALMIRON, M; TORMO, A; KOLTER, R			MICROBIAL COMPETITION - ESCHERICHIA-COLI MUTANTS THAT TAKE OVER STATIONARY PHASE CULTURES	SCIENCE			English	Article							SPONTANEOUS MUTATIONS; STARVATION SURVIVAL; GENERAL RESISTANCE; BACTERIA; KATF; EXPRESSION; SELECTION; EVOLUTION; PROTEINS; SEQUENCE	Many microorganisms, including Escherichia coli, can survive extended periods of starvation. The properties of cells that survived prolonged incubation in stationary phase were studied by mixture of 10-day-old (aged) cultures with 1-day-old (young) cultures of the same strain of Escherichia coli. Mutants from the aged cultures that could grow eventually took over the population, which resulted in the death of the cells from the young cultures. This phenotype was conferred by mutations in rpoS, which encodes a putative stationary phase-specific sigma factor. These rapid population shifts have implications for the studies of microbial evolution and ecology.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School			Zambrano, Maria Mercedes/AAD-2805-2019	Zambrano, Maria Mercedes/0000-0002-0796-4473; Siegele, Deborah/0000-0001-8935-0696				ATWOOD KC, 1951, P NATL ACAD SCI USA, V37, P146, DOI 10.1073/pnas.37.3.146; BENNETT AF, 1990, NATURE, V346, P79, DOI 10.1038/346079a0; BOHANNON DE, 1991, J BACTERIOL, V173, P4482, DOI 10.1128/JB.173.14.4482-4492.1991; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; GROAT RG, 1986, J BACTERIOL, V168, P486, DOI 10.1128/jb.168.2.486-493.1986; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1991, NEW BIOL, V3, P729; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HENGGEARONIS R, 1991, J BACTERIOL, V173, P7918, DOI 10.1128/jb.173.24.7918-7924.1991; KJELLEBERG S, 1987, ANNU REV MICROBIOL, V41, P25, DOI 10.1146/annurev.mi.41.100187.000325; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LANGE R, 1991, J BACTERIOL, V173, P4474, DOI 10.1128/JB.173.14.4474-4481.1991; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; MATIN A, 1989, ANNU REV MICROBIOL, V43, P293, DOI 10.1146/annurev.mi.43.100189.001453; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MCCANN MP, 1991, J BACTERIOL, V173, P4188, DOI 10.1128/jb.173.13.4188-4194.1991; Miller JH., 1972, EXPT MOL GENETICS; MITTLER JE, 1992, NATURE, V356, P446, DOI 10.1038/356446a0; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; NOVICK A, 1950, P NATL ACAD SCI USA, V36, P708, DOI 10.1073/pnas.36.12.708; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; SIEGELE DA, IN PRESS STARVATION; Small P. L. C., 1992, ASM B, V74, P38; SPECTOR MP, 1986, J BACTERIOL, V168, P420, DOI 10.1128/jb.168.1.420-424.1986; SYKES RB, 1982, ANTIMICROB AGENTS CH, V21, P85, DOI 10.1128/AAC.21.1.85; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X	29	430	433	0	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1757	1760		10.1126/science.7681219	http://dx.doi.org/10.1126/science.7681219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681219				2022-12-01	WOS:A1993KT81000038
J	FOULKES, NS; SCHLOTTER, F; PEVET, P; SASSONECORSI, P				FOULKES, NS; SCHLOTTER, F; PEVET, P; SASSONECORSI, P			PITUITARY-HORMONE FSH DIRECTS THE CREM FUNCTIONAL SWITCH DURING SPERMATOGENESIS	NATURE			English	Article							GOLDEN-HAMSTERS; GENE; TRANSCRIPTION; SEQUENCE	THE CREM (cyclic AMP-responsive element modulator) gene encodes multiple regulators of the cAMP-transcriptional response by alternative splicing1. A developmental switch in CREM expression occurs during spermatogenesis, whereby CREM function is converted from an antagonist to an activator (CREMtau; ref. 2) which accumulates to extremely high levels from the premeiotic spermatocyte stage onwards. To define the physiological mechanisms controlling the CREM developmental switch, we have hypophysectomized rats and observed the extinction of CREMtau expression in testis, thereby demonstrating a central role of the pituitary-hypothalamic axis. We then used the seasonal-dependent modulation of spermatogenesis in hamsters to dissect the hormonal programme controlling this developmental process. By this approach, combined with direct administration of pituitary-derived hormones, we have established that follicle-stimulating hormone (FSH) is responsible for the CREM switch. FSH appears to regulate CREM expression by alternative polyadenylation, which results in a dramatic enhancement of transcript stability.	CNRS, URA 1332, F-67000 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS)	SASSONECORSI, P (corresponding author), FAC MED STRASBOURG, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891				Bartke A., 1985, The hamster - reproduction and behavior., P73; CROWLEY WF, 1991, RECENT PROG HORM RES, V47, P27; DESJARDINS C, 1971, ENDOCRINOLOGY, V89, P791, DOI 10.1210/endo-89-3-791; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; JEGOU B, 1992, SCHERING F WORKSHOP, V4, P57; JETTON AE, 1991, ENDOCRINOLOGY, V129, P1025, DOI 10.1210/endo-129-2-1025; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KLEMCKE HG, 1987, BIOL REPROD, V37, P356, DOI 10.1095/biolreprod37.2.356; MAZLUFF WF, 1986, TRANSCRIPTION TRANSL; PEVET P, 1988, REPROD NUTR DEV, V28, P575; RAYNAUD F, 1991, J NEURAL TRANSM-GEN, V83, P235, DOI 10.1007/BF01253393; Reiter R J, 1980, Endocr Rev, V1, P109; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; Santen R. J., 1987, ENDOCRINOL METAB, P821; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VULLIAMY TJ, 1988, P NATL ACAD SCI USA, V85, P5171, DOI 10.1073/pnas.85.14.5171	19	232	235	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1993	362	6417					264	267		10.1038/362264a0	http://dx.doi.org/10.1038/362264a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	7681549				2022-12-01	WOS:A1993KT02600062
J	HYDE, SC; GILL, DR; HIGGINS, CF; TREZISE, AEO; MACVINISH, LJ; CUTHBERT, AW; RATCLIFF, R; EVANS, MJ; COLLEDGE, WH				HYDE, SC; GILL, DR; HIGGINS, CF; TREZISE, AEO; MACVINISH, LJ; CUTHBERT, AW; RATCLIFF, R; EVANS, MJ; COLLEDGE, WH			CORRECTION OF THE ION-TRANSPORT DEFECT IN CYSTIC-FIBROSIS TRANSGENIC MICE BY GENE-THERAPY	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESPIRATORY EPITHELIUM; CHLORIDE CHANNELS; LUNG-DISEASE; ACTIVATION; EXPRESSION; AMILORIDE; CFTR; MEMBRANE; CALCIUM	CYSTIC fibrosis (CF) is a lethal inherited disorder affecting about 1 in 2,000 Caucasians. The major cause of morbidity is permanent lung damage resulting from ion transport abnormalities in airway epithelia that lead to mucus accumulation and bacterial colonization. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene1 that encodes a cyclic-AMP-regulated chloride channel2,3. Cyclic-AMP-regulated chloride conductances are altered in airway epithelia from CF patients4-6, suggesting that the functional expression of CFTR in the airways of CF patients may be a strategy for treatment. Transgenic mice7-9 With a disrupted cftr gene are appropriate for testing gene therapy protocols. Here we report the use of liposomes to deliver a CFTR expression plasmid to epithelia of the airway and to alveoli deep in the lung, leading to the correction of the ion conductance defects found in the trachea of transgenic (cf/cf) mice. These studies illustrate the feasibility of gene therapy for the pulmonary aspects of CF in humans.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,WELLCOME CRC INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND	Cancer Research UK; University of Oxford; University of Cambridge; University of Cambridge; University of Cambridge			Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429; Gill, Deborah/0000-0002-5264-054X; Hyde, Stephen/0000-0002-8877-4005	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COLLEDGE WH, 1992, LANCET, V340, P680, DOI 10.1016/0140-6736(92)92223-3; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CUTHBERT AW, 1990, BRIT J CLIN PHARMACO, V29, P227, DOI 10.1111/j.1365-2125.1990.tb03624.x; DORIN JR, 1992, NATURE, V359, P211, DOI 10.1038/359211a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCCANN JD, 1990, AM J PHYSIOL, V258, pL334, DOI 10.1152/ajplung.1990.258.6.L334; RATCLIFF R, IN PRESS NATURE GENE; RIORDAN JR, 1989, SCIENCE, V245, P1066; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMITH SN, 1992, CLIN SCI, V82, P667, DOI 10.1042/cs0820667; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TREZISE AEO, IN PRESS HUM MOL GEN; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZEITLIN PL, 1991, P NATL ACAD SCI USA, V89, P1344	33	360	424	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					250	255		10.1038/362250a0	http://dx.doi.org/10.1038/362250a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	7681548				2022-12-01	WOS:A1993KT02600058
J	POPE, SK; WHITESIDE, L; BROOKSGUNN, J; KELLEHER, KJ; RICKERT, VI; BRADLEY, RH; CASEY, PH				POPE, SK; WHITESIDE, L; BROOKSGUNN, J; KELLEHER, KJ; RICKERT, VI; BRADLEY, RH; CASEY, PH			LOW-BIRTH-WEIGHT INFANTS BORN TO ADOLESCENT MOTHERS - EFFECTS OF CORESIDENCY WITH GRANDMOTHER ON CHILD-DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; LONGITUDINAL ANALYSIS; PRETERM INFANTS; PREGNANCY; TEENAGE; PROGRAMS; FAMILY; CHILDBEARING; IMPACT	Objective.-To explore the impact of young maternal age, coresidency with infant's grandmother, and other familial and environmental factors on development of low-birth-weight (LBW) infants. Design.-Prospective cohort analyses. Setting.-Eight medical institutions in different geographical locations participating in the Infant Health and Development Program. Participants.-Control population of 272 LBW, preterm infants enrolled in the Infant Health and Development Program born to mothers aged 15 to 24 years. Main Outcome Measure.-Child cognitive, behavioral, and health outcomes at 36 months' gestation-corrected age. Results.-Maternal age was not significantly related to child development. Coresidence with infant's grandmother was associated with improved cognitive and health outcomes. Maternal ethnicity, maternal verbal ability, and other environmental factors were also associated with child outcomes. Conclusions.-Findings of this study support the need for programs that include the extended family of at-risk infants, providing education and literacy skills to the mothers and encouraging participation of all care givers of the child.	UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT & PSYCHIAT,LITTLE ROCK,AR 72205; UNIV ARKANSAS,COLL EDUC,LITTLE ROCK,AR 72204; COLUMBIA UNIV TEACHERS COLL,NEW YORK,NY 10027	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Columbia University Teachers College			Kelleher, Kelly/E-3361-2011					ACHENBACH TM, 1987, J ABNORM CHILD PSYCH, V15, P629, DOI 10.1007/BF00917246; ADLER ES, 1985, FAM RELAT, V34, P183, DOI 10.2307/583890; BOYCE WT, 1991, AM J DIS CHILD, V145, P267, DOI 10.1001/archpedi.1991.02160030035017; Bronfenbrenner U., 1983, HDB CHILD PSYCHOL, VVol. 1; BROOKSGUNN J, 1991, PEDIATR ANN, V20, P467, DOI 10.3928/0090-4481-19910901-06; BROOKSGUNN J, 1992, J PEDIATR-US, V120, P350, DOI 10.1016/S0022-3476(05)80896-0; BROOKSGUNN J, IN PRESS CHILD DEV; BROOKSGUNN J, 1987, MALLEABILITY CHILDRE, P171; CARLSON DB, 1986, INT J BEHAV DEV, V9, P1; CASEY PH, 1990, J PEDIATR-US, V117, P298, DOI 10.1016/S0022-3476(05)80551-7; Chase-Lansdale P, 1993, ESCAPE POVERTY WHAT; CHASELANSADLE PL, IN PRESS CHILD DEV; CHASELANSDALE PL, 1991, FAM RELAT, V40, P396, DOI 10.2307/584896; CLAPP DF, 1978, SOC WORK, V23, P149; CLEWELL BC, 1989, FAM RELAT, V38, P201, DOI 10.2307/583676; COLL CG, 1986, J DEV BEHAV PEDIATR, V7, P230, DOI 10.1097/00004703-198608000-00003; DARABI KF, 1984, J MARRIAGE FAM, V46, P993; DUNCAN GJ, IN PRESS CHILD DEV; Dunn L., 1981, PEABODY PICTURE VOCA; Eisen MDC, 1990, CONCEPTUALIZATION ME; FIELD TM, 1980, CHILD DEV, V51, P426; FURSTENBERG FF, 1989, AM PSYCHOL, V44, P313, DOI 10.1037/0003-066X.44.2.313; FURSTENBERG FF, 1980, J SOC ISSUES, V36, P64, DOI 10.1111/j.1540-4560.1980.tb01899.x; Goldberg DP., 1972, DETECTION PSYCHIATRI; GROSS RT, 1992, PSYCHOL DEV LOW BIRT, P411; GULLO DF, 1988, CHILD STUDY J, V18, P223; HELD L, 1981, ADOLESCENCE, V16, P905; HUSTON AC, 1991, CHILDREN POVERTY; KING T, 1982, J ADOLESCENCE, V5, P333, DOI 10.1016/S0140-1971(82)80003-1; LANDY S, 1983, ADOLESCENCE, V18, P679; LEE VE, 1988, DEV PSYCHOL, V24, P210, DOI 10.1037/0012-1649.24.2.210; LIAW FR, IN PRESS DEV PSYCHOL; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; MCCORMICK MC, 1989, HDB MED SOCIOLOGY, P347; MERCER RT, 1985, ANN REV NURS RES, V3, P49; MILLER KA, 1984, MAYO CLIN PROC, V59, P311, DOI 10.1016/S0025-6196(12)61426-8; PARKER S, 1988, PEDIATR CLIN N AM, V35, P1227; RAMEY CT, 1992, PEDIATRICS, V89, P454; SCOTT DT, 1989, PEDIATR RES, V25, P263; SPENCER MB, 1990, CHILD DEV, V61, P267, DOI 10.1111/j.1467-8624.1990.tb02778.x; STEVENSSIMON C, 1991, PEDIATR ANN, V20, P322, DOI 10.3928/0090-4481-19910601-09; STEVENSSIMON C, 1992, CURR PROBL PEDIATR, P295; TERMAN LM, 1973, STANFORDBINET INTELL; VINCENT ML, 1987, JAMA-J AM MED ASSOC, V257, P3382, DOI 10.1001/jama.257.24.3382; 1990, JAMA-J AM MED ASSOC, V263, P3035	46	37	37	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1396	1400		10.1001/jama.269.11.1396	http://dx.doi.org/10.1001/jama.269.11.1396			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	7680076				2022-12-01	WOS:A1993KQ85700033
J	SINGHAL, A; DOHERTY, JF; RAYNES, JG; MCADAM, KPWJ; THOMAS, PW; SERJEANT, BE; SERJEANT, GR				SINGHAL, A; DOHERTY, JF; RAYNES, JG; MCADAM, KPWJ; THOMAS, PW; SERJEANT, BE; SERJEANT, GR			IS THERE AN ACUTE-PHASE RESPONSE IN STEADY-STATE SICKLE-CELL DISEASE	LANCET			English	Article							GROWTH; CHILDREN; ANEMIA	Metabolic and serum changes during steady-state homozygous sickle cell (SS) disease are consistent with an acute-phase response and raise the possibility that inflammation occurs in SS disease even during the steady state. To test this hypothesis, we measured concentrations of acute phase reactants in patients with SS disease, in patients with sickle cell haemoglobin C (SC) disease, and in normal (AA) control subjects. The concentrations of C-reactive protein and serum amyloid A were increased above 10 mg/L and 5 mg/L, respectively (our definition of an acute-phase response) in 18% (26/143) of subjects with SS disease even when they were symptom free, in 17% (6/35) of subjects with SC disease, and in 1% (1/80) of AA controls (p < 0.001). We suggest that subclinical vaso-occlusion may generate a covert inflammatory response and that the cytokine mediators of this response may contribute to the metabolic abnormalities and growth failure in sickle cell disease.	UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA; UNIV LONDON LONDON SCH HYG & TROP MED,DIV CLIN SCI,LONDON WC1E 7HT,ENGLAND	University West Indies Mona Jamaica; University of London; London School of Hygiene & Tropical Medicine	SINGHAL, A (corresponding author), UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA.		Raynes, John G/G-7932-2011	Raynes, John G/0000-0002-8536-1328; Thomas, Peter/0000-0003-2478-4324				AKINOLA NO, 1992, J CLIN PATHOL, V45, P902, DOI 10.1136/jcp.45.10.902; BADALOO A, 1989, CLIN SCI, V77, P93, DOI 10.1042/cs0770093; BECTON DL, 1989, J PEDIATR-US, V115, P99, DOI 10.1016/S0022-3476(89)80339-7; BETKE GH, 1959, J CLIN PATHOL, V184, P1877; COOPER ES, 1990, EUR J CLIN NUTR, V44, P285; ENWONWU CO, 1990, AM J MED SCI, V300, P366, DOI 10.1097/00000441-199012000-00005; GILLESPIE SH, 1991, J CLIN PATHOL, V44, P228, DOI 10.1136/jcp.44.3.228; GRIMBLE R F, 1990, Nutrition Research Reviews, V3, P193, DOI 10.1079/NRR19900012; HEYMAN MB, 1985, LANCET, V1, P903; JACKSON AA, 1988, EUR J CLIN NUTR, V42, P491; KELTS DG, 1979, GASTROENTEROLOGY, V76, P720; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; LUCAS GS, 1985, BRIT J HAEMATOL, V59, P363, DOI 10.1111/j.1365-2141.1985.tb03001.x; ODONKOR P O, 1982, IRCS (International Research Communications System) Medical Science Library Compendium, V10, P303; ODONKOR PO, 1984, HUM NUTR-CLIN NUTR, V38C, P23; PEPYS MB, 1981, LANCET, V1, P653; PETERSON CM, 1975, BLOOD, V46, P583; PHEBUS CK, 1988, AM J HEMATOL, V29, P67, DOI 10.1002/ajh.2830290203; PRASAD AS, 1976, JAMA-J AM MED ASSOC, V235, P2396, DOI 10.1001/jama.235.22.2396; STEVENS MCG, 1986, PEDIATRICS, V78, P124; TANGNEY CC, 1989, AM J HEMATOL, V32, P161, DOI 10.1002/ajh.2830320302; 1988, J CLIN PATHOL, V41, P1203	22	58	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					651	653		10.1016/0140-6736(93)90418-G	http://dx.doi.org/10.1016/0140-6736(93)90418-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	7680738				2022-12-01	WOS:A1993KR61300003
J	VOGEL, W; LAMMERS, R; HUANG, JT; ULLRICH, A				VOGEL, W; LAMMERS, R; HUANG, JT; ULLRICH, A			ACTIVATION OF A PHOSPHOTYROSINE PHOSPHATASE BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							CHIMERIC RECEPTOR; KINASE; DOMAIN; MECHANISM; SUBSTRATE; PROTEINS; SH2	Regulation of cell proliferation, differentiation, and metabolic homeostasis is associated with the phosphorylation and dephosphorylation of specific tyrosine residues of key regulatory proteins. The phosphotyrosine phosphatase 1D (PTP 1D) contains two amino terminally located Src homology 2 (SH2) domains and is similar to the Drosophila corkscrew gene product, which positively regulates the torso tyrosine kinase signal transduction pathway. PTP activity was found to be regulated by physical interaction with a protein tyrosine kinase. PTP 1D did not dephosphorylate receptor tyrosine kinases, despite the fact that it associated with the epidermal growth factor receptor and chimeric receptors containing the extracellular domain of the epidermal growth factor receptor and the cytoplasmic domain of either the HER2-neu, kit-SCF, or platelet-derived growth factor beta (betaPDGF) receptors. PTP 1D was phosphorylated on tyrosine in cells overexpressing the betaPDGF receptor kinase and this tyrosine phosphorylation correlated with an enhancement of its catalytic activity. Thus, protein tyrosine kinases and phosphatases do not simply oppose each other's action; rather, they may work in concert to maintain a fine balance of effector activation needed for the regulation of cell growth and differentiation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								BURGESS WH, 1990, MOL CELL BIOL, V10, P4470; FENG GS, IN PRESS SCIENCE; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HERBST R, 1991, J BIOL CHEM, V266, P19908; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P1; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TUNG HYL, 1987, ANAL BIOCHEM, V161, P412; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, UNPUB; YI T, 1992, MOL CELL BIOL, V12, P826; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	27	562	586	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1611	1614		10.1126/science.7681217	http://dx.doi.org/10.1126/science.7681217			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	7681217				2022-12-01	WOS:A1993KR54300039
J	WAKSMAN, G; SHOELSON, SE; PANT, N; COWBURN, D; KURIYAN, J				WAKSMAN, G; SHOELSON, SE; PANT, N; COWBURN, D; KURIYAN, J			BINDING OF A HIGH-AFFINITY PHOSPHOTYROSYL PEPTIDE TO THE SRC SH2 DOMAIN - CRYSTAL-STRUCTURES OF THE COMPLEXED AND PEPTIDE-FREE FORMS	CELL			English	Article							SIGNAL TRANSDUCTION; PROTEIN; REFINEMENT	The crystal structure of the Src SH2 domain complexed with a high affinity 11-residue phosphopeptide has been determined at 2.7 angstrom resolution by X-ray diffraction. The peptide binds in an extended conformation and makes primary interactions with the SH2 domain at six central residues: PQ(pY)EEI. The phosphotyrosine and the isoleucine are tightly bound by two well-defined pockets on the protein surface, resulting in a complex that resembles a two-pronged plug engaging a two-holed socket. The glutamate residues are in solvent-exposed environments in the vicinity of basic side chains of the SH2 domain, and the two N-terminal residues cap the phosphotyrosine-binding site. The crystal structure of Src SH2 in the absence of peptide has been determined at 2.5 angstrom resolution, and comparison with the structure of the high affinity complex reveals only localized and relatively small changes.	HOWARD HUGHES MED INST,NEW YORK,NY 10021; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115	Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.	WAKSMAN, G (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.		Cowburn, David/A-8448-2008	Cowburn, David/0000-0001-6770-7172				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1988, XPLOR VERSION 2 2 MA; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; ECK M, 1993, IN PRESS; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, IN PRESS MOL CELL BI; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIU X, 1993, IN PRESS ONCOGENE; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, IN PRESS; PAYNE G, 1993, IN PRESS P NATL ACAD; PICCIONE E, 1993, IN PRESS BIOCHEMISTR; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSSMANN MG, 1972, INT SCI REV SERIES, V13; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHOELSON SE, 1993, IN PRESS EMBO J, V6; SONGYANG Z, 1993, CELL, V72; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WILLIAMS KP, 1993, IN PRESS J BIOL CHEM; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	45	699	726	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					779	790		10.1016/0092-8674(93)90405-F	http://dx.doi.org/10.1016/0092-8674(93)90405-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680960				2022-12-01	WOS:A1993KR43600013
J	ZHOU, AM; HASSEL, BA; SILVERMAN, RH				ZHOU, AM; HASSEL, BA; SILVERMAN, RH			EXPRESSION CLONING OF 2-5A-DEPENDENT RNASE - A UNIQUELY REGULATED MEDIATOR OF INTERFERON ACTION	CELL			English	Article							ENCEPHALOMYOCARDITIS VIRUS-REPLICATION; ESCHERICHIA-COLI; MESSENGER-RNA; PROTEIN-SYNTHESIS; RIBOSOMAL-RNA; TREATED CELLS; 2'-5'-OLIGOADENYLATE SYNTHETASE; PPP(A2'P)NA-DEPENDENT RNASE; CONSTITUTIVE EXPRESSION; MOLECULAR-CLONING	2-5A-dependent RNAase, an interferon-induced enzyme that is activated by 5'-phosphorylated, 2',5'-linked oligoadenylates (2-SA), is implicated in both the molecular mechanisms of interferon action and the fundamental control of RNA stability in mammalian cells. Here we report the expression cloning and analysis of murine and human 2-5A-dependent RNAases. The 2-5A binding properties and RNAase activities of recombinant and naturally occurring forms of 2-5A-dependent RNAase were identical. Interferon induction of 2-5A-dependent RNAase expression was demonstrated by measuring the mRNA levels in cells treated with interferon and cycloheximide. Analysis of aligned murine and human 2-5A-dependent RNAase sequences revealed several intriguing features, including similarity to RNAase E, which is implicated in the control of mRNA stability in E. coli. Interestingly, a duplicated phosphate-binding loop motif was determined by deletion analysis and site-directed mutagenesis to function in the binding of 2-5A.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	ZHOU, AM (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195, USA.				NCI NIH HHS [2RO1 CA44059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APIRION D, 1978, J BIOL CHEM, V253, P1738; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; Brown R E, 1985, Prog Clin Biol Res, V202, P3; CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; ETIENNESMEKENS M, 1983, P NATL ACAD SCI-BIOL, V80, P4609, DOI 10.1073/pnas.80.15.4609; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLOYDSMITH G, 1981, SCIENCE, V212, P1020; FLOYDSMITH G, 1988, J CELL BIOCHEM, V38, P12; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; HOVANESSIAN AG, 1900, VIROLOGY, V101, P81; IMAI J, 1985, J BIOL CHEM, V260, P1390; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JACOBSEN H, 1983, VIROLOGY, V125, P496, DOI 10.1016/0042-6822(83)90222-2; JOHNSTON MI, 1987, J BIOL CHEM, V262, P8377; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; MARIE I, 1992, J BIOL CHEM, V267, P9933; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; Sambrook J., 1989, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; SILVERMAN RH, 1982, EUR J BIOCHEM, V124, P131, DOI 10.1111/j.1432-1033.1982.tb05915.x; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P581; TRUJILLO MA, 1987, EUR J BIOCHEM, V169, P167, DOI 10.1111/j.1432-1033.1987.tb13594.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATLING D, 1985, EMBO J, V4, P431, DOI 10.1002/j.1460-2075.1985.tb03647.x; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WILLIAMS BRG, 1978, EUR J BIOCHEM, V92, P455, DOI 10.1111/j.1432-1033.1978.tb12767.x; WILLIAMS BRG, 1979, NATURE, V282, P582, DOI 10.1038/282582a0; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; XIA ZG, 1990, J BIOL CHEM, V265, P6517	62	430	458	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					753	765		10.1016/0092-8674(93)90403-D	http://dx.doi.org/10.1016/0092-8674(93)90403-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680958	Bronze			2022-12-01	WOS:A1993KR43600011
J	ZHOU, SY; SHOELSON, SE; CHAUDHURI, M; GISH, G; PAWSON, T; HASER, WG; KING, F; ROBERTS, T; RATNOFSKY, S; LECHLEIDER, RJ; NEEL, BG; BIRGE, RB; FAJARDO, JE; CHOU, MM; HANAFUSA, H; SCHAFFHAUSEN, B; CANTLEY, LC				ZHOU, SY; SHOELSON, SE; CHAUDHURI, M; GISH, G; PAWSON, T; HASER, WG; KING, F; ROBERTS, T; RATNOFSKY, S; LECHLEIDER, RJ; NEEL, BG; BIRGE, RB; FAJARDO, JE; CHOU, MM; HANAFUSA, H; SCHAFFHAUSEN, B; CANTLEY, LC			SH2 DOMAINS RECOGNIZE SPECIFIC PHOSPHOPEPTIDE SEQUENCES	CELL			English	Article							MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; BINDING; POLYOMAVIRUS; PP60C-SRC; GAP; SRC	A phosphopeptide library was used to determine the sequence specificity of the peptide-binding sites of SH2 domains. One group of SH2 domains (Src, Fyn, Lck, Fgr, Abl, Crk, and Nck) preferred sequences with the general motif pTyr-hydrophilic-hydrophilic-Ile/Pro while another group (SH2 domains of p85, phospholipase C-gamma, and SHPTP2) selected the general motif pTyr-hydrophobic-X-hydrophobic. Individual members of these groups selected unique sequences, except the Src subfamily (Src, Fyn, Lck, and Fgr), which all selected the sequence pTyr-Glu-Glu-Ile. The variability in SH2 domain sequences at likely sites of contact provides a structural basis for the phosphopeptide selectivity of these families. Possible in vivo binding sites of the SH2 domains are discussed.	BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; BASF CORP, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; BASF; Rockefeller University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts University	ZHOU, SY (corresponding author), HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.		Pawson, Tony J/E-4578-2013; Cantley, Lewis C/D-1800-2014; Gish, Gerald D/C-7228-2017	Cantley, Lewis C/0000-0002-1298-7653; 				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, IN PRESS J BIOL CHEM; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; DOMCHEK S, 1993, BIOCHEMISTRY-US, V31, P9865; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIU X, 1993, IN PRESS ONCOGENE; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHUMACHER TNM, 1992, EUR J IMMUNOL, V22, P1405, DOI 10.1002/eji.1830220612; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	41	2486	2700	0	38	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					767	778		10.1016/0092-8674(93)90404-E	http://dx.doi.org/10.1016/0092-8674(93)90404-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680959				2022-12-01	WOS:A1993KR43600012
J	MACFARLANE, DE; DAHLE, CE				MACFARLANE, DE; DAHLE, CE			ISOLATING RNA FROM WHOLE-BLOOD - THE DAWN OF RNA-BASED DIAGNOSIS	NATURE			English	Article							POLYMERASE CHAIN-REACTION; BONE-MARROW TRANSPLANTATION; LEUKEMIA PATIENTS		UNIV IOWA,IOWA BIOTECHNOL CORP,INST TECHNOL INNOVAT,IOWA CITY,IA 52242	University of Iowa	MACFARLANE, DE (corresponding author), UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Macfarlane, Donald/0000-0001-8785-5690				AUBELSADRON G, 1961, BIOCHIM BIOPHYS ACTA, V53, P11, DOI 10.1016/0006-3002(61)90789-2; CHROMCZYNSKI P, 1991, CURRENT PROTOCOLS S, V14; DALLMAN MJ, 1991, IMMUNOL REV, V119, P163, DOI 10.1111/j.1600-065X.1991.tb00583.x; DELFAU MH, 1990, LEUKEMIA, V4, P1; Hayakawa K., 1991, CATIONIC SURFACTANTS; HIGUCHI R, 1989, PCR TECHNOLOGY; JONES AS, 1953, BIOCHIM BIOPHYS ACTA, V10, P607, DOI 10.1016/0006-3002(53)90304-7; KOWK S, 1992, PERKIN ELMER BIOTECH; MACFARLANE DE, 1989, ANAL BIOCHEM, V176, P457, DOI 10.1016/0003-2697(89)90342-4; MACFARLANE DE, 1991, Patent No. 5010183; NICHOLS J, 1992, BLOOD, V80, P2953; RALPH RK, 1984, BIOCHIM BIOPHYS ACTA, V87, P9; RECK RA, 1982, ENCY CHEM TECHNOLOGY, V19, P521; REDDI KK, 1976, P NATL ACAD SCI USA, V73, P2308, DOI 10.1073/pnas.73.7.2308; SAWYERS CL, 1990, P NATL ACAD SCI USA, V87, P563, DOI 10.1073/pnas.87.2.563; [No title captured]	16	49	58	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					186	188		10.1038/362186a0	http://dx.doi.org/10.1038/362186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680772				2022-12-01	WOS:A1993KR02800069
J	RUPPERT, S; WANG, EH; TJIAN, R				RUPPERT, S; WANG, EH; TJIAN, R			CLONING AND EXPRESSION OF HUMAN TAF(II)250 - A TBP-ASSOCIATED FACTOR IMPLICATED IN CELL-CYCLE REGULATION	NATURE			English	Article							BINDING-PROTEIN; TFIID COMPLEX; MUTANTS; TRANSCRIPTION; COACTIVATORS; PROGRESSION; ACTIVATION; SYSTEM; GENES; CCG1	BASAL transcription by human RNA polymerase II requires the coordinate action of several ancillary factors (TFIIA-J)1 and can be regulated by various promoter-specific DNA binding proteins. An additional class of factors, called coactivators, are dispensable for basal transcription but are indispensable for regulation by transcriptional activators2-4. Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex3-6. We therefore set out to define the relationship between TBP and these TBP-associated factors (TAFs). Here we describe the cloning, expression and properties of the first human TAF, hTAF(II)250. The hTAF(II)250 gene is identical to a gene, CCG1 (refs 7, 8), implicated in cell-cycle progression. Recombinant hTAF(II)250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex. This largest TAF may therefore play a central role in TFIID assembly by interacting with both TBP and other TAFs, as well as serving to link the control of transcription to the cell cycle.			RUPPERT, S (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,401 BARKER HALL,BERKELEY,CA 94720, USA.							CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOEY T, 1993, CELL, V72, P1; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LIU HT, 1985, J BIOL CHEM, V260, P3269; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	22	223	252	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					175	179		10.1038/362175a0	http://dx.doi.org/10.1038/362175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680771				2022-12-01	WOS:A1993KR02800065
J	OKSENBERG, JR; PANZARA, MA; BEGOVICH, AB; MITCHELL, D; ERLICH, HA; MURRAY, RS; SHIMONKEVITZ, R; SHERRITT, M; ROTHBARD, J; BERNARD, CCA; STEINMAN, L				OKSENBERG, JR; PANZARA, MA; BEGOVICH, AB; MITCHELL, D; ERLICH, HA; MURRAY, RS; SHIMONKEVITZ, R; SHERRITT, M; ROTHBARD, J; BERNARD, CCA; STEINMAN, L			SELECTION FOR T-CELL RECEPTOR V-BETA-D-BETA-J-BETA GENE REARRANGEMENTS WITH SPECIFICITY FOR A MYELIN BASIC-PROTEIN PEPTIDE IN BRAIN-LESIONS OF MULTIPLE-SCLEROSIS	NATURE			English	Article							NONRADIOACTIVE OLIGONUCLEOTIDE PROBES; AMPLIFIED DNA; SEQUENCE; POLYMORPHISM	MULTIPLE sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system in which a restricted cellular immune response has been observed. In order to establish whether such T cell responses are likely to be antigen-specific particularly with regard to myelin basic protein (MBP), we analysed T-cell receptor (TCR) gene rearrangements directly from MS brain plaques, using the polymerase chain reaction on reverse transcribed messenger RNA, and compared these with TCR of previously described MBP-specific T cell clones from MS and the rat model experimental allergic encephalomyelitis. Rearranged Vbeta5.2 genes were detected in the brains of all patients who were HLA DRB1*1501, DQA1*0102, DQB1*0602, DPB1*0401. The Vbeta5.2-Dbeta-Jbeta sequences in these MS brain plaques revealed five motifs. One of the common motifs was identical to that described for the VDJ region of a Vbeta5.2 T-cell clone. This clone was from an MS patient who was HLA DRB1*1501, DQB1*0602, DPB1*0401, and it was cytotoxic towards targets containing the MBP peptide 89-106 (ref. 1). The deduced amino-acid sequence of this VDJ rearrangement, Leu-Arg-Gly, has also been described in rat T cells cloned from experimental allergic encephalomyelitis lesions, which are specific for MBP peptide 87-99 (ref. 2). VDJ sequences with specificity for this MBP epitope constitute a large fraction (40%) of the TCR Vbeta5.2 N(D)N rearrangements in MS lesions. The capacity of rat T cells with these VDJ sequences to cause experimental allergic encephalomyelitis2 and the prevalence of such sequences in demyelinated human lesions indicate that T cells with this rearranged TCR may be critical in MS.	ROCHE MOLEC SYST,DEPT HUMAN GENET,EMERYVILLE,CA 94608; ROCKY MT MS CTR,ENGLEWOOD,CO 80150; LA TROBE UNIV,NEUROIMMUNOL LAB,BUNDOORA,VIC 3083,AUSTRALIA; IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304	La Trobe University	OKSENBERG, JR (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305, USA.			Steinman, Lawrence/0000-0002-2437-2250; Panzara, Michael/0000-0003-2810-4832				BEGOVICH AB, 1992, J IMMUNOL, V148, P249; BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235; BUGAWAN TL, 1990, IMMUNOGENETICS, V32, P231; GAUTAM AM, 1992, J EXP MED, V176, P605, DOI 10.1084/jem.176.2.605; GIEGERICH G, 1992, EUR J IMMUNOL, V22, P753, DOI 10.1002/eji.1830220319; GOLD DP, 1992, J IMMUNOL, V148, P1712; HELMUTH R, 1990, AM J HUM GENET, V47, P515; JAHNKE U, 1985, SCIENCE, V229, P282, DOI 10.1126/science.2409602; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MORAHAN G, 1989, IMMUNOGENETICS, V30, P311, DOI 10.1007/BF02421337; OKSENBERG JR, 1990, CURR OPIN IMMUNOL, V2, P619, DOI 10.1016/0952-7915(90)90021-8; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; PANZARA MA, 1992, BIOTECHNIQUES, V12, P728; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; TERASAKI PI, 1986, SCIENCE, V193, P1245; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549	18	422	433	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					68	70		10.1038/362068a0	http://dx.doi.org/10.1038/362068a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680433				2022-12-01	WOS:A1993KP97600062
J	SADOWSKI, HB; GILMAN, MZ				SADOWSKI, HB; GILMAN, MZ			CELL-FREE ACTIVATION OF A DNA-BINDING PROTEIN BY EPIDERMAL GROWTH-FACTOR	NATURE			English	Article							SERUM RESPONSE ELEMENT; SIGNAL TRANSDUCTION; 3T3 CELLS; FOS; TRANSCRIPTION; RECEPTORS; INSULIN; EXPRESSION; INDUCTION; COMPLEX	GROWTH factors such as platelet-derived growth factor and epidermal growth factor (EGF) bind to and activate cell-surface receptors with intrinsic tyrosine kinase activities1. Receptor activation elicits multiple physiological changes in target cells, including alterations in gene expression2-4. Receptor tyrosine kinase signalling involves recruitment of proteins into a signalling complex through interactions between receptor autophosphorylation sites and the src-homology region-2 (SH2) domains on these signalling proteins5-9. Diverse signals can subsequently be generated, depending on the specific receptor and Cell type 2,10. How such signals are transmitted to the nucleus is poorly understood, but because the transcriptional activation of many genes by growth factors occurs in the absence of new protein synthesis4, one or more signals emanating from growth factor receptors must directly affect transcription factors. We report here the activation by EGF of a DNA-binding protein in a cell-free system where activation of DNA binding requires ligand, receptor, ATP and phosphotyrosine-SH2 interactions.	COLD SPRING HARBOR LAB,BOX 100,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KANAKURA Y, 1990, BLOOD, V76, P706; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; Treisman R, 1990, Semin Cancer Biol, V1, P47; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	30	246	252	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					79	83		10.1038/362079a0	http://dx.doi.org/10.1038/362079a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680434				2022-12-01	WOS:A1993KP97600066
J	GOVERMAN, J; WOODS, A; LARSON, L; WEINER, LP; HOOD, L; ZALLER, DM				GOVERMAN, J; WOODS, A; LARSON, L; WEINER, LP; HOOD, L; ZALLER, DM			TRANSGENIC MICE THAT EXPRESS A MYELIN BASIC PROTEIN-SPECIFIC T-CELL RECEPTOR DEVELOP SPONTANEOUS AUTOIMMUNITY	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECEPTOR; EXTRATHYMIC TOLERANCE; CLONAL ELIMINATION; VIRUS-INFECTION; SELF-TOLERANCE; LYMPHOCYTES-T; INDUCTION; THYMUS; ANERGY	We constructed a transgenic mouse model that mimics the human autoimmune disease multiple sclerosis in its spontaneous induction and pathology. Transgenic mice were constructed expressing genes encoding a rearranged T cell receptor specific for myelin basic protein (MBP). T cell tolerance was not induced in the periphery, and functional, autoreactive T cells were found in the spleen and lymph nodes of these mice. Transgenic mice developed experimental allergic encephalomyelitis (EAE) following immunization with MBP and adjuvant plus pertussis toxin as well as with administration of pertussis toxin alone. Spontaneous EAE can develop in transgenic mice housed in a nonsterile facility but not in those maintained in a sterile, specific pathogen-free facility. This model system affords a unique opportunity to dissect the genetic and environmental variables that may contribute to the development of spontaneous autoimmune disease.	UNIV SO CALIF, SCH MED, DEPT NEUROBIOL, LOS ANGELES, CA 90033 USA; MERCK SHARP & DOHME LTD, DEPT MOLEC IMMUNOL, RAHWAY, NJ 07065 USA	University of Southern California; Merck & Company	GOVERMAN, J (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.			Goverman, Joan/0000-0002-7361-9424				Alvord E C Jr, 1984, Prog Clin Biol Res, V146, P503; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BROWN AM, 1981, LAB INVEST, V45, P278; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; HAMMERLING GJ, 1991, RES IMMUNOL, V142, P417, DOI 10.1016/0923-2494(91)90040-P; JAHNKE U, 1985, SCIENCE, V229, P282, DOI 10.1126/science.2409602; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; JONES LA, 1990, THYMUS, V16, P195; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAMRADT T, 1991, J IMMUNOL, V147, P3296; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LINTHICUM DS, 1982, IMMUNOBIOLOGY, V162, P211, DOI 10.1016/S0171-2985(11)80001-X; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LUBLIN FD, 1981, J IMMUNOL, V126, P819; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MILICH DR, 1991, P NATL ACAD SCI USA, V88, P4348, DOI 10.1073/pnas.88.10.4348; MILLER JFAP, 1991, IMMUNOL REV, V122, P103, DOI 10.1111/j.1600-065X.1991.tb00599.x; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; Raine C. S., 1983, MULTIPLE SCLEROSIS P, P413; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; Suckling A J, 1984, Prog Clin Biol Res, V146, P75; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	40	585	596	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					551	560		10.1016/0092-8674(93)90074-Z	http://dx.doi.org/10.1016/0092-8674(93)90074-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679952				2022-12-01	WOS:A1993KP16500010
J	LUAN, DD; KORMAN, MH; JAKUBCZAK, JL; EICKBUSH, TH				LUAN, DD; KORMAN, MH; JAKUBCZAK, JL; EICKBUSH, TH			REVERSE TRANSCRIPTION OF R2BM RNA IS PRIMED BY A NICK AT THE CHROMOSOMAL TARGET SITE - A MECHANISM FOR NON-LTR RETROTRANSPOSITION	CELL			English	Article							R HYBRID DYSGENESIS; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENT; MAMMALIAN LINES; BOMBYX-MORI; RETROVIRAL PROTEINS; I-FACTOR; DNA; SEQUENCE; INSERTION	R2 is a non-LTR retrotransposable element that inserts at a specific site in the 28S rRNA genes of most insects. We have expressed the open reading frame of the R2 element from Bombyx mori, R2Bm, in E. coli and shown that it encodes both sequence-specific endonuclease and reverse transcriptase activities. The R2 protein makes a specific nick in one of the DNA strands at the insertion site and uses the 3' hydroxyl group exposed by this nick to prime reverse transcription of its RNA transcript. After reverse transcription, cleavage of the second DNA strand occurs. A similar mechanism of insertion may be used by other non-LTR retrotransposable elements as well as short interspersed nucleotide elements.			LUAN, DD (corresponding author), UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA.				NIGMS NIH HHS [GM42790] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DS, 1986, J MOL BIOL, V187, P465, DOI 10.1016/0022-2836(86)90327-X; BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BOEKE JD, 1989, MOBILE DNA, P335; BRADFIELD JY, 1985, DNA-J MOLEC CELL BIO, V4, P357, DOI 10.1089/dna.1985.4.357; Brown N L, 1980, Methods Enzymol, V65, P391; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUCHETON A, 1990, TRENDS GENET, V6, P16, DOI 10.1016/0168-9525(90)90044-7; BURKE WD, 1987, MOL CELL BIOL, V7, P2221, DOI 10.1128/MCB.7.6.2221; BURKE WD, 1993, IN PRESS MOL BIOL EV, V10; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; DAWID IB, 1981, NUCLEIC ACIDS RES, V9, P5011, DOI 10.1093/nar/9.19.5011; Deininger PL, 1989, MOBILE DNA, P619; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EICKBUSH TH, 1992, NEW BIOL, V4, P430; EICKBUSH TH, 1985, EMBO J, V4, P2281, DOI 10.1002/j.1460-2075.1985.tb03927.x; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FINNEGAN DJ, 1989, MOBILE DNA, P503; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; IVANOV VA, 1991, EMBO J, V10, P2489, DOI 10.1002/j.1460-2075.1991.tb07788.x; JAKUBCZAK JL, 1991, P NATL ACAD SCI USA, V88, P3295, DOI 10.1073/pnas.88.8.3295; JAKUBCZAK JL, 1990, J MOL BIOL, V212, P37, DOI 10.1016/0022-2836(90)90303-4; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KIMMEL BE, 1987, MOL CELL BIOL, V7, P1465, DOI 10.1128/MCB.7.4.1465; Maniatis T., 1982, MOL CLONING; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; Martin SL, 1991, CURR OPIN GENET DEV, V1, P505, DOI 10.1016/S0959-437X(05)80199-6; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MOUNT SM, 1985, MOL CELL BIOL, V5, P1630, DOI 10.1128/MCB.5.7.1630; NISSON PE, 1988, NUCLEIC ACIDS RES, V16, P1431, DOI 10.1093/nar/16.4.1431; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROIHA H, 1981, NATURE, V290, P749, DOI 10.1038/290749a0; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TEMIN HM, 1989, NATURE, V339, P254, DOI 10.1038/339254a0; VARMUS H, 1989, MOBILE DNA, P53; VOYTAS DF, 1988, NATURE, V336, P242, DOI 10.1038/336242a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631; XIONG Y, 1988, MOL CELL BIOL, V8, P114, DOI 10.1128/MCB.8.1.114; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; [No title captured]	56	899	929	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					595	605		10.1016/0092-8674(93)90078-5	http://dx.doi.org/10.1016/0092-8674(93)90078-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679954				2022-12-01	WOS:A1993KP16500014
J	MIYATA, T; TAKEDA, J; IIDA, Y; YAMADA, N; INOUE, N; TAKAHASHI, M; MAEDA, K; KITANI, T; KINOSHITA, T				MIYATA, T; TAKEDA, J; IIDA, Y; YAMADA, N; INOUE, N; TAKAHASHI, M; MAEDA, K; KITANI, T; KINOSHITA, T			THE CLONING OF PIG-A, A COMPONENT IN THE EARLY STEP OF GPI-ANCHOR BIOSYNTHESIS	SCIENCE			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; VARIANT SURFACE GLYCOPROTEIN; THY-1 GLYCOPROTEIN; MEMBRANE-PROTEIN; CELLS; EXPRESSION; MUTANTS; VECTOR	The glycosylphosphatidylinositol (GPI) anchor is a membrane attachment structure of many proteins and occurs in a wide variety of eukaryotes from yeasts to mammals. The structure of the core of the GPI anchor is conserved in protozoa and mammals and so is its biosynthetic pathway. A complementary DNA encoding a human protein termed PIG-A (phosphatidylinositol glycan-class A) was cloned. PIG-A was necessary for synthesis of N-acetylglucosaminyl-phosphatidylinositol, the very early intermediate in GPI-anchor biosynthesis.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,BRANCH HOSP,SCH MED,DEPT INTERNAL MED,NAGOYA 461,JAPAN; GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN	Osaka University; Nagoya University; Gifu University			Kinoshita, Taroh/C-7353-2009; Takahashi, Minoru/G-4748-2011; Miyata, Toshio/A-4872-2010					ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; INOUE N, UNPUB; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAHASHI M, UNPUB; UETSUKI T, 1989, J BIOL CHEM, V264, P5791	29	421	429	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1318	1321		10.1126/science.7680492	http://dx.doi.org/10.1126/science.7680492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	7680492				2022-12-01	WOS:A1993KN88300029
J	TROYANOVSKY, SM; ESHKIND, LG; TROYANOVSKY, RB; LEUBE, RE; FRANKE, WW				TROYANOVSKY, SM; ESHKIND, LG; TROYANOVSKY, RB; LEUBE, RE; FRANKE, WW			CONTRIBUTIONS OF CYTOPLASMIC DOMAINS OF DESMOSOMAL CADHERINS TO DESMOSOME ASSEMBLY AND INTERMEDIATE FILAMENT ANCHORAGE	CELL			English	Article							CELL-ADHESION MOLECULES; AMINO-ACID-SEQUENCE; JUNCTIONAL PLAQUE PROTEIN; KIDNEY EPITHELIAL-CELLS; MESSENGER-RNA; GLYCOPROTEIN-3 DESMOCOLLINS; PEMPHIGUS-VULGARIS; HUMAN PLAKOGLOBIN; GAP-JUNCTIONS; CLONED CDNA	To examine the potential of cytoplasmic portions (''tails'') of desmosomal cadherins for assembly of desmosome plaque structures and anchorage of intermediate filaments (IFs), we transfected cultured human A-431 carcinoma cells, abundant in desmosomes and cytokeratin IFs, with constructs encoding chimeric proteins in which the transmembranous region of connexin 32 had been fused with tails of desmocollin (Dsc) or desmoglein (Dsg). The results show that the tail of the long splice form a of Dsc, but not its shorter splice form b, contains sufficient information to recruit desmoplakin and plakoglobin to connexon membrane paracrystals (gap junctions) and to form a novel kind of plaque at which cytokeratin IFs attach. By contrast, chimeras containing a Dsg tail, which accumulated in the plasma membrane, showed a dominant-negative effect: they not only were unable to form gap junction structures and plaques but also led to the disappearance of all endogenous desmosomes and the detachment of IFs from the plasma membrane.			TROYANOVSKY, SM (corresponding author), GERMAN CANC RES CTR,DIV CELL BIOL,W-6900 HEIDELBERG,GERMANY.			Leube, Rudolf/0000-0002-5519-7379; Franke, Werner W./0000-0002-4873-8448				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BUXTON RS, 1993, IN PRESS J CELL BIOL; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1984, J CELL SCI, V70, P41; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Cowin P, 1985, CELL CONTACT, P427; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRANKE WW, 1987, VIRCHOWS ARCH A, V411, P137, DOI 10.1007/BF00712737; FRANKE WW, 1987, EXP CELL RES, V173, P17, DOI 10.1016/0014-4827(87)90328-4; FRANKE WW, 1984, CELL, V36, P813, DOI 10.1016/0092-8674(84)90031-X; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HORST M, 1991, P NATL ACAD SCI USA, V82, P4137; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KARTENBECK J, 1982, EMBO J, V1, P725, DOI 10.1002/j.1460-2075.1982.tb01237.x; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KEMLER R, 1990, MORPHOREGULATORY MOL, P41; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOCH PJ, 1991, DIFFERENTIATION, V47, P29, DOI 10.1111/j.1432-0436.1991.tb00218.x; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1991, EUR J CELL BIOL, V55, P200; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KREIS TE, 1983, CELL, V32, P1125, DOI 10.1016/0092-8674(83)90296-9; LARSEN WJ, 1985, MOD CELL BIOL, V4, P151; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1986, LAB INVEST, V54, P4; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NILLES LA, 1991, J CELL SCI, V99, P809; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PARRISH EP, 1990, J CELL SCI, V96, P239; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PENN EJ, 1987, J CELL BIOL, V105, P57, DOI 10.1083/jcb.105.1.57; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P184; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SINGER SJ, 1992, NATURE, V255, P1671; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THEIS DG, 1993, IN PRESS INT J DEV T; TROYANOVSKY SM, 1989, J CELL SCI, V93, P419; TROYANOVSKY SM, 1992, EUR J CELL BIOL, V59, P127; TSUKITA S, 1990, CELL STRUCT FUNCT, V15, P7, DOI 10.1247/csf.15.7; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G	66	172	172	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					561	574		10.1016/0092-8674(93)90075-2	http://dx.doi.org/10.1016/0092-8674(93)90075-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679953				2022-12-01	WOS:A1993KP16500011
J	VIVILLE, S; NEEFJES, J; LOTTEAU, V; DIERICH, A; LEMEUR, M; PLOEGH, H; BENOIST, C; MATHIS, D				VIVILLE, S; NEEFJES, J; LOTTEAU, V; DIERICH, A; LEMEUR, M; PLOEGH, H; BENOIST, C; MATHIS, D			MICE LACKING THE MHC CLASS II-ASSOCIATED INVARIANT CHAIN	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL DETERMINANTS; HLA-DR MOLECULES; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; IA ANTIGENS; INTRACELLULAR-TRANSPORT; EXOGENOUS ANTIGEN; PEPTIDE BINDING	The invariant chain (Ii) has aroused much interest because of its close association with major histocompatibility complex (MHC) class II molecules. Various functions have been proposed for it; several of these have received experimental support, but most have not been definitively proven, owing largely to uncertainties inherent in the experimental systems employed. We have now generated a line of mice devoid of the invariant chain by introducing a drastic mutation into the Ii gene. Cells from mutant animals show aberrant transport of MHC class II molecules, resulting in reduced levels of class II complexes at the surface, and these do not have the typical compact conformation indicative of tight peptide binding. Consequently, mutant cells present protein antigens very poorly and mutant mice are deficient in producing and at negatively selecting CD4+ T cells.	NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; FAC MED PARIS,INST CORDELIERS,F-75006 PARIS,FRANCE	Netherlands Cancer Institute; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	VIVILLE, S (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Neefjes, Jacques J.C./H-8780-2017; lotteau, vincent/M-8143-2014	Neefjes, Jacques J.C./0000-0001-6763-2211; Lotteau, Vincent/0000-0003-0997-3282; Viville, Stephane/0000-0002-5088-3003				ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BECK BN, 1986, J IMMUNOL, V136, P2953; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1411, DOI 10.1002/eji.1830210613; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CLEASSONWELSH L, 1985, J IMMUNOL, V135, P3551; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FISCH A, 1992, EUR J IMMUNOL, V22, P1413, DOI 10.1002/eji.1830220613; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HACKETT CJ, 1991, J IMMUNOL, V146, P2944; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOBORI JA, 1992, P NATL ACAD SCI USA, V89, P2940, DOI 10.1073/pnas.89.7.2940; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOCH N, 1991, CURR OPIN IMMUNOL, V3, P10, DOI 10.1016/0952-7915(91)90069-D; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LEMEUR M, 1985, NATURE, V316, P38, DOI 10.1038/316038a0; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LORENZ RG, 1988, J IMMUNOL, V141, P4124; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MICHALEK MT, 1992, J IMMUNOL, V148, P1016; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORENO J, 1991, J IMMUNOL, V147, P3306; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RATH S, 1992, EUR J IMMUNOL, V22, P2121, DOI 10.1002/eji.1830220824; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SEKALY RP, 1988, P NATL ACAD SCI USA, V85, P1209, DOI 10.1073/pnas.85.4.1209; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SIMONIS S, 1989, J IMMUNOL, V143, P3619; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WEI BY, 1991, INT IMMUNOL, V3, P833, DOI 10.1093/intimm/3.8.833; WEISS S, 1991, CELL, V64, P797; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	72	350	353	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					635	648		10.1016/0092-8674(93)90081-Z	http://dx.doi.org/10.1016/0092-8674(93)90081-Z			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679955				2022-12-01	WOS:A1993KP16500017
J	AZZOPARDI, P; COWEY, A				AZZOPARDI, P; COWEY, A			PREFERENTIAL REPRESENTATION OF THE FOVEA IN THE PRIMARY VISUAL-CORTEX	NATURE			English	Article							CORTICAL MAGNIFICATION FACTOR; LATERAL GENICULATE-NUCLEUS; GANGLION-CELL DENSITY; MACAQUE MONKEYS; STRIATE CORTEX; RETINA; FIELD; UNIFORMITY; NEURONS; VISION	THE retinal fovea, which corresponds to the central degree or so of vision, is spatially over-represented in the visual cortex. It is about 0.01% of retina area, but at least 8% of the striate cortex1-3. Does this simply reflect an equivalently uneven distribution of ganglion cells in the retina4-7, or is the cortical representation of the fovea preferentially expanded8-13? The answer hinges on the resolution of long-standing discrepancies between the retinal and cortical magnification factors. We approached the problem in a different way, using a retrograde transneuronal tracer from cortex to retina to relate directly the number of ganglion cells projecting to marked areas of striate cortex. We report here that ganglion cells near the fovea were allocated 3.3 to 5.9 times more cortical tissue than more peripheral ones, and conclude that the cortical representation of the most central retina is much greater than expected from the density of its ganglion cells.			AZZOPARDI, P (corresponding author), UNIV OXFORD,DEPT EXPTL PSYCHOL,S PARKS RD,OXFORD OX1 3UD,ENGLAND.		Azzopardi, Paul/C-5694-2013	Azzopardi, Paul/0000-0001-7386-8191				[Anonymous], 1941, AM J OPHTHALMOL, DOI [10.1016/S0002-9394(41)91363-6, DOI 10.1016/S0002-9394(41)91363-6]; CONNOLLY M, 1984, J COMP NEUROL, V226, P544, DOI 10.1002/cne.902260408; COWEY A, 1964, J NEUROPHYSIOL, V27, P366, DOI 10.1152/jn.1964.27.3.366; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DOW BM, 1981, EXP BRAIN RES, V44, P213; DRASDO N, 1977, NATURE, V266, P554, DOI 10.1038/266554a0; FENDICK M, 1983, VISION RES, V23, P145, DOI 10.1016/0042-6989(83)90137-2; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; Kulikowski J. J., 1989, SEEING CONTOUR COLOU, P274; LEVAY S, 1990, EXP BRAIN RES, V82, P77; LEVI DM, 1984, VISION RES, V24, P789, DOI 10.1016/0042-6989(84)90150-0; LEVI DM, 1987, VISION RES, V27, P581, DOI 10.1016/0042-6989(87)90044-7; MALPELI JG, 1975, J COMP NEUROL, V161, P569, DOI 10.1002/cne.901610407; MYERSON J, 1977, SCIENCE, V192, P855; OKUSKY J, 1982, J COMP NEUROL, V210, P278, DOI 10.1002/cne.902100307; PERRY VH, 1985, VISION RES, V25, P1795, DOI 10.1016/0042-6989(85)90004-5; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PERRY VH, 1984, NEUROSCIENCE, V12, P1125, DOI 10.1016/0306-4522(84)90007-1; PERRY VH, 1988, NEUROSCIENCE, V25, P225, DOI 10.1016/0306-4522(88)90021-8; POTTS AM, 1972, INVEST OPHTH VISUAL, V11, P980; POWELL TPS, 1981, BRAIN RES, V216, P409, DOI 10.1016/0006-8993(81)90142-6; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; ROLLS ET, 1970, EXP BRAIN RES, V10, P298; ROVAMO J, 1979, EXP BRAIN RES, V37, P495, DOI 10.1007/bf00236819; SCHEIN SJ, 1988, J COMP NEUROL, V269, P479, DOI 10.1002/cne.902690403; SILVEIRA LCL, 1989, VISION RES, V29, P1471, DOI 10.1016/0042-6989(89)90131-4; STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183; WASSLE H, 1989, NATURE, V341, P643, DOI 10.1038/341643a0; WASSLE H, 1990, VISION RES, V30, P1897, DOI 10.1016/0042-6989(90)90166-I	30	134	135	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					719	721		10.1038/361719a0	http://dx.doi.org/10.1038/361719a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680108				2022-12-01	WOS:A1993KN78900054
J	HART, AC; KRAMER, H; ZIPURSKY, SL				HART, AC; KRAMER, H; ZIPURSKY, SL			EXTRACELLULAR DOMAIN OF THE BOSS TRANSMEMBRANE LIGAND ACTS AS AN ANTAGONIST OF THE SEV RECEPTOR	NATURE			English	Article							TYROSINE-KINASE RECEPTOR; DROSOPHILA RETINA; SEVENLESS PROTEIN; GROWTH-FACTOR; CELL FATE; SI-LOCUS; BRIDE; GENE; ENCODES; MOUSE	THE fate of the R7 photoreceptor cell in the Drosophila compound eye is established by a specific inductive interaction between the R8 photoreceptor neuron and the R7 precursor cell1. This induction is mediated by two cell-surface proteins: the ligand, bride of sevenless2 (boss), and sevenless (sev), a tyrosine-kinase receptor3-5 The structure of boss is unique for a ligand of a tyrosine-kinase receptor. It contains a large extracellular domain, seven transmembrane segments, and a carboxy-terminal cytoplasmic tail6,7. Here we report that: (1) boss activates tyrosine phosphorylation of the sev receptor; (2) the seven transmembrane domain of boss is necessary for its function; and (3) a soluble form of boss acts as an antagonist of the sev receptor both in vivo and in vitro.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT BIOL CHEM,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181				ANKELESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CAGAN RC, 1992, CELL, V69, P309; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JI I, 1991, J BIOL CHEM, V266, P13076; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	21	36	37	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					732	736		10.1038/361732a0	http://dx.doi.org/10.1038/361732a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680109				2022-12-01	WOS:A1993KN78900059
J	LINDSLEY, JE; WANG, JC				LINDSLEY, JE; WANG, JC			STUDY OF ALLOSTERIC COMMUNICATION BETWEEN PROTOMERS BY IMMUNOTAGGING	NATURE			English	Article							TOPOISOMERASE-II; TRANSITION; DNA	LIGAND-INDUCED allosteric changes in proteins are important in their cellular functions and regulation1,2, and both concerted and sequential examples are known3-5. The distinction has entailed elaborate analysis, however, and only a few systems have been unequivocally analysed. We have investigated the coupling between ATP usage and DNA transport by type II DNA topoisomerases6,7, and one key question concerning allostery in these dyadic enzymes is whether ATP binding to one protomer can induce a concerted conformational change in the entire enzyme. Here we use an enzyme with one immunotagged subunit defective in ATP binding and one wild-type subunit to show that it can. Our approach should be generally applicable in the study of allostery and communication between members of a macromolecular assembly.			LINDSLEY, JE (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							DEPEW RE, 1978, J BIOL CHEM, V253, P511; FERSHT A, 1984, ENZYME STRUCTURE MEC, P263; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583	9	61	62	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					749	750		10.1038/361749a0	http://dx.doi.org/10.1038/361749a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680110				2022-12-01	WOS:A1993KN78900064
J	RODECK, CH				RODECK, CH			PRENATAL-DIAGNOSIS - FETAL DEVELOPMENT AFTER CHORIONIC VILLUS SAMPLING	LANCET			English	Editorial Material							DEFECTS				RODECK, CH (corresponding author), UNIV LONDON UNIV COLL,DEPT OBSTET & GYNAECOL,LONDON WC1E 6BT,ENGLAND.							BURTON BK, 1992, OBSTET GYNECOL, V79, P726; FABRIS C, 1992, PRENATAL DIAG, V12, P1074, DOI 10.1002/pd.1970121216; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; KULIEV AM, 1992, IN PRESS PRENAT DIAG; LIN SP, 1992, NOV M AM SOC HUM GEN; QUINTERO RA, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90272-5; WEBSTER WS, 1990, TERATOLOGY, V41, P689, DOI 10.1002/tera.1420410605; WEBSTER WS, 1987, TERATOLOGY, V35, P253, DOI 10.1002/tera.1420350212	9	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					468	469		10.1016/0140-6736(93)90213-Z	http://dx.doi.org/10.1016/0140-6736(93)90213-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	7679461				2022-12-01	WOS:A1993KN13700010
J	CHOW, YK; HIRSCH, MS; MERRILL, DP; BECHTEL, LJ; ERON, JJ; KAPLAN, JC; DAQUILA, RT				CHOW, YK; HIRSCH, MS; MERRILL, DP; BECHTEL, LJ; ERON, JJ; KAPLAN, JC; DAQUILA, RT			USE OF EVOLUTIONARY LIMITATIONS OF HIV-1 MULTIDRUG RESISTANCE TO OPTIMIZE THERAPY	NATURE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; VIRUS; REPLICATION; ZIDOVUDINE; DERIVATIVES; SENSITIVITY; INVITRO; MUTANTS; AZT	WILD-TYPE reverse transcriptase has evolved for the survival of human immunodeficiency virus type 1 (HIV-1) by natural selection1. In contrast, therapy relying on inhibitors of reverse transcriptase by nucleosides like zidovudine (AZT) or dideoxyinosine (ddI), and by non-nucleosides like pyridinones or nevirapine2-6, may exert different selection pressures on this enzyme. Therefore the acquisition of resistance to reverse transcriptase inhibitors by selection of mutations in the pol gene7-15 may require compromises in enzyme function that affect viral replication. As single mutations are unlikely to confer broad resistance when combinations of reverse transcriptase inhibitors are used, multiple mutations may occur that result in further compromises. Certain drug combinations may prevent the co-existence of adequate reverse transcription function and multi-drug resistance (MDR). Unlike bacterial or eukaryotic drug resistance, retroviral drug resistance is conferred only by mutations in its own genome16 and is limited by genome size. Combining drugs directed against the same essential viral protein may thus prevent HIV-1 MDR, whereas the conventional approach of targeting different HIV-1 proteins for combination therapy may not, because genomes with resistance mutations in different HIV-1 genes might recombine to develop MDR17. Here we show that several mutations in the HIV-1 reverse transcriptase gene that confer resistance to inhibitors of this enzyme can attenuate viral replication. We tested whether combinations of mutations giving rise to single-agent resistance might further compromise or even abolish viral replication, and if multidrug-resistant viruses could be constructed. Certain combinations of mutations conferring resistance to AZT, ddI and pyridinone are incompatible with viral replication. These results indicate that evolutionary limitations exist to restrict development of MDR. Furthermore, a therapeutic strategy exploiting these limitations by using selected multidrug regimens directed against the same target may prevent development of MDR. This approach, which we call convergent combination therapy, eliminated HIV-1 replication and virus breakthrough in vitro, and may be applicable to other viral targets. Moreover, elimination of reverse transcription by convergent combination therapy may also limit MDR.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	CHOW, YK (corresponding author), MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,GRAY 5,BOSTON,MA 02114, USA.							ALBERT J, 1992, J VIROL, V66, P5627, DOI 10.1128/JVI.66.9.5627-5630.1992; BALZARINI J, 1992, ANTIMICROB AGENTS CH, V36, P1073, DOI 10.1128/AAC.36.5.1073; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; COEN DM, 1986, J ANTIMICROB CHEMOTH, V18, P1; ERON JJ, 1992, P NATL ACAD SCI USA, V89, P3241, DOI 10.1073/pnas.89.8.3241; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Johnson V., 1990, TECHNIQUES HIV RES; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; JOHNSON VA, 1990, J INFECT DIS, V161, P1057; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KORNFELD H, 1987, NATURE, V326, P610, DOI 10.1038/326610a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND S, 1992, J INFECT DIS, V166, P1139, DOI 10.1093/infdis/166.5.1139; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TEMIN HM, 1989, J ACQ IMMUN DEF SYND, V2, P1; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	30	154	166	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					650	654		10.1038/361650a0	http://dx.doi.org/10.1038/361650a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	7679778				2022-12-01	WOS:A1993KM77600068
J	JOHNSON, RJ; GRETCH, DR; YAMABE, H; HART, J; BACCHI, CE; HARTWELL, P; COUSER, WG; COREY, L; WENER, MH; ALPERS, CE; WILLSON, R				JOHNSON, RJ; GRETCH, DR; YAMABE, H; HART, J; BACCHI, CE; HARTWELL, P; COUSER, WG; COREY, L; WENER, MH; ALPERS, CE; WILLSON, R			MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS-C VIRUS-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESSENTIAL MIXED CRYOGLOBULINEMIA; RECOMBINANT INTERFERON-ALFA; B VIRUS; ALPHA-INTERFERON; CONTROLLED TRIAL; NON-A; ANTIBODIES; CLONE	Background and Methods. Hepatitis C virus (HCV) infection causes both acute and chronic liver disease and is also associated with mixed cryoglobulinemia. Whether HCV is also associated with renal disease, as is the hepatitis B virus, is not known. We describe the clinical, pathologic, virologic, and immunologic features of eight patients with HCV infection who were referred to nephrologists for glomerulonephritis. Four patients were treated with interferon alfa. Results. All eight patients had proteinuria, and seven had decreased renal function. Renal biopsy in all patients revealed membranoproliferative glomerulonephritis, characterized by the deposition of IgG, IgM, and C3 in glomeruli. Electron microscopy of the biopsy specimens showed cryoglobulin-like structures in three of four patients. All eight patients had HCV RNA detected in their serum, elevated serum aminotransferase concentrations, and hypocomplementemia, and the majority had cryoglobulins and circulating immune complexes in their serum. Cryoprecipitates from the three patients who were tested contained HCV RNA and IgG anti-HCV antibodies to the nucleocapsid core antigen (HCVc or c22-3). IgM rheumatoid factors, present in all patients, bound anti-HCV IgG in all six patients tested. Four patients received interferon alfa for 2 to 12 months; all had evidence of decreased HCV replication and improvement of their renal and liver disease. Conclusions. Chronic HCV infection is associated with cryoglobulinemia and membranoproliferative glomerulonephritis. The pathogenesis is unknown, but may relate to deposition within glomeruli of immune complexes containing HCV, anti-HCV IgG, and IgM rheumatoid factors.	UNIV WASHINGTON,MED CTR,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,MED CTR,DEPT PATHOL,SEATTLE,WA 98195; HIROSAKI UNIV,SCH MED,DEPT MED,DIV NEPHROL,HIROSAKI,AOMORI 036,JAPAN	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Hirosaki University	JOHNSON, RJ (corresponding author), UNIV WASHINGTON,MED CTR,DEPT MED,DIV NEPHROL,BB-1257 HLTH SCI,SEATTLE,WA 98195, USA.		Wener, Mark/ABE-4491-2021	Johnson, Richard/0000-0003-3312-8193	NIDDK NIH HHS [DK 43422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK043422, R01DK043422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; Berger J, 1977, Adv Nephrol Necker Hosp, V7, P3; BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; CACOUB P, 1992, ANN INTERN MED, V116, P605, DOI 10.7326/0003-4819-116-7-605_2; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAMMACCO F, 1992, CLIN EXP IMMUNOL, V87, P352, DOI 10.1111/j.1365-2249.1992.tb03001.x; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DEBANDT M, 1991, CLIN EXP RHEUMATOL, V9, P659; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DISDIER P, 1991, LANCET, V338, P1151, DOI 10.1016/0140-6736(91)92014-S; DRUET P, 1973, CLIN EXP IMMUNOL, V15, P483; DURAND JM, 1992, J INFECT DIS, V165, P778, DOI 10.1093/infdis/165.4.778; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P95; FIORINI G, 1986, CLIN EXP IMMUNOL, V64, P65; FLORINCH.A, 1974, CLIN EXP IMMUNOL, V16, P599; FRANKEL AH, 1992, Q J MED, V82, P101; GALLI M, 1992, LANCET, V339, P989, DOI 10.1016/0140-6736(92)91562-M; GRETCH D, 1992, J CLIN MICROBIOL, V30, P2145, DOI 10.1128/JCM.30.8.2145-2149.1992; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; JOHNSON RJ, 1990, KIDNEY INT, V37, P663, DOI 10.1038/ki.1990.32; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KNOX TA, 1991, AM J MED, V91, P554, DOI 10.1016/0002-9343(91)90196-5; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; Levo Y, 1977, Trans Assoc Am Physicians, V90, P167; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; NEGRO F, 1992, P NATL ACAD SCI USA, V89, P2247, DOI 10.1073/pnas.89.6.2247; NOBLEJAMIESON G, 1992, LANCET, V339, P706, DOI 10.1016/0140-6736(92)90600-8; OZAWA T, 1976, ARCH PATHOL LAB MED, V100, P484; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PETERS M, 1989, SEMIN LIVER DIS, V9, P235, DOI 10.1055/s-2008-1040516; POPP JW, 1980, ANN INTERN MED, V92, P379, DOI 10.7326/0003-4819-92-3-379; RODRIGUEZITURBE B, 1984, KIDNEY INT, V25, P129, DOI 10.1038/ki.1984.19; ROLLINO C, 1991, NEPHRON, V59, P319, DOI 10.1159/000186573; 1990, NEW ENGL J MED, V323, P1756	38	792	806	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					465	470		10.1056/NEJM199302183280703	http://dx.doi.org/10.1056/NEJM199302183280703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	7678440				2022-12-01	WOS:A1993KM41700003
J	ALLEN, RC; ARMITAGE, RJ; CONLEY, ME; ROSENBLATT, H; JENKINS, NA; COPELAND, NG; BEDELL, MA; EDELHOFF, S; DISTECHE, CM; SIMONEAUX, DK; FANSLOW, WC; BELMONT, J; SPRIGGS, MK				ALLEN, RC; ARMITAGE, RJ; CONLEY, ME; ROSENBLATT, H; JENKINS, NA; COPELAND, NG; BEDELL, MA; EDELHOFF, S; DISTECHE, CM; SIMONEAUX, DK; FANSLOW, WC; BELMONT, J; SPRIGGS, MK			CD40 LIGAND GENE DEFECTS RESPONSIBLE FOR X-LINKED HYPER-IGM SYNDROME	SCIENCE			English	Article							HUMAN B-CELLS; HYPERIMMUNOGLOBULINEMIA-M; T-CELLS; IMMUNODEFICIENCY; INTERLEUKIN-4; DIFFERENTIATION; SWITCH; PROLIFERATION; LOCALIZATION; ACTIVATION	The ligand for CD40 (CD40L) is a membrane glycoprotein on activated T cells that induces B cell proliferation and immunoglobulin secretion. Abnormalities in the CD40L gene were associated with an X-linked immunodeficiency in humans [hyper-IgM (immunoglobulin M) syndrome]. This disease is characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. CD40L complementary DNAs from three of four patients with this syndrome contained distinct point mutations. Recombinant expression of two of the mutant CD40L complementary DNAs resulted in proteins incapable of binding to CD40 and unable to induce proliferation or IgE secretion from normal B cells. Activated T cells from the four affected patients failed to express wild-type CD40L, although their B cells responded normally to wild-type CD40L. Thus, these CD40L defects lead to a T cell abnormality that results in the failure of patient B cells to undergo immunoglobulin class switching.	IMMUNEX RES & DEV CORP, DEPT MOLEC BIOL, SEATTLE, WA 98101 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC GENET, HOUSTON, TX 77030 USA; IMMUNEX RES & DEV CORP, DEPT IMMUNOL, SEATTLE, WA 98101 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; Baylor College of Medicine			Belmont, John W/AAI-2494-2019; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; PHS HHS [A125129] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1990, J IMMUNOL, V144, P938; ARMITAGE RJ, UNPUB; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BRAHMI Z, 1983, J CLIN IMMUNOL, V3, P127, DOI 10.1007/BF00915483; CLAASSEN JL, 1990, J IMMUNOL METHODS, V126, P213, DOI 10.1016/0022-1759(90)90153-M; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GALY AHM, 1992, J IMMUNOL, V149, P775; GEHA RS, 1979, J CLIN INVEST, V64, P385, DOI 10.1172/JCI109473; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GREEN EL, 1992, GENETICS PROBABILITY, P77; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JAMIESON WM, 1962, ARCH DIS CHILD, V37, P330, DOI 10.1136/adc.37.193.330; KYONG CU, 1978, PEDIATR RES, V12, P1024, DOI 10.1203/00006450-197810000-00015; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LEVITT D, 1983, J CLIN INVEST, V72, P1650, DOI 10.1172/JCI111124; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MALISZEWSKI CR, UNPUB; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WINFIELD JB, 1982, CLIN IMMUNOL IMMUNOP, V23, P58, DOI 10.1016/0090-1229(82)90070-8; ZHANG K, 1991, J IMMUNOL, V146, P1836	40	738	766	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1993	259	5097					990	993		10.1126/science.7679801	http://dx.doi.org/10.1126/science.7679801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	7679801				2022-12-01	WOS:A1993KL80000049
J	KASSAVETIS, GA; GEIDUSCHEK, EP				KASSAVETIS, GA; GEIDUSCHEK, EP			RNA-POLYMERASE MARCHING BACKWARD	SCIENCE			English	Editorial Material							TRANSCRIPTION ELONGATION; TERNARY COMPLEXES; GENE; TERMINATION; INVITRO; DOMAIN; TFIIS		UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	KASSAVETIS, GA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AGARWAL KL, COMMUNICATION; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, IN PRESS CELL; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; HAGLER J, IN PRESS J BIOL CHEM; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, COMMUNICATION; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1992, J BIOL CHEM, V267, P2795; REINES D, IN PRESS P NATL ACAD; ROZOVSKAYA TA, 1988, MOL BIOL, V15, P498; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	29	82	83	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					944	945		10.1126/science.7679800	http://dx.doi.org/10.1126/science.7679800			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	7679800				2022-12-01	WOS:A1993KL80000034
J	NEOTE, K; DIGREGORIO, D; MAK, JY; HORUK, R; SCHALL, TJ				NEOTE, K; DIGREGORIO, D; MAK, JY; HORUK, R; SCHALL, TJ			MOLECULAR-CLONING, FUNCTIONAL EXPRESSION, AND SIGNALING CHARACTERISTICS OF A C-C CHEMOKINE RECEPTOR	CELL			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEIN; NEUTROPHIL CHEMOTACTIC FACTOR; HUMAN INTERLEUKIN-8 RECEPTOR; HUMAN BETA-HEXOSAMINIDASE; CELL-SURFACE RECEPTORS; CYTOKINE FAMILY; LYMPHOCYTES-T; IDENTIFICATION; BINDING	The immunoregulatory proteins C-C chemokines are potent chemoattractants of lymphocytes and monocytes, as well as activators and attractants of eosinophils and basophils. We have isolated a cDNA that encodes a seven transmembrane-spanning receptor, with homology to other chemoattractant receptors, that encodes a protein designated C-C CKR-1 that acts as a receptor for the C-C chemokines. Human and murine macrophage inflammatory protein 1alpha (MIP-1alpha), human macrophage inflammatory protein 1beta (MIP-1beta), human monocyte chemotactic protein 1 (MCP-1), and RANTES all bind to the C-C CKR-1 with varying affinities. Chemokine binding affinity does not predict how well the ligand will transmit a signal through the receptor: RANTES and human MIP-1alpha induce a similar intracellular calcium flux while binding with disparate affinities, while MCP-1 and human MIP-1beta induce calcium mobilization only at high concentrations. Finally, C-C chemokines were shown to bind a C-C CKR-1-related gene product encoded by cytomegalovirus, suggesting a role for C-C chemokines in viral immunity.			NEOTE, K (corresponding author), GENENTECH INC, DEPT IMMUNOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.							ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BROWNE H, 1990, J VIROL, V64, P2181; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVATELIS G, 1989, SCIENCE, V243, P1066, DOI 10.1126/science.2646711; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUNLOP DJ, 1992, BLOOD, V79, P2221; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRAHAM GJ, 1992, DEV BIOL, V151, P377, DOI 10.1016/0012-1606(92)90177-I; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1987, J BIOL CHEM, V262, P16275; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; LARRICK JW, 1992, TRENDS BIOTECHNOL, V10, P146, DOI 10.1016/0167-7799(92)90202-7; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NACCACHE PH, 1989, J IMMUNOL, V142, P2438; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; NEOTE K, 1990, J BIOL CHEM, V265, P20799; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; NGUYEN T, 1991, GENE, V109, P211, DOI 10.1016/0378-1119(91)90611-E; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OH KO, 1991, J IMMUNOL, V147, P2978; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHILD HO, 1973, DRUG RECEPTORS, P29; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VALENTE AJ, 1991, BIOCHEM BIOPH RES CO, V176, P309, DOI 10.1016/0006-291X(91)90925-W; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1990, J IMMUNOL, V145, P292	61	744	885	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					415	425		10.1016/0092-8674(93)90118-A	http://dx.doi.org/10.1016/0092-8674(93)90118-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	7679328				2022-12-01	WOS:A1993KM16200011
J	IMAI, Y; LASKY, LA; ROSEN, SD				IMAI, Y; LASKY, LA; ROSEN, SD			SULFATION REQUIREMENT FOR GLYCAM-1, AN ENDOTHELIAL LIGAND FOR L-SELECTIN	NATURE			English	Article							LYMPHOCYTE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; SIALYL-LEX; RECOGNITION; ELAM-1; RECIRCULATION; CDNA	L-SELECTIN participates in the initial attachment of leukocytes to the vascular endothelium1-3. On lymphocytes, it mediates binding to high endothelial venules of lymph nodes. As a selectin 4-6 it functions as a calcium-dependent lectin7,8 recognizing carbohydrate-bearing ligands on endothelial cells9-11. Two lymph node ligands for L-selectin have been identified as sulphated glycoproteins of M(r) approximately 50K and approximately 90K, called Sgp50 and Sgp90 (ref. 10). The recently cloned Sgp50 (ref 12), now designated GlyCAM-1, is a high endothelial venule-associated, mucin-like glycoprotein containing predominantly O-linked carbohydrate chains. Sialylation of GlyCAM-1 is necessary for its ligand activity9,10,13 and a role for fucosylation is suspected13. We have used chlorate as a metabolic inhibitor of sulphation, and report here that GlyCAM-1 has an additional requirement for sulphate.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM IMMUNOL,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT IMMUNOBIOL,S SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Roche Holding; Genentech			Imai, Yasuyuki/E-8701-2010	Imai, Yasuyuki/0000-0002-8937-0221				BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; IMAI Y, IN PRESS GLYCOCONJUG; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725	29	338	350	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					555	557						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	7679207				2022-12-01	WOS:A1993KL71400067
J	KORTHAUER, U; GRAF, D; MAGES, HW; BRIERE, F; PADAYACHEE, M; MALCOLM, S; UGAZIO, AG; NOTARANGELO, LD; LEVINSKY, RJ; KROCZEK, RA				KORTHAUER, U; GRAF, D; MAGES, HW; BRIERE, F; PADAYACHEE, M; MALCOLM, S; UGAZIO, AG; NOTARANGELO, LD; LEVINSKY, RJ; KROCZEK, RA			DEFECTIVE EXPRESSION OF T-CELL CD40 LIGAND CAUSES X-LINKED IMMUNODEFICIENCY WITH HYPER-IGM	NATURE			English	Article							HUMAN LYMPHOCYTES-B; HYPERIMMUNOGLOBULINEMIA-M; ANTIGEN; PROLIFERATION; FORM	X CHROMOSOME-LINKED immunodeficiency with hyper-IgM (HIGM1, MIM number 308230) is a rare disorder characterized by recurrent bacterial infections, very low or absent IgG, IgA and IgE, and normal to increased IgM and IgD serum levels1-3. HIGM1 has been suggested to result from ineffective T-cell help for B cells4. We and others5-8 have identified a novel, TNF-related activation protein (TRAP) that is exclusively expressed on the surface of stimulated T cells6,8. TRAP, a type II transmembrane protein of M(r) 33,000, is the physiological ligand for CD40 (refs 5-8). Crosslinking of CD40 on B cells induces, in the presence of lymphokines, immunoglobulin class switching from IgM to IgG, IgA or IgE5,9-11. Mapping of the TRAP gene to the X-chromosomal location q26.3-q27.1 (ref. 6) suggested a causal relationship to HIGM1, which had previously been assigned to Xq26 (refs 12-14). Here we present evidence that point mutations in the TRAP gene give rise to nonfunctional or defective expression of TRAP on the surface of T cells in patients with HIGM1. The resultant failure of TRAP to interact with CD40 on functionally intact B cells is responsible for the observed immunoglobulin isotype defect in HIGM1.	UNIV ERLANGEN NURNBERG, INST KLIN IMMUNOL, ARBEITSGRP IMMUNOL, MAX PLANCK GESELLSCH, W-8520 ERLANGEN, GERMANY; SCHERING PLOUGH CORP, IMMUNOL RES LAB, F-69571 DARDILLY, FRANCE; INST CHILD HLTH, LONDON WC1N 1EH, ENGLAND; UNIV BRESCIA, I-25123 BRESCIA, ITALY	Max Planck Society; University of Erlangen Nuremberg; Merck & Company; Schering Plough Corporation; University of London; University College London; University of Brescia			Ugazio, Alberto/AAA-6092-2020; Notarangelo, Luigi D/F-9718-2016; Graf, Daniel/H-1214-2011	Notarangelo, Luigi D/0000-0002-8335-0262; Graf, Daniel/0000-0003-1163-8117				ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BURTIN P, 1961, REV FR ETUD CLIN BIO, V6, P286; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HERMANN P, IN PRESS EUR J IMMUN; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PADAYACHEE M, IN PRESS J MED GENET; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543	18	673	696	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 11	1993	361	6412					539	541		10.1038/361539a0	http://dx.doi.org/10.1038/361539a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	7679206				2022-12-01	WOS:A1993KL71400061
J	HORTON, R				HORTON, R			ESOPHAGEAL CANCER - LASER PALLIATION OF MALIGNANT DYSPHAGIA	LANCET			English	Editorial Material							CARCINOMA						Gandevia, Simon/D-5009-2011	Gandevia, Simon/0000-0002-1345-3821				BARR H, 1991, CANCER, V68, P1660, DOI 10.1002/1097-0142(19911001)68:7<1660::AID-CNCR2820680733>3.0.CO;2-L; GATZINSKY P, 1985, J THORAC CARDIOV SUR, V89, P71; LOIZOU LA, 1992, CANCER, V70, P386, DOI 10.1002/1097-0142(19920715)70:2<386::AID-CNCR2820700203>3.0.CO;2-H; MAUNOURY V, 1992, GUT, V33, P1602, DOI 10.1136/gut.33.12.1602; NAKAYAMA K, 1964, Clin Radiol, V15, P232, DOI 10.1016/S0009-9260(64)80073-8; SARGEANT IR, 1992, GUT, V33, P1597, DOI 10.1136/gut.33.12.1597; SKINNER DB, 1986, ANN SURG, V204, P391, DOI 10.1097/00000658-198610000-00007; WANG M, 1989, INT J RADIAT ONCOL, V16, P325; ZENONE T, 1992, EUR J CANCER, V28A, P1380, DOI 10.1016/0959-8049(92)90525-7	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					348	348		10.1016/0140-6736(93)90145-7	http://dx.doi.org/10.1016/0140-6736(93)90145-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	7679176				2022-12-01	WOS:A1993KK93900013
J	HOOVER, JE; STRICK, PL				HOOVER, JE; STRICK, PL			MULTIPLE OUTPUT CHANNELS IN THE BASAL GANGLIA	SCIENCE			English	Article							PRIMATE MOTOR CORTEX; FREE ARM MOVEMENTS; FRONTAL-LOBE; THALAMIC INPUTS; GLOBUS-PALLIDUS; CORTICOSPINAL PROJECTIONS; NEURONAL POPULATION; 3-DIMENSIONAL SPACE; ARCUATE PREMOTOR; VISUAL TARGETS	The neural circuits that link the basal ganglia with the cerebral cortex are critically involved in the generation and control of voluntary movement. Retrograde transneuronal transport of herpes simplex virus type 1 was used to examine the organization of connections in the cebus monkey between an output nucleus of the basal ganglia, the internal segment of the globus pallidus (GPi), and three cortical areas: the primary motor cortex, the supplementary motor area, and the ventral premotor area. Spatially separate regions of the GPi were labeled after virus injections into each cortical area. The GPi projects to multiple cortical motor areas, and this pallidal output is organized into discrete channels. This information provides a new anatomical framework for examining the function of the basal ganglia in skeletomotor control.	SUNY HLTH SCI CTR, VET ADM MED CTR, RES SERV, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24328, NS2957] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; Barbeau A., 1986, HDB CLIN NEUROLOGY, P87; BORTOFF GA, UNPUB; COOPER IS, 1958, J NEUROSURG, V15, P244, DOI 10.3171/jns.1958.15.3.0244; DeLong M. R., 1981, HDB PHYSL NERVOUS SY, P1017; DEVITO JL, 1982, EXP BRAIN RES, V46, P107; DUM RP, 1991, J NEUROSCI, V11, P667; EVARTS EV, 1984, TRENDS NEUROSCI, V7, P447, DOI 10.1016/S0166-2236(84)80151-4; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GIGUERE M, 1988, J COMP NEUROL, V277, P195, DOI 10.1002/cne.902770204; GOLDMANRAKIC PS, 1990, TRENDS NEUROSCI, V13, P241, DOI 10.1016/0166-2236(90)90103-H; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; HEINDEL WC, 1989, J NEUROSCI, V9, P582; HOLSAPPLE JW, 1991, J NEUROSCI, V11, P2644; HUMPHREY DR, 1991, DAHLEM WORKSHOP REPO, P413; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KEMP JM, 1970, BRAIN, V93, P525, DOI 10.1093/brain/93.3.525; KIM R, 1976, J COMP NEUROL, V169, P263, DOI 10.1002/cne.901690302; KUO JS, 1973, J COMP NEUROL, V151, P201, DOI 10.1002/cne.901510302; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Manocha S. L., 1968, STEREOTAXIC ATLAS BR; MARSDEN CD, 1982, NEUROLOGY, V32, P514, DOI 10.1212/WNL.32.5.514; MATELLI M, 1989, J COMP NEUROL, V280, P468, DOI 10.1002/cne.902800311; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; NAMBU A, 1991, EXP BRAIN RES, V84, P279; NAUTA WALLE J. H., 1966, BRAIN RES, V1, P3, DOI 10.1016/0006-8993(66)90103-X; SCHELL GR, 1984, J NEUROSCI, V4, P539; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; STRICK PL, IN PRESS EXPT NEUROA; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; UGOLINI G, 1989, SCIENCE, V243, P89, DOI 10.1126/science.2536188; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P91; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245; ZEMANICK MC, 1991, P NATL ACAD SCI USA, V88, P8048, DOI 10.1073/pnas.88.18.8048	38	466	471	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					819	821		10.1126/science.7679223	http://dx.doi.org/10.1126/science.7679223			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	7679223				2022-12-01	WOS:A1993KL11000035
J	ARUFFO, A; FARRINGTON, M; HOLLENBAUGH, D; LI, X; MILATOVICH, A; NONOYAMA, S; BAJORATH, J; GROSMAIRE, LS; STENKAMP, R; NEUBAUER, M; ROBERTS, RL; NOELLE, RJ; LEDBETTER, JA; FRANCKE, U; OCHS, HD				ARUFFO, A; FARRINGTON, M; HOLLENBAUGH, D; LI, X; MILATOVICH, A; NONOYAMA, S; BAJORATH, J; GROSMAIRE, LS; STENKAMP, R; NEUBAUER, M; ROBERTS, RL; NOELLE, RJ; LEDBETTER, JA; FRANCKE, U; OCHS, HD			THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME	CELL			English	Article							HUMAN B-CELLS; TUMOR NECROSIS FACTOR; HYPERIMMUNOGLOBULINEMIA-M; LYMPHOCYTES-B; RECEPTOR; IMMUNODEFICIENCY; SEQUENCES; INTERLEUKIN-4; CARCINOMAS; ANTIBODY	The prominent role of the CD40 receptor in B cell responses led us to investigate the role of the gp39-CD40 interaction in a group of primary immunodeficient patients with defective antibody production. Here we report that patients with hyper-IgM syndrome (HIM) have a defective gp39-CD40 interaction. B cells from HIM patients express functional CD40, but their T cells do not bind CD40-Ig. These patients expressed normal levels of gp39 mRNA, but these mRNAs encode defective gp39 proteins owing to mutations in the extracellular domain of gp39. Soluble recombinant forms of gp39 containing these mutations were unable to bind CD40 and drive normal B cell proliferation. The gene encoding gp39 was mapped to Xq26, the X chromosome region where the gene responsible for HIM had previously been mapped. These data suggest that a defect in gp39 is the basis of X-linked HIM.	UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV CALIF LOS ANGELES, MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; DARTMOUTH COLL, SCH MED, DEPT MICROBIOL, LEBANON, NH 03756 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; Howard Hughes Medical Institute; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Dartmouth College	ARUFFO, A (corresponding author), BRISTOL MEYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA.		Bajorath, Jürgen/F-7493-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017427, R01HD017427] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026296, R37AI026296] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00298] Funding Source: Medline; NIAID NIH HHS [AI26296] Funding Source: Medline; NICHD NIH HHS [HD17427] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; BURTIN P, 1961, REV FR ETUD CLIN BIO, V6, P286; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; GALY AHM, 1992, J IMMUNOL, V149, P775; GASCAN H, 1991, J IMMUNOL, V147, P8; GIACALONE J, 1992, NAT GENET, V1, P137, DOI 10.1038/ng0592-137; GORDON J, 1987, EUR J IMMUNOL, V17, P1535, DOI 10.1002/eji.1830171026; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; MOLLER P, 1989, LEUCOCYTE TYPING, V4, P175; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; OCHS HD, 1989, IMMUNOLOGIC DISORDER, P226; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PELTZ GA, 1988, J IMMUNOL, V141, P1891; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; Sambrook J., 1989, MOL CLONING LAB MANU; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WEDGWOOD RJ, 1980, INSERM S, V16, P69; WIEACKER P, 1984, AM J HUM GENET, V36, P265; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679; ZHANG K, 1991, J IMMUNOL, V146, P1836; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	47	768	801	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					291	300		10.1016/0092-8674(93)90668-G	http://dx.doi.org/10.1016/0092-8674(93)90668-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678782				2022-12-01	WOS:A1993KK03800013
J	HOEY, T; WEINZIERL, ROJ; GILL, G; CHEN, JL; DYNLACHT, BD; TJIAN, R				HOEY, T; WEINZIERL, ROJ; GILL, G; CHEN, JL; DYNLACHT, BD; TJIAN, R			MOLECULAR-CLONING AND FUNCTIONAL-ANALYSIS OF DROSOPHILA TAF110 REVEAL PROPERTIES EXPECTED OF COACTIVATORS	CELL			English	Article							TRANSCRIPTION FACTOR; SYNERGISTIC ACTIVATION; PREINITIATION COMPLEX; BINDING-PROTEIN; TFIID COMPLEX; GENE; SP1; INVITRO; EXPRESSION; MECHANISM	The general transcription factor TFIID is a multiprotein complex containing the TATA-binding protein and several associated factors (TAFs), some of which may function as coactivators that are essential for activated, but not basal, transcription. Here we describe the isolation and characterization of the first gene encoding a TAF protein. The deduced amino acid sequence of TAF110 revealed the presence of several glutamine- and serine/threonine-rich regions reminiscent of the protein-protein interaction domains of the regulatory transcription factor Spl that are involved in transcription activation and multimerization. In both Drosophila cells and yeast, TAF110 specifically interacts with the glutamine-rich activation domains of Sp1. Moreover, purified Spl selectively binds recombinant TAF110 in vitro. These findings taken together suggest that TAF110 may function as a coactivator by serving as a site of protein-protein contact between activators like Sp1 and the TFIID complex.			HOEY, T (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Weinzierl, Robert/0000-0003-4095-9921				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; DYNLACHT BD, 1991, GENE DEV, V66, P563; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SKELLY S, 1987, P NATL ACAD SCI USA, V84, P8365, DOI 10.1073/pnas.84.23.8365; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	53	551	563	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					247	260		10.1016/0092-8674(93)90664-C	http://dx.doi.org/10.1016/0092-8674(93)90664-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678780				2022-12-01	WOS:A1993KK03800009
J	NGUYEN, HQ; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				NGUYEN, HQ; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			THE ZINC FINGER TRANSCRIPTION FACTOR EGR-1 IS ESSENTIAL FOR AND RESTRICTS DIFFERENTIATION ALONG THE MACROPHAGE LINEAGE	CELL			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; IMMEDIATE EARLY RESPONSE; INDUCED TERMINAL DIFFERENTIATION; TETRADECANOYL PHORBOL ACETATE; COLONY-STIMULATING FACTORS; C-MYC; GENE-EXPRESSION; ONCOGENE EXPRESSION; INHIBITORY FACTOR; GROWTH-FACTORS	We have isolated cDNA clones of myeloid differentiation primary response (MyD) genes, activated in the absence of de novo protein synthesis following induction for differentiation along either the macrophage or granulocyte lineage in human myeloblastic leukemia HL-60 cells. One cDNA clone of a primary response gene, expressed upon macrophage differentiation, encoded for Egr-1, a zinc finger transcription factor. The Egr-1 gene was observed to be transcriptionally silent in HL-60 cells, but active in U-937 and M1 cells, the latter two being predetermined for macrophage differentiation. Egr-1 antisense oligomers in the culture media blocked macrophage differentiation in both myeloid leukemia cell lines and normal myeloblasts. HL-60 cells constitutively expressing an Egr-1 transgene (HL-60Egr-1) could be induced for macrophage, but not granulocyte, differentiation. These observations indicate that expression of Egr-1 is essential for and restricts differentiation of myeloblasts along the macrophage lineage.			NGUYEN, HQ (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.				NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACON TA, 1991, ONCOGENE RES, V6, P13; BERNSTEIN SH, 1991, CELL GROWTH DIFFER, V2, P273; BOISE LH, 1992, CELL GROWTH DIFFER, V3, P43; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DALTON WT, 1988, BLOOD, V71, P242; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GALLAGHER R, 1979, BLOOD, V54, P713; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HORAK H, 1982, EXP HEMATOL, V10, P123; JINGWEN L, 1991, J BIOL CHEM, V266, P5929; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KOEFFLER HP, 1983, BLOOD, V62, P709; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; METCALF D, 1985, CELL, V43, P5, DOI 10.1016/0092-8674(85)90004-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; NAGARAJAN L, 1990, BLOOD, V75, P82; NELSON DA, 1983, HEMATOLOGY, P1651; NEWBURGER PE, 1981, CANCER RES, V41, P1861; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SHABO Y, 1990, LEUKEMIA, V4, P797; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TORELLA C, 1982, CANCER RES, V42, P445; TOTORA G, 1990, P NATL ACAD SCI USA, V87, P705; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WINTROBE MM, 1981, CLIN HEMATOLOGY, P35; WU J, 1990, ONCOGENE, V5, P873	60	377	388	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					197	209		10.1016/0092-8674(93)90660-I	http://dx.doi.org/10.1016/0092-8674(93)90660-I			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678779				2022-12-01	WOS:A1993KK03800005
